U.S. patent application number 15/130279 was filed with the patent office on 2016-10-20 for indazolones as modulators of tnf signaling.
The applicant listed for this patent is AbbVie Inc.. Invention is credited to Maria Argiriadi, Eric Breinlinger, Justin D. Dietrich, Michael Friedman, David Ihle, Glora Y. Lo Schiavo, Michael Morytko, Kelly Mullen, Augustine Osuma, Noel S. Wilson.
Application Number | 20160304496 15/130279 |
Document ID | / |
Family ID | 57127036 |
Filed Date | 2016-10-20 |
United States Patent
Application |
20160304496 |
Kind Code |
A1 |
Argiriadi; Maria ; et
al. |
October 20, 2016 |
INDAZOLONES AS MODULATORS OF TNF SIGNALING
Abstract
The disclosure provides indazolone compounds, pharmaceutically
acceptable salts, pro-drugs, biologically active metabolites,
stereoisomers and isomers thereof wherein the variables are defined
herein. The compounds of the disclosure may be useful for treating
immunological and oncological conditions.
Inventors: |
Argiriadi; Maria;
(Southborough, MA) ; Breinlinger; Eric; (Charlton,
MA) ; Dietrich; Justin D.; (Charlton, MA) ;
Friedman; Michael; (Brookline, MA) ; Ihle; David;
(Worcester, MA) ; Morytko; Michael; (Framingham,
MA) ; Mullen; Kelly; (Charlton, MA) ; Osuma;
Augustine; (Lindenhurst, IL) ; Lo Schiavo; Glora
Y.; (Worcester, MA) ; Wilson; Noel S.;
(Kenosha, WI) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
AbbVie Inc. |
North Chicago |
IL |
US |
|
|
Family ID: |
57127036 |
Appl. No.: |
15/130279 |
Filed: |
April 15, 2016 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
62149232 |
Apr 17, 2015 |
|
|
|
62258651 |
Nov 23, 2015 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
C07D 413/04 20130101;
C07D 491/107 20130101; C07D 401/14 20130101; C07D 403/04 20130101;
A61P 17/06 20180101; C07D 405/04 20130101; C07D 403/14 20130101;
C07D 417/14 20130101; C07F 9/65583 20130101; A61P 19/02 20180101;
C07D 401/04 20130101; C07D 413/14 20130101; A61P 37/00 20180101;
C07D 471/04 20130101; C07D 417/04 20130101; C07D 487/04 20130101;
C07D 405/14 20130101; C07D 498/04 20130101 |
International
Class: |
C07D 403/04 20060101
C07D403/04; C07D 403/14 20060101 C07D403/14; C07D 491/107 20060101
C07D491/107; C07D 405/14 20060101 C07D405/14; C07D 487/04 20060101
C07D487/04; C07D 405/04 20060101 C07D405/04; C07D 417/14 20060101
C07D417/14; C07D 401/04 20060101 C07D401/04; C07D 417/04 20060101
C07D417/04; C07D 413/04 20060101 C07D413/04; C07D 471/04 20060101
C07D471/04; C07F 9/6558 20060101 C07F009/6558; C07D 401/14 20060101
C07D401/14; C07D 498/04 20060101 C07D498/04 |
Claims
1. A compound of Formula (I), ##STR00417## or a pharmaceutically
acceptable salt, prodrug or stereoisomer thereof, wherein X, Y and
Z are independently CR.sup.4 or N; provided that Y and Z are not
both N; L is a bond, optionally substituted
(C.sub.1-C.sub.3)alkylene or --C(O)--; R.sup.1 is H, CD.sub.3,
optionally substituted (C.sub.1-C.sub.3)alkyl, or optionally
substituted (C.sub.3-C.sub.6)cycloalkyl; R.sup.2 is optionally
substituted aryl or optionally substituted heteroaryl; R.sup.3 is
--R.sup.3a-R.sup.3b, wherein: R.sup.3a is an optionally substituted
saturated, unsaturated or partially saturated heterocyclyl or
optionally substituted heteroaryl; R.sup.3b is
--N(R.sup.a)(R.sup.b), --O(R.sup.a), optionally substituted
(C.sub.1-C.sub.5)alkyl, optionally substituted
(C.sub.3-C.sub.6)cycloalkyl, or --(CH.sub.2).sub.p-optionally
substituted heterocyclyl; wherein R.sup.a and R.sup.b are
independently selected from H, optionally substituted
(C.sub.1-C.sub.5)alkyl, and --(CH.sub.2).sub.n-optionally
substituted heterocyclyl; R.sup.4 is independently H, Cl, CN, F,
CF.sub.3, or optionally substituted (C.sub.1-C.sub.3)alkyl; and n
is 0 or 1; p is 0, 1 or 2.
2. The compound according to claim 1 wherein the compound is a
compound of Formula (Ia), Formula (Ib), Formula (Ic), Formula (Id),
or Formula (Ie) ##STR00418##
3. The compound according to claim 1 wherein R.sup.1 is optionally
substituted (C.sub.1-C.sub.3)alkyl or optionally substituted
cyclopropyl.
4. The compound according to claim 1 wherein R.sup.2 is optionally
substituted heteroaryl, or optionally substituted phenyl.
5. The compound according to claim 1 wherein R.sup.3a is optionally
substituted 1,2,4-oxadiazolyl, optionally substituted pyrazolyl,
optionally substituted pyridinyl, optionally substituted
pyrimidinyl, optionally substituted pyrazinyl, or optionally
substituted 1,2,4-thiadiazolyl.
6. The compound according to claim 1 wherein R.sup.3b is
--N(R.sup.a)(R.sup.b), --O(R.sup.a), optionally substituted
(C.sub.1-C.sub.3)alkyl, --(CH.sub.2).sub.p-optionally substituted
2-oxa-6-azaspiro[3.3]heptanyl, --(CH.sub.2).sub.p-optionally
substituted 2-azaspiro[3.3]heptanyl, --(CH.sub.2).sub.p-optionally
substituted 5-azaspiro[2.3]hexanyl, --(CH.sub.2).sub.p-optionally
substituted azetidinyl, --(CH.sub.2).sub.p-optionally substituted
morpholinyl, --(CH.sub.2).sub.p-optionally substituted oxetanyl,
--(CH.sub.2).sub.p-optionally substituted piperazinyl,
--(CH.sub.2).sub.p-optionally substituted piperidinyl,
--(CH.sub.2).sub.p-optionally substituted pyrrolidinyl,
--(CH.sub.2).sub.p-optionally substituted tetrahydropyranyl,
--(CH.sub.2).sub.p-optionally substituted
6-oxohexahydropyrrolo[1,2-a]pyrazinyl,
--(CH.sub.2).sub.p-optionally substituted
tetrahydro-1H-oxazolo[3,4-a]pyrazin-3(5H)-one or
--(CH.sub.2).sub.p-optionally substituted
hexahydroimidazo[1,5-a]pyrazin-3(2H)-one; wherein R.sup.a and
R.sup.b are independently selected from H, optionally substituted
(C.sub.1-C.sub.3)alkyl, --(CH.sub.2).sub.n-oxoazepanyl,
--(CH.sub.2).sub.n-optionally substituted tetrahydrofuranyl,
--(CH.sub.2).sub.n-optionally substituted oxetanyl,
--(CH.sub.2).sub.n-optionally substituted tetrahydropyranyl, and
--(CH.sub.2).sub.n-optionally substituted pyrrolidinyl.
7. The compound according to claim 1 wherein L is a bond or
optionally substituted (C.sub.1-C.sub.2)alkylene.
8. The compound according to claim 1 wherein R.sup.2 is phenyl,
pyridinyl or pyrimidinyl, and R.sup.2 is optionally substituted by
one or more substituents independently selected from halogen, CN,
haloalkoxy, CF.sub.3, or optionally substituted
(C.sub.1-C.sub.3)alkyl.
9. The compound according to claim 1 wherein R.sup.3b is
--N(H)CH.sub.2-optionally substituted pyrrolidinyl, --O(R.sup.a),
--N(H)-optionally substituted oxetanyl, optionally substituted
(C.sub.1-C.sub.3)alkyl, optionally substituted
2-oxa-6-azaspiro[3.3]heptanyl, optionally substituted
5-azaspiro[2.3]hexanyl, optionally substituted azetidinyl,
optionally substituted morpholinyl, --(CH.sub.2).sub.p-optionally
substituted oxetanyl, optionally substituted piperazinyl,
optionally substituted piperidinyl, --(CH.sub.2).sub.p-optionally
substituted pyrrolidinyl, or optionally substituted
tetrahydropyranyl; wherein R.sup.a is selected from H, optionally
substituted (C.sub.1-C.sub.3)alkyl, --(CH.sub.2).sub.n-oxoazepanyl,
--(CH.sub.2).sub.n-optionally substituted tetrahydrofuranyl,
--(CH.sub.2).sub.n-optionally substituted oxetanyl,
--(CH.sub.2).sub.n-optionally substituted tetrahydropyranyl, and
--(CH.sub.2).sub.n-optionally substituted pyrrolidinyl.
10. The compound according to claim 1 wherein R.sup.3b is
optionally substituted by one or more substituents independently
selected from halogen, CN, --C(O)OH, --C(O)CH.sub.3,
--C(O)NH.sub.2, NH.sub.2, .dbd.O, --OH, optionally substituted
(C.sub.1-C.sub.3)alkyl, optionally substituted
(C.sub.1-C.sub.3)alkoxy and optionally substituted oxetanyl.
11. The compound according to claim 1 wherein Y is CR.sup.4.
12. The compound according to claim 1 wherein Z is CR.sup.4.
13. The compound according to claim 1 wherein the compound is:
1-(2-(difluoromethoxy)benzyl)-2-methyl-6-(2-(((1-methyl-5-oxopyrrolidin-3-
-yl)methyl)amino)pyrimidin-5-yl)-1H-indazol-3(2H)-one;
(R)-1-(5-(1-(2-(difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-1H-ind-
azol-6-yl)pyrimidin-2-yl)pyrrolidine-3-carboxylic acid;
(S)-1-(5-(1-(2-(difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-1H-ind-
azol-6-yl)pyrimidin-2-yl)pyrrolidine-3-carboxylic acid;
1-(4-chloropyridin-3-yl)methyl)-2-methyl-6-(2-morpholinopyrimidin-5-yl)-1-
H-indazol-3(2H)-one;
(R)-1-(2-(difluoromethoxy)benzyl)-6-(2-(3-hydroxypyrrolidin-1-yl)pyrimidi-
n-5-yl)-2-methyl-1H-indazol-3(2H)-one;
2-(5-(1-(2-(difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-1H-indazol-
-6-yl)pyrimidin-2-yl)-2-azaspiro[3.3]heptane-6-carboxylic acid;
5-(5-(1-(2-(difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-1H-indazol-
-6-yl)pyrimidin-2-yl)-5-azaspiro[2.3]hexane-1-carboxylic acid;
1-(2-(difluoromethoxy)benzyl)-2-ethyl-6-(2-morpholinopyrimidin-5-yl)-1H-i-
ndazol-3(2H)-one;
1-(2-(difluoromethoxy)-5-fluorobenzyl)-2-methyl-6-(2-morpholinopyrimidin--
5-yl)-1H-indazol-3(2H)-one;
6-(2-(2-oxa-6-azaspiro[3.3]heptan-6-yl)pyrimidin-5-yl)-1-(2-(difluorometh-
oxy)benzyl)-2-methyl-1H-indazol-3(2H)-one;
1-(5-(1-(2-(difluoromethoxy)benzyl)-2,5-dimethyl-3-oxo-2,3-dihydro-1H-ind-
azol-6-yl)pyrimidin-2-yl)piperidine-4-carboxylic acid;
1-(2-(difluoromethoxy)benzyl)-2,5-dimethyl-6-(2-morpholinopyrimidin-5-yl)-
-1H-indazol-3(2H)-one;
1-(2-(difluoromethoxy)benzyl)-2,5-dimethyl-6-(2-(3-oxopiperazin-1-yl)pyri-
midin-5-yl)-1H-indazol-3(2H)-one;
1-((3,6-dichloropyridin-2-yl)methyl)-2-methyl-6-(2-morpholinopyrimidin-5--
yl)-1H-indazol-3(2H)-one;
6-(2-((1-acetylpyrrolidin-3-yl)amino)pyrimidin-5-yl)-1-(2-(difluoromethox-
y)benzyl)-2-methyl-1H-indazol-3(2H)-one;
1-(5-(1-(2-(difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-1H-indazol-
-6-yl)pyrimidin-2-yl)azetidine-3-carboxylic acid;
1-(2-(difluoromethoxy)benzyl)-6-(2-(2,2-dimethylmorpholino)pyrimidin-5-yl-
)-2-methyl-1H-indazol-3(2H)-one;
1-(2-(difluoromethoxy)benzyl)-6-(2-(3-(hydroxymethyl)azetidin-1-yl)pyrimi-
din-5-yl)-2-methyl-1H-indazol-3(2H)-one;
1-(2-(difluoromethoxy)benzyl)-6-(2-(3-hydroxyazetidin-1-yl)pyrimidin-5-yl-
)-2-methyl-1H-indazol-3(2H)-one;
1-(5-(1-(2,5-dichlorobenzyl)-2-methyl-3-oxo-2,3-dihydro-1H-indazol-6-yl)p-
yrimidin-2-yl)piperidine-4-carboxylic acid;
6-(5-chloro-2-morpholinopyridin-4-yl)-1-(2-(difluoromethoxy)benzyl)-2-met-
hyl-1H-indazol-3(2H)-one;
1-(2-(difluoromethoxy)benzyl)-2-methyl-6-(2-(oxetan-3-ylamino)pyrimidin-5-
-yl)-1H-indazol-3(2H)-one;
1-benzoyl-2-methyl-6-(2-morpholinopyrimidin-5-yl)-1H-indazol-3(2H)-one;
6-(5-chloro-2-morpholinopyridin-4-yl)-1-(3-fluorobenzyl)-2-methyl-1H-inda-
zol-3(2H)-one;
1-(2-(difluoromethoxy)benzoyl)-2-methyl-6-(2-morpholinopyrimidin-5-yl)-1H-
-indazol-3(2H)-one;
1-(2-(difluoromethoxy)benzyl)-6-(2-((2-hydroxyethyl)amino)pyrimidin-5-yl)-
-2-methyl-1H-indazol-3(2H)-one;
2-(1-(5-(1-(2-(difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-1H-inda-
zol-6-yl)pyrimidin-2-yl)azetidin-3-yl)acetic acid;
1-(2-(difluoromethoxy)benzyl)-2-methyl-6-(1-(tetrahydro-2H-pyran-4-yl)-1H-
-pyrazol-4-yl)-1H-indazol-3(2H)-one;
1-(2-(difluoromethoxy)benzyl)-2-methyl-6-(2-morpholinopyridin-4-yl)-1H-in-
dazol-3(2H)-one;
1-(3-fluorobenzyl)-2-methyl-6-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4--
yl)-1H-indazol-3(2H)-one;
1-(3-fluorobenzyl)-2-methyl-6-(2-morpholinopyridin-4-yl)-1H-indazol-3(2H)-
-one;
1-(2-(difluoromethoxy)-6-fluorobenzyl)-2-methyl-6-(2-morpholinopyrim-
idin-5-yl)-1H-indazol-3(2H)-one;
1-(1-(2-(difluoromethoxy)phenyl)ethyl)-2-methyl-6-(2-morpholinopyrimidin--
5-yl)-1H-indazol-3(2H)-one;
2-methyl-6-(2-morpholinopyrimidin-5-yl)-1-phenethyl-1H-indazol-3(2H)-one;
2-methyl-1-(2-methylbenzyl)-6-(2-morpholinopyrimidin-5-yl)-1H-indazol-3(2-
H)-one;
1-(2,6-dichlorobenzyl)-2-methyl-6-(2-morpholinopyrimidin-5-yl)-1H--
indazol-3(2H)-one;
1-(3-(difluoromethoxy)benzyl)-2-methyl-6-(2-morpholinopyrimidin-5-yl)-1H--
indazol-3(2H)-one;
1-(3-fluorobenzyl)-2-methyl-6-(2-morpholinopyrimidin-5-yl)-1H-indazol-3(2-
H)-one;
1-(2-fluorophenethyl)-2-methyl-6-(2-morpholinopyrimidin-5-yl)-1H-i-
ndazol-3(2H)-one;
1-(2-fluorobenzyl)-2-methyl-6-(2-morpholinopyrimidin-5-yl)-1H-indazol-3(2-
H)-one;
2-((2-methyl-6-(2-morpholinopyrimidin-5-yl)-3-oxo-2,3-dihydro-1H-i-
ndazol-1-yl)methyl)benzonitrile;
2-methyl-1-(3-methylbenzyl)-6-(2-morpholinopyrimidin-5-yl)-1H-indazol-3(2-
H)-one;
1-(4-fluorobenzyl)-2-methyl-6-(2-morpholinopyrimidin-5-yl)-1H-inda-
zol-3(2H)-one;
1-benzyl-2-methyl-6-(2-morpholinopyrimidin-5-yl)-1H-indazol-3(2H)-one;
1-(2,6-dichlorobenzyl)-2-methyl-6-(2-(3-oxopiperazin-1-yl)pyrimidin-5-yl)-
-1H-indazol-3(2H)-one;
1-(5-(1-(2-(difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-1H-indazol-
-6-yl)pyrimidin-2-yl)piperidine-4-carboxylic acid;
1-(2-(difluoromethoxy)benzyl)-6-(2-methoxypyrimidin-5-yl)-2-methyl-1H-ind-
azol-3(2H)-one;
1-(2-(difluoromethoxy)benzyl)-2-methyl-6-(2-(3-oxopiperazin-1-yl)pyrimidi-
n-5-yl)-1H-indazol-3(2H)-one;
1-(2-(difluoromethoxy)benzyl)-6-(2-morpholinopyrimidin-5-yl)-1H-indazol-3-
(2H)-one;
1-(2,5-dichlorobenzyl)-2-methyl-6-(2-(piperazin-1-yl)pyrimidin-5-
-yl)-1H-indazol-3(2H)-one;
1-(2,5-dichlorobenzyl)-2-methyl-6-(2-morpholinopyrimidin-5-yl)-1H-indazol-
-3(2H)-one;
1-(2-(difluoromethoxy)benzyl)-2-methyl-6-(2-morpholinopyrimidin-5-yl)-1H--
indazol-3(2H)-one;
1-(2-(difluoromethoxy)benzyl)-2-methyl-6-(6-(3-oxopiperazin-1-yl)pyridin--
3-yl)-1H-indazol-3(2H)-one;
1-(2-(difluoromethoxy)benzyl)-2-methyl-6-(6-(piperazin-1-yl)pyridin-3-yl)-
-1H-indazol-3(2H)-one;
1-(2-(difluoromethoxy)benzyl)-2-methyl-6-(6-morpholinopyridin-3-yl)-1H-in-
dazol-3(2H)-one;
1-(2-(difluoromethoxy)benzyl)-6-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)--
2-methyl-1H-indazol-3(2H)-one;
1-(2-(difluoromethoxy)benzyl)-2-methyl-6-(2-(3-(oxetan-3-yl)azetidin-1-yl-
)pyrimidin-5-yl)-1H-indazol-3(2H)-one;
2-((5-(1-(2-(difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-1H-indazo-
l-6-yl)pyrimidin-2-yl)amino)propanamide;
1-(2-(difluoromethoxy)benzyl)-2-methyl-6-(5-morpholinopyrazin-2-yl)-1H-in-
dazol-3(2H)-one;
1-((5-(1-(2-(difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-1H-indazo-
l-6-yl)pyrimidin-2-yl)methyl)azetidine-3-carboxylic acid;
1-(2-(difluoromethoxy)benzyl)-2-methyl-6-(2-(((5-oxopyrrolidin-3-yl)methy-
l)amino)pyrimidin-5-yl)-1H-indazol-3(2H)-one;
1-((3-chloropyridin-2-yl)methyl)-2-methyl-6-(2-morpholinopyrimidin-5-yl)--
1H-indazol-3(2H)-one;
2-cyclopropyl-1-(2-(difluoromethoxy)benzyl)-6-(2-morpholinopyrimidin-5-yl-
)-1H-indazol-3(2H)-one;
1-(2,5-dichlorophenyl)-2-methyl-6-(2-morpholinopyrimidin-5-yl)-1H-indazol-
-3(2H)-one;
1-(2-(difluoromethoxy)-6-fluorobenzyl)-2-methyl-6-(2-morpholinopyrimidin--
5-yl)-1H-indazol-3(2H)-one;
4-(5-(1-(2-(difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-1H-indazol-
-6-yl)pyrimidin-2-yl)piperazine-1-carboxamide;
1-(1-(2-(difluoromethoxy)phenyl)ethyl)-6-(2-((R)-2-(methoxymethyl)pyrroli-
din-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one;
6-(2-(4-acetylpiperazin-1-yl)pyrimidin-5-yl)-1-(2-(difluoromethoxy)benzyl-
)-2-methyl-1H-indazol-3(2H)-one;
1-(2-(difluoromethoxy)benzyl)-2-methyl-6-(2-((2-oxoazepan-3-yl)amino)pyri-
midin-5-yl)-1H-indazol-3(2H)-one;
1-(3-(difluoromethoxy)benzyl)-2-methyl-6-(2-((tetrahydrofuran-3-yl)amino)-
pyrimidin-5-yl)-1H-indazol-3(2H)-one;
1-(2-(difluoromethoxy)benzyl)-2-methyl-6-(2-((tetrahydro-2H-pyran-3-yl)am-
ino)pyrimidin-5-yl)-1H-indazol-3(2H)-one;
1-(2-(difluoromethoxy)benzyl)-6-(2-((3-methoxypropyl)amino)pyrimidin-5-yl-
)-2-methyl-1H-indazol-3(2H)-one;
1-(2,5-dichlorobenzyl)-2-methyl-6-(2-morpholinopyrimidin-5-yl)-1H-indazol-
-3(2H)-one;
1-(5-(1-(2-(difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-1H-indazol-
-6-yl)pyrazin-2-yl)piperidine-4-carboxylic acid;
1-(2-(difluoromethoxy)benzyl)-2-methyl-6-(5-morpholino-1,2,4-thiadiazol-3-
-yl)-1H-indazol-3(2H)-one;
1-(2-(difluoromethoxy)benzyl)-2-methyl-6-(2-morpholinopyrimidin-5-yl)-1H--
pyrazolo[4,3-b]pyridin-3(2H)-one;
1-(2-(difluoromethoxy)benzyl)-2-methyl-6-(2-((3-methyloxetan-3-yl)methyl)-
pyrimidin-5-yl)-1H-indazol-3(2H)-one;
1-(2-(difluoromethoxy)benzyl)-2-methyl-6-(3-morpholino-1,2,4-oxadiazol-5--
yl)-1H-indazol-3(2H)-one;
1-(2-(difluoromethoxy)benzyl)-2-methyl-6-(2-morpholinopyrimidin-5-yl)-1H--
pyrazolo[3,4-b]pyridin-3(2H)-one;
1-(2-(difluoromethoxy)benzyl)-6-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)--
2-methyl-1H-pyrazolo[3,4-b]pyridin-3(2H)-one.
1-(2-(difluoromethoxy)benzyl)-2-methyl-6-(2-morpholinopyrimidin-5-yl)-1H--
pyrazolo[4,3-c]pyridin-3(2H)-one;
1-(2-(difluoromethoxy)benzyl)-2-methyl-6-(2-(6-oxohexahydropyrrolo[1,2-a]-
pyrazin-2(1H)-yl)pyrimidin-5-yl)-1H-indazol-3(2H)-one;
(R)-1-(2-(difluoromethoxy)benzyl)-2-methyl-6-(2-((tetrahydrofuran-3-yl)am-
ino)pyrimidin-5-yl)-1H-indazol-3(2H)-one;
(R)-7-(5-(1-(2-(difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-1H-ind-
azol-6-yl)pyrimidin-2-yl)tetrahydro-1H-oxazolo[3,4-a]pyrazin-3(5H)-one;
(S)-7-(5-(1-(2-(difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-1H-ind-
azol-6-yl)pyrimidin-2-yl)tetrahydro-1H-oxazolo[3,4-a]pyrazin-3(5H)-one;
7-(5-(1-(2-(difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-1H-indazol-
-6-yl)pyrimidin-2-yl)hexahydroimidazo[1,5-a]pyrazin-3(2H)-one;
(R)-7-(5-(1-(2-(difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-1H-ind-
azol-6-yl)pyrimidin-2-yl)hexahydroimidazo[1,5-a]pyrazin-3(2H)-one;
(S)-7-(5-(1-(2-(difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-1H-ind-
azol-6-yl)pyrimidin-2-yl)hexahydroimidazo[1,5-a]pyrazin-3(2H)-one;
1-(2-(difluoromethoxy)-5-methylbenzyl)-2-methyl-6-(2-morpholinopyrimidin--
5-yl)-1H-indazol-3(2H)-one;
1-(2-(difluoromethoxy)-5-(hydroxymethyl)benzyl)-2-methyl-6-(2-morpholinop-
yrimidin-5-yl)-1H-indazol-3(2H)-one;
(R)-7-(5-(1-(2-(difluoromethoxy)-5-methylbenzyl)-2-methyl-3-oxo-2,3-dihyd-
ro-1H-indazol-6-yl)pyrimidin-2-yl)hexahydroimidazo[1,5-a]pyrazin-3(2H)-one-
;
(S)-7-(5-(1-(2-(difluoromethoxy)-5-methylbenzyl)-2-methyl-3-oxo-2,3-dihy-
dro-1H-indazol-6-yl)pyrimidin-2-yl)hexahydroimidazo[1,5-a]pyrazin-3(2H)-on-
e;
(S)-7-(5-(1-(2-(Difluoromethoxy)-5-(hydroxymethyl)benzyl)-2-methyl-3-ox-
o-2,3-dihydro-1H-indazol-6-yl)pyrimidin-2-yl)hexahydroimidazo[1,5-a]pyrazi-
n-3(2H)-one; or
7-(5-(1-(2-(difluoromethoxy)-5-(hydroxymethyl)benzyl)-2-methyl-3-oxo-2,3--
dihydro-1H-indazol-6-yl)pyrimidin-2-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]py-
razin-3(2H)-one;
1-(2-(difluoromethoxy)-5-methylbenzyl)-5-fluoro-6-(2-(2-hydroxypropan-2-y-
l)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one; or
(R)-1-(2-(difluoromethoxy)benzyl)-6-(2-(4-(2-hydroxyacetyl)-3-methylpiper-
azin-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one.
14. A compound of Formula (I), or a pharmaceutically acceptable
salt, prodrug or stereoisomer thereof, wherein X, Y and Z are
independently CR.sup.4 or N; provided that Y and Z are not both N;
L is a bond, optionally substituted (C.sub.1-C.sub.3)alkylene or
--C(O)--; R.sup.1 is H, CD.sub.3, CN, optionally substituted
(C.sub.1-C.sub.3)alkyl, --(CH.sub.2).sub.n-optionally substituted
phenyl, --(CH.sub.2).sub.n-optionally substituted heteroaryl or
--(CH.sub.2).sub.n-optionally substituted heterocyclyl; R.sup.2 is
optionally substituted aryl, optionally substituted heteroaryl,
optionally substituted heterocyclyl or optionally substituted
cycloalkyl; R.sup.3 is --R.sup.3a-R.sup.3b, wherein: R.sup.3a is an
optionally substituted saturated, unsaturated or partially
saturated heterocyclyl or optionally substituted heteroaryl;
R.sup.3b is --N(R.sup.a)(R.sup.b), --O(R.sup.a), optionally
substituted (C.sub.1-C.sub.5)alkyl, optionally substituted
(C.sub.3-C.sub.6)cycloalkyl, or --(CH.sub.2).sub.p-optionally
substituted heterocyclyl; wherein R.sup.a and R.sup.b are
independently selected from H, optionally substituted
(C.sub.1-C.sub.5)alkyl, and --(CH.sub.2).sub.n-optionally
substituted heterocyclyl; R.sup.4 is independently H, Cl, CN, F,
CF.sub.3, optionally substituted (C.sub.1-C.sub.3)alkyl or
optionally substituted (C.sub.1-C.sub.3) alkoxy; and n is 0 or 1; p
is 0, 1 or 2.
15. The compound according to claim 14 wherein R.sup.1 is H,
CD.sub.3, optionally substituted (C.sub.1-C.sub.3)alkyl or
--CH.sub.2-pyrimidinyl.
16. The compound according to claim 14 wherein R.sup.2 is
optionally substituted heteroaryl, optionally substituted
heterocyclyl or optionally substituted phenyl.
17. The compound according to claim 14 wherein R.sup.3a is
optionally substituted dihydropyranyl, optionally substituted
imidazo[1,2-b]pyridazinyl, optionally substituted
1,2,4-oxadiazolyl, optionally substituted pyrazolyl, optionally
substituted 3,6-dihydro-2H-pyranyl, optionally substituted
pyridinyl, optionally substituted pyrimidinyl, optionally
substituted pyrazinyl, or optionally substituted
1,2,4-thiadiazolyl.
18. The compound according to claim 14 wherein R.sup.3b is
--N(R.sup.a)(R.sup.b), --O(R.sup.a), optionally substituted
(C.sub.1-C.sub.3)alkyl, --(CH.sub.2).sub.p-optionally substituted
imidazo[1,2-b]pyridazinyl, --(CH.sub.2).sub.p-optionally
substituted morpholinyl, --(CH.sub.2).sub.p-optionally substituted
piperazinyl, --(CH.sub.2).sub.p-optionally substituted piperidinyl,
--(CH.sub.2).sub.p-optionally substituted pyrrolidinyl,
--(CH.sub.2).sub.p-optionally substituted tetrahydropyranyl,
--(CH.sub.2).sub.p-optionally substituted
tetrahydro-1H-oxazolo[3,4-a]pyrazin-3(5H)-one,
--(CH.sub.2).sub.p-optionally substituted
hydroimidazo[1,2-b]pyridazin-3(2H)-one; or
--(CH.sub.2).sub.p-optionally substituted
hexahydroimidazo[1,5-a]pyrazin-3(2H)-one; wherein R.sup.a and
R.sup.b are independently selected from H, optionally substituted
(C.sub.1-C.sub.3)alkyl, --(CH.sub.2).sub.n-morpholinyl
--(CH.sub.2).sub.n-oxoazepanyl, --(CH.sub.2).sub.n-optionally
substituted tetrahydrofuranyl, --(CH.sub.2).sub.n-optionally
substituted oxetanyl, --(CH.sub.2).sub.n-optionally substituted
piperidinyl, --(CH.sub.2).sub.n-optionally substituted
tetrahydropyranyl, --(CH.sub.2).sub.p-optionally substituted
hexahydroimidazo[1,5-a]pyrazin-3(2H)-one, and
--(CH.sub.2).sub.n-optionally substituted pyrrolidinyl.
19. The compound according to claim 14 wherein L is a bond or
optionally substituted (C.sub.1-C.sub.2)alkylene.
20. The compound according to claim 14 wherein R.sup.2 is
4,5-dihydrobenzo[f][1,5]thiazepin-3(2h)-one,
1.3-dihydroisobenzofuranyl, phenyl, pyridinyl, pyrimidinyl or
pyrrolyl, and R.sup.2 is optionally substituted by one or more
substituents independently selected from halogen, CN, haloalkoxy,
CF.sub.3, --SCHF.sub.2, optionally substituted
(C.sub.1-C.sub.3)alkyl, optionally substituted
(C.sub.3-C.sub.6)cycloalkyl, --CH.sub.2OC(O)C(H)NH.sub.2CH.sub.3,
--CH.sub.2NHC(O)OCH.sub.3, --CH.sub.2-pyridinyl,
--CH.sub.2-pyrrolyl, --CH.sub.2-optionally substituted pyrazolyl,
--CH.sub.2-triazolyl-, --CH.sub.2--O-pyrazolyl, --C(O)CH.sub.3,
--N(H)CH.sub.2C(OH)(CH.sub.3).sub.2,
--N(H)CH.sub.2C(H)(OH)CH.sub.3, or --N(H)(R.sup.c); wherein R.sup.c
is --(CH.sub.2).sub.n-optionally substituted heterocyclyl or
--(CH.sub.2).sub.n optionally substituted heteroaryl, wherein n is
0 or 1.
21. The compound according to claim 14 wherein R.sup.3b is
--N(H)-optionally substituted oxetanyl, --N(H)-optionally
substituted piperidin-2-one, --N(H)-optionally substituted
tetrahydropyranyl, --O-tetrahydropyranyl, optionally substituted
(C.sub.1-C.sub.3)alkyl, optionally substituted morpholinyl,
optionally substituted piperazinyl, optionally substituted
piperidinyl, optionally substituted pyrrolidinyl, -optionally
substituted tetrahydro-1H-oxazolo[3,4-a]pyrazin-3(5H)-one
--(CH.sub.2).sub.p-optionally substituted
hexahydroimidazo[1,5-a]pyrazin-3(2H)-one, or optionally substituted
tetrahydropyranyl.
22. The compound according to claim 14 wherein R.sup.3b is
optionally substituted by one or more substituents independently
selected from halogen, --CHO, CN, --C(O)OH, --C(O)CH.sub.3,
--C(O)CH.sub.2CN, --C(O)CH.sub.2OH, --C(O)CH.sub.2NH.sub.2,
C(O)CH.sub.2OCH.sub.3, --C(O)C(H)(CH.sub.3)NH.sub.2,
--C(O)C(H)(OH)CH.sub.2OH, --C(O)C(H)(OH)CH.sub.2C(O)OH,
--C(O)C(H)(OH)CH.sub.2NH.sub.2,
--C(O)CH.sub.2OC(O)C(H)(NH.sub.2)CH(CH.sub.3).sub.2,
--C(O)NH.sub.2, --C(O)OCH.sub.3, --C(O)CH.sub.2OP(O)(OH).sub.2,
--C(O)-- oxetanyl, NH.sub.2, .dbd.O, --OH, --S(O).sub.2CH.sub.3,
optionally substituted (C.sub.1-C.sub.3)alkyl, optionally
substituted (C.sub.1-C.sub.3)alkoxy and optionally substituted
oxetanyl.
23. The compound according to claim 14 wherein Y is CR.sup.4 and
R.sup.4 is H.
24. The compound according to claim 14 wherein Z is CR.sup.4 and
R.sup.4 is H or F.
25. The compound according to claim 14 wherein the compound is
(R)-1-(5-((1H-pyrazol-4-yl)methyl)-2-(difluoromethoxy)benzyl)-6-(2-(4-ace-
tyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one;
(R)-1-(2-(difluoromethoxy)benzyl)-7-fluoro-6-(2-(4-(2-hydroxyacetyl)-3-me-
thylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one;
(R)-2-(4-(difluoromethoxy)-3-((6-(2-(4-(2-hydroxyacetyl)-3-methylpiperazi-
n-1-yl)pyrimidin-5-yl)-2-methyl-3-oxo-2,3-dihydro-1H-indazol-1-yl)methyl)p-
henyl)acetonitrile;
(R)-2-(4-(5-(1-(2-(difluoromethoxy)-5-methylbenzyl)-2-methyl-3-oxo-2,3-di-
hydro-1H-indazol-6-yl)pyrimidin-2-yl)-2-methylpiperazin-1-yl)-2-oxoethyl
dihydrogen phosphate;)
(R)-1-(2-(difluoromethoxy)benzyl)-5,7-difluoro-6-(2-(4-(2-hydroxyacetyl)--
3-methylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one;
(R)-1-(2-chlorobenzyl)-7-fluoro-6-(2-(4-(2-hydroxyacetyl)-3-methylpiperaz-
in-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one;
(R)-1-(2-chlorobenzyl)-7-fluoro-6-(2-(4-(2-hydroxyacetyl)-3-methylpiperaz-
in-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one;
(R)-1-(2-(difluoromethoxy)-5-methylbenzyl)-5-fluoro-6-(2-(4-(2-hydroxyace-
tyl)-2-methylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one;
1-(5-((1H-pyrazol-5-yl)methyl)-2-(difluoromethoxy)benzyl)-6-(2-(2-hydroxy-
propan-2-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one;
1-(2-(difluoromethoxy)-5-methylbenzyl)-6-(3-(2-hydroxypropan-2-yl)imidazo-
[1,2-b]pyridazin-7-yl)-2-methyl-1H-indazol-3(2H)-one;
1-(2-(difluoromethoxy)-5-methylbenzyl)-2-methyl-6-(2-(3-methylpyrrolidin--
3-yl)pyrimidin-5-yl)-1H-indazol-3(2H)-one;
1-(1-(2,5-difluorophenyl)ethyl)-6-(2-((R)-4-(2-hydroxyacetyl)-3-methylpip-
erazin-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one;
1-(2-(difluoromethoxy)-5-methylbenzyl)-5-fluoro-6-(6-(1-hydroxyethyl)-5,6-
-dihydro-2H-pyran-3-yl)-2-methyl-1H-indazol-3(2H)-one;
1-(2-chloro-5-((2-hydroxy-2-methylpropyl)amino)benzyl)-6-(2-(2-hydroxypro-
pan-2-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one;
1-(2-(difluoromethoxy)-5-methylbenzyl)-6-(2-(1,3-dimethylpyrrolidin-3-yl)-
pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one acetate;
1-(2-(difluoromethoxy)-5-methylbenzyl)-6-(2-(1,3-dimethylpyrrolidin-3-yl)-
pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one;
(R)-1-(2-(difluoromethoxy)benzyl)-5-fluoro-6-(2-(4-(2-hydroxyacetyl)-3-me-
thylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one;
6-[2-[(3R)-4-acetyl-3-methyl-piperazin-1-yl]pyrimidin-5-yl]-1-[[2-(difluo-
romethoxy)-5-methyl-phenyl]methyl]-2(trideuteriomethyl)indazol-3-one;
(S)-6-(2-(4-acetyl-2-methylpiperazin-1-yl)pyrimidin-5-yl)-1-(2-(difluorom-
ethoxy)-5-methylbenzyl)-2-methyl-1H-indazol-3(2H)-one;
(R)-1-(2-(difluoromethoxy)-5-methylbenzyl)-6-(2-(4-(2-hydroxyacetyl)-3-me-
thylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one;
1-[[2-(difluoromethoxy)-5-methyl-phenyl]methyl]-6-[2-[(3R)-4-(2-hydroxyac-
etyl)-3-methyl-piperazin-1-yl]pyrimidin-5-yl]-2-(trideuteriomethyl)indazol-
-3-one;
(R)-1-(2-(difluoromethoxy)-5-methylbenzyl)-6-(2-(4-(2-hydroxyacety-
l)-2-methylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one;
(R)-6-(2-(4-acetyl-2-methylpiperazin-1-yl)pyrimidin-5-yl)-1-(2-(difluorom-
ethoxy)-6-(hydroxymethyl)benzyl)-2-methyl-1H-indazol-3(2H)-one;
(R)-1-(2-(difluoromethoxy)benzyl)-6-(2-(4-(2-hydroxyacetyl)-3-methylpiper-
azin-1-yl)-4-methylpyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one;
1-(2-(difluoromethoxy)-5-methylbenzyl)-5-fluoro-6-(6-(2-hydroxypropan-2-y-
l)-5,6-dihydro-2H-pyran-3-yl)-2-methyl-1H-indazol-3(2H)-one;
1-((S)-1-(2,6-difluorophenyl)ethyl)-6-(2-((R)-4-(2-hydroxyacetyl)-3-methy-
lpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one;
(R)-1-(2-(difluoromethoxy)-5-methylbenzyl)-2-methyl-6-(2-(3-methyl-4-(met-
hylsulfonyl)piperazin-1-yl)pyrimidin-5-yl)-1H-indazol-3(2H)-one;
(R)-methyl
4-(5-(1-(2-(difluoromethoxy)-5-methylbenzyl)-2-methyl-3-oxo-2,3-dihydro-1-
H-indazol-6-yl)pyrimidin-2-yl)-2-methylpiperazine-1-carboxylate;
(R)-6-(2-(4-acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-1-(2-(difluorom-
ethoxy)-6-(hydroxymethyl)benzyl)-2-methyl-1H-indazol-3(2H)-one;
(S)-7-(5-(1-(2-(difluoromethoxy)-5-methylbenzyl)-2-methyl-3-oxo-2,3-dihyd-
ro-1H-indazol-6-yl)pyrimidin-2-yl)tetrahydro-1H-oxazolo[3,4-a]pyrazin-3(5H-
)-one;
(R)-6-(2-(4-acetyl-2-methylpiperazin-1-yl)pyrimidin-5-yl)-1-(2-(dif-
luoromethoxy)-5-methylbenzyl)-2-methyl-1H-indazol-3(2H)-one;
(R)-1-(2-(difluoromethoxy)benzyl)-6-(2-(4-(2-hydroxyacetyl)-2-methylpiper-
azin-1-yl)-4-methylpyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one;
(R)-7-(5-(1-(5-((1H-1,2,4-triazol-1-yl)methyl)-2-(difluoromethoxy)benzyl)-
-2-methyl-3-oxo-2,3-dihydro-1H-indazol-6-yl)pyrimidin-2-yl)hexahydroimidaz-
o[1,5-a]pyrazin-3(2H)-one;
(R)-7-(5-(1-(2-(difluoromethoxy)-6-(hydroxymethyl)benzyl)-2-methyl-3-oxo--
2,3-dihydro-1H-indazol-6-yl)pyrimidin-2-yl)hexahydroimidazo[1,5-a]pyrazin--
3(2H)-one;
1-(5-((1H-pyrazol-4-yl)methyl)-2-(difluoromethoxy)benzyl)-6-(2--
(2-hydroxypropan-2-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one;
(R)-6-(2-(4-acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-1-(2-((difluoro-
methyl)thio)-5-methylbenzyl)-2-methyl-1H-pyrazolo[3,4-b]pyridin-3(2H)-one;
(R)-2-(4-acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-1-(2-chloro-5-meth-
ylbenzyl)-2-methyl-1H-pyrazolo[3,4-b]pyridin-3(2H)-one;
(R)-6-(2-(4-acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-1-(2-((difluoro-
methyl)thio)-5-methylbenzyl)-2-methyl-1H-indazol-3(2H)-one;
(R)-2-(4-acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-1-(2-(difluorometh-
oxy)-5-methylbenzyl)-2-methyl-1H-indazol-3(2H)-one;
(R)-2-(4-(difluoromethoxy)-3-((2-methyl-3-oxo-6-(2-(3-oxotetrahydro-1H-ox-
azolo[3,4-a]pyrazin-7(3H)-yl)pyrimidin-5-yl)-2,3-dihydro-1H-indazol-1-yl)m-
ethyl)phenyl)acetonitrile;
(S)-1-(2-(difluoromethoxy)benzyl)-6-(2-(4-(2-hydroxyacetyl)-2-methylpiper-
azin-1-yl)-4-methylpyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one;
(R)-6-(2-(4-(2-hydroxyacetyl)-3-methylpiperazin-1-yl)pyrimidin-5-yl)-2-me-
thyl-1-((6-methyl-3-(trifluoromethyl)pyridin-2-yl)methyl)-1H-indazol-3(2H)-
-one;
(R)-7-(5-(1-(2-(difluoromethoxy)-6-(methoxymethyl)benzyl)-2-methyl-3-
-oxo-2,3-dihydro-1H-indazol-6-yl)pyrimidin-2-yl)hexahydroimidazo[1,5-a]pyr-
azin-3(2H)-one;
(S)-1-(2-(difluoromethoxy)-5-methylbenzyl)-2-methyl-6-(2-(3-methyl-4-(met-
hylsulfonyl)piperazin-1-yl)pyrimidin-5-yl)-1H-indazol-3(2H)-one;
(R)-1-(2-(difluoromethoxy)benzyl)-5-fluoro-6-(2-(4-(2-hydroxyacetyl)-3-me-
thylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-1H-pyrazolo[3,4-b]pyridin-3(2H-
)-one;
6-(2-((R)-4-(2-hydroxyacetyl)-3-methylpiperazin-1-yl)pyrimidin-5-yl-
)-2-methyl-1-((S)-1-(m-tolyl)ethyl)-1H-indazol-3(2H)-one;
6-(2-(4-(3-amino-2-hydroxypropanoyl)-3-methylpiperazin-1-yl)pyrimidin-5-y-
l)-1-(2-(difluoromethoxy)-5-methylbenzyl)-2-methyl-1H-indazol-3(2H)-one;
1-(2-(difluoromethoxy)benzyl)-6-(2-((R)-4-((S)-2,3-dihydroxypropanoyl)-3--
methylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one;
(R)-1-(2-(difluoromethoxy)benzyl)-5-fluoro-6-(2-(4-(2-hydroxyacetyl)-2-me-
thylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one;
1-(2-(difluoromethoxy)-5-methylbenzyl)-2-methyl-6-(2-((3R)-3-methyl-4-(ox-
etane-2-carbonyl)piperazin-1-yl)pyrimidin-5-yl)-1H-indazol-3(2H)-one;
(R)-2-(4-(5-(1-(2-(difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-1H--
indazol-6-yl)pyrimidin-2-yl)-2-methylpiperazin-1-yl)-2-oxoethyl
phosphate;
(R)-1-(2-(difluoromethoxy)benzyl)-6-(2-(4-(2-hydroxyacetyl)-3-methylpiper-
azin-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one;
(R)-3-(4-(5-(1-(2-(difluoromethoxy)-5-methylbenzyl)-2-methyl-3-oxo-2,3-di-
hydro-1H-indazol-6-yl)pyrimidin-2-yl)-2-methylpiperazin-1-yl)-3-oxopropane-
nitrile;
1-(1-(2,6-difluorophenyl)ethyl)-6-(2-((R)-4-(2-hydroxyacetyl)-3-m-
ethylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one;
(S)-1-(2-(difluoromethoxy)benzyl)-6-(2-(4-(2-hydroxyacetyl)-2-methylpiper-
azin-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one;
1-(2-(difluoromethoxy)benzyl)-6-(2-((R)-4-((R)-2,3-dihydroxypropanoyl)-3--
methylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one;
(R)-6-(2-(4-acetyl-2-ethylpiperazin-1-yl)pyrimidin-5-yl)-1-(2-(difluorome-
thoxy)-5-methylbenzyl)-2-methyl-1H-indazol-3(2H)-one;
(R)-1-(2-(difluoromethoxy)-5-(hydroxymethyl)benzyl)-2-methyl-6-(2-((2-oxo-
piperidin-4-yl)amino)pyrimidin-5-yl)-1H-indazol-3(2H)-one;
(S)-7-(5-(1-(2-(difluoromethoxy)-5-(hydroxymethyl)benzyl)-2-methyl-3-oxo--
2,3-dihydro-1H-indazol-6-yl)pyrimidin-2-yl)tetrahydro-1H-oxazolo[3,4-a]pyr-
azin-3(5H)-one;
(R)-1-(2-(difluoromethoxy)benzyl)-5-fluoro-6-(6-(4-(2-hydroxyacetyl)-3-me-
thylpiperazin-1-yl)pyridin-3-yl)-2-methyl-1H-indazol-3(2H)-one;
(R)-1-(2-chlorobenzyl)-6-(2-(4-(2-hydroxyacetyl)-3-methylpiperazin-1-yl)p-
yrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one;
(R)-1-(2-(difluoromethoxy)-5-methylbenzyl)-2-methyl-6-(2-(3-methyl-4-(oxe-
tane-3-carbonyl)piperazin-1-yl)pyrimidin-5-yl)-1H-indazol-3(2H)-one;
4-(5-(1-(2-(difluoromethoxy)-5-(hydroxymethyl)benzyl)-2-methyl-3-oxo-2,3--
dihydro-1H-indazol-6-yl)pyrimidin-2-yl)piperazine-1-carbaldehyde;
(S)-2-((R)-4-(5-(1-(2-(difluoromethoxy)-5-methylbenzyl)-2-methyl-3-oxo-2,-
3-dihydro-1H-indazol-6-yl)pyrimidin-2-yl)-2-methylpiperazin-1-yl)-2-oxoeth-
yl 2-amino-3-methylbutanoate;
(R)-7-(5-(1-(2-(difluoromethoxy)-5-(hydroxymethyl)benzyl)-2-methyl-3-oxo--
2,3-dihydro-1H-indazol-6-yl)pyrimidin-2-yl)tetrahydro-1H-oxazolo[3,4-a]pyr-
azin-3(5H)-one;
(S)-7-(5-(1-(2-chloro-5-methylbenzyl)-2-methyl-3-oxo-2,3-dihydro-1H-indaz-
ol-6-yl)pyrimidin-2-yl)hexahydroimidazo[1,5-a]pyrazin-3(2H)-one;
(R)-1-(2-(difluoromethoxy)benzyl)-7-fluoro-6-(2-(4-(2-hydroxyacetyl)-2-me-
thylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one;
(R)-6-(2-(4-acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-1-((6--
methyl-3-(trifluoromethyl)pyridin-2-yl)methyl)-1H-indazol-3(2H)-one;
(R)-7-(5-(1-(2-(Difluoromethoxy)-5-methylbenzyl)-2-(methyl-d.sub.3)-3-oxo-
-2,3-dihydro-1H-indazol-6-yl)pyrimidin-2-yl)hexahydro-3H-oxazolo[3,4-a]pyr-
azin-3-one;
(R)-1-(2-(difluoromethoxy)-5-methylbenzyl)-6-(2-(4-(2-methoxyacetyl)-3-me-
thylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one;
(S)-7-(5-(2-methyl-1-(5-methyl-2-(trifluoromethyl)benzyl)-3-oxo-2,3-dihyd-
ro-1H-indazol-6-yl)pyrimidin-2-yl)hexahydroimidazo[1,5-a]pyrazin-3(2H)-one-
;
6-(2-(4-acetylpiperazin-1-yl)pyrimidin-5-yl)-1-(2-(difluoromethoxy)-5-(h-
ydroxymethyl)benzyl)-2-methyl-1H-indazol-3(2H)-one;
(S)-1-(2-(difluoromethoxy)-5-methylbenzyl)-6-(2-(4-(2-hydroxyacetyl)-3-me-
thylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one;
6-(2-((R)-4-(2-hydroxyacetyl)-3-methylpiperazin-1-yl)pyrimidin-5-yl)-2-me-
thyl-1-(1-(m-tolyl)propyl)-1H-indazol-3(2H)-one;
(S)-7-(5-(1-(5-((4H-1,2,4-triazol-4-yl)methyl)-2-(difluoromethoxy)benzyl)-
-2-methyl-3-oxo-2,3-dihydro-1H-indazol-6-yl)pyrimidin-2-yl)hexahydroimidaz-
o[1,5-a]pyrazin-3(2H)-one;
(R)-1-(2-(difluoromethoxy)benzyl)-6-(2-(4-(2-hydroxyacetyl)-2-methylpiper-
azin-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one;
(R)-6-(2-(4-acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-1-(2-(difluorom-
ethoxy)-5-methylbenzyl)-2-methyl-1H-pyrazolo[3,4-b]pyridin-3(2H)-one;
(R)-7-(5-(1-(3-(difluoromethoxy)-6-(hydroxymethyl)pyridin-2-yl)methyl)-2--
methyl-3-oxo-2,3-dihydro-1H-indazol-6-yl)pyrimidin-2-yl)hexahydroimidazo[1-
,5-a]pyrazin-3(2H)-one;
(R)-6-(2-(4-acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-1-(2-(difluorom-
ethoxy)benzyl)-2-methyl-1H-indazol-3(2H)-one;
(R)-6-(2-(4-acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-1-((6--
methyl-3-(trifluoromethyl)pyridin-2-yl)methyl)-1H-pyrazolo[3,4-b]pyridin-3-
(2H)-one;
(S)-4-(difluoromethoxy)-3-((2-methyl-3-oxo-6-(2-((R)-3-oxohexahy-
droimidazo[1,5-a]pyrazin-7(1H)-yl)pyrimidin-5-yl)-2,3-dihydro-1H-indazol-1-
-yl)methyl)benzyl 2-aminopropanoate hydrochloride;
(R)-6-(2-(4-acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-1-((4--
(trifluoromethyl)-1H-pyrrol-3-yl)methyl)-1H-indazol-3(2H)-one;
1-(2-(difluoromethoxy)-5-methylbenzyl)-6-(2-(2-hydroxypropan-2-yl)-4-meth-
ylpyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one;
6-(2-((R)-4-(2-hydroxyacetyl)-3-methylpiperazin-1-yl)pyrimidin-5-yl)-2-me-
thyl-1-(1-(m-tolyl)ethyl)-1H-indazol-3(2H)-one;
1-(2-chloro-5-((4,5,6,7-tetrahydro-1H-indazol-7-yl)amino)benzyl)-6-(2-(2--
hydroxypropan-2-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one;
(R)-2-(4-(difluoromethoxy)-3-((2-methyl-3-oxo-6-(2-(3-oxohexahydroimidazo-
[1,5-a]pyrazin-7(1H)-yl)pyrimidin-5-yl)-2,3-dihydro-1H-indazol-1-yl)methyl-
)phenyl)acetonitrile;
(R)-6-(2-(4-(2-aminoacetyl)-3-methylpiperazin-1-yl)pyrimidin-5-yl)-1-(2-(-
difluoromethoxy)-5-methylbenzyl)-2-methyl-1H-indazol-3(2H)-one;
1-(2-(difluoromethoxy)-5-methylbenzyl)-6-(2-(4-(2-hydroxyacetyl)piperazin-
-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one;
(R)-1-(5-(((1H-pyrazol-5-yl)oxy)methyl)-2-(difluoromethoxy)benzyl)-6-(2-(-
4-actyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-o-
ne;
(S)-6-(2-(4-acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-1-(2-(difluo-
romethoxy)-5-methylbenzyl)-2-methyl-1H-indazol-3(2H)-one;
1-(5-((1H-1,2,4-triazol-1-yl)methyl)-2-difluoromethoxy)benzyl)-5-fluoro-6-
-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one;
(R)-7-(5-(1-(2-(difluoromethoxy)-5-methylbenzyl)-2-methyl-3-oxo-2,3-dihyd-
ro-1H-indazol-6-yl)pyrimidin-2-yl)tetrahydro-1H-oxazolo[3,4-a]pyrazin-3(5H-
)-one;
(R)-1-(2-(difluoromethoxy)-5-(hydroxymethyl)benzyl)-2-methyl-6-(2-(-
(1-methyl-2-oxopiperidin-4-yl)amino)pyrimidin-5-yl)-1H-indazol-3(2H)-one;
(R)-1-(2-(difluoromethoxy)benzyl)-6-(2-(4-(2-hydroxyacetyl)-3-methylpiper-
azin-1-yl)pyrimidin-5-yl)-7-methoxy-2-methyl-1H-indazol-3(2H)-one;
1-((S)-1-(2-fluorophenyl)ethyl)-6-(2-((R)-4-(2-hydroxyacetyl)-3-methylpip-
erazin-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one;
(R)-6-(2-(4-acetyl-2-methylpiperazin-1-yl)pyrimidin-5-yl)-1-(2-(difluorom-
ethoxy)benzyl)-2-methyl-1H-indazol-3(2H)-one;
6-(2-((R)-4-((S)-2-aminopropanoyl)-3-methylpiperazin-1-yl)pyrimidin-5-yl)-
-1-(2-(difluoromethoxy)-5-methylbenzyl)-2-methyl-1H-indazol-3(2H)-one;
1-(2-(difluoromethoxy)-5-methylbenzyl)-5-fluoro-6-(2-(2-hydroxypropan-2-y-
l)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one;
1-(2-(difluoromethoxy)-5-(hydroxymethyl)benzyl)-2-methyl-6-(2-((2-oxopipe-
ridin-4-yl)amino)pyrimidin-5-yl)-1H-indazol-3(2H)-one; (R)-methyl
3-((6-(2-(4-acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-3-oxo--
2,3-dihydro-1H-indazol-1-yl)methyl)-4-(difluoromethoxy)benzylcarbamate;
1-(2-(difluoromethoxy)-5-methylbenzyl)-2-methyl-6-(2-((tetrahydro-2H-pyra-
n-4-yl)oxy)pyridin-4-yl)-1H-indazol-3(2H)-one;
(S)-3-(4-(5-(1-(2-(difluoromethoxy)-5-methylbenzyl)-2-methyl-3-oxo-2,3-di-
hydro-1H-indazol-6-yl)pyrimidin-2-yl)-2-methylpiperazin-1-yl)-3-oxopropane-
nitrile;
(S)-2-((R)-4-(5-(1-(2-(difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-
-dihydro-1H-indazol-6-yl)pyrimidin-2-yl)-2-methylpiperazin-1-yl)-2-oxoethy-
l 2-amino-3-methylbutanoate;
(R)-7-(5-(1-(2-(difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-1H-ind-
azol-6-yl)pyrimidin-2-yl)-2-(2-hydroxyethyl)hexahydroimidazo[1,5-a]pyrazin-
-3(2H)-one;
(R)-6-(2-(4-(2-hydroxyacetyl)-2-methylpiperazin-1-yl)pyrimidin-5-yl)-2-me-
thyl-1-((6-methyl-3-(trifluoromethyl)pyridin-2-yl)methyl)-1H-indazol-3(2H)-
-one;
(R)-7-(5-(2-methyl-1-((6-methyl-3-(trifluoromethyl)pyridin-2-yl)meth-
yl)-3-oxo-2,3-dihydro-1H-indazol-6-yl)pyrimidin-2-yl)tetrahydro-1H-oxazolo-
[3,4-a]pyrazin-3(5H)-one;
(R)-6-(2-(4-acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-1-((1-acetyl-4--
(trifluoromethyl)-1H-pyrrol-3-yl)methyl)-2-methyl-1H-indazol-3(2H)-one;
(R)-1-(2-(difluoromethoxy)-5-methylbenzyl)-6-(3-(1-hydroxyethyl)imidazo[1-
,2-b]pyridazin-7-yl)-2-methyl-1H-indazol-3(2H)-one;
(R)-2-(6-((6-(2-(4-acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-
-3-oxo-2,3-dihydro-1H-indazol-1-yl)methyl)-5-(trifluoromethyl)pyridin-2-yl-
)acetonitrile;
(R)-1-(2-(difluoromethoxy)benzyl)-6-(2-(4-(2-hydroxyacetyl)-3-methylpiper-
azin-1-yl)pyrimidin-5-yl)-2-methyl-3-oxo-2,3-dihydro-1H-indazole-7-carboni-
trile;
1-(2-(difluoromethoxy)-5-methylbenzyl)-5-fluoro-6-(2-(2-hydroxyprop-
an-2-yl)-4-methylpyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one;
(R)-4-((R)-4-(5-(1-(2-(difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-
-1H-indazol-6-yl)pyrimidin-2-yl)-2-methylpiperazin-1-yl)-3-hydroxy-4-oxobu-
tanoic acid;
1-(2-(difluoromethoxy)benzyl)-6-(2-((2R,4R)-4-hydroxy-2-methylpiperidin-1-
-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one;
6-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-1-((1-((4-methoxy-1H-pyrazol-3-
-yl)methyl)-4-(trifluoromethyl)-1H-pyrrol-3-yl)methyl)-2-methyl-1H-indazol-
-3(2H)-one;
(R)-2-(4-(difluoromethoxy)-3-((6-(2-(4-(2-hydroxyacetyl)-2-methylpiperazi-
n-1-yl)pyrimidin-5-yl)-2-methyl-3-oxo-2,3-dihydro-1H-indazol-1-yl)methyl)p-
henyl)acetonitrile;
(R)-2-(2-((6-(2-(4-acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-
-3-oxo-2,3-dihydro-1H-indazol-1-yl)methyl)-3-(difluoromethoxy)phenyl)aceto-
nitrile;
(R)-2-((R)-4-(5-(1-(2-(difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-
-dihydro-1H-indazol-6-yl)pyrimidin-2-yl)-2-methylpiperazin-1-yl)-2-oxoethy-
l 2-amino-3-methylbutanoate;
1-(2-(difluoromethoxy)-5-(hydroxymethyl)benzyl)-2-methyl-6-(2-((1-methyl--
2-oxopiperidin-4-yl)amino)pyrimidin-5-yl)-1H-indazol-3(2H)-one;
6-(2-(4-acetylpiperazin-1-yl)pyrimidin-5-yl)-1-(2-(difluoromethoxy)-5-met-
hylbenzyl)-2-methyl-1H-indazol-3(2H)-one;
1-(2,5-dimethylbenzyl)-2-methyl-6-(2-morpholinopyrimidin-5-yl)-1H-indazol-
-3(2H)-one;
(R)-1-(2-(difluoromethoxy)benzyl)-6-(2-(4-(2-hydroxyacetyl)-3-methylpiper-
azin-1-yl)pyrimidin-5-yl)-2,7-dimethyl-1H-indazol-3(2H)-one;
1-(2-(difluoromethoxy)-5-(hydroxymethyl)benzyl)-6-(2-(2-hydroxypropan-2-y-
l)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one;
(S)-7-(5-(2-methyl-1-(6-methyl-3-(trifluoromethyl)pyridin-2-yl)methyl)-3--
oxo-2,3-dihydro-1H-indazol-6-yl)pyrimidin-2-yl)hexahydroimidazo[1,5-a]pyra-
zin-3(2H)-one;
(R)-6-(2-(4-acetyl-2-methylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-1-((6--
methyl-3-(trifluoromethyl)pyridin-2-yl)methyl)-1H-indazol-3(2H)-one;
6-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-2-methyl-1-((1-(pyridin-3-ylme-
thyl)-4-(trifluoromethyl)-1H-pyrrol-3-yl)methyl)-1H-indazol-3(2H)-one;
6-(2-(4-(3-amino-2-hydroxypropanoyl)-3-methylpiperazin-1-yl)pyrimidin-5-y-
l)-1-(2-(difluoromethoxy)benzyl)-2-methyl-1H-indazol-3(2H)-one;
1-(2-(difluoromethoxy)-5-methylbenzyl)-5-fluoro-6-(2-(1-hydroxy-2-methylp-
ropan-2-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one;
(R)-1-(2-chloro-5-methylbenzyl)-6-(2-(4-(2-hydroxyacetyl)-2-methylpiperaz-
in-1-yl)pyrimidin-5-yl)-2-methyl-1H-pyrazolo[3,4-b]pyridin-3(2H)-one;
1-(2-(difluoromethoxy)-5-methylbenzyl)-6-(3-(1-hydroxyethyl)imidazo[1,2-b-
]pyridazin-7-yl)-2-methyl-1H-indazol-3(2H)-one;
6-(2-(2-aminopropan-2-yl)pyrimidin-5-yl)-1-(2-(difluoromethoxy)-5-methylb-
enzyl)-2-methyl-1H-indazol-3(2H)-one;
(1S,3S)-3-(4-fluoromethoxy)-3-((6-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl-
)-2-methyl-3-oxo-2,3-dihydro-1H-indazol-1-yl)methyl)phenyl)cyclopentanecar-
bonitrile;
(S)-1-(2-(difluoromethoxy)-5-methylbenzyl)-6-(3-(1-hydroxyethyl-
)imidazo[1,2-b]pyridazin-7-yl)-2-methyl-1H-indazol-3(2H)-one;
(S)-7-(5-(1-(5-chloro-2-(trifluoromethyl)benzyl)-2-methyl-3-oxo-2,3-dihyd-
ro-1H-indazol-6-yl)pyrimidin-2-yl)hexahydroimidazo[1,5-a]pyrazin-3(2H)-one-
;
(R)-6-(2-(4-acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-1-((3-chloro-6-
-methylpyridin-2-yl)methyl)-2-methyl-1H-indazol-3(2H)-one;
(R)-7-(5-(1-(2-(difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-1H-ind-
azol-6-yl)pyrimidin-2-yl)-2-methylhexahydroimidazo[1,5-a]pyrazin-3(2H)-one-
;
(S)-7-(5-(2-methyl-1-((1-methyl-4-(trifluoromethyl)-1H-pyrrol-3-yl)methy-
l)-3-oxo-2,3-dihydro-1H-indazol-6-yl)pyrimidin-2-yl)hexahydroimidazo[1,5-a-
]pyrazin-3(2H)-one;
(R)-1-(2-chlorobenzyl)-6-(2-(4-(2-hydroxyacetyl)-3-methylpiperazin-1-yl)p-
yrimidin-5-yl)-2-methyl-1H-pyrazolo[3,4-b]pyridin-3(2H)-one;
(S)-1-(2-(difluoromethoxy)-5-(hydroxymethyl)benzyl)-2-methyl-6-(2-((2-oxo-
piperidin-4-yl)amino)pyrimidin-5-yl)-1H-indazol-3(2H)-one;
1-(2-(difluoromethoxy)benzyl)-2-methyl-6-(2-((tetrahydro-2H-pyran-4-yl)ox-
y)pyridin-4-yl)-1H-indazol-3(2H)-one;
6-(2-((R)-4-(2-hydroxyacetyl)-3-methylpiperazin-1-yl)pyrimidin-5-yl)-2-me-
thyl-1-(1-phenylethyl)-1H-indazol-3(2H)-one;
1-(1-(2-fluorophenyl)ethyl)-6-(2-((R)-4-(2-hydroxyacetyl)-3-methylpiperaz-
in-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one;
(R)-1-((3-(difluoromethoxy)-6-methylpyridin-2-yl)methyl)-6-(2-(4-(2-hydro-
xyacetyl)-3-methylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-
-one;
(R)-6-(2-(4-acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-1-((1-(2-h-
ydroxyethyl)-4-(trifluoromethyl)-1H-pyrrol-3-yl)methyl)-2-methyl-1H-indazo-
l-3(2H)-one;
1-(5-((1H-1,2,4-triazol-1-yl)methyl)-2-(difluoromethoxy)benzyl)-6-(2-(2-h-
ydroxypropan-2-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one;
1-(2-(difluoromethoxy)-5-methylbenzyl)-6-(2-(4-hydroxypiperidin-1-yl)pyri-
midin-5-yl)-2-methyl-1H-indazol-3(2H)-one;
1-(2-(difluoromethoxy)-5-methylbenzyl)-6-(2-isopropylpyrimidin-5-yl)-2-me-
thyl-1H-indazol-3(2H)-one;
(R)-1-(2-chlorobenzyl)-6-(2-(4-(2-hydroxyacetyl)-3-methylpiperazin-1-yl)p-
yrimidin-5-yl)-2,7-dimethyl-1H-indazol-3(2H)-one;
6-(6-(2-aminopropan-2-yl)pyridin-3-yl)-1-(2-(difluoromethoxy)-5-methylben-
zyl)-5-fluoro-2-methyl-1H-indazol-3(2H)-one;
(S)-4-(difluoromethoxy)-3-((2-methyl-3-oxo-6-(2-((S)-3-oxotetrahydro-1H-o-
xazolo[3,4-a]pyrazin-7(3H)-yl)pyrimidin-5-yl)-2,3-dihydro-1H-indazol-1-yl)-
methyl)benzyl 2-aminopropanoate;
1-(2-(difluoromethoxy)benzyl)-6-(2-((2R,4S)-4-hydroxy-2-methylpiperidin-1-
-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one;
(R)-4-(difluoromethoxy)-3-((2-methyl-3-oxo-6-(2-(3-oxohexahydroimidazo[1,-
5-a]pyrazin-7(1H)-yl)pyrimidin-5-yl)-2,3-dihydro-1H-indazol-1-yl)methyl)be-
nzyl dimethylcarbamate;
(S)-6-(2-(4-(2-aminoacetyl)-3-methylpiperazin-1-yl)pyrimidin-5-yl)-1-(2-(-
difluoromethoxy)-5-methylbenzyl)-2-methyl-1H-indazol-3(2H)-one;
(R)-7-(5-(1-((6-(hydroxymethyl)-3-(trifluoromethyl)pyridin-2-yl)methyl)-2-
-methyl-3-oxo-2,3-dihydro-1H-indazol-6-yl)pyrimidin-2-yl)hexahydroimidazo[-
1,5-a]pyrazin-3(2H)-one;
(S)-7-(5-(1-((5-chloro-1,3-dihydroisobenzofuran-4-yl)methyl)-2-methyl-3-o-
xo-2,3-dihydro-1H-indazol-6-yl)pyrimidin-2-yl)hexahydroimidazo[1,5-a]pyraz-
in-3(2H)-one;
1-(2-(difluoromethoxy)-5-methylbenzyl)-7-fluoro-6-(2-(2-hydroxypropan-2-y-
l)-4-methylpyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one;
1-(2-(difluoromethoxy)-5-methylbenzyl)-5-fluoro-6-(2-(2-hydroxypropan-2-y-
l)-4-methylpyrimidin-5-yl)-2-methyl-1H-pyrazolo[3,4-b]pyridin-3(2H)-one;
1-(2-chloro-5-methylbenzyl)-6-(2-(2-hydroxypropan-2-yl)-4-methylpyrimidin-
-5-yl)-2-methyl-1H-pyrazolo[3,4-b]pyridin-3(2H)-one;
(R)-1-(2-(difluoromethoxy)benzyl)-2-(difluoromethyl)-6-(2-(4-(2-hydroxyac-
etyl)-3-methylpiperazin-1-yl)pyrimidin-5-yl)-1H-indazol-3(2H)-one;
1-(2-(difluoromethoxy)benzyl)-6-(2-(4-(2-hydroxyacetyl)piperazin-1-yl)pyr-
imidin-5-yl)-2-methyl-1H-indazol-3(2H)-one;
6-(2-((S)-4-((S)-2-aminopropanoyl)-3-methylpiperazin-1-yl)pyrimidin-5-yl)-
-1-(2-(difluoromethoxy)-5-methylbenzyl)-2-methyl-1H-indazol-3(2H)-one;
(S)-4-((R)-4-(5-(1-(2-(difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-
-1H-indazol-6-yl)pyrimidin-2-yl)-2-methylpiperazin-1-yl)-3-hydroxy-4-oxobu-
tanoic acid;
(S)-6-(2-(4-acetyl-3-(hydroxymethyl)piperazin-1-yl)pyrimidin-5-yl)-1-(2-(-
difluoromethoxy)-5-methylbenzyl)-2-methyl-1H-indazol-3(2H)-one;
(R)-6-(2-(4-acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-1-((3-(difluoro-
methoxy)-6-methylpyridin-2-yl)methyl)-2-methyl-1H-indazol-3(2H)-one;
6-(2-(4-acetylpiperazin-1-yl)pyrimidin-5-yl)-1-(5-(hydroxymethyl)-2-(trif-
luoromethyl)benzyl)-2-methyl-1H-indazol-3(2H)-one;
(R)-1-(2-chlorobenzyl)-6-(2-(4-(2-hydroxyacetyl)-3-methylpiperazin-1-yl)p-
yrimidin-5-yl)-7-methoxy-2-methyl-1H-indazol-3(2H)-one;
(R)-6-(2-(4-acetyl-3-(hydroxymethyl)piperazin-1-yl)pyrimidin-5-yl)-1-(2-(-
difluoromethoxy)-5-methylbenzyl)-2-methyl-1H-indazol-3(2H)-one;
(R)-1-(2-(difluoromethoxy)-5-methylbenzyl)-6-(2-(4-(2-hydroxyacetyl)-2-me-
thylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-1H-pyrazolo[3,4-b]pyridin-3(2H-
)-one;
(S)-4-(difluoromethoxy)-3-((2-methyl-3-oxo-6-(2-((R)-3-oxohexahydro-
imidazo[1,5-a]pyrazin-7(1H)-yl)pyrimidin-5-yl)-2,3-dihydro-1H-indazol-1-yl-
)methyl)benzyl 2-amino-3-methylbutanoate;
(S)-7-(5-(1-((3-(difluoromethoxy)-6-methylpyridin-2-yl)methyl)-2-methyl-3-
-oxo-2,3-dihydro-1H-indazol-6-yl)pyrimidin-2-yl)hexahydroimidazo[1,5-a]pyr-
azin-3(2H)-one;
(R)-9-((6-(2-(4-acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-3--
oxo-2,3-dihydro-1H-indazol-1-yl)methyl)-4,5-dihydrobenzo[f][1,4]thiazepin--
3(2H)-one;
1-(2-(difluoromethoxy)benzyl)-5-fluoro-6-(2-(2-hydroxypropan-2--
yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one;
6-(2-((R)-4-acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-1-(2-(difluorom-
ethoxy)-5-(2-hydroxypropyl)benzyl)-2-methyl-1H-indazol-3(2H)-one;
1-(2-(difluoromethoxy)-5-methylbenzyl)-5-fluoro-6-(2-(2-hydroxypropan-2-y-
l)pyrimidin-5-yl)-2-methyl-1H-pyrazolo[3,4-b]pyridin-3(2H)-one;
(R)-1-(2-(difluoromethoxy)benzyl)-6-(2-(4-(2-hydroxyacetyl)-3-methylpiper-
azin-1-yl)pyrimidin-5-yl)-5-methoxy-2-methyl-1H-indazol-3(2H)-one;
(R)-1-(2-(difluoromethoxy)-5-methylbenzyl)-2-methyl-6-(2-(3-methylpiperaz-
in-1-yl)pyrimidin-5-yl)-1H-indazol-3(2H)-one;
1-(5-(1-(2-(difluoromethoxy)-5-methylbenzyl)-2-methyl-3-oxo-2,3-dihydro-1-
H-indazol-6-yl)pyrimidin-2-yl)pyrrolidine-3-carboxamide;
1-(2-(difluoromethoxy)-5-methylbenzyl)-6-(2-(2-hydroxypropan-2-yl)-4-meth-
ylpyrimidin-5-yl)-2-methyl-1H-pyrazolo[3,4-b]pyridin-3(2H)-one;
1-(2-(difluoromethoxy)-5-methylbenzyl)-2-methyl-6-(2-((3aS,6aS)-4-oxohexa-
hydropyrrolo[3,4-c]pyrrol-2(1H)-yl)pyrimidin-5-yl)-1H-indazol-3(2H)-one;
(R)-6-(2-(4-acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-1-(2-(difluorom-
ethoxy)-5-((3-methyl-2-oxoimidazolidin-1-yl)methyl)benzyl)-2-methyl-1H-ind-
azol-3(2H)-one;
1-(2-(difluoromethoxy)-5-(hydroxymethyl)benzyl)-2-methyl-6-(2-((2-oxopyrr-
olidin-3-yl)amino)pyrimidin-5-yl)-1H-indazol-3(2H)-one;
2-(difluoromethoxy)-3-((5-fluoro-6-(2-(2-hydroxypropan-2-yl)pyrimidin-5-y-
l)-2-methyl-3-oxo-2,3-dihydro-1H-indazol-1-yl)methyl)phenyl)acetonitrile;
1-(5-((4H-1,2,4-triazol-4-yl)methyl)-2-(difluoromethoxy)benzyl)-5-fluoro--
6-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one;
1-(2-(difluoromethoxy)-5-methylbenzyl)-6-(2-(1-hydroxy-2-methylpropan-2-y-
l)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one;
1-(2-(difluoromethoxy)-5-(hydroxymethyl)benzyl)-2-methyl-6-(4-((1-methyl--
2-oxopyrrolidin-3-yl)amino)phenyl)-1H-indazol-3(2H)-one;
(S)-1-(2-(difluoromethoxy)-5-(hydroxymethyl)benzyl)-2-methyl-6-(2-((1-met-
hyl-2-oxopiperidin-4-yl)amino)pyrimidin-5-yl)-1H-indazol-3(2H)-one;
6-(2-((R)-4-(2-hydroxyacetyl)-3-methylpiperazin-1-yl)pyrimidin-5-yl)-2-me-
thyl-1-(1-(6-methylpyridin-2-yl)ethyl)-1H-indazol-3(2H)-one;
1-(2-(difluoromethoxy)benzyl)-2-methyl-6-(2-((tetrahydro-2H-pyran-3-yl)ox-
y)pyridin-4-yl)-1H-indazol-3(2H)-one;
1-(2-(difluoromethoxy)-5-methylbenzyl)-7-fluoro-6-(2-(2-hydroxypropan-2-y-
l)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one;
6-(2-((R)-4-(2-hydroxyacetyl)-3-methylpiperazin-1-yl)pyrimidin-5-yl)-2-me-
thyl-1-(1-(4-methylpyridin-2-yl)ethyl)-1H-indazol-3(2H)-one;
1-(2-chloro-5-((1-methyl-2-oxopiperidin-3-yl)amino)benzyl)-6-(2-(2-hydrox-
ypropan-2-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one;
(R)--N-(3-((6-(2-(4-acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-2-methy-
l-3-oxo-2,3-dihydro-1H-indazol-1-yl)methyl)-4-(difluoromethoxy)benzyl)acet-
amide;
(R)-6-(2-(4-acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-1-(2-chlo-
robenzyl)-2-(pyridin-4-ylmethyl)-1H-indazol-3(2H)-one;
(S)-4-(difluoromethoxy)-3-((2-methyl-3-oxo-6-(2-((S)-3-oxotetrahydro-1H-o-
xazolo[3,4-a]pyrazin-7(3H)-yl)pyrimidin-5-yl)-2,3-dihydro-1H-indazol-1-yl)-
methyl)benzyl 2-amino-3-methylbutanoate;
(R)-1-(2-(difluoromethoxy)-5-methylbenzyl)-6-(2-(2-(hydroxymethyl)pyrroli-
din-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one;
(S)-1-(2-(difluoromethoxy)-5-methylbenzyl)-6-(2-(2-(hydroxymethyl)pyrroli-
din-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one;
(S)-7-(5-(2-methyl-1-(5-methyl-2-(trifluoromethyl)pyridin-3-yl)methyl)-3--
oxo-2,3-dihydro-1H-indazol-6-yl)pyrimidin-2-yl)hexahydroimidazo[1,5-a]pyra-
zin-3(2H)-one;
(R)-1-(2-(difluoromethoxy)benzyl)-6-(2-(4-(2-hydroxyacetyl)-3-methylpiper-
azin-1-yl)pyrimidin-5-yl)-2-methyl-3-oxo-2,3-dihydro-1H-indazole-5-carboni-
trile;
(S)-4-methyl-2-((2-methyl-3-oxo-6-(2-(3-oxohexahydroimidazo[1,5-a]p-
yrazin-7(1H)-yl)pyrimidin-5-yl)-2,3-dihydro-1H-indazol-1-yl)methyl)benzoni-
trile;
3-(3-((6-(2-((R)-4-acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-2--
methyl-3-oxo-2,3-dihydro-1H-indazol-1-yl)methyl)-4-(difluoromethoxy)phenyl-
)-2-methylpropanenitrile;
2-(difluoromethoxy)-3-((6-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-2-meth-
yl-3-oxo-2,3-dihydro-1H-indazol-1-yl)methyl)phenyl)acetonitrile;
(R)-6-(2-(4-acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-1-(2-(difluorom-
ethoxy)-5-((3-oxo-2,3-dihydro-1H-pyrazol-1-yl)methyl)benzyl)-2-methyl-1H-i-
ndazol-3(2H)-one;
1-(1-(2-chlorophenyl)ethyl)-6-(2-((R)-4-(2-hydroxyacetyl)-3-methylpiperaz-
in-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one;
(R)-3-((6-(2-(4-acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-1-(2-chloro-
benzyl)-3-oxo-1H-indazol-2(3H)-yl)methyl)benzonitrile;
1-(2-(difluoromethoxy)-6-(methoxymethyl)benzyl)-6-(2-(2-hydroxypropan-2-y-
l)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one;
1-((R)-1-(2-fluorophenyl)ethyl)-6-(2-((R)-4-(2-hydroxyacetyl)-3-methylpip-
erazin-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one;
1-(2-chloro-5-((pyridin-3-ylmethyl)amino)benzyl)-6-(2-(2-hydroxypropan-2--
yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one;
(R)-1-(2-chlorobenzyl)-6-(2-(4-(2-hydroxyacetyl)-3-methylpiperazin-1-yl)p-
yrimidin-5-yl)-2-methyl-3-oxo-2,3-dihydro-1H-indazole-7-carbonitrile;
(R)-6-(2-(4-acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-1-(2-(difluorom-
ethoxy)benzyl)-2-(pyridin-4-ylmethyl)-1H-indazol-3(2H)-one;
(S)-7-(5-(2-methyl-1-((1-methyl-4-(trifluoromethyl)-1H-pyrazol-3-yl)methy-
l)-3-oxo-2,3-dihydro-1H-indazol-6-yl)pyrimidin-2-yl)hexahydroimidazo[1,5-a-
]pyrazin-3(2H)-one;
3-(1-(5-(1-(2-(difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-1H-inda-
zol-6-yl)pyrimidin-2-yl)piperidin-4-yl)-1,2,4-thiadiazol-5
(4H)-one;
1-(2-chloro-5-((1-methyl-2-oxopyrrolidin-3-yl)amino)benzyl)-6-(2-(2-hydro-
xypropan-2-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one;
1-(2-chloro-5-((pyridin-2-ylmethyl)amino)benzyl)-6-(2-(2-hydroxypropan-2--
yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one; methyl
4-(difluoromethoxy)-3-((6-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-2-meth-
yl-3-oxo-2,3-dihydro-1H-indazol-1-yl)methyl)benzylcarbamate;
(S)-7-(5-(2-methyl-3-oxo-1-((2-(fluoromethyl)pyridin-3-yl)methyl)-2,3-dih-
ydro-1H-indazol-6-yl)pyrimidin-2-yl)hexahydroimidazo[1,5-a]pyrazin-3(2H)-o-
ne;
1-(5-(hydroxymethyl)-2-methylbenzyl)-2-methyl-6-(2-morpholinopyrimidin-5--
yl)-1H-indazol-3(2H)-one;
1-(5-(((1H-pyrazol-3-yl)methyl)amino)-2-chlorobenzyl)-6-(2-(2-hydroxyprop-
an-2-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one;
6-(2-(4-acetylpiperazin-1-yl)pyrimidin-5-yl)-1-(2-(difluoromethoxy)-5-(me-
thoxymethyl)benzyl)-2-methyl-1H-indazol-3(2H)-one;
(R)--N-(3-((6-(2-(4-acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-2-methy-
l-3-oxo-2,3-dihydro-1H-indazol-1-yl)methyl)-4-(difluoromethoxy)benzyl)-N-e-
thylacetamide;
1-((1-((4-ethylpyridin-3-yl)methyl)-4-(trifluoromethyl)-1H-pyrrol-3-yl)me-
thyl)-6-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-
-one;
1-(2-(difluoromethoxy)benzyl)-6-(2-(dimethylamino)pyrimidin-5-yl)-2--
methyl-1H-indazol-3(2H)-one;
6-(2-(1-acetyl-4-hydroxypiperidin-4-yl)pyrimidin-5-yl)-1-(2-(difluorometh-
oxy)benzyl)-2-methyl-1H-indazol-3(2H)-one;
1-(5-((1-acetylazetidin-3-yl)methyl)-2-(difluoromethoxy)benzyl)-5-fluoro--
6-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one;
1-(2-(difluoromethoxy)-5-((5-oxo-1H-1,2,4-triazol-4(5H)-yl)methyl)benzyl)-
-6-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one;
6-(2-((R)-4-(2-hydroxyacetyl)-3-methylpiperazin-1-yl)pyrimidin-5-yl)-2-me-
thyl-1-((R)-1-(m-tolyl)ethyl)-1H-indazol-3(2H)-one;
6-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-2-methyl-1-((1-(pyridazin-4-yl-
methyl)-4-(trifluoromethyl)-1H-pyrrol-3-yl)methyl)-1H-indazol-3(2H)-one;
1-(2-(difluoromethoxy)-5-methylbenzyl)-2-(difluoromethyl)-6-(2-(2-hydroxy-
propan-2-yl)pyrimidin-5-yl)-1H-indazol-3(2H)-one;
(1R,2S)-2-(4-(difluoromethoxy)-3-((6-(2-(2-hydroxypropan-2-yl)pyrimidin-5-
-yl)-2-methyl-3-oxo-2,3-dihydro-1H-indazol-1-yl)methyl)phenyl)cyclopentane-
carbonitrile;
(1R,3S)-3-(4-(difluoromethoxy)-3-((6-(2-(2-hydroxypropan-2-yl)pyrimidin-5-
-yl)-2-methyl-3-oxo-2,3-dihydro-1H-indazol-1-yl)methyl)phenyl)cyclopentane-
carbonitrile;
6-(2-(1-(2-aminoacetyl)-4-hydroxypiperidin-4-yl)pyrimidin-5-yl)-1-(2-(dif-
luoromethoxy)benzyl)-2-methyl-1H-indazol-3(2H)-one;
4-(5-(1-(2-(difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-1H-indazol-
-6-yl)pyrimidin-2-yl)-4-hydroxypiperidine-1-carbaldehyde;
6-(2-((1-acetylpiperidin-4-yl)oxy)pyridin-4-yl)-1-(2-(difluoromethoxy)ben-
zyl)-2-methyl-1H-indazol-3(2H)-one;
1-(2-(difluoromethoxy)-5-morpholinobenzyl)-6-(2-(2-hydroxypropan-2-yl)pyr-
imidin-5-yl)-2-methyl-1H-indazol-3(2H)-one;
1-(2-(difluoromethoxy)benzyl)-6-(2-(3-hydroxy-1-(2-hydroxyacetyl)azetidin-
-3-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one;
(R)-2-(3-((6-(2-(4-acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-
-3-oxo-2,3-dihydro-1H-indazol-1-yl)methyl)-4-(difluoromethoxy)phenyl)aceto-
nitrile;
(R)-6-(2-(4-acetyl-2-methylpiperazin-1-yl)-4-methylpyrimidin-5-yl-
)-1-(2-(difluoromethoxy)-5-methylbenzyl)-2-methyl-1H-indazol-3(2H)-one;
(R)-1-(2-(difluoromethoxy)benzyl)-5,
7-difluoro-6-(2-(4-(2-hydroxyacetyl)-2-methylpiperazin-1-yl)pyrimidin-5-y-
l)-2-methyl-1H-indazol-3(2H)-one;
(R)-6-(2-(4-acetyl-2-methylpiperazin-1-yl)-4-methylpyrimidin-5-yl)-1-(2-(-
difluoromethoxy)-5-methylbenzyl)-2-methyl-1H-indazol-3(2H)-one;
(R)-1-(2-(difluoromethoxy)-5-(hydroxymethyl)benzyl)-2-methyl-6-(2-((1-met-
hyl-2-oxopiperidin-4-yl)amino)pyrimidin-5-yl)-1H-indazol-3(2H)-one;
(R)-1-(2-(difluoromethoxy)benzyl)-5-fluoro-6-(2-(4-(2-hydroxyacetyl)-3-me-
thylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one;
(R)-6-(2-(4-acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-1-(2-(difluorom-
ethoxy)-5-methylbenzyl)-2-methyl-d.sub.3-1H-indazol-3(2H)-one; or
(S)-1-(2-chloro-5-((2-hydroxypropyl)amino)benzyl)-6-(2-(2-hydroxypropan-2-
-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one.
26. A pharmaceutical composition comprising a compound according to
claim 1 and one or more pharmaceutically acceptable excipients.
27. A method of treating a disease comprising administering a
therapeutically effective amount of a compound or pharmaceutical
composition according to claim 1.
28. The method according to claim 27 wherein the disease is
rheumatoid arthritis, juvenile rheumatoid arthritis, psoriasis,
psoriatic arthritis, Crohn's disease, inflammatory bowel disease,
ulcerative colitis, psoriatic arthritis, psoriasis, ankylosing
spondylitis, systemic lupus erythematosus, lupus nephritis,
multiple sclerosis, uveitis or hidraenitis suppurativa.
Description
PRIORITY CLAIM
[0001] This application claims the benefit of U.S. Provisional
Application No. 62/258,651, filed Nov. 23, 2015, and 62/149,232,
filed Apr. 17, 2015, both of which are hereby incorporated by
reference in their entirety.
FIELD OF THE DISCLOSURE
[0002] The present disclosure relates to a class of indazolone
derivatives, and to their use in therapy. More particularly, this
disclosure is concerned with pharmacologically active substituted
indazolone derivatives. These compounds are modulators of the
signaling of TNF.alpha., and are accordingly of benefit as
pharmaceutical agents, especially in the treatment of adverse
inflammatory and autoimmune disorders, neurological and
neurodegenerative disorders, pain and nociceptive disorders,
cardiovascular disorders, metabolic disorders, ocular disorders,
and oncological disorders.
BACKGROUND
[0003] TNF.alpha. is the prototypical member of the Tumor Necrosis
Factor (TNF) superfamily of proteins that share a primary function
of regulating cell survival and cell death. One structural feature
common to all known members of the TNF superfamily is the formation
of trimeric complexes that bind to, and activate, specific TNF
superfamily receptors. By way of example, TNF.alpha. exists in
soluble and transmembrane forms and signals through two receptors,
known as TNFR1 and TNFR2, with distinct functional endpoints.
[0004] Various products capable of modulating TNF.alpha. activity
are already commercially available. All are approved for the
treatment of inflammatory and autoimmune disorders such as
rheumatoid arthritis and Crohn's disease. All currently approved
products are macromolecular and act by inhibiting the binding of
human TNF.alpha. to its receptor. Typical macromolecular TNF.alpha.
inhibitors include anti-TNF.alpha. antibodies and soluble
TNF.alpha. receptor fusion proteins. Examples of commercially
available anti-TNF.alpha. antibodies include fully human antibodies
such as adalimumab (Humira.RTM.) and golimumab (Simponi.RTM.),
chimeric antibodies such as infliximab (Remicade.RTM.), and
pegylated Fab' fragments such as certulizumab pegol (Cimzia.RTM.).
An example of a commercially available soluble TNF.alpha. receptor
fusion protein is etanercept (Enbrel.RTM.).
[0005] TNF superfamily members, including TNF.alpha. itself, are
implicated in a variety of physiological and pathological functions
that are believed to play a part in a range of conditions of
significant medical importance (see, for example, M. G. Tansey
& D. E. Szymkowski, Drug Discovery Today, 2009, 14, 1082-1088;
and F. S. Carneiro et al., J. Sexual Medicine, 2010, 7,
3823-3834).
SUMMARY OF THE DISCLOSURE
[0006] The compounds in accordance with the present disclosure,
being potent modulators of human TNF.alpha. activity, may be
beneficial in the treatment and/or prevention of various human
ailments. These include autoimmune and inflammatory disorders;
neurological and neurodegenerative disorders; pain and nociceptive
disorders; cardiovascular disorders; metabolic disorders; ocular
disorders; and oncological disorders.
[0007] In addition, the compounds in accordance with the present
disclosure may be beneficial as pharmacological standards for use
in the development of new biological tests and in the search for
new pharmacological agents. Thus, in one embodiment, the compounds
of this disclosure may be useful as radioligands in assays for
detecting pharmacologically active compounds. In an alternative
embodiment, certain compounds of this disclosure may be useful for
coupling to a fluorophore to provide fluorescent conjugates that
can be utilized in assays (e.g., a fluorescence polarization assay)
for detecting pharmacologically active compounds.
[0008] The compounds in accordance with the present disclosure
potently neutralize the activity of TNF.alpha. using the TNF.alpha.
fluorescence polarization competitive binding assay. When tested in
this assay, the compounds of the present disclosure exhibit an
IC.sub.50 value of 50 .mu.M or less, generally of 10 .mu.M or less,
usually of 5 .mu.M or less, typically of 1 .mu.M or less, suitably
of 500 nM or less, ideally of 100 nM or less, and preferably of 20
nM or less (the skilled person will appreciate that a lower
IC.sub.50 figure denotes a more active compound).
[0009] In a first embodiment, the present disclosure provides a
compound of Formula (I),
##STR00001##
or a pharmaceutically acceptable salt, prodrug or stereoisomer
thereof, wherein:
[0010] X, Y and Z are independently CR.sup.4 or N; [0011] provided
that Y and Z are not both N;
[0012] L is a bond, optionally substituted
(C.sub.1-C.sub.3)alkylene or --C(O)--;
[0013] R.sup.1 is H, CD.sub.3, optionally substituted
(C.sub.1-C.sub.3)alkyl, optionally substituted
(C.sub.3-C.sub.6)cycloalkyl, --(CH.sub.2).sub.q-optionally
substituted (C.sub.3-C.sub.6)aryl, or --(CH.sub.2).sub.q-optionally
substituted (C.sub.3-C.sub.6)heteroaryl;
[0014] R.sup.2 is optionally substituted aryl or optionally
substituted heteroaryl;
[0015] R.sup.3 is --R.sup.3a-R.sup.3b, wherein: [0016] R.sup.3a is
an optionally substituted saturated, unsaturated or partially
saturated heterocyclyl or optionally substituted heteroaryl; [0017]
R.sup.3b is --N(R.sup.a)(R.sup.b), --O(R.sup.a), optionally
substituted (C.sub.1-C.sub.5)alkyl, optionally substituted
(C.sub.3-C.sub.6)cycloalkyl, or --(CH.sub.2).sub.n-optionally
substituted heterocyclyl; wherein [0018] R.sup.a and R.sup.b are
independently selected from H, optionally substituted
(C.sub.1-C.sub.5)alkyl, and --(CH.sub.2).sub.n-optionally
substituted heterocyclyl;
[0019] R.sup.4 is independently H, Cl, CN, F, CF.sub.3 methoxy, or
optionally substituted (C.sub.1-C.sub.3)alkyl; and
[0020] n is 0 or 1;
[0021] p is 0, 1 or 2;
[0022] q is 0 or 1.
[0023] In a second embodiment, the disclosure provides a compound
according to the first embodiment wherein the compound is a
compound of Formula (Ia), Formula (Ib), Formula (Ic), Formula (Id)
or Formula (Ie)
##STR00002##
[0024] In a third embodiment, the disclosure provides a compound
according to any of the foregoing embodiments wherein R.sup.1 is
optionally substituted (C1-C3)alkyl or optionally substituted
cyclopropyl.
[0025] In a fourth embodiment, the disclosure provides a compound
according to any of the foregoing embodiments wherein R.sup.2 is
optionally substituted heteroaryl, or optionally substituted
phenyl.
[0026] In a fifth embodiment, the disclosure provides a compound
according to any of the foregoing embodiments wherein R.sup.3a is
optionally substituted 1,2,4-oxadiazolyl, optionally substituted
pyrazolyl, optionally substituted pyridinyl, optionally substituted
pyrimidinyl, optionally substituted pyrazinyl, or optionally
substituted 1,2,4-thiadiazolyl.
[0027] In a sixth embodiment, the disclosure provides a compound
according to any of the foregoing embodiments wherein R.sup.3b is
--N(R.sup.a)(R.sup.b), --O(R.sup.a), optionally substituted
(C.sub.1-C.sub.3)alkyl, --(CH.sub.2).sub.p-optionally substituted
2-oxa-6-azaspiro[3.3]heptanyl, --(CH.sub.2).sub.p-optionally
substituted 2-azaspiro[3.3]heptanyl, --(CH.sub.2).sub.p-optionally
substituted 5-azaspiro[2.3]hexanyl, --(CH.sub.2).sub.p-optionally
substituted azetidinyl, --(CH.sub.2).sub.p-optionally substituted
morpholinyl, --(CH.sub.2).sub.p-optionally substituted oxetanyl,
--(CH.sub.2).sub.p-optionally substituted piperazinyl,
--(CH.sub.2).sub.p-optionally substituted piperidinyl,
--(CH.sub.2).sub.p-optionally substituted pyrrolidinyl,
--(CH.sub.2).sub.p-optionally substituted tetrahydropyranyl,
--(CH.sub.2).sub.p-optionally substituted
6-oxohexahydropyrrolo[1,2-a]pyrazinyl,
--(CH.sub.2).sub.p-optionally substituted
tetrahydro-1H-oxazolo[3,4-a]pyrazin-3(5H)-one or
--(CH.sub.2).sub.p-optionally substituted
hexahydroimidazo[1,5-a]pyrazin-3(2H)-one; wherein R.sup.a and
R.sup.b are independently selected from H, optionally substituted
(C.sub.1-C.sub.3)alkyl, --(CH.sub.2).sub.n-oxoazepanyl,
--(CH.sub.2).sub.n-optionally substituted tetrahydrofuranyl,
--(CH.sub.2).sub.n-optionally substituted oxetanyl,
--(CH.sub.2).sub.n-optionally substituted tetrahydropyranyl, and
--(CH.sub.2).sub.n-optionally substituted pyrrolidinyl.
[0028] In a seventh embodiment, the disclosure provides a compound
according to any of the foregoing embodiments wherein L is a bond
or optionally substituted (C.sub.1-C.sub.2)alkylene.
[0029] In an eighth embodiment, the disclosure provides a compound
according to any of the foregoing embodiments wherein R.sup.2 is
phenyl, pyridinyl or pyrimidinyl, and R.sup.2 is optionally
substituted by one or more substituents independently selected from
halogen, CN, haloalkoxy, CF.sub.3, or optionally substituted
(C.sub.1-C.sub.3)alkyl.
[0030] In a ninth embodiment, the disclosure provides a compound
according to any of the foregoing embodiments wherein R.sup.3b is
--N(H)CH.sub.2-optionally substituted pyrrolidinyl, --O(R.sup.a),
--N(H)-optionally substituted oxetanyl, optionally substituted
(C.sub.1-C.sub.3)alkyl, optionally substituted
2-oxa-6-azaspiro[3.3]heptanyl, optionally substituted
5-azaspiro[2.3]hexanyl, optionally substituted azetidinyl,
optionally substituted morpholinyl, --(CH.sub.2).sub.p-optionally
substituted oxetanyl, optionally substituted piperazinyl,
optionally substituted piperidinyl, --(CH.sub.2).sub.p-optionally
substituted pyrrolidinyl, or optionally substituted
tetrahydropyranyl; wherein R.sup.a is selected from H, optionally
substituted (C.sub.1-C.sub.3)alkyl, --(CH.sub.2).sub.n-oxoazepanyl,
--(CH.sub.2).sub.n-optionally substituted tetrahydrofuranyl,
--(CH.sub.2).sub.n-optionally substituted oxetanyl,
--(CH.sub.2).sub.n-optionally substituted tetrahydropyranyl, and
--(CH.sub.2).sub.n-optionally substituted pyrrolidinyl.
[0031] In a tenth embodiment, the disclosure provides a compound
according to any of the foregoing embodiments wherein R.sup.3b is
optionally substituted by one or more substituents independently
selected from halogen, CN, --C(O)OH, --C(O)CH.sub.3,
--C(O)NH.sub.2, NH.sub.2, .dbd.O, --OH, optionally substituted
(C.sub.1-C.sub.3)alkyl, optionally substituted
(C.sub.1-C.sub.3)alkoxy and optionally substituted oxetanyl.
[0032] In an eleventh embodiment, the disclosure provides a
compound according to any of the foregoing embodiments wherein Y is
CR.sup.4.
[0033] In a twelfth embodiment, the disclosure provides a compound
according to any of the foregoing embodiments wherein Z is
CR.sup.4.
[0034] In a thirteenth embodiment, the disclosure provides a
compound according to any of the foregoing embodiments wherein the
compound is: [0035]
1-(2-(difluoromethoxy)benzyl)-2-methyl-6-(2-(((1-methyl-5-oxopyrro-
lidin-3-yl)methyl)amino)pyrimidin-5-yl)-1H-indazol-3(2H)-one;
[0036]
(R)-1-(5-(1-(2-(difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-1H-ind-
azol-6-yl)pyrimidin-2-yl)pyrrolidine-3-carboxylic acid; [0037]
(S)-1-(5-(1-(2-(difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-1H-ind-
azol-6-yl)pyrimidin-2-yl)pyrrolidine-3-carboxylic acid; [0038]
1-((4-chloropyridin-3-yl)methyl)-2-methyl-6-(2-morpholinopyrimidin-5-yl)--
1H-indazol-3(2H)-one; [0039]
(R)-1-(2-(difluoromethoxy)benzyl)-6-(2-(3-hydroxypyrrolidin-1-yl)pyrimidi-
n-5-yl)-2-methyl-1H-indazol-3(2H)-one; [0040]
2-(5-(1-(2-(difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-1H-indazol-
-6-yl)pyrimidin-2-yl)-2-azaspiro[3.3]heptane-6-carboxylic acid;
[0041]
5-(5-(1-(2-(difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-1H-indazol-
-6-yl)pyrimidin-2-yl)-5-azaspiro[2.3]hexane-1-carboxylic acid;
[0042]
1-(2-(difluoromethoxy)benzyl)-2-ethyl-6-(2-morpholinopyrimidin-5-yl)-1H-i-
ndazol-3(2H)-one; [0043]
1-(2-(difluoromethoxy)-5-fluorobenzyl)-2-methyl-6-(2-morpholinopyrimidin--
5-yl)-1H-indazol-3(2H)-one; [0044]
6-(2-(2-oxa-6-azaspiro[3.3]heptan-6-yl)pyrimidin-5-yl)-1-(2-(difluorometh-
oxy)benzyl)-2-methyl-1H-indazol-3(2H)-one; [0045]
1-(5-(1-(2-(difluoromethoxy)benzyl)-2,5-dimethyl-3-oxo-2,3-dihydro-1H-ind-
azol-6-yl)pyrimidin-2-yl)piperidine-4-carboxylic acid; [0046]
1-(2-(difluoromethoxy)benzyl)-2,5-dimethyl-6-(2-morpholinopyrimidin-5-yl)-
-1H-indazol-3(2H)-one; [0047]
1-(2-(difluoromethoxy)benzyl)-2,5-dimethyl-6-(2-(3-oxopiperazin-1-yl)pyri-
midin-5-yl)-1H-indazol-3(2H)-one; [0048]
1-((3,6-dichloropyridin-2-yl)methyl)-2-methyl-6-(2-morpholinopyrimidin-5--
yl)-1H-indazol-3(2H)-one; [0049]
6-(2-((1-acetylpyrrolidin-3-yl)amino)pyrimidin-5-yl)-1-(2-(difluoromethox-
y)benzyl)-2-methyl-1H-indazol-3(2H)-one; [0050]
1-(5-(1-(2-(difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-1H-indazol-
-6-yl)pyrimidin-2-yl)azetidine-3-carboxylic acid; [0051]
1-(2-(difluoromethoxy)benzyl)-6-(2-(2,2-dimethylmorpholino)pyrimidin-5-yl-
)-2-methyl-1H-indazol-3(2H)-one; [0052]
1-(2-(difluoromethoxy)benzyl)-6-(2-(3-(hydroxymethyl)azetidin-1-yl)pyrimi-
din-5-yl)-2-methyl-1H-indazol-3(2H)-one; [0053]
1-(2-(difluoromethoxy)benzyl)-6-(2-(3-hydroxyazetidin-1-yl)pyrimidin-5-yl-
)-2-methyl-1H-indazol-3(2H)-one; [0054]
1-(5-(1-(2,5-dichlorobenzyl)-2-methyl-3-oxo-2,3-dihydro-1H-indazol-6-yl)p-
yrimidin-2-yl)piperidine-4-carboxylic acid; [0055]
6-(5-chloro-2-morpholinopyridin-4-yl)-1-(2-(difluoromethoxy)benzyl)-2-met-
hyl-1H-indazol-3(2H)-one; [0056]
1-(2-(difluoromethoxy)benzyl)-2-methyl-6-(2-(oxetan-3-ylamino)pyrimidin-5-
-yl)-1H-indazol-3(2H)-one; [0057]
1-benzoyl-2-methyl-6-(2-morpholinopyrimidin-5-yl)-1H-indazol-3(2H)-one;
[0058]
6-(5-chloro-2-morpholinopyridin-4-yl)-1-(3-fluorobenzyl)-2-methyl--
1H-indazol-3(2H)-one; [0059]
1-(2-(difluoromethoxy)benzoyl)-2-methyl-6-(2-morpholinopyrimidin-5-yl)-1H-
-indazol-3(2H)-one; [0060]
1-(2-(difluoromethoxy)benzyl)-6-(2-((2-hydroxyethyl)amino)pyrimidin-5-yl)-
-2-methyl-1H-indazol-3(2H)-one; [0061]
2-(1-(5-(1-(2-(difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-1H-inda-
zol-6-yl)pyrimidin-2-yl)azetidin-3-yl)acetic acid; [0062]
1-(2-(difluoromethoxy)benzyl)-2-methyl-6-(1-(tetrahydro-2H-pyran-4-yl)-1H-
-pyrazol-4-yl)-1H-indazol-3(2H)-one; [0063]
1-(2-(difluoromethoxy)benzyl)-2-methyl-6-(2-morpholinopyridin-4-yl)-1H-in-
dazol-3(2H)-one; [0064]
1-(3-fluorobenzyl)-2-methyl-6-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4--
yl)-1H-indazol-3(2H)-one; [0065]
1-(3-fluorobenzyl)-2-methyl-6-(2-morpholinopyridin-4-yl)-1H-indazol-3(2H)-
-one; [0066]
1-(2-(difluoromethoxy)-6-fluorobenzyl)-2-methyl-6-(2-morpholinopyrimidin--
5-yl)-1H-indazol-3(2H)-one; [0067]
1-(1-(2-(difluoromethoxy)phenyl)ethyl)-2-methyl-6-(2-morpholinopyrimidin--
5-yl)-1H-indazol-3(2H)-one; [0068]
2-methyl-6-(2-morpholinopyrimidin-5-yl)-1-phenethyl-1H-indazol-3(2H)-one;
[0069]
2-methyl-1-(2-methylbenzyl)-6-(2-morpholinopyrimidin-5-yl)-1H-inda-
zol-3(2H)-one; [0070]
1-(2,6-dichlorobenzyl)-2-methyl-6-(2-morpholinopyrimidin-5-yl)-1H-indazol-
-3(2H)-one; [0071]
1-(3-(difluoromethoxy)benzyl)-2-methyl-6-(2-morpholinopyrimidin-5-yl)-1H--
indazol-3(2H)-one; [0072]
1-(3-fluorobenzyl)-2-methyl-6-(2-morpholinopyrimidin-5-yl)-1H-indazol-3(2-
H)-one; [0073]
1-(2-fluorophenethyl)-2-methyl-6-(2-morpholinopyrimidin-5-yl)-1H-indazol--
3(2H)-one [0074]
1-(2-fluorobenzyl)-2-methyl-6-(2-morpholinopyrimidin-5-yl)-1H-indazol-3(2-
H)-one; [0075]
2-((2-methyl-6-(2-morpholinopyrimidin-5-yl)-3-oxo-2,3-dihydro-1H-indazol--
1-yl)methyl)benzonitrile; [0076]
2-methyl-1-(3-methylbenzyl)-6-(2-morpholinopyrimidin-5-yl)-1H-indazol-3(2-
H)-one; [0077]
1-(4-fluorobenzyl)-2-methyl-6-(2-morpholinopyrimidin-5-yl)-1H-indazol-3(2-
H)-one; [0078]
1-benzyl-2-methyl-6-(2-morpholinopyrimidin-5-yl)-1H-indazol-3(2H)-one;
[0079]
1-(2,6-dichlorobenzyl)-2-methyl-6-(2-(3-oxopiperazin-1-yl)pyrimidi-
n-5-yl)-1H-indazol-3(2H)-one; [0080]
1-(5-(1-(2-(difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-1H-indazol-
-6-yl)pyrimidin-2-yl)piperidine-4-carboxylic acid; [0081]
1-(2-(difluoromethoxy)benzyl)-6-(2-methoxypyrimidin-5-yl)-2-methyl-1H-ind-
azol-3(2H)-one; [0082]
1-(2-(difluoromethoxy)benzyl)-2-methyl-6-(2-(3-oxopiperazin-1-yl)pyrimidi-
n-5-yl)-1H-indazol-3(2H)-one; [0083]
1-(2-(difluoromethoxy)benzyl)-6-(2-morpholinopyrimidin-5-yl)-1H-indazol-3-
(2H)-one; [0084]
1-(2,5-dichlorobenzyl)-2-methyl-6-(2-(piperazin-1-yl)pyrimidin-5-yl)-1H-i-
ndazol-3(2H)-one; [0085]
1-(2,5-dichlorobenzyl)-2-methyl-6-(2-morpholinopyrimidin-5-yl)-1H-indazol-
-3(2H)-one; [0086]
1-(2-(difluoromethoxy)benzyl)-2-methyl-6-(2-morpholinopyrimidin-5-yl)-1H--
indazol-3(2H)-one; [0087]
1-(2-(difluoromethoxy)benzyl)-2-methyl-6-(6-(3-oxopiperazin-1-yl)pyridin--
3-yl)-1H-indazol-3(2H)-one; [0088]
1-(2-(difluoromethoxy)benzyl)-2-methyl-6-(6-(piperazin-1-yl)pyridin-3-yl)-
-1H-indazol-3(2H)-one; [0089]
1-(2-(difluoromethoxy)benzyl)-2-methyl-6-(6-morpholinopyridin-3-yl)-1H-in-
dazol-3(2H)-one; [0090]
1-(2-(difluoromethoxy)benzyl)-6-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)--
2-methyl-1H-indazol-3(2H)-one; [0091]
1-(2-(difluoromethoxy)benzyl)-2-methyl-6-(2-(3-(oxetan-3-yl)azetidin-1-yl-
)pyrimidin-5-yl)-1H-indazol-3(2H)-one; [0092]
2-((5-(1-(2-(difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-1H-indazo-
l-6-yl)pyrimidin-2-yl)amino)propanamide; [0093]
1-(2-(difluoromethoxy)benzyl)-2-methyl-6-(5-morpholinopyrazin-2-yl)-1H-in-
dazol-3(2H)-one; [0094]
1-((5-(1-(2-(difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-1H-indazo-
l-6-yl)pyrimidin-2-yl)methyl)azetidine-3-carboxylic acid; [0095]
1-(2-(difluoromethoxy)benzyl)-2-methyl-6-(2-(((5-oxopyrrolidin-3-yl)methy-
l)amino)pyrimidin-5-yl)-1H-indazol-3(2H)-one; [0096]
1-((3-chloropyridin-2-yl)methyl)-2-methyl-6-(2-morpholinopyrimidin-5-yl)--
1H-indazol-3(2H)-one; [0097]
2-cyclopropyl-1-(2-(difluoromethoxy)benzyl)-6-(2-morpholinopyrimidin-5-yl-
)-1H-indazol-3(2H)-one; [0098]
1-(2,5-dichlorophenyl)-2-methyl-6-(2-morpholinopyrimidin-5-yl)-1H-indazol-
-3(2H)-one [0099]
1-(2-(difluoromethoxy)-6-fluorobenzyl)-2-methyl-6-(2-morpholinopyrimidin--
5-yl)-1H-indazol-3(2H)-one; [0100]
4-(5-(1-(2-(difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-1H-indazol-
-6-yl)pyrimidin-2-yl)piperazine-1-carboxamide; [0101]
1-(1-(2-(difluoromethoxy)phenyl)ethyl)-6-(2-((R)-2-(methoxymethyl)pyrroli-
din-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one; [0102]
6-(2-(4-acetylpiperazin-1-yl)pyrimidin-5-yl)-1-(2-(difluoromethoxy)benzyl-
)-2-methyl-1H-indazol-3(2H)-one; [0103]
1-(2-(difluoromethoxy)benzyl)-2-methyl-6-(2-((2-oxoazepan-3-yl)amino)pyri-
midin-5-yl)-1H-indazol-3(2H)-one; [0104]
1-(3-(difluoromethoxy)benzyl)-2-methyl-6-(2-((tetrahydrofuran-3-yl)amino)-
pyrimidin-5-yl)-1H-indazol-3(2H)-one; [0105]
1-(2-(difluoromethoxy)benzyl)-2-methyl-6-(2-((tetrahydro-2H-pyran-3-yl)am-
ino)pyrimidin-5-yl)-1H-indazol-3(2H)-one; [0106]
1-(2-(difluoromethoxy)benzyl)-6-(2-((3-methoxypropyl)amino)pyrimidin-5-yl-
)-2-methyl-1H-indazol-3(2H)-one; [0107]
1-(2,5-dichlorobenzyl)-2-methyl-6-(2-morpholinopyrimidin-5-yl)-1H-indazol-
-3(2H)-one; [0108]
1-(5-(1-(2-(difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-1H-indazol-
-6-yl)pyrazin-2-yl)piperidine-4-carboxylic acid; [0109]
1-(2-(difluoromethoxy)benzyl)-2-methyl-6-(5-morpholino-1,2,4-thiadiazol-3-
-yl)-1H-indazol-3(2H)-one; [0110]
1-(2-(difluoromethoxy)benzyl)-2-methyl-6-(2-morpholinopyrimidin-5-yl)-1H--
pyrazolo[4,3-b]pyridin-3(2H)-one; [0111]
1-(2-(difluoromethoxy)benzyl)-2-methyl-6-(2-((3-methyloxetan-3-yl)methyl)-
pyrimidin-5-yl)-1H-indazol-3(2H)-one; [0112]
1-(2-(difluoromethoxy)benzyl)-2-methyl-6-(3-morpholino-1,2,4-oxadiazol-5--
yl)-1H-indazol-3(2H)-one; [0113]
1-(2-(difluoromethoxy)benzyl)-2-methyl-6-(2-morpholinopyrimidin-5-yl)-1H--
pyrazolo[3,4-b]pyridin-3(2H)-one; [0114]
1-(2-(difluoromethoxy)benzyl)-6-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)--
2-methyl-1H-pyrazolo[3,4-b]pyridin-3(2H)-one. [0115]
1-(2-(difluoromethoxy)benzyl)-2-methyl-6-(2-morpholinopyrimidin-5-yl)-1H--
pyrazolo[4,3-c]pyridin-3(2H)-one; [0116]
1-(2-(difluoromethoxy)benzyl)-2-methyl-6-(2-(6-oxohexahydropyrrolo[1,2-a]-
pyrazin-2(1H)-yl)pyrimidin-5-yl)-1H-indazol-3(2H)-one; [0117]
(R)-1-(2-(difluoromethoxy)benzyl)-2-methyl-6-(2-((tetrahydrofuran-3-yl)am-
ino)pyrimidin-5-yl)-1H-indazol-3(2H)-one; [0118]
(R)-7-(5-(1-(2-(difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-1H-ind-
azol-6-yl)pyrimidin-2-yl)tetrahydro-1H-oxazolo[3,4-a]pyrazin-3(5H)-one;
[0119]
(S)-7-(5-(1-(2-(difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-
-1H-indazol-6-yl)pyrimidin-2-yl)tetrahydro-1H-oxazolo[3,4-a]pyrazin-3(5H)--
one; [0120]
7-(5-(1-(2-(difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-1H-indazol-
-6-yl)pyrimidin-2-yl)hexahydroimidazo[1,5-a]pyrazin-3(2H)-one;
[0121]
(R)-7-(5-(1-(2-(difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-1H-ind-
azol-6-yl)pyrimidin-2-yl)hexahydroimidazo[1,5-a]pyrazin-3(2H)-one;
[0122]
(S)-7-(5-(1-(2-(difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-1H-ind-
azol-6-yl)pyrimidin-2-yl)hexahydroimidazo[1,5-a]pyrazin-3(2H)-one;
[0123]
1-(2-(difluoromethoxy)-5-methylbenzyl)-2-methyl-6-(2-morpholinopyrimidin--
5-yl)-1H-indazol-3(2H)-one; [0124]
1-(2-(difluoromethoxy)-5-(hydroxymethyl)benzyl)-2-methyl-6-(2-morpholinop-
yrimidin-5-yl)-1H-indazol-3(2H)-one; [0125]
(R)-7-(5-(1-(2-(difluoromethoxy)-5-methylbenzyl)-2-methyl-3-oxo-2,3-dihyd-
ro-1H-indazol-6-yl)pyrimidin-2-yl)hexahydroimidazo[1,5-a]pyrazin-3(2H)-one-
; [0126]
(S)-7-(5-(1-(2-(difluoromethoxy)-5-methylbenzyl)-2-methyl-3-oxo-2-
,3-dihydro-1H-indazol-6-yl)pyrimidin-2-yl)hexahydroimidazo[1,5-a]pyrazin-3-
(2H)-one; [0127]
(S)-7-(5-(1-(2-(Difluoromethoxy)-5-(hydroxymethyl)benzyl)-2-methyl-3-oxo--
2,3-dihydro-1H-indazol-6-yl)pyrimidin-2-yl)hexahydroimidazo[1,5-a]pyrazin--
3(2H)-one; or [0128]
7-(5-(1-(2-(difluoromethoxy)-5-(hydroxymethyl)benzyl)-2-methyl-3-oxo-2,3--
dihydro-1H-indazol-6-yl)pyrimidin-2-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]py-
razin-3(2H)-one; [0129]
1-(2-(difluoromethoxy)-5-methylbenzyl)-5-fluoro-6-(2-(2-hydroxypropan-2-y-
l)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one; or [0130]
(R)-1-(2-(difluoromethoxy)benzyl)-6-(2-(4-(2-hydroxyacetyl)-3-methylpiper-
azin-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one.
[0131] In a fourteenth embodiment, the present disclosure provides
a compound of Formula (I), or a pharmaceutically acceptable salt,
prodrug or stereoisomer thereof, wherein
[0132] X, Y and Z are independently CR.sup.4 or N; [0133] provided
that Y and Z are not both N;
[0134] L is a bond, optionally substituted
(C.sub.1-C.sub.3)alkylene or --C(O)--;
[0135] R.sup.1 is H, CD.sub.3, CN, optionally substituted
(C.sub.1-C.sub.3)alkyl, --(CH.sub.2).sub.n-optionally substituted
phenyl, --(CH.sub.2).sub.n-optionally substituted heteroaryl or
--(CH.sub.2).sub.n-optionally substituted heterocyclyl;
[0136] R.sup.2 is optionally substituted aryl, optionally
substituted heteroaryl, optionally substituted heterocyclyl or
optionally substituted cycloalkyl;
[0137] R.sup.3 is --R.sup.3a-R.sup.3b, wherein: [0138] R.sup.3a is
an optionally substituted saturated, unsaturated or partially
saturated heterocyclyl or optionally substituted heteroaryl; [0139]
R.sup.3b is --N(R.sup.a)(R.sup.b), --O(R.sup.a), optionally
substituted (C.sub.1-C.sub.5)alkyl, optionally substituted
(C.sub.3-C.sub.6)cycloalkyl, or --(CH.sub.2).sub.p-optionally
substituted heterocyclyl; wherein [0140] R.sup.a and R.sup.b are
independently selected from H, optionally substituted
(C.sub.1-C.sub.5)alkyl, and --(CH.sub.2).sub.n-optionally
substituted heterocyclyl;
[0141] R.sup.4 is independently H, Cl, CN, F, CF.sub.3, optionally
substituted (C.sub.1-C.sub.3)alkyl or optionally substituted
(C.sub.1-C.sub.3) alkoxy; and
[0142] n is 0 or 1;
[0143] p is 0, 1 or 2.
[0144] In a fifteenth embodiment, the disclosure provides a
compound according to any of the foregoing embodiments wherein
R.sup.1 is H, CD.sub.3, optionally substituted
(C.sub.1-C.sub.3)alkyl or --CH.sub.2-pyrimidinyl.
[0145] In a sixteenth embodiment, the disclosure provides a
compound according to any of the foregoing embodiments wherein
R.sup.2 is optionally substituted heteroaryl, optionally
substituted heterocyclyl or optionally substituted phenyl.
[0146] In a seventeenth embodiment, the disclosure provides a
compound according to any of the foregoing embodiments wherein
R.sup.3a is optionally substituted dihydropyranyl, optionally
substituted imidazo[1,2-b]pyridazinyl, optionally substituted
1,2,4-oxadiazolyl, optionally substituted pyrazolyl, optionally
substituted 3,6-dihydro-2H-pyranyl, optionally substituted
pyridinyl, optionally substituted pyrimidinyl, optionally
substituted pyrazinyl, or optionally substituted
1,2,4-thiadiazolyl.
[0147] In a eighteenth embodiment, the disclosure provides a
compound according to any of the foregoing embodiments wherein
R.sup.3b is --N(R.sup.a)(R.sup.b), --O(R.sup.a), optionally
substituted (C.sub.1-C.sub.3)alkyl, --(CH.sub.2).sub.p-optionally
substituted imidazo[1,2-b]pyridazinyl,
--(CH.sub.2).sub.p-optionally substituted morpholinyl,
--(CH.sub.2).sub.p-optionally substituted piperazinyl,
--(CH.sub.2).sub.p-optionally substituted piperidinyl,
--(CH.sub.2).sub.p-optionally substituted pyrrolidinyl,
--(CH.sub.2).sub.p-optionally substituted tetrahydropyranyl,
--(CH.sub.2).sub.p-optionally substituted
tetrahydro-1H-oxazolo[3,4-a]pyrazin-3(5H)-one,
--(CH.sub.2).sub.p-optionally substituted
hydroimidazo[1,2-b]pyridazin-3(2H)-one; or
--(CH.sub.2).sub.p-optionally substituted
hexahydroimidazo[1,5-a]pyrazin-3(2H)-one; wherein R.sup.a and
R.sup.b are independently selected from H, optionally substituted
(C.sub.1-C.sub.3)alkyl, --(CH.sub.2).sub.n-morpholinyl
--(CH.sub.2).sub.n-oxoazepanyl, --(CH.sub.2).sub.n-optionally
substituted tetrahydrofuranyl, --(CH.sub.2).sub.n-optionally
substituted oxetanyl, --(CH.sub.2).sub.n-optionally substituted
piperidinyl, --(CH.sub.2).sub.n-optionally substituted
tetrahydropyranyl, --(CH.sub.2).sub.p-optionally substituted
hexahydroimidazo[1,5-a]pyrazin-3(2H)-one, and
--(CH.sub.2).sub.n-optionally substituted pyrrolidinyl.
[0148] In an nineteenth embodiment, the disclosure provides a
compound according to any of the foregoing embodiments wherein L is
a bond or optionally substituted (C.sub.1-C.sub.2)alkylene.
[0149] In a twentieth embodiment, the disclosure provides a
compound according to any of the foregoing embodiments wherein
R.sup.2 is 4,5-dihydrobenzo[f][1,5]thiazepin-3(2 h)-one,
1.3-dihydroisobenzofuranyl, phenyl, pyridinyl, pyrimidinyl or
pyrrolyl, and R.sup.2 is optionally substituted by one or more
substituents independently selected from halogen, CN, haloalkoxy,
CF.sub.3, --SCHF.sub.2, optionally substituted
(C.sub.1-C.sub.3)alkyl, optionally substituted
(C.sub.3-C.sub.6)cycloalkyl, --CH.sub.2OC(O)C(H)NH.sub.2CH.sub.3,
--CH.sub.2NHC(O)OCH.sub.3, --CH.sub.2-pyridinyl,
--CH.sub.2-pyrrolyl, --CH.sub.2-optionally substituted pyrazolyl,
--CH.sub.2-triazolyl-, --CH.sub.2--O-pyrazolyl, --C(O)CH.sub.3,
--N(H)CH.sub.2C(OH)(CH.sub.3).sub.2,
--N(H)CH.sub.2C(H)(OH)CH.sub.3, or --N(H)(R.sup.c); wherein R.sup.c
is --(CH.sub.2).sub.n-optionally substituted heterocyclyl or
--(CH.sub.2).sub.n optionally substituted heteroaryl, wherein n is
0 or 1.
[0150] In a twenty-first embodiment, the disclosure provides a
compound according to any of the foregoing embodiments wherein
R.sup.3b is --N(H)-optionally substituted oxetanyl,
--N(H)-optionally substituted piperidin-2-one, --N(H)-optionally
substituted tetrahydropyranyl, --O-tetrahydropyranyl, optionally
substituted (C.sub.1-C.sub.3)alkyl, optionally substituted
morpholinyl, optionally substituted piperazinyl, optionally
substituted piperidinyl, optionally substituted pyrrolidinyl,
-optionally substituted
tetrahydro-1H-oxazolo[3,4-a]pyrazin-3(5H)-one
--(CH.sub.2).sub.p-optionally substituted
hexahydroimidazo[1,5-a]pyrazin-3(2H)-one, or optionally substituted
tetrahydropyranyl.
[0151] In a twenty-second embodiment, the disclosure provides a
compound according to any of the foregoing embodiments wherein
R.sup.3b is optionally substituted by one or more substituents
independently selected from halogen, --CHO, CN, --C(O)OH,
--C(O)CH.sub.3, --C(O)CH.sub.2CN, --C(O)CH.sub.2OH,
--C(O)CH.sub.2NH.sub.2, C(O)CH.sub.2OCH.sub.3,
--C(O)C(H)(CH.sub.3)NH.sub.2, --C(O)C(H)(OH)CH.sub.2OH,
--C(O)C(H)(OH)CH.sub.2C(O)OH, --C(O)C(H)(OH)CH.sub.2NH.sub.2,
--C(O)CH.sub.2OC(O)C(H)(NH.sub.2)CH(CH.sub.3).sub.2,
--C(O)NH.sub.2, --C(O)OCH.sub.3, --C(O)CH.sub.2OP(O)(OH).sub.2,
--C(O)-oxetanyl, NH.sub.2, .dbd.O, --OH, --S(O).sub.2CH.sub.3,
optionally substituted (C.sub.1-C.sub.3)alkyl, optionally
substituted (C.sub.1-C.sub.3)alkoxy and optionally substituted
oxetanyl.
[0152] In a twenty-third embodiment, the disclosure provides a
compound according to any of the foregoing embodiments wherein Y is
CR.sup.4 and R.sup.4 is H.
[0153] In a twenty-fourth embodiment, the disclosure provides a
compound according to any of the foregoing embodiments wherein Z is
CR.sup.4 and R.sup.4 is H or F.
[0154] In a twenty-fifth embodiment, the disclosure provides a
compound according to any of the foregoing embodiments wherein the
compound is: [0155]
(R)-1-(5-((1H-pyrazol-4-yl)methyl)-2-(difluoromethoxy)benzyl)-6-(2-
-(4-acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H-
)-one; [0156]
(R)-1-(2-(difluoromethoxy)benzyl)-7-fluoro-6-(2-(4-(2-hydroxyacetyl)-3-me-
thylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one;
[0157]
(R)-2-(4-(difluoromethoxy)-3-((6-(2-(4-(2-hydroxyacetyl)-3-methylpiperazi-
n-1-yl)pyrimidin-5-yl)-2-methyl-3-oxo-2,3-dihydro-1H-indazol-1-yl)methyl)p-
henyl)acetonitrile; [0158]
(R)-2-(4-(5-(1-(2-(difluoromethoxy)-5-methylbenzyl)-2-methyl-3-oxo-2,3-di-
hydro-1H-indazol-6-yl)pyrimidin-2-yl)-2-methylpiperazin-1-yl)-2-oxoethyl
dihydrogen phosphate; [0159]
(R)-1-(2-(difluoromethoxy)benzyl)-5,7-difluoro-6-(2-(4-(2-hydroxyacetyl)--
3-methylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one;
[0160]
(R)-1-(2-chlorobenzyl)-7-fluoro-6-(2-(4-(2-hydroxyacetyl)-3-methyl-
piperazin-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one;
[0161]
(R)-1-(2-chlorobenzyl)-7-fluoro-6-(2-(4-(2-hydroxyacetyl)-3-methylpiperaz-
in-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one; [0162]
(R)-1-(2-(difluoromethoxy)-5-methylbenzyl)-5-fluoro-6-(2-(4-(2-hydroxyace-
tyl)-2-methylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one;
[0163]
1-(5-((1H-pyrazol-5-yl)methyl)-2-(difluoromethoxy)benzyl)-6-(2-(2--
hydroxypropan-2-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one;
[0164]
1-(2-(difluoromethoxy)-5-methylbenzyl)-6-(3-(2-hydroxypropan-2-yl)imidazo-
[1,2-b]pyridazin-7-yl)-2-methyl-1H-indazol-3(2H)-one; [0165]
1-(2-(difluoromethoxy)-5-methylbenzyl)-2-methyl-6-(2-(3-methylpyrrolidin--
3-yl)pyrimidin-5-yl)-1H-indazol-3(2H)-one; [0166]
1-(1-(2,5-difluorophenyl)ethyl)-6-(2-((R)-4-(2-hydroxyacetyl)-3-methylpip-
erazin-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one; [0167]
1-(2-(difluoromethoxy)-5-methylbenzyl)-5-fluoro-6-(6-(1-hydroxyethyl)-5,6-
-dihydro-2H-pyran-3-yl)-2-methyl-1H-indazol-3(2H)-one; [0168]
1-(2-chloro-5-((2-hydroxy-2-methylpropyl)amino)benzyl)-6-(2-(2-hydroxypro-
pan-2-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one; [0169]
1-(2-(difluoromethoxy)-5-methylbenzyl)-6-(2-(1,3-dimethylpyrrolidin-3-yl)-
pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one acetate; [0170]
1-(2-(difluoromethoxy)-5-methylbenzyl)-6-(2-(1,3-dimethylpyrrolidin-3-yl)-
pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one; [0171]
(R)-1-(2-(difluoromethoxy)benzyl)-5-fluoro-6-(2-(4-(2-hydroxyacetyl)-3-me-
thylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one;
[0172]
6-[2-[(3R)-4-acetyl-3-methyl-piperazin-1-yl]pyrimidin-5-yl]-1-[[2-(difluo-
romethoxy)-5-methyl-phenyl]methyl]-2(trideuteriomethyl)indazol-3-one;
[0173]
(S)-6-(2-(4-acetyl-2-methylpiperazin-1-yl)pyrimidin-5-yl)-1-(2-(di-
fluoromethoxy)-5-methylbenzyl)-2-methyl-1H-indazol-3(2H)-one;
[0174]
(R)-1-(2-(difluoromethoxy)-5-methylbenzyl)-6-(2-(4-(2-hydroxyacetyl)-3-me-
thylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one;
[0175]
1-[[2-(difluoromethoxy)-5-methyl-phenyl]methyl]-6-[2-[(3R)-4-(2-hydroxyac-
etyl)-3-methyl-piperazin-1-yl]pyrimidin-5-yl]-2-(trideuteriomethyl)indazol-
-3-one; [0176]
(R)-1-(2-(difluoromethoxy)-5-methylbenzyl)-6-(2-(4-(2-hydroxyacetyl)-2-me-
thylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one;
[0177]
(R)-6-(2-(4-acetyl-2-methylpiperazin-1-yl)pyrimidin-5-yl)-1-(2-(difluorom-
ethoxy)-6-(hydroxymethyl)benzyl)-2-methyl-1H-indazol-3(2H)-one;
[0178]
(R)-1-(2-(difluoromethoxy)benzyl)-6-(2-(4-(2-hydroxyacetyl)-3-methylpiper-
azin-1-yl)-4-methylpyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one;
[0179]
1-(2-(difluoromethoxy)-5-methylbenzyl)-5-fluoro-6-(6-(2-hydroxypropan-2-y-
l)-5,6-dihydro-2H-pyran-3-yl)-2-methyl-1H-indazol-3(2H)-one; [0180]
1-((S)-1-(2,6-difluorophenyl)ethyl)-6-(2-((R)-4-(2-hydroxyacetyl)-3-methy-
lpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one;
[0181]
(R)-1-(2-(difluoromethoxy)-5-methylbenzyl)-2-methyl-6-(2-(3-methyl-4-(met-
hylsulfonyl)piperazin-1-yl)pyrimidin-5-yl)-1H-indazol-3(2H)-one;
[0182] (R)-methyl
4-(5-(1-(2-(difluoromethoxy)-5-methylbenzyl)-2-methyl-3-oxo-2,3-dihydro-1-
H-indazol-6-yl)pyrimidin-2-yl)-2-methylpiperazine-1-carboxylate;
[0183]
(R)-6-(2-(4-acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-1-(2-(difluorom-
ethoxy)-6-(hydroxymethyl)benzyl)-2-methyl-1H-indazol-3(2H)-one;
[0184]
(S)-7-(5-(1-(2-(difluoromethoxy)-5-methylbenzyl)-2-methyl-3-oxo-2,3-dihyd-
ro-1H-indazol-6-yl)pyrimidin-2-yl)tetrahydro-1H-oxazolo[3,4-a]pyrazin-3(5H-
)-one; [0185]
(R)-6-(2-(4-acetyl-2-methylpiperazin-1-yl)pyrimidin-5-yl)-1-(2-(difluorom-
ethoxy)-5-methylbenzyl)-2-methyl-1H-indazol-3(2H)-one; [0186]
(R)-1-(2-(difluoromethoxy)benzyl)-6-(2-(4-(2-hydroxyacetyl)-2-methylpiper-
azin-1-yl)-4-methylpyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one;
[0187]
(R)-7-(5-(1-(5-((1H-1,2,4-triazol-1-yl)methyl)-2-(difluoromethoxy)benzyl)-
-2-methyl-3-oxo-2,3-dihydro-1H-indazol-6-yl)pyrimidin-2-yl)hexahydroimidaz-
o[1,5-a]pyrazin-3(2H)-one; [0188]
(R)-7-(5-(1-(2-(difluoromethoxy)-6-(hydroxymethyl)benzyl)-2-methyl-3-oxo--
2,3-dihydro-1H-indazol-6-yl)pyrimidin-2-yl)hexahydroimidazo[1,5-a]pyrazin--
3(2H)-one; [0189]
1-(5-((1H-pyrazol-4-yl)methyl)-2-(difluoromethoxy)benzyl)-6-(2-(2-hydroxy-
propan-2-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one; [0190]
(R)-6-(2-(4-acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-1-(2-((difluoro-
methyl)thio)-5-methylbenzyl)-2-methyl-1H-pyrazolo[3,4-b]pyridin-3(2H)-one;
[0191]
(R)-6-(2-(4-acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-1-(2-chl-
oro-5-methylbenzyl)-2-methyl-1H-pyrazolo[3,4-b]pyridin-3(2H)-one;
[0192]
(R)-6-(2-(4-acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-1-(2-((difluoro-
methyl)thio)-5-methylbenzyl)-2-methyl-1H-indazol-3(2H)-one; [0193]
(R)-6-(2-(4-acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-1-(2-(difluorom-
ethoxy)-5-methylbenzyl)-2-methyl-1H-indazol-3(2H)-one; [0194]
(R)-2-(4-(difluoromethoxy)-3-((2-methyl-3-oxo-6-(2-(3-oxotetrahydro-1H-ox-
azolo[3,4-a]pyrazin-7(3H)-yl)pyrimidin-5-yl)-2,3-dihydro-1H-indazol-1-yl)m-
ethyl)phenyl)acetonitrile; [0195]
(S)-1-(2-(difluoromethoxy)benzyl)-6-(2-(4-(2-hydroxyacetyl)-2-methylpiper-
azin-1-yl)-4-methylpyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one;
[0196]
(R)-6-(2-(4-(2-hydroxyacetyl)-3-methylpiperazin-1-yl)pyrimidin-5-yl)-2-me-
thyl-1-((6-methyl-3-(trifluoromethyl)pyridin-2-yl)methyl)-1H-indazol-3(2H)-
-one; [0197]
(R)-7-(5-(1-(2-(difluoromethoxy)-6-(methoxymethyl)benzyl)-2-methyl-3-oxo--
2,3-dihydro-1H-indazol-6-yl)pyrimidin-2-yl)hexahydroimidazo[1,5-a]pyrazin--
3(2H)-one; [0198]
(S)-1-(2-(difluoromethoxy)-5-methylbenzyl)-2-methyl-6-(2-(3-methyl-4-(met-
hylsulfonyl)piperazin-1-yl)pyrimidin-5-yl)-1H-indazol-3(2H)-one;
[0199]
(R)-1-(2-(difluoromethoxy)benzyl)-5-fluoro-6-(2-(4-(2-hydroxyacetyl)-3-me-
thylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-1H-pyrazolo[3,4-b]pyridin-3(2H-
)-one; [0200]
6-(2-((R)-4-(2-hydroxyacetyl)-3-methylpiperazin-1-yl)pyrimidin-5-yl)-2-me-
thyl-1-((S)-1-(m-tolyl)ethyl)-1H-indazol-3(2H)-one; [0201]
6-(2-(4-(3-amino-2-hydroxypropanoyl)-3-methylpiperazin-1-yl)pyrimidin-5-y-
l)-1-(2-(difluoromethoxy)-5-methylbenzyl)-2-methyl-1H-indazol-3(2H)-one;
[0202]
1-(2-(difluoromethoxy)benzyl)-6-(2-((R)-4-((S)-2,3-dihydroxypropan-
oyl)-3-methylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one;
[0203]
(R)-1-(2-(difluoromethoxy)benzyl)-5-fluoro-6-(2-(4-(2-hydroxyacety-
l)-2-methylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one;
[0204]
1-(2-(difluoromethoxy)-5-methylbenzyl)-2-methyl-6-(2-((3R)-3-methy-
l-4-(oxetane-2-carbonyl)piperazin-1-yl)pyrimidin-5-yl)-1H-indazol-3(2H)-on-
e; [0205]
(R)-2-(4-(5-(1-(2-(difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-di-
hydro-1H-indazol-6-yl)pyrimidin-2-yl)-2-methylpiperazin-1-yl)-2-oxoethyl
phosphate; [0206]
(R)-1-(2-(difluoromethoxy)benzyl)-6-(2-(4-(2-hydroxyacetyl)-3-methylpiper-
azin-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one; [0207]
(R)-3-(4-(5-(1-(2-(difluoromethoxy)-5-methylbenzyl)-2-methyl-3-oxo-2,3-di-
hydro-1H-indazol-6-yl)pyrimidin-2-yl)-2-methylpiperazin-1-yl)-3-oxopropane-
nitrile; [0208] 1-(1-(2,6-difluorophenyl
ethyl)-6-(2-((R)-4-(2-hydroxyacetyl)-3-methylpiperazin-1-yl)pyrimidin-5-y-
l)-2-methyl-1H-indazol-3(2H)-one; [0209]
(S)-1-(2-(difluoromethoxy)benzyl)-6-(2-(4-(2-hydroxyacetyl)-2-methylpiper-
azin-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one; [0210]
1-(2-(difluoromethoxy)benzyl)-6-(2-((R)-4-((R)-2,3-dihydroxypropanoyl)-3--
methylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one;
[0211]
(R)-6-(2-(4-acetyl-2-ethylpiperazin-1-yl)pyrimidin-5-yl)-1-(2-(difluorome-
thoxy)-5-methylbenzyl)-2-methyl-1H-indazol-3(2H)-one; [0212]
(R)-1-(2-(difluoromethoxy)-5-(hydroxymethyl)benzyl)-2-methyl-6-(2-((2-oxo-
piperidin-4-yl)amino)pyrimidin-5-yl)-1H-indazol-3(2H)-one; [0213]
(S)-7-(5-(1-(2-(difluoromethoxy)-5-(hydroxymethyl)benzyl)-2-methyl-3-oxo--
2,3-dihydro-1H-indazol-6-yl)pyrimidin-2-yl)tetrahydro-1H-oxazolo[3,4-a]pyr-
azin-3(5H)-one; [0214]
(R)-1-(2-(difluoromethoxy)benzyl)-5-fluoro-6-(6-(4-(2-hydroxyacetyl)-3-me-
thylpiperazin-1-yl)pyridin-3-yl)-2-methyl-1H-indazol-3(2H)-one;
[0215]
(R)-1-(2-chlorobenzyl)-6-(2-(4-(2-hydroxyacetyl)-3-methylpiperazin-1-yl)p-
yrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one; [0216]
(R)-1-(2-(difluoromethoxy)-5-methylbenzyl)-2-methyl-6-(2-(3-methyl-4-(oxe-
tane-3-carbonyl)piperazin-1-yl)pyrimidin-5-yl)-1H-indazol-3(2H)-one;
[0217]
4-(5-(1-(2-(difluoromethoxy)-5-(hydroxymethyl)benzyl)-2-methyl-3-o-
xo-2,3-dihydro-1H-indazol-6-yl)pyrimidin-2-yl)piperazine-1-carbaldehyde;
[0218]
(S)-2-((R)-4-(5-(1-(2-(difluoromethoxy)-5-methylbenzyl)-2-methyl-3-
-oxo-2,3-dihydro-1H-indazol-6-yl)pyrimidin-2-yl)-2-methylpiperazin-1-yl)-2-
-oxoethyl 2-amino-3-methylbutanoate hydrochloride; [0219]
(R)-7-(5-(1-(2-(difluoromethoxy)-5-(hydroxymethyl)benzyl)-2-methyl-3-oxo--
2,3-dihydro-1H-indazol-6-yl)pyrimidin-2-yl)tetrahydro-1H-oxazolo[3,4-a]pyr-
azin-3(5H)-one; [0220]
(S)-7-(5-(1-(2-chloro-5-methylbenzyl)-2-methyl-3-oxo-2,3-dihydro-1H-indaz-
ol-6-yl)pyrimidin-2-yl)hexahydroimidazo[1,5-a]pyrazin-3(2H)-one;
[0221]
(R)-1-(2-(difluoromethoxy)benzyl)-7-fluoro-6-(2-(4-(2-hydroxyacetyl)-2-me-
thylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one;
[0222]
(R)-6-(2-(4-acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-1-((6--
methyl-3-(trifluoromethyl)pyridin-2-yl)methyl)-1H-indazol-3(2H)-one;
[0223]
(R)-7-(5-(1-(2-(Difluoromethoxy)-5-methylbenzyl)-2-(methyl-d.sub.3-
)-3-oxo-2,3-dihydro-1H-indazol-6-yl)pyrimidin-2-yl)hexahydro-3H-oxazolo[3,-
4-a]pyrazin-3-one; [0224]
(R)-1-(2-(difluoromethoxy)-5-methylbenzyl)-6-(2-(4-(2-methoxyacetyl)-3-me-
thylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one;
[0225]
(S)-7-(5-(2-methyl-1-(5-methyl-2-(trifluoromethyl)benzyl)-3-oxo-2,3-dihyd-
ro-1H-indazol-6-yl)pyrimidin-2-yl)hexahydroimidazo[1,5-a]pyrazin-3(2H)-one-
; [0226]
6-(2-(4-acetylpiperazin-1-yl)pyrimidin-5-yl)-1-(2-(difluoromethox-
y)-5-(hydroxymethyl)benzyl)-2-methyl-1H-indazol-3(2H)-one; [0227]
(S)-1-(2-(difluoromethoxy)-5-methylbenzyl)-6-(2-(4-(2-hydroxyacetyl)-3-me-
thylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one;
[0228]
6-(2-((R)-4-(2-hydroxyacetyl)-3-methylpiperazin-1-yl)pyrimidin-5-yl)-2-me-
thyl-1-(1-(m-tolyl)propyl)-1H-indazol-3(2H)-one; [0229]
(S)-7-(5-(1-(5-((4H-1,2,4-triazol-4-yl)methyl)-2-(difluoromethoxy)benzyl)-
-2-methyl-3-oxo-2,3-dihydro-1H-indazol-6-yl)pyrimidin-2-yl)hexahydroimidaz-
o[1,5-a]pyrazin-3(2H)-one; [0230]
(R)-1-(2-(difluoromethoxy)benzyl)-6-(2-(4-(2-hydroxyacetyl)-2-methylpiper-
azin-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one; [0231]
(R)-6-(2-(4-acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-1-(2-(difluorom-
ethoxy)-5-methylbenzyl)-2-methyl-1H-pyrazolo[3,4-b]pyridin-3(2H)-one;
[0232]
(R)-7-(5-(1-((3-(difluoromethoxy)-6-(hydroxymethyl)pyridin-2-yl)me-
thyl)-2-methyl-3-oxo-2,3-dihydro-1H-indazol-6-yl)pyrimidin-2-yl)hexahydroi-
midazo[1,5-a]pyrazin-3(2H)-one; [0233]
(R)-6-(2-(4-acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-1-(2-(difluorom-
ethoxy)benzyl)-2-methyl-1H-indazol-3(2H)-one; [0234]
(R)-6-(2-(4-acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-1-((6--
methyl-3-(trifluoromethyl)pyridin-2-yl)methyl)-1H-pyrazolo[3,4-b]pyridin-3-
(2H)-one; [0235]
(S)-4-(difluoromethoxy)-3-((2-methyl-3-oxo-6-(2-((R)-3-oxohexahydroimidaz-
o[1,5-a]pyrazin-7(1H)-yl)pyrimidin-5-yl)-2,3-dihydro-1H-indazol-1-yl)methy-
l)benzyl 2-aminopropanoate hydrochloride; [0236]
(R)-6-(2-(4-acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-1-((4--
(trifluoromethyl)-1H-pyrrol-3-yl)methyl)-1H-indazol-3(2H)-one;
[0237]
1-(2-(difluoromethoxy)-5-methylbenzyl)-6-(2-(2-hydroxypropan-2-yl)-4-meth-
ylpyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one; [0238]
6-(2-((R)-4-(2-hydroxyacetyl)-3-methylpiperazin-1-yl)pyrimidin-5-yl)-2-me-
thyl-1-(1-(m-tolyl)ethyl)-1H-indazol-3(2H)-one; [0239]
1-(2-chloro-5-((4,5,6,7-tetrahydro-1H-indazol-7-yl)amino)benzyl)-6-(2-(2--
hydroxypropan-2-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one;
[0240]
(R)-2-(4-(difluoromethoxy)-3-((2-methyl-3-oxo-6-(2-(3-oxohexahydroimidazo-
[1,5-a]pyrazin-7(1H)-yl)pyrimidin-5-yl)-2,3-dihydro-1H-indazol-1-yl)methyl-
)phenyl)acetonitrile; [0241]
(R)-6-(2-(4-(2-aminoacetyl)-3-methylpiperazin-1-yl)pyrimidin-5-yl)-1-(2-(-
difluoromethoxy)-5-methylbenzyl)-2-methyl-1H-indazol-3(2H)-one;
[0242]
1-(2-(difluoromethoxy)-5-methylbenzyl)-6-(2-(4-(2-hydroxyacetyl)piperazin-
-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one; [0243]
(R)-1-(5-(((1H-pyrazol-5-yl)oxy)methyl)-2-(difluoromethoxy)benzyl)-6-(2-(-
4-acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)--
one; [0244]
(S)-6-(2-(4-acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-1-(2-(difluorom-
ethoxy)-5-methylbenzyl)-2-methyl-1H-indazol-3(2H)-one; [0245]
1-(5-((1H-1,2,4-triazol-1-yl)methyl)-2-(difluoromethoxy)benzyl)-5-fluoro--
6-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one;
[0246]
(R)-7-(5-(1-(2-(difluoromethoxy)-5-methylbenzyl)-2-methyl-3-oxo-2,-
3-dihydro-1H-indazol-6-yl)pyrimidin-2-yl)tetrahydro-1H-oxazolo[3,4-a]pyraz-
in-3(5H)-one; [0247]
(R)-1-(2-(difluoromethoxy)-5-(hydroxymethyl)benzyl)-2-methyl-6-(2-((1-met-
hyl-2-oxopiperidin-4-yl)amino)pyrimidin-5-yl)-1H-indazol-3(2H)-one;
[0248]
(R)-1-(2-(difluoromethoxy)benzyl)-6-(2-(4-(2-hydroxyacetyl)-3-methylpiper-
azin-1-yl)pyrimidin-5-yl)-7-methoxy-2-methyl-1H-indazol-3(2H)-one;
[0249]
1-((S)-1-(2-fluorophenyl)ethyl)-6-(2-((R)-4-(2-hydroxyacetyl)-3-methylpip-
erazin-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one; [0250]
(R)-6-(2-(4-acetyl-2-methylpiperazin-1-yl)pyrimidin-5-yl)-1-(2-(difluorom-
ethoxy)benzyl)-2-methyl-1H-indazol-3(2H)-one; [0251]
6-(2-((R)-4-((S)-2-aminopropanoyl)-3-methylpiperazin-1-yl)pyrimidin-5-yl)-
-1-(2-(difluoromethoxy)-5-methylbenzyl)-2-methyl-1H-indazol-3(2H)-one;
[0252]
1-(2-(difluoromethoxy)-5-methylbenzyl)-5-fluoro-6-(2-(2-hydroxypro-
pan-2-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one; [0253]
1-(2-(difluoromethoxy)-5-(hydroxymethyl)benzyl)-2-methyl-6-(2-((2-oxopipe-
ridin-4-yl)amino)pyrimidin-5-yl)-1H-indazol-3(2H)-one; [0254]
(R)-methyl
3-((6-(2-(4-acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-3-oxo--
2,3-dihydro-1H-indazol-1-yl)methyl)-4-(difluoromethoxy)benzylcarbamate;
[0255]
1-(2-(difluoromethoxy)-5-methylbenzyl)-2-methyl-6-(2-((tetrahydro--
2H-pyran-4-yl)oxy)pyridin-4-yl)-1H-indazol-3(2H)-one;
[0256]
(S)-3-(4-(5-(1-(2-(difluoromethoxy)-5-methylbenzyl)-2-methyl-3-oxo-
-2,3-dihydro-1H-indazol-6-yl)pyrimidin-2-yl)-2-methylpiperazin-1-yl)-3-oxo-
propanenitrile; [0257]
(S)-2-((R)-4-(5-(1-(2-(difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-
-1H-indazol-6-yl)pyrimidin-2-yl)-2-methylpiperazin-1-yl)-2-oxoethyl
2-amino-3-methylbutanoate; [0258]
(R)-7-(5-(1-(2-(difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-1H-ind-
azol-6-yl)pyrimidin-2-yl)-2-(2-hydroxyethyl)hexahydroimidazo[1,5-a]pyrazin-
-3(2H)-one; [0259]
(R)-6-(2-(4-(2-hydroxyacetyl)-2-methylpiperazin-1-yl)pyrimidin-5-yl)-2-me-
thyl-1-((6-methyl-3-(trifluoromethyl)pyridin-2-yl)methyl)-1H-indazol-3(2H)-
-one; [0260]
(R)-7-(5-(2-methyl-1-((6-methyl-3-(trifluoromethyl)pyridin-2-yl)methyl)-3-
-oxo-2,3-dihydro-1H-indazol-6-yl)pyrimidin-2-yl)tetrahydro-1H-oxazolo[3,4--
a]pyrazin-3(5H)-one; [0261]
(R)-6-(2-(4-acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-1-((1-acetyl-4--
(trifluoromethyl)-1H-pyrrol-3-yl)methyl)-2-methyl-1H-indazol-3(2H)-one;
[0262]
(R)-1-(2-(difluoromethoxy)-5-methylbenzyl)-6-(3-(1-hydroxyethyl)im-
idazo[1,2-b]pyridazin-7-yl)-2-methyl-1H-indazol-3(2H)-one; [0263]
(R)-2-(6-((6-(2-(4-acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-
-3-oxo-2,3-dihydro-1H-indazol-1-yl)methyl)-5-(trifluoromethyl)pyridin-2-yl-
)acetonitrile; [0264]
(R)-1-(2-(difluoromethoxy)benzyl)-6-(2-(4-(2-hydroxyacetyl)-3-methylpiper-
azin-1-yl)pyrimidin-5-yl)-2-methyl-3-oxo-2,3-dihydro-1H-indazole-7-carboni-
trile; [0265]
1-(2-(difluoromethoxy)-5-methylbenzyl)-5-fluoro-6-(2-(2-hydroxypropan-2-y-
l)-4-methylpyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one; [0266]
(R)-4-((R)-4-(5-(1-(2-(difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-
-1H-indazol-6-yl)pyrimidin-2-yl)-2-methylpiperazin-1-yl)-3-hydroxy-4-oxobu-
tanoic acid; [0267]
1-(2-(difluoromethoxy)benzyl)-6-(2-((2R,4R)-4-hydroxy-2-methylpiperidin-1-
-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one; [0268]
6-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-1-((1-((4-methoxy-1H-pyrazol-3-
-yl)methyl)-4-(trifluoromethyl)-1H-pyrrol-3-yl)methyl)-2-methyl-1H-indazol-
-3(2H)-one; [0269]
(R)-2-(4-(difluoromethoxy)-3-((6-(2-(4-(2-hydroxyacetyl)-2-methylpiperazi-
n-1-yl)pyrimidin-5-yl)-2-methyl-3-oxo-2,3-dihydro-1H-indazol-1-yl)methyl)p-
henyl)acetonitrile; [0270]
(R)-2-(2-((6-(2-(4-acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-
-3-oxo-2,3-dihydro-1H-indazol-1-yl)methyl)-3-(difluoromethoxy)phenyl)aceto-
nitrile; [0271]
(R)-2-((R)-4-(5-(1-(2-(difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-
-1H-indazol-6-yl)pyrimidin-2-yl)-2-methylpiperazin-1-yl)-2-oxoethyl
2-amino-3-methylbutanoate; [0272]
1-(2-(difluoromethoxy)-5-(hydroxymethyl)benzyl)-2-methyl-6-(2-((1-methyl--
2-oxopiperidin-4-yl)amino)pyrimidin-5-yl)-1H-indazol-3(2H)-one;
[0273]
6-(2-(4-acetylpiperazin-1-yl)pyrimidin-5-yl)-1-(2-(difluoromethoxy)-5-met-
hylbenzyl)-2-methyl-1H-indazol-3(2H)-one; [0274]
1-(2,5-dimethylbenzyl)-2-methyl-6-(2-morpholinopyrimidin-5-yl)-1H-indazol-
-3(2H)-one; [0275]
(R)-1-(2-(difluoromethoxy)benzyl)-6-(2-(4-(2-hydroxyacetyl)-3-methylpiper-
azin-1-yl)pyrimidin-5-yl)-2,7-dimethyl-1H-indazol-3(2H)-one; [0276]
1-(2-(difluoromethoxy)-5-(hydroxymethyl)benzyl)-6-(2-(2-hydroxypropan-2-y-
l)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one; [0277]
(S)-7-(5-(2-methyl-1-((6-methyl-3-(trifluoromethyl)pyridin-2-yl)methyl)-3-
-oxo-2,3-dihydro-1H-indazol-6-yl)pyrimidin-2-yl)hexahydroimidazo[1,5-a]pyr-
azin-3(2H)-one; [0278]
(R)-6-(2-(4-acetyl-2-methylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-1-((6--
methyl-3-(trifluoromethyl)pyridin-2-yl)methyl)-1H-indazol-3(2H)-one;
[0279]
6-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-2-methyl-1-((1-(pyridin-
-3-ylmethyl)-4-(trifluoromethyl)-1H-pyrrol-3-yl)methyl)-1H-indazol-3(2H)-o-
ne; [0280]
6-(2-(4-(3-amino-2-hydroxypropanoyl)-3-methylpiperazin-1-yl)pyr-
imidin-5-yl)-1-(2-(difluoromethoxy)benzyl)-2-methyl-1H-indazol-3(2H)-one
dihydrochloride; [0281]
1-(2-(difluoromethoxy)-5-methylbenzyl)-5-fluoro-6-(2-(1-hydroxy-2-methylp-
ropan-2-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one; [0282]
(R)-1-(2-chloro-5-methylbenzyl)-6-(2-(4-(2-hydroxyacetyl)-2-methylpiperaz-
in-1-yl)pyrimidin-5-yl)-2-methyl-1H-pyrazolo[3,4-b]pyridin-3(2H)-one;
[0283]
1-(2-(difluoromethoxy)-5-methylbenzyl)-6-(3-(1-hydroxyethyl)imidaz-
o[1,2-b]pyridazin-7-yl)-2-methyl-1H-indazol-3(2H)-one; [0284]
6-(2-(2-aminopropan-2-yl)pyrimidin-5-yl)-1-(2-(difluoromethoxy)-5-methylb-
enzyl)-2-methyl-1H-indazol-3(2H)-one; [0285] (1
S,3S)-3-(4-(difluoromethoxy)-3-((6-(2-(2-hydroxypropan-2-yl)pyrimidin-5-y-
l)-2-methyl-3-oxo-2,3-dihydro-1H-indazol-1-yl)methyl)phenyl)cyclopentaneca-
rbonitrile; [0286]
(S)-1-(2-(difluoromethoxy)-5-methylbenzyl)-6-(3-(1-hydroxyethyl)imidazo[1-
,2-b]pyridazin-7-yl)-2-methyl-1H-indazol-3(2H)-one; [0287]
(S)-7-(5-(1-(5-chloro-2-(trifluoromethyl)benzyl)-2-methyl-3-oxo-2,3-dihyd-
ro-1H-indazol-6-yl)pyrimidin-2-yl)hexahydroimidazo[1,5-a]pyrazin-3(2H)-one-
; [0288]
(R)-6-(2-(4-acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-1-((3-c-
hloro-6-methylpyridin-2-yl)methyl)-2-methyl-1H-indazol-3(2H)-one;
[0289]
(R)-7-(5-(1-(2-(difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-1H-ind-
azol-6-yl)pyrimidin-2-yl)-2-methylhexahydroimidazo[1,5-a]pyrazin-3(2H)-one-
; [0290]
(S)-7-(5-(2-methyl-1-((1-methyl-4-(trifluoromethyl)-1H-pyrrol-3-y-
l)methyl)-3-oxo-2,3-dihydro-1H-indazol-6-yl)pyrimidin-2-yl)hexahydroimidaz-
o[1,5-a]pyrazin-3(2H)-one; [0291]
(R)-1-(2-chlorobenzyl)-6-(2-(4-(2-hydroxyacetyl)-3-methylpiperazin-1-yl)p-
yrimidin-5-yl)-2-methyl-1H-pyrazolo[3,4-b]pyridin-3(2H)-one; [0292]
(S)-1-(2-(difluoromethoxy)-5-(hydroxymethyl)benzyl)-2-methyl-6-(2-((2-oxo-
piperidin-4-yl)amino)pyrimidin-5-yl)-1H-indazol-3(2H)-one; [0293]
1-(2-(difluoromethoxy)benzyl)-2-methyl-6-(2-((tetrahydro-2H-pyran-4-yl)ox-
y)pyridin-4-yl)-1H-indazol-3(2H)-one; [0294]
6-(2-((R)-4-(2-hydroxyacetyl)-3-methylpiperazin-1-yl)pyrimidin-5-yl)-2-me-
thyl-1-(1-phenylethyl)-1H-indazol-3(2H)-one; [0295]
1-(1-(2-fluorophenyl)ethyl)-6-(2-((R)-4-(2-hydroxyacetyl)-3-methylpiperaz-
in-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one; [0296]
(R)-1-((3-(difluoromethoxy)-6-methylpyridin-2-yl)methyl)-6-(2-(4-(2-hydro-
xyacetyl)-3-methylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-
-one; [0297]
(R)-6-(2-(4-acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-1-((1-(2-hydrox-
yethyl)-4-(trifluoromethyl)-1H-pyrrol-3-yl)methyl)-2-methyl-1H-indazol-3(2-
H)-one; [0298]
1-(5-((1H-1,2,4-triazol-1-yl)methyl)-2-(difluoromethoxy)benzyl)-6-(2-(2-h-
ydroxypropan-2-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one;
[0299]
1-(2-(difluoromethoxy)-5-methylbenzyl)-6-(2-(4-hydroxypiperidin-1-yl)pyri-
midin-5-yl)-2-methyl-1H-indazol-3(2H)-one; [0300]
1-(2-(difluoromethoxy)-5-methylbenzyl)-6-(2-isopropylpyrimidin-5-yl)-2-me-
thyl-1H-indazol-3(2H)-one; [0301]
(R)-1-(2-chlorobenzyl)-6-(2-(4-(2-hydroxyacetyl)-3-methylpiperazin-1-yl)p-
yrimidin-5-yl)-2,7-dimethyl-1H-indazol-3(2H)-one; [0302]
6-(6-(2-aminopropan-2-yl)pyridin-3-yl)-1-(2-(difluoromethoxy)-5-methylben-
zyl)-5-fluoro-2-methyl-1H-indazol-3(2H)-one; [0303]
(S)-4-(difluoromethoxy)-3-((2-methyl-3-oxo-6-(2-((S)-3-oxotetrahydro-1H-o-
xazolo[3,4-a]pyrazin-7(3H)-yl)pyrimidin-5-yl)-2,3-dihydro-1H-indazol-1-yl)-
methyl)benzyl 2-aminopropanoate; [0304]
1-(2-(difluoromethoxy)benzyl)-6-(2-((2R,4S)-4-hydroxy-2-methylpiperidin-1-
-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one; [0305]
(R)-4-(difluoromethoxy)-3-((2-methyl-3-oxo-6-(2-(3-oxohexahydroimidazo[1,-
5-a]pyrazin-7(1H)-yl)pyrimidin-5-yl)-2,3-dihydro-1H-indazol-1-yl)methyl)be-
nzyl dimethylcarbamate; [0306]
(S)-6-(2-(4-(2-aminoacetyl)-3-methylpiperazin-1-yl)pyrimidin-5-yl)-1-(2-(-
difluoromethoxy)-5-methylbenzyl)-2-methyl-1H-indazol-3(2H)-one
hydrochloride; [0307]
(R)-7-(5-(1-((6-(hydroxymethyl)-3-(trifluoromethyl)pyridin-2-yl)methyl)-2-
-methyl-3-oxo-2,3-dihydro-1H-indazol-6-yl)pyrimidin-2-yl)hexahydroimidazo[-
1,5-a]pyrazin-3(2H)-one; [0308]
(S)-7-(5-(1-((5-chloro-1,3-dihydroisobenzofuran-4-yl)methyl)-2-methyl-3-o-
xo-2,3-dihydro-1H-indazol-6-yl)pyrimidin-2-yl)hexahydroimidazo[1,5-a]pyraz-
in-3(2H)-one; [0309]
1-(2-(difluoromethoxy)-5-methylbenzyl)-7-fluoro-6-(2-(2-hydroxypropan-2-y-
l)-4-methylpyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one; [0310]
1-(2-(difluoromethoxy)-5-methylbenzyl)-5-fluoro-6-(2-(2-hydroxypropan-2-y-
l)-4-methylpyrimidin-5-yl)-2-methyl-1H-pyrazolo[3,4-b]pyridin-3(2H)-one;
[0311]
1-(2-chloro-5-methylbenzyl)-6-(2-(2-hydroxypropan-2-yl)-4-methylpy-
rimidin-5-yl)-2-methyl-1H-pyrazolo[3,4-b]pyridin-3(2H)-one; [0312]
(R)-1-(2-(difluoromethoxy)benzyl)-2-(difluoromethyl)-6-(2-(4-(2-hydroxyac-
etyl)-3-methylpiperazin-1-yl)pyrimidin-5-yl)-1H-indazol-3(2H)-one;
[0313]
1-(2-(difluoromethoxy)benzyl)-6-(2-(4-(2-hydroxyacetyl)piperazin-1-yl)pyr-
imidin-5-yl)-2-methyl-1H-indazol-3(2H)-one; [0314]
6-(2-((S)-4-((S)-2-aminopropanoyl)-3-methylpiperazin-1-yl)pyrimidin-5-yl)-
-1-(2-(difluoromethoxy)-5-methylbenzyl)-2-methyl-1H-indazol-3(2H)-one;
[0315]
(S)-4-((R)-4-(5-(1-(2-(difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3--
dihydro-1H-indazol-6-yl)pyrimidin-2-yl)-2-methylpiperazin-1-yl)-3-hydroxy--
4-oxobutanoic acid; [0316]
(S)-6-(2-(4-acetyl-3-(hydroxymethyl)piperazin-1-yl)pyrimidin-5-yl)-1-(2-(-
difluoromethoxy)-5-methylbenzyl)-2-methyl-1H-indazol-3(2H)-one;
[0317]
(R)-6-(2-(4-acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-1-((3-(difluoro-
methoxy)-6-methylpyridin-2-yl)methyl)-2-methyl-1H-indazol-3(2H)-one;
[0318]
6-(2-(4-acetylpiperazin-1-yl)pyrimidin-5-yl)-1-(5-(hydroxymethyl)--
2-(trifluoromethyl)benzyl)-2-methyl-1H-indazol-3(2H)-one; [0319]
(R)-1-(2-chlorobenzyl)-6-(2-(4-(2-hydroxyacetyl)-3-methylpiperazin-1-yl)p-
yrimidin-5-yl)-7-methoxy-2-methyl-1H-indazol-3(2H)-one; [0320]
(R)-6-(2-(4-acetyl-3-(hydroxymethyl)piperazin-1-yl)pyrimidin-5-yl)-1-(2-(-
difluoromethoxy)-5-methylbenzyl)-2-methyl-1H-indazol-3(2H)-one;
[0321]
(R)-1-(2-(difluoromethoxy)-5-methylbenzyl)-6-(2-(4-(2-hydroxyacetyl)-2-me-
thylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-1H-pyrazolo[3,4-b]pyridin-3(2H-
)-one; [0322]
(S)-4-(difluoromethoxy)-3-((2-methyl-3-oxo-6-(2-((R)-3-oxohexahydroimidaz-
o[1,5-a]pyrazin-7(1H)-yl)pyrimidin-5-yl)-2,3-dihydro-1H-indazol-1-yl)methy-
l)benzyl 2-amino-3-methylbutanoate hydrochloride; [0323]
(S)-7-(5-(1-((3-(difluoromethoxy)-6-methylpyridin-2-yl)methyl)-2-methyl-3-
-oxo-2,3-dihydro-1H-indazol-6-yl)pyrimidin-2-yl)hexahydroimidazo[1,5-a]pyr-
azin-3(2H)-one; [0324]
(R)-9-((6-(2-(4-acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-3--
oxo-2,3-dihydro-1H-indazol-1-yl)methyl)-4,5-dihydrobenzo[f][1,4]thiazepin--
3(2H)-one; [0325]
1-(2-(difluoromethoxy)benzyl)-5-fluoro-6-(2-(2-hydroxypropan-2-yl)pyrimid-
in-5-yl)-2-methyl-1H-indazol-3(2H)-one; [0326]
6-(2-((R)-4-acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-1-(2-(difluorom-
ethoxy)-5-(2-hydroxypropyl)benzyl)-2-methyl-1H-indazol-3(2H)-one;
[0327]
1-(2-(difluoromethoxy)-5-methylbenzyl)-5-fluoro-6-(2-(2-hydroxypropan-2-y-
l)pyrimidin-5-yl)-2-methyl-1H-pyrazolo[3,4-b]pyridin-3(2H)-one;
[0328]
(R)-1-(2-(difluoromethoxy)benzyl)-6-(2-(4-(2-hydroxyacetyl)-3-methylpiper-
azin-1-yl)pyrimidin-5-yl)-5-methoxy-2-methyl-1H-indazol-3(2H)-one;
[0329]
(R)-1-(2-(difluoromethoxy)-5-methylbenzyl)-2-methyl-6-(2-(3-methylpiperaz-
in-1-yl)pyrimidin-5-yl)-1H-indazol-3(2H)-one; [0330]
1-(5-(1-(2-(difluoromethoxy)-5-methylbenzyl)-2-methyl-3-oxo-2,3-dihydro-1-
H-indazol-6-yl)pyrimidin-2-yl)pyrrolidine-3-carboxamide; [0331]
1-(2-(difluoromethoxy)-5-methylbenzyl)-6-(2-(2-hydroxypropan-2-yl)-4-meth-
ylpyrimidin-5-yl)-2-methyl-1H-pyrazolo[3,4-b]pyridin-3(2H)-one;
[0332]
1-(2-(difluoromethoxy)-5-methylbenzyl)-2-methyl-6-(2-((3aS,6aS)-4-oxohexa-
hydropyrrolo[3,4-c]pyrrol-2(1H)-yl)pyrimidin-5-yl)-1H-indazol-3(2H)-one;
[0333]
(R)-6-(2-(4-acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-1-(2-(di-
fluoromethoxy)-5-((3-methyl-2-oxoimidazolidin-1-yl)methyl)benzyl)-2-methyl-
-1H-indazol-3(2H)-one; [0334]
1-(2-(difluoromethoxy)-5-(hydroxymethyl)benzyl)-2-methyl-6-(2-((2-oxopyrr-
olidin-3-yl)amino)pyrimidin-5-yl)-1H-indazol-3(2H)-one; [0335]
2-(4-(difluoromethoxy)-3-((5-fluoro-6-(2-(2-hydroxypropan-2-yl)pyrimidin--
5-yl)-2-methyl-3-oxo-2,3-dihydro-1H-indazol-1-yl)methyl)phenyl)acetonitril-
e; [0336]
1-(5-((4H-1,2,4-triazol-4-yl)methyl)-2-(difluoromethoxy)benzyl)--
5-fluoro-6-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(-
2H)-one; [0337]
1-(2-(difluoromethoxy)-5-methylbenzyl)-6-(2-(1-hydroxy-2-methylpropan-2-y-
l)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one; [0338]
1-(2-(difluoromethoxy)-5-(hydroxymethyl)benzyl)-2-methyl-6-(4-((1-methyl--
2-oxopyrrolidin-3-yl)amino)phenyl)-1H-indazol-3(2H)-one; [0339]
(S)-1-(2-(difluoromethoxy)-5-(hydroxymethyl)benzyl)-2-methyl-6-(2-((1-met-
hyl-2-oxopiperidin-4-yl)amino)pyrimidin-5-yl)-1H-indazol-3(2H)-one;
[0340]
6-(2-((R)-4-(2-hydroxyacetyl)-3-methylpiperazin-1-yl)pyrimidin-5-yl)-2-me-
thyl-1-(1-(6-methylpyridin-2-yl)ethyl)-1H-indazol-3(2H)-one; [0341]
1-(2-(difluoromethoxy)benzyl)-2-methyl-6-(2-((tetrahydro-2H-pyran-3-yl)ox-
y)pyridin-4-yl)-1H-indazol-3(2H)-one; [0342]
1-(2-(difluoromethoxy)-5-methylbenzyl)-7-fluoro-6-(2-(2-hydroxypropan-2-y-
l)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one; [0343]
6-(2-((R)-4-(2-hydroxyacetyl)-3-methylpiperazin-1-yl)pyrimidin-5-yl)-2-me-
thyl-1-(1-(4-methylpyridin-2-yl)ethyl)-1H-indazol-3(2H)-one; [0344]
1-(2-chloro-5-((1-methyl-2-oxopiperidin-3-yl)amino)benzyl)-6-(2-(2-hydrox-
ypropan-2-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one; [0345]
(R)--N-(3-((6-(2-(4-acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-2-methy-
l-3-oxo-2,3-dihydro-1H-indazol-1-yl)methyl)-4-(difluoromethoxy)benzyl)acet-
amide; [0346]
(R)-6-(2-(4-acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-1-(2-chlorobenz-
yl)-2-(pyridin-4-ylmethyl)-1H-indazol-3(2H)-one; [0347]
(S)-4-(difluoromethoxy)-3-((2-methyl-3-oxo-6-(2-((S)-3-oxotetrahydro-1H-o-
xazolo[3,4-a]pyrazin-7(3H)-yl)pyrimidin-5-yl)-2,3-dihydro-1H-indazol-1-yl)-
methyl)benzyl 2-amino-3-methylbutanoate; [0348]
(R)-1-(2-(difluoromethoxy)-5-methylbenzyl)-6-(2-(2-(hydroxymethyl)pyrroli-
din-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one; [0349]
(S)-1-(2-(difluoromethoxy)-5-methylbenzyl)-6-(2-(2-(hydroxymethyl)pyrroli-
din-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one; [0350]
(S)-7-(5-(2-methyl-1-((5-methyl-2-(trifluoromethyl)pyridin-3-yl)methyl)-3-
-oxo-2,3-dihydro-1H-indazol-6-yl)pyrimidin-2-yl)hexahydroimidazo[1,5-a]pyr-
azin-3(2H)-one; [0351]
(R)-1-(2-(difluoromethoxy)benzyl)-6-(2-(4-(2-hydroxyacetyl)-3-methylpiper-
azin-1-yl)pyrimidin-5-yl)-2-methyl-3-oxo-2,3-dihydro-1-indazole-5-carbonit-
rile; [0352]
(S)-4-methyl-2-((2-methyl-3-oxo-6-(2-(3-oxohexahydroimidazo[1,5-a]pyrazin-
-7(1H)-yl)pyrimidin-5-yl)-2,3-dihydro-1H-indazol-1-yl)methyl)benzonitrile;
[0353]
3-(3-((6-(2-((R)-4-acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-2-
-methyl-3-oxo-2,3-dihydro-1H-indazol-1-yl)methyl)-4-(difluoromethoxy)pheny-
l)-2-methylpropanenitrile; [0354]
2-(4-(difluoromethoxy)-3-((6-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-2-m-
ethyl-3-oxo-2,3-dihydro-1H-indazol-1-yl)methyl)phenyl)acetonitrile;
0 [0355]
(R)-6-(2-(4-acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-1-(2-(di-
fluoromethoxy)-5-((3-oxo-2,3-dihydro-1H-pyrazol-1-yl)methyl)benzyl)-2-meth-
yl-1H-indazol-3(2H)-one; [0356]
1-(1-(2-chlorophenyl)ethyl)-6-(2-((R)-4-(2-hydroxyacetyl)-3-methylpiperaz-
in-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one;
[0357]
(R)-3-((6-(2-(4-acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-1-(2-
-chlorobenzyl)-3-oxo-1H-indazol-2(3H)-yl)methyl)benzonitrile;
[0358]
1-(2-(difluoromethoxy)-6-(methoxymethyl)benzyl)-6-(2-(2-hydroxypropan-2-y-
l)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one; [0359]
1-((R)-1-(2-fluorophenyl)ethyl)-6-(2-((R)-4-(2-hydroxyacetyl)-3-methylpip-
erazin-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one; [0360]
1-(2-chloro-5-((pyridin-3-ylmethyl)amino)benzyl)-6-(2-(2-hydroxypropan-2--
yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one; [0361]
(R)-1-(2-chlorobenzyl)-6-(2-(4-(2-hydroxyacetyl)-3-methylpiperazin-1-yl)p-
yrimidin-5-yl)-2-methyl-3-oxo-2,3-dihydro-1H-indazole-7-carbonitrile;
[0362]
(R)-6-(2-(4-acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-1-(2-(di-
fluoromethoxy)benzyl)-2-(pyridin-4-ylmethyl)-1H-indazol-3(2H)-one;
[0363]
(S)-7-(5-(2-methyl-1-((1-methyl-4-(trifluoromethyl)-1H-pyrazol-3-yl)methy-
l)-3-oxo-2,3-dihydro-1H-indazol-6-yl)pyrimidin-2-yl)hexahydroimidazo[1,5-a-
]pyrazin-3(2H)-one; [0364]
3-(1-(5-(1-(2-(difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-1H-inda-
zol-6-yl)pyrimidin-2-yl)piperidin-4-yl)-1,2,4-thiadiazol-5(4H)-one;
[0365]
1-(2-chloro-5-((1-methyl-2-oxopyrrolidin-3-yl)amino)benzyl)-6-(2-(2-hydro-
xypropan-2-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one; [0366]
1-(2-chloro-5-((pyridin-2-ylmethyl)amino)benzyl)-6-(2-(2-hydroxypropan-2--
yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one; [0367] methyl
4-(difluoromethoxy)-3-((6-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-2-meth-
yl-3-oxo-2,3-dihydro-1H-indazol-1-yl)methyl)benzylcarbamate; [0368]
(S)-7-(5-(2-methyl-3-oxo-1-((2-(trifluoromethyl)pyridin-3-yl)methyl)-2,3--
dihydro-1H-indazol-6-yl)pyrimidin-2-yl)hexahydroimidazo[1,5-a]pyrazin-3(2H-
)-one; [0369]
1-(5-(hydroxymethyl)-2-methylbenzyl)-2-methyl-6-(2-morpholinopyrimidin-5--
yl)-1H-indazol-3(2H)-one; [0370]
1-(5-(((1H-pyrazol-3-yl)methyl)amino)-2-chlorobenzyl)-6-(2-(2-hydroxyprop-
an-2-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one; [0371]
6-(2-(4-acetylpiperazin-1-yl)pyrimidin-5-yl)-1-(2-(difluoromethoxy)-5-(me-
thoxymethyl)benzyl)-2-methyl-1H-indazol-3(2H)-one; [0372]
(R)--N-(3-((6-(2-(4-acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-2-methy-
l-3-oxo-2,3-dihydro-1H-indazol-1-yl)methyl)-4-(difluoromethoxy)benzyl)-N-e-
thylacetamide; [0373]
1-((1-((4-ethylpyridin-3-yl)methyl)-4-(trifluoromethyl)-1H-pyrrol-3-yl)me-
thyl)-6-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-
-one; [0374]
1-(2-(difluoromethoxy)benzyl)-6-(2-(dimethylamino)pyrimidin-5-yl)-2-methy-
l-1H-indazol-3(2H)-one; [0375]
6-(2-(1-acetyl-4-hydroxypiperidin-4-yl)pyrimidin-5-yl)-1-(2-(difluorometh-
oxy)benzyl)-2-methyl-1H-indazol-3(2H)-one; [0376]
1-(5-((1-acetylazetidin-3-yl)methyl)-2-(difluoromethoxy)benzyl)-5-fluoro--
6-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one;
[0377]
1-(2-(difluoromethoxy)-5-((5-oxo-1H-1,2,4-triazol-4(5H)-yl)methyl)-
benzyl)-6-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2-
H)-one; [0378]
6-(2-((R)-4-(2-hydroxyacetyl)-3-methylpiperazin-1-yl)pyrimidin-5-yl)-2-me-
thyl-1-((R)-1-(m-tolyl)ethyl)-1H-indazol-3(2H)-one; [0379]
6-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-2-methyl-1-((1-(pyridazin-4-yl-
methyl)-4-(trifluoromethyl)-1H-pyrrol-3-yl)methyl)-1H-indazol-3(2H)-one;
[0380]
1-(2-(difluoromethoxy)-5-methylbenzyl)-2-(difluoromethyl)-6-(2-(2--
hydroxypropan-2-yl)pyrimidin-5-yl)-1H-indazol-3(2H)-one; [0381]
(1R,2S)-2-(4-(difluoromethoxy)-3-((6-(2-(2-hydroxypropan-2-yl)pyrimidin-5-
-yl)-2-methyl-3-oxo-2,3-dihydro-1H-indazol-1-yl)methyl)phenyl)cyclopentane-
carbonitrile; [0382]
(1R,3S)-3-(4-(difluoromethoxy)-3-((6-(2-(2-hydroxypropan-2-yl)pyrimidin-5-
-yl)-2-methyl-3-oxo-2,3-dihydro-1H-indazol-1-yl)methyl)phenyl)cyclopentane-
carbonitrile; [0383]
6-(2-(1-(2-aminoacetyl)-4-hydroxypiperidin-4-yl)pyrimidin-5-yl)-1-(2-(dif-
luoromethoxy)benzyl)-2-methyl-1-indazol-3(2H)-one; [0384]
4-(5-(1-(2-(difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-1H-indazol-
-6-yl)pyrimidin-2-yl)-4-hydroxypiperidine-1-carbaldehyde; [0385]
6-(2-((1-acetylpiperidin-4-yl)oxy)pyridin-4-yl)-1-(2-(difluoromethoxy)ben-
zyl)-2-methyl-1H-indazol-3(2H)-one; [0386]
1-(2-(difluoromethoxy)-5-morpholinobenzyl)-6-(2-(2-hydroxypropan-2-yl)pyr-
imidin-5-yl)-2-methyl-1H-indazol-3(2H)-one; [0387]
1-(2-(difluoromethoxy)benzyl)-6-(2-(3-hydroxy-1-(2-hydroxyacetyl)azetidin-
-3-yl)pyrimidin-5-yl)-2-methyl-1-indazol-3(2H)-one; [0388]
(R)-2-(3-((6-(2-(4-acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-
-3-oxo-2,3-dihydro-1H-indazol-1-yl)methyl)-4-(difluoromethoxy)phenyl)aceto-
nitrile; [0389]
(R)-6-(2-(4-acetyl-2-methylpiperazin-1-yl)-4-methylpyrimidin-5-yl)-1-(2-(-
difluoromethoxy)-5-methylbenzyl)-2-methyl-1H-indazol-3(2H)-one;
[0390]
(R)-1-(2-(difluoromethoxy)benzyl)-5,7-difluoro-6-(2-(4-(2-hydroxyacetyl)--
2-methylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one;
or [0391]
(R)-6-(2-(4-acetyl-2-methylpiperazin-1-yl)-4-methylpyrimidin-5-yl)-
-1-(2-(difluoromethoxy)-5-methylbenzyl)-2-methyl-1H-indazol-3(2H)-one.
[0392] In a twenty-sixth embodiment, the disclosure provides a
pharmaceutical composition comprising a compound according to any
of the foregoing embodiments and one or more pharmaceutically
acceptable excipients.
[0393] In a twenty-seventh embodiment, the disclosure provides a
method of treating a disease comprising administering a
therapeutically effective amount of a compound or pharmaceutical
composition according to any of the foregoing embodiments.
[0394] In a twenty-eighth embodiment, the disclosure provides a
method of the twenty-seventh embodiment, wherein the disease is
rheumatoid arthritis, juvenile rheumatoid arthritis, psoriasis,
psoriatic arthritis, Crohn's disease, inflammatory bowel disease,
ulcerative colitis, psoriatic arthritis, psoriasis, ankylosing
spondylitis, systemic lupus erythematosus, lupus nephritis,
multiple sclerosis, uveitis or hidraenitis suppurativa.
[0395] In a twenty-ninth embodiment, the disclosure provides a kit
comprising a packaged product comprising components with which to
adminster a compound or composition of any of the foregoing
embodiments for the treatment of an autoimmune disorder.
[0396] In a thirtieth embodiment, the disclosure provides a kit
according to the twenty-ninth embodiment, wherein the packaged
product comprises a compound or pharmaceutical composition of any
of the foregoing embodiments and instructions for use.
DETAILED DESCRIPTION OF THE DISCLOSURE
Definitions
[0397] In this disclosure, the following definitions are
applicable:
[0398] A "therapeutically effective amount" is an amount of a
compound of Formula (I) or a combination of two or more such
compounds, which inhibits, totally or partially, the progression of
the condition or alleviates, at least partially, one or more
symptoms of the condition. A therapeutically effective amount can
also be an amount which is prophylactically effective. The amount
which is therapeutically effective will depend upon the patient's
size and gender, the condition to be treated, the severity of the
condition and the result sought. For a given patient, a
therapeutically effective amount can be determined by methods known
to those of skill in the art.
[0399] "Pharmaceutically acceptable salts" refers to those salts
which retain the biological effectiveness and properties of the
free bases and which are obtained by reaction with inorganic acids,
for example, hydrochloric acid, hydrobromic acid, sulfuric acid,
nitric acid, and phosphoric acid or organic acids such as sulfonic
acid, carboxylic acid, organic phosphoric acid, methanesulfonic
acid, ethanesulfonic acid, p-toluenesulfonic acid, citric acid,
fumaric acid, maleic acid, succinic acid, benzoic acid, salicylic
acid, lactic acid, tartaric acid (e.g., (+) or (-)-tartaric acid or
mixtures thereof), amino acids (e.g., (+) or (-)-amino acids or
mixtures thereof), and the like. These salts can be prepared by
methods known to those skilled in the art.
[0400] As used herein the term "pro-drug" refers to an agent which
is converted into the parent drug in vivo by some physiological
chemical process (e.g., a prodrug on being brought to the
physiological pH is converted to the desired drug form). Pro-drugs
are often useful because, in some situations, they may be easier to
administer than the parent drug. They may, for instance, be
bioavailable by oral administration whereas the parent drug is not.
The pro-drug may also have improved solubility in pharmacological
compositions over the parent drug. An example, without limitation,
of a pro-drug would be a compound of the present disclosure wherein
it is administered as an ester (the "pro-drug") to facilitate
transmittal across a cell membrane where water solubility is not
beneficial, but then it is metabolically hydrolyzed to the
carboxylic acid once inside the cell where water solubility is
beneficial.
[0401] The term "heterocycle," "heterocyclic," "heterocyclyl" or
"heterocyclylene," as used herein, include non-aromatic, ring
systems, including, but not limited to, monocyclic, bicyclic,
tricyclic and spirocyclic rings, which can be completely saturated
or which can contain one or more units of unsaturation, for the
avoidance of doubt, the degree of unsaturation does not result in
an aromatic ring system) and have 5 to 12 atoms including at least
one heteroatom, such as nitrogen, oxygen, or sulfur. For purposes
of exemplification, which should not be construed as limiting the
scope of this disclosure, the following are examples of
heterocyclic rings: azepinyl, azetidinyl, indolinyl, isoindolinyl,
morpholinyl, piperazinyl, piperidinyl, pyrrolidinyl, quinucludinyl,
thiomorpholinyl, tetrahydropyranyl, tetrahydrofuranyl,
tetrahydroindolyl, thiomorpholinyl and tropanyl.
[0402] The term "heteroaryl" or "heteroarylene" as used herein,
include aromatic ring systems, including, but not limited to,
monocyclic, bicyclic and tricyclic rings, and have 5 to 12 atoms
including at least one heteroatom, such as nitrogen, oxygen, or
sulfur. For purposes of exemplification, which should not be
construed as limiting the scope of this disclosure: azaindolyl,
benzo(b)thienyl, benzimidazolyl, benzofuranyl, benzoxazolyl,
benzothiazolyl, benzothiadiazolyl, benzoxadiazolyl, furanyl,
imidazolyl, imidazopyridinyl, indolyl, indazolyl, isoxazolyl,
isothiazolyl, oxadiazolyl, oxazolyl, purinyl, pyranyl, pyrazinyl,
pyrazolyl, pyridinyl, pyrimidinyl, pyrrolyl,
pyrrolo[2,3-d]pyrimidinyl, pyrazolo[3,4-d]pyrimidinyl, quinolinyl,
quinazolinyl, triazolyl, thiazolyl, thiophenyl, tetrazolyl,
thiadiazolyl, thienyl,
6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyrazinyl,
6H-imidazo[1,5-a]pyrrolo[2,3-e]pyrazinyl,
1,6-dihydropyrazolo[3,4-d]pyrrolo[2,3-b]pyridine,
3H-3,4,6,8a-tetraaza-asindacenyl,
3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazinyl,
pyrazolo[3,4-d]pyrrolo[2,3-b]pyridinyl,
1,6-dihydro-1,2,5,6-tetraza-as-indacenyl,
3H-3,4,8a-triaza-as-indacenyl, 6H-3-oxa-2,5,6-triaza-as-indacenyl,
3,6-dihydro-2,3,6-tetraaza-as-indacenyl,
1,6-dihydro-dipyrrolo[2,3-b;2'3'-d]pyridinyl,
6H-3-thia-2,5,6-triaza-as-indacenyl,
4,5-dihydro-1H-benzo[b]azepin-2(3H)-one,
3,4-dihydroquinolin-2(1H)-one, 2H-benzo[b][1,4]oxazin-3(4H)-one, or
6,7-dihydro-4H-pyrazolo[5,1-c][1,4]oxazinyl or
1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine.
[0403] As used herein, "alkyl," "alkylene" or notations such as
"(C.sub.1-C.sub.8)" include straight chained or branched
hydrocarbons which are completely saturated. An alkyl is a
monovalent radical while an alkylene is a bivalent radical.
Examples of alkyls are methyl, ethyl, propyl, isopropyl, butyl,
pentyl, hexyl and isomers thereof. Examples of alkylenes include
methylene (--CH.sub.2--), ethylene (--CH.sub.2CH.sub.2--),
propylene (--CH.sub.2CH.sub.2CH.sub.2--), isopropylene
(--CH(CH.sub.3)CH.sub.2--) and the like. As used herein, "alkenyl,"
"alkenylene," "alkynylene" and "alkynyl" means C.sub.2-C.sub.8 and
includes straight chained or branched hydrocarbons which contain
one or more units of unsaturation, one or more double bonds for
alkenyl and one or more triple bonds for alkynyl.
[0404] The term "alkoxy" as used herein, refers to an alkyl group,
as defined herein, appended to the parent molecular moiety through
an oxygen atom. Representative examples of alkoxy include, but are
not limited to, methoxy, ethoxy, propoxy, 2-propoxy, butoxy and
tert-butoxy.
[0405] The term "alkoxyalkyl" as used herein, refers to an alkoxy
group, as defined herein, appended to the parent molecular moiety
through an alkyl group, as defined herein. Representative examples
of alkoxyalkyl include, but are not limited to, methoxymethyl,
methoxyethyl, and methoxypropyl.
[0406] As used herein, "aromatic" groups (or "aryl" or "arylene"
groups) include aromatic carbocyclic ring systems (e.g., phenyl)
and fused polycyclic aromatic ring systems (e.g., naphthyl,
biphenyl and 1,2,3,4-tetrahydronaphthyl).
[0407] As used herein, "cycloalkyl" or "cycloalkylene" means
C.sub.3-C.sub.12 monocyclic or multicyclic (e.g., bicyclic,
tricyclic, spirocyclic, etc.) hydrocarbons that are completely
saturated. Examples of cycloalkyl groups are cyclopropyl,
cyclobutyl, cyclopentyl, bicyclo[1.1.1]pentyl, and cyclohexyl.
[0408] As used herein, "cycloalkenyl" means C.sub.3-C.sub.12
monocyclic or multicyclic (e.g., bicyclic, tricyclic, spirocyclic,
etc.) hydrocarbons that has one or more unsaturated bonds but does
not amount to an aromatic group. Examples of cycloalkenyl groups
are cyclopentenyl and cyclohexenyl.
[0409] As used herein, many moieties or substituents are termed as
being either "substituted" or "optionally substituted." When a
moiety is modified by one of these terms, unless otherwise noted,
it denotes that any portion of the moiety that is known to one
skilled in the art as being available for substitution can be
substituted, which includes one or more substituents, where if more
than one substituent then each substituent is independently
selected. Such means for substitution are well-known in the art
and/or taught by the instant disclosure. For purposes of
exemplification, which should not be construed as limiting the
scope of this disclosure, some examples of groups that are
substituents are: (C.sub.1-C.sub.8)alkyl groups optionally
substituted with --OH, (C.sub.2-C.sub.8)alkenyl groups,
(C.sub.2-C.sub.8)alkynyl groups, (C.sub.3-C.sub.10)cycloalkyl
groups optionally substituted with --CN, halogen (F, Cl, Br or I),
halogenated (C.sub.1-C.sub.8)alkyl groups (for example but not
limited to --CF.sub.3), --O--(C.sub.1-C.sub.8)alkyl groups,
--(C.sub.1-C.sub.6)alkyl-C(O)OH, .dbd.O, .dbd.CH.sub.2, --OH,
--CH.sub.2OH, --CH.sub.2NH.sub.2, (C.sub.1-C.sub.4)alkyl-OH,
--CH.sub.2CH.sub.2OCH.sub.2CH.sub.3, --S--(C.sub.1-C.sub.8)alkyl
groups, --SH, --NH(C.sub.1-C.sub.8)alkyl groups,
--N((C.sub.1-C.sub.8)alkyl).sub.2 groups, --NH.sub.2,
--C(O)NH.sub.2, --C(O)CH.sub.2NH.sub.2, --C(O)CH(CH.sub.3NH.sub.2,
--C(O)CH(OH)CH.sub.2NH.sub.2, --C(O)CH(OH)CH.sub.2C(O)OH,
--C(O)CH.sub.2OC(O)CH(NH.sub.2)(C.sub.1-C.sub.6)alkyl,
--C(O)(C.sub.1-C.sub.6)alkyl(C.sub.1-C.sub.6)alkoxy,
--(C.sub.1-C.sub.6)alkyl(C.sub.1-C.sub.6)alkoxy,
--C(O)(C.sub.1-C.sub.6)alkyl-CN, --(C.sub.1-C.sub.6)alkyl-CN,
--C(O)CH(OH)CH.sub.2OH, --C(O)(C.sub.1-C.sub.6)alkyl-P(O).sub.4,
--CH.sub.2NHC(O)(C.sub.1-C.sub.4)alkyl optionally substituted with
(C.sub.1-C.sub.4)alkyl), --CH.sub.2NHC(O)(C.sub.1-C.sub.4)alkoxy,
--CH.sub.2NHC(O)CH.sub.2Cl, --CH.sub.2NHC(O)CH.sub.2CN,
--CH.sub.2NHC(O)CH.sub.2CH.sub.2N(CH.sub.3).sub.2,
--CH.sub.2OC(O)N(CH.sub.3).sub.2,
--CH.sub.2OC(O)(C.sub.1-C.sub.6)alkyl optionally substituted with
NH.sub.2, --CH.sub.2NHC(O)C(.dbd.CH.sub.2)CH.sub.3,
--CH.sub.2NHC(O)(C.sub.2-C.sub.4)alkynyl,
--CH.sub.2NHC(O)CH.sub.2CH.sub.2-piperidinyl,
--(C.sub.1-C.sub.4)alkyl-morpholinyl,
--CH.sub.2NHC(O)CH.sub.2O-phenyl wherein the phenyl is optionally
substituted with halogen, (C.sub.1-C.sub.4)alkoxy,
--C(O)(C.sub.1-C.sub.4)alkyl, --C(O)(C.sub.1-C.sub.4)alkyl-OH,
--C(O)N(H).sub.2, --C(O)N(CH.sub.3).sub.2,
--C(O)(C.sub.1-C.sub.6)heteroaryl, --N(CH.sub.3).sub.2,
--NHC(O)(C.sub.1-C.sub.4)alkyl, --NHC(O)(C.sub.2-C.sub.4)alkenyl,
--NHC(O)CH.sub.2CN, --S(O).sub.2(C.sub.1-C.sub.4)alkyl,
--S(O).sub.2(C.sub.1-C.sub.6)heteroaryl,
--S(O).sub.2(C.sub.1-C.sub.6) (C.sub.1-C.sub.6)heterocyclyl,
4-methylpiperazinecarbonyl, --(C.sub.1-C.sub.4)alkyl-C(O)NH.sub.2,
--C(O)NH(C.sub.1-C.sub.8)alkyl groups,
--C(O)N((C.sub.1-C.sub.8)alkyl).sub.2,
--C(O)N(H)(C.sub.3-C.sub.8)cycloalkyl groups,
--C(O)(C.sub.1-C.sub.4)alkoxy, --NHC(O)H,
--NHC(O)(C.sub.1-C.sub.8)alkyl groups,
--NHC(O)(C.sub.3-C.sub.8)cycloalkyl groups,
--N((C.sub.1-C.sub.8)alkyl)C(O)H,
--N((C.sub.1-C.sub.8)alkyl)C(O)(C.sub.1-C.sub.8)alkyl groups,
--NHC(O)NH.sub.2, --NHC(O)NH(C.sub.1-C.sub.8)alkyl groups,
--N((C.sub.1-C.sub.8)alkyl)C(O)NH.sub.2 groups,
--NHC(O)N((C.sub.1-C.sub.8)alkyl).sub.2 groups,
--N((C.sub.1-C.sub.8)alkyl)C(O)N((C.sub.1-C.sub.8)alkyl).sub.2
groups, --N((C.sub.1-C.sub.8)alkyl)C(O)NH((C.sub.1-C.sub.8)alkyl),
--NH(C.sub.1-C.sub.6)alkyl optionally substituted with --OH,
--NHCH.sub.2-heteroaryl, benzyl, --OCH.sub.2-heteroaryl, --C(O)H,
--C(O)(C.sub.1-C.sub.8)alkyl groups, --CN, --NO.sub.2,
--S(O)(C.sub.1-C.sub.8)alkyl groups,
--S(O).sub.2(C.sub.1-C.sub.8)alkyl groups,
--S(O).sub.2N((C.sub.1-C.sub.8)alkyl).sub.2 groups,
--S(O).sub.2NH(C.sub.1-C.sub.8)alkyl groups,
--S(O).sub.2NH(C.sub.3-C.sub.8)cycloalkyl groups,
--S(O).sub.2NH.sub.2 groups, --NHS(O).sub.2(C.sub.1-C.sub.8)alkyl
groups, --N((C.sub.1-C.sub.8)alkyl)S(O).sub.2(C.sub.1-C.sub.8)alkyl
groups, --(C.sub.1-C.sub.8)alkyl-O--(C.sub.1-C.sub.8)alkyl groups,
--O--(C.sub.1-C.sub.8)alkyl-O--(C.sub.1-C.sub.8)alkyl groups,
--C(O)OH, --C(O)O(C.sub.1-C.sub.8)alkyl groups, NHOH,
NHO(C.sub.1-C.sub.8)alkyl groups, --O-halogenated
(C.sub.1-C.sub.8)alkyl groups (for example but not limited to
--OCF.sub.3), --S(O).sub.2-halogenated (C.sub.1-C.sub.8)alkyl
groups (for example but not limited to --S(O).sub.2CF.sub.3),
--S-halogenated (C.sub.1-C.sub.8)alkyl groups (for example but not
limited to --SCF.sub.3), -(substituted or
unsubstituted)(C.sub.1-C.sub.6)heterocyclyl (for example but not
limited to pyrrolidine, tetrahydrofuran, pyran or morpholine),
--NH-heterocyclyl, --C(O)-(substituted or
unsubstituted)(C.sub.1-C.sub.6)heterocyclyl
--(C.sub.1-C.sub.6)alkyl-(substituted or
unsubstituted)heterocyclyl, -(substituted or
unsubstituted)(C.sub.1-C.sub.6)heteroaryl (for example but not
limited to tetrazole, imidazole, furan, pyrazine or pyrazole),
--(C.sub.1-C.sub.6)alkyl-(substituted or unsubstituted)heteroaryl,
--(C.sub.1-C.sub.6)alkyl-O-(substituted or
unsubstituted)heteroaryl, -phenyl, optionally substituted benzyl,
--NHC(O)O--(C.sub.1-C.sub.6)alkyl groups,
--N((C.sub.1-C.sub.6)alkyl)C(O)O--(C.sub.1-C.sub.6)alkyl groups,
--C(.dbd.NH)--(C.sub.1-C.sub.6)alkyl groups,
--C(.dbd.NOH)--(C.sub.1-C.sub.6)alkyl groups, or
--C(.dbd.N--O--(C.sub.1-C.sub.6)alkyl)-(C.sub.1-C.sub.6)alkyl
groups.
[0410] The term "kit" as used herein refers to a packaged product
comprising components with which to administer a compound of
Formula (I) of the disclosure for treatment of an autoimmune
disorder. The kit preferably comprises a box or container that
holds the components of the kit. The box or container is affixed
with a label or a Food and Drug Administration approved protocol.
The box or container holds components of the disclosure which are
preferably contained within plastic, polyethylene, polypropylene,
ethylene, or propylene vessels. The vessels can be capped-tubes or
bottles. The kit can also include instructions for administering a
compound of Formula (I).
Compounds
[0411] Compounds of this disclosure include compounds of Formula
(I), which include compounds of Formula (Ia), (Ib), (Ic), (Id) and
(Ie) as described herein.
[0412] For example, compounds of the disclosure include compounds
of Formula (I),
##STR00003##
or a pharmaceutically acceptable salt, prodrug or stereoisomer
thereof, wherein
[0413] X, Y and Z are independently CR.sup.4 or N; [0414] provided
that Y and Z are not both N;
[0415] L is a bond, optionally substituted
(C.sub.1-C.sub.3)alkylene or --C(O)--;
[0416] R.sup.1 is H, CD.sub.3, optionally substituted
(C.sub.1-C.sub.3)alkyl or optionally substituted
(C.sub.3-C.sub.6)cycloalkyl;
[0417] R.sup.2 is optionally substituted aryl or optionally
substituted heteroaryl;
[0418] R.sup.3 is --R.sup.3a-R.sup.3b, wherein: [0419] R.sup.3a is
an optionally substituted saturated, unsaturated or partially
saturated heterocyclyl or optionally substituted heteroaryl; [0420]
R.sup.3b is --N(R.sup.a)(R.sup.b), --O(R.sup.a), optionally
substituted (C.sub.1-C.sub.5)alkyl, optionally substituted
(C.sub.3-C.sub.6)cycloalkyl, or --(CH.sub.2).sub.p-optionally
substituted heterocyclyl; wherein [0421] R.sup.a and R.sup.b are
independently selected from H, optionally substituted
(C.sub.1-C.sub.5)alkyl, and --(CH.sub.2).sub.n-optionally
substituted heterocyclyl;
[0422] R.sup.4 is independently H, Cl, CN, F, CF.sub.3, or
optionally substituted (C.sub.1-C.sub.3)alkyl; and
[0423] p is 0, 1 or 2.
[0424] The compound of Formula (I) may be a compound of Formula
(Ia), Formula (Ib), Formula (Ic), Formula (Id) or Formula (Ie):
##STR00004##
[0425] It is to be understood that throughout this disclosure, any
reference to a compound of Formula (I) includes references to
compounds of Formula (Ia), Formula (Ib), Formula (Ic), Formula (Id)
and Formula (Ie).
[0426] In some embodiments, R.sup.1 is optionally substituted
(C.sub.1-C.sub.3)alkyl (e.g., --CH.sub.3) or optionally substituted
cyclopropyl (e.g., unsubstituted cyclopropyl).
[0427] In some embodiments, R.sup.2 is optionally substituted
heteroaryl, or optionally substituted phenyl. For example, in some
embodiments R.sup.2 is unsubstituted phenyl, unsubstituted
pyridinyl, or unsubstituted pyrimidinyl. In some embodiments,
R.sup.2 is phenyl, pyridinyl or pyrimidinyl that is substituted by
one or more substituents (e.g., one substituent or two
substituents) independently selected from halogen (e.g., F or Cl),
CN, haloalkoxy (e.g., --OCHF.sub.2), CF.sub.3, an optionally
substituted (C.sub.1-C.sub.3)alkyl (e.g., --CH.sub.3 or
--CH.sub.2OH).
[0428] In some embodiments, R.sup.3a is optionally substituted
1,2,4-oxadiazolyl, optionally substituted pyrazolyl, optionally
substituted pyridinyl, optionally substituted pyrimidinyl,
optionally substituted pyrazinyl, or optionally substituted
1,2,4-thiadiazolyl. For example, R.sup.3a may be 1,2,4-oxadiazolyl,
pyrazolyl, pyridinyl, pyrimidinyl, pyrazinyl, or
1,2,4-thiadiazolyl. In some embodiments, R.sup.3a may be
substituted 1,2,4-oxadiazolyl, substituted pyrazolyl, substituted
pyridinyl, substituted pyrimidinyl, substituted pyrazinyl, or
substituted 1,2,4-thiadiazolyl; for example, R.sup.3a may be
substituted with one or more substituents (e.g., one substituent or
two substituents) such as halogen (e.g., Cl).
[0429] In some embodiments, R.sup.3b is --N(R.sup.a)(R.sup.b),
--O(R.sup.a), optionally substituted (C.sub.1-C.sub.3)alkyl,
--(CH.sub.2).sub.p-optionally substituted
2-oxa-6-azaspiro[3.3]heptanyl, --(CH.sub.2).sub.p-optionally
substituted 2-azaspiro[3.3]heptanyl, --(CH.sub.2).sub.p-optionally
substituted 5-azaspiro[2.3]hexanyl, --(CH.sub.2).sub.p-optionally
substituted azetidinyl, --(CH.sub.2).sub.p-optionally substituted
morpholinyl, --(CH.sub.2).sub.p-optionally substituted oxetanyl,
--(CH.sub.2).sub.p-optionally substituted piperazinyl,
--(CH.sub.2).sub.p-optionally substituted piperidinyl,
--(CH.sub.2).sub.p-optionally substituted pyrrolidinyl,
--(CH.sub.2).sub.p-optionally substituted tetrahydropyranyl,
--(CH.sub.2).sub.p-optionally substituted
6-oxohexahydropyrrolo[1,2-a]pyrazinyl,
--(CH.sub.2).sub.p-optionally substituted
tetrahydro-1H-oxazolo[3,4-a]pyrazin-3(5H)-one or
--(CH.sub.2).sub.p-optionally substituted
hexahydroimidazo[1,5-a]pyrazin-3(2H)-one; [0430] wherein R.sup.a
and R.sup.b are independently selected from H, optionally
substituted (C.sub.1-C.sub.3)alkyl, --(CH.sub.2).sub.n-oxoazepanyl,
--(CH.sub.2).sub.n-optionally substituted tetrahydrofuranyl,
--(CH.sub.2).sub.n-optionally substituted oxetanyl,
--(CH.sub.2).sub.n-optionally substituted tetrahydropyranyl, and
--(CH.sub.2).sub.n-optionally substituted pyrrolidinyl.
[0431] For example, R.sup.3b may be --N(H)CH.sub.2-optionally
substituted pyrrolidinyl, --O(R.sup.a), --N(H)-optionally
substituted oxetanyl, optionally substituted
(C.sub.1-C.sub.3)alkyl, optionally substituted
2-oxa-6-azaspiro[3.3]heptanyl, optionally substituted
5-azaspiro[2.3]hexanyl, optionally substituted azetidinyl,
optionally substituted morpholinyl, --(CH.sub.2).sub.p-optionally
substituted oxetanyl, optionally substituted piperazinyl,
optionally substituted piperidinyl, --(CH.sub.2).sub.p-optionally
substituted pyrrolidinyl, or optionally substituted
tetrahydropyranyl. In some embodiments, R.sup.3b may be optionally
substituted by one or more substituents independently selected from
halogen, CN, --C(O)OH, --C(O)CH.sub.3, --C(O)NH.sub.2, NH.sub.2,
.dbd.O, --OH, optionally substituted (C.sub.1-C.sub.3)alkyl,
optionally substituted (C.sub.1-C.sub.3)alkoxy and optionally
substituted oxetanyl.
[0432] In some embodiments, L is a bond or optionally substituted
(C.sub.1-C.sub.2)alkylene (e.g., --CH.sub.2--,
--CH.sub.2CH.sub.2--, --CH(CH.sub.3)--, --C(O)--).
[0433] In some embodiments, X is CR.sup.4. In some embodiments, Y
is CR.sup.4. In some embodiments, Z is CR.sup.4.
[0434] Exemplary compounds of Formula (I) include: [0435]
1-(2-(difluoromethoxy)benzyl)-2-methyl-6-(2-(((1-methyl-5-oxopyrrolidin-3-
-yl)methyl)amino)pyrimidin-5-yl)-1H-indazol-3(2H)-one; [0436]
(R)-1-(5-(1-(2-(difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-1H-ind-
azol-6-yl)pyrimidin-2-yl)pyrrolidine-3-carboxylic acid; [0437]
(S)-1-(5-(1-(2-(difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-1H-ind-
azol-6-yl)pyrimidin-2-yl)pyrrolidine-3-carboxylic acid; [0438]
1-((4-chloropyridin-3-yl)methyl)-2-methyl-6-(2-morpholinopyrimidin-5-yl)--
1H-indazol-3(2H)-one; [0439]
(R)-1-(2-(difluoromethoxy)benzyl)-6-(2-(3-hydroxypyrrolidin-1-yl)pyrimidi-
n-5-yl)-2-methyl-1H-indazol-3(2H)-one; [0440]
2-(5-(1-(2-(difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-1H-indazol-
-6-yl)pyrimidin-2-yl)-2-azaspiro[3.3]heptane-6-carboxylic acid;
[0441]
5-(5-(1-(2-(difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-1H-indazol-
-6-yl)pyrimidin-2-yl)-5-azaspiro[2.3]hexane-1-carboxylic acid;
[0442]
1-(2-(difluoromethoxy)benzyl)-2-ethyl-6-(2-morpholinopyrimidin-5-yl)-1H-i-
ndazol-3(2H)-one; [0443]
1-(2-(difluoromethoxy)-5-fluorobenzyl)-2-methyl-6-(2-morpholinopyrimidin--
5-yl)-1H-indazol-3(2H)-one; [0444]
6-(2-(2-oxa-6-azaspiro[3.3]heptan-6-yl)pyrimidin-5-yl)-1-(2-(difluorometh-
oxy)benzyl)-2-methyl-1H-indazol-3(2H)-one; [0445]
1-(5-(I-(2-(difluoromethoxy)benzyl)-2,5-dimethyl-3-oxo-2,3-dihydro-1H-ind-
azol-6-yl)pyrimidin-2-yl)piperidine-4-carboxylic acid; [0446]
1-(2-(difluoromethoxy)benzyl)-2,5-dimethyl-6-(2-morpholinopyrimidin-5-yl)-
-1H-indazol-3(2H)-one; [0447]
1-(2-(difluoromethoxy)benzyl)-2,5-dimethyl-6-(2-(3-oxopiperazin-1-yl)pyri-
midin-5-yl)-1H-indazol-3(2H)-one; [0448]
1-((3,6-dichloropyridin-2-yl)methyl)-2-methyl-6-(2-morpholinopyrimidin-5--
yl)-1H-indazol-3(2H)-one; [0449]
6-(2-((1-acetylpyrrolidin-3-yl)amino)pyrimidin-5-yl)-1-(2-(difluoromethox-
y)benzyl)-2-methyl-1H-indazol-3(2H)-one; [0450]
1-(5-(1-(2-(difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-1H-indazol-
-6-yl)pyrimidin-2-yl)azetidine-3-carboxylic acid; [0451]
1-(2-(difluoromethoxy)benzyl)-6-(2-(2,2-dimethylmorpholino)pyrimidin-5-yl-
)-2-methyl-1H-indazol-3(2H)-one; [0452]
1-(2-(difluoromethoxy)benzyl)-6-(2-(3-(hydroxymethyl)azetidin-1-yl)pyrimi-
din-5-yl)-2-methyl-1H-indazol-3(2H)-one; [0453]
1-(2-(difluoromethoxy)benzyl)-6-(2-(3-hydroxyazetidin-1-yl)pyrimidin-5-yl-
)-2-methyl-1H-indazol-3(2H)-one; [0454]
1-(5-(1-(2,5-dichlorobenzyl)-2-methyl-3-oxo-2,3-dihydro-1H-indazol-6-yl)p-
yrimidin-2-yl)piperidine-4-carboxylic acid; [0455]
6-(5-chloro-2-morpholinopyridin-4-yl)-1-(2-(difluoromethoxy)benzyl)-2-met-
hyl-1H-indazol-3(2H)-one; [0456]
1-(2-(difluoromethoxy)benzyl)-2-methyl-6-(2-(oxetan-3-ylamino)pyrimidin-5-
-yl)-1H-indazol-3(2H)-one; [0457]
1-benzoyl-2-methyl-6-(2-morpholinopyrimidin-5-yl)-1H-indazol-3(2H)-one;
[0458]
6-(5-chloro-2-morpholinopyridin-4-yl)-1-(3-fluorobenzyl)-2-methyl--
1H-indazol-3(2H)-one; [0459]
1-(2-(difluoromethoxy)benzoyl)-2-methyl-6-(2-morpholinopyrimidin-5-yl)-1H-
-indazol-3(2H)-one; [0460]
1-(2-(difluoromethoxy)benzyl)-6-(2-((2-hydroxyethyl)amino)pyrimidin-5-yl)-
-2-methyl-1H-indazol-3(2H)-one; [0461]
2-(1-(5-(1-(2-(difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-1H-inda-
zol-6-yl)pyrimidin-2-yl)azetidin-3-yl)acetic acid; [0462]
1-(2-(difluoromethoxy)benzyl)-2-methyl-6-(1-(tetrahydro-2H-pyran-4-yl)-1H-
-pyrazol-4-yl)-1H-indazol-3(2H)-one; [0463]
1-(2-(difluoromethoxy)benzyl)-2-methyl-6-(2-morpholinopyridin-4-yl)-1H-in-
dazol-3(2H)-one; [0464]
1-(3-fluorobenzyl)-2-methyl-6-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4--
yl)-1H-indazol-3(2H)-one; [0465]
1-(3-fluorobenzyl)-2-methyl-6-(2-morpholinopyridin-4-yl)-1H-indazol-3(2H)-
-one; [0466]
1-(2-(difluoromethoxy)-6-fluorobenzyl)-2-methyl-6-(2-morpholinopyrimidin--
5-yl)-1H-indazol-3(2H)-one; [0467]
1-(1-(2-(difluoromethoxy)phenyl)ethyl)-2-methyl-6-(2-morpholinopyrimidin--
5-yl)-1H-indazol-3(2H)-one; [0468]
2-methyl-6-(2-morpholinopyrimidin-5-yl)-1-phenethyl-1H-indazol-3(2H)-one;
[0469]
2-methyl-1-(2-methylbenzyl)-6-(2-morpholinopyrimidin-5-yl)-1H-inda-
zol-3(2H)-one; [0470]
1-(2,6-dichlorobenzyl)-2-methyl-6-(2-morpholinopyrimidin-5-yl)-1H-indazol-
-3(2H)-one; [0471]
1-(3-(difluoromethoxy)benzyl)-2-methyl-6-(2-morpholinopyrimidin-5-yl)-1H--
indazol-3(2H)-one; [0472]
1-(3-fluorobenzyl)-2-methyl-6-(2-morpholinopyrimidin-5-yl)-1H-indazol-3(2-
H)-one; [0473]
1-(2-fluorophenethyl)-2-methyl-6-(2-morpholinopyrimidin-5-yl)-1H-indazol--
3(2H)-one; [0474]
1-(2-fluorobenzyl)-2-methyl-6-(2-morpholinopyrimidin-5-yl)-1H-indazol-3(2-
H)-one; [0475]
2-((2-methyl-6-(2-morpholinopyrimidin-5-yl)-3-oxo-2,3-dihydro-1H-indazol--
1-yl)methyl)benzonitrile; [0476]
2-methyl-1-(3-methylbenzyl)-6-(2-morpholinopyrimidin-5-yl)-1H-indazol-3(2-
H)-one; [0477]
1-(4-fluorobenzyl)-2-methyl-6-(2-morpholinopyrimidin-5-yl)-1H-indazol-3(2-
H)-one; [0478]
1-benzyl-2-methyl-6-(2-morpholinopyrimidin-5-yl)-1H-indazol-3(2H)-one;
[0479]
1-(2,6-dichlorobenzyl)-2-methyl-6-(2-(3-oxopiperazin-1-yl)pyrimidi-
n-5-yl)-1H-indazol-3(2H)-one; [0480]
1-(5-(1-(2-(difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-1H-indazol-
-6-yl)pyrimidin-2-yl)piperidine-4-carboxylic acid; [0481]
1-(2-(difluoromethoxy)benzyl)-6-(2-methoxypyrimidin-5-yl)-2-methyl-1H-ind-
azol-3(2H)-one; [0482]
1-(2-(difluoromethoxy)benzyl)-2-methyl-6-(2-(3-oxopiperazin-1-yl)pyrimidi-
n-5-yl)-1H-indazol-3(2H)-one; [0483]
1-(2-(difluoromethoxy)benzyl)-6-(2-morpholinopyrimidin-5-yl)-1H-indazol-3-
(2H)-one; [0484]
1-(2,5-dichlorobenzyl)-2-methyl-6-(2-(piperazin-1-yl)pyrimidin-5-yl)-1H-i-
ndazol-3(2H)-one; [0485]
1-(2,5-dichlorobenzyl)-2-methyl-6-(2-morpholinopyrimidin-5-yl)-1H-indazol-
-3(2H)-one; [0486]
1-(2-(difluoromethoxy)benzyl)-2-methyl-6-(2-morpholinopyrimidin-5-yl)-1H--
indazol-3(2H)-one; [0487]
1-(2-(difluoromethoxy)benzyl)-2-methyl-6-(6-(3-oxopiperazin-1-yl)pyridin--
3-yl)-1H-indazol-3(2H)-one; [0488]
1-(2-(difluoromethoxy)benzyl)-2-methyl-6-(6-(piperazin-1-yl)pyridin-3-yl)-
-1H-indazol-3(2H)-one; [0489]
1-(2-(difluoromethoxy)benzyl)-2-methyl-6-(6-morpholinopyridin-3-yl)-1H-in-
dazol-3(2H)-one; [0490]
1-(2-(difluoromethoxy)benzyl)-6-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)--
2-methyl-1H-indazol-3(2H)-one; [0491]
1-(2-(difluoromethoxy)benzyl)-2-methyl-6-(2-(3-(oxetan-3-yl)azetidin-1-yl-
)pyrimidin-5-yl)-1H-indazol-3(2H)-one; [0492]
2-((5-(1-(2-(difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-1H-indazo-
l-6-yl)pyrimidin-2-yl)amino)propanamide; [0493]
1-(2-(difluoromethoxy)benzyl)-2-methyl-6-(5-morpholinopyrazin-2-yl)-1H-in-
dazol-3(2H)-one; [0494]
1-((5-(1-(2-(difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-1H-indazo-
l-6-yl)pyrimidin-2-yl)methyl)azetidine-3-carboxylic acid; [0495]
1-(2-(difluoromethoxy)benzyl)-2-methyl-6-(2-(((5-oxopyrrolidin-3-yl)methy-
l)amino)pyrimidin-5-yl)-1H-indazol-3(2H)-one; [0496]
1-((3-chloropyridin-2-yl)methyl)-2-methyl-6-(2-morpholinopyrimidin-5-yl)--
1H-indazol-3(2H)-one; [0497]
2-cyclopropyl-1-(2-(difluoromethoxy)benzyl)-6-(2-morpholinopyrimidin-5-yl-
)-1H-indazol-3(2H)-one; [0498]
1-(2,5-dichlorophenyl)-2-methyl-6-(2-morpholinopyrimidin-5-yl)-1H-indazol-
-3(2H)-one; [0499]
1-(2-(difluoromethoxy)-6-fluorobenzyl)-2-methyl-6-(2-morpholinopyrimidin--
5-yl)-1H-indazol-3(2H)-one; [0500]
4-(5-(1-(2-(difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-1H-indazol-
-6-yl)pyrimidin-2-yl)piperazine-1-carboxamide; [0501]
1-(1-(2-(difluoromethoxy)phenyl)ethyl)-6-(2-((R)-2-(methoxymethyl)pyrroli-
din-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one; [0502]
6-(2-(4-acetylpiperazin-1-yl)pyrimidin-5-yl)-1-(2-(difluoromethoxy)benzyl-
)-2-methyl-1H-indazol-3(2H)-one; [0503]
1-(2-(difluoromethoxy)benzyl)-2-methyl-6-(2-((2-oxoazepan-3-yl)amino)pyri-
midin-5-yl)-1H-indazol-3(2H)-one; [0504]
1-(3-(difluoromethoxy)benzyl)-2-methyl-6-(2-((tetrahydrofuran-3-yl)amino)-
pyrimidin-5-yl)-1H-indazol-3(2H)-one; [0505]
1-(2-(difluoromethoxy)benzyl)-2-methyl-6-(2-((tetrahydro-2H-pyran-3-yl)am-
ino)pyrimidin-5-yl)-1H-indazol-3(2H)-one; [0506]
1-(2-(difluoromethoxy)benzyl)-6-(2-((3-methoxypropyl)amino)pyrimidin-5-yl-
)-2-methyl-1H-indazol-3(2H)-one; [0507]
1-(2,5-dichlorobenzyl)-2-methyl-6-(2-morpholinopyrimidin-5-yl)-1H-indazol-
-3(2H)-one; [0508]
1-(5-(1-(2-(difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-1H-indazol-
-6-yl)pyrazin-2-yl)piperidine-4-carboxylic acid; [0509]
1-(2-(difluoromethoxy)benzyl)-2-methyl-6-(5-morpholino-1,2,4-thiadiazol-3-
-yl)-1H-indazol-3(2H)-one; [0510]
1-(2-(difluoromethoxy)benzyl)-2-methyl-6-(2-morpholinopyrimidin-5-yl)-1H--
pyrazolo[4,3-b]pyridin-3(2H)-one; [0511]
1-(2-(difluoromethoxy)benzyl)-2-methyl-6-(2-((3-methyloxetan-3-yl)methyl)-
pyrimidin-5-yl)-1H-indazol-3(2H)-one; [0512]
1-(2-(difluoromethoxy)benzyl)-2-methyl-6-(3-morpholino-1,2,4-oxadiazol-5--
yl)-1H-indazol-3(2H)-one; [0513]
1-(2-(difluoromethoxy)benzyl)-2-methyl-6-(2-morpholinopyrimidin-5-yl)-1H--
pyrazolo[3,4-b]pyridin-3(2H)-one; [0514]
1-(2-(difluoromethoxy)benzyl)-6-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)--
2-methyl-1H-pyrazolo[3,4-b]pyridin-3(2H)-one; [0515]
1-(2-(difluoromethoxy)benzyl)-2-methyl-6-(2-morpholinopyrimidin-5-yl)-1H--
pyrazolo[4,3-c]pyridin-3(2H)-one; [0516]
1-(2-(difluoromethoxy)benzyl)-2-methyl-6-(2-(6-oxohexahydropyrrolo[1,2-a]-
pyrazin-2(1H)-yl)pyrimidin-5-yl)-1H-indazol-3(2H)-one; [0517]
(R)-1-(2-(difluoromethoxy)benzyl)-2-methyl-6-(2-((tetrahydrofuran-3-yl)am-
ino)pyrimidin-5-yl)-1H-indazol-3(2H)-one; [0518]
(R)-7-(5-(1-(2-(difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-1H-ind-
azol-6-yl)pyrimidin-2-yl)tetrahydro-1H-oxazolo[3,4-a]pyrazin-3(5H)-one;
[0519]
(S)-7-(5-(1-(2-(difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-
-1H-indazol-6-yl)pyrimidin-2-yl)tetrahydro-1H-oxazolo[3,4-a]pyrazin-3(5H)--
one; [0520]
7-(5-(1-(2-(difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-1H-indazol-
-6-yl)pyrimidin-2-yl)hexahydroimidazo[1,5-a]pyrazin-3(2H)-one;
[0521]
(R)-7-(5-(1-(2-(difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-1H-ind-
azol-6-yl)pyrimidin-2-yl)hexahydroimidazo[1,5-a]pyrazin-3(2H)-one;
[0522]
(S)-7-(5-(1-(2-(difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-1H-ind-
azol-6-yl)pyrimidin-2-yl)hexahydroimidazo[1,5-a]pyrazin-3(2H)-one;
[0523]
1-(2-(difluoromethoxy)-5-methylbenzyl)-2-methyl-6-(2-morpholinopyrimidin--
5-yl)-1H-indazol-3(2H)-one; [0524]
1-(2-(difluoromethoxy)-5-(hydroxymethyl)benzyl)-2-methyl-6-(2-morpholinop-
yrimidin-5-yl)-1H-indazol-3(2H)-one; [0525]
(R)-7-(5-(1-(2-(difluoromethoxy)-5-methylbenzyl)-2-methyl-3-oxo-2,3-dihyd-
ro-1H-indazol-6-yl)pyrimidin-2-yl)hexahydroimidazo[1,5-a]pyrazin-3(2H)-one-
; [0526]
(S)-7-(5-(1-(2-(difluoromethoxy)-5-methylbenzyl)-2-methyl-3-oxo-2-
,3-dihydro-1H-indazol-6-yl)pyrimidin-2-yl)hexahydroimidazo[1,5-a]pyrazin-3-
(2H)-one; [0527]
(S)-7-(5-(1-(2-(Difluoromethoxy)-5-(hydroxymethyl)benzyl)-2-methyl-3-oxo--
2,3-dihydro-1H-indazol-6-yl)pyrimidin-2-yl)hexahydroimidazo[1,5-a]pyrazin--
3(2H)-one; or [0528]
7-(5-(1-(2-(difluoromethoxy)-5-(hydroxymethyl)benzyl)-2-methyl-3-oxo-2,3--
dihydro-1H-indazol-6-yl)pyrimidin-2-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]py-
razin-3(2H)-one.
[0529] As another example, compounds of the disclosure include
compounds of Formula (I), wherein X, Y and Z are independently
CR.sup.4 or N; [0530] provided that Y and Z are not both N;
[0531] L is a bond, optionally substituted
(C.sub.1-C.sub.3)alkylene or --C(O)--;
[0532] R.sup.1 is H, CD.sub.3, CN, optionally substituted
(C.sub.1-C.sub.3)alkyl, --(CH.sub.2).sub.n-optionally substituted
phenyl, --(CH.sub.2).sub.n-optionally substituted heteroaryl or
--(CH.sub.2).sub.n-optionally substituted heterocyclyl;
[0533] R.sup.2 is optionally substituted aryl, optionally
substituted heteroaryl, optionally substituted heterocyclyl or
optionally substituted cycloalkyl;
[0534] R.sup.3 is --R.sup.3a-R.sup.3b, wherein: [0535] R.sup.3a is
an optionally substituted saturated, unsaturated or partially
saturated heterocyclyl or optionally substituted heteroaryl; [0536]
R.sup.3b is --N(R.sup.a)(R.sup.b), --O(R.sup.a), optionally
substituted (C.sub.1-C.sub.5)alkyl, optionally substituted
(C.sub.3-C.sub.6)cycloalkyl, or --(CH.sub.2).sub.p-optionally
substituted heterocyclyl; wherein [0537] R.sup.a and R.sup.b are
independently selected from H, optionally substituted
(C.sub.1-C.sub.5)alkyl, and --(CH.sub.2).sub.n-optionally
substituted heterocyclyl;
[0538] R.sup.4 is independently H, Cl, CN, F, CF.sub.3, optionally
substituted (C.sub.1-C.sub.3)alkyl or optionally substituted
(C.sub.1-C.sub.3) alkoxy; and
[0539] n is 0 or 1;
[0540] p is 0, 1 or 2.
[0541] Certain compounds of Formula (I) which have acidic
substituents may exist as salts with pharmaceutically acceptable
bases. The present disclosure includes such salts. Examples of such
salts include sodium salts, potassium salts, lysine salts and
arginine salts. These salts may be prepared by methods known to
those skilled in the art.
[0542] Certain compounds of Formula (I) and their salts may exist
in more than one crystal form and the present disclosure includes
each crystal form and mixtures thereof.
[0543] Certain compounds of Formula (I) and their salts may also
exist in the form of solvates, for example hydrates, and the
present disclosure includes each solvate and mixtures thereof.
[0544] Certain compounds of Formula (I) may contain one or more
chiral centers, and exist in different optically active forms. When
compounds of Formula (I) contain one chiral center, the compounds
exist in two enantiomeric forms and the present disclosure includes
both enantiomers and mixtures of enantiomers, such as racemic
mixtures. The enantiomers may be resolved by methods known to those
skilled in the art, for example by formation of diastereoisomeric
salts which may be separated, for example, by crystallization;
formation of diastereoisomeric derivatives or complexes which may
be separated, for example, by crystallization, gas-liquid or liquid
chromatography; selective reaction of one enantiomer with an
enantiomer-specific reagent, for example enzymatic esterification;
or gas-liquid or liquid chromatography in a chiral environment, for
example on a chiral support for example silica with a bound chiral
ligand or in the presence of a chiral solvent. It will be
appreciated that where the desired enantiomer is converted into
another chemical entity by one of the separation procedures
described above, a further step is required to liberate the desired
enantiomeric form. Alternatively, specific enantiomers may be
synthesized by asymmetric synthesis using optically active
reagents, substrates, catalysts or solvents, or by converting one
enantiomer into the other by asymmetric transformation.
[0545] When a compound of Formula (I) contains more than one chiral
center, it may exist in diastereoisomeric forms. The
diastereoisomeric compounds may be separated by methods known to
those skilled in the art, for example chromatography or
crystallization and the individual enantiomers may be separated as
described above. The present disclosure includes each
diastereoisomer of compounds of Formula (I) (and mixtures
thereof.
[0546] Certain compounds of Formula (I) may exist in different
tautomeric forms or as different geometric isomers, and the present
disclosure includes each tautomer and/or geometric isomer of
compounds of Formula (I) and mixtures thereof.
[0547] Certain compounds of Formula (I) may exist in different
stable conformational forms which may be separable. Torsional
asymmetry due to restricted rotation about an asymmetric single
bond, for example because of steric hindrance or ring strain, may
permit separation of different conformers. The present disclosure
includes each conformational isomer of compounds of Formula (I) and
mixtures thereof.
[0548] Certain compounds of Formula (I) may exist in zwitterionic
form and the present disclosure includes each zwitterionic form of
compounds of Formula (I) (and mixtures thereof.
[0549] Certain compounds of Formula (I) may further be in the form
of a pro-drug. Pro-drugs have many useful properties. For example,
a pro-drug may be more water soluble than the ultimate drug,
thereby facilitating intravenous administration of the drug. A
pro-drug may also have a higher level of oral bioavailability than
the ultimate drug. After administration, the prodrug is
enzymatically or chemically cleaved to deliver the ultimate drug in
the blood or tissue.
[0550] Exemplary pro-drugs upon cleavage release the corresponding
free acid, and such hydrolyzable ester-forming residues of the
compounds of this disclosure include but are not limited to
carboxylic acid substituents wherein the free hydrogen is replaced
by (C.sub.1-C.sub.4)alkyl, (C.sub.1-C.sub.12)alkanoyloxymethyl,
(C.sub.4-C.sub.9)1-(alkanoyloxy)ethyl,
1-methyl-1-(alkanoyloxy)-ethyl having from 5 to 10 carbon atoms,
alkoxycarbonyloxymethyl having from 3 to 6 carbon atoms,
1-(alkoxycarbonyloxy)ethyl having from 4 to 7 carbon atoms,
1-methyl-1-(alkoxycarbonyloxy)ethyl having from 5 to 8 carbon
atoms, N-(alkoxycarbonyl)aminomethyl having from 3 to 9 carbon
atoms, 1-(N-(alkoxycarbonyl)amino)ethyl having from 4 to 10 carbon
atoms, 3-phthalidyl, 4-crotonolactonyl, gamma-butyrolacton-4-yl,
di-N,N--(C.sub.1-C.sub.2)alkylamino(C.sub.2-C.sub.3)alkyl (such as
.beta.-dimethylaminoethyl), carbamoyl-(C.sub.1-C.sub.2)alkyl,
N,N-di(C.sub.1-C.sub.2)-alkylcarbamoyl-(C.sub.1-C.sub.2)alkyl and
piperidino-, pyrrolidino- or morpholino(C.sub.2-C.sub.3)alkyl.
[0551] Other exemplary pro-drugs release an alcohol of Formula (I)
wherein the free hydrogen of the hydroxyl substituent (e.g.,
R.sup.1 contains hydroxyl) is replaced by
(C.sub.1-C.sub.6)alkanoyloxymethyl,
1-((C.sub.1-C.sub.6)alkanoyloxy)ethyl,
1-methyl-1-((C.sub.1-C.sub.6)alkanoyloxy)ethyl,
(C.sub.1-C.sub.12)alkoxycarbonyloxymethyl,
N--(C.sub.1-C.sub.6)alkoxycarbonylamino-methyl, succinoyl,
(C.sub.1-C.sub.6)alkanoyl, .alpha.-amino(C.sub.1-C.sub.4)alkanoyl,
arylacyl and .alpha.-aminoacyl, or
.alpha.-aminoacyl-.alpha.-aminoacyl wherein said .alpha.-aminoacyl
moieties are independently any of the naturally occurring L-amino
acids found in proteins, P(O)(OH).sub.2,
--P(O)(O(C.sub.1-C.sub.6)alkyl).sub.2 or glycosyl (the radical
resulting from detachment of the hydroxyl of the hemiacetal of a
carbohydrate).
[0552] Compounds of Formula (I) also include compounds with one or
more isotopic substitutions. For example, H may be in any isotopic
form, including .sup.1H, .sup.2H (D), and .sup.3H (T); C may be in
any isotopic form, including .sup.12C, .sup.13C, and .sup.14C; O
may be in any isotopic form, including .sup.16O and .sup.18O; and
the like.
Methods of Treatment
[0553] Many autoimmune diseases and disease associated with chronic
inflammation, as well as acute responses, have been linked to
excessive or unregulated production or activity of one or more
cytokines.
[0554] The compounds of the disclosure are also useful in the
treatment of rheumatoid arthritis, asthma, allergic asthma,
osteoarthritis, juvenile arthritis, ankylosing spondylitis,
hidradenitis supportive, ulcerative colitis. Crohn's disease, and
inflammatory bowel disease.
Combination Therapies
[0555] Compounds of Formula (I) of the disclosure can be used alone
or in combination with an additional agent, e.g., a therapeutic
agent, said additional agent being selected by the skilled artisan
for its intended purpose. For example, the additional agent can be
a therapeutic agent art-recognized as being useful to treat the
disease or condition being treated by the compound of the present
disclosure. The additional agent also can be an agent that imparts
a beneficial attribute to the therapeutic composition e.g., an
agent that affects the viscosity of the composition.
[0556] It should further be understood that the combinations which
are to be included within this disclosure are those combinations
useful for their intended purpose. The agents set forth below are
illustrative for purposes and not intended to be limited. The
combinations, which are part of this disclosure, can be the
compounds of the present disclosure and at least one additional
agent selected from the lists below. The combination can also
include more than one additional agent, e.g., two or three
additional agents if the combination is such that the formed
composition can perform its intended function.
[0557] Preferred combinations are non-steroidal anti-inflammatory
drug(s) also referred to as NSAIDs which include drugs like
ibuprofen. Other preferred combinations are corticosteroids
including prednisolone; the well-known side-effects of steroid use
can be reduced or even eliminated by tapering the steroid dose
required when treating patients in combination with the compounds
of this disclosure. Non-limiting examples of therapeutic agents for
rheumatoid arthritis with which a compound of Formula (I) of the
disclosure can be combined include the following: cytokine
suppressive anti-inflammatory drug(s) (CSAIDs); antibodies to or
antagonists of other human cytokines or growth factors, for
example, LT, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-12,
IL-15, IL-16, IL-21, IL-23, interferons, EMAP-II, GM-CSF, FGF,
MMP-13 and PDGF. Compounds of the disclosure can be combined with
antibodies to cell surface molecules such as CD2, CD3, CD4, CD8,
CD25, CD28, CD30, CD40, CD45, CD69, CD80 (B7.1), CD86 (B7.2), CD90,
CTLA or their ligands including CD154 (gp39 or CD40L).
[0558] Preferred combinations of therapeutic agents may interfere
at different points in the autoimmune and subsequent inflammatory
cascade, preferred examples include IL-1 inhibitors
(Interleukin-1-converting enzyme inhibitors, IL-1RA etc.) may be
effective for the same reason. Other preferred combinations include
Interleukin 11. Yet other preferred combinations are the other key
players of the autoimmune response which may act parallel to,
dependent on or in concert with IL-18 function; especially
preferred are IL-12 antagonists including IL-12 antibodies or
soluble IL-12 receptors, or IL-12 binding proteins. It has been
shown that IL-12 and IL-18 have overlapping but distinct functions
and a combination of antagonists to both may be most effective. Yet
another preferred combination is non-depleting anti-CD4 inhibitors.
Yet other preferred combinations include antagonists of the
co-stimulatory pathway CD80 (B7.1) or CD86 (B7.2) including
antibodies, soluble receptors or antagonistic ligands.
[0559] A compound of Formula (I) of the disclosure may also be
combined with agents, such as methotrexate, 6-mercaptopurine,
azathioprine sulphasalazine, mesalazine, olsalazine
chloroquinine/hydroxychloroquine, pencillamine, aurothiomalate
(intramuscular and oral), azathioprine, cochicine, corticosteroids
(oral, inhaled and local injection), beta-2 adrenoreceptor agonists
(salbutamol, terbutaline, salmeteral), xanthines (theophylline,
aminophylline), cromoglycate, nedocromil, ketotifen, ipratropium
and oxitropium, cyclosporin, FK506, rapamycin, mycophenolate
mofetil, leflunomide, NSAIDs, for example, ibuprofen,
corticosteroids such as prednisolone, phosphodiesterase inhibitors,
adensosine agonists, antithrombotic agents, complement inhibitors,
adrenergic agents, agents which interfere with signaling by
proinflammatory cytokines such as IL-1 (e.g., NIK, IKK, JAK1, JAK2,
JAK3, p38 or MAP kinase inhibitors), IL-1.beta. converting enzyme
inhibitors, T-cell signaling inhibitors such as kinase inhibitors,
metalloproteinase inhibitors, sulfasalazine, 6-mercaptopurines,
angiotensin converting enzyme inhibitors, soluble cytokine
receptors and derivatives thereof (e.g., sIL-1RI, sIL-1RII,
sIL-6R), anti-inflammatory cytokines (e.g., IL-4, IL-10, IL-11,
IL-13), celecoxib, folic acid, hydroxychloroquine sulfate,
rofecoxib, naproxen, valdecoxib, sulfasalazine, methylprednisolone,
meloxicam, methylprednisolone acetate, gold sodium thiomalate,
aspirin, triamcinolone acetonide, propoxyphene napsylate/apap,
folate, nabumetone, diclofenac, piroxicam, etodolac, diclofenac
sodium, oxaprozin, oxycodone HCl, hydrocodone bitartrate/apap,
diclofenac sodium/misoprostol, fentanyl, anakinra, tramadol HCl,
salsalate, sulindac, cyanocobalamin/fa/pyridoxine, acetaminophen,
alendronate sodium, prednisolone, morphine sulfate, lidocaine
hydrochloride, indomethacin, glucosamine sulf/chondroitin,
amitriptyline HCl, sulfadiazine, oxycodone HCl/acetaminophen,
olopatadine HCl misoprostol, naproxen sodium, omeprazole,
cyclophosphamide, rituximab, tofacitinib, IL-1 TRAP, MRA, CTLA4-IG,
IL-18 BP, anti-IL-12, Anti-IL15, BIRB-796, SCIO-469, VX-702,
AMG-548, VX-740, Roflumilast, IC-485, CDC-801, S1P1 agonists (such
as FTY720), PKC family inhibitors (such as Ruboxistaurin or
AEB-071) and Mesopram. Preferred combinations include methotrexate
or leflunomide and in moderate or severe rheumatoid arthritis
cases, and cyclosporine.
[0560] Non-limiting examples of therapeutic agents for inflammatory
bowel disease with which a compound of Formula (I) of the
disclosure can be combined include the following: budenoside;
epidermal growth factor; corticosteroids; cyclosporin,
sulfasalazine; aminosalicylates; 6-mercaptopurine; azathioprine;
metronidazole; lipoxygenase inhibitors; mesalamine; olsalazine;
balsalazide; antioxidants; thromboxane inhibitors; IL-1 receptor
antagonists; anti-IL-1.beta. monoclonal antibodies; anti-IL-6
monoclonal antibodies; growth factors; elastase inhibitors;
pyridinyl-imidazole compounds; antibodies to or antagonists of
other human cytokines or growth factors, for example, LT, IL-1,
IL-2, IL-6, IL-7, IL-8, IL-12, IL-15, IL-16, IL-23, EMAP-II,
GM-CSF, FGF, and PDGF; cell surface molecules such as CD2, CD3,
CD4, CD8, CD25, CD28, CD30, CD40, CD45, CD69, CD90 or their
ligands; methotrexate; cyclosporine; FK506; rapamycin;
mycophenolate mofetil; leflunomide; NSAIDs, for example, ibuprofen;
corticosteroids such as prednisolone; phosphodiesterase inhibitors;
adenosine agonists; antithrombotic agents; complement inhibitors;
adrenergic agents; agents which interfere with signaling by
proinflammatory cytokines such as IL-1 (e.g., NIK, IKK, p38 or MAP
kinase inhibitors); IL-1.beta. converting enzyme inhibitors; T-cell
signaling inhibitors such as kinase inhibitors; metalloproteinase
inhibitors; sulfasalazine; azathioprine; 6-mercaptopurines;
angiotensin converting enzyme inhibitors; soluble cytokine
receptors and derivatives thereof (e.g., sIL-1RI, sIL-1RII, sIL-6R)
and anti-inflammatory cytokines (e.g., IL-4, IL-10, IL-11, IL-13).
Preferred examples of therapeutic agents for Crohn's disease with
which a compound of Formula (I) can be combined include PDE4
inhibitors. A compound of Formula (I) can be combined with
corticosteroids, for example, budenoside and dexamethasone;
sulfasalazine, 5-aminosalicylic acid; olsalazine; and agents which
interfere with synthesis or action of proinflammatory cytokines
such as IL-1, for example, IL-1.beta. converting enzyme inhibitors
and IL-1ra; T cell signaling inhibitors, for example, tyrosine
kinase inhibitors; 6-mercaptopurine; IL-11; mesalamine; prednisone;
azathioprine; mercaptopurine; infliximab; methylprednisolone sodium
succinate; diphenoxylate/atropine sulfate; loperamide
hydrochloride; methotrexate; omeprazole; folate;
ciprofloxacin/dextrose-water; hydrocodone bitartrate/apap;
tetracycline hydrochloride; fluocinonide; metronidazole;
thimerosal/boric acid; cholestyramine/sucrose; ciprofloxacin
hydrochloride; hyoscyamine sulfate; meperidine hydrochloride;
midazolam hydrochloride; oxycodone HCl/acetaminophen; promethazine
hydrochloride; sodium phosphate; sulfamethoxazole/trimethoprim;
celecoxib; polycarbophil; propoxyphene napsylate; hydrocortisone;
multivitamins; balsalazide disodium; codeine phosphate/apap;
colesevelam HCl; cyanocobalamin; folic acid; levofloxacin;
methylprednisolone; natalizumab and interferon-gamma.
[0561] Non-limiting examples of therapeutic agents for multiple
sclerosis with which a compound of Formula (I) can be combined
include the following: corticosteroids; prednisolone;
methylprednisolone; azathioprine; cyclophosphamide; cyclosporine;
methotrexate; 4-aminopyridine; tizanidine; interferon-.beta.1a
(AVONEX.RTM.; Biogen); interferon-.beta.1b (BETASERON.RTM.;
Chiron/Berlex); interferon .alpha.-n3) (Interferon
Sciences/Fujimoto), interferon-.alpha. (Alfa Wassermann/J&J),
interferon .beta.1A-IF (Serono/Inhale Therapeutics), Peginterferon
.alpha. 2b (Enzon/Schering-Plough), Copolymer 1 (Cop-1;
COPAXONE.RTM.; Teva Pharmaceutical Industries, Inc.); hyperbaric
oxygen; intravenous immunoglobulin; cladribine; antibodies to or
antagonists of other human cytokines or growth factors and their
receptors, for example, LT, IL-1, IL-2, IL-6, IL-7, IL-8, IL-12,
IL-23, IL-15, IL-16, EMAP-II, GM-CSF, FGF, and PDGF. A compound of
Formula (I) can be combined with antibodies to cell surface
molecules such as CD2, CD3, CD4, CD8, CD19, CD20, CD25, CD28, CD30,
CD40, CD45, CD69, CD80, CD86, CD90 or their ligands. A compound of
Formula (I) may also be combined with agents such as methotrexate,
cyclosporine, FK506, rapamycin, mycophenolate mofetil, leflunomide,
an S1P1 agonist, NSAIDs, for example, ibuprofen, corticosteroids
such as prednisolone, phosphodiesterase inhibitors, adensosine
agonists, antithrombotic agents, complement inhibitors, adrenergic
agents, agents which interfere with signaling by proinflammatory
cytokines such as IL-1 (e.g., NIK, IKK, p38 or MAP kinase
inhibitors), IL-1.beta. converting enzyme inhibitors, TACE
inhibitors, T-cell signaling inhibitors such as kinase inhibitors,
metalloproteinase inhibitors, sulfasalazine, azathioprine,
6-mercaptopurines, angiotensin converting enzyme inhibitors,
soluble cytokine receptors and derivatives thereof (e.g., sIL-1RI,
sIL-1RII, sIL-6R) and anti-inflammatory cytokines (e.g., IL-4,
IL-10, IL-13 and TGF.beta.).
[0562] Preferred examples of therapeutic agents for multiple
sclerosis in which a compound of Formula (I) can be combined to
include interferon-.beta., for example, IFN.beta.1a and
IFN.beta.1b; copaxone, corticosteroids, caspase inhibitors, for
example inhibitors of caspase-1, IL-1 inhibitors, and antibodies to
CD40 ligand and CD80.
[0563] A compound of Formula (I) may also be combined with agents,
such as alemtuzumab, dronabinol, daclizumab, mitoxantrone,
xaliproden hydrochloride, fampridine, glatiramer acetate,
natalizumab, sinnabidol, .alpha.-immunokine NNSO3, ABR-215062,
AnergiX.MS, chemokine receptor antagonists, BBR-2778, calagualine,
CPI-1189, LEM (liposome encapsulated mitoxantrone), THC.CBD
(cannabinoid agonist), MBP-8298, mesopram (PDE4 inhibitor),
MNA-715, anti-IL-6 receptor antibody, neurovax, pirfenidone
allotrap 1258 (RDP-1258), sTNF-R1, talampanel, teriflunomide,
TGF-beta2, tiplimotide, VLA-4 antagonists (for example, TR-14035,
VLA4 Ultrahaler, Antegran-ELAN/Biogen), interferon gamma
antagonists and IL-4 agonists.
[0564] Non-limiting examples of therapeutic agents for ankylosing
spondylitis with which a compound of Formula (I) can be combined
include the following: ibuprofen, diclofenac, misoprostol,
naproxen, meloxicam, indomethacin, diclofenac, celecoxib,
rofecoxib, sulfasalazine, methotrexate, azathioprine, minocyclin,
and prednisone
[0565] Non-limiting examples of therapeutic agents for asthma with
which a compound of Formula (I) can be combined include the
following: albuterol, salmeterol/fluticasone, montelukast sodium,
fluticasone propionate, budesonide, prednisone, salmeterol
xinafoate, levalbuterol HCl, albuterol sulfate/ipratropium,
prednisolone sodium phosphate, triamcinolone acetonide,
beclomethasone dipropionate, ipratropium bromide, azithromycin,
pirbuterol acetate, prednisolone, theophylline anhydrous,
methylprednisolone sodium succinate, clarithromycin, zafirlukast,
formoterol fumarate, influenza virus vaccine, amoxicillin
trihydrate, flunisolide, allergy injection, cromolyn sodium,
fexofenadine hydrochloride, flunisolide/menthol,
amoxicillin/clavulanate, levofloxacin, inhaler assist device,
guaifenesin, dexamethasone sodium phosphate, moxifloxacin HCl,
doxycycline hyclate, guaifenesin/d-methorphan,
p-ephedrine/cod/chlorphenir, gatifloxacin, cetirizine
hydrochloride, mometasone furoate, salmeterol xinafoate,
benzonatate, cephalexin, pe/hydrocodone/chlorphenir, cetirizine
HCl/pseudoephed, phenylephrine/cod/promethazine,
codeine/promethazine, cefprozil, dexamethasone,
guaifenesin/pseudoephedrine, chlorpheniramine/hydrocodone,
nedocromil sodium, terbutaline sulfate, epinephrine,
methylprednisolone, anti-IL-13 antibody, and metaproterenol
sulfate.
[0566] Non-limiting examples of therapeutic agents for COPD with
which a compound of Formula (I) can be combined include the
following: albuterol sulfate/ipratropium, ipratropium bromide,
salmeterol/fluticasone, albuterol, salmeterol xinafoate,
fluticasone propionate, prednisone, theophylline anhydrous,
methylprednisolone sodium succinate, montelukast sodium,
budesonide, formoterol fumarate, triamcinolone acetonide,
levofloxacin, guaifenesin, azithromycin, beclomethasone
dipropionate, levalbuterol HCl, flunisolide, ceftriaxone sodium,
amoxicillin trihydrate, gatifloxacin, zafirlukast,
amoxicillin/clavulanate, flunisolide/menthol,
chlorpheniramine/hydrocodone, metaproterenol sulfate,
methylprednisolone, mometasone furoate,
p-ephedrine/cod/chlorphenir, pirbuterol acetate,
p-ephedrine/loratadine, terbutaline sulfate, tiotropium bromide,
(R,R)-formoterol, TgAAT, cilomilast and roflumilast.
[0567] Non-limiting examples of therapeutic agents for Idiopathic
Pulmonary Fibrosis with which a compound of Formula (I) (can be
combined include the following: prednisone, azathioprine,
albuterol, colchicine, albuterol sulfate, digoxin, gamma
interferon, methylprednisolone sodium succinate, lorazepam,
furosemide, lisinopril, nitroglycerin, spironolactone,
cyclophosphamide, ipratropium bromide, actinomycin d, alteplase,
fluticasone propionate, levofloxacin, metaproterenol sulfate,
morphine sulfate, oxycodone HCl, potassium chloride, triamcinolone
acetonide, tacrolimus anhydrous, calcium, interferon-alpha,
methotrexate, mycophenolate mofetil and
interferon-gamma-1.beta..
[0568] Non-limiting examples of therapeutic agents for psoriasis
with which a compound of Formula (I) can be combined include the
following: calcipotriene, clobetasol propionate, triamcinolone
acetonide, halobetasol propionate, tazarotene, methotrexate,
fluocinonide, betamethasone dipropionate augmented, fluocinolone
acetonide, acitretin, tar shampoo, betamethasone valerate,
mometasone furoate, ketoconazole, pramoxine/fluocinolone,
hydrocortisone valerate, flurandrenolide, urea, betamethasone,
clobetasol propionate/emollient, fluticasone propionate,
azithromycin, hydrocortisone, moisturizing formula, folic acid,
desonide, pimecrolimus, coal tar, diflorasone diacetate, etanercept
folate, lactic acid, methoxsalen, hc/bismuth subgal/znox/resor,
methylprednisolone acetate, prednisone, sunscreen, halcinonide,
salicylic acid, anthralin, clocortolone pivalate, coal extract,
coal tar/salicylic acid, coal tar/salicylic acid/sulfur,
desoximetasone, diazepam, emollient, fluocinonide/emollient,
mineral oil/castor oil/na lact, mineral oil/peanut oil,
petroleum/isopropyl myristate, psoralen, salicylic acid,
soap/tribromsalan, thimerosal/boric acid, celecoxib, infliximab,
cyclosporine, alefacept, efalizumab, tacrolimus, pimecrolimus,
PUVA, UVB, sulfasalazine, ABT-874 and ustekinamab.
[0569] Non-limiting examples of therapeutic agents for psoriatic
arthritis with which a compound of Formula (I) can be combined
include the following: methotrexate, etanercept, rofecoxib,
celecoxib, folic acid, sulfasalazine, naproxen, leflunomide,
methylprednisolone acetate, indomethacin, hydroxychloroquine
sulfate, prednisone, sulindac, betamethasone dipropionate
augmented, infliximab, methotrexate, folate, triamcinolone
acetonide, diclofenac, dimethylsulfoxide, piroxicam, diclofenac
sodium, ketoprofen, meloxicam, methylprednisolone, nabumetone,
tolmetin sodium, calcipotriene, cyclosporine, diclofenac
sodium/misoprostol, fluocinonide, glucosamine sulfate, gold sodium
thiomalate, hydrocodone bitartrate/apap, ibuprofen, risedronate
sodium, sulfadiazine, thioguanine, valdecoxib, and alefacept.
[0570] Non-limiting examples of therapeutic agents for restenosis
with which a compound of Formula (I) can be combined include the
following: sirolimus, paclitaxel, everolimus, tacrolimus, ABT-578,
and acetaminophen.
[0571] Preferred examples of therapeutic agents for SLE (Lupus)
with which a compound of Formula (I) can be combined include the
following: NSAIDS, for example, diclofenac, naproxen, ibuprofen,
piroxicam, indomethacin; COX2 inhibitors, for example, celecoxib,
rofecoxib, valdecoxib; anti-malarials, for example,
hydroxychloroquine; steroids, for example, prednisone,
prednisolone, budenoside, dexamethasone; cytotoxics, for example,
azathioprine, cyclophosphamide, mycophenolate mofetil,
methotrexate; inhibitors of PDE4 or purine synthesis inhibitor, for
example Cellcept.RTM.. A compound of Formula (I) may also be
combined with agents such as sulfasalazine, 5-aminosalicylic acid,
olsalazine, Imuran.RTM. and agents which interfere with synthesis,
production or action of proinflammatory cytokines such as IL-1, for
example, caspase inhibitors like IL-1.beta. converting enzyme
inhibitors and IL-1ra. A compound of Formula (I) may also be used
with T cell signaling inhibitors, for example, tyrosine kinase
inhibitors; or molecules that target T cell activation molecules,
for example, CTLA-4-IgG or anti-B7 family antibodies, anti-PD-1
family antibodies. A compound of Formula (I) (can be combined with
IL-11 or anti-cytokine antibodies, for example, fonotolizumab
(anti-IFNg antibody), or anti-receptor receptor antibodies, for
example, anti-IL-6 receptor antibody and antibodies to B-cell
surface molecules. A compound of Formula (I) may also be used with
UP 394 (abetimus), agents that deplete or inactivate B-cells, for
example, Rituximab (anti-CD20 antibody), and lymphostat-B
(anti-BlyS antibody).
Compositions and Routes of Administration
[0572] One or more compounds of this disclosure can be administered
to a human patient by themselves or in pharmaceutical compositions
where they are mixed with biologically suitable carriers or
excipient(s) at doses to treat or ameliorate a disease or condition
as described herein. Mixtures of these compounds can also be
administered to the patient as a simple mixture or in suitable
formulated pharmaceutical compositions. A therapeutically effective
dose refers to that amount of the compound or compounds sufficient
to result in the prevention or attenuation of a disease or
condition as described herein. Techniques for formulation and
administration of the compounds of the instant application may be
found in references well known to one of ordinary skill in the art,
such as "Remington's Pharmaceutical Sciences," Mack Publishing Co.,
Easton, Pa., latest edition.
[0573] Suitable routes of administration may, for example, include
oral, eye drop, rectal, transmucosal, topical, or intestinal
administration; parenteral delivery, including intramuscular,
subcutaneous, intramedullary injections, as well as intrathecal,
direct intraventricular, intravenous, intraperitoneal, intranasal,
or intraocular injections.
[0574] Alternatively, one may administer the compound in a local
rather than a systemic manner, for example, via injection of the
compound directly into an edematous site, often in a depot or
sustained release formulation.
[0575] Furthermore, one may administer the drug in a targeted drug
delivery system, for example, in a liposome coated with endothelial
cell-specific antibody.
[0576] The pharmaceutical compositions of the present disclosure
may be manufactured in a manner that is itself known, e.g., by
means of conventional mixing, dissolving, granulating,
dragee-making, levigating, emulsifying, encapsulating, entrapping
or lyophilizing processes.
[0577] Pharmaceutical compositions for use in accordance with the
present disclosure thus may be formulated in a conventional manner
using one or more physiologically acceptable carriers comprising
excipients and auxiliaries which facilitate processing of the
active compounds into preparations which can be used
pharmaceutically. Proper formulation is dependent upon the route of
administration chosen.
[0578] For injection, the agents of the disclosure may be
formulated in aqueous solutions, preferably in physiologically
compatible buffers such as Hanks' solution, Ringer's solution, or
physiological saline buffer. For transmucosal administration,
penetrants appropriate to the barrier to be permeated are used in
the formulation. Such penetrants are generally known in the
art.
[0579] For oral administration, the compounds can be formulated
readily by combining the active compounds with pharmaceutically
acceptable carriers well known in the art. Such carriers enable the
compounds of the disclosure to be formulated as tablets, pills,
dragees, capsules, liquids, gels, syrups, slurries, suspensions and
the like, for oral ingestion by a patient to be treated.
Pharmaceutical preparations for oral use can be obtained by
combining the active compound with a solid excipient, optionally
grinding a resulting mixture, and processing the mixture of
granules, after adding suitable auxiliaries, if desired, to obtain
tablets or dragee cores. Suitable excipients are, in particular,
fillers such as sugars, including lactose, sucrose, mannitol, or
sorbitol; cellulose preparations such as, for example, maize
starch, wheat starch, rice starch, potato starch, gelatin, gum
tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium
carboxymethylcellulose, and/or polyvinylpyrrolidone (PVP). If
desired, disintegrating agents may be added, such as the
cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt
thereof such as sodium alginate.
[0580] Dragee cores are provided with suitable coatings. For this
purpose, concentrated sugar solutions may be used, which may
optionally contain gum arabic, talc, polyvinyl pyrrolidone,
carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer
solutions, and suitable organic solvents or solvent mixtures.
Dyestuffs or pigments may be added to the tablets or dragee
coatings for identification or to characterize different
combinations of active compound doses.
[0581] Pharmaceutical preparations that can be used orally include
push-fit capsules made of gelatin, as well as soft, sealed capsules
made of gelatin and a plasticizer, such as glycerol or sorbitol.
The push-fit capsules can contain the active ingredients in
admixture with filler such as lactose, binders such as starches,
and/or lubricants such as talc or magnesium stearate and,
optionally, stabilizers. In soft capsules, the active compounds may
be dissolved or suspended in suitable liquids, such as fatty oils,
liquid paraffin, or liquid polyethylene glycols. In addition,
stabilizers may be added. All formulations for oral administration
should be in dosages suitable for such administration.
[0582] For buccal administration, the compositions may take the
form of tablets or lozenges formulated in conventional manner.
[0583] For administration by inhalation, the compounds for use
according to the present disclosure are conveniently delivered in
the form of an aerosol spray presentation from pressurized packs or
a nebulizer, with the use of a suitable propellant, e.g.,
dichlorodifluoromethane, trichlorofluoromethane,
dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In
the case of pressurized aerosol the dosage unit may be determined
by providing a valve to deliver a metered amount. Capsules and
cartridges of, e.g., gelatin, for use in an inhaler or insufflator
may be formulated containing a powder mix of the compound and a
suitable powder base such as lactose or starch.
[0584] The compounds can be formulated for parenteral
administration by injection, e.g., bolus injection or continuous
infusion. Formulations for injection may be presented in unit
dosage form, e.g., in ampoules or in multi-dose containers, with an
added preservative. The compositions may take such forms as
suspensions, solutions or emulsions in oily or aqueous vehicles,
and may contain formulatory agents such as suspending, stabilizing
and/or dispersing agents.
[0585] Pharmaceutical formulations for parenteral administration
include aqueous solutions of the active compounds in water-soluble
form. Additionally, suspensions of the active compounds may be
prepared as appropriate oily injection suspensions. Suitable
lipophilic solvents or vehicles include fatty oils such as sesame
oil, or synthetic fatty acid esters, such as ethyl oleate or
triglycerides, or liposomes. Aqueous injection suspensions may
contain substances which increase the viscosity of the suspension,
such as sodium carboxymethyl cellulose, sorbitol, or dextran.
Optionally, the suspension may also contain suitable stabilizers or
agents which increase the solubility of the compounds to allow for
the preparation of highly concentrated solutions.
[0586] Alternatively, the active ingredient may be in powder form
for constitution with a suitable vehicle, e.g., sterile
pyrogen-free water, before use.
[0587] The compounds may also be formulated in rectal compositions
such as suppositories or retention enemas, e.g., containing
conventional suppository bases such as cocoa butter or other
glycerides.
[0588] In addition to the formulations described previously, the
compounds may also be formulated as a depot preparation. Such long
acting formulations may be administered by implantation (for
example subcutaneously or intramuscularly or by intramuscular
injection). Thus, for example, the compounds may be formulated with
suitable polymeric or hydrophobic materials (for example as an
emulsion in an acceptable oil) or ion exchange resins, or as
sparingly soluble derivatives, for example, as a sparingly soluble
salt.
[0589] An example of a pharmaceutical carrier for the hydrophobic
compounds of the disclosure is a cosolvent system comprising benzyl
alcohol, a nonpolar surfactant, a water-miscible organic polymer,
and an aqueous phase. The cosolvent system may be the VPD
co-solvent system. VPD is a solution of 3% w/v benzyl alcohol, 8%
w/v of the nonpolar surfactant polysorbate 80, and 65% w/v
polyethylene glycol 300, made up to volume in absolute ethanol. The
VPD co-solvent system (VPD:5W) consists of VPD diluted 1:1 with a
5% dextrose in water solution. This co-solvent system dissolves
hydrophobic compounds well, and itself produces low toxicity upon
systemic administration. Naturally, the proportions of a co-solvent
system may be varied considerably without destroying its solubility
and toxicity characteristics. Furthermore, the identity of the
co-solvent components may be varied: for example, other
low-toxicity nonpolar surfactants may be used instead of
polysorbate 80; the fraction size of polyethylene glycol may be
varied; other biocompatible polymers may replace polyethylene
glycol, e.g., polyvinyl pyrrolidone; and other sugars or
polysaccharides may substitute for dextrose.
[0590] Alternatively, other delivery systems for hydrophobic
pharmaceutical compounds may be employed. Liposomes and emulsions
are well known examples of delivery vehicles or carriers for
hydrophobic drugs. Certain organic solvents such as
dimethysulfoxide also may be employed, although usually at the cost
of greater toxicity. Additionally, the compounds may be delivered
using a sustained-release system, such as semipermeable matrices of
solid hydrophobic polymers containing the therapeutic agent.
Various sustained-release materials have been established and are
well known by those skilled in the art. Sustained-release capsules
may, depending on their chemical nature, release the compounds for
a few weeks up to over 100 days. Depending on the chemical nature
and the biological stability of the therapeutic reagent, additional
strategies for protein stabilization may be employed.
[0591] The pharmaceutical compositions also may comprise suitable
solid or gel phase carriers or excipients. Examples of such
carriers or excipients include but are not limited to calcium
carbonate, calcium phosphate, various sugars, starches, cellulose
derivatives, gelatin, and polymers such as polyethylene
glycols.
[0592] Many of the compounds of the disclosure may be provided as
salts with pharmaceutically compatible counter ions.
Pharmaceutically compatible salts may be formed with many acids,
including but not limited to hydrochloric, sulfuric, acetic,
lactic, tartaric, malic, succinic, etc. Salts tend to be more
soluble in aqueous or other protonic solvents than are the
corresponding free base forms.
[0593] Pharmaceutical compositions suitable for use in the present
disclosure include compositions wherein the active ingredients are
contained in an effective amount to achieve its intended purpose.
More specifically, a therapeutically effective amount means an
amount effective to prevent development of or to alleviate the
existing symptoms of the subject being treated. Determination of
the effective amounts is well within the capability of those
skilled in the art.
[0594] For any compound used in a method of the present disclosure,
the therapeutically effective dose can be estimated initially from
cellular assays. For example, a dose can be formulated in cellular
and animal models to achieve a circulating concentration range that
includes the IC.sub.50 as determined in cellular assays (e.g., the
concentration of the test compound which achieves a half-maximal
inhibition of a given protein kinase activity). In some cases it is
appropriate to determine the IC.sub.50 in the presence of 3 to 5%
serum albumin since such a determination approximates the binding
effects of plasma protein on the compound. Such information can be
used to more accurately determine useful doses in humans. Further,
the most preferred compounds for systemic administration
effectively inhibit protein kinase signaling in intact cells at
levels that are safely achievable in plasma.
[0595] A therapeutically effective dose refers to that amount of
the compound that results in amelioration of symptoms in a patient.
Toxicity and therapeutic efficacy of such compounds can be
determined by standard pharmaceutical procedures in cell cultures
or experimental animals, e.g., for determining the maximum
tolerated dose (MTD) and the ED.sub.50 (effective dose for 50%
maximal response). The dose ratio between toxic and therapeutic
effects is the therapeutic index and it can be expressed as the
ratio between MTD and ED.sub.50. Compounds which exhibit high
therapeutic indices are preferred. The data obtained from these
cell culture assays and animal studies can be used in formulating a
range of dosage for use in humans. The dosage of such compounds
lies preferably within a range of circulating concentrations that
include the ED.sub.50 with little or no toxicity. The dosage may
vary within this range depending upon the dosage form employed and
the route of administration utilized. The exact formulation, route
of administration and dosage can be chosen by the individual
physician in view of the patient's condition (see, e.g., Fingl et
al., 1975, in The Pharmacological Basis of Therapeutics, Ch. 1, p.
1). In the treatment of crises, the administration of an acute
bolus or an infusion approaching the MTD may be required to obtain
a rapid response.
[0596] Dosage amount and interval may be adjusted individually to
provide plasma levels of the active moiety which are sufficient to
maintain the kinase modulating effects, or minimal effective
concentration (MEC). The MEC will vary for each compound but can be
estimated from in vitro data; e.g., the concentration necessary to
achieve 50-90% inhibition of protein kinase using the assays
described herein. Dosages necessary to achieve the MEC will depend
on individual characteristics and route of administration. However,
HPLC assays or bioassays can be used to determine plasma
concentrations.
[0597] Dosage intervals can also be determined using the MEC value.
Compounds should be administered using a regimen which maintains
plasma levels above the MEC for 10-90% of the time, preferably
between 30-90% and most preferably between 50-90% until the desired
amelioration of symptoms is achieved. In cases of local
administration or selective uptake, the effective local
concentration of the drug may not be related to plasma
concentration.
[0598] The amount of composition administered will, of course, be
dependent on the subject being treated, on the subject's weight,
the severity of the affliction, the manner of administration and
the judgment of the prescribing physician.
[0599] The compositions may, if desired, be presented in a pack or
dispenser device which may contain one or more unit dosage forms
containing the active ingredient. The pack may for example comprise
metal or plastic foil, such as a blister pack. The pack or
dispenser device may be accompanied by instructions for
administration. Compositions comprising a compound of the
disclosure formulated in a compatible pharmaceutical carrier may
also be prepared, placed in an appropriate container, and labeled
for treatment of an indicated condition.
[0600] In some formulations it may be beneficial to use the
compounds of the present disclosure in the form of particles of
very small size, for example as obtained by fluid energy
milling.
[0601] The use of compounds of the present disclosure in the
manufacture of pharmaceutical compositions is illustrated by the
following description. In this description the term "active
compound" denotes any compound of the disclosure but particularly
any compound which is the final product of one of the following
Examples.
a) Capsules
[0602] In the preparation of capsules, 10 parts by weight of active
compound and 240 parts by weight of lactose can be de-aggregated
and blended. The mixture can be filled into hard gelatin capsules,
each capsule containing a unit dose or part of a unit dose of
active compound.
b) Tablets
[0603] Tablets can be prepared, for example, from the following
ingredients.
TABLE-US-00001 Parts by weight Active compound 10 Lactose 190 Maize
starch 22 Polyvinylpyrrolidone 10 Magnesium stearate 3
[0604] The active compound, the lactose and some of the starch can
be de-aggregated, blended and the resulting mixture can be
granulated with a solution of the polyvinylpyrrolidone in ethanol.
The dry granulate can be blended with the magnesium stearate and
the rest of the starch. The mixture is then compressed in a
tabletting machine to give tablets each containing a unit dose or a
part of a unit dose of active compound.
c) Enteric Coated Tablets
[0605] Tablets can be prepared by the method described in (b)
above. The tablets can be enteric coated in a conventional manner
using a solution of 20% cellulose acetate phthalate and 3% diethyl
phthalate in ethanol:dichloromethane (1:1).
d) Suppositories
[0606] In the preparation of suppositories, for example, 100 parts
by weight of active compound can be incorporated in 1300 parts by
weight of triglyceride suppository base and the mixture formed into
suppositories each containing a therapeutically effective amount of
active ingredient.
[0607] In the compositions of the present disclosure the active
compound may, if desired, be associated with other compatible
pharmacologically active ingredients. For example, the compounds of
this disclosure can be administered in combination with another
therapeutic agent that is known to treat a disease or condition
described herein. For example, with one or more additional
pharmaceutical agents that inhibit or prevent the production of
VEGF or angiopoietins, attenuate intracellular responses to VEGF or
angiopoietins, block intracellular signal transduction, inhibit
vascular hyperpermeability, reduce inflammation, or inhibit or
prevent the formation of edema or neovascularization. The compounds
of the disclosure can be administered prior to, subsequent to or
simultaneously with the additional pharmaceutical agent, whichever
course of administration is appropriate. The additional
pharmaceutical agents include, but are not limited to, anti-edemic
steroids, NSAIDS, ras inhibitors, anti-IL1 agents, antihistamines,
PAF-antagonists, COX-1 inhibitors, COX-2 inhibitors, NO synthase
inhibitors, Akt/PTB inhibitors, IGF-1R inhibitors, PKC inhibitors,
PI3 kinase inhibitors, calcineurin inhibitors and
immunosuppressants. The compounds of the disclosure and the
additional pharmaceutical agents act either additively or
synergistically. Thus, the administration of such a combination of
substances that inhibit angiogenesis, vascular hyperpermeability
and/or inhibit the formation of edema can provide greater relief
from the deleterious effects of a hyperproliferative disorder,
angiogenesis, vascular hyperpermeability or edema than the
administration of either substance alone. In the treatment of
malignant disorders combinations with antiproliferative or
cytotoxic chemotherapies or radiation are included in the scope of
the present disclosure.
[0608] The present disclosure also comprises the use of a compound
of Formula (I) as a medicament.
[0609] A further aspect of the present disclosure provides the use
of a compound of Formula (I) or a salt thereof in the manufacture
of a medicament for treating vascular hyperpermeability,
angiogenesis-dependent disorders, proliferative diseases and/or
disorders of the immune system in mammals, particularly human
beings.
[0610] The present disclosure also provides a method of treating
vascular hyperpermeability, inappropriate neovascularization,
proliferative diseases and/or disorders of the immune system which
comprises the administration of a therapeutically effective amount
of a compound of Formula (I) to a mammal, particularly a human
being, in need thereof.
EXAMPLES
Abbreviations
TABLE-US-00002 [0611] Ac Acetyl n- Normal (nonbranched) AcOH
Glacial acetic acid mmol Millimole aq. Aqueous N Normal Boc
t-Butoxycarbonyl N.sub.2 Nitrogen Bu Butyl NaBH(OAc).sub.3 Sodium
triacetoxyborohydride d Doublet NBS N-Bromosuccinimide dba
Dibenzylideneacetone NH.sub.4OAc Ammonium acetate dd Doublet of
doublets NMP 1-Methyl-2-pyrrolidinone DCM Dichloromethane
(methylene NMR Nuclear magnetic resonance chloride) DIEA
N,N-Diisopropylethylamine Pd(OAc).sub.2 Palladium(II) acetate DMAP
4-Dimethylaminopyridine pH -log[H.sup.+] DMF N,N-Dimethylformamide
Pd(dppf)Cl.sub.2 [1,1'-
Bis(diphenylphosphino)ferrocene]dichloropalladium (II) DMSO
Dimethyl sulfoxide Pd.sub.2(dba).sub.3
Tris(dibenzylideneacetone)dipalladium(0) dppf 1,1'-
Pd(PPh.sub.3).sub.4 Tetrakis(triphenylphosphine)palladium(0)
Bis(diphenylphosphino)ferrocene EDTA Ethylene diamine tetraacetic
PPh.sub.3 Triphenylphosphine acid Et Ethyl PBr.sub.3 Phosphorus
tribromide EtOAc Ethyl acetate ppm Parts per million EtOH Ethanol
R.sub.t Retention time Et.sub.2O Diethyl ether rt Room temperature
g Gram(s) s Singlet h Hour(s) sat. Saturated HEPES N-2- SEM
2-(Trimethylsilyl)ethoxymethyl Hydroxyethylpiperazine-N'-
2-ethanesulfonic acid HPLC High-pressure liquid SPE Solid phase
extraction chromatography IPA Isopropyl alcohol Soln Solution KOAc
Potassium acetate SM Small molecule LC/MS Liquid
chromatography/mass t Triplet spectrometry LiHMDS Lithium TBS
tert-Butyldimethylsilyl bis(trimethylsilyl)amide m Multiplet TBDPS
tert-Butyldiphenylsilyl M Molar TEA Triethylamine Me Methyl tert-
Tertiary MeCN Acetonitrile TNF.alpha. Tumor necrosis factor alpha
MeI Iodomethane TEA Trifluoroacetic acid MeOH Methyl alcohol THF
Tetrahydrofuran min Minute(s) THP Tetrahydro-2H-pyran-2-yl MS Mass
spectrometry trt Trityl MsCl Methanesulfonyl chloride UV
Ultraviolet q Quartet
TNF.alpha. FP Competitive Binding Assay
Solution Preparation
[0612] 1. Assay Buffer: Prepare 1.times. Assay Buffer (Water with
47 mM HEPES, 47 mM NaCl, 0.9 mM EDTA, 0.0071% Triton X-100) by
adding 25 mL of 1 M HEPES, 5 mL of 5 M NaCl, 1 mL of 0.5 M EDTA,
and 375 .mu.L of a 10% Triton X-100 stock to a fresh 500 mL bottle
of water. [0613] 2. Assay Mixture: Prepare fresh Assay Mixture
containing 20 nM TNF.alpha. trimer (60 nM protein) and 1 nM
2',7'-difluoro-3',6'-dihydroxy-N-(2-(2-(2-((4-(isoquinolin-8-yl)-3-(4-(is-
oquinolin-8-yl)phenethoxy)benzyl)oxy)ethoxy)ethoxy)ethyl)-3-oxo-3H-spiro[i-
sobenzofuran-1,9'-xanthene]-5-carboxamide probe in 1.times. Assay
Buffer.
Compound Plate Preparation
[0614] Manual 12-point 1:3 Dilution Plates: (384 well polypropylene
plates)
[0615] Top concentration of compounds, 10 mM in DMSO, dispensed in
rows A-O in columns 1 and 13.
[0616] Compounds are serially diluted 1:3 with DMSO in columns 2-12
or 14-24 using a 16-channel Matrix pipettor. Plates stored at
-20.degree. C.
Discovery Preps 12-point 1:3 Dilution Plates: (384 well assay
plates)
[0617] Top concentration, 5 mM in DMSO, of compounds placed in rows
A-O in columns 1 and 13.
[0618] Compounds are serially diluted 1:3 with DMSO in columns 2-12
or 14-24. Compound solutions are dispensed into replicate assay
plates at 410 nL per well. Plates stored at 4.degree. C.
TNF.alpha. FP Competitive Binding Assay Protocol
[0619] 1. Compound plates warmed to rt. [0620] 2. Fresh Assay
Mixture is prepared. [0621] 3. Assay Mixture (20 .mu.L) is
dispensed each well of 384 assay plates using a Thermo Multidrop
Combi or 16-channel Matrix pipettor. If Manual 12-point 1:3
Dilution Plates are to be tested, Assay Mix is dispensed into empty
plates. Discovery Preps 12-point 1:3 Dilution Plates already
contain 410 nL compound solution in DMSO. [0622] 4. For Manual
12-point 1:3 Dilution Plates, 0.7 .mu.L is manually transferred
using a 16-channel Matrix pipettor to replicate assay plates
containing 20 .mu.L Assay Mixture for a final top compound
concentration of 338 .mu.M (3.4% DMSO). [0623] 5. For Discovery
Preps 12-point 1:3 Dilution Plates, 20 .mu.L Assay Mixture added
the 410 nL compound solution already in the plates yields a final
top compound concentration of 100 .mu.M (2.0% DMSO). [0624] 6.
Background subtraction controls are wells P1-P8 containing only
Assay Buffer. The low % inhibition controls are wells P9-P16
containing only Assay Mix. The high % inhibition are wells P17-P24
containing only 1 nM
2',7'-difluoro-3',6'-dihydroxy-N-(2-(2-(2-((4-(isoquinolin-8-yl)-3-(4-(is-
oquinolin-8-yl)phenethoxy)benzyl)oxy)ethoxy)ethoxy)ethyl)-3-oxo-3H-spiro[i-
sobenzofuran-1,9'-xanthene]-5-carboxamide probe in 1.times. Assay
Buffer. [0625] 7. Plates are incubated at rt for 18-24 h in
37.degree. C. incubator (CO.sub.2 is off). [0626] 8. Prior to
reading the assay, the plates are placed in a dark cabinet to
equilibrate at rt for one hour. [0627] 9. Background-subtracted
fluorescence polarization (mP) is measured using a PerkinElmer
Envision plate reader. [0628] 10. Raw data is entered into Assay
Explorer and dose-response curves are generated using a variable
slope curve.
Supplies, Materials, and Reagents
TABLE-US-00003 [0629] Item Vendor Catalog # HEPES (1M) Invitrogen
15630-080 EDTA (0.5M) Invitrogen 15575-038 NaCl (5M) Sigma S5150
Triton X-100 Sigma T8787 Water Invitrogen 10977-015
SM-antiTNF.alpha. Abbvie 2',7'-difluoro-3',6'-dihydroxy-
OregonGreen488 N-(2-(2-(2-((4-(isoquinolin-8- probe
yl)-3-(4-(isoquinolin-8-yl)phenethoxy)
benzyl)oxy)ethoxy)ethoxy)ethyl)- 3-oxo-3H-spiro[isobenzofuran-1,9'-
xanthene]-5-carboxamide Corning 3676 Corning 3676 Compound Plate:
384 Well Low Volume Black Round Bottom Polystyrene NBS
[0630] For the purpose of the Tables and Examples below, the FP
binding assay IC.sub.50 of each compound is expressed as follows:
A=a compound with IC.sub.50 less than 1 .mu.M, B=a compound with
IC.sub.50 within the range of 1 .mu.M to 10 .mu.M, and C=a compound
with a TNF.alpha. IC.sub.50 greater than 10 .mu.M.
Preparation A: SM-AntiTNF.alpha. OregonGreen488 Probe
Preparation of 2-(4-(isoquinolin-8-yl)phenyl)ethanol
##STR00005##
[0631] Step 1:
2-(4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethanol
[0632] KOAc (4.88 g, 49.7 mmol),
4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (7.6 g,
30 mmol) and PdCl.sub.2(dppf) (0.91 g, 1.2 mmol) were added to a
solution of 2-(4-bromophenyl)ethanol (5.0 g, 25 mmol) in
1,4-dioxane (100 mL) under N.sub.2. The mixture was purged with
N.sub.2 then stirred under N.sub.2 at about 85.degree. C. for about
12 h. After cooling to rt, water (100 mL) was added and the mixture
was extracted with EtOAc (2.times.100 mL). The combined organic
layers were washed with sat. aq. NaCl (100 mL) and dried over
Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure.
The residue was purified by flash chromatography on silica gel (17%
EtOAc/petroleum ether). The appropriate fractions were collected
and concentrated under reduced pressure to afford the title product
(6.2 g, 100%). .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.78 (d,
J=7.9 Hz, 2H), 7.29-7.23 (m, 2H), 3.87 (t, J=6.6 Hz, 2H), 2.90 (t,
J=6.6 Hz, 2H), 1.36 (s, 12H).
Step 2: 2-(4-(Isoquinolin-8-yl)phenyl)ethanol
[0633] A vigorously stirred mixture of
2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethanol
(2.0 g, 8.1 mmol), 8-bromoisoquinoline (1.7 g, 8.1 mmol), cesium
carbonate (5.3 g, 16 mmol), and 1,4-dioxane (80 mL) was degassed
with N.sub.2. PdCl.sub.2(dppf) (0.30 g, 0.40 mmol) was added. The
mixture was purged with N.sub.2 and then stirred at about
100.degree. C. for about 2 h. After cooling to rt, the reaction
mixture was partitioned between water (50 mL) and EtOAc (3.times.50
mL). The combined organic layers were dried over Na.sub.2SO.sub.4,
filtered, and concentrated under reduced pressure. The residue was
purified by flash chromatography on silica gel (0-5% MeOH/DCM). The
appropriate fractions were collected and concentrated under reduced
pressure to afford the title product (169 mg, 88%). MS m/z: 250
(M+H).sup.+.
Preparation B: Methyl 3-hydroxy-4-(isoquinolin-8-yl)benzoate
##STR00006##
[0634] Step 1: Methyl
3-hydroxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate
[0635] KOAc (1.27 g, 13.0 mmol) was added to a solution of methyl
4-bromo-3-hydroxybenzoate (1.0 g, 4.3 mmol) in 1,4-dioxane (20 mL)
under N.sub.2 followed by addition of
4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (2.2 g,
8.7 mmol) and PdCl.sub.2(dppf) (0.18 g, 0.22 mmol). The mixture was
purged with N.sub.2 then stirred at about 80.degree. C. for about 3
h. The reaction mixture was cooled to rt and water (50 mL) was
added. The mixture was extracted with EtOAc (3.times.50 mL). The
combined organics were dried over Na.sub.2SO.sub.4, filtered, and
concentrated under reduced pressure. The residue was purified by
flash chromatography on silica gel (0-10% MeOH/DCM). The
appropriate fractions were combined and concentrated under reduced
pressure to afford the title product (1.13 g, 94%). .sup.1H NMR
(400 MHz, CDCl.sub.3) .delta. 7.81 (s, 1H), 7.60 (d, J=8.1 Hz, 1H),
7.50-7.40 (m, 2H), 3.84 (s, 3H), 1.31 (s, 12H).
Step 2: Methyl 3-hydroxy-4-(isoquinolin-8-yl)benzoate
[0636] EtOH (100 mL) was added to a mixture of sodium carbonate
(2.04 g, 19.2 mmol), Pd(OAc).sub.2 (0.022 g, 0.096 mmol),
8-bromoisoquinoline (2.00 g, 9.61 mmol), methyl
3-hydroxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate
(2.67 g, 9.61 mmol), and
dicyclohexyl(2',6'-dimethoxy-[1,1'-biphenyl]-2-yl)phosphine (0.079
g, 0.19 mmol) under N.sub.2. The mixture was degassed with N.sub.2
and then heated to about 80.degree. C. for about 16 h. Water (200
mL) was added and the resulting solid was collected by filtration
then dried to afford the title product (1.27 g, 47%). MS m/z: 280
(M+H).sup.+.
Preparation #C:
2',7'-Difluoro-3',6'-dihydroxy-N-(2-(2-(2-((4-(isoquinolin-8-yl)-3-(4-(is-
oquinolin-8-yl)phenethoxy)benzyl)oxy)ethoxy)ethoxy)ethyl)-3-oxo-3H-spiro[i-
sobenzofuran-1,9'-xanthene]-5-carboxamide
##STR00007## ##STR00008##
[0637] Step 1: Methyl
4-(isoquinolin-8-yl)-3-(4-(isoquinolin-8-yl)phenethoxy)benzoate
[0638] Cyanomethylenetributylphosphorane (0.90 mL, 3.4 mmol) was
added to a mixture of methyl 3-hydroxy-4-(isoquinolin-8-yl)benzoate
(800 mg, 2.86 mmol), 2-(4-(isoquinolin-8-yl)phenyl)ethanol (714 mg,
2.86 mmol), and toluene (30 mL). After stirring for about 4 h at
about 100.degree. C., the reaction mixture was allowed to cool to
rt. Tri-n-butylphosphine (0.71 mL, 2.9 mmol) and
(E)-N1,N1,N2,N2-tetramethyldiazene-1,2-dicarboxamide (493 mg, 2.86
mmol) were added respectively. After stirring at rt for about 18 h,
the organic volatiles were removed under reduced pressure. The
residue was purified by flash chromatography on silica gel (20%
acetone/hexanes). The appropriate fractions were collected and
concentrated under reduced pressure to afford the title product
(1.07 g, 73%). MS m/z: 511 (M+H).sup.+.
Step 2:
(4-(Isoquinolin-8-yl)-3-(4-(isoquinolin-8-yl)phenethoxy)phenyl)met-
hanol
[0639] Lithium aluminum hydride (1 M solution in THF, 0.4 mL, 0.4
mmol) was added to a solution of methyl
4-(isoquinolin-8-yl)phenethoxy)benzoate (204 mg, 0.400 mmol) and
THF (3.6 mL) under N.sub.2 at about 0.degree. C. After about 1 h,
10% aqueous sodium potassium tartrate (6 mL) was added. The
reaction was allowed to warm to rt. After about 10 min at rt, EtOAc
(10 mL) was added. The layers were separated and the aqueous layer
was extracted with EtOAc (10 mL). The combined organics were washed
with sat. aq. NaCl (10 mL), dried over MgSO.sub.4, filtered and
concentrated under reduced pressure. The residue was purified by
flash chromatography on silica gel (0-5% MeOH/CHCl.sub.3). The
appropriate fractions were collected and concentrated under reduced
pressure to afford the title product (169 mg, 88%). MS m/z: 483
(M+H).sup.+.
Step 3:
2-(2-(2-((4-(Isoquinolin-8-yl)-3-(4-(isoquinolin-8-yl)phenethoxy)b-
enzyl)oxy)ethoxy)ethoxy)ethanamine
[0640]
(4-(Isoquinolin-8-yl)-3-(4-(isoquinolin-8-yl)phenethoxy)phenyl)meth-
anol (31 mg, 0.064 mmol) and
2,2-dimethyl-4-oxo-3,8,11-trioxa-5-azatridecan-13-yl
methanesulfonate (32 mg, 0.096 mmol) were combined in DMF (1 mL).
Sodium hydride (10 mg, 0.26 mmol) was added in one portion. The
reaction was stirred at rt for about 16 h. 50% MeCN/water (1 mL)
was added and the resulting mixture was lyophilized to dryness. The
residue was diluted with 90% DMSO/water (3 mL) and purified in one
injection using RP-HPLC (Waters Deltapak C18 200.times.25 mm
column) with time collection. The appropriate peak was collected
and lyophilized. The residue was dissolved in TFA (2 mL) and shaken
at rt for about 1 min. The volatiles were evaporated under a stream
of dry nitrogen gas. The film was dissolved in 50% MeCN/water (1
mL) and lyophilized to afford a trifluoroacetate salt of the title
compound (10 mg, 19%). MS m/z: 614 (M+H).sup.+.
Step 4:
2',7'-difluoro-3',6'-dihydroxy-N-(2-(2-(2(4-(Isoquinolin-8-yl)-3-(-
4-(isoquinolin-8-yl)phenethoxy)benzyl)oxy)ethoxy)ethoxy)ethyl)-3-oxo-3H-sp-
iro[isobenzofuran-1,9'-xanthene]-5-carboxamide
[0641]
2-(2-(2-((4-(Isoquinolin-8-yl)-3-(4-(isoquinolin-8-yl)phenethoxy)be-
nzyl)oxy)ethoxy)ethoxy)ethanamine (9.38 mg, 9.82 .mu.mol) and
2,5-dioxopyrrolidin-1-yl
2',7'-difluoro-3',6'-dihydroxy-3-oxo-3H-spiro[isobenzofuran-1,9'-xanthene-
]-5-carboxylate (5 mg, 10 .mu.mol) were combined in 1% DIEA/DMF (1
mL) and shaken at rt. After completion, the reaction was diluted
with 90% DMSO/water (2 mL) and purified in one injection using
RP-HPLC (Waters Deltapak C18 200.times.25 mm column) with slope
collection. The appropriate peak was collected and lyophilized to
afford the title product (4.1 mg, 41%). MS m/z: 1008
(M+H).sup.+.
Analytical Methods
[0642] Analytical data was included within the procedures below or
in the tables of examples. Unless otherwise stated, all .sup.1H NMR
data were collected on a Varian 400 MHz Mercury Plus, Inova, or
400-MR instrument and chemical shifts are quoted in parts per
million (ppm). LC/MS and HPLC data are referenced to the table of
LC/MS and HPLC conditions using the lower case method letter
provided in Table A.
TABLE-US-00004 TABLE A LC/MS and HPLC methods Method Conditions a
LC/MS: The gradient was 5-60% B in 1.5 min then 60-95% B to 2.5 min
with a hold at 95% B for 1.2 min (1.3 mL/min flow rate). Mobile
phase A was 10 mM NH.sub.4OAc, mobile phase B was HPLC grade MeCN.
The column used for the chromatography is a 4.6 .times. 50 mm
MAC-MOD Halo C18 column (2.7 .mu.m particles). Detection methods
are diode array (DAD) and evaporative light scattering (ELSD)
detection as well as positive/negative electrospray ionization. b
LC/MS: The gradient was 10% B for 0.1 min, 10-100% from 0.1 to 1.1
min, hold till 1.3 min, and then back to 10% till over 0.1 min (1.0
mL/min flow rate). Mobile phase A was 0.1% TFA. in water, mobile
phase B was HPLC grade MeCN. The column used for the chromatography
was a 2.1 .times. 30 mm Waters BEH C8 (1.7 .mu.m particles).
Detection methods were diode array (DAD) and evaporative light
scattering (ELSD) detection as well as positive/negative
electrospray ionization c HPLC: The gradient was 10-100% B over 25
min (21 mL/min flow rate). Mobile phase A was 0.05N NH.sub.4OAc
buffer (pH = 4.5), mobile phase B was HPLC grade MeCN. The column
used for the chromatography is 250 .times. 21.1 mm Hypersil HS C18
(8 .mu.m particles). Detection method is UV (245 nm) d HPLC: The
gradient was 20-100% B over 25 min (21 mL/min flow rate). Mobile
phase A was 0.05N NH.sub.4OAc buffer (pH = 4.5), mobile phase B was
HPLC grade MeCN. The column used for the chromatography is 250
.times. 21.1 mm Hypersil HS C18 (8 .mu.m particles). Detection
method is UV (360 nm) e LC/MS: The gradient was 5-60% B in 1.50 min
then 60-95% B to 2.5 min with a hold at 95% B for 1.2 min (1.3
mL/min flow rate). Mobile phase A was 10 mM NH.sub.4OAc, mobile
phase B was HPLC grade MeCN. The column used for the chromatography
was a 4.6 .times. 50 mm MAC-MOD Halo C8 column (2.7 .mu.m
particles), Detection methods were diode array (DAD) and
evaporative light scattering (ELSD) detection as well as
positive/negative electrospray ionization. f HPLC: The gradient was
5-45% B in 9.5 min then 45-95% B to 10 min with a hold at 95% B for
2 min (25 mL/min flow rate). Mobile phase A was 0.1% formic acid in
water, mobile phase B was HPLC grade MeCN. The column used for the
chromatography is a 19 .times. 50 mm Waters Atlantis C18 column (5
.mu.m particles). Detection methods are diode array (DAD) and
positive/negative APCI ionization. g HPLC: The gradient was 10-100%
B over 25 min (21 mL/min flow rate). Mobile phase A was 0.05N
NH.sub.4OAc buffer (pH = 4.5), mobile phase B was HPLC grade MeCN.
The column used for the chromatography is 250 .times. 21.1 mm
Hypersil HS C18 (8 .mu.m particles). Detection method is UV (280
nm) h LC/MS: The gradient was 5-60% B in 1.6 min then 60-95% B to
2.2 min with a hold at 95% B for 0.1 min (1.0 mL/min flow rate).
Mobile phase A was 10 mM NH.sub.4OAc, mobile phase B was HPLC grade
MeCN. The column used for the chromatography is a 2.1 .times. 30 mm
Waters Cortecs C18 column (1.6 .mu.m particles). Detection methods
are diode array (DAD) and evaporative light scattering (ELSD)
detection as well as positive/negative electrospray ionization. i
LC/MS: The gradient was 5-60% B in 1.6 min then 60-95% B to 2.2 min
with a hold at 95% B for 0.1 min (1.0 mL/min flow rate). Mobile
phase A was 10 mM NH.sub.4OAc, mobile phase B was HPLC grade MeCN.
The column used for the chromatography is a 2.1 .times. 30 mm
Waters Cortecs C18 column (1.6 .mu.m particles). Detection methods
are diode array (DAD) and evaporative light scattering (ELSD)
detection as well as positive/negative electrospray ionization.) j
LC/MS: Halo-2 C8 monitoring method: The gradient was 5-60% B in 1.6
min then 60-95% B to 2.2 min with a hold at 95% B for 0.1 min (1.0
mL/min flow rate). Mobile phase A was 10 mM NH.sub.4OAc, mobile
phase B was HPLC grade MeCN. The column used for the chromatography
is a 2.1 .times. 30 mm Halo-2 C8 column (2 .mu.m particles).
Detection methods are diode array (DAD) and evaporative light
scattering (ELSD) detection as well as positive/negative
electrospray ionization.) k LC/MS: The gradient was 25-95% B in 1.6
min then a hold at 95% B for 1.2 min (1.0 mL/min flow rate). Mobile
phase A was 10 mM NH.sub.4OAc, mobile phase B was HPLC grade MeCN.
The column used for the chromatography is a 2.1 .times. 30 mm
Waters Cortecs C18 column (1.6 .mu.m particles). Detection methods
are diode array (DAD) and evaporative light scattering (ELSD)
detection as well as positive/negative electrospray ionization. l
HPLC: The gradient was a hold at 5% B for 1.4 min, then 5-95% B
over 8.5 min, then a hold at 95% B for 1.1 min (83 mL/min flow
rate). Mobile phase A was 10 mM NH.sub.4OAc buffer (pH = 4.2),
mobile phase B was HPLC grade MeCN. The column used for the
chromatography is a 100 .times. 50 mm Atlantis Prep T3 OBD C18
column (5 .mu.m particles). Detection method is UV (254 nm). m
HPLC: Step gradient separation method wherein mobile phase B was
MeCN, mobile phase A was 0.10% formic acid in water. Flow rate was
25 mL/min. Gradient was held at 15% B for 2.5 min, then ramp to 40%
B in 28.5 min, then ramp to 95% B in 0.1 min and hold for 8.4 min.
The column used for the chromatography was a Phenomenex: Kinetek
EVO Prep (21.2 .times. 150 mm, 5 .mu.m particles).
TABLE-US-00005 TABLE B Chiral HPLC methods Method conditions a Step
gradient separation method wherein mobile phase B was EtOH (200
proof), mobile phase A was HPLC grade heptane with 0.20%
diethylamine. Flow rate was 20 mL/min. Gradient was held at 30% B
for 12.4 min, then ramp to 60% B in 0.2 min, hold for 5.4 min. The
column used for the chromatography was a YMC-SA column (20 .times.
250 mm, 5 .mu.m particles). b Isocratic - 20% B for 36 min (20
mL/min flow rate). Mobile phase B was EtOH (200 proof), mobile
phase A was HPLC grade heptane with 0.2% diethylamine added. The
column used for the chromatography used a Daicel ADH column (20
.times. 250 mm, 5 .mu.m particles). c Gradient separation method
wherein mobile phase B was 50% EtOH (200 proof)/MeOH, mobile phase
A was HPLC grade heptane with 0.2% diethylamine added. Flow rate
was 20 mL/min. Gradient was 10-35% B in 0.5 min then 35-70% B over
24.5 min then hold at 70% for 10 min. The column used for the
chromatography was a Daicel ID column (20 .times. 250 mm, 5 .mu.m
particles). d Step gradient separation method wherein mobile phase
B was 80:20 HPLC grade isopropanol:MeCN, mobile phase A was HPLC
grade heptane with 0.2% diethylamine added. Flow rate was 20
mL/min. Gradient was 60% B for 12 min then step to 80% B in 0.5 min
and hold at 80% B for 5 min. The column used for the chromatography
was a YMC-SA (20 .times. 250 mm, 5 .mu.m particles). e Step
gradient separation method wherein mobile phase B was HPLC grade
isopropanol, mobile phase A was HPLC grade heptane with 0.2%
diethylamine added. Flow rate was 20 mL/min. Gradient was 20% B for
2 min then 20-70% B in 1 min, hold at 70% B for 10 min then step to
80% B for 4 min. The column used for the chromatography was a YMC-
SB (20 .times. 250 mm, 5 .mu.m particles). f Step gradient
separation method wherein mobile phase B was IPA, mobile phase A
was HPLC grade heptane with 0.10% DEA. Flow rate was 4 mL/min.
Gradient was held at 10% B for 1.0 min, then ramp to 55% B in 6.0
min, hold for 1.0 min. The column used for the chromatography was a
YMC-SB column (4.6 .times. 250 mm, 5 .mu.m particles).
TABLE-US-00006 TABLE C SFC methods Method Conditions a 30% ethanol
in CO.sub.2 (60 mL/min, 130 bar, 35.degree. C.) Cycle time was 4.8
min, with single run time of 10 min. 200 proof ethanol was used
with SFC grade CO.sub.2. The chromatography used a YMC-SA, 21
.times. 250 mm column (5 .mu.m particles). b A gradient of (10%
ethanol for 0.7 min, then 10-55% ethanol over 5.3 min then hold at
55% ethanol for 1.5 min) in CO.sub.2 (3.5 mL/min, 110 bar,
340.degree. C.). Run time was 9 min. 200 proof ethanol was used
with SFC grade CO.sub.2. The chromatography used a YMC-SB, 4.6
.times. 100 mm column (3 .mu.m particles). c 30% methanol in
CO.sub.2 (56 mL/min, 226 bar, 39.degree. C.). Cycle time was 4.1
min, with single run time of 10 min. HPLC grade methanol was used
with SFC grade CO.sub.2. The chromatography used a YMC Amylose-C,
30 .times. 250 mm column (5 .mu.m particles). d 25% (80:20)
isopropanol:MeCN (0.2% diethylamine modifier) in CO.sub.2 (45
mL/min, 140 bar, 35.degree. C.). Cycle time was 10.5 min, with
single run time of 22 min. HPLC grade isopropanol and MeCN were
used with SFC grade CO.sub.2. The chromatography used a YMC-SA, 20
.times. 250 mm column (5 .mu.m particles). e 27% 80:20
isopropanol:MeCN (0.2% diethylamine modifier) in CO.sub.2 (65
mL/min, 140 bar, 35.degree. C.). Cycle time was 6 min, with single
run time of 12 min. HPLC grade isopropanol and MeCN were used with
SFC grade CO.sub.2. The chromatography used a YMC-SA, 20 .times.
250 mm column (5 .mu.m particles). f Gradient 15-28% methanol in
CO.sub.2 (55 mL/min, 140 bar, 35.degree. C.). Cycle time and run
times were 16.9 min. HPLC grade methanol was used with SFC grade
CO.sub.2. The chromatography used a YMC-SA, 20 .times. 250 mm
column. (5 .mu.m particles).
Compound Syntheses
[0643] Starting materials are commercially available, may be
prepared by the procedures described herein, by literature
procedures, or by procedures that would be well known to one
skilled in the art of organic chemistry. Reagent/reactant names
given are as named on the commercial bottle or as generated by
IUPAC conventions, CambridgeSoft.RTM. ChemDraw Ultra 12.0,
CambridgeSoft.RTM. ChemDraw Professional 15.0,
CambridgeSoft.RTM..times.Chemistry E-Notebook 11, or AutoNom 2000.
None of the specific conditions and reagents noted herein are to be
construed as limiting the scope of the disclosure and are provided
for illustrative purposes only. Compounds designated as salts
(e.g., hydrochloride, trifluoroacetate) may contain more than one
molar equivalent of the salt or may contain the acid as an
excipient. Compounds of the disclosure where the absolute
stereochemistry has been determined by the use of a commercially
available enantiomerically pure starting material or a
stereochemically defined intermediate or by X-ray diffraction are
denoted by an asterisk after the example number. Otherwise the
absolute stereochemistry is unknown and assigned randomly as
drawn.
[0644] Compounds of the disclosure may be prepared using synthetic
transformations shown herein. For groups of compounds that have
been prepared in a similar fashion, a representative example is
given followed by a table of these similarly prepared compounds. It
should be appreciated by one skilled in the art that minor
modifications to the representative example may be necessary to
successfully execute these syntheses. Prepared compounds may be
purified by any technique or combination of techniques known to one
skilled in the art. Some examples that are not limiting include
column chromatography with a solid phase (i.e. silica gel, alumina,
etc.) and a solvent (or combination of solvents) that elutes the
desired compounds (i.e. hexanes, heptane, EtOAc, DCM, MeOH, EtOH,
MeCN, water, etc.); preparatory TLC with a solid phase (i.e. silica
gel, alumina etc.) and a solvent (or combination of solvents) that
elutes the desired compounds (i.e. hexanes, heptane, EtOAc, DCM,
MeOH, EtOH, MeCN, water, etc.); reverse phase HPLC (see Table 1 for
some non-limiting conditions); recrystallization from an
appropriate solvent (i.e. MeOH, EtOH, IPA, EtOAc, toluene, etc.) or
combination of solvents (i.e. EtOAc/heptane, EtOAc/MeOH, etc.);
chiral LC with a solid phase and an appropriate solvent (i.e.
EtOH/heptane, MeOH/heptane, IPA/heptane, etc. with or without a
modifier such as diethylamine, TFA, etc.) to elute the desired
compound; chiral SFC with a solid phase and CO.sub.2 with an
appropriate modifier (i.e. MeOH, EtOH, IPA with or without
additional modifier such as diethylamine, TFA, etc.); precipitation
from a combination of solvents (i.e. DMF/water, DMSO/DCM,
EtOAc/heptane, etc.); trituration with an appropriate solvent (i.e.
EtOAc, DCM, MeCN, MeOH, EtOH, IPA, n-PrOH, etc.); extractions by
dissolving a compound in a liquid and washing with an appropriately
immiscible liquid (i.e. DCM/water, EtOAc/water, DCM/sat. aq.
NaHCO.sub.3, EtOAc/sat. aq. NaHCO.sub.3, DCM/10% aqueous HCl,
EtOAc/10% aqueous HCl, etc.); distillation (i.e. simple,
fractional, Kugelrohr, etc.); gas chromatography using an
appropriate temperature, carrier gas and flow rate; sublimation at
an appropriate temperature and pressure; filtration through a media
(i.e. Florosil.RTM., alumina, Celite.RTM., silica gel, etc.) with a
solvent (i.e. heptane, hexanes, EtOAc, DCM, MeOH, etc.) or
combination of solvents; salt formation with solid support (resin
based, i.e. ion exchange) or without. Some descriptions of these
techniques can be found in the following references, Gordon, A. J.
and Ford, R. A. "The Chemist's Companion", 1972; Palleros, D. R.
"Experimental Organic Chemistry", 2000; Still, W. C., Kahn, M. and
Mitra, A. J. Org. Chem. 1978, 43, 2923; Yan. B. "Analysis and
Purification Methods in Combinatorial Chemistry" 2003; Harwood, L.
M., Moody, C. J. and Percy, J. M. "Experimental Organic Chemistry:
Standard and Microscale, 2.sup.nd Edition", 1999; Stichlmair, J. G.
and Fair, J. R. "Distillation; Principles and Practices" 1998;
Beesley T. E. and Scott, R. P. W. "Chiral Chromatography", 1999;
Landgrebe, J. A. "Theory and Practice in the Organic Laboratory,
4.sup.th Edition", 1993; Skoog, D. A. and Leary, J. J. "Principles
of Instrumental Analysis, 4.sup.th Edition" 1992; Subramanian, G.
"Chiral Separation Techniques 3.sup.th Edition" 2007; Kazakevich,
Y. and Lobrutto, R. "HPLC for Pharmaceutical Scientists" 2007.
Preparations
Preparation #1: 6-Bromo-2-methyl-1H-indazol-3(2H)-one
##STR00009##
[0645] Step 1: 4-Bromo-2-fluoro-N-methylbenzohydrazide
[0646] A flask was charged with 4-bromo-2-fluorobenzoic acid (5.00
g, 22.8 mmol) and DCM (125 mL). The suspension was treated with
DIEA (4.20 mL, 24.1 mmol) and stirred for about 10 min. The
reaction mixture was cooled to about -45.degree. C., MsCl (1.88 mL,
24.1 mmol) was added and the mixture was allowed to warm to rt.
After about 10 min, the mixture was added to a solution of
methylhydrazine (3.16 g, 68.5 mmol) in DCM (100 mL) at about
-40.degree. C. After the addition was complete, the mixture was
warmed to rt, concentrated and then partitioned between water (100
mL) and EtOAc (100 mL). The aqueous layer was extracted with EtOAc
(50 mL) and the combined organics were washed with water (50 mL)
and sat. aq. NaCl (30 mL), dried over MgSO.sub.4, filtered and
evaporated under reduced pressure to yield the title product (4.66
g, 83%); LC/MS (Table A, Method e) R.sub.t=1.56 min; MS m/z: 247,
249 (M+H).sup.+.
Step 2: 6-Bromo-2-methyl-1H-indazol-3(2H)-one
[0647] 4-Bromo-2-fluoro-N-methylbenzohydrazide (4.50 g, 18.2 mmol)
in DMF (90 mL) was treated with potassium 2-methylpropan-2-olate
(4.29 g, 38.2 mmol) and stirred for about 5 min at rt then heated
to about 85.degree. C. for about 1 h. The reaction mixture was then
cooled, concentrated under reduced pressure and then dissolved in
water (30 mL). The pH was adjusted to about 4 with AcOH and the
mixture was diluted with EtOAc (50 mL) then filtered. The
precipitate was washed with EtOAc (10 mL) to give the first crop of
the desired product. The layers were separated and the aqueous
layer was further extracted with EtOAc (3.times.50 mL). The
combined organics were washed with sat. aq. NaCl (25 mL), dried
over MgSO.sub.4, filtered and concentrated under reduced pressure.
EtOAc (20 mL) was added and the mixture was stirred at rt for about
16 h. The precipitate was collected via filtration rinsing with
EtOAc (5 mL) and then combined with the first crop to give the
title product (1.77 g, 43%); LC/MS (Table A, Method e) R.sub.t=1.43
min; MS m/z: 227 and 229 (M+H).sup.+.
Preparation #2:
2-Methyl-6-(2-morpholinopyrimidin-5-yl)-1H-indazol-3(2H)-one
##STR00010##
[0649] Pd(PPh.sub.3).sub.4(0.6 g, 0.5 mmol) was added to a
suspension of 6-bromo-2-methyl-1H-indazol-3(2H)-one (1.67 g, 7.35
mmol) (Preparation #1),
4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-yl)mor-
pholine (2.57 g, 8.83 mmol) and Cs.sub.2CO.sub.3(5.99 g, 18.4 mmol)
in 1,4-dioxane (20 mL) and water (5.0 mL) under N.sub.2. The
mixture purged with N.sub.2 and then heated to about 90.degree. C.
for about 2 h. The reaction mixture was allowed to cool to rt. DCM
(30 mL) with a few drops of MeOH and water (20 mL) were added. The
solid was collected by filtration then dried to give the title
product (1.88 g, 82%); LC/MS (Table A, Method e) R.sub.t=1.41 min;
MS m/z: 312 (M+H).sup.+
Preparation #3: 1-(1-Bromoethyl)-2-(difluoromethoxy)benzene
##STR00011##
[0650] Step 1: 1-(2-(Difluoromethoxy)phenyl)ethanol
[0651] A solution of 2-(difluoromethoxy)benzaldehyde (0.39 mL, 2.9
mmol) in THF (15 mL) was cooled to about -10.degree. C.
Methylmagnesium bromide (3 M in ether, 1.5 mL, 4.5 mmol) was added
dropwise over about 10 min. The resulting solution was left in the
cooling bath which was allowed to warm to rt and then the reaction
was left to stir for about 16 h. The reaction mixture was cooled to
about 0.degree. C. and then quenched by careful addition of sat.
aq. NH.sub.4Cl (10 mL). After separating the layers, the aqueous
phase was extracted with EtOAc (3.times.10 mL). The combined
organic phases were washed with sat. aq. NaCl (25 mL), dried over
Na.sub.2SO.sub.4, filtered, and concentrated under reduced pressure
to give the title product (0.54 g, 99%); .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 7.56 (dd, J=7.3, 2.1 Hz, 1H), 7.33-7.20 (m,
2H), 7.10-7.05 (m, 1H), 6.55 (t, J=74.2 Hz, 1), 5.24 (q, J=6.5 Hz,
1H), 1.50 (d, J=6.4 Hz, 3H).
Step 2: 6-Bromo-2-methyl-1H-indazol-3(2H)-one
[0652] PBr.sub.3 (1 M in DCM, 2.9 mL, 2.9 mmol) was added to a
solution of 1-(2-(difluoromethoxy)phenyl)ethanol (0.50 g, 2.7 mmol)
and DCM (13.3 mL) at about -10.degree. C. under N.sub.2. The
reaction was allowed to warm to rt over about 1 h by thawing of the
bath and then stirred at rt for about 16 h. The reaction mixture
was quenched at rt by careful addition of sat. aq. NaHCO.sub.3 (2
mL) and partitioned between DCM (10 mL) and water (5 mL). After
separating the layers, the organic phase was washed with sat. aq.
NaCl (10 mL), dried over Na.sub.2SO.sub.4, filtered, and
concentrated under reduced pressure to give the title product (0.55
g, 82%); .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.69-7.57 (m,
1H), 7.38-7.19 (m, 2H), 7.16-7.07 (m, 1H), 6.55 (dd, J=76.0, 72.0
Hz, 1H), 5.59 (q, J=7.0 Hz, 1H), 2.03 (d, J=7.3 Hz, 3H).
Preparation #4:
6-(2-Chloropyrimidin-5-yl)-1-(2-(difluoromethoxy)benzyl)-2-methyl-1H-inda-
zol-3(2H)-one
##STR00012##
[0653] Step 1:
6-Bromo-1-(2-(difluoromethoxy)benzyl)-2-methyl-1H-indazol-3(2H)-one
[0654] 6-Bromo-2-methyl-1H-indazol-3(2H)-one (1.25 g, 5.51 mmol)
(Preparation #1) in DMF (25 mL) with potassium carbonate (0.89 g,
6.4 mmol) was treated with
1-(bromomethyl)-2-(difluoromethoxy)benzene (1.38 g, 5.83 mmol).
After about 90 min, 1-(bromomethyl)-2-(difluoromethoxy)benzene
(0.090 g, 0.38 mmol) was added. After about 15 min, the organic
volatiles were removed under reduced pressure. Water (15 mL) and
ether (10 mL) were added. After stirring for about 15 min, the
solid was collected by filtration and then dried under reduced
pressure at about 65.degree. C. to give the title product (1.66 g,
79%); (Table A, Method e) R.sub.t=2.20 min; MS m/z: 383 and 385
(M+H).sup.+
Step 2:
1-(2-(Difluoromethoxy)benzyl)-2-methyl-6-(4,4,5,5-tetramethyl-1,3,-
2-dioxaborolan-2-yl)-1H-indazol-3(2H)-one
[0655] A flask was charged with
6-bromo-1-(2-(difluoromethoxy)benzyl)-2-methyl-1H-indazol-3(2H)-one
(1.66 g, 4.33 mmol) and DMF (20 mL). Nitrogen was bubbled through
the solution for about 15 min then the flask was charged with KOAc
(1.49 g, 15.2 mmol),
4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (1.54
g, 6.06 mmol) and PdCl.sub.2(dppf) (0.19 g, 0.26 mmol). The
reaction mixture was heated to about 90.degree. C. for about 1 h
then cooled, concentrated under reduced pressure, triturated with
DCM (30 mL) and filtered rinsing with DCM (10 mL). The filtrate was
concentrated under reduced pressure and the residue was purified
via flash chromatography on silica gel (0-50% EtOAc/DCM). The
appropriate fractions were collected and concentrated under reduced
pressure to yield the title product (1.64 g, 68%); (Table A, Method
e) R.sub.t=2.41 min; MS m/z: 431 (M+H).sup.+.
Step 3:
6-(2-Chloropyrimidin-5-yl)-1-(2-(difluoromethoxy)benzyl)-2-methyl--
1H-indazol-3(2H)-one
[0656] The reaction was performed using
1-(2-(difluoromethoxy)benzyl)-2-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxa-
borolan-2-yl)-1H-indazol-3(2H)-one and 5-bromo-2-chloropyrimidine
in a similar fashion to Preparation #2 to give the title product
(62%); (Table A, Method e) R.sub.t=2.08 min; MS m/z: 417
(M+H).sup.+.
Preparation #5:
6-Bromo-1-(2,6-dichlorobenzyl)-2-methylethyl-1H-indazol-3(2H)-one
##STR00013##
[0657] Step 1:
6-Bromo-1-(2,6-dichlorobenzyl)-1H-indazol-3(2H)-one
[0658] The reaction was performed using
6-bromo-1H-indazol-3(2H)-one and
2-(bromomethyl)-1,3-dichlorobenzene in a similar fashion to Example
#1 to give the title product (69%); (Table A, Method e)
R.sub.t=2.47 min; MS m/z: 371 and 373 (M+H).sup.+.
Step 2:
6-Bromo-1-(2,6-dichlorobenzyl)-2-methyl-1H-indazol-3(2H)-one
[0659] The reaction was performed using
6-bromo-1-(2,6-dichlorobenzyl)-1H-indazol-3(2H)-one and MeI in a
similar fashion to Example #14, step 3 to give the title product
(34%); (Table A, Method e) R.sub.t=2.41 min; MS m/z: 385 and 387
(M+H).sup.+.
Preparation #6:
6-Bromo-1-(2,5-dichlorophenyl)-2-methyl-1H-indazol-3(2H)-one
##STR00014##
[0660] Step 1:
4-Bromo-N'-(2,5-dichlorophenyl)-2-iodobenzohydrazide
[0661] To a solution of 4-bromo-2-iodobenzoic acid (0.500 g, 1.53
mmol) in THF (10 mL) was added di(1H-imidazol-1-yl)methanone (0.273
g, 1.68 mmol) and DMAP (0.019 g, 0.15 mmol). After stirring at rt
for about 2 h, the reaction was added dropwise to a solution of
(2,5-dichlorophenyl)hydrazine (0.298 g, 1.68 mmol) in THF (10 mL).
After about 1 h, the reaction was partitioned between DCM (30 mL)
and sat. aq. NaHCO.sub.3 (30 mL). The organic layer was washed with
sat. aq. NaCl (30 mL), dried over Na.sub.2SO.sub.4, filtered and
concentrated under reduced pressure. The residue was triturated in
DCM (20 mL), filtered and washed with DCM (10 mL) to give the title
product (0.51 g, 69%); LC/MS (Table A, Method e) R.sub.t2.57 min;
MS m/z: 483 and 485 (M-H).sup.-.
Step 2: 6-Bromo-1-(2,5-dichlorophenyl)-1H-indazol-3(2H)-one
[0662] A degassed solution of
4-bromo-N'-(2,5-dichlorophenyl)-2-iodobenzohydrazide (0.500 g, 1.03
mmol), L-proline (0.024 g, 0.21 mmol), K.sub.2CO.sub.3 (0.284 g,
2.06 mmol) and CuI (0.020 g, 0.10 mmol) in DMSO (10 mL) was stirred
under N.sub.2 at rt for about 1 h. The reaction was partitioned
between EtOAc (50 mL) and sat. aq. NaHCO.sub.3 (50 mL). The organic
layer was washed with sat. aq. NaCl (50 mL), dried over
Na.sub.2SO.sub.4, filtered, concentrated under reduced pressure.
The residue was purified by flash chromatography on silica gel
(0-20% EtOAc/heptane) to afford the title product (0.24 g, 64%);
LC/MS (Table A, Method e) R.sub.t=2.56 min; MS m/z: 357 and 359
(M+H).sup.+.
Step 3:
6-Bromo-1-(2,5-dichlorophenyl)-2-methyl-1H-indazol-3(2H)-one
[0663] 6-Bromo-1-(2,5-dichlorophenyl)-1H-indazol-3(2H)-one was
alkylated with MeI in a similar fashion to Example #14, step 3 to
give the title product (35%); LC/MS (Table A, Method e)
R.sub.t=2.44 min; MS m/z: 371 and 373 (M+H).sup.+.
Preparation #7: 1-(5-bromopyrazin-2-yl)piperidine-4-carboxylic
acid
##STR00015##
[0665] A suspension of piperidine-4-carboxylic acid (0.500 g, 3.87
mmol) in THF (10 mL) was added to a suspension of sodium hydride
(60 wt % in mineral oil, 0.325 g, 8.13 mmol) in THF (5 mL) at about
0.degree. C. After about 15 min, a solution of 2,5-dibromopyrazine
(0.921 g, 3.87 mmol) and THF (5 mL) was added. The mixture was
warmed to about 60.degree. C. After about 3 h, the reaction was
allowed to cool to rt. Sat. aq. NH.sub.4Cl (50 mL) was added. The
mixture was adjusted to .about.pH 2 with 1 N aqueous HCl and then
extracted with EtOAc (100 mL). The organics were dried over MgSO4,
filtered, and concentrated under reduced pressure. The residue was
purified by flash chromatography on silica gel (0-80% EtOAc/DCM) to
give the title product (0.130 g, 12%); LC/MS (Table A, Method e)
R.sub.t=1.75 min; MS m/z: 286 and 288 (M+H).sup.+.
Preparation #8:
4-(5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)piperazin--
2-one
##STR00016##
[0667] 4-(5-Bromopyridin-2-yl)piperazin-2-one (1.00 g, 3.90 mmol),
4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (2.97
g, 11.7 mmol), and KOAc (1.15 g, 11.7 mmol) were added to
1,4-dioxane (10 mL) and the mixture was purged with N.sub.2.
2-(Dicyclohexylphosphino)-2',4',6'-triisopropylbiphenyl (0.074 g,
0.16 mmol) and Pd.sub.2(dba).sub.3 (0.286 g, 0.312 mmol) were
added. The mixture and was purged with N.sub.2 and then heated to
about 100.degree. C. After about 2 h, the mixture was allowed to
cool to rt. EtOAc (10 mL) and MeOH (1 mL) were added and the
mixture was filtered through a pad of Celite.RTM., rinsing with
EtOAc. The organic volatiles were partially removed under reduced
pressure. The solid was collected by filtration, slurried in MeOH
(.about.5 mL) and then sonicated. The solid was collected by
filtration to give the title product (0.570 g, 48%); LC/MS (Table
A, Method e) R.sub.t=1.75 min; MS m/z: 304 (M+H).sup.+.
Preparation #9: (2-(Difluoromethoxy)-6-fluorophenyl)methanol
##STR00017##
[0669] Sodium borohydride (0.149 g, 3.94 mmol) was added to a
solution of 2-(difluoromethoxy)-6-fluorobenzaldehyde (0.250 g, 1.32
mmol) and MeOH (6.6 mL) at about -10.degree. C. After about 1 h,
water (5 mL) was added and the volatiles were removed under reduced
pressure. The residue was partitioned between EtOAc (10 mL) and
sat. aq. NaHCO.sub.3 (10 mL). The organic phase was washed with
sat. aq. NaCl (10 mL), dried over Na.sub.2SO.sub.4, filtered, and
concentrated under reduced pressure to give the title product
(0.219 g, 87%); .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.35-7.24
(m, 1H), 7.05-6.93 (m, 2H), 6.59 (t, J=73.3 Hz, 1H), 4.79 (d, J=1.5
Hz, 2H).
Preparation #10: (2-(Difluoromethoxy)-5-fluorophenyl)methanol
##STR00018##
[0671] Sodium chlorodifluoroacetate (1.80 g, 11.8 mmol) was added
in one portion to a mixture of methyl 5-fluoro-2-hydroxybenzoate
(1.00 g, 5.88 mmol), K.sub.2CO.sub.3 (3.25 g, 23.5 mmol), and DMF
(10.0 mL) under N.sub.2. The mixture was warmed to about 80.degree.
C. After about 5 h, water (1.0 mL) was added. The mixture was
warmed to about 100.degree. C. After about 15 h, the mixture was
allowed to cool rt. 2 M aqueous HCl (20 mL) was added portionwise
over about 30 min to adjust the reaction mixture to about pH 1. The
reaction mixture was extracted with Et.sub.2O (2.times.25 mL). The
combined organics were washed with sat. aq. NaCl (20 mL), dried
over Na.sub.2SO.sub.4, filtered, and concentrated under reduced
pressure. The residue was dissolved in Et.sub.2O (20 mL) under
N.sub.2 and then LiAlH.sub.4 (0.168 g, 4.42 mmol) was added in one
portion. After about 1 h, THF (10 mL) was added. After about 16 h,
the mixture was cooled to about 0.degree. C. Sodium sulfate
decahydrate was slowly added. The cold bath was removed and the
mixture was left to vigorously stir for about 43 h. The mixture was
filtered rinsing with Et.sub.2O (50 mL). The organics were washed
with 2 M aqueous NaOH (2.times.20 mL) and sat. aq. NaCl (10 mL).
The aqueous layers were extracted with Et.sub.2O (20 mL). The
combined organics were dried over Na.sub.2SO.sub.4, filtered and
concentrated under reduced pressure. The residue was purified via
flash chromatography on silica gel (0-20% EtOAc/heptane). The
appropriate fractions were collected and concentrated under reduced
pressure to give the title product (0.178 g, 16%); .sup.1H NMR (400
MHz, CDCl.sub.3) .delta. 7.23 (dd, J=8.8, 3.1 Hz, 1H), 7.14-7.07
(m, 1H), 7.02-6.94 (m, 1H), 6.49 (t, J=73.8 Hz, 1H), 4.74 (s,
2H).
Preparation #11: (2-(Difluoromethoxy)-5-methylphenyl)methanol
##STR00019##
[0673] Potassium carbonate (8.38 g, 60.7 mmol) was added to a
solution of methyl 2-hydroxy-5-methylbenzoate (2.52 g, 15.2 mmol)
and DMF (30.0 mL) under N.sub.2. Sodium chlorodifluoroacetate (4.62
g, 30.3 mmol) was added. The mixture was warmed to about 80.degree.
C. After about 2.5 h, water (3.00 mL) was added and the mixture was
warmed to about 100.degree. C. After about 14 h, the mixture was
cooled to rt and was then slowly acidified to about pH 1 using 2 N
aqueous HCl (50 mL). Et.sub.2O (100 mL) was added. The layers were
separated and the organics were dried over Na.sub.2SO.sub.4,
filtered and concentrated under reduced pressure. The residue was
dissolved in Et.sub.2O (50 mL) then washed with water (2.times.25
mL). The organic layer was dried over Na.sub.2SO.sub.4, filtered
and concentrated under reduced pressure. The residue was dissolved
in THF (60.0 mL) under N.sub.2 and LiAlH.sub.4 (0.557 g, 14.7 mmol)
was added portionwise over 15 min. After about 15 min, the ice bath
was removed. After about 3 h, LiAlH.sub.4 (0.557 g, 14.7 mmol) was
added portionwise. After about 2 h, the mixture was cooled to about
0.degree. C. then Et.sub.2O (50 mL) was added. Sodium sulfate
decahydrate was slowly added until reaction was not observed during
addition. The ice bath was removed and the mixture was left to
vigorously stir for about 17 h. The solids were removed by
filtration rinsing with Et.sub.2O (200 mL). The volatiles were
removed under reduced pressure. The residue was dissolved in
Et.sub.2O (10 mL) and DCM (20 mL). The solution was dried over
Na.sub.2SO.sub.4, filtered, and concentrated under reduced
pressure. The residue was purified using flash chromatography on
silica gel (DCM) to give the title product (0.217 g, 8%); .sup.1H
NMR (400 MHz, CDCl.sub.3) .delta. 7.31-7.23 (m, 1H), 7.14-7.07 (m,
1H), 7.04-6.98 (m, 1H), 6.51 (t, J=74.3 Hz, 1H), 4.71 (s, 2H), 2.34
(s, 3H).
Preparation #12: (5-Bromo-2-(Difluoromethoxy)phenyl)methanol
##STR00020##
[0675] Ethyl bromodifluoroacetate (7.00 mL, 54.6 mmol) was added in
one portion to a mixture of methyl 5-bromosalicylate (10.0 g, 43.3
mmol), K.sub.2CO.sub.3 (8.97 g, 64.9 mmol) and DMF (120 mL) under
N.sub.2. The mixture was warmed to about 80.degree. C. for about 4
h. After stirring at rt for about 20 h, ethyl
2-bromo-2,2-difluoroacetate (3.50 mL, 27.3 mmol) and
K.sub.2CO.sub.3(3.01 g, 21.78 mmol) were added. The mixture was
warmed to about 80.degree. C. for about 90 min. A solution of water
(100 mL) and potassium hydroxide (7.26 g, 129 mmol) was added and
the reaction was warmed to about 100.degree. C. After about 3 h,
the mixture was cooled to rt. The reaction mixture was acidified to
.about.pH 1 by slowly adding 2 M aqueous HCl (250 mL). Et.sub.2O
(200 mL) was added. The layers were separated and the organics were
washed with water (100 mL). The aqueous layers were extracted with
Et.sub.2O (100 mL). The combined organics were dried over
Na.sub.2SO.sub.4, filtered, and concentrated under reduced
pressure. The residue was dissolved in Et.sub.2O (100 mL) then
washed with water (2.times.50 mL). The organics were dried over
Na.sub.2SO.sub.4, filtered, and concentrated under reduced
pressure. The residue was dried under high vacuum for about 24 h
then dissolved in THF (20.0 mL). The solution was placed under
N.sub.2 then cooled to about 0.degree. C. Borane-THF complex (1 M
solution in THF, 9.00 mL, 9.00 mmol) was added dropwise. After
about 45 min, the ice bath was removed. After stirring at rt for
about 1 h, borane-THF complex (1 M solution in THF, 9.00 mL, 9.00
mmol) was added. The solution was warmed to about 60.degree. C.
After about 1 h, the solution was cooled to about 0.degree. C. MeOH
(5.00 mL, 124 mmol) was added dropwise. After completion of
addition, the ice bath was removed. The solution was stirred for
about 30 min and then the volatiles were removed under reduced
pressure. The residue was dissolved in EtOAc (50 mL) and then
washed with 1 M aqueous HCl (2.times.50 mL) and 50 mL sat. aq. NaCl
(50 mL). The organics were dried over Na.sub.2SO.sub.4, filtered,
and concentrated under reduced pressure. The residue was purified
using flash chromatography on silica gel (0-25% EtOAc/heptane) to
give the title product (0.865 g, 8%); .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 7.67-7.62 (m, 1H), 7.44-7.39 (m, 1H), 7.03-6.98
(m, 1H), 6.52 (t, J=73.5 Hz, 1H), 4.73 (s, 2H).
Preparation #13:
(S)-7-(5-Bromopyrimidin-2-yl)hexahydroimidazo[1,5-a]pyrazin-3(2H)-one
and
(R)-7-(5-bromopyrimidin-2-yl)hexahydroimidazo[1,5-a]pyrazin-3(2H)-one
##STR00021##
[0676] Step 1:
7-(5-Bromopyrimidin-2-yl)hexahydroimidazo[1,5-a]pyrazin-3(2H)-one
[0677] A mixture of hexahydroimidazo[1,5-a]pyrazin-3(2H)-one
hydrochloride (1.50 g, 8.44 mmol), 5-bromo-2-chloropyrimidine (1.87
g, 9.67 mmol), TEA (4.19 mL, 30.0 mmol), and EtOH (70 mL) was
warmed to about 78.degree. C. After about 5 h, the mixture was
allowed to cool to rt. After stirring about 1 h, the solids were
collected by filtration rinsing with EtOH (10 mL). The mother
liquor was concentrated under reduced pressure. Diethyl ether (25
mL) and water (25 mL) were added to the residue. After about 10
min, the solids were collected by filtration rinsing with diethyl
ether (10 mL). The two crops of solids were combined then dried in
a vacuum oven at about 60.degree. C. for about 16 h to afford the
title product as a white solid (2.32 g, 92%); LC/MS (Table A,
Method e) R.sub.t=1.63 min; MS m/z: 298 and 300 (M+H).sup.+.
Step 2:
(S)-7-(5-Bromopyrimidin-2-yl)hexahydroimidazo[1,5-a]pyrazin-3(2H)--
one and
(R)-7-(5-bromopyrimidin-2-yl)hexahydroimidazo[1,5-a]pyrazin-3(2H)--
one
[0678]
7-(5-Bromopyrimidin-2-yl)hexahydroimidazo[1,5-a]pyrazin-3(2H)-one
(2.32 g, 7.79 mmol) was submitted for chiral purification (Table B,
Method a). Fractions from the first eluting component were combined
and concentrated under reduced pressure then dried in a vacuum oven
at about 60.degree. C. for about 16 h to afford
(S)-7-(5-bromopyrimidin-2-yl)hexahydroimidazo[1,5-a]pyrazin-3(2H)-one
(1.02 g, 41%) with positive optical rotation. (Table A, Method e)
R.sub.t=1.63 min; MS m/z: 298 and 300 (M+H).sup.+. Fractions from
the second eluding component were combined and concentrated under
reduced pressure then dried in a vacuum oven at about 60.degree. C.
for about 16 h to afford
(R)-7-(5-bromopyrimidin-2-yl)hexahydroimidazo[1,5-a]pyrazin-3(2H)-one
(1.03 g, 41%) with negative optical rotation. (Table A, Method e)
R.sub.t=1.63 min; MS m/z: 298 and 300 (M+H).sup.+.
Preparation #14:
(((3-(Bromomethyl)-4-(difluoromethoxy)benzyl)oxy)methanetriyl)tribenzene
##STR00022##
[0679] Step 1: 3-Bromo-4-(difluoromethoxy)benzaldehyde
[0680] DMF (50 mL) was added to a 250 mL flask charged with
3-bromo-4-hydroxybenzaldehyde (5.0 g, 25 mmol), sodium
chlorodifluoroacetate (9.48 g, 62.2 mmol), and cesium carbonate
(12.2 g, 37.3 mmol). The mixture was warmed to about 65.degree. C.
for about 1 h. After cooling to about 35.degree. C., the reaction
mixture was poured slowly into ice water (600 mL). The mixture was
extracted with EtOAc (2.times.200 mL). The combined organic layers
were washed with sat. aq. NaCl (100 mL), dried over
Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure.
The residue was purified on silica gel (220 g) using a gradient of
10-25% EtOAc in heptane. Product fractions were combined and
concentrated to yield the title compound (3.50 g, 56%). .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. 9.94 (d, J=0.5 Hz, 1H), 8.24 (d,
J=2.0 Hz, 1H), 7.98 (dd, J=8.5, 2.0 Hz, 1H), 7.54-7.49 (m, 1H),
7.46 (t, J=72.5 Hz, 1H).
Step 2: (3-Bromo-4-(difluoromethoxy)phenyl)methanol
[0681] Sodium borohydride (0.63 g, 17 mmol) was added to a solution
of 3-bromo-4-(difluoromethoxy)benzaldehyde (3.5 g, 14 mmol) in
ethanol (70 mL) at rt. After about 90 min, the reaction was
quenched by slow addition of 2 N aqueous HCl (30 mL) with cooling.
The reaction mixture was concentrated to about 30 mL and then
extracted with EtOAc (2.times.50 mL). The combined organics were
dried over Na.sub.2SO.sub.4, filtered and concentrated under
reduced pressure to yield the title compound (3.53 g, 100%).
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 7.63 (dd, J=1.9, 0.9
Hz, 1H), 7.37-7.32 (m, 1H), 7.27 (dt, J=8.4, 0.9 Hz, 1H), 7.21 (t,
J=73.5 Hz, 1H), 5.55-5.09 (bs, 1H), 4.47 (s, 2H).
Step 3:
(((3-Bromo-4-(difluoromethoxy)benzyl)oxy)methanetriyl)tribenzene
[0682] N,N-Dimethylpyridin-4-amine (0.077 g, 0.63 mmol) was added
to a solution of (3-bromo-4-(difluoromethoxy)phenyl)methanol (1.60
g, 6.32 mmol) and (chloromethanetriyl)tribenzene (1.76 g, 6.32
mmol) in pyridine (20 mL) at rt. The reaction mixture was warmed to
about 80.degree. C. After about 2 h, the reaction was concentrated.
The residue was dissolved in DCM (100 mL) and washed with sat. aq.
NH.sub.4Cl (2.times.100 mL). The organic layer was dried over
Na.sub.2SO.sub.4, filtered, and concentrated under reduced pressure
onto silica gel (15 g). The residue was purified on silica gel (120
g) using a gradient of 50-100% DCM in heptane. Product fractions
were combined and concentrated to yield the title compound (1.44 g,
46%). .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 7.58 (d, J=2.1
Hz, 1H), 7.44-7.38 (m, 7H), 7.38-7.32 (m, 6H), 7.31-7.24 (m, 4H),
7.23 (t, J=74.5 Hz, 1H), 4.12 (s, 2H).
Step 4: Methyl
2-(difluoromethoxy)-5-((trityloxy)methyl)benzoate
[0683] A solution of
(((3-bromo-4-(difluoromethoxy)benzyl)oxy)methanetriyl)tribenzene
(4.41 g, 8.90 mmol), Pd.sub.2(dba).sub.3 (0.326 g, 0.356 mmol) and
(9,9-dimethyl-9H-xanthene-4,5-diyl)bis(diphenylphosphine) (0.618 g,
1.07 mmol) in DMF (40 mL) was degassed with a stream of nitrogen,
evacuated, then an atmosphere of carbon monoxide was introduced.
TEA (2.50 mL, 17.8 mmol) and methanol (0.72 mL, 18 mmol) were added
and the reaction was warmed to about 105.degree. C. MeOH (2.2 mL,
53 mmol) was added while maintaining the reaction temperature at
about 105.degree. C. After about 3 h, the reaction mixture was
cooled to rt and concentrated under reduced pressure. The residue
was dissolved with 40% DCM/heptane (50 mL) and filtered. The
filtrate was purified on silica gel (120 g) using a gradient of
40-80% DCM in heptane. Product fractions were combined and
concentrated under reduced pressure to yield the title compound
(2.1 g, 50%). .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 7.73 (d,
J=2.3 Hz, 1H), 7.62 (dd, J=8.5, 2.3 Hz, 1H), 7.44-7.39 (m, 6H),
7.38-7.31 (m, 6H), 7.31-7.24 (m, 4H), 7.14 (t, J=74.1 Hz, 1H), 4.14
(s, 2H), 3.81 (s, 3H).
Step 5:
(2-(Difluoromethoxy)-5-((trityloxy)methyl)phenyl)methanol
[0684] A solution of ethyl
2-(difluoromethoxy)-5-((trityloxy)methyl)benzoate (1.64 g, 3.36
mmol) and lithium borohydride (0.18 g, 8.1 mmol) in THF (32 mL) was
warmed at about 60.degree. C. under nitrogen for about 16 h. The
reaction was cooled to rt and concentrated under reduced pressure.
The residue was dissolved in DCM (50 mL) and washed with sat. aq.
NaHCO.sub.3 (2.times.30 mL) and sat. aq. NaCl (30 mL). The organic
layer was dried over Na.sub.2SO.sub.4 and passed through a pad of
silica gel (4 cm), rinsing with EtOAc (50 mL). The filtrate was
concentrated under reduced pressure and the resulting solid was
dried to yield the title compound (1.44 g, 96%). .sup.1H NMR (400
MHz, DMSO-d.sub.6) .delta. 7.49 (d, J=2.2 Hz, 1H), 7.45-7.39 (m,
6H), 7.39-7.32 (m, 6H), 7.30-7.23 (m, 4H), 7.13 (t, J=74.4 Hz, 1H),
7.13-7.10 (m, 1H), 5.22 (t, J=5.7 Hz, 1H), 4.52 (d, J=5.7 Hz, 2H),
4.04 (s, 2H).
Step 6:
(((3-(Bromomethyl)-4-(difluoromethoxy)benzyl)oxy)methanetriyl)trib-
enzene
[0685] A solution of
(2-(difluoromethoxy)-5-((trityloxy)methyl)phenyl)methanol (1.25 g,
2.45 mmol) and PPh.sub.3 (0.987 g, 3.76 mmol) in DCM (50 mL) was
cooled to about 0.degree. C. and 1-bromopyrrolidine-2,5-dione
(0.670 g, 3.76 mmol) was added in portions, maintaining the
reaction temperature between about 2-4.degree. C. After about 90
min at about 0.degree. C., sat. aq. NaHCO.sub.3 (50 mL) was added.
The layers were separated and the organic layer was dried over
Na.sub.2SO.sub.4, filtered, and concentrated onto silica gel (about
10 g). The residue was purified on silica gel (40 g) using a
gradient of 30-100% DCM in heptane to afford the target compound
(1.25 g, 78%). .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.56-7.46
(m, 6H), 7.37 (t, J=0.9 Hz, 1H), 7.36-7.21 (m, 10H), 7.12 (dt,
J=8.7, 1.1 Hz, 1H), 6.47 (d, J=73.9 Hz, 1H), 4.53 (s, 2H), 4.16 (t,
J=0.8 Hz, 2H).
Preparation #15:
(R)-1-(4-(5-Bromopyrimidin-2-yl)-2-methylpiperazin-1-yl)-2-hydroxyethanon-
e
##STR00023##
[0687] Trethylamine (20.0 mL, 143 mmol) was added to a slurry of
(R)-5-bromo-2-(3-methylpiperazin-1-yl)pyrimidine dihydrochloride
(10.0 g, 30.3 mmol) (synthesized in a similar fashion to Example
#3, step 1 from (R)-tert-butyl
4-(5-bromopyrimidin-2-yl)-2-methylpiperazine-1-carboxylate
(synthesized in a similar fashion to Preparation #13, step 1 from
(R)-1-N-Boc-2-methylpiperazine)), glycolic acid (3.52 g, 46.3 mmol)
and DMF (150 mL). After stirring for about 5 min,
1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-B]pyridinium
3-oxide hexafluorophosphate (13.8 g, 36.4 mmol) was added. After
about 2 h,
1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-B]pyridinium
3-oxide hexafluorophosphate (1.73 g, 4.54 mmol) was added. After
about 2 h, the volatiles were removed under reduced pressure. EtOAc
(300 mL), water (300 mL) and sat. aq. NaHCO.sub.3 (100 mL) were
added. The layers were separated and the aqueous layer was
extracted with EtOAc (2.times.100 mL). The combined organic layers
were dried over Na.sub.2SO.sub.4, filtered, and concentrated under
reduced pressure. The residue was purified on silica gel (0-100%
EtOAc/heptane) to afford the title product (8.29 g, 87%); LC/MS
(Table A, Method h) R.sub.t=0.96 min; MS m/z: 315 and 317
(M+H).sup.+
Preparation #16:
(R)-1-(4-(5-bromopyrimidin-2-yl)-2-methylpiperazin-1-yl)ethanone
##STR00024##
[0689] A suspension of
(R)-5-bromo-2-(3-methylpiperazin-1-yl)pyrimidine dihydrochloride
(3.75 g, 11.4 mmol) (synthesized in a similar fashion to Example
#3, step 1 from (R)-tert-butyl
4-(5-bromopyrimidin-2-yl)-2-methylpiperazine-1-carboxylate
(synthesized in a similar fashion to Preparation #13, step 1 from
(R)-1-N-Boc-2-methylpiperazine) in DCM (114 mL) under N.sub.2 was
treated with TEA (5.23 mL, 37.5 mmol) and stirred for about 15 min.
The reaction mixture was cooled to about 0.degree. C. for about 15
min and acetyl chloride (0.880 mL, 12.5 mmol) was added dropwise
via syringe. The resulting suspension was allowed to stir at about
0.degree. C. for about 10 min. Water (20 mL) was added. The organic
layer was separated and washed with sat. aq. NaHCO.sub.3 (20 mL)
and sat. aq. NaCl (30 mL), dried over MgSO.sub.4, filtered and
concentrated under reduced pressure to afford the title product
(3.43 g, 100%); LC/MS (Table A, Method i) R.sub.t=1.07 min.; MS
m/z: 299, 301 (M+H).sup.+.
Preparation #17:
(6-Methyl-3-(trifluoromethyl)pyridin-2-yl)methanol
##STR00025##
[0690] Step 1: 6-Methyl-3-(trifluoromethyl)picolinonitrile
[0691] A flask was charged with
2-chloro-6-methyl-3-(trifluoromethyl)pyridine (1.95 g, 9.97 mmol),
dicyanozinc (1.41 g, 11.9 mmol), zinc (0.078 g, 1.2 mmol) then
evacuated and back-filled with N.sub.2 three times.
Dimethylacetamide (39.7 mL) and PdCl.sub.2(dppf) (0.292 g, 0.399
mmol) were added and the mixture was purged with N.sub.2 for about
25 min at rt. The mixture was placed on a preheated mantle at about
140.degree. C. and the temperature was adjusted until an internal
temperature of about 140.degree. C. was reached. After about 90
min, the reaction mixture was cooled to about room temperature and
filtered through a pad of Celite.RTM. rinsing with EtOAc (350 mL).
The solution was washed with a sat. aq. 5% NH.sub.4OH solution (100
mL) and sat. aq. NaCl (2.times.100 mL). The organic layer was dried
over MgSO.sub.4, filtered and concentrated under reduced pressure.
The material was purified via flash chromatography on silica gel
(0-20% EtOAc/DCM). The appropriate fractions were collected and
concentrated under reduced pressure to yield the title product
(1.70 g, 92%); .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 8.38 (d,
J=8.4 Hz, 1H), 7.86 (d, J=8.3 Hz, 1H), 2.65 (s, 3H).
Step 2: 6-Methyl-3-(trifluoromethyl)picolinic acid
[0692] A mixture of 6-methyl-3-(trifluoromethyl)picolinonitrile
(1.70 g, 9.13 mmol) and 5 N NaOH (10.9 mL, 54.8 mmol) in EtOH (12.6
mL) was heated to about 85.degree. C. for about 7 h. The reaction
was cooled to ambient temperature and stirred for about 16 h at
room temperature. The ethanol was removed under reduced pressure
and the aqueous layer was acidified with 5 N aq. HCl (10.9 mL, 54.8
mmol). DCM (100 mL) was added and layers were separated. The
aqueous layer was extracted with DCM (100 mL). The combined organic
layers were dried over MgSO.sub.4, filtered, concentrated under
reduced pressure. The residue was dried under vacuum oven at about
65.degree. C. for about 3 h to yield the title product (1.73 g,
92%); .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 13.93 (s, 1H),
8.18 (d, J=8.3 Hz, 1H), 7.60 (d, J=8.2 Hz, 1H), 2.58 (s, 3H).
Step 3: Methyl 6-methyl-3-(trifluoromethyl)picolinate
[0693] Sulfuric acid (4.50 mL, 84.0 mmol) was added dropwise to a
mixture of 6-methyl-3-(trifluoromethyl)picolinic acid (1.73 g, 8.43
mmol) in MeOH (17.3 mL). The reaction mixture was refluxed for
about 20 h and then cooled to ambient temperature. Sat. aq.
NaHCO.sub.3 (110 mL) was added slowly. EtOAc (100 mL) was added and
the layers were separated. The aqueous layer was extracted with
EtOAc (100 mL). The combined organic layers were washed with sat.
aq. NaCl (50 mL), dried over MgSO.sub.4, filtered and concentrated
under reduced pressure to afford the title product (1.56 g, 84%);
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 8.24 (d, J=8.3 Hz, 1H),
7.67 (d, J=8.3 Hz, 1H), 3.91 (s, 3H), 2.60 (s, 3H).
Step 4: (6-Methyl-3-(trifluoromethyl)pyridin-2-yl)methanol
[0694] NaBH.sub.4 (0.93 g, 24.6 mmol) was added portionwise to a
mixture of methyl 6-methyl-3-(trifluoromethyl)picolinate (0.912 g,
4.16 mmol)) in EtOH (40 mL) under N.sub.2. The mixture was heated
to about 50.degree. C. for about 4 h. Additional NaBH.sub.4 (0.35
g, 9.25 mmol) was added. After about 16 h, additional NaBH.sub.4
(0.35 g, 9.25 mmol) and EtOH (3 mL) were added. After about 4 h.
NaBH.sub.4 (0.40 g, 10.6 mmol) was added. Additional NaBH.sub.4
(0.945 g, 24.9 mmol) and EtOH (10 mL) were added after about 16 h.
After about 8 h, the reaction mixture was cooled to ambient
temperature and partially concentrated under reduced pressure. To
the mixture was added sat. aq. NH.sub.4Cl (100 mL) then EtOAc (150
mL) and stirred for about 20 min. The layers were separated and the
aqueous layer was extracted with EtOAc (3.times.150 mL). The
combined organic layers were dried over MgSO.sub.4, filtered and
concentrated under reduced pressure. The material was purified via
flash chromatography on silica gel (0-20% EtOAc/heptane). The
appropriate fractions were collected and concentrated under reduced
pressure to yield the title product (0.307 g, 26%, 67% purity);
LC/MS (Table A, Method i) R.sub.t=0.80 min.; MS m/z: 192
(M+H).sup.+.
Preparation #18:
(2-((Difluoromethyl)thio)-5-methylphenyl)methanol
##STR00026##
[0695] Step 1: 2-((Difluoromethyl)thio)-5-methylbenzaldehyde
[0696] 6,6'-Disulfanediylbis(3-methylbenzaldehyde) (688 mg, 2.28
mmol) and TEA (0.698 mL, 5.01 mmol) was dissolved in a degassed
mixture of DMF (11 mL) and water (0.5 mL). The reaction was purged
with argon, then tris(2-carboxyethyl)phosphine hydrochloride (1.30
g, 4.55 mmol) was added and the reaction was stirred for about 30
min at room temperature. Degassed water (2 mL) was added while
maintaining inert atmosphere, then extracted with degassed
Et.sub.2O (2.times.10 mL). The organic layer was transferred via
syringe to an argon-filled flask. The solvent was removed in vacuo,
and the resulting residue was dissolved in MeCN (1.7 mL) and cooled
to about -78.degree. C. Degassed 4 M aq. potassium hydroxide (23
mL, 91 mmol) was added, followed by diethyl
(bromodifluoromethyl)phosphonate (1.62 mL, 9.10 mmol) in one
portion. The frozen mixture was placed in an ice bath for about 30
min, then warmed to rt for about 60 min. The reaction mixture was
extracted into Et.sub.2O (2.times.40 mL). The organic layer was
washed with water and sat. aq. NaCl (40 mL each), then dried over
MgSO.sub.4 filtered, and concentrated in vacuo. Purification via
flash chromatography on silica gel (0-40% DCM in heptane) yielded
the title compound (520 mg, 57%); .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 10.56 (s, 1H), 7.84 (d, J=2.1 Hz, 1H), 7.60 (d, J=7.9 Hz,
1H), 7.44 (dd, J=7.9, 2.1 Hz, 1H), 6.84 (t, J=56.3 Hz, 1H), 2.45
(s, 3H).
Step 2: (2-((Difluoromethyl)thio)-5-methylphenyl)methanol
[0697] 2-((Difluoromethyl)thio)-5-methylbenzaldehyde (296 mg, 1.46
mmol) in dry methanol (7 mL) under nitrogen atmosphere was cooled
to about 0.degree. C. Sodium borohydride (111 mg, 2.93 mmol) was
added and the reaction stirred at about 0.degree. C. for about 15
min, then allowed to warm to room temperature for about 30 min. The
solvent was removed in vacuo and the resulting residue was
partitioned between EtOAc (20 mL) and water (20 mL). The aqueous
layer was extracted with additional EtOAc (20 mL), then the
combined organic layers were dried over MgSO.sub.4, filtered, and
concentrated to yield the title compound (289 mg, 97%), used
without further purification. .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 7.51 (d, J=7.8 Hz, 1H), 7.38 (s, 1H), 7.15 (d, J=7.8 Hz,
1H), 6.80 (t, J=57.1 Hz, 1H), 4.86 (s, 2H), 2.39 (s, 3H), 1.75 (s,
1H).
Preparation #19:
6-(2-(2-Hydroxypropan-2-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one
##STR00027##
[0698] Step 1: tert-Butyl
6-bromo-2-methyl-3-oxo-2,3-dihydro-1H-indazole-1-carboxylate
[0699] To a suspension of 6-bromo-2-methyl-1H-indazol-3(2H)-one
(5.00 g, 22.0 mmol) (Preparation #1) in DCM (60 mL) was added TEA
(4.00 mL, 28.6 mmol) and N,N-dimethylpyridin-4-amine (0.27 g, 2.2
mmol). The mixture was stirred under nitrogen and cooled to about
0.degree. C. A mixture of di-tert-butyl dicarbonate (5.89 g, 24.2
mmol) in DCM (25.0 mL) was added and the mixture was stirred an
additional 5 min at about 0.degree. C. The reaction was allowed to
warm to rt, diluted with DCM (150 mL) and washed with water (150
mL). The organic layer was dried over Na.sub.2SO.sub.4 and
concentrated. The residue was purified on silica gel using a
gradient of 5-30% EtOAc in heptane. The product fractions were
concentrated to dryness to provide the title product (5.65 g, 78%);
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 8.00 (dd, J=1.6, 0.5
Hz, 1H), 7.72 (dd, J=8.2, 0.5 Hz, 1H), 7.55 (dd, J=8.2, 1.6 Hz,
1H), 3.48 (s, 3H), 1.58 (s, 91H).
Step 2: tert-Butyl
2-methyl-3-oxo-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3-dihydr-
o-1H-indazole-1-carboxylate
[0700] tert-Butyl
2-methyl-3-oxo-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3-dihydr-
o-1H-indazole-1-carboxylate was prepared in a similar fashion to
Preparation #4, step 2 using tert-butyl
6-bromo-2-methyl-3-oxo-2,3-dihydro-1H-indazole-1-carboxylate to
give the title compound (1.38 g, 23%); LC/MS (Table A, Method e)
R.sub.t=2.63 min; MS m/z: 375 (M+H).sup.+.
Step 3: tert-Butyl
6-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-2-methyl-3-oxo-2,3-dihydro-1H--
indazole-1-carboxylate
[0701] tert-Butyl
6-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-2-methyl-3-oxo-2,3-dihydro-1H--
indazole-1-carboxylate was prepared in a similar fashion to Example
#14, step 4 using tert-butyl
2-methyl-3-oxo-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3-dihydr-
o-1H-indazole-1-carboxylate and
2-(5-bromopyrimidin-2-yl)propan-2-ol to give the title compound
(0.138 g, 90%); LC/MS (Table A, Method e) R.sub.t=1.97 min; MS m/z:
385 (M+H).sup.+.
Step 4:
6-(2-(2-Hydroxypropan-2-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2-
H)-one
[0702] TFA (0.270 mL, 3.51 mmol) was added to a solution of
tert-butyl
6-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-2-methyl-3-oxo-2,3-dihydro-1H--
indazole-1-carboxylate (0.135 g, 0.351 mmol) in DCM (3 mL). The
reaction was stirred at rt for about 1 h. TFA (0.271 mL, 3.51 mmol)
was added to the reaction which continued to stir at rt for about 5
h. The reaction was concentrated under reduced pressure. DCM
(2.times.10 mL) was added to the residue and was concentrated under
reduced pressure to give an off-white solid. The residue was
triturated with Et.sub.2O (10 mL), filtered and washed with
Et.sub.2O (10 mL) to give the title compound (0.065 g, 65%); LC/MS
(Table A, Method e) R.sub.t=1.18 min; MS m/z: 285 (M+H).sup.+.
Preparation #20:
2-(3-((6-Bromo-2-methyl-3-oxo-2,3-dihydro-1H-indazol-1-yl)methyl)-4-(difl-
uoromethoxy)phenyl)acetonitrile
##STR00028##
[0703] Step 1:
6-Bromo-1-(2-(difluoromethoxy)-5-((trityloxy)methyl)benzyl)-2-methyl-1,2--
dihydro-3H-indazol-3-one
[0704] A suspension of
(((3-(bromomethyl)-4-(difluoromethoxy)benzyl)oxy)methanetriyl)tribenzene
(12.5 g, 24.5 mmol) (Preparation #14),
6-bromo-2-methyl-1H-indazol-3(2H)-one (5.70 g, 25.1 mmol)
(Preparation #1), and potassium carbonate (4.00 g, 28.9 mmol) in
DMF (100 mL) was stirred at ambient temperature for about 45 min.
The mixture was partitioned between water (500 mL) and EtOAc (250
mL), and after separating the layers the aqueous phase was
extracted with EtOAc (2.times.125 mL). The combined organic phases
were washed with sat. aq. NaCl (500 mL), dried over
Na.sub.2SO.sub.4, filtered, and concentrated. The residue was
purified on silica gel using a gradient of 0-100% EtOAc in heptane
to afford the target compound (11.3 g, 70%). .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 7.95 (d, J=1.5 Hz, 1H), 7.50 (d, J=8.3 Hz,
1H), 7.43-7.04 (m, 19H), 6.99-6.96 (m, 1H), 5.24 (s, 2H), 3.87 (s,
2H), 3.31 (s, 3H).
Step 2:
6-Bromo-1-(2-(difluoromethoxy)-5-(hydroxymethyl)benzyl)-2-methyl-1-
,2-dihydro-3H-indazol-3-one
[0705] A solution of
6-bromo-1-(2-(difluoromethoxy)-5-((trityloxy)methyl)benzyl)-2-methyl-1,2--
dihydro-3H-indazol-3-one (11.3 g, 17.2 mmol) and triisopropylsilane
(5.30 mL, 25.9 mmol) in DCM (100 mL) was treated with TFA (25.0 mL,
324 mmol) and the mixture was stirred at ambient temperature for
about 30 min. The reaction mixture was cooled in an ice water bath
before addition of sat. aq. NaHCO.sub.3 (200 mL). The organic phase
was dried over Na.sub.2SO.sub.4, filtered, and concentrated under
reduced pressure. The material was purified on silica gel using 5%
MeOH in DCM to afford the target compound (5.66 g, 79%); LC/MS
(Table A, Method i) R.sub.t=1.23 min; MS m/z: 413 and 415
(M+H).sup.+.
Step 3:
6-bromo-1-(5-(bromomethyl)-2-(difluoromethoxy)benzyl)-2-methyl-1,2-
-dihydro-3H-indazol-3-one
[0706] A solution of
6-bromo-1-(2-(difluoromethoxy)-5-(hydroxymethyl)benzyl)-2-methyl-1,2-dihy-
dro-3H-indazol-3-one (5.64 g, 13.6 mmol) and PPh.sub.3 (3.60 g,
13.7 mmol) in DCM (180 mL) at about 0.degree. C. was treated with
NBS (2.43 g, 13.7 mmol) and was then stirred at about 0.degree. C.
for about 20 min. Additional portions of PPh.sub.3 (0.358 g, 1.37
mmol) and NBS (0.243 g, 1.37 mmol) were added and stirring was
continued for about 5 min; final portions of PPh.sub.3 (0.358 g,
1.37 mmol) and NBS (0.243 g, 1.37 mmol) were added followed by
about an additional 5 min of stirring. Sat. aq. NaHCO.sub.3 (150
mL) was added to the reaction mixture and after separating the
layers the aqueous phase was extracted with DCM (2.times.20 mL).
The combined organics were dried over Na.sub.2SO.sub.4, filtered,
and concentrated under reduced pressure. The material was purified
on silica gel using 5% MeOH in DCM to afford the target compound
(5.95 g, 92%); LC/MS (Table A, Method i) R.sub.t=1.55 min; MS m/z:
477 (M+H).sup.+.
Step 4:
2-(3-((6-Bromo-2-methyl-3-oxo-2,3-dihydro-1H-indazol-1-yl)methyl)--
4-(difluoromethoxy)phenyl)acetonitrile
[0707] A suspension of
6-bromo-1-(5-(bromomethyl)-2-(difluoromethoxy)benzyl)-2-methyl-1,2-dihydr-
o-3H-indazol-3-one (0.12 g, 0.25 mmol) and sodium cyanide (0.037 g,
0.76 mmol) in DMF (2 mL) was stirred at ambient temperature for
about 1 h. The reaction mixture was partitioned between water (5
mL) and EtOAc (5 mL) and after separating the layers the aqueous
phase was extracted with EtOAc (2.times.5 mL). The combined organic
phases were washed with sat. aq. NaCl (10 mL), dried over
Na.sub.2SO.sub.4, filtered, and concentrated under reduced pressure
to give the title compound (0.102 g, 96%); LC/MS (Table A, Method
i) R.sub.t=1.31 min; MS m/z: 422 and 424 (M+H).sup.+.
Preparation #21: 1-(1-Bromopropyl)-3-methylbenzene
##STR00029##
[0708] Step 1: 1-(m-Tolyl)propan-1-ol
[0709] To a solution of ethylmagnesium bromide (3.0 M in diethyl
ether) (8.30 mL, 24.9 mmol) in THF (8.5 mL) under N.sub.2 at about
0.degree. C. was added dropwise a solution of 3-methylbenzaldehyde
(1.47 mL, 12.5 mmol) in THF (8.5 mL). The mixture was allowed to
stir at about 0.degree. C. for about 10 min. The ice bath was
removed and the reaction mixture stirred for about 1 h at ambient
temperature. The reaction mixture was cooled to about 0.degree. C.
and quenched slowly by dropwise addition of sat. aq. NH.sub.4Cl.
The solvent was partially removed under reduced pressure. EtOAc (30
mL) and water (15 mL) were added. The organic layer was separated
and the aqueous layer was back extracted with EtOAc (20 mL). The
combined organic layers were washed with sat. aq. NaCl (15 mL),
dried over MgSO.sub.4, filtered and concentrated under reduced
pressure to give the title product (1.87 g, 99%); .sup.1H NMR (400
MHz, DMSO-d.sub.6) .delta. 7.40-6.72 (m, 4H), 5.01 (dd, J=4.4, 0.8
Hz, 1H), 4.42-4.34 (m, 1H), 2.29 (s, 3H), 1.67-1.50 (m, 2H), 0.81
(t, J=7.4 Hz, 3H).
Step 2: 1-(1-Bromopropyl)-3-methylbenzene
[0710] To a solution of 1-(m-tolyl)propan-1-ol (1.87, 12.5 mmol) in
DCM (41 mL) under N.sub.2 was added PPh.sub.3 (3.27 g, 12.4 mmol)
and perbromomethane (4.13 g, 12.4 mmol). After about 4 h, the
solvent was removed under reduced pressure. The residue was
triturated with heptane (3.times.20 mL). The filtrate was
concentrated under reduced pressure to provide the title compound
(1.14 g, 43.0%, 50% purity); .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 7.30-7.22 (m, 4H), 5.16-5.11 (m, 1H), 2.30 (s, 3H), 1.83
(dd, J=6.4, 1.4 Hz, 1H), 1.64-1.54 (m, 1H), 0.92 (s, 3H).
Preparation #22:
(R)-1-(4-(5-Bromopyrimidin-2-yl)-3-methylpiperazin-1-yl)-2-hydroxyethanon-
e
##STR00030##
[0712] To a mixture of glycolic acid (0.11 g, 1.45 mmol),
(R)-5-bromo-2-(2-methylpiperazin-1-yl)pyrimidine dihydrochloride
(0.40 g, 1.21 mmol) (synthesized in a similar fashion to Example
#3, step 1 from (R)-tert-butyl
4-(5-bromopyrimidin-2-yl)-3-methylpiperazine-1-carboxylate
(synthesized in a similar fashion to Preparation #13, step 1 from
(R)-tert-butyl 3-methylpiperazine-1-carboxylate)), and
1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo{4,5-b]pyridinium
3-oxid hexafluorophosphate (0.55 g, 1.45 mmol) under N.sub.2 was
added DCM (6.89 mL) then TEA (0.45 mL, 3.23 mmol). After stirring
for 90 min at ambient temperature, DCM (20 mL) and sat. aq.
NaHCO.sub.3 (10 mL) were added. The organic layer was separated,
washed with sat. aq. NaCl (10 mL), dried over MgSO.sub.4, filtered
and concentrated under reduced pressure. The material was purified
via flash chromatography on silica gel (20-40% EtOAc/heptane). The
appropriate fractions were concentrated under reduced pressure. The
solid was sonicated in ether (10 mL) for about 5 min, filtered and
rinsed with ether (2.times.10 mL) then dried in a vacuum oven at
about 65.degree. C. for about 15 min to provide the title product
(0.178 g, 46%); LC/MS (Table A, Method i) R.sub.t=0.96 min.; MS
m/z: 315 and 317 (M+H).sup.+.
Preparation #23:
6-(2-Chloropyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one
##STR00031##
[0713] Step 1: tert-Butyl
6-(2-chloropyrimidin-5-yl)-2-methyl-3-oxo-2,3-dihydro-1H-indazole-1-carbo-
xylate
[0714] The reaction was performed using tert-butyl
6-bromo-2-methyl-3-oxo-2,3-dihydro-1H-indazole-1-carboxylate
(Preparation #19, step 1) and
2-chloro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine
in a similar fashion to Example #5 to afford the title product
(0.70 g, 62%); LC/MS (Table A, Method e) R.sub.t=2.18 min; MS m/z:
361 (M+H).sup.+
Step 2:
6-(2-Chloropyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one
[0715] The reaction was performed using tert-butyl
6-(2-chloropyrimidin-5-yl)-2-methyl-3-oxo-2,3-dihydro-1H-indazole-1-carbo-
xylate in a similar fashion to Preparation #19, step 4 to give the
title compound (485 mg, 100%); LC/MS (Table A, Method e)
R.sub.t=1.33 min; MS m/z: 261 (M+H).sup.+.
Preparation #24:
6-(2-Chloropyrimidin-5-yl)-1-(2-(difluoromethoxy)-5-((trityloxy)methyl)be-
nzyl)-2-methyl-1H-indazol-3(2H)-one
##STR00032##
[0717]
6-(2-Chloropyrimidin-5-yl)-1-(2-(difluoromethoxy)-5-((trityloxy)met-
hyl)benzyl)-2-methyl-1H-indazol-3(2H)-one was prepared in a similar
fashion to Preparation #4, step 1 using
(((3-(bromomethyl)-4-(difluoromethoxy)benzyl)oxy)methanetriyl)tribenzene
(Preparation #14) and
6-(2-chloropyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one
(Preparation #23) to give the title compound (1.09 g, 76%); LC/MS
(Table A, Method e) R.sub.t=2.83 min; MS m/z: 689 and 691
(M+H).sup.+.
Preparation #25:
6-Bromo-5,7-difluoro-2-methyl-1H-indazol-3(2H)-one
##STR00033##
[0718] Step 1: Methyl 4-bromo-2,3,5-trifluorobenzoate
[0719] A solution of methyl 4-amino-2,3,5-trifluorobenzoate (2.00
g, 9.75 mmol) (prepared according to Sui XiongCai, et. al. J. Org.
Chem. 1992, 57, 1299-1304) in MeCN (40 mL) was cooled to about
0.degree. C. under N.sub.2 and copper(II) bromide (3.27 g, 14.6
mmol) was added. After stirring for about 2 min, tert-butyl nitrite
(1.51 g, 14.6 mmol) was added dropwise over about 2 min. The
cooling bath was removed and the reaction was allowed to warm to rt
for about 1 h. The reaction was poured into water (200 mL) and
extracted with EtOAc (400 mL). The organic layer layer was washed
with sat. aq. NH.sub.4Cl (2.times.200 mL), dried over
Na.sub.2SO.sub.4, filtered and concentrated to yield the title
product (2.50 g, 95%); LC/MS (Table A, Method h) R.sub.t=1.56 min;
MS m/z: not detected; .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.
7.75-7.67 (m, 1H), 3.88 (s, 3H).
Step 2: 4-Bromo-2,3,5-trifluorobenzoic acid
[0720] To a solution of methyl 4-bromo-2,3,5-trifluorobenzoate
(2.50 g, 9.29 mmol) in MeOH (20 mL) was added lithium hydroxide
monohydrate (0.780 g, 18.6 mmol) and water (2 mL). The mixture was
stirred at rt for about 30 min. The reaction was diluted with water
(100 mL) and washed with ether (2.times.50 mL). The mixture was
acidified with 2 N aq. HCl (10 mL) and extracted with EtOAc (100
mL). The organic extracts were washed with sat. aq. NaCl (50 mL),
dried over Na.sub.2SO.sub.4, filtered, concentrated to solids and
dried under vacuum to yield the title product (2.30 g, 97%); LC/MS
(Table A, Method h) R.sub.t=0.55 min; MS m/z: 253/255
(M-H).sup.-.
Step 3: 4-Bromo-2,3,5-trifluoro-N-methylbenzohydrazide
[0721] The reaction was performed using
4-bromo-2,3,5-trifluorobenzoic acid in a similar fashion to
Preparation #1, step 1 to give the title product (84%); (Table A,
Method h) R.sub.t=0.88 min; MS m/z: 371 and 283/285
(M+H).sup.+.
Step 4: 6-Bromo-5,7-difluoro-2-methyl-1H-indazol-3(2H)-one
[0722] A solution of 4-bromo-2,3,5-trifluoro-N-methylbenzohydrazide
(450 mg, 1.59 mmol) in DMF (150 mL) was added dropwise to a
solution of potassium tert-butoxide (803 mg, 7.15 mmol) and DMF
(150 mL) under nitrogen at about 0.degree. C. over about 40 min.
AcOH (1.0 mL, 18 mmol) was added and the volatiles were removed
under reduced pressure. Water (15 mL) was added and the mixture was
extracted with DCM (2.times.25 mL). The crude product was
concentrated onto silica gel and purified on silica gel using a
gradient of 0-10% MeOH in DCM. Product containing fractions were
combined and concentrate to yield the title product (0.33 g, 80%,
about 50% purity); LC/MS (Table A, Method j) R.sub.t=0.83 min; MS
m/z: 263 and 265 (M+H).sup.+, which was used without further
purification.
Preparation #26:
(R)-6-(2-(4-(2-(tert-Butoxy)acetyl)-2-methylpiperazin-1-yl)pyrimidin-5-yl-
)-1-(2-(difluoromethoxy)benzyl)-5,7-difluoro-2-methyl-1H-indazol-3(2H)-one
##STR00034##
[0723] Step 1:
(R)-1-(4-(5-Bromopyrimidin-2-yl)-3-methylpiperazin-1-yl)-2-(tert-butoxy)e-
thanone
[0724] DIEA (6.61 mL, 37.9 mmol) was added to a slurry of
(R)-5-bromo-2-(2-methylpiperazin-1-yl)pyrimidine dihydrochloride
(2.50 g, 7.57 mmol) (synthesized in a similar fashion to Example
#3, step 1 from (R)-tert-butyl
4-(5-bromopyrimidin-2-yl)-3-methylpiperazine-1-carboxylate
(synthesized in a similar fashion to Preparation #13, step 1 from
(R)-tert-butyl 3-methylpiperazine-1-carboxylate)),
2-(tert-butoxy)acetic acid (1.00 g, 7.57 mmol),
1H-benzo[d][1,2,3]triazol-1-ol hydrate (1.22 g, 7.95 mmol), and DCM
(30 mL). After stirring for about 5 min,
1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (1.53
g, 7.95 mmol) was added. The reaction was stirred for about 72 h,
then transferred to a separatory funnel and washed with sat. aq.
NaHCO.sub.3 solution (2.times.10 mL) and with sat. aq. NH.sub.4Cl
(2.times.10 mL). The organic layer was dried over Na.sub.2SO.sub.4,
filtered and concentrated. The residue was purified on silica gel
using a gradient of 30-60% EtOAc/heptane. Product fractions were
combined and concentrated to yield the title product (2.44 g, 87%);
LC/MS (Table A, Method i) R.sub.t=1.47 min; MS m/z: 371 and 373
(M+H).sup.+.
Step 2:
(R)-2-(tert-Butoxy)-1-(3-methyl-4-(5-(4,4,5,5-tetramethyl-1,3,2-di-
oxaborolan-2-yl)pyrimidin-2-yl)piperazin-1-yl)ethanone
[0725] A mixture of
(R)-1-(4-(5-bromopyrimidin-2-yl)-3-methylpiperazin-1-yl)-2-(tert-butoxy)e-
thanone (2.44 g, 6.57 mmol), KOAc (2.06 g, 21.0 mmol), and
bis(pinacolato)diboron (2.17 g, 8.54 mmol) in 1,4-dioxane (30 mL)
was degassed with a stream of nitrogen. PdCl.sub.2(dppf) (0.337 g,
0.460 mmol) was added and the reaction was further degassed for
about 5 min. The reaction was heated at about 95.degree. C. for
about 5 h and then cooled to rt. The mixture was filtered rinsing
with EtOAc. The filtrate was concentrated and the residue was
purified on silica gel using a gradient of 0-100% EtOAc in DCM.
Product fractions were combined and concentrated to yield the title
product (2.17 g, 79%); LC/MS (Table A, Method i) R.sub.t=1.63 min;
MS m/z: 419 (M+H).sup.+.
Step 3:
(R)-6-(2-(4-(2-(tert-Butoxy)acetyl)-2-methylpiperazin-1-yl)pyrimid-
in-5-yl)-5,7-difluoro-2-methyl-1H-indazol-3(2H)-one
[0726] A mixture of
(R)-2-(tert-butoxy)-1-(3-methyl-4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaboro-
lan-2-yl)pyrimidin-2-yl)piperazin-1-yl)ethanone (91 mg, 0.28 mmol),
6-bromo-5,7-difluoro-2-methyl-1H-indazol-3(2H)-one (95 mg, 0.14
mmol) (Preparation #25) and Cs.sub.2CO.sub.3 (94 mg, 0.29 mmol) was
diluted with toluene (2 mL) and water (2 mL). The mixture was
degassed with a stream of nitrogen and 2.sup.nd Generation XPhos
precatalyst (5 mg, 6 .mu.mol) was added. The mixture was further
degassed with nitrogen for about 5 min, then the reaction was
heated to about 110.degree. C. under nitrogen for about 6 h. The
reaction was cooled to rt and diluted with water (5 mL) and EtOAc
(10 mL). The organic layer was extracted again with 1 N aq. NaOH (5
mL). The combined aqueous extracts were washed once with EtOAc (10
mL), then acidified with HOAc to about pH 4. The aqueous layer was
extracted with EtOAc (2.times.10 mL). The combined organics were
dried over Na.sub.2SO.sub.4, filtered and concentrated. The
material was purified on silica gel using a gradient of 0-10% MeOH
in DCM. Product fractions were combined and concentrated to yield
the title product (25 mg, 360%); LC/MS (Table A, Method i)
R.sub.t=1.11 min; MS m/z: 475 (M+H).sup.+.
Step 4:
(R)-6-(2-(4-(2-(tert-Butoxy)acetyl)-2-methylpiperazin-1-yl)pyrimid-
in-5-yl)-1-(2-(difluoromethoxy)benzyl)-5,7-difluoro-2-methyl-1H-indazol-3(-
2H)-one
[0727] To a mixture of
(R)-6-(2-(4-(2-(tert-butoxy)acetyl)-2-methylpiperazin-1-yl)pyrimidin-5-yl-
)-5,7-difluoro-2-methyl-1H-indazol-3(2H)-one (51 mg, 0.11 mmol) and
K.sub.2CO.sub.3 (18 mg, 0.13 mmol) in DMF (1.0 mL) was added
1-(bromomethyl)-2-(difluoromethoxy)benzene (28.0 mg, 0.118 mmol)
and the mixture was stirred at rt for about 1 h. The reaction was
quenched with AcOH (0.012 mL, 0.22 mmol), diluted with water (10
mL) and extracted with EtOAc (2.times.10 mL). The extracts were
washed with sat. aq. NaCl (10 mL), dried over Na.sub.2SO.sub.4,
filtered and concentrated. The residue was purified on silica gel
using EtOAc. The product fractions were combined and concentrated
to yield the title product (44 mg, 65%); LC/MS (Table A, Method i)
R.sub.t=1.63 min; MS m/z: 631 (M+H).sup.+.
Preparation #27:
4-Bromo-2-((tetrahydro-2H-pyran-3-yl)oxy)pyridine
##STR00035##
[0729] To a solution of tetrahydro-2H-pyran-3-ol (0.10 g, 0.97
mmol) in THF (2.5 mL) was added sodium hydride (60% dispersion in
mineral oil, 0.065 g, 1.6 mmol) and stirred at ambient temperature
for about 2 h. To the reaction mixture was added
4-bromo-2-fluoropyridine (0.144 g, 0.816 mmol) in THF (2.5 mL).
After about 16 h, water (5 mL) and EtOAc (10 mL) were added. The
organic layer was separated and the aqueous layer was back
extracted with EtOAc (10 mL). The combined organic layers were
dried over MgSO.sub.4, filtered and concentrated under reduced
pressure. The material was purified via flash chromatography on
silica gel (0-50% EtOAc/heptane). The appropriate fractions were
collected and concentrated under reduced pressure to provide the
title product (0.117 g, 55%); LC/MS (Table A, Method i)
R.sub.t=1.33 min.; MS m/z: 258 and 260 (M+H).sup.+.
Preparation #28:
(R)-6-(2-(4-Acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-1H-ind-
azol-3(2H)-one
##STR00036##
[0731] A mixture of bis(pinacolato)diboron (0.239 g, 0.942 mmol),
(R)-1-(4-(5-bromopyrimidin-2-yl)-2-methylpiperazin-1-yl)ethanone
(0.174 g, 0.581 mmol) (Preparation #16), KOAc (0.144 g, 1.47 mmol),
PdCl.sub.2(dppf) (0.026 g, 0.035 mmol), and 1,4-dioxane (5.03 mL)
was purged with N.sub.2 for about 10 min. then warmed to about
95.degree. C. After about 2 h, the mixture was allowed to cool to
ambient temperature and 6-bromo-2-methyl-1H-indazol-3(2H)-one (0.11
g, 0.48 mmol) (Preparation #1), Cs.sub.2CO.sub.3 (0.432 g, 1.33
mmol), and PdCl.sub.2(PPh.sub.3).sub.2 (0.026 g, 0.036 mmol) and
water (1.3 mL) were added. The reaction mixture was purged with
N.sub.2 for about 10 min then heated to about 85.degree. C. for
about 1 h. The mixture was cooled to ambient temperature and water
(5 mL) and EtOAc (10 mL) were added. The organic layer was
separated and the aqueous layer was extracted with EtOAc (10 mL).
The aqueous layer was acidified to about pH 4 with 1 N aq. HCl and
EtOAc (5 mL) was added and the organic layer was separated. The
organic layers were combined, dried over MgSO.sub.4, filtered and
concentrated under reduced pressure. The material was purified by
flash chromatography on silica gel (0-10% MeOH/DCM) to afford the
title product (0.135 g, 76%); LC/MS (Table A, Method i)
R.sub.t=0.75 min; MS m/z: 367 (M+H).sup.+.
Preparation #29: 6-Chloro-2-methyl-1H-indazol-3(2H)-one
##STR00037##
[0733] The reaction was performed using
4-chloro-2-fluoro-N-methylbenzohydrazide (prepared in a similar
fashion to Example #1, step 1 using 4-chloro-2-fluorobenzoic acid)
in a similar fashion to Example #1, step 2 to give the title
product (57%); LC/MS (Table A, Method j) R.sub.t=0.63 min; MS m/z:
183 (M+H).sup.+.
Preparation #30:
(R)-2-(tert-Butoxy)-1-(2-methyl-4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaboro-
lan-2-yl)pyrimidin-2-yl)piperazin-1-yl)ethanone
##STR00038##
[0734] Step 1:
(R)-1-(4-(5-Bromopyrimidin-2-yl)-2-methylpiperazin-1-yl)-2-(ter-butoxy)et-
hanone
[0735] To a mixture of 2-(tert-butoxy)acetic acid (0.50 g, 3.8
mmol), (R)-5-bromo-2-(3-methylpiperazin-1-yl)pyrimidine, 2
hydrochloric acid (1.25 g, 3.78 mmol) (synthesized in a similar
fashion to Example #3, step 1 from (R)-tert-butyl
4-(5-bromopyrimidin-2-yl)-3-methylpiperazine-1-carboxylate
(synthesized in a similar fashion to Preparation #13, step 1 from
(R)-ter-butyl 3-methylpiperazine-1-carboxylate)),
1H-benzo[d][1,2,3]triazol-1-ol hydrate (0.61 g, 3.97 mmol), and
DIEA (3.3 mL, 19 mmol) in DCM (15 mL) was added
1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.76
g, 4.0 mmol) and the mixture was stirred at rt for about 72 h. The
mixture was washed with sat. aq. NaHCO.sub.3 (2.times.10 mL), then
with sat. aq. NH.sub.4Cl (2.times.10 mL) and with water (10 mL).
The organic layer was dried over sodium sulfate, filtered and
concentrated. The residue was purified on silica gel using a
gradient of 30-60% EtOAc/heptane. Product fractions were combined
and concentrated to yield the title compound (1.27 g, 90%); LC/MS
(Table A, Method i) R.sub.t=1.45 min; MS m/z: 371/373
(M+H).sup.+.
Step 2:
(R)-2-(tert-Butoxy)-1-(2-methyl-4-(5-(4,4,5,5-tetramethyl-1,3,2-di-
oxaborolan-2-yl)pyrimidin-2-yl)piperazin-1-yl)ethanone
[0736] The reaction was performed using
(R)-1-(4-(5-bromopyrimidin-2-yl)-2-methylpiperazin-1-yl)-2-(tert-butoxy)e-
thanone in a similar fashion to Preparation #26, step 2 to give the
title product (70%); LC/MS (Table A, Method i) R.sub.t=1.63 min; MS
m/z: 419 (M+H).sup.+.
Preparation #31:
6-Chloro-5-methoxy-2-methyl-1H-indazol-3(2H)-one
##STR00039##
[0737] Step 1:
6-Chloro-2-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-3(2H)-o-
ne
[0738] A suspension of 6-chloro-2-methyl-1H-indazol-3(2H)-one (5.00
g, 27.4 mmol) (Preparation #29) in THF (100 mL) was treated with
NaH (60% dispersion in mineral oil, 1.31 g, 32.9 mmol) under
nitrogen. The reaction stirred until reaction subsided, then SEM-Cl
(7.28 mL, 41.1 mmol) was added dropwise over about 5 min. The
reaction was stirred for about 2.5 h. The mixture was partitioned
between EtOAc (400 mL) and water (200 mL). The organic layer was
washed with water (200 mL) and sat. aq. NaCl (200 mL). The organic
layer was dried over Na.sub.2SO.sub.4, filtered and concentrated
under reduced pressure. The residue was purified on silica gel
using a gradient of 30-100% EtOAc in heptane. Product fractions
were combined and concentrated to yield the title compound (7.32 g,
85%); LC/MS (Table A, Method i) R.sub.t=1.61 min; MS m/z: 313
(M+H).sup.+.
Step 2:
5-Bromo-6-chloro-2-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H--
indazol-3(2H)-one
[0739] A solution of
6-chloro-2-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-3(2H)-o-
ne (0.90 g, 2.9 mmol) in DCM (15 mL) was treated with NBS (0.563 g,
3.16 mmol) and the suspension was stirred at rt for about 24 h. NBS
(0.256 g, 1.44 mmol) was added in one portion and the mixture was
stirred about 18 h. The reaction mixture was partitioned between
DCM (100 mL) and sat. aq. NaHCO.sub.3 (75 mL). The aqueous phase
was extracted with DCM (25 mL) and the combined organic layers were
washed with sat. Aq. NaCl (50 mL), dried over Na.sub.2SO.sub.4,
filtered, and concentrated under reduced pressure. The residue was
purified on silica gel using a gradient of 0-50% EtOAc in heptane.
Product fractions were combined and concentrated under reduced
pressure to yield the title compound (0.74 g, 66%); LC/MS (Table A,
Method k) R.sub.t=0.89 min; MS m/z: 391 and 393 (M+H).sup.+.
Step 3:
6-Chloro-5-methoxy-2-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1-
H-indazol-3(2H)-one
[0740] A mixture of
5-bromo-6-chloro-2-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-
-3(2H)-one (0.74 g, 1.9 mmol), cesium carbonate (0.923 g, 2.83
mmol), Pd.sub.2(dba).sub.3 (0.035 g, 0.038 mmol) and
di-tert-butyl(2',4',6'-triisopropyl-[1,1'-biphenyl]-2-yl)phosphine
(0.048 g, 0.11 mmol) was diluted with toluene (12 mL) and degassed
with a stream of nitrogen. Methanol (0.400 mL, 9.89 mmol) was added
and the mixture was heated at reflux under a balloon. After about 5
h, the reaction was cooled to rt, methanol (0.400 mL, 9.89 mmol)
and
di-tert-butyl(2',4',6'-triisopropyl-[1,1'-biphenyl]-2-yl)phosphine
(0.048 g, 0.11 mmol) were added and the mixture was heated at
reflux for about 3 h. The reaction was cooled to rt, diluted with
EtOAc (30 mL) and filtered, rinsing with EtOAc (20 mL). Solvents
were removed under reduced pressure and the residue was purified on
silica gel using a gradient of 30-80% EtOAc in heptane. Product
fractions were combined and concentrated to yield the title
compound (0.176 g, 27%); LC/MS (Table A, Method i) R.sub.t=1.62
min; MS m/z: 343 (M+H).sup.+.
Step 4: 6-Chloro-5-methoxy-2-methyl-1H-indazol-3(2H)-one
[0741] To a solution of
6-chloro-5-methoxy-2-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indaz-
ol-3(2H)-one (170 mg, 0.496 mmol) in EtOH (3 mL) was added
concentrated HCl (2 mL) and the mixture was heated to about
80.degree. C. for about 10 min. The reaction was cooled to rt and
concentrated under reduced pressure. The residue was treated with
water (5 mL) and the product was collected by filtration rinsing
with diethyl ether (3.times.5 mL). The solid was dried under vacuum
to yield the title compound (0.095 g, 90%); LC/MS (Table A, Method
i) R.sub.t=0.65 min; MS m/z: 213 (M+H).sup.+.
Preparation #32:
9-(Bromomethyl)-4,5-dihydrobenzo[f][1,4]thiazepin-3(2H)-one
##STR00040##
[0742] Step 1: N-(3-Bromo-2-fluorobenzyl)-2-mercaptoacetamide
[0743] (3-Bromo-2-fluorophenyl)methanamine (1.50 g, 7.35 mmol) was
added to mercaptoacetic acid (0.613 mL, 8.82 mmol) under nitrogen.
The mixture was heated to reflux using a Dean-Stark apparatus for
about 18 h. The volatiles were evaporated in vacuo and the residue
was purified on silica gel using a gradient of 10-50% EtOAc/heptane
to afford the title product (1.53 g, 75%). .sup.1H NMR (500 MHz,
DMSO-d.sub.6) .delta. 8.56 (t, J=5.8 Hz, 1H), 7.60 (ddd, J=8.2,
6.7, 1.7 Hz, 1H), 7.34 (dddd, J=7.7, 6.9, 1.7, 0.8 Hz, 1H), 7.14
(td, J=7.8, 0.9 Hz, 1H), 4.42-4.29 (m, 2H), 3.16 (s, 2H), 2.80 (s,
1H).
Step 2: 9-Bromo-4,5-dihydrobenzo[f][1,4]thiazepin-3(2H)-one
[0744] N-(3-Bromo-2-fluorobenzyl)-2-mercaptoacetamide (1.52 g, 5.46
mmol) was flushed with nitrogen and DMF (25 mL) was added. The
reaction was cooled to about 0.degree. C. before addition of
potassium tert-butoxide (0.613 g, 5.46 mmol). After about 10 min,
the mixture was warmed to ambient temperature and then to about
100.degree. C. After about 16 h, the mixture was cooled to ambient
temperature. Water (50 mL), 1 M aq. KHSO.sub.4 (10 mL), and EtOAc
(300 mL) were added. The organic layer was washed with water
(2.times.50 mL), sat. aq. NaCl (20 mL), dried over MgSO.sub.4 and
evaporated in vacuo. The residue was purified on silica gel using a
gradient of 20-50% (75% EtOAc/EtOH)/heptane. The appropriate
fractions were combined and concentrated. The resulting solid was
dissolved in a minimum amount of refluxing ethanol (.about.100 mL)
and left to cool and crystallize. The solid was isolated by
filtration and a second crop was obtained from the liquors in a
same fashion affording the title product (366 mg, 26%). .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. 8.20 (t, J=6.5 Hz, 1H), 7.52 (dd,
J=8.0, 1.4 Hz, 1H), 7.17 (dd, J=7.6, 1.3 Hz, 1H), 6.99 (t, J=7.8
Hz, 1H), 4.43 (d, J=6.6 Hz, 2H), 3.94 (s, 2H).
Step 3: Methyl
3-oxo-2,3,4,5-tetrahydrobenzo[f][1,4]thiazepine-9-carboxylate
[0745] 9-Bromo-4,5-dihydrobenzo[f][1,4]thiazepin-3(2H)-one (100 mg,
0.387 mmol), Pd(dppf)C.sub.2 (10 mg, 0.014 mmol), MeOH (10 mL), and
TEA (0.108 mL, 0.775 mmol) were added to a 50 mL pressure vessel.
The reactor was degassed with argon several times followed by
carbon monoxide. The mixture was heated at about 100.degree. C. for
about 16 h at about 60 psi. The volatiles were evaporated in vacuo
and the residue was purified on silica gel eluting with a gradient
of 0-100% (75% EtOAc/EtOH)/heptane to afford the title product
(49.7 mg, 54%). .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. 8.14
(t, J=6.4 Hz, 1H), 7.67 (dd, J=7.8, 1.6 Hz, 1H), 7.34 (dd, J=7.5,
1.6 Hz, 1H), 7.15 (t, J=7.6 Hz, 1H), 4.45 (d, J=6.4 Hz, 2H), 3.83
(s, 2H), 3.80 (s, 3H).
Step 4:
9-(Hydroxymethyl)-4,5-dihydrobenzo[f][1,4]thiazepin-3(2H)-one
[0746] A solution of methyl
3-oxo-2,3,4,5-tetrahydrobenzo[f][1,4]thiazepine-9-carboxylate (45
mg, 0.19 mmol) in THF (5 mL) was cooled to about -78.degree. C.
under nitrogen and LiAlH.sub.4 (1 M in diethyl ether, 0.379 mL,
0.379 mmol) was added. The cold bath was allowed to warm to ambient
temperature. After about 16 h, 10% aq. HCl (5 mL) was added
dropwise and the mixture was extracted with EtOAc (2.times.25 mL).
The organic layer was dried over sodium sulfate, filtered, and
evaporated in vacuo. The residue was purified on silica gel
(0.5-25% MeOH/DCM) to afford the title product (12 mg, 30%,
.about.90% purity). .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
8.14 (t, J=6.2 Hz, 1H), 7.39 (dd, J=7.3, 1.8 Hz, 1H), 7.18-7.00 (m,
2H), 5.28 (t, J=5.5 Hz, 1H), 4.42 (dd, J=22.3, 6.0 Hz, 4H), 3.84
(s, 2H).
Step 5:
9-(Bromomethyl)-4,5-dihydrobenzo[f][1,4]thiazepin-3(2H)-one
[0747]
9-(Hydroxymethyl)-4,5-dihydrobenzo[f][1,4]thiazepin-3(2H)-one (100
mg, 0.478 mmol), AcOH (1 mL) and hydrobromic acid (33% in AcOH,
1.17 g, 4.78 mmol) were stirred at ambient temperature under
nitrogen for about 1 h. The reaction was diluted with toluene (10
mL) and evaporated in vacuo. EtOAc (30 mL) was added. The solution
was washed with sat. aq. sodium bicarbonate (2.times.10 mL), water
(5 mL), dried over MgSO.sub.4 and evaporated in vacuo to give the
title compound (80 mg, 62%); LC/MS (Table A, Method j) R.sub.t=0.99
min; MS m/z: 272 and 274 (M+H).sup.+
Preparation #33:
(R)-1-(2-(Difluoromethoxy)benzyl)-2-methyl-6-(2-(3-methylpiperazin-1-yl)p-
yrimidin-5-yl)-1H-indazol-3(2H)-one
##STR00041##
[0749] The reaction was performed using
(R)-5-bromo-2-(2-methylpiperazin-1-yl)pyrimidine dihydrochloride
(synthesized in a similar fashion to Example #3, step 1 from
(R)-tert-butyl
4-(5-bromopyrimidin-2-yl)-3-methylpiperazine-1-carboxylate
(synthesized in a similar fashion to Preparation #13, step 1 from
(R)-tert-butyl 3-methylpiperazine-1-carboxylate)) and
1-(2-(difluoromethoxy)benzyl)-2-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxa-
borolan-2-yl)-1H-indazol-3(2H)-one (Preparation #4, step 2) in a
similar fashion to Example #14, step 4 to afford the title product
(0.62 g, 67%); LC/MS (Table A, Method i) R.sub.t=0.83 min; MS m/z:
481 (M+H).sup.+.
Preparation #34:
1-(4-(5-Bromopyrimidin-2-yl)piperazin-1-yl)-2-hydroxyethanone
##STR00042##
[0751] The reaction was performed using
5-bromo-2-(piperazin-1-yl)pyrimidine, hydrochloric acid
(synthesized in a similar fashion to Example #3, step 1 from
1-(4-(5-bromopyrimidin-2-yl)piperazin-1-yl)-3,3-dimethylbutan-1-one
and glycolic acid) in a similar fashion to Preparation #15 to
afford the title product (0.20 g, 52%); LC/MS (Table A, Method i)
R.sub.t=0.79 min; MS m/z: 301 and 303 (M+H).sup.+.
Preparation #35:
(1-Methyl-4-(trifluoromethyl)-1H-pyrazol-3-yl)methanol
##STR00043##
[0752] Step 1: Ethyl
1-methyl-4-(trifluoromethyl)-1H-pyrazole-3-carboxylate
[0753] To a solution of ethyl
4-(trifluoromethyl)-1H-pyrazole-3-carboxylate (0.77 mg, 3.7 mmol)
(WO2007/045868) in THF (23 mL) under N.sub.2 was added sodium
hydride (60% dispersion in mineral oil) (0.178 g, 4.44 mmol) and
stirred for about 10 min at ambient temperature. MeI (0.463 mL,
7.40 mmol) was added. After about 1 h, sat. aq. NH.sub.4Cl (5 mL)
and EtOAc (20 mL) was added. The organic layer was separated and
the aqueous layer was back extracted with EtOAc (10 mL). The
combined organic layers were dried over MgSO.sub.4, filtered and
concentrated under reduced pressure. The material was purified via
flash chromatography on silica gel (0-60% EtOAc/heptane). The
appropriate fractions were collected and concentrated under reduced
pressure to provide the title product (0.695 g, 85%); LC/MS (Table
A, Method i) R.sub.t=1.02 min.; MS m/z: 223 (M+H).sup.+.
Step 2: (1-Methyl-4-(trifluoromethyl)-1H-pyrazol-3-yl)methanol
[0754] The reaction was performed with ethyl
1-methyl-4-(trifluoromethyl)-1H-pyrazole-3-carboxylate (0.695 g,
3.13 mmol) in a similar fashion to Preparation #32, step 4 to give
the title compound (0.453 g, 76%); .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 8.21 (s, 1H), 5.12 (t, J=5.6 Hz, 1H), 4.44
(d, J=5.5 Hz, 2H), 3.83 (s, 3H).
Preparation #36:
(S)-1-(4-(5-Bromopyrimidin-2-yl)-3-methylpiperazin-1-yl)ethanone
##STR00044##
[0756] The title compound was prepared in a manner similar to
Example #3, Steps 1 and 2 from (S)-tert-butyl
4-(5-bromopyrimidin-2-yl)-3-methylpiperazine-1-carboxylate
(prepared in a similar manner Example #2 from
5-bromo-2-chloropyrimidine and (S)-tert-butyl
3-methylpiperazine-1-carboxylate); LC/MS (Table A, Method i)
R.sub.t=2.34 min; MS m/z: 299 and 301 (M+H).sup.+.
Preparation #37:
6-Bromo-1-(2-(difluoromethoxy)benzyl)-2-(difluoromethyl)-1H-indazol-3(2H)-
-one
##STR00045##
[0757] Step 1:
6-Bromo-1-(2-(difluoromethoxy)benzyl)-1H-indazol-3(2H)-one
[0758] 6-Bromo-1-(2-(difluoromethoxy)benzyl)-1H-indazol-3(2H)-one
was prepared in a similar fashion to Preparation #4, step 1 using
6-bromo-1H-indazol-3(2H)-one and
1-(bromomethyl)-2-(difluoromethoxy)benzene to give the title
compound (1.10 g, 32%); LC/MS (Table A, Method e) R.sub.t=2.34 min;
MS m/z: 369 and 371 (M+H).sup.+.
Step 2:
6-Bromo-1-(2-(difluoromethoxy)benzyl)-2-(difluoromethyl)-1H-indazo-
l-3(2H)-one
[0759] A solution of
6-bromo-1-(2-(difluoromethoxy)benzyl)-1H-indazol-3(2H)-one (0.750
g, 2.03 mmol) and cesium carbonate (6.62 g, 20.3 mmol) in DMF (6
mL) at about 0.degree. C. was added diethyl
(bromodifluoromethyl)phosphonate (1.09 g, 4.06 mmol) dropwise. The
ice bath was allowed to melt and the reaction was stirred at rt for
about 2 days. The reaction was partitioned between EtOAc (50 mL)
and sat. aq. NaCl (100 mL). The organic layer was dried over
Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure.
The residue was purified on silica gel using 0-10% EtOAc in
heptanes to give the title compound (0.105 g, 12%); LC/MS (Table A,
Method e) R.sub.t=1.82 min; MS m/z: 219 and 221 (M+H).sup.+.
Preparation #38: 6-Bromo-7-fluoro-2-methyl-1H-indazol-3(2H)-one
##STR00046##
[0760] Step 1: 4-Bromo-2,3-difluoro-N-methylbenzohydrazide
[0761] 4-Bromo-2,3-difluoro-N-methylbenzohydrazide was prepared in
a similar fashion to Preparation #1, step 1 using
4-bromo-2,3-difluorobenzoic acid to give the title compound (4.29
g, 77%); LC/MS (Table A, Method i) Rt=0.85 min; MS m/z: 265 and 267
(M+H).sup.+.
Step 2: 6-Bromo-7-fluoro-2-methyl-1H-indazol-3(2H)-one
[0762] 6-Bromo-7-fluoro-2-methyl-1H-indazol-3(2H)-one was prepared
in a similar fashion to Preparation #1, step 2 using
4-bromo-2,3-difluoro-N-methylbenzohydrazide to give the title
compound (3.20 g, 81%); LC/MS (Table A, Method e) R.sub.t=1.49 min;
MS m/z: 245 and 247 (M+H).sup.+.
Preparation #39: Methyl
3-((6-bromo-2-methyl-3-oxo-2,3-dihydro-1H-indazol-1-yl)methyl)-4-(difluor-
omethoxy)benzylcarbamate
##STR00047##
[0763] Step 1:
1-(5-(Azidomethyl)-2-(difluoromethoxy)benzyl)-6-bromo-2-methyl-1H-indazol-
-3(2H)-one
[0764] A flask was charged with sodium azide (30 mg, 0.5 mmol),
6-bromo-1-(5-(bromomethyl)-2-(difluoromethoxy)benzyl)-2-methyl-1H-indazol-
-3(2H)-one (192 mg, 0.403 mmol) (Preparation #20, step 3) and DMF
(2 mL) at room temperature. After about 1 h, the mixture was
diluted with H.sub.2O (100 mL) and extracted with 10% MeOH in
CH.sub.2Cl.sub.2 (3.times.20 mL). The organic layer was dried over
Na.sub.2SO.sub.4, filtered, and concentrated under reduced pressure
to afford the title product (155 mg, 88%); LC/MS (Table A, Method
i) R.sub.t=1.55 min; MS m/z: 438 and 440 (M+H).sup.+.
Step 2:
1-(5-(Aminomethyl)-2-(difluoromethoxy)benzyl)-6-bromo-2-methyl-1H--
indazol-3(2H)-one
[0765] A flask was charged with
1-(5-(azidomethyl)-2-(difluoromethoxy)benzyl)-6-bromo-2-methyl-1H-indazol-
-3(2H)-one (155 mg, 0.354 mmol), THF (2 mL), H.sub.2O (0.2 mL) and
trimethylphosphine (1M in toluene, 0.4 mL, 0.4 mmol) at room
temperature. After about 1 h, the solution was diluted with 10%
MeOH in CH.sub.2Cl.sub.2 (20 mL), dried over Na.sub.2SO.sub.4,
filtered, and concentrated under reduced pressure to afford the
title product (140 mg, 96%); LC/MS (Table A, Method i) R.sub.t=0.88
min; MS m/z: 412 and 414 (M+H).sup.+.
Step 3: Methyl
3-((6-bromo-2-methyl-3-oxo-2,3-dihydro-1H-indazol-1-yl)methyl)-4-(difluor-
omethoxy)benzylcarbamate
[0766] A flask was charged with
1-(5-(aminomethyl)-2-(difluoromethoxy)benzyl)-6-bromo-2-methyl-1H-indazol-
-3(2H)-one (140 mg, 0.34 mmol), CH.sub.2Cl.sub.2 (2 mL), TEA (0.1
mL, 0.7 mmol) followed by triphosgene (111 mg, 0.374 mmol) at room
temperature. After about 1 h, MeOH (0.5 mL) was added. After about
2 h, the volatiles were removed under reduced pressure. The residue
was purified by flash chromatography on silica gel (0-10%
MeOH/CH.sub.2Cl.sub.2) to afford the title product (107 mg, 67%);
LC/MS (Table A, Method i) R.sub.t=1.27 min; MS m/z: 470 and 472
(M+H).sup.+.
Preparation #40:
6-Bromo-1-(2-(difluoromethoxy)benzyl)-5-fluoro-2-methyl-1H-indazol-3(2H)--
one
##STR00048##
[0768] Potassium tert-butoxide (10.3 g, 92 mmol) was added in one
portion to a solution of
4-bromo-2,5-difluoro-N-methylbenzohydrazide (11.0 g, 41.5 mmol)
(prepared in a similar fashion to Example #17, step 1 using
4-bromo-2,5-difluorobenzoic acid) and DMF (220 mL). The mixture was
warmed to about 85.degree. C. After about 10 min, the reaction
vessel was transferred to an ice bath. After about 15 min,
2-(difluormethoxy)benzyl bromide (7.50 mL, 49.2 mmol) was added
dropwise over about 4 min. The ice bath was removed. After about 90
min, AcOH (0.600 mL, 10.5 mmol) was added to adjust the pH to about
5. The volatiles were mostly removed under reduced pressure at
about 60.degree. C. Water (250 mL) and DCM (250 mL) were added. The
layers were separated and the aqueous layer was extracted with DCM
(2.times.100 mL). The combined organic layers were dried over
Na.sub.2SO.sub.4, filtered, and concentrated. The residue was
purified by flash chromatography on silica gel eluding with a
gradient of 0-25% EtOAc/DCM The appropriate fractions were
collected and concentrated under reduced pressure to afford the
title compound (8.75 g, 53%); LC/MS (Table A, Method i)
R.sub.t=1.45 min; MS m/z: 401 and 403 (M+H).sup.+.
Preparation #41:
(S)-2-((R)-4-(5-(1-(2-(Difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-
-1H-indazol-6-yl)pyrimidin-2-yl)-2-methylpiperazin-1-yl)-2-oxoethyl
2-((tert-butoxycarbonyl)amino)-3-methylbutanoate
##STR00049##
[0770]
(R)-1-(2-(Difluoromethoxy)benzyl)-6-(2-(4-(2-hydroxyacetyl)-3-methy-
lpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one (150
mg, 0.279 mmol),
(S)-2-((tert-butoxycarbonyl)amino)-3-methylbutanoic acid (73 mg,
0.33 mmol), DMAP (17 mg, 0.139 mmol), and
1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (80 mg,
0.42 mmol) were combined in DMF (2.8 mL). TEA (97 .mu.L, 0.70 mmol)
was added, and the reaction was allowed to stir for about 20 h.
Additional 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide
hydrochloride (80 mg, 0.42 mmol) and
(S)-2-((tert-butoxycarbonyl)amino)-3-methylbutanoic acid (73 mg,
0.33 mmol) were added and the reaction mixture was allowed to stir
for about 28 h. The reaction was partitioned between EtOAc (15 mL)
and water (15 mL). The aqueous layer was back-extracted with
additional EtOAc (15 mL), then the combined organic layers were
washed sequentially with sat. aq. NH.sub.4Cl (20 mL), sat. aq.
NaHCO.sub.3 (20 mL), and sat. aq. NaCl (20 mL). The organic layer
was dried over MgSO.sub.4, filtered, and concentrated in vacuo. The
residue was purified via flash chromatography (0-5% MeOH in DCM).
Concentration of the relevant fractions yielded the title compound
(132 mg, 64%); LC/MS (Table A, Method i) R.sub.t=1.75 min; MS m/z:
738 (M+H).sup.+.
Preparation #42: 3-Iodo-1-methylpiperidin-2-one
##STR00050##
[0772] 1-Methylpiperidin-2-one (0.97 mL, 8.8 mmol) was dissolved in
anhydrous toluene (33 mL) and cooled to about 0.degree. C.
Tetramethylethylenediamine (4.00 mL, 26.5 mmol) was added and the
solution was stirred for about 5 min, then chlorotrimethylsilane
(2.26 mL, 17.7 mmol) was added dropwise. The solution was allowed
to stir about 30 min at about 0.degree. C., then iodine (2.47 g,
9.72 mmol) was added in one portion. The flask was removed from the
ice bath and allowed to stir while warming to rt for about 2 h. The
reaction was partitioned between sat. aq. sodium thiosulfate (50
mL) and EtOAc (30 mL). The organic layer was washed with sat. aq.
sodium thiosulfate (20 mL) and sat. aq. NaCl (20 mL). The organic
layer was dried over MgSO.sub.4, vacuum filtered, and concentrated
in vacuo. Further purification via silica gel chromatography
(30-100% EtOAc in heptane) isolated the title compound (1.31 g,
62%); LC/MS (Table A, Method i) R.sub.t=0.45 min; MS m/z: 240
(M+H).sup.+.
Preparation #43:
3-((4-Chloro-3-(hydroxymethyl)phenyl)amino)-1-methylpiperidin-2-one
##STR00051##
[0773] Step 1:
(3-(((tert-Butyldimethylsilyl)oxy)methyl)-4-chloroaniline)
[0774] (5-Amino-2-chlorophenyl)methanol (1.50 g, 9.52 mmol),
imidazole (0.97 g, 14 mmol) and tert-butyldimethylsilyl chloride
(1.58 g, 10.5 mmol) were combined in anhydrous DMF (15.9 mL) and
cooled to about 0.degree. C. The reaction was allowed to stir for
about 16 h while warming to rt. Additional tert-butyldimethylsilyl
chloride (0.70 g, 4.6 mmol) was added in two equal portions over
about 3 h, then stirred for about an additional 3 h at rt. The
reaction was quenched via the addition of sat. aq. NH.sub.4Cl (45
mL) then extracted with EtOAc (3.times.20 mL). The organic layer
was washed with water (2.times.50 mL) and sat. aq. NaCl (50 mL),
then dried over MgSO.sub.4, filtered, and concentrated in vacuo.
Further purification via flash chromatography (0-30% EtOAc in
heptane) isolated the title compound (2.37 g, 92%); LC/MS (Table A,
Method k) R.sub.t=1.34 min; MS m/z: 272 (M+H).sup.+.
Step 2:
(3-((3-(((tert-Butyldimethylsilyl)oxy)methyl)-4-chlorophenyl)amino-
)-1-methylpiperidin-2-one)
[0775] A solution of
3-(((tert-butyldimethylsilyl)oxy)methyl)-4-chloroaniline (682 mg,
2.51 mmol) in anhydrous THF (2 mL) was added to an oven-dried vial
and cooled to about 0.degree. C. A solution of LiHMDS (1 M in THF,
4.18 mL, 4.18 mmol) was added dropwise, then the reaction was
stirred for approximately 20 min at about 0.degree. C. A solution
of 3-iodo-1-methylpiperidin-2-one (500 mg, 2.09 mmol) (Preparation
#42) in anhydrous THF (2 mL) was added dropwise. The reaction was
diluted with additional anhydrous THF (3 mL) and allowed to stir
about 30 min while warming to rt. The reaction was quenched by the
addition of cold sat. aq. NH.sub.4Cl solution (20 mL) and extracted
into EtOAc (2.times.10 mL). The organic layer was washed with water
(20 mL) and sat. aq. NaCl (20 mL), then dried over MgSO.sub.4,
filtered, and concentrated in vacuo. The residue was further
purified via flash chromatography (0-70% EtOAc in heptane) to
isolate the title compound (609 mg, 76%); LC/MS (Table A, Method k)
R.sub.t=1.40 min; MS m/z 383 (M+H).sup.+.
Step 3:
(3-((4-Chloro-3-(hydroxymethyl)phenyl)amino)-1-methylpiperidin-2-o-
ne)
[0776]
3-((3-(((tert-Butyldimethylsilyl)oxy)methyl)-4-chlorophenyl)amino)--
1-methylpiperidin-2-one (694 mg, 1.81 mmol) was dissolved in
anhydrous THF (9 mL) and cooled to about 0.degree. C.
Tetrabutylammonium fluoride (1.0 M in THF, 3.63 mL, 3.63 mmol) was
added and the reaction was stirred for about 2 h at about 0.degree.
C. The reaction mixture was concentrated in vacuo and partitioned
between EtOAc (20 mL) and sat. aq. NaCl (20 mL). The organic layer
was washed with sat. aq. NaCl (20 mL), dried over MgSO.sub.4,
filtered, and concentrated in vacuo. Purification via silica gel
chromatography (50-100% EtOAc in heptane) isolated the title
compound (450 mg, 92%); LC/MS (Table A, Method i) R.sub.t=0.83 min;
MS m/z: 269 (M+H).sup.+.
Preparation #44:
3-((4-Chloro-3-(hydroxymethyl)phenyl)amino)-1-methylpyrrolidin-2-one
##STR00052##
[0777] Step 1:
3-((3-(((tert-Butyldimethylsilyl)oxy)methyl)-4-chlorophenyl)amino)-1-meth-
ylpyrrolidin-2-one
[0778] The title compound was prepared in a manner similar to
Preparation #43, step 2, from 3-bromo-1-methylpyrrolidin-2-one
(synthesized in a manner similar to preparation found in
WO2008050101 A2) and
3-(((tert-butyldimethylsilyl)oxy)methyl)-4-chloroaniline
(Preparation #43, step 1) (67%); LC/MS (Table A, Method i)
R.sub.t=2.05 min; MS m/z: 369 (M+H).sup.+.
Step 2:
3-((4-Chloro-3-(hydroxymethyl)phenyl)amino)-1-methylpyrrolidin-2-o-
ne
[0779] The title compound was synthesized in a manner similar to
Preparation #43, step 3, from
3-((3-(((tert-butyldimethylsilyl)oxy)methyl)-4-chlorophenyl)amino)-1-meth-
ylpyrrolidin-2-one (90%); LC/MS (Table A, Method i) R.sub.t=0.74
min; MS m/z: 255 (M+H).sup.+.
Preparation #45:
1-(7-Chloroimidazo[1,2-b]pyridazin-3-yl)ethanol
##STR00053##
[0780] Step 1: 7-Chloro-3-iodoimidazo[1,2-b]pyridazine
[0781] A mixture of 7-chloroimidazo[1,2-b]pyridazine (900 mg, 5.86
mmol) and N-iodosuccinimide (1.58 g, 7.03 mmol) in MeCN (25 mL) was
heated to about 60.degree. C. for approximately 16 h. The reaction
was cooled to rt and partitioned between DCM (200 mL) and sat. aq.
sodium thiosulfate (100 mL). The organic layer was washed with sat.
aq. NaHCO.sub.3 (100 mL) and sat. aq. NaCl (50 mL), dried over
Na.sub.2SO.sub.4, filtered, and concentrated under reduced pressure
to give the title compound (1.63 g, 100%); LC/MS (Table A, Method
i) R.sub.t=0.95 min; MS m/z=280 (M+H).sup.+.
Step 2: 7-Chloro-3-vinylimidazo[1,2-b]pyridazine
[0782] The compound was synthesized in a manner similar to Example
#14, step 4 from 7-chloro-3-iodoimidazo[1,2-b]pyridazine (79%);
LC/MS (Table A, Method h) R.sub.t=1.02 min; MS nm/z=180
(M+H).sup.+.
Step 3: 7-Chloroimidazo[1,2-b]pyridazine-3-carbaldehyde
[0783] The compound was synthesized in a manner similar to Example
#4, step 1 from 7-chloro-3-vinylimidazo[1,2-b]pyridazine (76%);
LC/MS (Table A, Method j) R.sub.t=0.32 min; MS m/z=182
(M+H).sup.+.
Step 4: 1-(7-Chloroimidazo[1,2-b]pyridazin-3-yl)ethanol
[0784] 7-Chloroimidazo[1,2-b]pyridazine-3-carbaldehyde (640 mg,
3.52 mmol) was dissolved in anhydrous THF (20 mL) and cooled to
about -25 to -30.degree. C., then methylmagnesium bromide (3.0 M in
diethyl ether, 2.70 mL, 8.11 mmol) was added dropwise while
maintaining a temperature below about -10.degree. C. The reaction
was allowed to stir while warming to rt over about 30 min, then the
reaction was quenched with a combination of ice water (20 mL), sat.
aq. NH.sub.4Cl (20 mL), and sat. aq. NaCl (20 mL). The resulting
suspension was extracted with EtOAc (2.times.30 mL). The aqueous
layer was saturated with NaCl and extracted with additional EtOAc
(2.times.30 mL). The combined organic layers were dried over
MgSO.sub.4, filtered, and concentrated under reduced pressure.
Further purification via flash chromatography (0-10% MeOH in DCM)
isolated the title compound (218 mg, 31%); LC/MS (Table A, Method
j) R.sub.t=0.52 min; MS m/z=198 (M+H).sup.+.
Preparation #46: (R)-Hexahydroimidazo[1,5-a]pyrazin-3(2H)-one and
(S)-hexahydroimidazo[1,5-a]pyrazin-3(2H)-one
##STR00054##
[0786] A solution of tert-butyl (piperazin-2-ylmethyl)carbamate
(WO2006014580A1) (21 g, 98 mmol) and DIEA (85 mL, 490 mmol) in DCM
(420 mL) was cooled to about 0.degree. C. before benzyl
chloroformate (41.8 mL, 293 mmol) was added drop-wise over about 50
min. The mixture was allowed to warm to rt and then was added to
sat. aq. NH.sub.4C (150 mL). The layers were separated and the
aqueous layer was extracted with DCM (100 mL). The combined organic
layers were dried over Na.sub.2SO.sub.4, filtered and concentrated
under reduced pressure to give dibenzyl
2-(((tert-butoxycarbonyl)amino)methyl)piperazine-1,4-dicarboxylate
(56.5 g, 96.0 mmol) which was used without further purification.
This product was taken up in 1,4-dioxane (250 mL) and the resulting
suspension was filtered through a frit funnel and washed with
1,4-dioxane (.about.25 mL). The combined filtrate was stirred and
then treated with HCl (4 M in 1,4-dioxane) (120 mL, 479 mmol) and
subsequently heated to about 70.degree. C. for about 45 min. The
slurry was allowed to cool to ambient temperature and the mixture
was quenched with sat. aq. NaHCO.sub.3 (500 mL). The mixture was
extracted with EtOAc (500 mL). The aqueous layer was then
neutralized with 1 M aq. NaOH (500 mL) and extracted with EtOAc
(500 mL). The combined organic layers were dried over
Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure.
The crude mixture was purified on silica gel (0-20% MeOH in DCM) to
give dibenzyl 2-(aminomethyl)piperazine-1,4-dicarboxylate (7.1 g,
18%) which was used directly in the next step. To a suspension of
dibenzyl 2-(aminomethyl)piperazine-1,4-dicarboxylate (4.70 g, 12.3
mmol) in THF (120 mL) at about ambient temperature was added sodium
tert-butoxide (2 M in THF) (9.19 mL, 18.4 mmol) and the resulting
solution was stirred for about 2 h. A solution of sat. aq.
NH.sub.4Cl and water (1:1) was added, and the aqueous layer was
extracted twice with EtOAc. The combined organic layers were dried
over Na.sub.2SO.sub.4, filtered and concentrated under reduced
pressure. The resulting material was dissolved in EtOAc and the
product precipitated by adding heptane. The solid was collected by
filtration and dried under vacuum to give benzyl
3-oxohexahydroimidazo[1,5-a]pyrazine-7(1H)-carboxylate (2.9 g,
76%). Chiral separation according to Table B, method f gave, in
order of elution, benzyl
(S)-3-oxohexahydroimidazo[1,5-a]pyrazine-7(1H)-carboxylate (1.60 g)
and benzyl
(R)-3-oxohexahydroimidazo[1,5-a]pyrazine-7(1H)-carboxylate (1.51
g). A 50 mL Parr reactor was charged with benzyl
(S)-3-oxohexahydroimidazo[1,5-a]pyrazine-7(1H)-carboxylate (1.50 g,
5.45 mmol), 10% Pd(OH).sub.2/C (42.6 weight % in water) (0.352 g)
and THF (16.5 mL). The mixture was stirred at about 50.degree. C.
under about 50 psi of hydrogen for about 6 h, after which the
suspension was filtered and the filter cake washed with THF and
MeOH. The combined filtrates were concentrated to give
(R)-hexahydroimidazo[1,5-a]pyrazin-3(2H)-one (0.75 g); SFC/MS
(Table C, Method c) R.sub.t=4.66 min; MS m/z: 140 (M-H).sup.-.
Benzyl (S)-3-oxohexahydroimidazo[1,5-a]pyrazine-7(1H)-carboxylate
(1.40 g, 5.09 mmol) was used in the same fashion to prepare
(S)-hexahydroimidazo[1,5-a]pyrazin-3(2H)-one (0.60 g); SFC/MS
(Table C, Method c) R.sub.t=4.83 min; MS m/z: 140 (M-H).sup.-.
Preparation #47:
6-(2-Chloropyrimidin-5-yl)-2-methyl-1-((5-methyl-2-(trifluoromethyl)pyrid-
in-3-yl)methyl)-1,2-dihydro-3H-indazol-3-one
##STR00055##
[0787] Step 1:
(5-Methyl-2-(trifluoromethyl)pyridin-3-yl)methanol
[0788] Ethyl 5-methyl-2-(trifluoromethyl)nicotinate (0.495 g, 2.12
mmol) (prepared as described in European Journal of Organic
Chemistry, 2013(19), 4131-4145) in EtOH (10 mL) was heated to about
50.degree. C. and treated with NaBH.sub.4 (0.360 g, 9.54 mmol)
added in three equal portions over about 90 min. The reaction was
concentrated under reduced pressure and the residue was partitioned
between EtOAc (15 mL) and water (10 mL). After separating the
layers, the aqueous phase was extracted with EtOAc (2.times.5 mL).
The combined organic phases were washed with sat. aq. NaCl (25 mL),
dried over Na.sub.2SO.sub.4, filtered, and concentrated via rotary
evaporation. The residue was purified on silica gel using a
gradient of 0-100% EtOAc in heptane to give the title product
(0.290 g, 71%). (Table A, Method e) R.sub.t=1.55 min; MS m/z: 192
(M+H).sup.+.
Step 2: 3-(Bromomethyl)-5-methyl-2-(trifluoromethyl)pyridine
[0789] The reaction was performed using
(5-methyl-2-(trifluoromethyl)pyridin-3-yl)methanol and PBr.sub.3 in
a similar fashion to Preparation #3, step 2 to give the title
product (63%); .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.44 (s,
1H), 7.74 (s, 1H), 4.59 (s, 2H), 2.44 (s, 3H).
Step 3:
6-(2-Chloropyrimidin-5-yl)-2-methyl-1-((5-methyl-2-(trifluoromethy-
l)pyridin-3-yl)methyl)-1,2-dihydro-3H-indazol-3-one
[0790] The reaction was performed using
3-(bromomethyl)-5-methyl-2-(trifluoromethyl)pyridine and potassium
carbonate with
6-(2-chloropyrimidin-5-yl)-2-methyl-1-1H-indazol-3(2H)-one
(Preparation #23) in a similar fashion to Example #1 to give the
title product (35%); (Table A, Method e) R.sub.t=2.02 min; MS m/z:
434 (M+H).sup.+.
Preparation #48:
6-(2-Chloropyrimidin-5-yl)-2-methyl-1-((2-(trifluoromethyl)pyridin-3-yl)m-
ethyl)-1,2-dihydro-3H-indazol-3-one
##STR00056##
[0791] Step 1:
(5-Methyl-2-(trifluoromethyl)pyridin-3-yl)methanol
[0792] Methyl 2-(trifluoromethyl)nicotinate was treated with sodium
borohydride in a fashion similar to Preparation #14, step 2 to give
the title product (34%); .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.
8.62 (d, J=4.7 Hz, 1H), 8.16 (d, J=7.9 Hz, 1H), 7.55 (dd, J=7.9,
4.7 Hz, 1H), 4.95 (s, 2H).
Step 2: 3-(Bromomethyl)-2-(trifluoromethyl)pyridine
[0793] The reaction was performed using
(5-methyl-2-(trifluoromethyl)pyridin-3-yl)methanol and PBr.sub.3 in
a similar fashion to Preparation #3, step 2 to give the title
product (63%); .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.73-8.60
(m, 1H), 8.06-7.93 (m, 1H), 7.59-7.47 (m, 1H), 5.42-5.28 (m,
2H).
Step 3:
6-(2-Chloropyrimidin-5-yl)-2-methyl-1-((5-methyl-2-(trifluoromethy-
l)pyridin-3-yl)methyl)-1,2-dihydro-3H-indazol-3-one
[0794] The reaction was performed using
3-(bromomethyl)-2-(trifluoromethyl)pyridine and potassium carbonate
with 6-(2-chloropyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one
(Preparation #23) in a similar fashion to Example #1 to give the
title product (25%); (Table A, Method e) R.sub.t=1.93 min; MS m/z:
420 (M+H).sup.+.
Preparation #49:
6-(2-Chloropyrimidin-5-yl)-2-methyl-1-(5-methyl-2-(trifluoromethyl)benzyl-
)-1,2-dihydro-3H-indazol-3-one
##STR00057##
[0795] Step 1: (5-Methyl-2-(trifluoromethyl)phenyl)methanol
[0796] A solution of 5-methyl-2-(trifluoromethyl)benzoic acid
(0.500 g, 2.45 mmol) in THF (10 mL) was treated with borane THF
complex (1.0 M in THF) (4.90 mL, 4.90 mmol) and the reaction
mixture was heated at about reflux for about 1.5 h. The reaction
was cooled to rt and then MeOH (5 mL) was added slowly and the
mixture refluxed for 1 h. The mixture was concentrated under
reduced pressure and the crude material was purified on silica gel
(25 g, using 0 to 50% EtOAc in heptane) to give the title product
(0.414 g, 89%); .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.58-7.46
(m, 2H), 7.18 (d, J=7.8 Hz, 1H), 4.85 (s, 2H), 2.42 (s, 3H).
Step 2: 2-(Bromomethyl)-4-methyl-1-(trifluoromethyl)benzene
[0797] The reaction was performed using
(5-methyl-2-(trifluoromethyl)phenyl)methanol and PBr.sub.3 in a
similar fashion to Preparation #3, step 2 to give the title product
(59%); .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.52 (d, J=8.1 Hz,
1H), 7.39 (s, 1H), 7.20 (d, J=8.0 Hz, 1H), 4.60 (s, 2H), 2.41 (s,
3H).
Step 3:
6-(2-Chloropyrimidin-5-yl)-2-methyl-1-(5-methyl-2-(trifluoromethyl-
)benzyl)-1,2-dihydro-3H-indazol-3-one
[0798] The reaction was performed using
2-(bromomethyl)-4-methyl-1-(trifluoromethyl)benzene and potassium
carbonate with
6-(2-chloropyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one
(Preparation #23) in a similar fashion to Example #1 to give the
title product (25%); (Table A, Method e) R.sub.t=2.35 min; MS m/z:
435 (M+H).sup.+.
Preparation #50:
1-((5-Chloro-1,3-dihydroisobenzofuran-4-yl)methyl)-6-(2-chloropyrimidin-5-
-yl)-2-methyl-1,2-dihydro-3H-indazol-3-one
##STR00058##
[0799] Step 1: 5-Chloro-1,3-dihydroisobenzofuran-4-ol
[0800] A solution of 1,3-dihydroisobenzofuran-4-ol (2.60 g, 12.6
mmol) (prepared as described in Journal of the American Chemical
Society, 125(19), 5757-5766; 2003) and diisopropylamine (0.180 mL,
1.26 mmol) in toluene (80 mL) was treated with sulfuryl chloride
(1.03 mL, 12.6 mmol) added dropwise. Water (50 mL) was added and
the reaction was stirred for about 5 min. The mixture was extracted
with EtOAc (3.times.50 mL) and the combined organic phases were
washed with sat. aq. NaCl (75 mL), dried over Na.sub.2SO.sub.4,
filtered, and concentrated under reduced pressure to give a mixture
of regioisomers. The mixture was purified by reverse phase
chromatography (Atlantis.RTM. Prep T3 OBDTM 5 .mu.m 50.times.100 mm
column in 25-40% MeCN/water over 12 min) to give the title compound
(1.29 g, 60%); (Table A, Method e) R.sub.t=1.75 min; MS m/z: 169
(M-H).sup.-.
Step 2: 5-Chloro-1,3-dihydroisobenzofuran-4-yl
trifluoromethanesulfonate
[0801] A suspension of 5-chloro-1,3-dihydroisobenzofuran-4-ol (1.45
g, 8.52 mmol) and N,N-bis(trifluoromethylsulfonyl)aniline (3.35 g,
9.38 mmol) in DCM (40 mL) was treated with TEA (3.56 mL, 25.6 mmol)
and the mixture was stirred at about rt. After about 1.5 h,
additional N,N-bis(trifluoromethylsulfonyl)aniline (0.457 g, 1.28
mmol) was added and stirring was continued for about 30 min. The
reaction mixture was partitioned between DCM (25 mL) and water (25
mL), the aqueous phase was extracted with DCM (10 mL). The combined
organic phases were washed with 1N aq. NaOH (25 mL) and sat. aq.
NaCl (50 mL), dried over Na.sub.2SO.sub.4, filtered, and
concentrated under reduced pressure. The sample was purified on
silica gel using a gradient of 0-50% EtOAc in heptane to afford the
title compound (2.23 g, 86%); .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 7.44 (d, J=8.2 Hz, 1H), 7.18 (d, J=7.9 Hz, 1H), 5.24-5.19
(m, 2H), 5.14-5.10 (m, 2H).
Step 3: (E)-5-Chloro-4-styryl-1,3-dihydroisobenzofuran
[0802] The reaction was performed using
5-chloro-1,3-dihydroisobenzofuran-4-yl trifluoromethanesulfonate
with (E)-phenylethenylboronic acid in a similar fashion to Example
#14, step 4 to give the title product (53%); .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 7.57-7.49 (m, 2H), 7.48-7.27 (m, 5H), 7.06 (d,
J=8.0 Hz, 1H), 6.71 (d, J=16.7 Hz, 1H), 5.33-5.28 (m, 2H),
5.15-5.06 (m, 2H).
Step 4: 5-Chloro-1,3-dihydroisobenzofuran-4-carbaldehyde
[0803] The reaction was performed using
(E)-5-chloro-4-styryl-1,3-dihydroisobenzofuran in a similar fashion
to Example #4, step 1 to give the title product (69%); .sup.1H NMR
(400 MHz, CDCl.sub.3) .delta. 10.56 (d, J=0.5 Hz, 1H), 7.45-7.33
(m, 2H), 5.41-5.36 (m, 2H), 5.10-5.02 (m, 2H).
Step 5: (5-Chloro-1,3-dihydroisobenzofuran-4-yl)methanol
[0804] The reaction was performed using
5-chloro-1,3-dihydroisobenzofuran-4-carbaldehyde in a similar
fashion to Preparation #9 to give the title product (87%); .sup.1H
NMR (400 MHz, CDCl.sub.3) .delta. 7.29 (d, J=8.0 Hz, 1H), 7.10 (d,
J=8.0 Hz, 1H), 5.25 (s, 2H), 5.07 (s, 2H), 4.78 (s, 2H).
Step 6: 5-Chloro-4-(chloromethyl)-1,3-dihydroisobenzofuran
[0805] A solution of
(5-chloro-1,3-dihydroisobenzofuran-4-yl)methanol (0.118 g, 0.639
mmol) in DCM (5 mL) cooled to about 0.degree. C. was treated with
thionyl chloride (0.070 mL, 0.96 mmol). The ice bath was removed.
After stirring at rt for about 4 h, additional thionyl chloride
(0.030 mL, 0.41 mmol) was added and stirring was continued for
about 3 days. The reaction mixture was partitioned between DCM (5
mL) and sat aq. NaHCO.sub.3 (5 mL). After separating the layers,
the aqueous phase was extracted with DCM (5 mL). The combined
organic phases were dried using a phase separator, and concentrated
under reduced pressure to give the title product (0.120 g, 92%);
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.33 (d, J=8.0 Hz, 1H),
7.14 (d, J=8.0 Hz, 1H), 5.24-5.04 (m, 4H), 4.64 (s, 2H).
Step 7:
1-((5-chloro-1,3-dihydroisobenzofuran-4-yl)methyl)-6-(2-chloropyri-
midin-5-yl)-2-methyl-1,2-dihydro-3H-indazol-3-one
[0806] The reaction was performed using
5-chloro-4-(chloromethyl)-1,3-dihydroisobenzofuran with
6-(2-chloropyrimidin-5-yl)-2-methyl-1,2-dihydro-3H-indazol-3-one in
a similar fashion to Example #1 to give the title product (58%);
(Table A, Method e) R.sub.t=2.08 min; MS m/z: 427 (M+H).sup.+.
[0807] Preparation #51:
6-Bromo-2-methyl-1-(1-(6-methylpyridin-2-yl)ethyl)-1H-indazol-3(2H)-one
##STR00059##
[0808] The reaction was performed using
2-(1-bromoethyl)-6-methylpyridine (synthesized in a similar fashion
to Preparation #21, step 2 from 1-(6-methylpyridin-2-yl)ethanol
(synthesized in a similar fashion to Preparation #21, step 1 from
6-methyl-2-pyridinecarboxaldehyde)) and
6-bromo-2-methyl-1H-indazol-3(2H)-one (Preparation #1, step 2) in a
similar fashion to Preparation #4, step 1 to afford the title
product (0.40 g, 63%); LC/MS (Table A, Method j) R.sub.t=1.26 min;
MS m/z: 346 and 348 (M+H).sup.+
Preparation #52: 2-(5-Bromopyrimidin-2-yl)-2-methylpropan-1-ol
##STR00060##
[0809] Step 1: Ethyl
2-(5-bromopyrimidin-2-yl)-2-methylpropanoate
[0810] LiHMDS (1 M solution in hexanes, 4.80 mL, 4.80 mmol) was
added over about 10 min to a solution of ethyl
2-(5-bromopyrimidin-2-yl)acetate (1.06 g, 4.33 mmol) and THF (15.0
mL) under N.sub.2 at about -78.degree. C. After stirring for about
15 min, MeI (0.300 mL, 4.80 mmol) was added. The reaction was
allowed to warm to rt over about 1 h. The solution was cooled to
about -78.degree. C. LiHMDS (1 M solution in hexanes) (4.80 mL,
4.80 mmol) was added over about 10 min. After about 15 min, MeI
(0.300 mL, 4.80 mmol) was added in one portion. The solution was
allowed to warm to rt over about 1 h. After about 30 min, the
solution was cooled to about 0.degree. C. Sat. aq. NH.sub.4Cl (40
mL), water (10 mL) and EtOAc (50 mL) were added. The layers were
separated and the aqueous layer was extracted with EtOAc (20 mL).
The combined organic layers were dried over Na.sub.2SO.sub.4,
filtered, and concentrated. The residue was purified on silica gel
using a gradient of 0-10% EtOAc/heptane to afford the title product
(1.00 g, 85%). LC/MS (Table A, Method i) R.sub.t=1.37 min; MS m/z:
273 and 275 (M+H).sup.+.
Step 2: 2-(5-Bromopyrimidin-2-yl)-2-methylpropan-1-ol
[0811] Diisobutylaluminum hydride (1 M solution in toluene, 11 mL,
11 mmol) was added dropwise to a solution of ethyl
2-(5-bromopyrimidin-2-yl)-2-methylpropanoate (2.0 g, 7.3 mmol) and
DCM (50 mL) under N.sub.2 at about 0.degree. C. over about 50 min.
After about 1 h, diisobutylaluminum hydride (1 M solution in
toluene, 3.5 mL, 3.5 mmol) was added over about 10 min. After about
1 h, 5% aq. potassium sodium tartrate (50 mL) and DCM (50 mL) were
added at rt and the mixture was stirred for about 1 h. 10% Aq.
potassium sodium tartrate (25 mL) was added and the mixture was
stirred vigorously for about 16 h. The layers were separated and
the aqueous layer was extracted with DCM (2.times.10 mL). The
combined organic layers were dried over MgSO.sub.4, filtered,
concentrated and purified on silica gel using a gradient of 0-30%
EtOAc/DCM to afford the title product (1.3 g, 77%); LC/MS (Table A,
Method j) R.sub.t=0.75 min; MS m/z: 231 and 233 (M+H).sup.+
Preparation #53:
6-Chloro-1-(2-(difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-1H-inda-
zole-5-carbonitrile
##STR00061##
[0812] Step 1:
6-Chloro-2-methyl-3-oxo-1-((2-(trimethylsilyl)ethoxy)methyl)-2,3-dihydro--
1H-indazole-5-carbonitrile
[0813] The reaction was performed using
5-bromo-6-chloro-2-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-
-3(2H)-one (Preparation #31, step 2) in a similar fashion to
Preparation #17, step 1 to afford the title product (1.43 g, 73%);
LC/MS (Table A, Method k) R.sub.t=0.89 min; MS m/z: 338
(M+H).sup.+.
Step 2:
6-Chloro-2-methyl-3-oxo-2,3-dihydro-1H-indazole-5-carbonitrile
trifluoroacetic acid
[0814] TFA (0.300 mL, 3.89 mmol) was added to a solution of
6-chloro-2-methyl-3-oxo-1-((2-(trimethylsilyl)ethoxy)methyl)-2,3-dihydro--
1H-indazole-5-carbonitrile (0.50 g, 1.34 mmol) at about 0.degree.
C. under N.sub.2. The reaction was warmed to rt and stirred for
about 4 h then concentrated under reduced pressure. EtOAc
(3.times.10 mL) was added and concentrated under reduced pressure.
To the solid was added MeOH (5.times.10 mL) and concentrated under
reduced pressure each time to provide the title product (0.31 g,
72%); LC/MS (Table A, Method i) R.sub.t=0.58 min; MS m/z: 208
(M+H).sup.+.
Step 3:
6-Chloro-1-(2-(difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro--
1H-indazole-5-carbonitrile
[0815] Potassium carbonate (0.180 g, 1.27 mmol) was added to a
solution of
6-chloro-2-methyl-3-oxo-2,3-dihydro-1H-indazole-5-carbonitrile
trifluoroacetic acid (0.15 g, 0.42 mmol) in DMF (4 mL) under
N.sub.2. After stirring for about 2 min at rt,
1-(bromomethyl)-2-(difluoromethoxy)benzene (0.100 mL, 0.656 mmol)
was added and stirring was continued for about 20 min. EtOAc (30
mL) and water (10 mL) were added to the reaction mixture. The
layers were separated and the aqueous layer was back extracted with
EtOAc (2.times.10 mL). The combined organic layers were dried over
MgSO.sub.4, filtered and concentrated under reduced pressure. The
material was purified via flash chromatography on silica gel
(0-100% EtOAc/heptane). The appropriate fractions were collected
and concentrated under reduced pressure to yield the title product
(0.15 g, 51%); LC/MS (Table A, Method i) R.sub.t=1.32 min; MS m/z:
364 (M+H).sup.+.
Preparation #54:
(S)-1-(4-(5-bromopyrimidin-2-yl)-3-methylpiperazin-1-yl)-2-hydroxyethanon-
e
##STR00062##
[0817] (S)-5-Bromo-2-(2-methylpiperazin-1-yl)pyrimidine
dihydrochloride (1.0 g, 3.0 mmol) (synthesized in a similar fashion
to Example #3, step 1 from (S)-tert-butyl
4-(5-bromopyrimidin-2-yl)-3-methylpiperazine-1-carboxylate
(synthesized in a similar fashion to Preparation #13, step 1 from
(S)-tert-butyl 3-methylpiperazine-1-carboxylate)) in DMF (15 mL)
was treated with 2-hydroxyacetic acid (0.35 g, 4.5 mmol),
2-(3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-1,1,3,3-tetramethylisouronium
hexafluorophosphate(V) (1.38 g, 3.64 mmol) and TEA (1.7 mL, 12
mmol). After about 30 min, the volatiles were removed under reduced
pressure and water (20 mL) and EtOAc (20 mL) were added. The
organic layer was separated and the aqueous layer was back
extracted with EtOAc (3.times.10 mL). The combined organic layers
were dried over MgSO.sub.4, filtered and concentrated under reduced
pressure. The material was purified via flash chromatography on
silica gel (0-100% EtOAc/heptane). The appropriate fractions were
collected and concentrated under reduced pressure to yield the
title product (0.76 g, 80%); LC/MS (Table A, Method i) R.sub.t=0.93
min.; MS m/z: 315 and 317 (M+H).sup.+.
Preparation #55:
(R)-1-(4-(5-Bromopyridin-2-yl)-2-methylpiperazin-1-yl)-2-hydroxyethanone
##STR00063##
[0818] Step 1: (R)-tert-Butyl
4-(5-bromopyridin-2-yl)-2-methylpiperazine-1-carboxylate
[0819] Toluene (215 ml) was degassed under vacuum then placed under
an atmosphere of nitrogen then Pd.sub.2(dba).sub.3 (0.394 g, 0.430
mmol), (9,9-dimethyl-9H-xanthene-4,5-diyl)bis(diphenylphosphine)
(0.746 g, 1.290 mmol), (R)-tert-butyl
2-methylpiperazine-1-carboxylate (4.31 g, 21.5 mmol) and
2,5-dibromopyridine (6.6 g, 27.9 mmol) were added. The mixture was
stirred about 10 min then sodium tert-butoxide (3.10 g, 32.3 mmol)
was added and the mixture was heated to about 100.degree. C. for
about 3 h. The mixture was cooled to rt then washed with water,
dried over magnesium sulfate, filtered and concentrated. The
material was purified via flash chromatography on silica gel (0-50%
EtOAc/Heptane) to give the title compound (5.6 g, 73%); LC/MS
(Table A, Method i) R.sub.t=1.91 min; MS m/z: 356, 358
(M+H).sup.+.
Step 2:
(R)-1-(4-(5-Bromopyridin-2-yl)-2-methylpiperazin-1-yl)-2-hydroxyet-
hanone
[0820] The title compound was synthesized in a manner similar to
Preparation #15 from glycolic acid and
(R)-1-(5-bromopyridin-2-yl)-3-methylpiperazine dihydrochloride
(synthesized in a manner similar to Example #3, step 1 from
(R)-tert-butyl
4-(5-bromopyridin-2-yl)-2-methylpiperazine-1-carboxylate); LC/MS
(Table A, Method i) R.sub.t=1.00 min; MS m/z: 314, 316
(M+H).sup.+.
Preparation #56:
3-(3-((6-Bromo-2-methyl-3-oxo-2,3-dihydro-1H-indazol-1-yl)methyl)-4-(difl-
uoromethoxy)phenyl)-2-methylpropanenitrile
##STR00064##
[0822] A flask, purged with nitrogen, was charged with
diisopropylamine (0.14 mL, 0.98 mmol), then cooled on an ice-water
bath for 10 min. Following cooling, n-butyllithium (2.5M in
hexanes) (0.40 mL, 1.0 mmol) was added, followed by THF (5 mL). The
solution was then cooled to about -78.degree. C., then
propiononitrile (51 mg, 0.93 mmol) was added, and the solution was
stirred for about 10 min. After stirring, this solution was added
to a separate flask containing
6-bromo-1-(5-(bromomethyl)-2-(difluoromethoxy)benzyl)-2-methyl-1H-indazol-
-3(2H)-one (417 mg, 0.876 mmol) (Preparation #20, step 3) and THF
(5 mL) that was pre-cooled to about -78.degree. C. The mixture was
stirred for about 3 h, then quenched with sat. aq. NH.sub.4Cl (20
mL). The mixture was extracted with EtOAc (4.times.10 mL). The
combined organic layers were dried over Na.sub.2SO.sub.4, filtered
and concentrated. The residue was purified by flash chromatography
on silica gel (0-7% MeOH/CH.sub.2Cl.sub.2) to afford the title
product (121 mg, 31%); LC/MS (Table A, Method i) R.sub.t=1.44 min;
MS m/z: 450 and 452 (M+H).sup.+.
Preparation #57:
6-(2-Chloropyrimidin-5-yl)-1-((3-(difluoromethoxy)-6-methylpyridin-2-yl)m-
ethyl)-2-methyl-1H-indazol-3(2H)-one
##STR00065##
[0824]
6-(2-Chloropyrimidin-5-yl)-1-((3-(difluoromethoxy)-6-methylpyridin--
2-yl)methyl)-2-methyl-1H-indazol-3(2H)-one was prepared in a
similar fashion to Example #1, from
6-(2-chloropyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one
(Preparation #23) and
2-(bromomethyl)-3-(difluoromethoxy)-6-methylpyridine (prepared from
(3-(difluoromethoxy)-6-methylpyridin-2-yl)methanol (prepared from
3-(difluoromethoxy)-6-methylpicolinaldehyde (prepared from
(E)-3-(difluoromethoxy)-6-methyl-2-styrylpyridine (prepared from
2-bromo-3-(difluoromethoxy)-6-methylpyridine (prepared from
2-bromo-6-methylpyridin-3-ol in a similar fashion to Preparation
#14, step 1) in a similar fashion to Example #14, step 4) in a
similar fashion to Example #4, step 1) in a similar fashion to
Preparation of #14, step 2) in a similar fashion to Preparation
#14, step 6) to afford the title product (79%); LC/MS (Table A,
Method i) R.sub.t=1.31 min; MS m/z: 432 (M+H).sup.+.
Preparation #58:
6-(2-(4-Acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-1-(2-(difluorometho-
xy)-5-methylbenzyl)-2-methyl-1H-indazol-3(2H)-one
##STR00066##
[0826]
6-(2-(4-Acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-1-(2-(difluor-
omethoxy)-5-methylbenzyl)-2-methyl-1H-indazol-3(2H)-one was
prepared in a similar fashion to Preparation #16 using
1-(2-(difluoromethoxy)-5-methylbenzyl)-2-methyl-6-(2-(3-methylpiperazin-1-
-yl)pyrimidin-5-yl)-1H-indazol-3(2H)-one, hydrochloric acid
(prepared in a similar fashion to Example #3, step 1 using
tert-butyl
4-(5-(1-(2-(difluoromethoxy)-5-methylbenzyl)-2-methyl-3-oxo-2,3-dihydro-1-
H-indazol-6-yl)pyrimidin-2-yl)-2-methylpiperazine-1-carboxylate
(prepared in a similar fashion to Example #2 using
1-Boc-2-methylpiperazine and
6-(2-chloropyrimidin-5-yl)-1-(2-(difluoromethoxy)-5-methylbenzyl)-2-methy-
l-1H-indazol-3(2H)-one (Example #22, step 3))) to give the title
compound (100%); LC/MS (Table A, Method i) R.sub.t=1.28 min; MS
m/z: 537 (M+H).sup.+.
Preparation #59:
1-(2-(Difluoromethoxy)-5-methylbenzyl)-2-(methyl-d.sub.3)-6-(4,4,5,5-tetr-
amethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3(2H)-one
##STR00067##
[0828]
1-(2-(Difluoromethoxy)-5-methylbenzyl)-2-(methyl-d.sub.3)-6-(4,4,5,-
5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3(2H)-one was
prepared in a similar fashion to Preparation #4, step 2 using
6-bromo-1-(2-(difluoromethoxy)-5-methylbenzyl)-2-(methyl-d.sub.3)-1H-inda-
zol-3(2H)-one (prepared in a similar fashion to Example #14, step 3
from iodomethane-d.sub.3 and
6-bromo-1-(2-(difluoromethoxy)-5-methylbenzyl)-1H-indazol-3(2H)-one
(prepared in a similar fashion to Example #1 using
6-bromo-1H-indazol-3(2H)-one and
2-(bromomethyl)-1-(difluoromethoxy)-4-methylbenzene (prepared in a
similar fashion to Preparation #3, step 2 using
(2-(difluoromethoxy)-5-methylphenyl)methanol (Preparation #11))))
to give the title compound (81%); LC/MS (Table A, Method i)
R.sub.t=1.78 min; MS m/z: 448 (M+H).sup.+.
Preparation #60:
(R)-6-(2-(4-(2-(tert-Butoxy)acetyl)-3-methylpiperazin-1-yl)pyrimidin-5-yl-
)-2-methyl-1H-indazol-3(2H)-one
##STR00068##
[0830]
(R)-6-(2-(4-(2-(tert-Butoxy)acetyl)-3-methylpiperazin-1-yl)pyrimidi-
n-5-yl)-2-methyl-1H-indazol-3(2H)-one was prepared in a similar
fashion to Example #8 using 6-bromo-2-methyl-1H-indazol-3(2H)-one
(Preparation #1) and
(R)-1-(4-(5-bromopyrimidin-2-yl)-2-methylpiperazin-1-yl)-2-(tert-buto-
xy)ethanone (Preparation #30, step 1) to give the title compound to
give the title compound (46%); LC/MS (Table A, Method j)
R.sub.t=0.98 min; MS m/z: 439 (M+H).sup.+.
Preparation #61:
2-(Bromomethyl)-3-(trifluoromethyl)-6-((trityloxy)methyl)pyridine
##STR00069##
[0831] Step 1:
3-(Trifluoromethyl)-6-((trityloxy)methyl)-2-vinylpyridine
[0832] 2-Chloro-3-(trifluoromethyl)-6-((trityloxy)methyl)pyridine
(1.54 g, 3.39 mmol) (synthesized in a manner similar to Preparation
#14, step 3 from (6-chloro-5-(trifluoromethyl)pyridin-2-yl)methanol
(synthesized in a manner similar to Preparation #9 from methyl
6-chloro-5-(trifluoromethyl)picolinate)) and
tributyl(vinyl)stannane (1.10 mL, 3.73 mmol) in 1,4-dioxane (15 mL)
was treated with Pd(Ph.sub.3P).sub.4 (0.196 g, 0.170 mmol) then the
mixture was heated at about 95.degree. C. for about 14 h.
Additional portions of tributyl(vinyl)stannane (0.299 mL, 1.02
mmol) and Pd(Ph.sub.3P).sub.4 (0.196 g, 0.170 mmol) were added then
the mixture was heated at about 95.degree. C. for about 7 h. The
mixture was cooled and concentrated under reduced pressure then the
material was purified via flash chromatography on silica gel (0-20%
EtOAc/Heptane) to give the title compound (2.14 g, 142%). The
material was used without further manipulation; LC/MS (Table A,
Method i) R.sub.t=2.45 min; MS m/z: 446 (M+H).sup.+.
Step 2:
2-(Bromomethyl)-3-(trifluoromethyl)-6-((trityloxy)methyl)pyridine
[0833] The title compound was synthesized in a manner similar to
Preparation #3, step 2 from
(3-(trifluoromethyl)-6-((trityloxy)methyl)pyridin-2-yl)methanol
(synthesized in a manner similar to Preparation #9 from
3-(trifluoromethyl)-6-((trityloxy)methyl)picolinaldehyde
(synthesized in a manner similar to Example #4, step 1 from
3-(trifluoromethyl)-6-((trityloxy)methyl)-2-vinylpyridine)); LC/MS
(Table A, Method i) R.sub.4=2.31 min; MS m/z: 243 (M+H).sup.+.
Preparation #62:
1-(5-((1H-1,2,4-Triazol-1-yl)methyl)-2-(difluoromethoxy)benzyl)-6-bromo-5-
-fluoro-2-methyl-1H-indazol-3(2H)-one and
1-(5-((4H-1,2,4-triazol-4-yl)methyl)-2-(difluoromethoxy)benzyl)-6-bromo-5-
-fluoro-2-methyl-1H-indazol-3(2H)-one
##STR00070##
[0835] A mixture of
6-bromo-1-(5-(bromomethyl)-2-(difluoromethoxy)benzyl)-5-fluoro-2-methyl-1-
H-indazol-3(2H)-one (200 mg, 0.405 mmol) (synthesized in a manner
similar to Preparation #14, step 6 from
6-bromo-1-(2-(difluoromethoxy)-5-(hydroxymethyl)benzyl)-5-fluoro-2-methyl-
-1H-indazol-3(2H)-one (synthesized in a manner similar to Example
#18 from
6-bromo-1-(2-(difluoromethoxy)-5-((trityloxy)methyl)benzyl)-5-fluoro-2-me-
thyl-1H-indazol-3(2H)-one (synthesized in a manner similar to
Preparation #4, step 1 from
6-bromo-5-fluoro-2-methyl-1H-indazol-3(2H)-one (synthesized in a
manner similar to Preparation #1 from 4-bromo-2,5-difluorobenzoic
acid) and
(((3-(bromomethyl)-4-(difluoromethoxy)benzyl)oxy)methanetriyl)tribenzene
(Preparation #14)))), 1H-1,2,4-triazole (61.5 mg, 0.891 mmol), and
potassium carbonate (67.1 mg, 0.486 mmol) in MeCN (4 mL) was
stirred at about 50.degree. C. for about 1 h. The reaction was
cooled to rt and partitioned between EtOAc (20 mL) and water (5
mL). The organic layer was dried over MgSO.sub.4, filtered,
concentrated and the residue was purified on silica gel (0-10%
MeOH/DCM then 10% MeOH/DCM spiked with 1% 7 N NH.sub.3 in MeOH) to
afford
1-(5-((1H-1,2,4-triazol-1-yl)methyl)-2-(difluoromethoxy)benzyl)-6-bromo-5-
-fluoro-2-methyl-1H-indazol-3(2H)-one (160 mg, 82%); LC/MS (Table
A, Method i) R.sub.t=1.17 min; MS m/z: 482 and 484 (M+H).sup.+ and
1-(5-((4H-1,2,4-triazol-4-yl)methyl)-2-(difluoromethoxy)benzyl)-6-bromo-5-
-fluoro-2-methyl-1H-indazol-3(2H)-one (30 mg, 15%); LC/MS (Table A,
Method i) R.sub.t=1.08 min; MS m/z: 482 and 484 (M+H).sup.+.
Preparation #63:
1-(5-((1-Acetylazetidin-3-yl)methyl)-2-(difluoromethoxy)benzyl)-6-bromo-5-
-fluoro-2-methyl-1H-indazol-3(2H)-one
##STR00071## ##STR00072##
[0836] Step 1:
(3-(((tert-Butyldimethylsilyl)oxy)methyl)-4-(difluoromethoxy)benzyl)triph-
enylphosphonium bromide
[0837] A mixture of
((5-(bromomethyl)-2-(difluoromethoxy)benzyl)oxy)(tert-butyl)dimethylsilan-
e (prepared in a similar fashion to Preparation #14, step 6 using
(3-(((tert-butyldimethylsilyl)oxy)methyl)-4-(difluoromethoxy)phenyl)metha-
nol) (prepared in a similar fashion to Preparation #14, step 5
using methyl
3-(((tert-butyldimethylsilyl)oxy)methyl)-4-(difluoromethoxy)benzoa-
te (prepared in a similar fashion to Example #9, step 1 using
((5-bromo-2-(difluoromethoxy)benzyl)oxy)(tert-butyl)dimethylsilane
(prepared in a similar fashion to Preparation #43, step 1 using
(5-bromo-2-(difluoromethoxy)phenyl)methanol (Preparation #12))))
and PPh.sub.3 (1.57 g, 6.01 mmol) in toluene (40 mL) was refluxed
for about 5 h. The reaction was allowed to cool to rt. Et.sub.2O
(30 mL) was added and the precipitate was triturated, filtered and
washed with Et.sub.2O (30 mL) to give the title compound (2.92 g,
76%); LC/MS (Table A, Method i) R.sub.t=1.98 min; MS m/z: 563
(M+H).sup.+.
Step 2:
1-Benzhydryl-3-(3-(((tert-butyldimethylsilyl)oxy)methyl)-4-(difluo-
romethoxy)benzylidene)azetidine
[0838] 60% Sodium hydride in mineral oil (0.186 g, 4.66 mmol) was
added to a mixture of
(3-(((tert-butyldimethylsilyl)oxy)methyl)-4-(difluoromethoxy)benzyl)triph-
enylphosphonium bromide (2.72 g, 4.23 mmol) and THF (40 mL). The
reaction was stirred at rt for about 1 h then the reaction
temperature was gradually raised to about 60.degree. C. over about
1 h. 1-Benzhydrylazetidin-3-one (1.00 g, 4.23 mmol) was added.
After about 2 h, the reaction was allowed to cool to rt. The
reaction was partitioned between EtOAc (200 mL) and 20% aq.
NH.sub.4Cl (200 mL). The organic layer was washed with sat. aq.
NaCl (200 mL), dried over Na.sub.2SO.sub.4, filtered and was
concentrated under reduced pressure. The residue was purified on
silica gel using 2-5% EtOAc in heptanes to give the title compound
(0.950 g, 43%); LC/MS (Table A, Method k) R.sub.t=1.92 min; MS m/z:
522 (M+H).sup.+.
Step 3:
1-(3-(3-(((tert-Butyldimethylsilyl)oxy)methyl)-4-(difluoromethoxy)-
benzyl)azetidin-1-yl)ethanone
[0839] A mixture of
1-benzhydryl-3-(3-(((tert-butyldimethylsilyl)oxy)methyl)-4-(difluorometho-
xy)benzylidene)azetidine (0.950 g, 1.82 mmol) and palladium
hydroxide on carbon (0.256 g, 0.182 mmol) in MeOH (30 mL)/THF (10
mL) at about 60.degree. C. was shaken under 50 psi hydrogen for
about 3 h. The reaction was allowed to cool to rt and filtered
through Celite.RTM.. The filtrate was concentrated under reduced
pressure. The residue was dissolved in DCM (20 mL) then TEA (0.507
mL, 3.64 mmol), acetic anhydride (0.206 mL, 2.18 mmol) and DMAP
(0.022 g, 0.18 mmol) were added. The reaction was stirred at rt for
about 2 h. The reaction was diluted with DCM (20 mL) and washed
with a sat. aq. NaHCO.sub.3 (20 mL) and sat. aq. NaCl (20 mL). The
organic layer was dried over Na.sub.2SO.sub.4, filtered and
concentrated under reduced pressure. The residue was purified on
silica gel using 30-100% EtOAc in heptanes to give the title
compound (0.460 g, 63%); LC/MS (Table A, Method i) R.sub.t=1.95
min; MS m/z: 400 (M+H).sup.+.
Step 4:
1-(3-(4-(Difluoromethoxy)-3-(hydroxymethyl)benzyl)azetidin-1-yl)et-
hanone
[0840]
1-(3-(4-(Difluoromethoxy)-3-(hydroxymethyl)benzyl)azetidin-1-yl)eth-
anone was prepared in a similar fashion to Example #35, step 3
using
1-(3-(3-(((tert-butyldimethylsilyl)oxy)methyl)-4-(difluoromethoxy)benzyl)-
azetidin-1-yl)ethanone to give the title compound (0.223 g, 80%);
LC/MS (Table A, Method i) R.sub.t=0.82 min; MS m/z: 286
(M+H).sup.+.
Step 5:
1-(5-((1-Acetylazetidin-3-yl)methyl)-2-(difluoromethoxy)benzyl)-6--
bromo-5-fluoro-2-methyl-1H-indazol-3(2H)-one
[0841]
1-(5-((1-Acetylazetidin-3-yl)methyl)-2-(difluoromethoxy)benzyl)-6-b-
romo-5-fluoro-2-methyl-1H-indazol-3(2H)-one was prepared in a
similar fashion to Example #42, step 1 using
1-(3-(4-(difluoromethoxy)-3-(hydroxymethyl)benzyl)azetidin-1-yl)ethanone
to prepare the solution of
1-(3-(3-(bromomethyl)-4-(difluoromethoxy)benzyl)azetidin-1-yl)ethanone
to react with 6-bromo-5-fluoro-2-methyl-1H-indazol-3(2H)-one
((synthesized in a similar fashion to Preparation #1 from
4-bromo-2,5-difluorobenzoic acid)) to give the title compound
(0.349 g, 88%); LC/MS (Table A, Method i) R.sub.t=1.28 min; MS m/z:
512 and 514 (M+H).sup.+.
Preparation #64: 3-(Piperidin-4-yl)-1,2,4-thiadiazol-5(4H)-one
hydrochloride
##STR00073##
[0842] Step 1: (Z)-tert-Butyl
4-(N'-hydroxycarbamimidoyl)piperidine-1-carboxylate
[0843] A mixture of tert-butyl 4-cyanopiperidine-1-carboxylate
(0.500 g, 2.38 mmol), hydroxylamine hydrochloride (0.330 g, 4.76
mmol), and DIEA (0.831 mL, 4.76 mmol) in EtOH (10 mL) was heated at
about 80.degree. C. for about 15 h. The reaction mixture was
concentrated under reduced pressure and the residue was partitioned
between EtOAc (25 mL) and water (25 mL). After separating the
layers, the aqueous phase was extracted with EtOAc (3.times.10 mL).
The combined organic phases were washed with sat. aq. NaCl (50 mL),
dried over Na.sub.2SO.sub.4, filtered, and concentrated under
reduced pressure to give the title product (0.45 g, 78%); LC/MS
(Table A, Method e) R.sub.t=1.33 min; MS m/z: 244 (M+H).sup.+.
Step 2: tert-Butyl
4-(5-oxo-4,5-dihydro-1,2,4-thiadiazol-3-yl)piperidine-1-carboxylate
[0844] A mixture of (Z)-tert-butyl
4-(N'-hydroxycarbamimidoyl)piperidine-1-carboxylate (0.454 g, 1.87
mmol), 1,8-diazabicyclo[5.4.0]undec-7-ene (0.422 mL, 2.80 mmol),
and 1,1'-thiocarbonyldiimidazole (0.499 g, 2.80 mmol) in
1,4-dioxane (10 mL) was heated at about 80.degree. C. for about 75
min. The reaction was concentrated under reduced pressure and the
resulting solid was triturated with diethyl ether (10 mL) and
isolated by vacuum filtration to give the title product (0.33 g,
62%); LC/MS (Table A, Method i) R.sub.t=0.93 min; MS m/z: 284
(M-H).sup.-.
Step 3: 3-(Piperidin-4-yl)-1,2,4-thiadiazol-5(4H)-one
hydrochloride
[0845] The reaction was performed using tert-butyl
4-(5-oxo-4,5-dihydro-1,2,4-thiadiazol-3-yl)piperidine-1-carboxylate
in a similar fashion to Example #3, step 1 to give the title
product (90%/); LC/MS (Table A, Method e) R.sub.t=0.42 min; MS m/z:
186 (M+H).sup.+.
Preparation #65:
6-Bromo-1-(2-chlorobenzyl)-7-methoxy-2-methyl-1H-indazol-3(2H)-one
##STR00074##
[0847]
6-Bromo-1-(2-chlorobenzyl)-7-methoxy-2-methyl-1H-indazol-3(2H)-one
was prepared in a similar manner to Example #1 using 2-chlorobenzyl
bromide and 6-bromo-7-methoxy-2-methyl-1H-indazol-3(2H)-one
(prepared in a similar manner to Preparation #1 using
4-bromo-2-fluoro-3-methoxybenzoic acid); LC/MS (Table A, Method i)
R.sub.t=1.59 min; MS m/z: 381 and 383 (M+H).sup.+.
Preparation #66:
6-Bromo-1-(2-(difluoromethoxy)benzyl)-7-methoxy-2-methyl-1H-indazol-3(2H)-
-one
##STR00075##
[0849]
6-Bromo-1-(2-(difluoromethoxy)benzyl)-7-methoxy-2-methyl-1H-indazol-
-3(2H)-one was prepared in a similar manner to Example #1 using
1-(bromomethyl)-2-(difluoromethoxy)benzene and
6-bromo-7-methoxy-2-methyl-1H-indazol-3(2H)-one (prepared in a
similar manner to Preparation #1 using
4-bromo-2-fluoro-3-methoxybenzoic acid); LC/MS (Table A, Method i)
R.sub.t=1.53 min; MS m/z: 413 and 415 (M+H).sup.+.
Preparation #67:
6-Chloro-2-methyl-3-oxo-2,3-dihydro-1H-indazole-7-carbonitrile
##STR00076##
[0850] Step 1: 4-Chloro-3-cyano-2-fluorobenzoic acid
[0851] A solution of 2-chloro-6-fluorobenzonitrile (10 g, 64 mmol)
and THF (200 mL) under N.sub.2 was cooled to about -65.degree. C. A
freshly prepared solution of lithium diisopropylamide (0.5 M in
THF, 130 mL, 66 mmol) was added over about 15 min. Immediately
after completion of addition, carbon dioxide was bubbled through
the resulting solution. The reaction was maintained at about
-50.degree. C. for 15 min then allowed to thaw to rt over about 90
min. Water (200 mL) and Et.sub.2O (200 mL) were added. The layers
were separated. The organic layer was extracted with 1 M aq. NaOH
(50 mL). The aqueous layers were combined then washed with
Et.sub.2O (200 mL). The aqueous layer was acidified with 2 M aq.
HCl (85 mL). EtOAc (300 mL) was added. The layers were separated.
The organic layer was washed with sat. aq. NaCl (200 mL). The
aqueous layers were extracted with EtOAc (200 mL). The combined
organic layers were dried over Na.sub.2SO.sub.4, filtered, and
concentrated under reduced pressure to afford the title compound
(5.96 g, 42%); .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 13.86
(broad s, 1H), 8.17 (dd, J=8.5, 7.3 Hz, 1H), 7.70 (dd, J=8.6, 1.0
Hz, 1H).
Step 2:
6-Chloro-2-methyl-3-oxo-2,3-dihydro-1H-indazole-7-carbonitrile
[0852]
6-Chloro-2-methyl-3-oxo-2,3-dihydro-1H-indazole-7-carbonitrile was
prepared in a similar manner to Preparation 1 using
4-chloro-3-cyano-2-fluorobenzoic acid to afford the title compound
(77%); LC/MS (Table A, Method i) R.sub.t=0.68 min; MS m/z: 208
(M+H).sup.+.
Preparation #68: tert-Butyl
(2-(5-bromopyridin-2-yl)propan-2-yl)carbamate
##STR00077##
[0853] Step 1: 2-(5-Bromopyridin-2-yl)propan-2-amine
[0854] Methyl magnesium bromide (3 M in Et.sub.2O) (4.00 mL, 12.0
mmol) was slowly added to a solution of 5-bromopicolinonitrile
(1.00 g, 5.46 mmol) in toluene (13 mL) at about 0.degree. C. After
completion of addition, the ice bath was removed and the reaction
was heated at about 100.degree. C. for about 16 h. The reaction was
cooled to rt then 2-methyl tetrahydrofuran (6 mL) was added and
heating was continued at about 100.degree. C. for about 1 h. The
reaction was cooled to rt then methyl magnesium bromide (3 M in
Et.sub.2O) (4.00 mL, 12.0 mmol) was added. The reaction was heated
at 100.degree. C. for about 12 h. The reaction was allowed to cool
to rt then was added carefully to ice cold stirring 2 N aq. HCl (50
mL, 100 mmol). The aqueous solution was extracted with EtOAc
(2.times.50 mL) then the aqueous layer was basified with 5 N aq.
sodium hydroxide (25.0 mL, 125 mmol). The aqueous layer was
extracted with EtOAc (2.times.50 mL). The combined organic extracts
were washed with sat. aq. NaCl (25 mL), dried over
Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure
to give the title compound (0.53 g, 45%); LC/MS (Table A, Method i)
R.sub.t=0.21 min; MS m/z: 215 and 217 (M+H).sup.+.
Step 2: tert-Butyl
(2-(5-bromopyridin-2-yl)propan-2-yl)carbamate
[0855] A solution of sodium carbonate (0.197 g, 1.86 mmol) in water
(3.0 mL) was added to a mixture of
2-(5-bromopyridin-2-yl)propan-2-amine (0.400 g, 1.86 mmol) in
1,4-dioxane (5.0 mL) and water (5.0 mL). The mixture was cooled in
an ice bath then di-tert-butyl dicarbonate (0.406 g, 1.86 mmol) was
added in one portion. About 5 min after the addition, the ice bath
was removed and the reaction was stirred at rt for about 16 h. The
reaction was extracted with EtOAc (2.times.20 mL). The combined
organic layers were dried over Na.sub.2SO.sub.4, filtered and
concentrated under reduced pressure. The residue was purified on
silica gel using a gradient of 5-20% EtOAc in heptane to give the
title compound (0.136 g, 23%); LC/MS (Table A, Method i)
R.sub.t=1.52 min; MS m/z: 315 and 317 (M+H).sup.+.
Preparation #69:
2-(1-Benzyl-3-methylpyrrolidin-3-yl)-5-bromopyrimidine
##STR00078##
[0856] Step 1: 5-Bromo-2-(prop-1-en-2-yl)pyrimidine
[0857] 5-Bromo-2-iodopyrimidine (2.00 g, 7.02 mmol), cesium
carbonate (5.72 g, 17.6 mmol),
4,4,5,5-tetramethyl-2-(prop-1-en-2-yl)-1,3,2-dioxaborolane (1.36 g,
8.07 mmol), 1,4-dioxane (40 mL) and water (10 mL) were stirred
under an atmosphere of nitrogen then PdCl.sub.2(PPh.sub.3).sub.2
(0.246 g, 0.351 mmol) was added. The mixture was heated to about
90.degree. C. for about 1.5 h then XPhos Pd G2 catalyst (0.100 g,
0.127 mmol) was added. The mixture was stirred at about 90.degree.
C. for about 3 h then cooled and diluted with EtOAc (30 mL). The
organic layer was separated from the aqueous layer then washed with
sat. aq. NaCl (25 mL). The organic solution was dried over
magnesium sulfate, filtered and concentrated under reduced
pressure. The residue was purified via flash chromatography on
silica gel (0-20% EtOAc/heptane) to give the title compound (1.32
g, 94%); LC/MS (Table A, Method i) R.sub.t=1.20 min; MS m/z: 199,
201 (M+H).sup.+.
Step 2: 2-(1-Benzyl-3-methylpyrrolidin-3-yl)-5-bromopyrimidine
[0858] To 5-bromo-2-(prop-1-en-2-yl)pyrimidine (1.32 g, 6.63 mmol)
in DCM (8 mL) was added TFA (0.19 mL, 2.5 mmol) then
N-benzyl-1-methoxy-N-((trimethylsilyl)methyl)methanamine (2.05 g,
8.62 mmol) in DCM (8 mL) over about 10 min. The mixture was stirred
at rt for about 12 h then a second portion of TFA (0.72 mL, 9.3
mmol) and N-benzyl-1-methoxy-N-((trimethylsilyl)methyl)methanamine
(2.05 g, 8.62 mmol) were added. The mixture was stirred for about
1.5 h then diluted with DCM and washed with sat. aq. sodium
bicarbonate. The organic solution was dried over magnesium sulfate,
filtered then concentrated under reduced pressure. The residue was
purified via flash chromatography on silica gel (0-10% DCM/MeOH) to
give the title compound (0.335 g, 15%); LC/MS (Table A, Method i)
R.sub.t=0.79 min; MS m/z: 332, 334 (M+H).sup.+.
Preparation #70:
(2-(Difluoromethoxy)-5-((1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol--
4-yl)methyl)phenyl)methanol
##STR00079##
[0859] Step 1:
4-Bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole
[0860] Sodium hydride (60 wt % in mineral oil, 327 mg, 8.16 mmol)
was added to a dry reaction vessel, followed by anhydrous THF (30
mL). The reaction was cooled to about 0.degree. C., then
4-bromo-1H-pyrazole (1.00 g, 6.80 mmol) in anhydrous THF (4 mL) was
added dropwise over about 5 min. The reaction was allowed to warm
to rt for about 30 min before re-cooling to about 0.degree. C.
2-(Trimethylsilyl)ethoxymethyl chloride (1.57 mL, 8.85 mmol) was
added dropwise over about 5 min, and the reaction was allowed to
stir for about 16 h while warming to rt. The reaction was quenched
with sat. aq. NH.sub.4Cl (30 mL). EtOAc (50 mL) and water (50 mL)
were added and the layers were separated. The aqueous layer was
extracted with additional EtOAc (30 mL), then the combined organic
layers were washed with water (50 mL) and sat. aq. NaCl (50 mL),
dried over MgSO.sub.4, filtered, and concentrated in vacuo. The
resulting residue was further purified via flash chromatography
(0-40% EtOAc in heptane) to afford the title compound (1.72 g,
91%); LC/MS (Table A, Method i) R.sub.t=1.78 min; MS m/z: 277
(M+H).sup.+.
Step 2:
(3-(((tert-Butyldimethylsilyl)oxy)methyl)-4-(difluoromethoxy)pheny-
l)(1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-yl)methanol
[0861] 4-Bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole
(550 mg, 1.99 mmol) in anhydrous THF (3.0 mL) was added to an
oven-dried reaction vial and cooled to about -78.degree. C. for
about 5 min, then n-butyllithium (2.5 M solution in hexane, 0.794
mL, 1.99 mmol) was added dropwise over about 5 min. The reaction
was stirred at about -78.degree. C. for about 5 min, then an
anhydrous solution of
3-(((tert-butyldimethylsilyl)oxy)methyl)-4-(difluoromethoxy)benzaldehyde
(synthesized in a manner similar to Example #4, step 1 from
tert-butyl((2-(difluoromethoxy)-5-vinylbenzyl)oxy)dimethylsilane
(synthesized in a manner similar to Example #14, step 4 from
((5-bromo-2-(difluoromethoxy)benzyl)oxy)(tert-butyl)dimethylsilane
(synthesized in a manner similar to Preparation #43, step 1 from
(5-bromo-2-(difluoromethoxy)phenyl)methanol (Preparation #12))))
(571 mg, 1.81 mmol) in anhydrous THF (3 mL) was added slowly
dropwise over about 5 min. The reaction was stirred for about 5
additional min at about -78.degree. C., then allowed to stir about
15 min while warming to rt. The reaction was quenched via dropwise
addition of water (2 mL) and diethyl ether (2 mL). The aqueous
layer was extracted with additional diethyl ether (5 mL), then the
combined organic layers were washed with water (5 mL) and sat. aq.
NaCl (5 mL). The organic extract was dried over MgSO.sub.4,
filtered, and concentrated in vacuo. Further purification via flash
chromatography (0-80% EtOAc in heptane) isolated the title compound
(654 mg, 70%); LC/MS (Table A, Method k) R.sub.t=1.51 min; MS m/z:
515 (M+H).sup.+.
Step 3:
(3-(((tert-Butyldimethylsilyl)oxy)methyl)-4-(difluoromethoxy)pheny-
l)(1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-yl)methyl
acetate
[0862] The compound was synthesized in a manner similar to Example
#3, step 1 from
(3-(((tert-butyldimethylsilyl)oxy)methyl)-4-(difluoromethoxy)phenyl)(1-((-
2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-yl)methanol (92%);
LC/MS (Table A, Method k) R.sub.t=1.69 min; MS m/z: 557
(M+H).sup.+.
Step 4:
4-(3-(((tert-Butyldimethylsilyl)oxy)methyl)-4-(difluoromethoxy)ben-
zyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole
[0863]
(3-(((tert-Butyldimethylsilyl)oxy)methyl)-4-(difluoromethoxy)phenyl-
)(1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-yl)methyl
acetate (526 mg, 0.945 mmol) and palladium on carbon (10 wt %, 50
mg) were added to EtOH (29 mL) in a 3-neck flask. The atmosphere
was evacuated and replaced with H.sub.2 from a balloon. The
reaction was warmed to about 55.degree. C. and stirred for about 30
min, then cooled and filtered through Celite.RTM.. The filter was
washed with EtOH (75 mL), then the combined filtrates were
concentrated and used without further purification (437 mg, 93%);
LC/MS (Table A, Method k) R.sub.t=1.76 min; MS m/z:
499(M+H).sup.+.
Step 5:
(2-(Difluoromethoxy)-5-((1-((2-(trimethylsilyl)ethoxy)methyl)-1H-p-
yrazol-4-yl)methyl)phenyl)methanol
[0864] The compound was synthesized in a manner similar to Example
#35, step 3 from
4-(3-(((tert-butyldimethylsilyl)oxy)methyl)-4-(difluoromethoxy)benzyl)-1--
((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole (74%); LC/MS (Table
A, Method k) R.sub.t=0.98 min; MS m/z: 385 (M+H).sup.+.
Preparation #71:
6-Bromo-1-(2-(difluoromethoxy)benzyl)-2,7-dimethyl-1H-indazol-3(2H)-one
##STR00080##
[0866] Potassium tert-butoxide (0.29 g, 2.63 mmol) was added in one
portion to a solution of
4-bromo-2-fluoro-N,3-dimethylbenzohydrazide (0.310 g, 1.19 mmol)
(prepared in a similar fashion to Example #17, step 1 using
4-bromo-2-fluoro-3-methylbenzoic acid) and DMF (2.8 mL). The
mixture was warmed to about 85.degree. C. After about 10 min, the
reaction vessel was transferred to an ice bath. After about 10 min,
1-(bromomethyl)-2-(difluoromethoxy)benzene (0.20 mL, 1.3 mmol) in
DMF (0.28 mL) was added dropwise over about 1 min and the ice bath
was removed. After about 30 min, the volatiles were mostly removed
under reduced pressure and water (5 mL) and EtOAc (10 mL) were
added. The layers were separated and the aqueous layer was
extracted with EtOAc (2.times.5 mL). The combined organic layers
were dried over MgSO.sub.4, filtered and concentrated under reduced
pressure. The material was purified via flash chromatography on
silica gel (0-40% EtOAc/DCM). The appropriate fractions were
collected and concentrated under reduced pressure to provide the
title product (0.29 g, 61%); LC/MS (Table A, Method i) R.sub.t=1.54
min.; MS m/z: 397 and 399 (M+H).sup.+.
Preparation #72:
6-Bromo-2-methyl-1-((4-(trifluoromethyl)-1H-pyrrol-3-yl)methyl)-1H-indazo-
l-3(2H)-one
##STR00081##
[0867] Step 1:
6-Bromo-2-methyl-1-((4-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)met-
hyl)-1H-pyrrol-3-yl)methyl)-1H-indazol-3(2H)-one
[0868] CBr.sub.4 (3.67 g, 11.1 mmol) was added in one portion to a
solution of
(4-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrol-3-yl)-
methanol (2.95 g, 9.99 mmol) (prepared in a similar manner to
Preparation #52, step 2 using ethyl
4-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrole-3-car-
boxylate (prepared in a similar manner to Preparation #31, step 1
using ethyl 4-(trifluoromethyl)-1H-pyrrole-3-carboxylate (WO
2009147167 A1))) and DMF (50.0 mL) under N.sub.2. After about 5
min, the solution was cooled to about 0.degree. C. PPh.sub.3 (3.41
g, 13.0 mmol) was added in one portion. After about 30 min,
6-bromo-2-methyl-1H-indazol-3(2H)-one (2.27 g, 10.00 mmol)
(Preparation #1) and K.sub.2CO.sub.3 (2.76 g, 20.0 mmol) were added
respectively, each in one portion. The reaction vessel was
evacuated and back-filled with N.sub.2. The ice bath was removed.
After about 90 min, DCM (200 mL) and water (200 mL) were added. The
layers were separated and the aqueous layer was extracted with DCM
(100 mL). The combined organic layers were dried over
Na.sub.2SO.sub.4, filtered, and concentrated under reduced
pressure. The residue was purified via flash chromatography on
silica gel (0-75% EtOAc/heptane). The appropriate fractions were
combined and concentrated to afford the title compound (47%); LC/MS
(Table A, Method i) R.sub.t=2.04 min; MS m/z: 504 and 506
(M+H).sup.+.
Step 2:
6-Bromo-2-methyl-1-((4-(trifluoromethyl)-1H-pyrrol-3-yl)methyl)-1H-
-indazol-3(2H)-one
[0869] TFA (4.80 mL, 62.3 mmol) was added over about 5 min to a
solution of
6-bromo-2-methyl-1-((4-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)-
methyl)-1H-pyrrol-3-yl)methyl)-1H-indazol-3(2H)-one (1.60 g, 3.17
mmol) and DCM (30.0 mL) under N.sub.2 at about 0.degree. C. The ice
bath was removed. After about 17 h, heptane (20 mL) was added and
the volatiles were removed under reduced pressure. The residue was
dissolved in DCM (about 20 mL), heptane (about 20 mL) was added and
the volatiles were removed under reduced pressure. A solution of
ammonium hydroxide (1.20 mL, 30.8 mmol) and MeOH (30.0 mL) was
added. After about 5 min, the solution was warmed to about
40.degree. C. After about 12 h, the solution was allowed to cool to
rt. The volatiles were removed under reduced pressure. The material
was dissolved in about 10% MeOH/DCM (80 mL), silica gel (12 g) was
added and the volatiles were removed under reduced pressure. The
resulting solid was purified via flash chromatography on silica gel
(0-100% EtOAc/heptane then EtOAc). The appropriate fractions were
combined and concentrated under reduced pressure to afford the
title compound (61%); LC/MS (Table A, Method i) R.sub.t=1.35 min;
MS m/z: 374 and 376 (M+H).sup.+.
Preparation #73:
6-Bromo-2-(pyridin-4-ylmethyl)-1H-indazol-3(2H)-one
##STR00082##
[0871] 4-(Bromomethyl)pyridine hydrobromide (1.78 g, 7.04 mmol) was
added to 6-bromo-1H-indazol-3(2H)-one (1.5 g, 7.0 mmol) in NMP (25
mL). The mixture was warmed to about 100.degree. C. for about 12 h
then cooled to it. Ice water was added and the mixture was
filtered. The aqueous layer was then washed with EtOAc and
DCM/MeOH. The aqueous layer was concentrated under reduced pressure
to afford the title product (0.400 g, 19%); LC/MS (Table A, Method
I) R.sub.t=0.73 min; MS m/z: 304 and 306 (M+H).sup.+.
Preparation #74:
6-Bromo-1-(2-(difluoromethoxy)-5-methylbenzyl)-1H-indazol-3(2H)-one
##STR00083##
[0873] A solution of
2-(bromomethyl)-1-(difluoromethoxy)-4-methylbenzene (2.67 g, 10.6
mmol) (prepared in a similar manner to Preparation #3, step 2 using
(2-(difluoromethoxy)-5-methylphenyl)methanol (Preparation #11)) in
DMF (6.00 mL) was added over about 5 min to a mixture of
6-bromo-1H-indazol-3(2H)-one (2.27 g, 10.6 mmol) and potassium
carbonate (1.62 g, 11.7 mmol) in DMF (30.0 mL) under N.sub.2 at
about 0.degree. C. The ice bath was allowed to thaw to rt over
about 2 h. Water (60 mL) was added. After stirring for about 5 min,
the mixture was cooled to about 0.degree. C. After about 5 min, the
solid was collected by filtration rinsing with water (2.times.10
mL). The aqueous layer was extracted with EtOAc (2.times.25 mL).
The aqueous layer was acidified with sat. aq. NH.sub.4Cl then
extracted with EtOAc (50 mL). The solid from the filtration was
combined with the organic layers and the volatiles were removed
under reduced pressure. The residue was slurried in Et.sub.2O (20
mL). The solid was collected by filtration rinsing with Et.sub.2O
(2.times.15 mL) and dried in a vacuum oven at about 50.degree. C.
for about 30 min to afford the title compound (2.22 g, 55%); LC/MS
(Table A, Method i) R.sub.t=1.70 min; MS m/z: 383 and 385
(M+H).sup.+.
Example #1
1-(2-(Difluoromethoxy)-6-fluorobenzyl)-2-methyl-6-(2-morpholinopyrimidin-5-
-yl)-1H-indazol-3(2H)-one
##STR00084##
[0875] A flask was charged with
2-methyl-6-(2-morpholinopyrimidin-5-yl)-1H-indazol-3(2H)-one (0.060
g, 0.19 mmol) (Preparation #2), K.sub.2CO.sub.3 (0.027 g, 0.19
mmol) and 2-(bromomethyl)-1-(difluoromethoxy)-3-fluorobenzene
(0.079 g, 0.31 mmol) (prepared in a similar fashion to Preparation
#3, step 2 from (2-(difluoromethoxy)-6-fluorophenyl)methanol
(Preparation #9)) and DMF (1 mL). After about 2 h, the reaction
mixture was partitioned between water (5 mL) and EtOAc (5 mL). The
aqueous phase was extracted with EtOAc (2.times.5 mL). The combined
organic phases were washed with sat. aq. NaCl (10 mL), dried over
Na.sub.2SO.sub.4, filtered, and concentrated under reduced
pressure. The residue was purified using flash chromatography on
silica gel (0-100% EtOAc/DCM) to give the title product (0.073 g,
78%); LC/MS (Table A, Method a) R.sub.t=2.05 min; MS m/z: 486
(M+H).sup.+; (TNF IC.sub.50=A).
[0876] The compounds shown in Table 1 were synthesized in a manner
similar to Example #1 from
2-methyl-6-(2-morpholinopyrimidin-5-yl)-1H-indazol-3(2H)-one
(Preparation #2) and the corresponding halides or acid halides.
TABLE-US-00007 TABLE 1 R.sub.t min Example (Table A, m/z ESI+ TNF
Halide/acid halide Product # Method) (M + H).sup.+ IC.sub.50
3-Fluorobenzyl bromide ##STR00085## 1.1 2.01 (a) 420 B
3-(Difluoromethoxy)benzyl bromide ##STR00086## 1.2 2.07 (a) 468 B
1-(Bromomethyl)-2- methylbenzene ##STR00087## 1.3 2.10 (a) 416 B
(2-Bromoethyl)benzene ##STR00088## 1.4 2.07 (a) 416 C
1-(1-Bromoethyl)-2- (difluoromethoxy)benzene (Preparation #3, step
2) ##STR00089## 1.5 2.20 (a) 482 B 2-(Bromomethyl)-1-
(difluoromethoxy)-4- fluorobenzene (synthesized in a similar
fashion to Preparation #3, step 2 from 2-(difluoromethoxy)-
5-fluorophenyl)methanol (Preparation #10) ##STR00090## 1.6 2.12 (a)
486 B 2-(Difluoromethoxy)benzoyl chloride ##STR00091## 1.7 2.17 (a)
482 C Benzoyl chloride ##STR00092## 1.8 2.07 (a) 416 C
1-(Bromomethyl)-3- methylbenzene ##STR00093## 1.9 1.99 (e) 416 B
(Bromomethyl)benzene ##STR00094## 1.10 1.89 (e) 402 B
1-(Bromomethyl)-4- fluorobenzene ##STR00095## 1.11 1.92 (e) 420 C
2-(Bromomethyl)benzonitrile ##STR00096## 1.12 1.83 (e) 427 B
1-(2-bromoethyl)-2- fluorobenzene ##STR00097## 1.13 2.05 (e) 434 C
2-(Bromomethyl)-3- chloropyridine (synthesized in a similar fashion
to Preparation #3, step 2 from (3-chloropyridin-2- yl)methanol)
##STR00098## 1.14 1.83 (e) 437, 438 B 1-(Bromomethyl)-2-
fluorobenzene ##STR00099## 1.15 2.03 (a) 420 B 2-(Bromomethyl)-3,6-
dichloropyridine (synthesized in a similar fashion to Preparation
#3, step 2 from (3,6-dichloropyridin-2- yl)methanol) ##STR00100##
1.16 2.04 (a) 471 B 3-(Bromomethyl)-4- chloropyridine (synthesized
in a similar fashion to Preparation #3, step 2 from
(4-chloropyridin-3- yl)methanol) ##STR00101## 1.17 1.68 (a) 437 C
2-(Bromomethyl)-1- (difluoromethoxy)-4- methylbenzene (synthesized
in a similar fashion to Preparation #3, step 2 from
(2-(difluoromethoxy)-5- methylphenyl)methanol (Preparation #11))
##STR00102## 1.18 2.18 (a) 482 A 2-(Bromomethyl)-1,4-
dimethylbenzene methylbenzene (synthesized in a similar fashion to
Preparation #21, step 2 from (2,5- dimethylphenyl)methanol)
##STR00103## 1.19 2.24 (a) 430 A
Example #2
1-(2-(Difluoromethoxy)benzyl)-6-(2-(2,2-dimethylmorpholino)pyrimidin-5-yl)-
-2-methyl-1H-indazol-3(2H)-one
##STR00104##
[0878] A flask was charged with
6-(2-chloropyrimidin-5-yl)-1-(2-(difluoromethoxy)benzyl)-2-methyl-1H-inda-
zol-3(2H)-one (50 mg, 0.12 mmol) (Preparation #4),
2,2-dimethylmorpholine (28 mg, 0.24 mmol), EtOH (1.5 mL) and TEA
(0.033 mL, 0.24 mmol). The reaction mixture was heated at about
80.degree. C. for about 20 h. The reaction mixture was cooled to rt
and then purified via reverse phase HPLC (Table 1, Method g) to
give the title product (36 mg, 61%); LC/MS (Table A, Method a)
R.sub.t=2.31 min; MS m/z: 496 (M+H).sup.+ (TNF IC.sub.50=A).
[0879] The compounds shown in Table 2 were synthesized in a manner
similar to Example #2 from
6-(2-chloropyrimidin-5-yl)-1-(2-(difluoromethoxy)benzyl)-2-methyl-1H-inda-
zol-3(2H)-one (Preparation #4) and the corresponding amines.
TABLE-US-00008 TABLE 2 R.sub.t min Example (Table A, m/z ESI+ TNF
Amine Product # Method) (M + H).sup.+ IC.sub.50
Piperazine-1-carboxamide ##STR00105## 2.1 0.63 (b) 510 A (R)-2-
(Methoxymethyl)pyrrolidine ##STR00106## 2.2* 0.75 (b) 496 A
1-(Piperazin-1-yl)ethanone ##STR00107## 2.3 0.68 (b) 509 A
2-Oxa-6-azaspiro[3.3]heptane ##STR00108## 2.4 1.78 (a) 480 B
(R)-3-Hydroxypyrrolidine hydrochloride ##STR00109## 2.5* 1.65 (a)
468 C (R)-Pyrrolidine-3-carboxylic acid ##STR00110## 2.6* 1.70 (e)
496 C 4-(Aminomethyl)pyrrolidin-2- one ##STR00111## 2.7 1.60 (e)
495 B 3-(Oxetan-3-yl)azetidine ##STR00112## 2.8 1.80 (e) 494 B
Azetidin-3-ol hydrochloride ##STR00113## 2.9 1.64 (e) 454 B
Oxetan-3-amine ##STR00114## 2.10 1.69 (a) 454 B
Azetidin-3-ylmethanol hydrochloride ##STR00115## 2.11 1.66 (a) 468
B Ethanolamine ##STR00116## 2.12 1.62 (a) 442 B
Azetidine-3-carboxylic acid ##STR00117## 2.13 1.53 (a) 482 C
5-Azaspiro[2.3]hexane-1- carboxylic acid (synthesized from
5-(tert-butoxycarbonyl)- 5-azaspiro[2.3]hexane-1- carboxylic acid
via Boc cleavage using methods similar to Example #3, step 1)
##STR00118## 2.14 1.68 (a) 508 C (5)-Pyrrolidine-3-carboxylic acid
##STR00119## 2.15* 1.64 (a) 496 C 4-(Aminomethyl)-1-
methylpyrrolidin-2-one ##STR00120## 2.16 1.61 (a) 509 B
2-Azaspiro[3.3]heptane-6- carboxylic acid, hydrochloric acid
(synthesized from 2-(tert-butoxycarbonyl)-2-
azaspiro[3.3]heptane-6- carboxylic acid via Boc cleavage using
methods similar to Example #3, step 1) ##STR00121## 2.17 1.70 (a)
522 B 2-(Azetidin-3-yl)acetic acid hydrochloride ##STR00122## 2.18
1.60 (a) 496 C 3-Aminoazepan-2-one ##STR00123## 2.19 0.67 (b) 509 B
Tetrahydrofuran-3-amine ##STR00124## 2.20 0.65 (b) 468 B
Tetrahydro-2H-pyran-3-amine ##STR00125## 2.21 0.54 (b) 482 B
3-Methoxypropan-1-amine ##STR00126## 2.22 0.66 (b) 470 B
Hexahydropyrrolo[1,2- a]pyrazin-6-one ##STR00127## 2.23 1.83 (a)
521 A (R)-Tetrahydrofuran-3-amine ##STR00128## 2.24* 1.81 (a) 468 B
(R)-Hexahydrooxazolo[3,4- a]pyrazin-3-one hydrochloride
##STR00129## 2.25* 1.91 (a) 523 A (S)-Hexahydrooxazolo[3,4-
a]pyrazin-3-one hydrochloride ##STR00130## 2.26* 1.91 (a) 523 A
Octahydroimidazolidino[1,5- a]piperazin-3-one hydrochloride
##STR00131## 2.27 1.74 (a) 522 A 3-(Piperidin-4-yl)-1,2,4-
thiadiazol-5(4H)-one hydrochloride (Preparation #64) ##STR00132##
2.28 1.83 (a) 566 B
[0880] The compound shown in Table 3 was synthesized in a manner
similar to Example #2 from
6-(2,5-dichloropyridin-4-yl)-1-(3-fluorobenzyl)-2-methyl-1H-indazol-3(2H)-
-one (synthesized from 6-bromo-1H-indazol-3(2H)-one and
1-(bromomethyl)-3-fluorobenzene in a similar fashion to Example 1,
alkylation with MeI in a similar fashion to Example #14, step 3,
Suzuki reaction with
2,5-dichloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine
in a similar fashion to Example #5) and the corresponding
amine.
TABLE-US-00009 TABLE 3 R.sub.t min Example (Table A, m/z ESI+ TNF
Amine Product # Method) (M + H).sup.+ IC.sub.50 Morpholine
##STR00133## 3.1 2.14 (e) 453 C
[0881] The compound shown in Table 4 was synthesized in a manner
similar to Example #2 from
6-(2,5-dichloropyridin-4-yl)-1-(2-(difluoromethoxy)benzyl)-2-methyl-1H-in-
dazol-3(2H)-one (synthesized from
6-bromo-1-(2-(difluoromethoxy)benzyl)-2-methyl-1H-indazol-3(2H)-one
(Preparation #4, step 1) and
2,5-dichloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine
in a similar fashion to Example #5) and the corresponding
amine.
TABLE-US-00010 TABLE 4 R.sub.t min Example (Table A, m/z ESI+ TNF
Amine Product # Method) (M + H).sup.+ IC.sub.50 Morpholine
##STR00134## 4.1 2.20 (e) 501 C
Example #3*
(S)-6-(2-((I-Acetylpyrrolidin-3-yl)amino)pyrimidin-5-yl)-1-(2-(difluoromet-
hoxy)benzyl)-2-methyl-1H-indazol-3(2H)-one
##STR00135##
[0882] Step 1:
(S)-12-(Difluoromethoxy)benzyl)-2-methyl-6-(2-(pyrrolidin-3-ylamino)pyrim-
idin-5-yl)-1H-indazol-3(2H)-one
[0883] HCl (4 M solution in 1,4-dioxane, 1.20 mL, 4.80 mmol) was
added to a solution of(S)-tert-butyl
3-((5-(1-(2-(difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-1H-indazo-
l-6-yl)pyrimidin-2-yl)amino)pyrrolidine-1-carboxylate (0.134 g,
0.236 mmol) (synthesized from
6-(2-chloropyrimidin-5-yl)-1-(2-(difluoromethoxy)benzyl)-2-methyl-1H-inda-
zol-3(2H)-one (Preparation 4) and (S)-tert-butyl
3-aminopyrrolidine-1-carboxylate in a similar fashion to Example
#2) and 1,4-dioxane (1.0 mL). After about 90 min, MeOH (5 mL) was
added. The reaction mixture was concentrated under reduced pressure
and the residue was dried under high vacuum for about 18 h to
afford a HCl salt of the title product (0.119 g, 96%); LC/MS (Table
A, Method e) R.sub.t=1.47 min; MS m/z: 467 (M+H).sup.+.
Step 2:
(S)-6-(2-((1-Acetylpyrrolidin-3-yl)amino)pyrimidin-5-yl)-1-(2-(dif-
luoromethoxy)benzyl)-2-methyl-1H-indazol-3(2H)-one
[0884] TEA (0.30 mL, 2.2 mmol) was added to a slurry of
(S)-1-(2-(difluoromethoxy)benzyl)-2-methyl-6-(2-(pyrrolidin-3-ylamino)pyr-
imidin-5-yl)-1H-indazol-3(2H)-one, hydrochloric acid (0.098 g, 0.20
mmol) and DCM (1.30 mL). A solution of acetic anhydride (0.022 mL,
0.24 mmol) and DCM (0.650 mL) was added. After about 30 min, the
reaction mixture was concentrated under reduced pressure. The
residue was dissolved in EtOAc (20 mL) and the resulting solution
was washed with sat. aq. NH.sub.4Cl (5 mL), sat. aq. NaHCO.sub.3 (5
mL), and sat. aq. NaCl (5 mL). The aqueous layers were extracted
with EtOAc (5 mL). The combined organics were dried over
Na.sub.2SO.sub.4, filtered, concentrated under reduced pressure.
The residue was purified using flash chromatography on silica gel
(2-10% MeOH/DCM) to afford the title product (72 mg, 72%); LC/MS
(Table A, Method a) R.sub.t=1.63 min; MS m/z: 509 (M+H).sup.+ (TNF
IC.sub.50=B).
Example #4
1-((5-(1-(2-(Difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-1H-indazol-
-6-yl)pyrimidin-2-yl)methyl)azetidine-3-carboxylic acid
##STR00136##
[0885] Step 1:
5-(1-(2-(Difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-1H-indazol-6--
yl)pyrimidine-2-carbaldehyde
[0886] Sodium periodate (0.306 g, 1.43 mmol) was added to a mixture
of
1-(2-(difluoromethoxy)benzyl)-2-methyl-6-(2-vinylpyrimidin-5-yl)-1H-indaz-
ol-3(2H)-one (0.195 g, 0.477 mmol) (prepared using
6-(2-chloropyrimidin-5-yl)-1-(2-(difluoromethoxy)benzyl)-2-methyl-1H-inda-
zol-3(2H)-one (Preparation #4) and
4,4,5,5-tetramethyl-2-vinyl-1,3,2-dioxaborolane in a similar
fashion to Preparation #2), 4% osmium tetroxide in water (0.060 mL,
9.6 .mu.mol), 2,6-dimethylpyridine (0.11 mL, 0.96 mmol) in
1,4-dioxane (3 mL) and water (2 mL). The reaction was stirred at rt
for about 1 h. 4% osmium tetroxide in H.sub.2O (0.120 mL, 19
.mu.mol) was added and the mixture was stirred at rt for about 1 h.
10% aqueous sodium thiosulfate (20 mL) was added. The solution was
stirred for about 30 min and then extracted with EtOAc (2.times.20
mL). The combined organic layers were dried over Na.sub.2SO.sub.4,
filtered, and concentrated under reduced pressure. The residue was
purified on silica gel (10-100% EtOAc/heptane) to afford the title
product (0.051 g, 26%); LC/MS (Table A, Method e) R.sub.t=1.82 min;
MS m/z: 411 (M+H).sup.+
Step 2:
1-((5-(1-(2-(Difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-1H-
-indazol-6-yl)pyrimidin-2-yl)methyl)azetidine-3-carboxylic acid
[0887] A solution of azetidine-3-carboxylic acid (0.014 g, 0.14
mmol) in AcOH (0.3 mL) was added to a suspension of
5-(1-(2-(difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-1H-indazol-6--
yl)pyrimidine-2-carbaldehyde (0.048 g, 0.12 mmol) in DMF (1 mL).
NaBH(OAc).sub.3 (0.037 g, 0.18 mmol) was added. The reaction was
stirred at rt for about 2 h. Water (0.5 mL) was added and the
reaction mixture was concentrated under reduced pressure. The
residue was purified via HPLC (Table A, Method f). Product
containing fractions were combined and concentrated under reduced
pressure to remove the organic volatiles. The aqueous solution was
lyophilized to give the formic acid salt of the title product (14
mg, 23%); LC/MS (Table A, Method e) R.sub.t=1.34 min; MS m/z: 496
(M+H).sup.+ (TNF IC.sub.50=C).
Example #5
1-(2-(Difluoromethoxy)benzyl)-2-methyl-6-(2-morpholinopyrimidin-5-yl)-1H-i-
ndazol-3(2H)-one
##STR00137##
[0889] 1,4-Dioxane (2 mL) and water (0.5 mL) were added to
6-bromo-1-(2-(difluoromethoxy)benzyl)-2-methyl-1H-indazol-3(2H)-one
(0.060 g, 0.16 mmol) (Preparation #4, step 1),
4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-yl)morpholi-
ne (0.059 g, 0.20 mmol) and Cs.sub.2CO.sub.3 (0.128 g, 0.391 mmol).
The mixture was placed under N.sub.2. Pd(PPh.sub.3).sub.4(0.013 g,
11 .mu.mol) was added. The mixture was purged with N.sub.2 and then
heated to about 100.degree. C. After about 2 h, the reaction
mixture was allowed to cool to rt. Water (5 mL) was added and then
the mixture was extracted with 5% MeOH/DCM (2.times.10 mL). The
combined organics were dried over MgSO.sub.4, filtered and
concentrated under reduced pressure. The residue was purified via
chromatography on silica gel (10-100% EtOAc/DCM) to give the title
product (60 mg, 82%); LC/MS (Table A, Method a) R.sub.t=2.07 min;
MS m/z: 468 (M+H).sup.+ (TNF IC.sub.50=A).
[0890] The compounds shown in Table 5 were synthesized in a manner
similar to Example #5 from
6-bromo-1-(2-(difluoromethoxy)benzyl)-2-methyl-1H-indazol-3(2H)-one
(Preparation #4, step 1) and the corresponding boronic
acid/boronate.
TABLE-US-00011 TABLE 5 R.sub.t min m/z Example (Table A, ESI+ TNF
Boronic acid/boronate Product # Method) (M + H).sup.+ IC.sub.50
(2-(3-Oxopiperazin-1- yl)pyrimidin-5-yl)boronic acid (synthesized
as described in WO 2014/009296) ##STR00138## 5.1 1.67 (a) 481 B
(6-Morpholinopyridin-3- yl)boronic acid ##STR00139## 5.2 2.07 (a)
467 B 4-(5-(4,4,5,5-Tetramethyl- 1,3,2-dioxaborolan-2-
yl)pyridin-2-yl)piperazin- 2-one (Preparation #8) ##STR00140## 5.3
1.69 (a) 480 B (2-Methoxypyrimidin-5- yl)boronic acid ##STR00141##
5.4 1.94 (a) 413 B 1-(5-Boronopyrimidin-2-
yl)piperidine-4-carboxylic acid (synthesized as described in
WO2014009295A1) ##STR00142## 5.5 1.90 (a) 510 B
4-(4-(4,4,5,5-Tetramethyl- 1,3,2-dioxaborolan-2- yl)pyridin-2-yl)
morpholine ##STR00143## 5.6 1.97 (e) 467 C 1-(Tetrahydro-2H-
pyran-4-yl)-4-(4,4,5,5- tetramethyl-1,3,2- dioxaborolan-2-yl)-1H-
pyrazole ##STR00144## 5.7 1.84 (e) 455 C
[0891] The compound shown in Table 6 was synthesized in a manner
similar to Example #5 from
6-bromo-1-(2-(difluoromethoxy)benzyl)-1H-indazol-3(2H)-one
(prepared from 6-bromo-1H-indazol-3(2H)-one (Preparation #1) and
1-(bromomethyl)-2-(difluoromethoxy)benzene using methods similar to
those described for Example #1) and the corresponding boronic
acid/boronate.
TABLE-US-00012 TABLE 6 R.sub.t min Example (Table A, m/z ESI+ TNF
Boronic acid/boronate Product # Method) (M + H).sup.+ IC.sub.50
4-(5-(4,4,5,5-Tetramethyl- 1,3,2-dioxaborolan-2-
yl)pyrimidin-2-yl)morpholine ##STR00145## 6.1 2.15 (a) 454 C
[0892] The compounds shown in Table 7 were synthesized in a manner
similar to Example #5 from
6-bromo-1-(2,5-dichlorobenzyl)-2-methyl-1H-indazol-3(2H)-one
(synthesized from 6-bromo-2-methyl-1H-indazol-3(2H)-one
(Preparation #1) and 2-(bromomethyl)-1,4-dichlorobenzene in a
similar fashion to Example #1) and the corresponding boronic
acid/boronate.
TABLE-US-00013 TABLE 7 R.sub.t min Example (Table A, m/z ESI+ TNF
Boronic acid/boronate Product # Method) (M + H).sup.+ IC.sub.50
4-(5-(4,4,5,5-Tetramethyl- 1,3,2-dioxaborolan-2-
yl)pyrimidin-2-yl)morpholine ##STR00146## 7.1 2.31 (a) 470 A
1-(5-Boronopyrimidin-2- yl)piperidine-4-carboxylic acid
(synthesized as described in WO2014009295A1) ##STR00147## 7.2 2.05
(e) 512 B
[0893] The compounds shown in Table 8 were synthesized in a manner
similar to Example #5 from
6-bromo-1-(2,6-dichlorobenzyl)-2-methyl-1H-indazol-3(2H)-one
(Preparation #5) and the corresponding boronic acid/boronate.
TABLE-US-00014 TABLE 8 R.sub.t min Example (Table A, m/z ESI+ TNF
Boronic acid/boronate Product # Method) (M + H).sup.+ IC.sub.50 (2-
Morpholinopyrimidin- 5-yl)boronic acid ##STR00148## 8.1 2.34 (a)
470 B (2-(3-Oxopiperazin-1- yl)pyrimidin-5- yl)boronic acid
(synthesized as described in WO 2014/009296) ##STR00149## 8.2 1.80
(a) 483 B
[0894] The compound shown in Table 9 was synthesized in a manner
similar to Example #5 from
6-bromo-1-(2,5-dichlorobenzyl)-1H-indazol-3(2H)-one (synthesized in
a similar fashion to Preparation #5, step 1, from
6-bromo-1H-indazol-3(2H)-one and
2-(bromomethyl)-1,4-dichlorobenzene) and the corresponding boronic
acid/boronate.
TABLE-US-00015 TABLE 9 R.sub.t min Example (Table A, m/z ESI+ TNF
Boronic acid/boronate Product # Method) (M + H).sup.+ IC.sub.50
4-(5-(4,4,5,5-Tetramethyl- 1,3,2-dioxaborolan-2-
yl)pyrimidin-2-yl)morpholine ##STR00150## 9.1 2.26 (e) 456 C
[0895] The compounds shown in Table 10 were synthesized in a manner
similar to Example #5 from
1-(2-(difluoromethoxy)benzyl)-2-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxa-
borolan-2-yl)-1H-indazol-3(2H)-one (Preparation #4, step 2) and the
corresponding bromide.
TABLE-US-00016 TABLE 10 R.sub.t min m/z Exam- (Table ESI+ ple A, (M
+ TNF Bromide Product # Method) H).sup.+ IC.sub.50
2-(5-Bromopyrimidin-2- yl)propan-2-ol ##STR00151## 10.1 1.87 (a)
441 B 4-(5-Bromopyrazin-2- yl)morpholine (synthesized from
2,5-dibromopyrazine and morpholine using methods similar to
Preparation #7) ##STR00152## 10.2 2.04 (a) 468 B
1-(5-Bromopyrazin-2- yl)piperidine-4-carboxylic acid (Preparation
#7) ##STR00153## 10.3 1.86 (a) 510 C 2-((5-Bromopyrimidin-2-
yl)amino)propanamide (synthesized from 5-bromo-2-chloropyrimidine
and 2-aminopropanamide using methods similar to Example #2)
##STR00154## 10.4 1.57 (a) 469 B 4-(3-Bromo-1,2,4-thiadiazol-5-
yl)morpholine (synthesized from 3-bromo-5-chloro-1,2,4- thiadiazole
and morpholine using methods similar to Example #2) ##STR00155##
10.5 2.14 (a) 474 C (R)-1-(4-(5-Bromopyrimidin-2-
yl)-2-methylpiperazin-1-yl)-2- hydroxyethanone (Preparation #15)
##STR00156## 10.6* 1.80 (a) 539 A (S)-1-(4-(5-Bromo-4-
methylpyrimidin-2-yl)-3- methylpiperazin-1-yl)-2- hydroxyethanone
(synthesized in a method similar to Preparation 13, step 1 using
(S)-5-bromo-4-methyl-2- (2-methylpiperazin-1-yl) pyrimidine
(synthesized in a method similar to Example 3, step 1 using
(S)-tert- butyl 4-(5-bromo-4- methylpyrimidin-2-yl)-
3-methylpiperazine-1- carboxylate (prepared in a ##STR00157## 10.7*
1.87 (a) 553 A method similar to Example 2 using (S)- tert-butyl
3-methylpiperazine- 1-carboxylate and 5- bromo-2-chloro-4-
methylpyrimidine))) (R)-1-(4-(5-Bromo-4-methyl- pyrimidin-2-yl)-2-
methylpiperazin-1-yl)-2- hydroxyethanone (synthesized in a method
similar to Preparation 13 using (R)-5-bromo- 4-methyl-2-(3-methyl-
piperazin-1-yl)pyrimidine (synthesized in a method similar to
Example 3, step 1 using (R)-tert-butyl 4-(5-
bromo-4-methylpyrimidin- 2-yl)-2-methylpiperazine- 1-carboxylate
(prepared in a method similar to Example ##STR00158## 10.8* 1.87
(a) 553 A 2 using (R)-tert-butyl 2- methylpiperazine-1-carboxy-
late and 5-bromo-2-chloro-4- methylpyrimidine)))
(2R,4R)-1-(5-Bromopyrimidin- 2-yl)-2-methylpiperidin- 4-ol
(prepared in a similar fashion to Preparation 13, step 1)
##STR00159## 10.9* 1.97 (a) 496 A (R)-1-(4-(5-Bromo-4-
methylpyrimidin-2-yl)-3- methylpiperazin-1-yl)-2- hydroxyethanone
(prepared in a similar fashion to Preparation #15 using glycolic
acid and (R)-5- bromo-4-methyl-2-(2- methylpiperazin-1-yl)
pyrimidine dihydrochloride (prepared in a similar fashion to
Example #3, step 1 from (R)-tert-butyl 4-(5-
bromo-4-methylpyrimidin- 2-yl)-3-methylpiperazine-1- ##STR00160##
10.10* 12.4 (i) 553 A carboxylate (prepared in a similar fashion to
Preparation #13, step 1 using (R)-tert-butyl 3-
methylpiperazine-1-carboxylate and 5-bromo-2-chloro-4-
methylpyrimidine))). 4-Bromo-2-((tetrahydro-2H-
pyran-4-yl)oxy)pyridine (synthesized in a similar fashion to
Preparation #27, from tetrahydro-2H-pyran-4-ol) ##STR00161## 10.11
2.19 (a) 482 A 1-(4-((4-Bromopyridin-2-
yl)oxy)piperidin-1-yl)ethanone (synthesized in a similar fashion to
Preparation #27, from 1- acetyl-4-hydroxy- piperidine).
##STR00162## 10.12 1.91 (a) 523 B 4-Bromo-2-((tetrahydro-2H-
pyran-3-yl)oxy)pyridine (Preparation #27) ##STR00163## 10.13 2.27
(a) 482 B (R)-1-(4-(5-Bromopyrimidin-2-
yl)-3-methylpiperazin-1-yl)-2- hydroxyethanone (Preparation #22)
##STR00164## 10.14* 1.79 (a) 539 A 5-Bromo-2-
(dimethylamino)pyrimidine ##STR00165## 10.15 2.12 (a) 426 B
(R)-1-(4-(5-Bromopyrimidin- 2-yl)-3-methylpiperazin-1- yl)ethanone
(synthesized a manner similar to Preparation #13 from 5-
bromo-2-chloropyrimidine and (R)-1-(3-methylpiperazin-
1-yl)ethanone (synthesized in a manner similar to Preparation #19,
step 4 from (R)-tert-butyl 4-acetyl- 2-methylpiperazine-1-
carboxylate (synthesized in a manner similar to Preparation
##STR00166## 10.16* 1.93 (a) 523 A #16 from (R)-tert-butyl 2-
methylpiperazine-1- carboxylate))) (S)-1-(4-(5-bromopyrimidin-2-
yl)-3-methylpiperazin-1-yl)-2- hydroxyethanone (Preparation #54)
##STR00167## 10.17* 1.79 (a) 539 A 1-(4-(5-Bromopyrimidin-
2-yl)piperazin-1-yl)-2- hydroxyethanone (synthesized in a manner
similar to Preparation #15 from glycolic acid and 5-bromo-
2-(piperazin-1-yl)pyrimidine (synthesized in a manner similar to
Example #3, Step 1 from tert-butyl 4-(5- bromopyrimidin-2-yl)
piperazine-1-carboxylate)) ##STR00168## 10.7 1.75 (e) 525 A
(R)-1-(4-(5-Bromopyrimidin-2- yl)-2-methylpiperazin-1- yl)ethanone
(Preparation #16) ##STR00169## 10.8* 1.89 (e) 523 A
[0896] The compounds shown in Table 11 were synthesized in a manner
similar to Example #5 from
6-bromo-1-(3-fluorobenzyl)-2-methyl-1H-indazol-3(2H)-one
(synthesized from 6-bromo-1H-indazol-3(2H)-one (Preparation #1) and
1-(bromomethyl)-3-fluorobenzene using a similar method to
Preparation #5, step 1, alkylation with MeI using a similar method
to Example #14, step 3) and the corresponding boronic
acid/boronate.
TABLE-US-00017 TABLE 11 R.sub.t min Example (Table A, m/z ESI+ TNF
Boronic acid/boronate Product # Method) (M + H).sup.+ IC.sub.50
4-(4-(4,4,5,5-Tetramethyl- 1,3,2-dioxaborolan-2-
yl)pyridin-2-yl)morpholine ##STR00170## 11.1 1.89 (e) 419 C
1-(Tetrahydro-2H-pyran-4- yl)-4-(4,4,5,5-tetramethyl-
1,3,2-dioxaborolan-2-yl)- 1H-pyrazole ##STR00171## 11.2 1.74 (e)
407 C
[0897] The compound shown in Table 12 was synthesized in a manner
similar to Example #5 from
6-bromo-1-(2,5-dichlorophenyl)-2-methyl-1H-indazol-3(2H)-one
(Preparation #6) and the corresponding boronic acid/boronate.
TABLE-US-00018 TABLE 12 R.sub.t min Example (Table A, m/z ESI+ TNF
Boronic acid/boronate Product # Method) (M + H).sup.+ IC.sub.50
4-(5-(4,4,5,5-Tetramethyl- 1,3,2-dioxaborolan-2-
yl)pyrimidin-2-yl)morpholine ##STR00172## 12.1 2.23 (e) 456, 458
B
[0898] The compounds shown in Table 13 were synthesized in a manner
similar to Example #5 from
6-bromo-1-(2-(difluoromethoxy)benzyl)-2,5-dimethyl-1H-indazol-3(2H)-one
(synthesized from 4-bromo-2-fluoro-5-methylbenzoic acid in a
similar fashion to Preparation #1, alkylation with
1-(bromomethyl)-2-(difluoromethoxy)benzene in a similar fashion to
Preparation #4, step 1) and the corresponding boronic
acid/boronate.
TABLE-US-00019 TABLE 13 R.sub.t min Example (Table A, m/z ESI+ TNF
Boronic acid/boronate Product # Method) (M + H).sup.+ IC.sub.50
4-(5-(4,4,5,5-Tetramethyl-1,3,2- dioxaborolan-2-yl)pyrimidin-2-
yl)morpholine ##STR00173## 13.1 2.11 (a) 482 A
(2-(3-Oxopiperazin-1- yl)pyrimidin-5-yl)boronic acid (synthesized
from 2-chloropyrimidine-5-boronic acid and piperazin-2-one using a
similar method to Example #2) ##STR00174## 13.2 1.67 (a) 495 B
1-(5-Boronopyrimidin-2- yl)piperidine-4-carboxylic acid
(synthesized as described in WO2014009295A1) ##STR00175## 13.3 1.89
(a) 524 B
[0899] The compounds shown in Table 14 were synthesized in a manner
similar to Example #3, step 1 from the corresponding Boc-protected
amine.
TABLE-US-00020 TABLE 14 R.sub.t min m/z (Table ESI+ Example A, (M +
TNF Boc-protected amine Product # Method) H).sup.+ IC.sub.50
tert-Butyl 4-(5-(1-(2- (difluoromethoxy)benzyl)-2-
methyl-3-oxo-2,3-dihydro-1H- indazol-6-yl)pyridin-2-
yl)piperazine-1-carboxylate (synthesized from 6-bromo-1-
(2-(difluoromethoxy)benzyl)-2- methyl-1H-indazol-3(2H)-one
[Preparation #4, step 1] and tert-butyl 4-(5-(4,4,5,5-tetra-
methyl-1,3,2-dioxaborolan-2- yl)pyridin-2-yl)piperazine-1-
carboxylate using a similar method to Example #5) ##STR00176## 14.1
1.46 (a) 466 B tert-Butyl 4-(5-(1-(2,5-dichloro-
benzyl)-2-methyl-3-oxo-2,3- dihydro-1H-indazol-6-yl)
pyrimidin-2-yl)piperazine-1- carboxylate (synthesized from
6-bromo-1-(2,5-dichlorobenzyl)- 2-methyl-1H-indazol-3(2H)-one
(synthesized from 6-bromo-1H- indazol-3(2H)-one using a similar
method to Preparation #5) and tert-butyl 4-(5-(4,4,5,5-tetra-
methyl-1,3,2-dioxaborolan-2- yl)pyrimidin-2-yl)piperazine-1-
##STR00177## 14.2 1.51 (a) 469 B carboxylate using a similar method
to Example #5) tert-Butyl (2-(4-(5-(1-(2-
(difluoromethoxy)benzyl)-2- methyl-3-oxo-2,3-dihydro-1H-
indazol-6-yl)pyrimidin-2-yl)-4- hydroxypiperidin-1-yl)-2-
oxoethyl)carbamate (synthesized from 1-(2-(difluoromethoxy)
benzyl)-6-(2-(4-hydroxy- piperidin-4-yl)pyrimidin-5-yl)-2-
methyl-1H-indazol-3(2H)-one, hydrochloride acid (Example #20, step
3) with 2-((tert-butoxy- carbonyl)amino)acetic acid using methods
similar to Preparation #15) ##STR00178## 14.3 1.34 (a) 539 B
(S)-4-(Difluoromethoxy)-3-((2- methyl-3-oxo-6-(2-((S)-3-
oxotetrahydro-7(3H)-yl) pyrimidin-5-yl)-2,3-dihydro-1H-
indazol-1-yl)methyl)benzyl 2- ((tert-butyoxycarbonyl)amino)-
3-methylbutanoate (synthesized in a similar fashion to Example #21,
step 1 from (S)-7-(5-(1-(2- (difluoromethoxy)-5-
(hydroxymethyl)benzyl)-2- methyl-3-oxo-2,3-dihydro-1H- ##STR00179##
14.4* 1.52 (a) 653 B indazol-6-yl)pyrimidin-2-
yl)tetrahydro-1H-oxazolo[3,4-a] pyrazin-3(5H)-one (Example #16.3)
and N-tert-butoxy- carbonyl)-L-valine) (R)-tert-Butyl 4-(5-(1-(2-
(difluoromethoxy)-5-methyl- benzyl)-2-methyl-3-oxo-2,3-
dihydro-1H-indazol-6-yl) pyrimidin-2-yl)-2-methyl-
piperazine-1-carboxylate (synthesized in a similar manner to
Example #15, step 4 from 1-(2-(difluoromethoxy)-5-
methylbenzyl)-2-methyl-6- (4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)-1H-indazol- 3(2H)-one (Example #22, step 2) and
(R)-tert-butyl 4-(5- ##STR00180## 14.5* 1.51 (a) 495 B
bromopyrimidin-2-yl)-2- methylpiperazine-1-carboxylate (synthesized
in a similar fashion to Preparation #13, step 1 from
(R)-1-N-Boc-2-methylpiperazine)) tert-Butyl ((S)-1-((S)-4-(5-(1-(2-
(difluoromethoxy)-5- methylbenzyl)-2-methyl-3-oxo-
2,3-dihydro-1H-indazol-6- yl)pyrimidin-2-yl)-2-methyl-
piperazin-1-yl)-1-oxopropan-2- yl)carbamate (synthesized in a
similar fashion to Preparation #15 from (S)-1-(2-(difluoro-
methoxy)-5-methylbenzyl)-2- methyl-6-(2-(3-methylpiperazin-
1-yl)pyrimidin-5-yl)-1H- ##STR00181## 14.6* 1.54 (a) 566 A
indazol-3(2H)-one, hydrochloric acid (Example #36, step 2) and N-
(tert-butoxycarbonyl)-L-alanine) (S)-tert-Butyl (2-(4-(5-(1-(2-
(difluoromethoxy)-5-methyl- benzyl)-2-methyl-3-oxo-2,3-
dihydro-1H-indazol-6-yl) pyrimidin-2-yl)-2-methyl-
piperazin-1-yl)-2-oxoethyl) carbamate (synthesized in a similar
fashion to Preparation #15 from (S)-1-(2-(difluoro-
methoxy)-5-methylbenzyl)-2- methyl-6-(2-(3-methylpiperazin-
1-yl)pyrimidin-5-yl)-1H- ##STR00182## 14.7* 1.54 (a) 552 A
indazol-3(2H)-one, hydrochloric acid (Example #36, step 2) and
N-tert-butoxycarbonyl)glycine) tert-Butyl (3-((R)-4-(5-(1-(2-
(difluoromethoxy)benzyl)-2- methyl-3-oxo-2,3-dihydro-1H-
indazol-6-yl)pyrimidin-2-yl)-2- methylpiperazin-1-yl)-2-hydroxy-
3-oxopropyl)carbamate (synthesized in a manner similar to
Preparation #30, step 1 from 3- ((tert-butoxycarbonyl)amino)-2-
hydroxypropanoic acid (WO 2011146354 A1) and (R)-1-(2-
(difluoromethoxy)benzyl)-2- methyl-6-(2-(3-methylpiperazin-
##STR00183## 14.8 1.46 (a) 568 A 1-yl)pyrimidin-5-yl)-1H-indazol-
3(2H)-one (Preparation #33)) tert-Butyl (3-((R)-4-(5-(1-(2-
(difluoromethoxy)-5-methyl- benzyl)-2-methyl-3-oxo-2,3-
dihydro-1H-indazol-6-yl) pyrimidin-2-yl)-2-methyl-
piperazin-1-yl)-2-hydroxy-3- oxopropyl)carbamate (synthesized in a
manner similar to Preparation #30, step 1 from 3-
((tert-butoxycarbonyl)amino)-2- hydroxypropanoic acid (WO
2011146354 A1) and (R)-1-(2- (difluoromethoxy)-5-methyl-
##STR00184## 14.9 1.52 (a) 582 A benzyl)-2-methyl-6-(2-(3-
methylpiperazin-1-yl)pyrimidin- 5-yl)-1H-indazol-3(2H)-one (Example
#14.5)) (R)-tert-Butyl (2-(4-(5-(1-(2- (difluoromethoxy)-5-methyl-
benzyl)-2-methyl-3-oxo-2,3- dihydro-1H-indazol-6-
yl)pyrimidin-2-yl)-2-methyl- piperazin-1-yl)-2-oxoethyl) carbamate
(prepared in a similar fashion to Preparation #15 using
N-(tert-butoxycarbonyl)glycine and (R)-1-(2-(difluoromethoxy)-
5-methylbenzyl)-2-methyl-6-(2- (3-methylpiperazin-1-yl)
pyrimidin-5-yl)-1H-indazol- 3(2H)-one, hydrochloric acid (Example
#14.5)) ##STR00185## 14.10* 1.53 (a) 552 A tert-Butyl
((S)-1-((R)-4-(5-(1-(2- (difluoromethoxy)-5-
methylbenzyl)-2-methyl-3-oxo- 2,3-dihydro-1H-indazol-6-
yl)pyrimidin-2-yl)-2- methylpiperazin-1-yl)-1-
oxopropan-2-yl)carbamate (prepared in a similar fashion to
Preparation #15 using N-(tert- butoxycarbonyl)-L-alanine and
(R)-1-(2-(difluoromethoxy)-5- methylbenzyl)-2-methyl-6-(2-(3-
methylpiperazin-1-yl)pyrimidin- 5-yl)-1H-indazol-3(2H)-one,
hydrochloric acid (Example #14.5)) ##STR00186## 14.11* 1.56 (a) 566
A (S)-2-((R)-4-(5-(1-(2- (Difluoromethoxy)benzyl)-2-
methyl-3-oxo-2,3-dihydro-1H- indazol-6-yl)pyrimidin-2-yl)-2-
methylpiperazin-1-yl)-2-oxoethyl 2-((tert-butoxycarbonyl)amino)-3-
methylbutanoate (Preparation #41) ##STR00187## 14.12* 1.62 (e) 639
A (R)-2-((R)-4-(5-(1-(2- (Difluoromethoxy)benzyl)-2-
methyl-3-oxo-2,3-dihydro-1H- indazol-6-yl)pyrimidin-2-yl)-2-
methylpiperazin-1-yl)-2-oxoethyl 2-((tert-butoxycarbonyl)amino)-3-
methylbutanoate (prepared in a manner similar to Preparation #41
from (R)-1-(2- (difluoromethoxy)benzyl)-6-(2-
(4-(2-hydroxyacetyl)-3- methylpiperazin-1-yl)pyrimidin-
5-yl)-2-methyl-1H-indazol-3(2H)- one (Example #10.6) and (R)-2-
((tert-butoxycarbonyl)amino)-3- methylbutanoic acid) ##STR00188##
14.13* 1.62 (e) 639 A (S)-2-((R)-4-(5-(1-(2-(Difluoro-
methoxy)-5-methylbenzyl)-2- methyl-3-oxo-2,3-dihydro-1H-
indazol-6-yl)pyrimidin-2-yl)-2- methylpiperazin-1-yl)-2-oxoethyl
2-((tert-butoxycarbonyl)amino)-3- methylbutanoate (prepared in a
similar manner to Preparation #41 using (R)-1-(2-(difluoromethoxy)-
5-methylbenzyl)-6-(2-(4-(2- hydroxyacetyl)-3-methyl-
piperazin-1-yl)pyrimidin-5-yl)-2- methyl-1H-indazol-3(2H)-one
(Example #22.1) and N-tert- butoxycarbonyl)-L-valine) ##STR00189##
14.14* 1.70 (a) 653 A (S)-4-(Difluoromethoxy)-3-((2-
methyl-3-oxo-6-(2-((R)-3- oxohexahydroimidazo[1,5-a]
pyrazin-7(1H)-yl)pyrimidin-5- yl)-2,3-dihydro-1H-indazol-1-
yl)methyl)benzyl 2-((tert-butoxy- carbonyl)amino)propanoate
(prepared in a similar manner to Preparation #41 using (R)-7-(5-(1-
(2-(difluoromethoxy)-5- (hydroxymethyl)benzyl)-2-
methyl-3-oxo-2,3-dihydro-1H- indazol-6-yl)pyrimidin-2-yl)
##STR00190## 14.15 1.41 (a) 623 A hexahydroimidazo[1,5-a]pyrazin-
3(2H)-one (Example #16.1) and N-(tert-butoxycarbonyl)-L- alanine)
(S)-4-(Difluoromethoxy)-3-((2- methyl-3-oxo-6-(2-((R)-3-oxo-
hexahydroimidazo[1,5-a]pyrazin- 7(1H)-yl)pyrimidin-5-yl)-2,3-
dihydro-1H-indazol-1-yl)methyl) benzyl 2-((tert-butoxycarbonyl)
amino)-3-methylbutanoate (prepared in a similar manner to
Preparation #41 using (R)-7-(5- (1-(2-(difluoromethoxy)-5-
(hydroxymethyl)benzyl)-2- methyl-3-oxo-2,3-dihydro-1H-
indazol-6-yl)pyrimidin-2- ##STR00191## 14.16 1.47 (a) 651 A
yl)hexahydroimidazo[1,5-a] pyrazin-3(2H)-one (Example #16.1) and
N-tert-butoxy- carbonyl)-L-valine)
Example #6
(R)-7-(5-(1-(2-(Difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-1H-inda-
zol-6-yl)pyrimidin-2-yl)hexahydroimidazo[1,5-a]pyrazin-3(2H)-one
##STR00192##
[0901]
7-(5-(1-(2-(Difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-1H-i-
ndazol-6-yl)pyrimidin-2-yl)hexahydroimidazo[1,5-a]pyrazin-3(2H)-one
(0.100 g, 0.192 mmol) (Example #2.27) was submitted for chiral
separation (Table B, Method b). Fractions from the first eluting
component were combined and concentrated under reduced pressure
then dried in a vacuum oven at about 60.degree. C. for about 16 h
to afford the title product (0.033 g, 33%) with undetermined
optical rotation. LC/MS (Table A, Method a) R.sub.t=1.76 min; MS
m/z: 522 (M+H).sup.+ (TNF IC.sub.50=A).
Example #7
(S)-7-(5-(1-(2-(Difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-1H-inda-
zol-6-yl)pyrimidin-2-yl)hexahydroimidazo[1,5-a]pyrazin-3(2H)-one
##STR00193##
[0903]
7-(5-(1-(2-(Difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-1H-i-
ndazol-6-yl)pyrimidin-2-yl)hexahydroimidazo[1,5-a]pyrazin-3(2H)-one
(0.100 g, 0.192 mmol) (Example #2.27) was submitted for chiral
separation (Table B, Method b). Fractions from the first eluting
component were combined and concentrated under reduced pressure
then dried in a vacuum oven at about 60.degree. C. for about 16 h
to afford the title product (0.033 g, 33%) with undetermined
optical rotation. LC/MS (Table A, Method a) R.sub.t=1.76 min; MS
m/z: 522 (M+H).sup.+ (TNF IC.sub.50=A).
Example #8
(R)-7-(5-(1-(2-(Difluoromethoxy)-5-methylbenzyl)-2-methyl-3-oxo-2,3-dihydr-
o-1H-indazol-6-yl)pyrimidin-2-yl)hexahydroimidazo[1,5-a]pyrazin-3(2H)-one
##STR00194##
[0905] A mixture of bis(pinacolato)diboron (0.0445 g, 0.175 mmol),
(R)-7-(5-bromopyrimidin-2-yl)hexahydroimidazo[1,5-a]pyrazin-3(2H)-one
(0.0350 g, 0.117 mmol) (Preparation #13), KOAc (0.0282 g, 0.287
mmol), PdCl.sub.2(dppf) (0.0061 g, 8.3 .mu.mol), and dioxane (1.0
mL) was evacuated then back-filled with N.sub.2 three times then
purged with N.sub.2 for about 15 min. The mixture was warmed to
about 95.degree. C. After about 90 min, the mixture was allowed to
cool to rt.
6-bromo-1-(2-(difluoromethoxy)-5-methylbenzyl)-2-methyl-1H-indazol-3(2H)--
one (0.0393 g, 0.099 mmol) (synthesized from
6-bromo-1H-indazol-3(2H)-one (Preparation #1) and
2-(bromomethyl)-1-(difluoromethoxy)-4-methylbenzene (synthesized in
a similar fashion to Preparation #3, step 2 from
(2-(difluoromethoxy)-5-methylphenyl)methanol (Preparation #11),
Cs.sub.2CO.sub.3 (0.102 g, 0.313 mmol), and
bis(triphenylphosphine)palladium(II) dichloride were added in one
portion. Water (0.25 mL) was added. The reaction was evacuated then
back-filled with N.sub.2 three times then purged with N.sub.2 for
about 15 min. The mixture was warmed to about 80.degree. C. After
about 2 h, the mixture was allowed to cool to rt. Water (5 mL), DCM
(10 mL), and MeOH (0.5 mL) were added. The mixture was filtered
then the layers were separated. The aqueous layer was extracted
with 5% MeOH/DCM (2.times.10 mL). The combined organics were dried
over Na.sub.2SO.sub.4, filtered and concentrated under reduced
pressure. The residue was purified using flash chromatography on
silica gel (1-5% MeOH/DCM) to give the title product (0.0431 g,
81%). (Table A, Method a) R.sub.t=1.82 min; MS m/z: 536 (M+H).sup.+
(TNF IC.sub.50=A).
[0906] The compounds shown in Table 15 were synthesized in a manner
similar to Example #8 from
6-bromo-1-(2-(difluoromethoxy)-5-methylbenzyl)-2-methyl-1H-indazol-3(2H)--
one (synthesized from 6-bromo-1H-indazol-3(2H)-one (Preparation #1)
and 2-(bromomethyl)-1-(difluoromethoxy)-4-methylbenzene
(synthesized in a similar fashion to Preparation #3, step 2 from
(2-(difluoromethoxy)-5-methylphenyl)methanol (Preparation #11)) and
the corresponding halide.
TABLE-US-00021 TABLE 15 R.sub.t min Example (Table A, m/z ESI+ TNF
Halide Product # Method) (M + H).sup.+ IC.sub.50
(S)-7-(5-Bromopyrimidin-2- yl)hexahydroimidazo[1,5-a]
pyrazin-3(2H)-one (Preparation #13) ##STR00195## 15.1 1.82 (a) 536
A
Example #9
1-(2-(Difluoromethoxy)-5-(hydroxymethyl)benzyl)-2-methyl-6-(2-morpholinopy-
rimidin-5-yl)-1H-indazol-3(2H)-one
##STR00196##
[0907] Step 1: Methyl
4-(difluoromethoxy)-3-((2-methyl-6-(2-morpholinopyrimidin-5-yl)-3-oxo-2,3-
-dihydro-1H-indazol-1-yl)methyl)benzoate
[0908] PdCl.sub.2(dppf) complex with DCM (0.070 g, 0.086 mmol) was
added to a solution of
1-(5-bromo-2-(difluoromethoxy)benzyl)-2-methyl-6-(2-morpholinopyrimidin-5-
-yl)-1H-indazol-3(2H)-one (0.459 g, 0.580 mmol) (prepared using
2-methyl-6-(2-morpholinopyrimidin-5-yl)-1H-indazol-3(2H)-one
(Preparation #2) and
4-bromo-2-(bromomethyl)-1-(difluoromethoxy)benzene (prepared using
(5-bromo-2-(difluoromethoxy)phenyl)methanol (Preparation #12) in a
similar fashion to Preparation #3, step 2) in a similar fashion to
Example #1) and DMF (4.00 mL) under N.sub.2. MeOH (2.00 mL, 49.4
mmol) and TEA (0.250 mL, 1.79 mmol) were added respectively. The
reaction vessel was evacuated then back-filled with N.sub.2 three
times then evacuated and back-filled with carbon monoxide twice.
The reaction was warmed to about 80.degree. C. After about 3 h, the
reaction was allowed to cool to rt. The organic volatiles were
removed under reduced pressure. The residue was slurried in water
(25 mL) and EtOAc (25 mL). The solids were removed by filtration
rinsing with EtOAc. The layers were separated and the aqueous layer
was extracted with EtOAc (25 mL). The combined organics were dried
over Na.sub.2SO.sub.4, filtered, and concentrated under reduced
pressure. The residue was purified using flash chromatography on
silica gel (75-100% EtOAc/heptane) to give the title product (0.244
g, 80%). (Table A, Method e) R.sub.t=2.03 min; MS m/z: 526
(M+H).sup.+.
Step 2:
1-(2-(Difluoromethoxy)-5-(hydroxymethyl)benzyl)-2-methyl-6-(2-morp-
holinopyrimidin-5-yl)-1H-indazol-3(2H)-one
[0909] Lithium borohydride (0.0152 g, 0.698 mmol) was added in one
portion to a mixture of methyl
4-(difluoromethoxy)-3-((2-methyl-6-(2-morpholinopyrimidin-5-yl)-3-oxo-2,3-
-dihydro-1H-indazol-1-yl)methyl)benzoate (0.119 g, 0.226 mmol) and
THF (2.20 mL) under N.sub.2. After about 90 min, MeOH (5 mL) was
added. The solution was left to vigorously stir for about 25 h. 5%
MeOH/DCM (10 mL), sat. aq. NH.sub.4Cl (5 mL), and water (2 mL) were
added. The biphasic solution was left to vigorously stir for about
16 h. The layers were separated and the aqueous layer was extracted
with DCM (2.times.5 mL). The combined organics were dried over
Na.sub.2SO.sub.4, filtered, and concentrated under reduced
pressure. The residue was purified using flash chromatography on
silica gel (0-7.5% MeOH/DCM) to give the title product (0.0756 g,
66%). (Table A, Method a) R.sub.t=1.79 min; MS m/z: 498 (M+H).sup.+
(TNF IC.sub.50=A).
Example #10
1-(2-(Difluoromethoxy)benzyl)-2-ethyl-6-(2-morpholinopyrimidin-5-yl)-1H-in-
dazol-3(2H)-one
##STR00197##
[0911] Iodoethane (0.017 mL, 0.21 mmol) was added to a solution of
1-(2-(difluoromethoxy)benzyl)-6-(2-morpholinopyrimidin-5-yl)-1H-indazol-3-
(2H)-one (Example #6.1) (0.080 g, 0.18 mmol), LiOH hydrate (10 mg,
0.25 mmol), and DMF (1.8 mL). The reaction mixture was heated to
about 100.degree. C. for about 1 h. After cooling to rt, the
reaction was partitioned between EtOAc (15 mL) and water (2 mL).
The aqueous layer was extracted with EtOAc (15 mL) and the combined
organic layers were dried over MgSO.sub.4, filtered, and
concentrated under reduced pressure. The residue was purified via
flash chromatography on silica gel (0-100% EtOAc/heptane) to
provide the title product (4.8 mg, 6%); LC/MS (Table A, Method e)
R.sub.t=2.15 min; MS m/z: 482 (M+H).sup.+ (TNF IC.sub.50=B).
Example #11
2-Cyclopropyl-1-(2-(difluoromethoxy)benzyl)-6-(2-morpholinopyrimidin-5-yl)-
-1H-indazol-3(2H)-one
##STR00198##
[0913] A mixture of
1-(2-(difluoromethoxy)benzyl)-6-(2-morpholinopyrimidin-5-yl)-1H-indazol-3-
(2H)-one (0.050 g, 0.11 mmol) (Example #6.1), cyclopropylboronic
acid (0.019 g, 0.22 mmol), Cs.sub.2CO.sub.3(0.018 g, 0.055 mmol),
pyridine (0.027 mL, 0.33 mmol), diacetoxycopper (0.020 g, 0.11
mmol) in toluene (0.22 mL) was heated to about 110.degree. C. under
dry air. After about 1 h, the reaction was allowed to cool to rt
and then partitioned between EtOAc (10 mL) and water (10 mL). The
organic layer was separated and the aqueous layer was extracted
with EtOAc (10 mL). The combined organics were dried over
MgSO.sub.4, filtered and concentrated under reduced pressure. The
residue was purified on silica gel (0-100% EtOAc/heptane) to
provide the title product (23.4 mg, 42%); LC/MS (Table A, Method e)
R.sub.t=2.14 min; MS m/z: 494 (M+H).sup.+ (TNF IC.sub.50=B).
Example #12
1-(2-(Difluoromethoxy)benzyl)-2-methyl-6-(2-((3-methyloxetan-3-yl)methyl)p-
yrimidin-5-yl)-1H-indazol-3(2H)-one
##STR00199##
[0915] A solution of 3-(bromomethyl)-3-methyloxetane (0.495 g, 3.00
mmol), THF (6 mL) and 1,2-dibromoethane (0.020 g, 0.11 mmol) was
added to acid-washed and oven-dried magnesium turnings (0.109 g,
4.50 mmol) under N.sub.2. The reaction mixture was heated unstirred
to about 55.degree. C. When bubbling began, the mixture was gently
stirred to maintain the magnesium below the reaction surface. The
reaction was then warmed to about 65.degree. C. for about 45 min
until the bubbling ceased. The mixture was allowed to cool,
stirring was ceased, and the solids were allowed to settle to the
bottom of the reaction vessel. A portion of the
(((3-methyloxetan-3-yl)methyl)magnesium bromide solution (0.48 mL)
was removed via syringe and then added dropwise over about 15 min
to a flask containing a mixture of
6-(2-chloropyrimidin-5-yl)-1-(2-(difluoromethoxy)benzyl)-2-methyl-1H-inda-
zol-3(2H)-one (0.100 g, 0.240 mmol) (Preparation #4), PPh.sub.3
(0.025 g, 0.096 mmol) and nickel acetylacetonate (7.4 mg, 0.029
mmol) in THF (1 mL) at about 0.degree. C. After about 1 h, the
reaction was removed from the ice bath and stirred at rt for about
1 h. ((3-methyloxetan-3-yl)methyl)magnesium bromide solution (0.480
mL) and nickel acetylacetonate (7.4 mg, 0.029 mmol) were added and
the reaction was stirred at rt for about 1 h. The reaction was
heated at about 60.degree. C. for about 1 h. The reaction was
allowed to cool to rt and nickel acetylacetonate (62 mg, 0.24 mmol)
and ((3-methyloxetan-3-yl)methyl)magnesium bromide solution (0.48
mL) were added. The reaction was stirred at rt for about 50 h. The
reaction mixture was partitioned between EtOAc (10 mL) and sat. aq.
NH.sub.4Cl (10 mL). The organic layer was washed with sat. aq. NaCl
(10 mL) and concentrated under reduced pressure. The residue was
purified on silica gel (20-80% EtOAc/heptane) to give the title
product (10 mg, 8%); LC/MS (Table A, Method e) R.sub.t=2.13 min; MS
m/z: 467 (M+H).sup.+ (TNF IC.sub.50=B).
Example #13
1-(2-(Difluoromethoxy)benzyl)-2-methyl-6-(3-morpholino-1,2,4-oxadiazol-5-y-
l)-1H-indazol-3(2H)-one
##STR00200##
[0916] Step 1: Methyl
1-(2-(difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-1H-indazole-6-ca-
rboxylate
[0917] A flask was charged with
6-bromo-1-(2-(difluoromethoxy)benzyl)-2-methyl-1H-indazol-3(2H)-one
(400 mg, 1.04 mmol) (Preparation #4, step 1), Pd(OAc).sub.2 (0.023
g, 0.10 mmol) and dppf (0.116 g, 0.209 mmol) under N.sub.2. DMF
(6.1 mL) was added and the mixture was evacuated and back-filled
with CO. MeOH (2.1 mL, 52 mmol) and TEA (0.78 mL, 5.2 mmol) were
added. The mixture was warmed to about 85.degree. C. for about 18
h. The reaction mixture was allowed to cool to rt. EtOAc (40 mL)
and water (40 mL) were added. The organic layer was separated and
washed with water (2.times.40 mL), dried over MgSO.sub.4, filtered
and concentrated under reduced pressure. The residue was purified
on silica gel (0-100% EtOAc/heptane) to provide the title product
(319 mg, 84%); LC/MS (Table A, Method e) R.sub.t=2.03 min; MS m/z:
363 (M+H).sup.+
Step 2:
1-(2-(Difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-1H-indazo-
le-6-carboxylic acid
[0918] LiOH (42 mg, 1.8 mmol) was added to a solution of methyl
1-(2-(difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-1H-indazole-6-ca-
rboxylate (319 mg, 0.880 mmol) in THF (5.5 mL), water (2.8 mL) and
MeOH (2.8 mL) was added LiOH (42 mg, 1.8 mmol). The reaction was
warmed to about 55.degree. C. for about 4 h then allowed to cool to
rt. The organic volatiles were removed under reduced pressure. The
reaction mixture was acidified with 1 N aqueous HCl. The solid was
collected by filtration and washed with EtOAc (10 mL). The filtrate
was partially concentrated under reduced pressure and the resulting
solid was collected by filtration. The solids were collected and
blended to provide the title product (253 mg, 83%); LC/MS (Table A,
Method e) R.sub.t=1.50 min; MS m/z: 349 (M+H).sup.+
Step 3:
1-(2-(Difluoromethoxy)benzyl)-2-methyl-N-(morpholine-4-carbonothio-
yl)-3-oxo-2,3-dihydro-1H-indazole-6-carboxamide
[0919] Oxalyl dichloride (2 M solution in DCM, 0.73 mL, 1.5 mmol)
was added to a solution of
1-(2-(difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-1H-indazole-6-ca-
rboxylic acid (253 mg, 0.726 mmol) in DCM (1.7 mL) at about
0.degree. C. A drop of DMF was added. The ice bath was removed and
reaction was allowed to warm to rt. After about 3 h, the volatiles
were removed under reduced pressure. The residue was dissolved in
MeCN (2.2 mL). The resulting solution was added dropwise to a
solution of potassium thiocyanate (0.076 g, 0.78 mmol) in MeCN (2.2
mL). After about 16 h, the reaction mixture was concentrated under
reduced pressure. DCM (2.2 mL) was added. The solid was removed by
filtration and then the filtrate was added dropwise to a solution
of morpholine (0.062 mL, 0.71 mmol), TEA (0.18 mL, 1.3 mmol) and
DCM (2.2 mL). After about 1 h, water (20 mL) was added and the
organic layer was separated, dried over MgSO.sub.4, filtered, and
concentrated under reduced pressure. The residue was purified on
silica gel (0-100% EtOAc/heptane) to provide the title product (82
mg, 26%); LC/MS (Table A, Method e) R.sub.t=1.88 min; MS m/z: 477
(M+H).sup.+
Step 4: (Z)-Methyl
N-(1-(2-(difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-1H-indazole-6-
-carbonyl)morpholine-4-carbimidothioate
[0920] MeI (11 .mu.L, 0.17 mmol) was added to a solution of
1-(2-(difluoromethoxy)benzyl)-2-methyl-N-(morpholine-4-carbonothioyl)-3-o-
xo-2,3-dihydro-1H-indazole-6-carboxamide (82 mg, 0.17 mmol) in DMF
(1 mL). After about 1 h, EtOAc (30 mL) and water (10 mL) were
added. The organic layer was separated and then washed with water
(2.times.10 mL), dried over MgSO.sub.4, filtered and concentrated
under reduced pressure to provide the title compound (84 mg, 100%);
LC/MS (Table A, Method e) R.sub.t=1.78 min; MS m/z: 491
(M+H).sup.+
Step 5:
1-(2-(Difluoromethoxy)benzyl)-2-methyl-6-(3-morpholino-1,2,4-oxadi-
azol-5-yl)-1H-indazol-3(2H)-one
[0921] Sodium acetate (45.2 mg, 0.550 mmol) was added to
hydroxylamine hydrochloride (38.3 mg, 0.55 mmol) in MeOH (0.180 mL)
at about 0.degree. C. After about 30 min, (Z)-methyl
N-(1-(2-(difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-1H-indazole-6-
-carbonyl)morpholine-4-carbimidothioate (90 mg, 0.18 mmol) in MeOH
(0.180 mL) was added. After about 2 h, the ice bath was removed and
the reaction was allowed to warm to rt. Additional MeOH (3 mL) was
added and the reaction mixture was stirred at rt for about 2 h. The
reaction mixture was concentrated under reduced pressure. EtOAc (10
mL) and water (5 mL) were added. The layers were separated and the
aqueous layer was extracted with EtOAc (10 mL). The combined
organic layers were washed with sat. aq. NaCl (5 mL), dried over
MgSO.sub.4, filtered, and concentrated under reduced pressure. The
residue was purified on silica gel (0-60% EtOAc/DCM) to provide the
title product (18.3 mg, 22%); LC/MS (Table A, Method e)
R.sub.t=2.06 min; MS m/z: 458 (M+H).sup.+ (TNF IC.sub.50=B).
Example #14
1-(2-(Difluoromethoxy)benzyl)-2-methyl-6-(2-morpholinopyrimidin-5-yl)-1H-p-
yrazolo[4,3-b]pyridin-3(2H)-one
##STR00201##
[0922] Step 1: 6-Bromo-1H-pyrazolo[4,3-b]pyridin-3(2H)-one
[0923] A mixture of 5-bromo-3-fluoropicolinic acid hydrochloride
(2.0 g, 7.8 mmol) in MeCN (50 mL) was treated with DIEA (4.1 mL, 23
mmol). After stirring for about 10 min,
2-(3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-1,1,3,3-tetramethylisouronium
hexafluorophosphate(V) (3.56 g, 9.36 mmol) was added. After
stirring for about 15 min, a solution of hydrazine hydrate (1.88 g,
37.6 mmol) in MeCN (25 mL) was added to the mixture. After stirring
for about 1 h, the mixture was diluted with water (150 mL) then
extracted with DCM (3.times.100 mL). The combined organic layers
were concentrated under reduced pressure. The residue was dissolved
in n-butanol (50 mL) and hydrazine hydrate (1.5 g, 30 mmol) then
the mixture was heated to about 100.degree. C. After about 12 h,
the reaction mixture was cooled to rt then diluted with ethyl ether
(50 mL). After stirring for about 15 min, the solids were collected
by filtration rinsing with ethyl ether (25 mL). The material was
dried under reduced pressure at about 60.degree. C. to yield the
title compound (0.485 g, 29%); LC/MS (Table A, Method e)
R.sub.t=1.21 min; MS m/z: 214 and 216 (M+H).sup.+.
Step 2:
6-Bromo-1-(2-(difluoromethoxy)benzyl)-1H-pyrazolo[4,3-b]pyridin-3(-
2H)-one
[0924] A solution of 6-bromo-1H-pyrazolo[4,3-b]pyridin-3(2H)-one
(0.30 g, 1.4 mmol) in DMF (7 mL) was treated with potassium
carbonate (0.194 g, 1.40 mmol). After stirring for about 10 min,
the mixture was treated with
1-(bromomethyl)-2-(difluoromethoxy)benzene (0.34 g, 1.4 mmol).
After stirring for about 2 days, the mixture was concentrated under
reduced pressure and the residue was partitioned between EtOAc (20
mL) and water (10 mL). The aqueous layer was extracted with EtOAc
(10 mL) then neutralized with AcOH. EtOAc (20 mL) was added. The
mixture was stirred and filtered. The filtrate layers were
separated and the aqueous layer was extracted with EtOAc (10 mL).
The organic solutions were combined, dried over sodium sulfate,
filtered and concentrated under reduced pressure. The residue was
triturated with EtOAc (5 mL) then the solids were collected by
filtration rinsing with EtOAc (1 mL). The solid was dried to yield
the title compound (0.23 g, 44%); LC/MS (Table A, Method e)
R.sub.t=2.14 min; MS m/z: 370 and 372 (M+H).sup.+.
Step 3:
6-Bromo-1-(2-(difluoromethoxy)benzyl)-2-methyl-1H-pyrazolo[4,3-b]p-
yridin-3(2H)-one
[0925] A solution of
6-bromo-1-(2-(difluoromethoxy)benzyl)-1H-pyrazolo[4,3-b]pyridin-3(2H)-one
(0.23 g, 0.62 mmol) in acetone (6 mL) was treated with potassium
carbonate (0.094 g, 0.68 mmol) and MeI (0.31 mL, 4.9 mmol). The
mixture was heated to about 50.degree. C. for about 10 h then
concentrated under reduced pressure. The residue was partitioned
between water (10 mL) and EtOAc (20 mL). The aqueous layer was
extracted with EtOAc (10 mL). The combined organic solutions were
dried over sodium sulfate, filtered, and concentrated under reduced
pressure. The material was purified via flash chromatography on
silica gel (0-50% EtOAc/DCM) to yield the title compound (0.026 g,
11%); LC/MS (Table A, Method e) R.sub.t=2.14 min; MS m/z: 384 and
386 (M+H).sup.+
Step 4:
1-(2-(Difluoromethoxy)benzyl)-2-methyl-6-(2-morpholinopyrimidin-5--
yl)-1H-pyrazolo[4,3-b]pyridin-3(2H)-one
[0926] A mixture of
6-bromo-1-(2-(difluoromethoxy)benzyl)-2-methyl-1H-pyrazolo[4,3-b]pyridin--
3(2H)-one (0.025 g, 0.065 mmol,
4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-yl)morpholi-
ne (0.023 g, 0.078 mmol), cesium carbonate (0.045 g, 0.14 mmol) and
PdCl.sub.2(PPh.sub.3).sub.2 (0.004 g, 0.006 mmol) in 1,4-dioxane (1
mL) and water (0.25 mL) was degassed with N.sub.2 then heated to
about 85.degree. C. for about 45 min. The reaction mixture was
cooled, filtered through a 0.45 .mu.M filter then purified by
preparative reverse phase HPLC (Table A, Method c). Lyophilization
of the appropriate fractions yielded the title compound (0.012 g,
40%); LC/MS (Table A, Method a) R.sub.t=1.88 min; MS m/z: 469
(M+H).sup.+ (TNF IC.sub.50=C).
Example #15
1-(2-(Difluoromethoxy)benzyl)-2-methyl-6-(2-morpholinopyrimidin-5-yl)-1H-p-
yrazolo[3,4-b]pyridin-3(2H)-one
##STR00202##
[0927] Step 1: 2,6-Dichloro-N-methylnicotinohydrazide
[0928] 2,6-Dichloronicotinic acid (tech .about.90%) (1.5 g, 7.8
mmol) in DCM (35 mL) was treated with oxalyl dichloride (0.84 mL,
9.6 mmol) and a few drops of DMF then stirred at rt for about 14 h.
The mixture was concentrated under reduced pressure then dissolved
in DCM (35 mL). The solution was added to methylhydrazine (1.1 g,
24 mmol) in DCM (35 mL) cooled to about -50.degree. C. keeping the
reaction temp between -40.degree. C. and -45.degree. C. during the
addition. After completion of addition, the mixture was allowed to
warm slowly to rt. The solvent was removed under reduced pressure
then the residue was partitioned between EtOAc (50 mL) and water
(50 mL). The aqueous layer was extracted with EtOAc (2.times.25 mL)
then the combined organics were washed with sat. aq. NaCl (20 mL),
dried over magnesium sulfate, filtered, and concentrated under
reduced pressure to yield the title compound which was used without
further manipulation (1.78 g, 104%); LC/MS (Table A, Method e)
R.sub.t=1.26 min; MS m/z: 220 (M+H).sup.+.
Step 2: 6-Chloro-2-methyl-1H-pyrazolo[3,4-b]pyridin-3(2H)-one
[0929] A mixture of 2,6-dichloro-N-methylnicotinohydrazide (1.78 g,
8.09 mmol), n-butanol (60 mL) and sodium carbonate (0.88 g, 8.3
mmol) was heated to reflux with stirring for about 23 h. The
mixture was concentrated under reduced pressure then the material
was dissolved in water (25 mL). The pH of the solution was adjusted
to about 6 with AcOH. EtOAc (50 mL) was added to the mixture then
the solids were collected by filtration rinsing with EtOAc (10 mL).
The filtrate layers were separated then the organic layer was dried
over magnesium sulfate, filtered, concentrated under reduced
pressure. The material was triturated with EtOAc (10 mL) then the
solids were collected by filtration and washed with EtOAc (2 mL).
The collected solids were combined and dried under reduced pressure
to yield the title compound (0.90 g, 61%); LC/MS (Table A, Method
e) R.sub.t=1.12 min; MS m/z: 184 (M+H).sup.+
Step 3:
6-Chloro-1-(2-(difluoromethoxy)benzyl)-2-methyl-1H-pyrazolo[3,4-b]-
pyridin-3(2H)-one
[0930] 6-Chloro-2-methyl-1H-pyrazolo[3,4-b]pyridin-3(2H)-one (0.250
g, 1.36 mmol) in DMF (7 mL) was treated with potassium carbonate
(0.230 g, 1.66 mmol). After stirring for about 10 min,
1-(bromomethyl)-2-(difluoromethoxy)benzene (0.365 g, 1.54 mmol) was
added over about 5 min. After stirring for about 30 min at rt, the
reaction mixture was concentrated under reduced pressure then the
residue was partitioned between EtOAc (20 mL) and water (5 mL). The
layers were separated then the organic layer was washed with water
(10 mL) and sat. aq. NaCl (10 mL), dried over magnesium sulfate,
filtered and concentrated under reduced pressure. The material was
stirred with 10:1 heptane/EtOAc (5.5 mL) until a solid formed. The
mixture was diluted with heptane (5 mL). The solids were collected
by filtration rinsing with heptane (2 mL) and then dried under
reduced pressure at about 60.degree. C. to provide the title
compound (0.384 g, 83%); LC/MS (Table A, Method e) R.sub.t=2.11
min; MS m/z: 340 (M+H).sup.+.
Step 4:
1-(2-(Difluoromethoxy)benzyl)-2-methyl-6-(2-morpholinopyrimidin-5--
yl)-1H-pyrazolo[3,4-b]pyridin-3(2H)-one
[0931] A mixture of
6-chloro-1-(2-(difluoromethoxy)benzyl)-2-methyl-1H-pyrazolo[3,4-b]pyridin-
-3(2H)-one (0.075 g, 0.22 mmol),
4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-yl)morpholi-
ne (0.081 g, 0.28 mmol) and cesium carbonate (0.18 g, 0.55 mmol) in
1,4-dioxane (2 mL) and water (0.5 mL) under N.sub.2 was treated
with PdCl.sub.2(PPh.sub.3).sub.2 (0.011 g, 0.015 mmol). The mixture
was purged with N.sub.2 and then heated to about 100.degree. C. for
about 30 min. The reaction mixture was cooled, filtered through a
0.45 .mu.M filter then purified by preparative reverse phase HPLC
(Table A, Method d). Lyophilization of the appropriate fractions
yielded the title compound (0.086 g, 83%); LC/MS (Table A, Method
a) R.sub.t=2.15 min; MS m/z: 469 (M+H).sup.+ (TNF IC.sub.50=B).
Example #16
1-(2-(Difluoromethoxy)benzyl)-6-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-2-
-methyl-1H-pyrazolo[3,4-b]pyridin-3(2H)-one
##STR00203##
[0933] A mixture of 2-(5-bromopyrimidin-2-yl)propan-2-ol (0.065 g,
0.30 mmol),
4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (0.15
g, 0.60 mmol), KOAc (0.072 g, 0.73 mmol) and PdCl.sub.2(dppf)
(0.011 g, 0.015 mmol in 1,4-dioxane (2 mL) under N.sub.2 was heated
to about 95.degree. C. for about 90 min. The mixture was cooled to
rt then
6-chloro-1-(2-(difluoromethoxy)benzyl)-2-methyl-1H-pyrazolo[3,4-b]pyridin-
-3(2H)-one (0.075 g, 0.221 mmol) (Example #15, step 3), water
(0.500 mL), cesium carbonate (0.18 g, 0.55 mmol) and
PdCl.sub.2(PPh.sub.3).sub.2 (0.08 g, 0.01 mmol) were added. The
mixture was placed under N.sub.2 and then heated at about
100.degree. C. for about 30 min. The reaction mixture was cooled,
filtered through a 0.45 M filter then purified by preparative
reverse phase HPLC (Table A, Method d). Lyophilization of the
appropriate fractions yielded the title compound (0.070 g, 72%);
LC/MS (Table A, Method a) R.sub.t=1.93 min; MS m/z: 442 (M+H).sup.+
(TNF IC.sub.50=B).
Example #17
1-(2-(Difluoromethoxy)benzyl)-2-methyl-6-(2-morpholinopyrimidin-5-yl)-1H-p-
yrazolo[4,3-c]pyridin-3(2H)-one
##STR00204##
[0934] Step 1: 4,6-Dichloro-N-methylnicotinohydrazide
[0935] Oxalyl dichloride (5.5 mL, 63 mmol) was added to a
suspension of 4,6-dichloronicotinic acid (10.0 g, 52.1 mmol) in DCM
(240 mL). DMF (0.10 mL, 1.3 mmol) was added to the reaction
dropwise and the reaction was stirred at rt for about 16 h. The
reaction was concentrated under reduced pressure. The residue was
dissolved in DCM (240 mL). The solution was added to a solution of
methylhydrazine (8.2 mL, 160 mmol) in DCM (240 mL) cooled to about
-50.degree. C. at a rate to maintain the reaction temp between
about -40.degree. C. and -45.degree. C. After the complete
addition, the reaction was allowed to slowly warm to about
0.degree. C. The reaction was quenched with sat. aq.
NaHCO.sub.3(200 mL) and the layers were separated. The aqueous
layer was extracted with DCM (2.times.200 mL). The combined organic
layers were dried over Na.sub.2SO.sub.4, filtered and concentrated
under reduced pressure to give the title compound (11.2 g, 83%);
LC/MS (Table A, Method e) R.sub.t=1.22 min; MS m/z: 220
(M+H).sup.+.
Step 2:
5-Chloro-2-methyl-2,3-dihydro-1H-pyrazolo[4,3-c]pyridin-1-one
[0936] A mixture of 4,6-dichloro-N-methylnicotinohydrazide (0.50 g,
2.3 mmol) and sodium carbonate (0.250 g, 2.36 mmol) in
cyclopentanol (20 mL) was gently refluxed for about 8 h. The
reaction was allowed to cool to rt. AcOH (0.130 mL, 2.27 mmol) was
added. The reaction mixture was concentrated under reduced
pressure. The residue was triturated in DCM (25 mL) washing with
DCM (25 mL) to give the title compound (0.420 g, 70%); LC/MS (Table
A, Method e) R.sub.t=0.87 min; MS m/z: 184 (M+H).sup.+.
Step 3:
6-Chloro-1-(2-(difluoromethoxy)benzyl)-2-methyl-1H-pyrazolo[3,4-c]-
pyridin-3(2H)-one
[0937] 6-Chloro-2-methyl-1H-pyrazolo[4,3-c]pyridin-3(2H)-one (0.420
g, 2.29 mmol) in DMF (10 mL) was treated with potassium carbonate
(0.632 g, 4.58 mmol). After stirring for about 10 min,
1-(bromomethyl)-2-(difluoromethoxy)benzene (0.596 g, 2.52 mmol) was
added dropwise. The reaction was stirred at rt for about 30 min.
The reaction was partitioned between EtOAc (100 mL) and sat. aq.
NaCl (100 mL). The organic layer was washed with sat. aq. NaCl (100
mL), dried over Na.sub.2SO.sub.4, filtered, and concentrated under
reduced pressure. The material was purified via flash
chromatography on silica gel (0-3% MeOH/DCM) to yield the title
compound (0.273 g, 35%); LC/MS (Table A, Method e) R.sub.t=1.85
min; MS m/z: 340 (M+H).sup.+.
Step 4:
1-(2-(Difluoromethoxy)benzyl)-2-methyl-6-(2-morpholinopyrimidin-5--
yl)-1H-pyrazolo[4,3-c]pyridin-3(2H)-one
[0938] A mixture of
6-chloro-1-(2-(difluoromethoxy)benzyl)-2-methyl-1H-pyrazolo[4,3-c]pyridin-
-3(2H)-one (0.270 g, 0.795 mmol),
4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-yl)morpholi-
ne (0.301 g, 1.03 mmol), cesium carbonate (0.647 g, 1.99 mmol),
1,4-dioxane (6.0 mL) and water (1.5 mL) was degassed with N.sub.2.
PdCl.sub.2(PPh.sub.3).sub.2(0.056 g, 0.079 mmol) was added to the
mixture. The reaction was degassed under N.sub.2 and heated at
about 100.degree. C. for about 1 h then allowed to cool to rt. The
reaction mixture was partitioned between EtOAc (30 mL) and sat. aq.
NaCl (30 mL). The organic layer was dried over Na.sub.2SO.sub.4,
filtered and concentrated under reduced pressure. The material was
purified via flash chromatography on silica gel (0-3% MeOH/DCM) to
yield the title compound (0.280 g, 71%); LC/MS (Table A, Method e)
R.sub.t=1.88 min; MS m/z: 469 (M+H).sup.+. (TNF IC.sub.50=C).
Example #18
(S)-7-(5-(1-(2-(Difluoromethoxy)-5-(hydroxymethyl)benzyl)-2-methyl-3-oxo-2-
,3-dihydro-1H-indazol-6-yl)pyrimidin-2-yl)hexahydroimidazo[1,5-a]pyrazin-3-
(2H)-one
##STR00205##
[0940] Triisopropylsilane (12 .mu.L, 0.059 mmol) and TFA (2 mL)
were added to a solution of
(S)-7-(5-(1-(2-(difluoromethoxy)-5-((trityloxy)methyl)benzyl)-2-methyl-3--
oxo-2,3-dihydro-1H-indazol-6-yl)pyrimidin-2-yl)hexahydroimidazo[1,5-a]pyra-
zin-3(2H)-one (47 mg, 0.059 mmol) (synthesized from
1-(2-(difluoromethoxy)-5-((trityloxy)methyl)benzyl)-2-methyl-6-(4,4,5,5-t-
etramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3(2H)-one
(synthesized using 6-bromo-2-methyl-1H-indazol-3(2H)-one
(Preparation #1) and
(((3-(bromomethyl)-4-(difluoromethoxy)benzyl)oxy)methanetriyl)tribenzene
(Preparation #14) in a method similar to Preparation #4, steps 1
and 2) and
(S)-2-(5-bromopyrimidin-2-yl)hexahydroimidazo[1,5-a]pyrazin-3(2H)-one
(Preparation #13) using a similar method to Example #5) in DCM (2
mL). After about 10 min, the reaction mixture was concentrated
under reduced pressure. The residue was triturated twice with
diethyl ether (5 mL), decanting the diethyl ether layer each time.
MeCN (5 mL) and water (3 mL) were added and the resulting solution
was made basic with sat. aq. NaHCO.sub.3 (0.2 mL). The solution was
concentrated under reduced pressure to about 2 mL. The product was
collected by filtration rinsing with water (1 mL). The material was
air dried on the funnel then dried in the vacuum oven to yield the
title compound (25 mg, 77%). LC/MS (Table A, Method a) Rt=1.56 min;
MS m/z: 552 (M+H).sup.+. (TNF IC.sub.50=A).
[0941] The compounds shown in Table 16 were synthesized in a manner
similar to Example #18 from the corresponding Trt-protected
alcohol.
TABLE-US-00022 TABLE 16 R.sub.t min (Table m/z A, ESI+ Ex Meth- (M
+ TNF Trt-protected alcohol Product # od) H).sup.+ IC.sub.50
(R)-7-(5-(1-(2-(Difluoro- methoxy)-5-((trityloxy)methyl)
benzyl)-2-methyl-3-oxo-2,3- dihydro-1H-indazol-6-yl)
pyrimidin-2-yl)hexahydro- imidazo[1,5-a]pyrazin-3(2H)- one
(synthesized using 6- bromo-2-methyl-1H-indazol- 3(2H)-one
(Preparation #1) and (((3-(bromomethyl)-4-
(difluoromethoxy)benzyl)oxy) methanetriyl)tribenzene (Preparation
#14) in a method similar to Preparation #4, steps 1 and 2) and
(R)-2-(5-bromo- pyrimidin-2-yl)hexahydro-
imidazo[1,5-a]pyrazin-3(2H)- ##STR00206## 16.1 1.56 (a) 552 A one
(Preparation #13) using a similar method to Example #5)
1-(2-(Difluoromethoxy)-5- (trityloxymethyl)benzyl)-2-
methyl-6-(2-((1-methyl-2-oxo- pyrrolidin-3-yl)amino)
pyrimidin-5-yl)-1H-indazol-3 (2H)-one (synthesized using 6-
bromo-2-methyl-1H-indazol- 3(2H)-one (Preparation #1) and
(((3-(bromomethyl)-4-(difluoro- methoxy)benzyl)oxy)methane-
triyl)tribenzene (Preparation #14) in a method similar to
Preparation #4, steps 1 and 2) and 3-((5-bromopyrimidin-2-
yl)amino)-1-methylpyrrolidin- 2-one(synthesized in a method similar
to Preparation #13, step ##STR00207## 16.2 1.47 (a) 525 B 1 using
3-amino-1-methyl- pyrrolidin-2-one) using a similar method to
Example #5) (S)-7-(5-(1-(2-(Difluoro- methoxy)-5-(trityloxymethyl)
benzyl)-2-methyl-3-oxo-2,3- dihydro-1H-indazol-6-yl)
pyrimidin-2-yl)tetrahydro-1H- oxazolo[3,4-a]pyrazin-3(5H)- one
(synthesized using 6- bromo-2-methyl-1H-indazol-3 (2H)-one
(Preparation #1) and (((3-bromomethyl)-4-
(difluoromethoxy)benzyl)oxy) methanetriyl)tribenzene (Preparation
#14) in a method similar to Preparation #4, steps 1 and 2) and
(S)-7-(5- bromopyrimidin-2-yl)tetra- ##STR00208## 16.3* 1.66 (a)
553 A hydro-1H-oxazole[3,4-a]pyrazin- 3(5H)-one (synthesized in a
method similar to Preparation #13, step 1 using (S)-tetrahydro-
1H-oxazolo[3,4-a]pyrazin- 3(5H)-one) using a similar method to
Example #5 (R)-7-(5-(1-(2-(Difluorometh-
oxy)-5-(trityloxymethyl)benzyl)- 2-methyl-3-oxo-2,3-dihydro-
1H-indazol-6-yl)pyrimidin-2- yl)tetrahydro-1H-oxazolo[3,4-a]
pyrazin-3(5H)-one (synthesized using 6-bromo-2-methyl-1H-
indazol-3(2H)-one (Preparation #1) and (((3-
(bromomethyl)-4-(difluoro- methoxy)benzyl)oxy)methane-
triyl)tribenzene (Preparation #14) in a method similar to
Preparation #4, steps 1 and 2) and (R)-7-(5-
bromopyrimidin-2-yl)tetra- ##STR00209## 16.4* 1.66 (a) 553 A
hydro-1H-oxazolo[3,4-a] pyrazin-3(5H)-one (synthesized in a method
similar to Preparation #13, step 1 using
(R)-tetrahydro-1H-oxazolo[3,4- a]pyrazin-3(5H)-one) using a similar
method to Example #5 1-(2-(Difluoromethoxy)-5-
((trityloxy)methyl)benzyl)-2- methyl-6-(2-((2-oxopiperidin-4-
yl)amino)pyrimidin-5-yl)-1H- indazol-3(2H)-one (prepared in a
similar fashion to Example #2, from 6-(2-chloropyrimidin-5-yl)-
1-(2-(difluoromethoxy)-5- ((trityloxy)methyl)benzyl)-2-
methyl-1H-indazol-3(2H)-one (Preparation #24) and 4-
aminopiperidin-2-one hydrochloride) ##STR00210## 16.5 1.42 (a) 525
A 1-(2-(Difluoromethoxy)-5- ((trityloxy)methyl)benzyl)-2-
methyl-6-(2-((2-oxopyrrolidin- 3-yl)amino)pyrimidin-5-yl)-1H-
indazol-3(2H)-one (prepared in a similar fashion to Example #2,
from 6-(2-chloropyrimidin- 5-yl)-1-(2-(difluoromethoxy)-5-
((trityloxy)methyl)benzyl)-2- methyl-1H-indazol-3(2H)-one
(Preparation #24) and 3- aminopyrrolidin-2-one) ##STR00211## 16.6
1.42 (e) 511 B 1-(2-(Difluoromethoxy)-5-
((trityloxy)methyl)benzyl)-6-(2- (2-hydroxypropan-2-yl)
pyrimidin-5-yl)-2-methyl-1H- indazol-3(2H)-one (prepared in a
similar fashion to Preparation #4, step 1 from 6-(2-(2-hydroxy-
propan-2-yl)pyrimidin-5-yl)-2- methyl-1H-indazol-3(2H)-one
(Preparation #19) and (((3- (bromomethyl)-4-(difluoro-
methoxy)benzyl)oxy)methane- triyl)tribenzene (Preparation #14))
##STR00212## 16.7 1.61 (e) 471 A 6-(2-(4-Acetylpiperazin-1-
yl)pyrimidin-5-yl)-1-(2- (difluoromethoxy)-5-
((trityloxy)methyl)benzyl)-2- methyl-1H-indazol-3(2H)-one (prepared
in a similar fashion to Example #2, from 6-(2-chloro-
pyrimidin-5-yl)-1-(2- (difluoromethoxy)-5-
((trityloxy)methyl)benzyl)-2- methyl-1H-indazol-3(2H)-one
(Preparation #24) and 1- (piperazin-1-yl)ethanone) ##STR00213##
16.8 1.63 (e) 539 A 1-(2-(Difluoromethoxy)-5-
((trityloxy)methyl)benzyl)-2- methyl-6-(2-((1-methyl-2-
oxopiperidin-4-yl)amino) pyrimidin-5-yl)-1H- indazol-3(2H)-one
(prepared in a similar fashion to Example #2, from
6-(2-chloropyrimidin- 5-yl)-1-(2-(difluoromethoxy)-5-
((trityloxy)methyl)benzyl)-2- methyl-1H-indazol-3(2H)-one
(Preparation #24) and 4-amino- 1-methylpiperidin-2-one
hydrochloride) ##STR00214## 16.9 1.50 (e) 539 A
(R)-7-(5-(2-Methyl-3-oxo-1-((3- (trifluoromethyl)-6-((trityloxy)
methyl)pyridin-2-yl)methyl)-2,3- dihydro-1H-indazol-6-yl)
pyrimidin-2-yl)hexahydro- imidazo[1,5-a]pyrazin-3(2H)- one
(synthesized in a manner similar to Preparation #13 from
(S)-hexahydroimidazo[1,5-a] pyrazin-3(2H)-one hydrochloride
(Preparation #46) and 6-(2- chloropyrimidin-5-yl)-2-methyl-
1-((3-(trifluoromethyl)-6- ((trityloxy)methyl)pyridin-2-
yl)methyl)-1H-indazol-3(2H)- ##STR00215## 16.10 1.56 (a) 555 A one
(synthesized a manner similar to Preparation #4, step 1 from
6-(2-chloropyrimidin-5- yl)-2-methyl-1H-indazol-3(2H)- one
(Preparation #23) and 2- (bromomethyl)-3-(trifluoro-
methyl)-6-((trityloxy)methyl) pyridine (Preparation #61)))
[0942] The compounds shown in Table 17 were synthesized in a manner
similar to Example #8 from
6-bromo-1-(2-(difluoromethoxy)benzyl)-5-fluoro-2-methyl-1H-indazol-3(2H)--
one (synthesized in a similar fashion to Preparation #4, step 1
from 6-bromo-5-fluoro-2-methyl-1H-indazol-3(2H)-one (synthesized in
a similar fashion to Preparation #1 from
4-bromo-2,5-difluorobenzoic acid) and
2-(bromomethyl)-1-(difluoromethoxy)-4-methylbenzene (synthesized in
a similar fashion to Preparation #3, step 2 from
(2-(difluoromethoxy)-5-methylphenyl)methanol (Preparation #11)))
and the corresponding halide.
TABLE-US-00023 TABLE 17 m/z Exam- R.sub.t min ESI+ ple (Table A, (M
+ TNF Halide Product # Method) H).sup.+ IC.sub.50
2-(5-Bromopyrimidin- 2-yl)propan-2-ol ##STR00216## 17.1 2.05 (a)
473 A 2-(5-Bromo-4- methylpyrimidin-2- yl)propan-2-ol (synthesized
as described in WO2015/86506 A1) ##STR00217## 17.2 2.15 (a) 487 A
(R)-1-(4-(5- Bromopyrimidin-2-yl)- 3-methylpiperazin-1-yl)-2-
hydroxyethanone (Preparation #22) ##STR00218## 17.3* 1.94 (a) 571 A
2-(5-Bromopyrimidin-2-yl)- 2-methylpropan-1-ol (Preparation #52)
##STR00219## 17.4 2.09 (a) 487 A
[0943] The compounds shown in Table 18 were synthesized in a manner
similar to Example #17, step 3 from
(R)-6-(2-(4-acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-1H-pyr-
azolo[3,4-b]pyridin-3(2H)-one (synthesized in a similar manner to
Example #8 using
6-chloro-2-methyl-1H-pyrazolo[3,4-b]pyridin-3(2H)-one (Example #15,
step 2) and
(R)-1-(4-(5-bromopyrimidin-2-yl)-2-methylpiperazin-1-yl)ethanone
(Preparation #16)) and the corresponding halides.
TABLE-US-00024 TABLE 18 R.sub.t min Example (Table A, m/z ESI+ TNF
Halide Product # Method) (M + H).sup.+ IC.sub.50
(2-(Bromomethyl)-4- methylphenyl)(difluoromethyl) sulfane
(synthesized in a manner similar to Preparation #14, step 6, from
(2- ((difluoromethyl)thio)-5- methylphenyl)methanol (Preparation
#18) ##STR00220## 18.1* 2.13 (e) 554 A 2-(Bromomethyl)-1-
(difluoromethoxy)-4- methylbenzene (synthesized in a similar
fashion to Preparation #3, step 2 from (2-(difluoro-
methoxy)-5-methylphenyl) methanol (Preparation #11)) ##STR00221##
18.2* 2.01 (a) 538 A 2-(Bromomethyl)-1-chloro-4- methylbenzene
(synthesized in a similar fashion to Preparation #3, step 2 from
(2-chloro-5- methylphenyl)methanol (prepared in a similar fashion
to Preparation #14, step 2 from methyl 2-chloro-5- methylbenzoate))
##STR00222## 18.3* 2.15 (a) 506 A
[0944] The compounds shown in Table 19 were synthesized in a manner
similar to Example #8 from
6-bromo-2-methyl-1-((6-methyl-3-(trifluoromethyl)pyridin-2-yl)methyl)-1H--
indazol-3(2H)-one (synthesized in a similar fashion to Preparation
#4, step 1 from 6-bromo-2-methyl-1H-indazol-3(2H)-one (Preparation
#1) and 2-(bromomethyl)-6-methyl-3-(trifluoromethyl)pyridine
(synthesized in a similar fashion to Preparation #14, step 6 from
(6-methyl-3-(trifluoromethyl)pyridin-2-yl)methanol (Preparation
#17)) and the corresponding halide.
TABLE-US-00025 TABLE 19 R.sub.t min (Table A, m/z ESI+ TNF Halide
Product Example # Method) (M + H).sup.+ IC.sub.50 (R)-1-(4-(5-
bromopyrimidin- 2-yl)-2- methylpiperazin-1- yl)ethanone
(Preparation #16) ##STR00223## 19.1* 1.96 (e) 540 A (S)-7-(5-
bromopyrimidin-2- yl)hexahydroimidazo [1,5-a]pyrazin-3(2H)- one
(Preparation #13) ##STR00224## 19.2 1.81 (e) 539 A (R)-1-(4-(5-
Bromopyrimidin- 2-yl)-2- methylpiperazin-1- yl)-2-hydroxyethanone
(Preparation #15) ##STR00225## 19.3* 1.79 (a) 556 A (R)-7-(5-
bromopyrimidin-2- yl)tetrahydro-1H- oxazolo[3,4-a]
pyrazin-3(5H)-one (synthesized in a similar fashion to Preparation
#13, step 1 using (R)- hexahydro- oxazolo[3,4- A]pyrazine- 3-one
HCl ##STR00226## 19.4* 1.91 (a) 540 A (R)-1-(4-(5- bromopyrimidin-
2-yl)-3- methylpiperazin- 1-yl)-2- hydroxyethanone (Preparation
#22) ##STR00227## 19.5* 1.79 (a) 556 A
Example #19
1-(2-(Difluoromethoxy)benzyl)-6-(2-((2R,4S)-4-hydroxy-2-methylpiperidin-1--
yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one
##STR00228##
[0945] Step 1:
(2R,4S)-1-(5-Bromopyrimidin-2-yl)-2-methylpiperidin-4-yl
4-nitrobenzoate
[0946] To a solution of
(2R,4R)-1-(5-bromopyrimidin-2-yl)-2-methylpiperidin-4-ol (265 mg,
0.974 mmol) (prepared in a similar fashion to Preparation 13, step
1), Ph.sub.3P (255 mg, 0.970 mmol) and 4-nitrobenzoic acid (163 mg,
0.97 mmol) was added di-tert-butyl azodicarboxylate (224 mg, 0.970
mmol) in THF (1 mL) dropwise. The mixture was stirred for about 3 h
and then Ph.sub.3P (255 mg, 0.970 mmol) and di-tert-butyl
azodicarboxylate (224 mg, 0.970 mmol) in THF (1 mL) were added. The
mixture was stirred for about 72 h at rt. The mixture was dried
onto silica gel (3 g) and purified on silica gel using a gradient
of 0-30% EtOAc in heptane. Product fractions were combined and
concentrated to yield the title product (90 mg, 22%); LC/MS (Table
A, Method j) R.sub.t=2.17 min; MS m/z: 421/423 (M+H).sup.+.
Step 2:
1-(2-(Difluoromethoxy)benzyl)-6-(2-((2R,4S)-4-hydroxy-2-methylpipe-
ridin-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one
[0947] A mixture of
(2R,4S)-1-(5-bromopyrimidin-2-yl)-2-methylpiperidin-4-yl
4-nitrobenzoate (87 mg, 0.21 mmol),
1-(2-(difluoromethoxy)benzyl)-2-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxa-
borolan-2-yl)-1H-indazol-3(2H)-one (89 mg, 0.21 mmol) (Preparation
4, step 2), and cesium carbonate (236 mg, 0.723 mmol) under
nitrogen was diluted with 1,4-dioxane (2 mL) and water (0.5 mL).
The mixture was degassed with a stream of nitrogen for about 5 min.
PdCl.sub.2(PPh.sub.3).sub.2(11 mg, 0.016 mmol) was added and the
reaction was further degassed for an additional 5 min. The reaction
was heated to about 80.degree. C. for about 1 h. The mixture was
cooled to rt and the layers were separated. The organic layer was
dried over Na.sub.2SO.sub.4, filtered, and concentrated onto silica
gel (2 g). The residue was purified on silica gel using a gradient
of 0-70% EtOAc/DCM. The appropriate fractions were combined and
concentrated. The residue was dissolved in dioxane (2 mL) and a
solution of lithium hydroxide (25 mg, 1.0 mmol) and water (0.5 mL)
was added. After about 1 h, AcOH (0.5 mL) was added and the
reaction was concentrated. The residue was dissolved in EtOAc (5
mL) and washed with sat. aq. NaHCO.sub.3 (3 mL). The organic layer
was dried over Na.sub.2SO.sub.4, filtered and concentrated to yield
the title product (65 mg, 63%); LC/MS (Table A, Method a)
R.sub.t=1.98 min; MS m/z: 496 (M+H).sup.+. (TNF IC.sub.50=A).
Example #20
4-(5-(1-(2-(Difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-1H-indazol--
6-yl)pyrimidin-2-yl)-4-hydroxypiperidine-1-carbaldehyde
##STR00229##
[0948] Step 1: tert-Butyl
4-(5-bromopyrimidin-2-yl)-4-hydroxypiperidine-1-carboxylate
[0949] Toluene (80 mL) was added to 5-bromo-2-iodopyrimidine (4.00
g, 14.0 mmol). The solution was cooled to about -78.degree. C.
n-Butyllithium (2.5 M in hexane, 5.90 mL, 14.7 mmol) was added
dropwise via syringe to the suspension. The reaction was mixed at
about -78.degree. C. for about 30 min. A solution of tert-butyl
4-oxopiperidine-1-carboxylate (3.08 g, 15.5 mmol) in toluene (20
mL) was added dropwise via syringe. The reaction was stirred for
about 30 min at about -78.degree. C. The dry ice/acetone bath was
removed. The reaction was quenched with water (100 mL), extracted
with EtOAc (150 mL). The aqueous layer was extracted with EtOAc
(2.times.25 mL). The organic layer was dried over MgSO.sub.4,
filtered, concentrated. The residue was purified on silica gel
(0-50% EtOAc/DCM) to afford the title product (1.86 g, 37%); LC/MS
(Table A, Method e) R.sub.t=2.16 min; MS m/z: 258 and 260
(M+H).sup.+.
Step 2: tert-Butyl
4-(5-(1-(2-(difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-1H-indazol-
-6-yl)pyrimidin-2-yl)-4-hydroxypiperidine-1-carboxylate
[0950] The reaction was performed using tert-butyl
4-(5-bromopyrimidin-2-yl)-4-hydroxypiperidine-1-carboxylate and
1-(2-(difluoromethoxy)benzyl)-2-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxa-
borolan-2-yl)-1H-indazol-3(2H)-one (Preparation #4, step 2) in a
similar fashion to Example #15, step 4 to give the title compound
(1.30 g, 97%); LC/MS (Table A, Method e) R.sub.t=2.27 min; MS m/z:
582 (M+H).sup.+
Step 3:
1-(2-(Difluoromethoxy)benzyl)-6-(2-(4-hydroxypiperidin-4-yl)pyrimi-
din-5-yl)-2-methyl-1H-indazol-3(2H)-one, hydrochloric acid
[0951] The reaction was performed using tert-butyl
4-(5-(1-(2-(difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-1H-indazol-
-6-yl)pyrimidin-2-yl)-4-hydroxypiperidine-1-carboxylate in a
similar fashion to Example #3 step 1 to give the title compound
(1.20 g, 100%); LC/MS (Table A, Method i) R.sub.t=0.77 min; MS m/z:
482 (M+H).sup.+.
Step 4:
4-(5-(1-(2-(Difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-1H--
indazol-6-yl)pyrimidin-2-yl)-4-hydroxypiperidine-1-carbaldehyde
[0952] Ethyl formate (2.60 mL, 32.4 mmol) and TEA (0.045 mL, 0.32
mmol) were added to
1-(2-(difluoromethoxy)benzyl)-6-(2-(4-hydroxypiperidin-4-yl)pyrimidin-5-y-
l)-2-methyl-1H-indazol-3(2H)-one, hydrochloric acid (84.0 mg, 0.162
mmol) to give a white suspension. The reaction was warmed to about
58.degree. C. THF (1 mL) was added. After about 24 h, the reaction
was quenched with water (10 mL) and extracted with EtOAc (30 mL).
The organic layer was dried over MgSO.sub.4, filtered, and
concentrated. The residue was purified on silica gel (0-8%
MeOH/DCM) to afford the title product (33 mg, 39%); LC/MS (Table A,
Method a) R.sub.t=1.61 min; MS m/z: 510 (M+H).sup.+. (TNF
IC.sub.50=B).
Example #21*
(S)-4-(Difluoromethoxy)-3-((2-methyl-3-oxo-6-(2-((S)-3-oxotetrahydro-1H-ox-
azolo[3,4-a]pyrazin-7(3H)-yl)pyrimidin-5-yl)-2,3-dihydro-1H-indazol-1-yl)m-
ethyl)benzyl 2-aminopropanoate
##STR00230##
[0953] Step 1:
(S)-4-(Difluoromethoxy)-3-((2-methyl-3-oxo-6-(2-((S)-3-oxotetrahydro-1H-o-
xazolo[3,4-a]pyrazin-7(3H)-yl)pyrimidin-5-yl)-2,3-dihydro-1H-indazol-1-yl)-
methyl)benzyl 2-((tert-butoxycarbonyl)amino)propanoate
[0954] A flask was charged with N-(tert-butoxycarbonyl)-L-alanine
(70.0 mg, 0.400 mmol), DMAP (11 mg, 0.090 mmol),
N,N'-dicyclohexylcarbodiimide (96 mg, 0.50 mmol),
(S)-7-(5-(1-(2-(difluoromethoxy)-5-(hydroxymethyl)benzyl)-2-methyl-3-oxo--
2,3-dihydro-1H-indazol-6-yl)pyrimidin-2-yl)tetrahydro-1H-oxazolo[3,4-a]pyr-
azin-3(5H)-one (170 mg, 0.31 mmol) (Example #16.3), and
CH.sub.2Cl.sub.2 (2 mL) at room temperature. After stirring for 15
h, the solution was diluted with CH.sub.2Cl.sub.2 (5 mL), and
filtered off solid. The filtrate was concentrated under reduced
pressure. The residue was purified on silica gel (0-10%
MeOH/CH.sub.2Cl.sub.2) to afford the title product (113 mg, 51%);
LC/MS (Table A, Method i) R.sub.t=1.49 min; MS m/z: 723.72 and
724.62 (M+H).sup.+
Step 2:
(S)-4-(Difluoromethoxy)-3-((2-methyl-3-oxo-6-(2-((S)-3-oxotetrahyd-
ro-1H-oxazolo[3,4-a]pyrazin-7(3H)-yl)pyrimidin-5-yl)-2,3-dihydro-1H-indazo-
l-1-yl)methyl)benzyl 2-aminopropanoate
[0955]
(S)-4-(Difluoromethoxy)-3-((2-methyl-3-oxo-6-(2-((S)-3-oxotetrahydr-
o-1H-oxazolo[3,4-a]pyrazin-7(3H)-yl)pyrimidin-5-yl)-2,3-dihydro-1H-indazol-
-1-yl)methyl)benzyl 2-aminopropanoate was synthesized in a manner
similar to Example #3 (step 1) from
(S)-4-(difluoromethoxy)-3-((2-methyl-3-oxo-6-(2-((S)-3-oxotetrahydro-1H-o-
xazolo[3,4-a]pyrazin-7(3H)-yl)pyrimidin-5-yl)-2,3-dihydro-1H-indazol-1-yl)-
methyl)benzyl 2-((tert-butoxycarbonyl)amino)propanoate. LC/MS
(Table A, Method a) R.sub.t=1.46 min; MS m/z: 623.61 and 624.50
(M+H).sup.+. (TNF IC.sub.50=A).
Example #22
1-(2-(Difluoromethoxy)-5-methylbenzyl)-6-(2-(4-hydroxypiperidin-1-yl)pyrim-
idin-5-yl)-2-methyl-1H-indazol-3(2H)-one
##STR00231##
[0956] Step 1:
6-Bromo-1-(2-(difluoromethoxy)-5-methylbenzyl)-2-methyl-1H-indazol-3(2H)--
one
[0957] The reaction was performed using
6-bromo-2-methyl-1H-indazol-3(2H)-one (Preparation #1) and
2-(bromomethyl)-1-(difluoromethoxy)-4-methylbenzene (synthesized in
a similar fashion to Preparation #3, step 2 from
(2-(difluoromethoxy)-5-methylphenyl)methanol (Preparation #11)) in
a similar fashion to Preparation #4, step 1 to give the title
product (62%); (Table A, Method e) R.sub.t=2.28 min; MS m/z: 397
and 399 (M+H).sup.+.
Step 2:
1-(2-(Difluoromethoxy)-5-methylbenzyl)-2-methyl-6-(4,4,5,5-tetrame-
thyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3(2H)-one
[0958] The reaction was performed using
6-bromo-1-(2-(difluoromethoxy)-5-methylbenzyl)-2-methyl-1H-indazol-3(2H)--
one in a similar fashion to Preparation #4, step 2 to give the
title product (90%); (Table A, Method e) R.sub.t=2.48 min; MS m/z:
445 (M+H).sup.+.
Step 3:
6-(2-Chloropyrimidin-5-yl)-1-(2-(difluoromethoxy)-5-methylbenzyl)--
2-methyl-1H-indazol-3(2H)-one
[0959] Dimethyl acetamide (8.00 mL) and water (2.00 mL) were add to
a mixture of PdCl.sub.2(dppf) complex with DCM (0.0876 g, 0.107
mmol),
1-(2-(difluoromethoxy)-5-methylbenzyl)-2-methyl-6-(4,4,5,5-tetramethyl-1,-
3,2-dioxaborolan-2-yl)-1H-indazol-3(2H)-one (0.471 g, 1.06 mmol),
5-bromo-2-chloropyrimidine (0.369 g, 1.91 mmol), and
Na.sub.2CO.sub.3 (0.295 g, 2.78 mmol). The reaction vessel was
evacuated then back-filled with N.sub.2 three times then purged
with N.sub.2 for about 10 min. The mixture was warmed to about
70.degree. C. After about 45 min, the mixture was allowed to cool
to rt. DCM (20 mL) and water (20 mL) were added. The layers were
separated and the aqueous layer was extracted with DCM (2.times.10
mL). The combined organic layers were dried over Na.sub.2SO.sub.4,
filtered and concentrated. The residue was purified by flash
chromatography on silica gel (0-50% EtOAc/DCM). The appropriate
fractions were collected and concentrated under reduced pressure to
afford the title product (0.293 g, 64%); (Table A, Method e)
R.sub.t=2.14 min; MS m/z: 431 (M+H).sup.+.
Step 4:
1-(2-(Difluoromethoxy)-5-methylbenzyl)-6-(2-(4-hydroxypiperidin-1--
yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one
[0960] The reaction was performed using
6-(2-chloropyrimidin-5-yl)-1-(2-(difluoromethoxy)-5-methylbenzyl)-2-methy-
l-1H-indazol-3(2H)-one and 4-hydroxypiperidine in a similar fashion
to Example #2 to give the title product (83%); (Table A, Method a)
R.sub.t=1.88 min; MS m/z: 496 (M+H).sup.+. (TNF IC.sub.50=A).
[0961] The compounds shown in Table 20 were synthesized in a manner
similar to Example #2 from
6-(2-chloropyrimidin-5-yl)-1-(2-(difluoromethoxy)-5-methylbenzyl)-2-methy-
l-1H-indazol-3(2H)-one (Example #22, step 3) and the corresponding
amines.
TABLE-US-00026 TABLE 20 R.sub.t min (Table A, m/z ESI+ TNF Amine
Product Example # Method) (M + H).sup.+ IC.sub.50
Pyrrolidine-3-carboxamide ##STR00232## 20.1 1.67 (a) 509 B
(S)-Tetrahydro- 1H-oxazolo[3,4- a]pyrazin-3(5H)-one, hydrochloric
acid ##STR00233## 20.2* 1.97 (a) 537 A rac-(3aR,6aS)-
Hexahydropyrrolo [3,4-c]pyrrol- 1(2H)-one hydrochloride
##STR00234## 20.3 1.69 (a) 521 B (R)-1-(3-Methylpiperazin-1-
yl)ethanone hydrochloride (Prepared in a similar fashion to Example
#3, step 1 from (R)-tert-butyl 4-acetyl-2- methylpiperazine-1-
carboxylate (Prepared in similar fashion to Preparation #16, from
(R)-tert-butyl 2- methylpiperazine-1- carboxylate)) ##STR00235##
20.4* 1.99 (a) 537 A (R)-1-(3-Ethylpiperazin-1- yl)ethanone
hydrochloride (Prepared in a similar fashion to Example #3, step 1
from (R)-tert-butyl 4-acetyl-2- ethylpiperazine-1-carboxylate
(Prepared in similar fashion to Preparation #16, from (R)-
tert-butyl 2- ethylpiperazine-1- carboxylate)) ##STR00236## 20.5*
2.09 (a) 552 A
Example #23*
(R)-Methyl
4-(5-(1-(2-(difluoromethoxy)-5-methylbenzyl)-2-methyl-3-oxo-2,3-
-dihydro-1H-indazol-6-yl)pyrimidin-2-yl)pyrimidin-2-yl)-2-methylpiperazine-
-1-carboxylate
##STR00237##
[0963]
(R)-1-(2-(Difluoromethoxy)-5-methylbenzyl)-2-methyl-6-(2-(3-methylp-
iperazin-1-yl)pyrimidin-5-yl)-1H-indazol-3(2H)-one, hydrochloric
acid (96.0 mg, 0.181 mmol) (Example #14.5) and TEA (0.100 mL, 0.723
mmol) in THF (3.00 mL) were added to give a yellow solution. The
reaction was cooled to about 0.degree. C. A solution of methyl
carbonochloridate (18.8 mg, 0.199 mmol) in THF (1.00 mL) was added
dropwise via syringe. After about 1 h, the reaction mixture was
filtered rinsing with EtOAc (30 mL). The filtrate was washed with
sat. aq. NaCl (10 mL). The organic layer was dried over MgSO.sub.4,
filtered, and concentrated. The residue was purified on silica gel
(0-100% EtOAc/DCM then 10% MeOH/DCM) to afford the title product
(58 mg, 55%); LC/MS (Table A, Method a) R.sub.t=2.28 min; MS m/z:
553 (M+H).sup.+. (TNF IC.sub.50=A).
[0964] The compounds shown in Table 21 were synthesized in a manner
similar to Preparation #15 from
(R)-1-(2-(difluoromethoxy)-5-methylbenzyl)-2-methyl-6-(2-(3-methylpiperaz-
in-1-yl)pyrimidin-5-yl)-1H-indazol-3(2H)-one (Example #14.5) and
the corresponding carboxylic acid.
TABLE-US-00027 TABLE 21 R.sub.t min (Table A, m/z ESI+ TNF
Carboxylic Acid Product Example # Method) (M + H).sup.+ IC.sub.50
2-Methoxyacetic acid ##STR00238## 21.1* 1.96 (a) 567 A Oxetane-3-
carboxylic acid ##STR00239## 21.2* 1.93 (a) 579 A Oxetane-2-
carboxylic acid ##STR00240## 21.3* 1.94 (a) 579 A 2-Cyanoacetic
acid ##STR00241## 21.4* 2.02 (a) 562 A
Example #24*
(R)-1-(2-(Difluoromethoxy)-5-methylbenzyl)-2-methyl-6-(2-(3-methyl-4-(meth-
ylsulfonyl)piperazin-1-yl)pyrimidin-5-yl)-1H-indazol-3(2H)-one
##STR00242##
[0966] MsCl (0.012 mL, 0.16 mmol) and TEA (0.092 mL, 0.66 mmol) in
DCM (1.00 mL) were added to
(R)-1-(2-(difluoromethoxy)-5-methylbenzyl)-2-methyl-6-(2-(3-methylpiperaz-
in-1-yl)pyrimidin-5-yl)-1H-indazol-3(2H)-one (65.0 mg, 0.131 mmol)
(Example #14.5). After about 1 h, MsCl (0.040 mL, 0.52 mmol) and
TEA (180 mL, 1.3 mmol) were added. After about 1 h, the reaction
was quenched with water (5 mL) and extracted with DCM (10 mL). The
organic layer was washed with NaHCO.sub.3 (5 mL), dried over MgSO4,
filtered, and concentrated. The residue was purified on silica gel
(0-87% EtOAc/DCM) to afford the title product (50 mg, 64%); LC/MS
(Table A, Method a) R.sub.t=2.15 min; MS m/z: 573 (M+H).sup.+. (TNF
IC.sub.50=A).
[0967] The compounds shown in Table 22 were synthesized in a manner
similar to Example #14, step 4 from
1-(2-(difluoromethoxy)-5-methylbenzyl)-2-methyl-6-(4,4,5,5-tetramethyl-1,-
3,2-dioxaborolan-2-yl)-1H-indazol-3(2H)-one (Example #22, step 2)
and the corresponding halide.
TABLE-US-00028 TABLE 22 R.sub.t min (Table A, m/z ESI+ TNF Halide
Product Example # Method) (M + H).sup.+ IC.sub.50
1-(4-(5-Bromopyrimidin-2- yl)piperazin-1-yl)-2- hydroxyethanone
(Preparation #34) ##STR00243## 22.1 1.80 (a) 539 A
(S)-1-(4-(5-Bromopyrimidin- 2-yl)-3-methylpiperazin-1- yl)ethanone
(Preparation #36) ##STR00244## 22.2* 1.99 (a) 537 A
(R)-1-(4-(5-Bromopyrimidin- 2-yl)-2-methylpiperazin-1-yl)-
2-hydroxyethanone (Preparation #15) ##STR00245## 22.3* 1.90 (a) 553
A (R)-1-(4-(5-Bromopyrimidin- 2-yl)-3-methylpiperazin-1-yl)-
2-hydroxyethanone (Preparation #22) ##STR00246## 22.4* 1.89 (a) 553
A 2-(5-Bromo-4- methylpyrimidin-2-yl)propan- 2-ol (synthesized as
described in WO2015/ 86506 A1) ##STR00247## 22.5 2.09 (a) 469 A
1-(4-(5-Bromopyrimidin-2- yl)piperazin-1-yl)ethanone (prepared in a
similar fashion to Preparation #13, step 1 using 1-(piperazin-1-
yl)ethanone) ##STR00248## 22.6 1.93 (a) 523 A
(S)-(1-(5-Bromopyrimidin-2- yl)pyrrolidin-2-yl)methanol
(synthesized in a similar fashion to Preparation #13, step 1 using
(S)-pyrrolidin- 2-ylmethanol) ##STR00249## 22.7* 2.06 (a) 496 B
(R)-(1-(5-Bromopyrimidin- 2-yl)pyrrolidin-2- yl)methanol
(synthesized in a similar fashion to Preparation #13, step 1 using
(R)-pyrrolidin-2- ylmethanol) ##STR00250## 22.8* 2.03 (a) 496 B
2-(5-bromopyrimidin- 2-yl)-2-methylpropan-1-ol (Preparation #52,
step 2) ##STR00251## 22.9 2.00 (a) 469 B (S)-1-(4-(5-
Bromopyrimidin-2- yl)-2-(hydroxymethyl) piperazin-1-yl)ethanone
(synthesized in a manner similar to Example #3, step 2 from
(S)-(4-(5- bromopyrimidin-2- yl)piperazin-2- yl)methanol,
Hydrochloric Acid (synthesized in a manner similar to Example #3,
step 1 from (S)-tert- butyl 4-(5-bromopyrimidin-
2-yl)-2-(hydroxymethyl) ##STR00252## 22.10* 1.74 (a) 553 A
piperazine-1-carboxylate (synthesized in a manner similar to
Preparation #13, step 1 from (S)-tert-butyl 2-(hydroxymethyl)
piperazine-1-carboxylate))) (R)-1-(4-(5- Bromopyrimidin-2-
yl)-2-(hydroxymethyl) piperazin-1-yl)ethanone (synthesized in a
similar manner to Example #3, step 2 from (R)-(4-(5-
bromopyrimidin-2- yl)piperazin-2-yl)methanol hydrochloride
(synthesized in a similar manner to Example #3, step 1 from
(R)-tert-butyl 4-(5- bromopyrimidin-2-yl)-2-
(hydroxymethyl)piperazine- ##STR00253## 22.11* 1.78 (a) 553 A
1-carboxylate (synthesized in a similar manner to Preparation #13,
step 1 from (R)-tert-butyl 2- (hydroxymethyl)piperazine-
1-carboxylate (R)-7-(5-Bromopyrimidin- 2-yl)tetrahydro-1H-
oxazolo[3,4-a]pyrazin- 3(5H)-one (prepared in a similar fashion to
Example #2 using (R)- hexahydro-oxazolo[3,4-a] pyrazine-3-one HCl
and 5-bromo-2- chloropyrimidine) ##STR00254## 22.12* 2.00 (a) 537 A
4-Bromo-2-((tetrahydro- 2H-pyran-4-yl)oxy) pyridine (prepared in a
similar fashion to Preparation #27 using tetrahydro-2H-pyran-4-ol)
##STR00255## 22.13 2.33 (a) 496 A (R)-1-(4-(5-Bromo-4-
methylpyrimidin-2-yl)- 3-methylpiperazin-1- yl)ethanone
(synthesized in a manner similar to Example #3, step 2 from
(R)-5-bromo-4-methyl- 2-(2-methylpiperazin- 1-yl)pyrimidine
dihydrochloride (synthesized in a manner similar to Example #3,
step 1 from (R)-tert-butyl 4-(5-bromo-4- methylpyrimidin-2-yl)-3-
##STR00256## 22.14* 2.08 (h) 551 A methylpiperazine-1- carboxylate
(synthesized in a manner similar to Preparation #13 from 5-
bromo-2-chloro-4- methylpyrimidine and (R)-tert-butyl 3-
methylpiperazine-1- carboxylate))) (S)-1-(4-(5- Bromopyrimidin-2-
yl)-3-methylpiperazin- 1-yl)-2-hydroxyethanone (Preparation #54)
##STR00257## 22.15* 1.87 (a) 553 A
Example #25
(S)-1-(2-(Difluoromethoxy)-5-(hydroxymethyl)benzyl)-2-methyl-6-(2-((2-oxop-
iperidin-4-yl)amino)pyrimidin-5-yl)-1H-indazol-3(2H)-one
##STR00258##
[0969]
1-(2-(Difluoromethoxy)-5-(hydroxymethyl)benzyl)-2-methyl-6-(2-((2-o-
xopiperidin-4-yl)amino)pyrimidin-5-yl)-1H-indazol-3(2H)-one (0.238
g, 0.454 mmol) (Example #16.5) was submitted for chiral separation
(Table B, Method d). Fractions from the first eluting component
were concentrated under reduced pressure to afford the title
product (0.060 g, 25%) with undetermined optical rotation. LC/MS
(Table A, Method e) R.sub.t=1.42 min; MS m/z: 525 (M+H).sup.+. (TNF
IC.sub.50=A).
Example #26
(R)-1-(2-(Difluoromethoxy)-5-(hydroxymethyl)benzyl)-2-methyl-6-(2-((2-oxop-
iperidin-4-yl)amino)pyrimidin-5-yl)-1H-indazol-3(2H)-one
##STR00259##
[0971]
1-(2-(Difluoromethoxy)-5-(hydroxymethyl)benzyl)-2-methyl-6-(2-((2-o-
xopiperidin-4-yl)amino)pyrimidin-5-yl)-1H-indazol-3(2H)-one (0.238
g, 0.454 mmol) (Example #16.5) was submitted for chiral separation
(Table B, Method d). Fractions from the second eluting component
were concentrated under reduced pressure to afford the title
product (0.053 g, 22%) with undetermined optical rotation. LC/MS
(Table A, Method e) R.sub.t=1.42 min; MS m/z: 525 (M+H).sup.+. (TNF
IC.sub.50=A).
Example #27
(S)-1-(2-(Difluoromethoxy)-5-(hydroxymethyl)benzyl)-2-methyl-6-(2-((1-meth-
yl-2-oxopiperidin-4-yl)amino)pyrimidin-5-yl)-1H-indazol-3(2H)-one
##STR00260##
[0973]
1-(2-(Difluoromethoxy)-5-(hydroxymethyl)benzyl)-2-methyl-6-(2-((1-m-
ethyl-2-oxopiperidin-4-yl)amino)pyrimidin-5-yl)-1H-indazol-3(2H)-one
(0.159 g, 0.295 mmol) (Example #16.9) was submitted for chiral
separation (Table B, Method e). Fractions from the first eluting
component were concentrated under reduced pressure to afford the
title product (0.051 g, 32%) with undetermined optical rotation.
LC/MS (Table A, Method e) R.sub.t=1.50 min; MS m/z: 539
(M+H).sup.+. (TNF IC.sub.50=B).
Example #28
(R)-1-(2-(Difluoromethoxy)-5-(hydroxymethyl)benzyl)-2-methyl-6-(2-((1-meth-
yl-2-oxopiperidin-4-yl)amino)pyrimidin-5-yl)-1H-indazol-3(2H)-one
##STR00261##
[0975]
1-(2-(Difluoromethoxy)-5-(hydroxymethyl)benzyl)-2-methyl-6-(2-((1-m-
ethyl-2-oxopiperidin-4-yl)amino)pyrimidin-5-yl)-1H-indazol-3(2H)-one
(0.159 g, 0.295 mmol) (Example #16.9) was submitted for chiral
separation (Table B, Method e). Fractions from the second eluting
component were concentrated under reduced pressure to afford the
title product (0.052 g, 32%) with undetermined optical rotation.
LC/MS (Table A, Method e) R.sub.t=1.50 min; MS m/z: 539
(M+H).sup.+. (TNF IC.sub.50=A).
Example #29
4-(5-(1-(2-(Difluoromethoxy)-5-(hydroxymethyl)benzyl)-2-methyl-3-oxo-2,3-d-
ihydro-1H-indazol-6-yl)pyrimidin-2-yl)piperazine-1-carbaldehyde
##STR00262##
[0976] Step 1: tert-Butyl
4-(5-(1-(2-(difluoromethoxy)methyl)benzyl)-2-methyl-3-oxo-2,3-dihydro-1H--
indazol-6-yl)pyrimidin-2-yl)piperazine-1-carboxylate
[0977] A solution of
6-(2-chloropyrimidin-5-yl)-1-(2-(difluoromethoxy)-5-((trityloxy)methyl)be-
nzyl)-2-methyl-1H-indazol-3(2H)-one (100 mg, 0.133 mmol)
(Preparation #24), 1-Boc-piperazine (50 mg, 0.27 mmol) and TEA (56
.mu.L, 0.40 mmol) in ethanol (1 mL) was sealed and heated at about
80.degree. C. for about 2 h. The reaction was cooled to rt and
concentrated. DCM (5 mL) and water (5 mL) were added. The organic
layer was dried over Na.sub.2SO.sub.4, filtered and concentrated to
yield the title product; LC/MS (Table A, Method e) R.sub.t=3.00
min; MS m/z: 839 (M+H).sup.+.
Step 2:
4-(5-(1-(2-(Difluoromethoxy)-5-(hydroxyethyl)benzyl)methyl-3-oxo-2-
,3-dihydro-1H-indazol-6-yl)pyrimidin-2-yl)piperazine-1-carbaldehyde
[0978] To a mixture of tert-butyl
4-(5-(1-(2-(difluoromethoxy)-5-((trityloxy)methyl)benzyl)-2-methyl-3-oxo--
2,3-dihydro-1H-indazol-6-yl)pyrimidin-2-yl)piperazine-1-carboxylate
(112 mg, 0.134 mmol) and triisopropylsilane (43 mg, 0.27 mmol) in
DCM (1 mL) was added TFA (1 mL) at rt. The mixture was stirred for
about 10 min at rt and then concentrated under reduced pressure.
The residue was triturated with ether (2.times.10 mL), decanting
the ether layers. The residue was dissolved in ethyl formate (3 mL)
and heated at reflux with TEA (0.065 mL, 0.47 mmol) for about 16 h.
The reaction was cooled and concentrated under reduced pressure.
The residue was purified on silica gel using a gradient of 0-10%
MeOH in DCM. Product fractions were combined and concentrated. The
residue was dissolved in MeCN (5 mL) and water (5 mL) and
concentrated to water. Product was collected by filtration and
dried overnight in the vacuum oven to yield the title compound (30
mg, 41%); LC/MS (Table A, Method e) R.sub.t=1.60 min; MS m/z: 525
(M+H).sup.+. (TNF IC.sub.50=A).
Example #30*
1-(2-(Difluoromethoxy)benzyl)-5,7-difluoro-6-(2-(4-(2-hydroxyacetyl)pipera-
zin-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one
##STR00263##
[0980] To a solution of
(R)-6-(2-(4-(2-(tert-butoxy)acetyl)-2-methylpiperazin-1-yl)pyrimidin-5-yl-
)-1-(2-(difluoromethoxy)benzyl)-5,7-difluoro-2-methyl-1H-indazol-3(2H)-one
(Preparation #26) (44 mg, 0.070 mmol) in DCM (3 mL) was added TFA
(3 mL) and the mixture was stirred at rt for about 45 min. The
reaction was concentrated under reduced pressure. The residue was
dissolved with DCM (5 mL) and washed with aq. sat. NaHCO.sub.3 (5
mL). The organic layer was dried over Na.sub.2SO.sub.4, filtered
and concentrated to yield the title product (37 mg, 92%); LC/MS
(Table A, Method a) R.sub.t=1.92 min; MS m/z: 575 (M+H).sup.+. (TNF
IC.sub.50=A).
Example #31*
(R)-2-(4-(5-(1-(2-(Difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-1H-i-
ndazol-6-yl)pyrimidin-2-yl)-2-methylpiperazin-1-yl)-2-oxoethyl
phosphate
##STR00264##
[0981] Step 1: (R)-Di-tert-butyl
(2-(4-(5-(1-(2-(difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-1H-ind-
azol-6-yl)pyrimidin-2-yl)-2-methylpiperazin-1-yl)-2-oxoethyl)
phosphate
[0982]
(R)-1-(2-(Difluoromethoxy)benzyl)-6-(2-(4-(2-hydroxyacetyl)-3-methy-
lpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one (130
mg, 0.24 mmol) (Example #10.6), imidazole (25 mg, 0.36 mmol), and
imidazole hydrochloride (57 mg, 0.54 mmol) were added to anhydrous
DMF (2.4 mL) in a dry reaction vessel. The atmosphere was removed
and replaced with N.sub.2. Di-tert-butyl
N,N-diisopropylphosphoramidite (114 .mu.L, 0.360 mmol) was added
dropwise, and the reaction was stirred for about 16 h at rt.
Additional di-tert-butyl N,N-diisopropylphosphoramidite (38 .mu.L,
0.12 mmol) was added to the reaction mixture. After about 4 h, the
reaction mixture was cooled to about 0.degree. C., then hydrogen
peroxide (30 wt % in water, 222 .mu.L, 2.17 mmol) was added and the
reaction was stirred while warming to rt for about 1 h. The
reaction was quenched with a cold sat. aq. sodium thiosulfate (10
mL), then extracted with EtOAc (2.times.10 mL). The combined
organic layers were washed with water (2.times.20 mL) and sat. aq.
NaCl (20 mL), dried over MgSO.sub.4, filtered, and concentrated in
vacuo. Purification via silica gel chromatography (0-5% MeOH in
DCM) afforded the title compound (93 mg, 53%); LC/MS (Table A,
Method i) R.sub.t=1.57 min; MS m/z: 731 (M+H).sup.+.
Step 2:
(R)-2-(4(5-(1-(2-(Difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihyd-
ro-1H-indazol-6-yl)pyrimidin-2-yl)-2-methylpiperazin-1-yl)-2-oxoethyl
phosphate
[0983] (R)-Di-tert-butyl
(2-(4-(5-(1-(2-(difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-1H-ind-
azol-6-yl)pyrimidin-2-yl)-2-methylpiperazin-1-yl)-2-oxoethyl)
phosphate (160 mg, 0.22 mmol) was dissolved in anhydrous dioxane
(2.3 mL). A solution of HCl in dioxane (4 M, 2.3 mL, 9.20 mmol) was
added, and the reaction was allowed to stir for about 30 min at rt.
The solvent was removed in vacuo, and the resulting residue was
purified by preparative reverse phase HPLC (Table A, Method I). The
relevant fractions were collected and lyophilized to yield the
title compound as the diammonium salt (90 mg, 64%); LC/MS (Table A,
Method e) R.sub.t=1.45 min; MS m/z: 619 (M+H).sup.+.
Example #32
6-(2-(1-Acetyl-4-hydroxypiperidin-4-yl)pyrimidin-5-yl)-1-(2-(difluorometho-
xy)benzyl)-2-methyl-1H-indazol-3(2H)-one
##STR00265##
[0985] A mixture of
1-(2-(difluoromethoxy)benzyl)-6-(2-(4-hydroxypiperidin-4-yl)pyrimidin-5-y-
l)-2-methyl-1H-indazol-3(2H)-one, hydrochloric acid (0.10 g, 0.193
mmol) (Example #20, step 3) and TEA (0.160 mL, 1.16 mmol) in MeCN
(3 mL) and water (0.5 mL) was cooled to 0.degree. C. and a dropwise
solution of acetyl chloride (0.014 mL, 0.19 mmol) in MeCN (3 mL)
was added. The ice bath was removed and stirring was continued at
ambient temperature for about 1 h. Methanol (1 mL) was added to the
mixture and the volatiles were removed under reduced pressure. To
the residue was added DCM (10 mL) and sat. aq. NaHCO.sub.3 (5 mL).
The organic layer was removed and washed with sat. aq. NaHCO.sub.3
(5 mL). The combined organic layers were dried over MgSO.sub.4,
filtered and concentrated under reduced pressure. The material was
purified by flash chromatography on silica gel (0-10% MeOH/DCM) to
afford the title product (0.062 g, 62%); LC/MS (Table A, Method a)
R.sub.t=1.64 min; MS m/z: 524 (M+H).sup.+. (TNF IC.sub.50=B).
Example #33
(R)-7-(5-(1-(2-(Difluoromethoxy)-6-(methoxymethyl)benzyl)-2-methyl-3-oxo-2-
,3-dihydro-1H-indazol-6-yl)pyrimidin-2-yl)hexahydroimidazo[1,5-a]pyrazin-3-
(2H)-one
##STR00266## ##STR00267##
[0986] Step 1: 2-Bromo-6-(difluoromethoxy)benzaldehyde
[0987] A solution of 2-bromo-6-hydroxybenzaldehyde (5.0 g, 25 mmol)
in MeCN (120 mL) and a solution of potassium hydroxide (27.9 g, 497
mmol) in H.sub.2O (124 mL) was cooled to below -25.degree. C.
Diethyl (bromodifluoromethyl)phosphonate (7.1 mL, 40 mmol) was
added dropwise at a rate to maintain the reaction temperature below
about -20.degree. C. After about 15 min at or below about
-20.degree. C., the bath was allowed to warm to rt. After about 1
h, the reaction was extracted with EtOAc (2.times.100 mL). The
combined organic layers were washed with sat. aq. NaCl (100 mL),
dried over Na.sub.2SO.sub.4, filtered and concentrated under
reduced pressure. The residue was purified on silica gel using 10%
EtOAc in heptanes to give the title product (3.70 g, 59%); .sup.1H
NMR (400 MHz, CDCl.sub.3) .delta. 10.34 (s, 1H), 7.57 (dd, J=8.1,
1.0 Hz, 1H), 7.41 (t, J=8.2 Hz, 1H), 7.28-7.22 (m, 1H), 6.60 (t,
J=73.5 Hz, 1H).
Step 2: (2-Bromo-6-(difluoromethoxy)phenyl)methanol
[0988] (2-Bromo-6-(difluoromethoxy)phenyl)methanol was prepared in
a similar fashion to Preparation #9 using
2-bromo-6-(difluoromethoxy)benzaldehyde to give the title product
(3.35 g, 92%); .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.47 (dd,
J=7.9, 1.3 Hz, 1H), 7.20 (t, J=8.1 Hz, 1H), 7.17-7.09 (m, 1H), 6.56
(t, J=73.6 Hz, 1H), 4.88 (s, 2H).
Step 3: 1-Bromo-2-(bromomethyl)-3-(difluoromethoxy)benzene
[0989] 1-Bromo-2-(bromomethyl)-3-(difluoromethoxy)benzene was
prepared in a similar fashion to Preparation #14, step 6 using
(2-bromo-6-(difluoromethoxy)phenyl)methanol to give the title
product (2.89 g, 69%) as a clear oil; .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 7.47 (dd, J=8.0, 1.2 Hz, 1H), 7.20 (t, J=8.1
Hz, 1H), 7.16 0 7.11 (m, 1H), 6.58 (t, J=73.2 Hz, 1H), 4.70 (s,
2H).
Step 4:
1-(2-Bromo-6-(difluoromethoxy)benzyl)-6-chloro-2-methyl-1H-indazol-
-3(2H)-one
[0990]
1-(2-Bromo-6-(difluoromethoxy)benzyl)-6-chloro-2-methyl-1H-indazol--
3(2H)-one was prepared in a similar fashion to Preparation #4, step
1 using 1-bromo-2-(bromomethyl)-3-(difluoromethoxy)benzene and
6-chloro-2-methyl-1H-indazol-3(2H)-one (Preparation #29) to give
the title compound (3.60 g, 55%); LC/MS (Table A, Method e)
R.sub.t=2.36 min; MS m/z: 417 and 419 (M+H).sup.+.
Step 5:
6-Chloro-1-(2-(difluoromethoxy)-6-vinylbenzyl)-2-methyl-1H-indazol-
-3(2H)-one
[0991]
6-Chloro-1-(2-(difluoromethoxy)-6-vinylbenzyl)-2-methyl-1H-indazol--
3(2H)-one was prepared in a similar fashion to Example #14, step 4
using
1-(2-bromo-6-(difluoromethoxy)benzyl)-6-chloro-2-methyl-1H-indazol-3(2H)--
one and 4,4,5,5-tetramethyl-2-vinyl-1,3,2-dioxaborolane to give the
title compound (1.46 g, 84%) as a yellow solid; LC/MS (Table A,
Method e) R.sub.t=2.35 min; MS m/z: 365 (M+H).sup.+.
Step 6:
2-((6-Chloro-2-methyl-3-oxo-2,3-dihydro-1H-indazol-1-yl)methyl)-3--
(difluoromethoxy)benzaldehyde
[0992]
2-((6-Chloro-2-methyl-3-oxo-2,3-dihydro-1H-indazol-1-yl)methyl)-3-(-
difluoromethoxy)benzaldehyde was prepared in a similar fashion to
Example #4, step 1 using
6-chloro-1-(2-(difluoromethoxy)-6-vinylbenzyl)-2-methyl-1H-indazol-3(2H)--
one to give the title compound (1.33 g, 91%); LC/MS (Table A,
Method e) R.sub.t=2.10 min; MS m/z: 367 (M+H).sup.+.
Step 7:
6-Chloro-1-(2-(difluoromethoxy)-6-(hydroxymethyl)benzyl)-2-methyl--
1H-indazol-3(2H)-one
[0993]
6-Chloro-1-(2-(difluoromethoxy)-6-(hydroxymethyl)benzyl)-2-methyl-1-
H-indazol-3(2H)-one was prepared in a similar fashion to
Preparation #9 using
2-((6-chloro-2-methyl-3-oxo-2,3-dihydro-1H-indazol-1-yl)methyl)-3-(-
difluoromethoxy)benzaldehyde to give the title compound (1.14 g,
85%) as a yellow solid; LC/MS (Table A, Method e) R.sub.t=1.91 min;
MS m/z: 369 (M+H).sup.+.
Step 8:
6-Chloro-1-(2-(difluoromethoxy)-6-(methoxymethyl)benzyl)-2-methyl--
1H-Indazol-3(2H)-one
[0994] Sodium hydride (60% in mineral oil, 0.065 g, 1.6 mmol) was
added to a mixture of
6-chloro-1-(2-(difluoromethoxy)-6-(hydroxymethyl)benzyl)-2-methyl-1H-inda-
zol-3(2H)-one (0.300 g, 0.814 mmol) and MeI (0.51 mL, 8.1 mmol) in
THF (6 mL) was at about 0.degree. C. The reaction was stirred at
about 0.degree. C. for about 2 h then was quenched with 20% aq.
NH.sub.4Cl (20 mL) and extracted with EtOAc (20 mL). The organic
layer was washed with sat. aq. NaCl (20 mL), dried over
Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure.
The residue was purified on silica gel using 5-40% EtOAc in
heptanes to give the title compound (0.271 g, 87%); LC/MS (Table A,
Method e) Rt=2.24 min; MS m/z: 383 (M+H).sup.+.
Step 9: (R)-7-(5-(1-(2
(Difluoromethoxy)-6-(methoxymethyl)benzyl)-2-methyl-3-oxo-2,3-dihydro-1H--
indazol-6-yl)pyrimidin-2-yl)hexahydroimidazo[1,5-a]pyrazin-3(2H)-one
[0995] A mixture of bis(pinacolato)diboron (0.119 g, 0.470 mmol),
(R)-7-(5-bromopyrimidin-2-yl)hexahydroimidazo[1,5-a]pyrazin-3(2H)-one
(0.078 g, 0.261 mmol) (Preparation #13), KOAc (0.083 g, 0.84 mmol),
PdCl.sub.2(dppf) (0.015 g, 0.021 mmol), and 1,4-dioxane (2 mL) was
purged with N.sub.2 three times and degassed for about 5 min. The
mixture was placed in a preheated oil bath at about 95.degree. C.
and stirred for about 2 h. The reaction was cooled to ambient
temperature.
6-Chloro-1-(2-(difluoromethoxy)-6-(methoxymethyl)benzyl)-2-methyl-1H-inda-
zol-3(2H)-one (0.100 g, 0.261 mmol), Cs.sub.2CO.sub.3 (0.213 g,
0.653 mmol), H.sub.2O (0.500 mL) and 2.sup.ND generation XPHOS
precatalyst (0.021 g, 0.026 mmol) were added to the above mixture.
The reaction mixture was purged with N.sub.2 for about 10 min and
placed in a preheated oil bath at about 85.degree. C. After about
16 h, the reaction was cooled to ambient temperature. The reaction
was partitioned between DCM (50 mL) and H.sub.2O (30 mL). The
organic layer was washed with sat. aq. NaCl (30 mL), dried over
Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure.
The residue was purified on silica gel using 1-4% MeOH in DCM to
give the title compound (0.066 g, 42%); LC/MS (Table A, Method e)
R.sub.t=1.84 min; MS m/z: 566 (M+H).sup.+. (TNF IC.sub.50=A).
[0996] The compounds shown in Table 23 were synthesized in a manner
similar to Example #33, step 9 from
(R)-1-(4-(5-bromopyrimidin-2-yl)-2-methylpiperazin-1-yl)-2-hydroxyethanon-
e (Preparation #15) and the corresponding halide.
TABLE-US-00029 TABLE 23 R.sub.t min (Table A, m/z ESI+ TNF Halide
Product Example # Method) (M + H).sup.+ IC.sub.50 6-Chloro-1-(2-
chlorobenzyl)- 2-methyl-1H-pyrazolo [3,4-b]pyridin-3(2H)- one
(synthesized in a similar fashion to Example #1, from
1-(bromomethyl)- 2-chlorobenzene and 6-chloro-2-methyl-1H-
pyrazolo[3,4-b] pyridin-3(2H)-one (Example #15, step 2))
##STR00268## 23.1* 1.89 (a) 508 A 6-Chloro-1-(2- (difluoromethoxy)
benzyl)-2-methyl-3- oxo-2,3-dihydro-1H- indazole-5-carbonitrile
(Preparation #53) ##STR00269## 23.2* 1.79 (a) 564 B 6-Chloro-1-(2-
(difluoromethoxy) benzyl)-2-methyl-3- oxo-2,3-dihydro-
1H-indazole-7- carbonitrile (prepared in a similar manner to
Example #1 using 6-chloro-2-methyl-3- oxo-2,3-dihydro-1H-
indazole-7-carbonitrile (Preparation #67) and 1-(bromomethyl)-
2-(difluoromethoxy) benzene) ##STR00270## 23.3* 1.81 (a) 564 A
[0997] The compounds shown in Table 24 were synthesized in a manner
similar to Example #8 from
(R)-1-(4-(5-bromopyrimidin-2-yl)-2-methylpiperazin-1-yl)-2-hydroxyethanon-
e (Preparation #15) and the corresponding halide.
TABLE-US-00030 TABLE 24 R.sub.t min (Table A, m/z ESI+ TNF Halide
Product Example # Method) (M + H).sup.+ IC.sub.50
2-(3-((6-Bromo-2-methyl- 3-oxo-2,3-dihydro-1H-
indazol-1-yl)methyl)-4- (difluoromethoxy)phenyl) acetonitrile
(Preparation #20) ##STR00271## 24.1* 1.74 (a) 578 A
6-bromo-2-methyl-1-(1- (6-methylpyridin-2-yl)
ethyl)-1H-indazol-3(2H)- one (Preparation #51) ##STR00272## 24.2
0.99 (h) 502 B 6-Bromo-2-methyl-1-(1- (m-tolyl)propyl)-1H-
indazol-3(2H)-one (synthesized in a similar fashion to Preparation
#4, step 1 from 6-bromo-2- methyl-1H-indazol- 3(2H)-one
(Preparation #1) and 1-(1-bromopropyl)-3- methylbenzene
(Preparation #21)) ##STR00273## 24.3 1.31 (h) 515 A 6-Bromo-1-(2-
(difluoromethoxy)benzyl)- 2-(difluoromethyl)-1H- indazol-3(2H)-one
(Preparation #37) ##STR00274## 24.4* 1.51 (e) 575 A 6-Bromo-1-(2-
chlorobenzyl)-7-fluoro-2- methyl-1H-indazol-3(2H)- one (prepared in
a similar fashion to Preparation #4, step 1 using 6-bromo-7-
fluoro-2-methyl-1H indazol-3(2H)-one (Preparation #38) and 1-
(bromomethyl)-2- chlorobenzene) ##STR00275## 24.5* 1.31 (e) 525 A
6-Bromo-1-(2- (difluoromethoxy) benzyl)-7-fluoro-2-
methyl-1H-indazol- 3(2H)-one (prepared in a similar fashion to
Preparation #4, step 1 using 6-bromo-7- fluoro-2-methyl-1H
indazol-3(2H)-one (Preparation #38) and 1-(bromomethyl)-
2-(difluoromethoxy) benzene) ##STR00276## 24.6* 1.25 (e) 557 A
6-Bromo-1-(1-(2,5- difluorophenyl)ethyl)- 2-methyl-1H-indazol-
3(2H)-one (synthesized in a manner similar to Preparation #4, step
1 from 6-bromo-2-methyl- 1H-indazol-3(2H)-one and 2-(1-bromoethyl)-
1,4-difluorobenzene (synthesized in a manner similar to Preparation
#21, step 2 from 1-(2,5- difluorophenyl)ethanol)) ##STR00277## 24.7
1.17 (h) 523 A 1-(2-Chlorobenzyl)-2- methyl-6-(4,4,5,5-
tetramethyl-1,3,2- dioxaborolan-2-yl)-1H- indazol-3(2H)-one
(prepared in a similar fashion to Preparation #4, step 2 using
6-bromo-1- (2-chlorobenzyl)-2- methyl-1H-indazol- 3(2H)-one
(prepared in a similar fashion to Preparation #4, step 1 using
2-chlorobenzyl bromide)) ##STR00278## 24.8* 1.82 (a) 507 A
6-Bromo-1-(2- chlorobenzyl)- 7-methoxy-2-methyl-
1H-indazol-3(2H)-one (Preparation #65) ##STR00279## 24.9* 1.92 (a)
537 A 6-Bromo-2-methyl-1- (1-(4-methylpyridin-
2-yl)ethyl)-1H-indazol- 3(2H)-one (prepared in a manner similar to
Example #1 from 6- bromo-2-methyl-1H- indazol-3(2H)-one
(Preparation #1) and 2-(1-bromoethyl)-4- methylpyridine (prepared
in a manner similar to Preparation #21 step 2 from 1-(4-
methylpyridin-2- yl)ethanol (prepared ##STR00280## 24.10 0.98 (h)
502 B in a manner similar to Preparation #9 from
1-(4-methylpyridin-2- yl)ethanone))) 6-Chloro-1-(2-
(difluoromethoxy) benzyl)-5-fluoro-2- methyl-1H-pyrazolo
[3,4-b]pyridin-3(2H)- one (prepared in a manner similar to Example
#15, step 3 from 6-chloro-5- fluoro-2-methyl- 1H-pyrazolo[3,4-
b]pyridin-3(2H)-one (Example #98, step 1) and 1-(bromomethyl)-
2-(difluoromethoxy) benzene) ##STR00281## 24.11* 1.91 (e) 558 A
6-Bromo-1-(2- (difluoromethoxy)benzyl)- 2,7-dimethyl-1H-indazol-
3(2H)-one (Preparation #71) ##STR00282## 24.12* 1.85 (a) 553 A
6-Bromo-1-(2-chlorobenzyl)- 2,7-dimethyl-1H-indazol- 3(2H)-one
(prepared in a similar fashion to Preparation #71 from
1-(bromomethyl)-2- chlorobenzene and 4-bromo- 2-fluoro-N,3-
dimethylbenzohydrazide (prepared in a similar fashion to Example
#17, step 1 using 4-bromo-2-fluoro-3- methylbenzoic acid)
##STR00283## 24.13* 1.91 (a) 521 A
[0998] The compound shown in Table 25 was synthesized in a manner
similar to Preparation #15 from
(S)-1-(2-(difluoromethoxy)-5-methylbenzyl)-2-methyl-6-(2-(3-methylpiperaz-
in-1-yl)pyrimidin-5-yl)-1H-indazol-3(2H)-one, hydrochloric acid
(Example #36, step 2) and the corresponding carboxylic acid.
TABLE-US-00031 TABLE 25 R.sub.t min (Table A, m/z ESI+ TNF
Carboxylic Acid Product Example # Method) (M + H).sup.+ IC.sub.50
2-Cyanoacetic acid ##STR00284## 25.1* 2.02 (a) 562 A
Example #34
(R)-7-(5-(1-(2-(Difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-1H-inda-
zol-6-yl)pyrimidin-2-yl)-2-methylhexahydroimidazo[1,5-a]pyrazin-3(2H)-one
##STR00285##
[1000] A flask was charged with
(S)-7-(5-(1-(2-(difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-1H-ind-
azol-6-yl)pyrimidin-2-yl)hexahydroimidazo[1,5-a]pyrazin-3(2H)-one
(89 mg, 0.17 mmol) (Example #7), DMF (1.5 mL), MeI (0.015 mL, 0.25
mmol) followed by cesium carbonate (67 mg, 0.21 mmol) at room
temperature and stirred for about 9 h. MeI (0.033 mL, 0.53 mmol)
was added. After about 15 h, MeI (0.11 mL, 1.7 mmol) was added. The
reaction vessel was sealed and stirred at about 50.degree. C. for
about 24 h. The mixture was cooled to room temperature, diluted
with water (10 mL) and extracted with 10% MeOH in CH.sub.2Cl.sub.2
(2.times.10 mL). The organic layer was dried over Na.sub.2SO.sub.4,
filtered and concentrated. The residue was purified by flash
chromatography on silica gel (0-10% MeOH/CH.sub.2Cl.sub.2) to
afford the title product (51 mg, 56%); LC/MS (Table A, Method a)
R.sub.t=1.88 min; MS m/z: 536 (M+H).sup.+. (TNF IC.sub.50=A).
Example #35
(R)-7-(5-Bromopyrimidin-2-yl)-2-(2-((tert-butyldimethylsilyl)oxy)ethyl)hex-
ahydroimidazo[1,5-a]pyrazin-3(2H)-one
##STR00286##
[1001] Step 1:
(R)-7-(5-Bromopyrimidin-2-yl)-2-(2-((tert-butyldimethylsilyl)oxy)ethyl)he-
xahydroimidazo[1,5-a]pyrazin-3(2H)-one
[1002] A flask, purged with nitrogen, was charged with cesium
carbonate (5.6 g, 17 mmol),
(S)-7-(5-bromopyrimidin-2-yl)hexahydroimidazo[1,5-a]pyrazin-3(2H)-one
(450 mg, 1.51 mmol) (Preparation #13), DMF (10 mL) then
(2-bromomethoxy)-tert-butyldimethylsilane (410 mg, 1.71 mmol) at
rt. After stirring at about 70.degree. C. for about 26 h,
additional (2-bromomethoxy)-tert-butyldimethylsilane (408 mg, 1.71
mmol) was added. After stirring at about 70.degree. C. for about 27
h, the reaction mixture was cooled to rt and concentrated under
reduced pressure. To the resulting residue was added H.sub.2O (15
mL) and 10% MeOH in CH.sub.2Cl.sub.2 (10 mL). The organic layer was
separated, and the aqueous layer was extracted with 10% MeOH in
CH.sub.2Cl.sub.2 (2.times.10 mL). The combined organic layers were
dried over Na.sub.2SO.sub.4, filtered and concentrated under
reduced pressure. The residue was purified by flash chromatography
on silica gel (0-10% MeOH/CH.sub.2Cl.sub.2) to afford the title
product (511 mg, 74%); LC/MS (Table A, Method i) R.sub.t=1.90 min;
MS m/z: 456 and 458 (M+H).sup.+.
Step 2:
(R)-2-(2-((tert-Butyldimethylsilyl)oxy)ethyl)-7-(5-(1-(2-(difluoro-
methoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-1H-indazol-6-yl)pyrimidin-2-yl)-
hexahydroimidazo[1,5-a]pyrazin-3(2H)-one
[1003] The reaction was performed using
(R)-2-(2-((tert-butyldimethylsilyl)oxy)ethyl)-7-(5-(1-(2-(difluoromethoxy-
)benzyl)-2-methyl-3-oxo-2,3-dihydro-1H-indazol-6-yl)pyrimidin-2-yl)hexahyd-
roimidazo[1,5-a]pyrazin-3(2H)-one and
6-bromo-1-(2-(difluoromethoxy)benzyl)-2-methyl-1H-indazol-3(2H)-one
(Preparation #4, step 1) in a similar fashion to Example #8, to
give the title compound (170 mg, 66%); LC/MS (Table A, Method i)
R.sub.t=1.76 min; MS m/z: 680 (M+H).sup.+.
Step 3:
(R)-7-(5-(1-(2-(Difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-
-1H-indazol-6-yl)pyrimidin-2-yl)-2-(2-hydroxyethyl)hexahydroimidazo[1,5-a]-
pyrazin-3(2H)-one
[1004] A round-bottomed flask was charged with
(R)-2-(2-((tert-butyldimethylsilyl)oxy)ethyl)-7-(5-(1-(2-(difluoromethoxy-
)benzyl)-2-methyl-3-oxo-2,3-dihydro-1H-indazol-6-yl)pyrimidin-2-yl)hexahyd-
roimidazo[1,5-a]pyrazin-3(2H)-one (170 mg, 0.25 mmol), THF (1 mL)
and TBAF (1 M in THF, 0.8 mL, 0.8 mmol). The solution was stirred
at rt for about 90 min, then concentrated under reduced pressure.
The residue was purified by flash chromatography on silica gel
(0-10% MeOH/CH.sub.2Cl.sub.2) to afford the title product (98 mg,
67%); LC/MS (Table A, Method a) R.sub.t=1.70 min; MS m/z: 567
(M+H).sup.+. (TNF IC.sub.50=A).
Example #36*
(S)-1-(2-(Difluoromethoxy)-5-methylbenzyl)-6-(2-(4-(2-hydroxyacetyl)-3-met-
hylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one
##STR00287##
[1005] Step 1: (S)-tert-Butyl
4-(5-(1-(2-(difluoromethoxy)-5-methylbenzyl)-2-methyl-3-oxo-2,3-dihydro-1-
H-indazol-6-yl)pyrimidin-2-yl)-2-methylpiperazine-1-carboxylate
[1006] The reaction was performed using
1-(2-(difluoromethoxy)-5-methylbenzyl)-2-methyl-6-(4,4,5,5-tetramethyl-1,-
3,2-dioxaborolan-2-yl)-1H-indazol-3(2H)-one (Example #22, step 2)
and (S)-tert-butyl
4-(5-bromopyrimidin-2-yl)-2-methylpiperazine-1-carboxylate
(synthesized in a similar fashion to Preparation #13, step 1 using
(S)-1-N-Boc-2-methylpiperazine) in a similar fashion to Example
#14, step 4 to afford the title product (62%); LC/MS (Table A,
Method i) R.sub.t=1.87 min; MS m/z: 595 (M+H).sup.+.
Step 2:
(S)-1-(2-(Difluoromethoxy)-5-methylbenzyl)-2-methyl-6-(2-(3-methyl-
piperazin-1-yl)pyrimidin-5-yl)-1H-indazol-3(2H)-one, hydrochloric
acid
[1007] The reaction was performed using (S)-tert-butyl
4-(5-(1-(2-(difluoromethoxy)-5-methylbenzyl)-2-methyl-3-oxo-2,3-dihydro-1-
H-indazol-6-yl)pyrimidin-2-yl)-2-methylpiperazine-1-carboxylate in
a similar fashion to Example #3, step 1 to afford the title product
(98%); LC/MS (Table A, Method i) R.sub.t=0.97 min; MS m/z: 495
(M+H).sup.+.
Step 3:
(S)-1-(2-(Difluoromethoxy)-5-methylbenzyl)-6-(2-(4-(2-hydroxyacety-
l)-3-methylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one
[1008] The reaction was performed using
(S)-1-(2-(difluoromethoxy)-5-methylbenzyl)-2-methyl-6-(2-(3-methylpiperaz-
in-1-yl)pyrimidin-5-yl)-1H-indazol-3(2H)-one, hydrochloric acid in
a similar fashion to Preparation #15 to afford the title product
(35%); LC/MS (Table A, Method a) R.sub.t=1.89 min; MS m/z: 553
(M+H).sup.+. (TNF IC.sub.50=A).
Example #37
(S)-4-Methyl-2-((2-methyl-3-oxo-6-(2-(3-oxohexahydroimidazo[1,5-a]pyrazin--
7(1H)-yl)pyrimidin-5-yl)-2,3-dihydro-1H-indazol-1-yl)methyl)benzonitrile
##STR00288##
[1009] Step 1: 4-Bromo-2-(bromomethyl)benzonitrile
[1010] A mixture of 4-bromo-2-methylbenzonitrile (2.0 g, 10 mmol),
1-bromopyrrolidine-2,5-dione (1.82 g, 10.2 mmol) and benzoic
peroxyanhydride (0.124 g, 0.510 mmol) in CCl.sub.4 (10 mL) was
heated at reflux under nitrogen for about 18 h. The reaction was
cooled to rt, diluted with DCM (25 mL) and washed with sat. aq.
NaHCO.sub.3 (20 mL) and water (20 mL). The organic layer was dried
over Na.sub.2SO.sub.4 and filtered. The residue was dried onto
silica gel and purified on silica gel using a gradient of 0-20%
EtOAc in heptane. The product fractions were combined and
concentrated to yield the title compound (1.57 g, 56%); .sup.1H NMR
(400 MHz, CDCl.sub.3) .delta. 7.73 (d, J=1.8 Hz, 1H), 7.57 (dd,
J=8.3, 1.8 Hz, 1H), 7.52 (d, J=8.3 Hz, 1H), 4.57 (s, 2H).
Step 2:
4-Bromo-2-((6-chloro-2-methyl-3-oxo-2,3-dihydro-1H-indazol-1-yl)me-
thyl)benzonitrile
[1011] The reaction was performed using
4-bromo-2-(bromomethyl)benzonitrile and
6-chloro-2-methyl-1H-indazol-3(2H)-one (Preparation #29) in a
similar fashion to Preparation #4, step 1 to give the title product
(90%); (Table A, Method j) R.sub.t=1.34 min; MS m/z: 376 and 378
(M+H).sup.+.
Step 3:
2-((6-Chloro-2-methyl-3-oxo-2,3-dihydro-1H-indazol-1-yl)methyl)-4--
methylbenzonitrile
[1012] The reaction was performed using
2,4,6-trimethyl-1,3,5,2,4,6-trioxatriborinane in a similar fashion
to Preparation #14, step 4 to give the title product (56%); (Table
A, Method j) R.sub.t=1.27 min; MS m/z: 312 (M+H).sup.+.
Step 4:
(S)-4-Methyl-2-((2-methyl-3-oxo-6-(2-(3-oxohexahydroimidazo[1,5-a]-
pyrazin-7(1H)-yl)pyrimidin-5-yl)-2,3-dihydro-1H-indazol-1-yl)methyl)benzon-
itrile
[1013] The reaction was performed using
(S)-7-(5-bromopyrimidin-2-yl)hexahydroimidazo[1,5-a]pyrazin-3(2H)-one
(Preparation #13) in a similar fashion to Example #8 to give the
title product (32%); (Table A, Method j) R.sub.t=1.66 min; MS m/z:
495 (M+H).sup.+. (TNF IC.sub.50=B).
Example #38*
1-(2-(Difluoromethoxy)benzyl)-6-(2-((R)-4-((S)-3-hydroxy-2-methylpropanoyl-
)-3-methylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one
##STR00289##
[1014] Step 1:
1-(2-(Difluoromethoxy)benzyl)-6-(2-((R)-4-((S)-2,2-dimethyl-1,3-dioxolane-
-4-carbonyl)-3-methylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(-
2H)-one
[1015] To a solution of (S)-methyl
2,2-dimethyl-1,3-dioxolane-4-carboxylate (0.45 g, 2.8 mmol) in THF
(5 mL) at 0.degree. C. was added a solution of lithium hydroxide
monohydrate (0.218 g, 5.20 mmol) in water (5 mL) at about 6.degree.
C. dropwise over about 10 min. After about 1 h, the mixture was
diluted with water (15 mL) and extracted with EtOAc (15 mL). The
aqueous layer was acidified with H.sub.3PO.sub.4 to about pH=2. The
product was extracted with EtOAc (4.times.15 mL). The combined
organic layers were washed with water (15 mL) and sat. aq. NaCl (15
mL), dried over Na.sub.2SO.sub.4, filtered and concentrated under
reduced pressure. The residue (57 mg, 0.39 mmol) was dissolved in
TEA (0.109 mL, 0.780 mmol) and DCM (2 mL).
Bis(tetramethylene)fluoroformamidiniumhexafluorophosphate (0.082 g,
0.26 mmol) was added and the mixture was stirred for about 5 min.
(R)-1-(2-(Difluoromethoxy)benzyl)-2-methyl-6-(2-(3-methylpiperazin-1-yl)p-
yrimidin-5-yl)-1H-indazol-3(2H)-one (0.125 g, 0.260 mmol) was
added. The mixture was stirred for about 1 h. The mixture was
purified on silica gel using a gradient of 0-100% EtOAc in DCM.
Product fractions were combined and concentrated under reduced
pressure to yield the title product (68 mg, 43%); (Table A, Method
j) R.sub.t=1.47 min; MS m/z: 609 (M+H).sup.+. (TNF
IC.sub.50=A).
Step 2:
1-(2-(Difluoromethoxy)benzyl)-6-(2-((R)-4-((S)-2,3-dihydroxypropan-
oyl)-3-methylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one
[1016] A solution containing
1-(2-(difluoromethoxy)benzyl)-6-(2-((R)-4-((S)-2,2-dimethyl-1,3-dioxolane-
-4-carbonyl)-3-methylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(-
2H)-one (68 mg, 0.11 mmol) in AcOH (3 mL) and water (0.75 mL) was
heated at 70.degree. C. for about 90 min. The reaction was cooled
and concentrated under reduced pressure to yield the title product
(56 mg, 88%); (Table A, Method a) R.sub.t=1.64 min; MS m/z: 569
(M+H).sup.+. (TNF IC.sub.50=A).
Example #39*
1-(2-(Difluoromethoxy)benzyl)-6-(2-((R)-4-((R)-3-hydroxy-2-methylpropanoyl-
)-3-methylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one
##STR00290##
[1017] Step 1:
1-(2-(Difluoromethoxy)benzyl)-6-(2-((R)-4-((R)-2,2-dimethyl-1,3-dioxolane-
-4-carbonyl)-3-methylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(-
2H)-one
[1018] The reaction was performed using (R)-methyl
2,2-dimethyl-1,3-dioxolane-4-carboxylate in a similar fashion to
Example #38, step 1 to yield the title product (80 mg, 50%); (Table
A, Method j) R.sub.t=1.47 min; MS m/z: 609 (M+H).sup.+.
Step 2:
1-(2-(Difluoromethoxy)benzyl)-6-(2-((R)-4-((R)-2,3-dihydroxypropan-
oyl)-3-methylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one
[1019] The reaction was performed in a similar fashion to Example
#38, step 2 to yield the title product (71 mg, 95%); (Table A,
Method a) R.sub.t=1.65 min; MS m/z: 569 (M+H).sup.+. (TNF
IC.sub.50=A).
Example #40
1-(2-(Difluoromethoxy)benzyl)-5-fluoro-6-(2-(2-hydroxypropan-2-yl)pyrimidi-
n-5-yl)-2-methyl-1H-indazol-3(2H)-one
##STR00291##
[1021] DMF (7 mL) was added to a mixture of
6-bromo-1-(2-(difluoromethoxy)benzyl)-5-fluoro-2-methyl-1H-indazol-3(2H)--
one (0.31 g, 0.77 mmol) (synthesized in a manner similar to
Preparation #4, step 1 from
6-bromo-5-fluoro-2-methyl-1H-indazol-3(2H)-one (synthesized in a
manner similar to Preparation #1 from 4-bromo-2,5-difluorobenzoic
acid)), bis(pinacolato)diboron (0.334 g, 1.31 mmol), KOAc (0.228 g,
2.32 mmol), and PdCl.sub.2(dppf) DCM complex (0.050 g, 0.062 mmol).
The reaction vessel was evacuated then back-filled with N.sub.2
three times then purged with N.sub.2 for about 5 min. The mixture
was warmed to about 90.degree. C. for about 90 min. The mixture was
allowed to cool to rt. The volatiles were removed under reduced
pressure at about 70.degree. C.
2-(5-bromopyrimidin-2-yl)propan-2-ol (139 mg, 0.639 mmol), cesium
carbonate (481 mg, 1.48 mmol), dioxane (4 mL), and water (1 mL)
were added. The reaction vessel was evacuated then back-filled with
N.sub.2 three times. PdCl.sub.2(PPh.sub.3).sub.2(27.6 mg, 0.039
mmol) was added. The reaction vessel was evacuated then back-filled
with N.sub.2 three times. The reaction was stirred at about
80.degree. C. for about 1 h then cooled to rt. EtOAc (20 mL) was
added to the reaction and the solids were removed by filtration.
The organic layer was washed with water (10 mL). The combined
organic layers were dried over MgSO.sub.4, filtered, concentrated
and purified on silica gel (0-73% EtOAc/DCM) then preparative
reverse phase HPLC (The gradient was a hold at 10% B for 1.5 min,
10%-95% B to 12.5 min and then a hold at 95% B for 3 min. Mobile
phase A was 0.1% formic acid in water, mobile phase B was HPLC
grade MeCN. The column used for the chromatography is a
21.2.times.150 mm Phenomenex Kinetex Biphenyl (5 .mu.m particles).
Detection methods are diode array (DAD) and positive/negative ESI
ionization.). The fractions were concentrated, partitioned between
DCM (20 mL) and sat. aq. NaHCO.sub.3 (10 mL), washed with sat. aq.
NaCl (10 mL), dried over MgSO.sub.4, filtered, concentrated. The
residue was chased with EtOAc/heptane then ACN/water and dried in a
70.degree. C. vacuum oven to afford the title product (26 mg, 11%).
LC/MS (Table A, Method a) R.sub.t=1.92 min; MS m/z: 459
(M+H).sup.+. (TNF IC.sub.50=B).
Example #41*
(S)-1-(2-(Difluoromethoxy)-5-methylbenzyl)-2-methyl-6-(2-(3-methyl-4-(meth-
ylsulfonyl)piperazin-1-yl)pyrimidin-5-yl)-1H-indazol-3(2H)-one
##STR00292##
[1023]
(S)-1-(2-(Difluoromethoxy)-5-methylbenzyl)-2-methyl-6-(2-(3-methyl--
4-(methylsulfonyl)piperazin-1-yl)pyrimidin-5-yl)-1H-indazol-3(2H)-one
was prepared in a similar fashion to Example #24 using
(S)-1-(2-(difluoromethoxy)-5-methylbenzyl)-2-methyl-6-(2-(3-methylpiperaz-
in-1-yl)pyrimidin-5-yl)-1H-indazol-3(2H)-one (Example #36, step 2)
and MsCl to give the title compound (0.041 g, 48%); LC/MS (Table A,
Method e) R.sub.t=2.17 min; MS m/z: 573 (M+H).sup.+. (TNF
IC.sub.50=A).
[1024] The compounds shown in Table 26 were synthesized in a manner
similar to Example #8 from 2-(5-bromopyrimidin-2-yl)propan-2-ol and
the corresponding halide.
TABLE-US-00032 TABLE 26 R.sub.t min (Table A, m/z ESI+ TNF Halide
Product Example # Method) (M + H).sup.+ IC.sub.50 6-Bromo-1-(2-
(difluoromethoxy)-5- methylbenzyl)-7-fluoro- 2-methyl-1H-indazol-
3(2H)-one (prepared in a similar fashion to Preparation #4, step 1
using 6-bromo-7-fluoro- 2-methyl-1H indazol- 3(2H)-one (Preparation
#38) and 2- (bromomethyl)-1- (difluoromethoxy)-4- methylbenzene
(prepared in a similar fashion to Preparation ##STR00293## 26.1
2.09 (e) 473 B #3, step 2 using (2- (difluoromethoxy)-5-
methylphenyl)methanol (Preparation #11))) 6-Bromo-1-(2-
(difluoromethoxy)-5- methylbenzyl)-2- (difluoromethyl)-1H-
indazol-3(2H)-one (prepared in a similar fashion to Preparation
#37, step 2 using 6- bromo-1-(2- (difluoromethoxy)-5-
methylbenzyl)-1H- indazol-3(2H)-one (Preparation #74) ##STR00294##
26.2 2.40 (e) 491 B Methyl 3-((6-bromo- 2-methyl-3-oxo-2,3-
dihydro-1H-indazol- 1-yl)methyl)-4- (difluoromethoxy)
benzylcarbamate (Preparation #39) ##STR00295## 26.3 1.72 (a) 528 B
1-(5-((1H-1,2,4- Triazol-1-yl)methyl)- 2-(difluoromethoxy)
benzyl)-6-bromo-5- fluoro-2-methyl-1H- indazol-3(2H)-one
(Preparation #62) ##STR00296## 26.4 1.64 (a) 540 A 1-(5-((4H-1,2,4-
Triazol-4-yl)methyl)- 2-(difluoromethoxy) benzyl)-6-bromo-5-
fluoro-2-methyl-1H- indazol-3(2H)-one (Preparation #62)
##STR00297## 26.5 1.54 (a) 540 B 1-(5-((1- Acetylazetidin-3-
yl)methyl)-2- (difluoromethoxy) benzyl)-6-bromo-5-
fluoro-2-methyl-1H- indazol-3(2H)-one (Preparation #63)
##STR00298## 26.6 1.71 (e) 570 B 6-Chloro-1-(2-
(difluoromethoxy)-5- methylbenzyl)-5- fluoro-2-methyl-1,2-
dihydro-3H-pyrazolo [3,4-b]pyridin-3-one (Example #98, step 2)
##STR00299## 26.7 2.14 (a) 474 B 2-(3-((6-Bromo-2-
methyl-3-oxo-2,3- dihydro-1H-indazol- 1-yl)methyl)-4-
(difluoromethoxy) phenyl)acetonitrile (Preparation #20)
##STR00300## 26.8 1.78 (a) 480 B
Example #42
1-(2-Chloro-5-((pyridin-2-ylmethyl)amino)benzyl)-6-(2-(2-hydroxypropan-2-y-
l)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one
##STR00301##
[1025] Step 1:
1-(2-Chloro-5-nitrobenzyl)-6-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-2-m-
ethyl-1H-indazol-3(2H)-one
[1026] Carbon tetrabromide (0.389 g, 1.17 mmol) was added to a
mixture of (2-chloro-5-nitrophenyl)methanol (0.200 g, 1.07 mmol)
and PPh.sub.3 (0.308 g, 1.17 mmol) in THF (3.00 mL). The mixture
was stirred at rt for about 1 h. Immediately after adding the
CBr.sub.4, in a separate vial, DMF (5.00 mL) was added to a mixture
of
6-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one
(0.303 g, 1.066 mmol) (Preparation #19) and potassium carbonate
(0.295 g, 2.132 mmol). The crude DCM solution containing the
bromide was added to the reaction which was stirred at rt for about
16 h. The reaction was partitioned between EtOAc (50 mL) and 20%
aq, NH.sub.4Cl (50 mL). The organic layer was washed with sat. aq.
NaCl (50 mL), dried over Na.sub.2SO.sub.4, filtered and was
concentrated under reduced pressure. The residue was purified on
silica gel using 40-100% EtOAc in heptanes to give the title
compound (0.39 g, 81%); LC/MS (Table A, Method e) R.sub.t=1.84 min;
MS m/z: 454 (M+H).sup.+.
Step 2:
1-(5-Amino-2-chlorobenzyl)-6-(2-(2-hydroxypropan-2-yl)pyrimidin-5--
yl)-2-methyl-1H-indazol-3(2H)-one
[1027] A mixture of
1-(2-chloro-5-nitrobenzyl)-6-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-2-m-
ethyl-1H-indazol-3(2H)-one (1.39 g, 3.06 mmol) and 10% palladium on
carbon (0.326 g, 0.306 mmol) was rapidly stirred under a hydrogen
balloon for about 8 h. The reaction was filtered through
Celite.RTM. and concentrated under reduced pressure. The residue
was triturated in MeOH and filtered. The precipitate from the
filtrate was also triturated the filtered. The combined filtrates
were concentrated under reduced pressure. The residue was purified
on silica gel using 0-5% MeOH in DCM then further purified by
mass-triggered reverse-phase purification (The gradient was a hold
at 10% B for 1.5 min, 10%-75% B to 12.5 min, 75%-95% in 0.1 min and
then a hold at 95% B for 3 min. Mobile phase A was 0.1% formic acid
in water and mobile phase B was HPLC grade MeCN. The column used
for the chromatography is a 21.2.times.150 mm Mac-Mod ACE C18 (5
.mu.m particles). Detection methods are diode array (DAD) and
positive/negative ESI ionization.). The product-containing
fractions were concentrated under reduced pressure to remove the
volatiles then filtered to give the title compound (0.473 g, 36%);
LC/MS (Table A, Method i) R.sub.t=1.03 min; MS m/z: 424
(M+H).sup.+.
Step 3:
1-(2-Chloro-5-((pyridin-2-ylmethyl)amino)benzyl)-6-(2-(2-hydroxypr-
opan-2-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one
[1028] A mixture of
1-(5-amino-2-chlorobenzyl)-6-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-2-m-
ethyl-1H-indazol-3(2H)-one (0.075 g, 0.18 mmol), picolinaldehyde
(0.017 mL, 0.18 mmol) and AcOH (0.030 ml, 0.53 mmol) in DMF (0.500
mL) was stirred at rt for about 1 h then sodium cyanoborohydride
(0.056 g, 0.89 mmol) was added. The reaction was stirred at rt for
about 2 h. The reaction was partitioned between EtOAc (5 mL) and
sat. aq. NaHCO.sub.3 (5 mL). The organic layer was washed with sat.
aq. NaCl (5 mL), dried over Na.sub.2SO.sub.4, filtered and
concentrated under reduced pressure. The residue was purified by
mass triggered reverse-phase purification (The gradient was a hold
at 10% B for 1.5 min, 10%-75% B to 12.5 min, 75%-95% in 0.1 min and
then a hold at 95% B for 3 min. Mobile phase A was 0.1% formic acid
in water and mobile phase B was HPLC grade MeCN. The column used
for the chromatography is a 21.2.times.150 mm Phenomenex Kinetex
C18 (5 .mu.m particles). Detection methods are diode array (DAD)
and positive/negative ESI ionization.). The product-containing
fractions were concentrated under reduced pressure to remove the
volatiles then freeze-dried to give the title compound (0.029 g,
30%); LC/MS (Table A, Method e) R.sub.t=1.81 min; MS m/z: 515
(M+H).sup.+. (TNF IC.sub.50=B).
Example #43
(R)-1-(4-(5-Bromopyridin-2-yl)-2-methylpiperazin-1-yl)-2-hydroxyethanone
##STR00302##
[1030] The title compound was synthesized in a manner similar to
Preparation #19, step 4 from (tert-butyl
3-(((4-chloro-3-((6-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-2-methyl-3-o-
xo-2,3-dihydro-1H-indazol-1-yl)methyl)phenyl)amino)methyl)-1H-pyrazole-1-c-
arboxylate (synthesized in a manner similar to Preparation #21,
step 2 then Preparation #4, step 1 from
6-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one
(Preparation #19) and tert-butyl
3-(((4-chloro-3-(hydroxymethyl)phenyl)amino)methyl)-1H-pyrazole-1-carboxy-
late (synthesized in a manner similar to Example #4, step 2 from
tert-butyl 3-formyl-1H-pyrazole-1-carboxylate and
(5-amino-2-chlorophenyl)methanol)); LC/MS (Table A, Method i)
R.sub.t=1.73 min; MS m/z: 504 (M+H).sup.+. (TNF IC.sub.50=B).
Example #44
1-(2-Chloro-5-((4,5,6,7-tetrahydro-1H-indazol-7-yl)amino)benzyl)-6-(2-(2-h-
ydroxypropan-2-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one
##STR00303##
[1031] Step 1: 2-Ethoxycyclohex-2-enone
[1032] A flask with stir bar and distillation apparatus was charged
with cyclohexane-1,2-dione (5.00 g, 44.6 mmol), EtOH (75 mL) and
4-methylbenzenesulfonic acid hydrate (0.848 g, 4.46 mmol). The
mixture was heated to reflux until about 30 mL of solvent was
distilled off. The flask was charged with EtOH (50 mL) then
reheated to reflux until about 50 mL of solvent was distilled of.
The flask was charged with EtOH (100 mL) then reheated to reflux
until about 100 mL of solvent was distilled off. The mixture was
cooled then concentrated under reduce pressure. The material was
purified via flash chromatography on silica gel (0-100%
EtOAc/heptane) to give the title compound (6.14 g, 98%); LC/MS
(Table A, Method i) R.sub.t=0.53 min; MS m/z: 141 (M+H).sup.+.
Step 2:
(E)-6-((Dimethylamino)methylene)-2-ethoxycyclohex-2-enone
[1033] 2-Ethoxycyclohex-2-enone (6.14 g, 43.8 mmol) in DMF (30 mL)
with 1,1-dimethoxy-N,N-dimethylmethanamine (60 mL, 450 mmol) was
heated to about 130.degree. C. for about 3 h. The flask was charged
with 1,1-dimethoxy-N,N-dimethylmethanamine (15 mL, 110 mmol) then
the mixture was heated at about 130.degree. C. for about 18 h. The
mixture was cooled then concentrated under reduced pressure to give
the title compound (8.1 g, 95%); LC/MS (Table A, Method i)
R.sub.t=0.77 min; MS m/z: 196 (M+H).sup.+.
Step 3: 5,6-Dihydro-1H-indazol-7(4H)-one
[1034] (E)-6-((Dimethylamino)methylene)-2-ethoxycyclohex-2-enone
(8.10 g, 41.5 mmol) in EtOH (200 mL) was treated with hydrazine
hydrate (4.15 g, 830 mmol) then stirred for about 10 min. AcOH (1.2
mL, 21 mmol) was added then the mixture was warmed to about
70.degree. C. for about 18 h. The mixture was cooled then
concentrated under reduced pressure. The material was dissolved in
MeOH (200 mL) then treated with 3 M aq. sulfuric acid (70 mL, 210
mmol). The mixture was stirred for about 3 h. Water (50 mL) was
added to the mixture then it was concentrated under reduced
pressure to remove most of the volatile organic solvents. The
mixture was filtered. The filtrate was extracted with EtOAc
(7.times.100 mL). The combined organic extracts were dried over
magnesium sulfate, filtered and concentrated. The material was
purified via flash chromatography on silica gel (EtOAc) to give the
title compound (3.23 g, 57%); LC/MS (Table A, Method i)
R.sub.t=0.24 min; MS m/z: 137 (M+H).sup.+.
Step 4: tert-Butyl
7-oxo-4,5,6,7-tetrahydro-2H-indazole-2-carboxylate
[1035] The title compound was synthesized in a manner similar to
Preparation #19, step 1 from 5,6-dihydro-1H-indazol-7(4H)-one;
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.00 (s, 1H), 2.82-2.74
(m, 2H), 2.71-2.61 (m, 2H), 2.19-2.07 (m, 2H), 1.65 (s, 9H).
Step 5: tert-Butyl
7-((4-chloro-3-(hydroxymethyl)phenyl)amino)-4,5,6,7-tetrahydro-2H-indazol-
e-2-carboxylate
[1036] A flask with stir bar, Dean Stark apparatus and nitrogen
line charged with tert-butyl
7-oxo-4,5,6,7-tetrahydro-2H-indazole-2-carboxylate (1.11 g, 4.70
mmol), (5-amino-2-chlorophenyl)methanol (0.890 g, 5.65 mmol),
4-methylbenzenesulfonic acid hydrate (0.040 g, 0.21 mmol) and
toluene (75 mL). The mixture was heated to reflux for about 45 min.
The mixture was cooled and concentrated under reduced pressure then
dissolved in MeOH (25 mL). The mixture was cooled in an ice/water
bath then sodium tetrahydroborate (0.485 g, 12.8 mmol) was added.
The mixture was stirred for about 15 min then concentrated under
reduced pressure. The residue was partitioned between EtOAc (30 mL)
and water (30 mL). The aqueous layer was extracted with EtOAc (20
mL) then the combined organic solutions were dried over magnesium
sulfate, filtered and concentrated. The mixture was stirred with
EtOAc (20 mL) for about 1 h then filtered. The filtrate was
concentrated under reduced pressure then the material was purified
via flash chromatography on silica gel (0-100% EtOAc/heptane) to
give the title compound (0.42 g, 24%); .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 7.95 (s, 1H), 7.03 (d, J=8.6 Hz, 1H), 6.88
(d, J=2.8 Hz, 1H), 6.58 (dd, J=8.7, 2.9 Hz, 1H), 6.02 (d, J=7.8 Hz,
1H), 5.16 (t, J=5.6 Hz, 1H), 4.61-4.50 (m, 1H), 4.43 (d, J=5.6 Hz,
2H), 2.55-2.49 (m, 2H), 1.96-1.89 (m, 1H), 1.80-1.84 (m, 1H),
1.67-1.70 (m, 2H), 1.53 (s, 9H).
Step 6: tert-Butyl
7-((4-chloro-3-((6-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-2-methyl-3-ox-
o-2,3-dihydro-1H-indazol-1-yl)methyl)phenyl)amino)-4,5,6,7-tetrahydro-2H-i-
ndazole-2-carboxylate
[1037] The title compound was synthesized in a manner similar to
Preparation #21, step 2 then Preparation #4, step 1 from
6-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one
(Preparation #19) and tert-butyl
7-((4-chloro-3-(hydroxymethyl)phenyl)amino)-4,5,6,7-tetrahydro-2H-indazol-
e-2-carboxylate; LC/MS (Table A, Method i) R.sub.t=1.65 min; MS
m/z: 644 (M+H).sup.+.
Step 7:
1-(2-Chloro-5-((4,5,6,7-tetrahydro-1H-indazol-7-yl)amino)benzyl)-6-
-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one
[1038] The title compound was synthesized in a manner similar to
Preparation #19, step 4 from tert-butyl
7-((4-chloro-3-((6-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-2-methyl-3-ox-
o-2,3-dihydro-1H-indazol-1-yl)methyl)phenyl)amino)-4,5,6,7-tetrahydro-2H-i-
ndazole-2-carboxylate; LC/MS (Table A, Method a) R.sub.t=1.95 min;
MS m/z: 544 (M+H).sup.+. (TNF IC.sub.50=A).
##STR00304##
Example #45
1-(2-(Difluoromethoxy)-5-methylbenzyl)-7-fluoro-6-(2-(2-hydroxypropan-2-yl-
)-4-methylpyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one
[1039] The title compound was synthesized in a manner similar to
Example #8 from 2-(5-bromo-4-methylpyrimidin-2-yl)propan-2-ol
(synthesized as described in WO2015/86506 A1) and
6-bromo-1-(2-(difluoromethoxy)-5-methylbenzyl)-7-fluoro-2-methyl-1H-indaz-
ol-3(2H)-one (synthesized in a manner similar to Preparation #21,
step 2 then Preparation #4, step 1 from
6-bromo-7-fluoro-2-methyl-1H-indazol-3(2H)-one (Preparation #38)
and (2-(difluoromethoxy)-5-methylphenyl)methanol (Preparation #11);
LC/MS (Table A, Method a) R.sub.t=2.19 min; MS m/z: 487
(M+H).sup.+. (TNF IC.sub.50=A).
[1040] The compounds shown in Table 27 were synthesized in a manner
similar to Example #8 from
(R)-1-(4-(5-bromopyrimidin-2-yl)-2-methylpiperazin-1-yl)ethanone
(Preparation #16) and the corresponding halide.
TABLE-US-00033 TABLE 27 Ex- R.sub.t min m/z am- (Table A, ESI+ TNF
Halide Product ple # Method) (M + H).sup.+ IC.sub.50
N-(3-((6-Bromo- 2-methyl-3-oxo- 2,3-dihydro-1H- indazol-1-yl)
methyl)-4- (difluoromethoxy) benzyl)acetamide (synthesized from
1-(5- (aminomethyl)-2- (difluoromethoxy) benzyl)-6-bromo-
2-methyl-1H- indazol-3(2H)-one (Preparation #39, step 2) in a
similar ##STR00305## 27.1* 1.61 (a) 594 B fashion to Preparation
#16) Methyl 3-((6- bromo-2-methyl- 3-oxo-2,3-dihydro- 1H-indazol-1-
yl)methyl)-4- (difluoromethoxy) benzylcarbamate (Preparation #39)
##STR00306## 27.2* 1.78 (a) 610 A 2-(3-((6-Bromo-2-
methyl-3-oxo-2,3- dihydro-1H- indazol-1-yl) methyl)-4-
(difluoromethoxy) phenyl)acetonitrile (Preparation #20)
##STR00307## 27.3* 1.82 (a) 562 A 3-(3-((6-Bromo-2-
methyl-3-oxa-2,3- dihydro-1H- indazol-1- yl)methyl)-4-
(difluoromethoxy) phenyl)-2-methyl- propanenitrile (Preparation
#56) ##STR00308## 27.4 1.92 (a) 590 B 6-Bromo-2-methyl- 1-((4-
(trifluoromethyl)- 1H-pyrrol-3- yl)methyl)-1H- indazol-3(2H)-one
(Preparation #72) ##STR00309## 27.5* 1.77 (a) 514 A 6-Bromo-1-(2-
(difluoromethoxy) benzyl)-2-(pyridin- 4-ylmethyl)-1H-
indazol-3(2H)-one (prepared in a similar manner to Example #1 using
6-bromo-2-(pyridin- 4-ylmethyl)-1H- indazol-3(2H)-one (Preparation
#73) and 1- (bromomethyl)-2- (difluoromethoxy) benzene)
##STR00310## 27.6* 1.85 (a) 600 B 6-Bromo-1-(2- chlorobenzyl)-
2-(pyridin-4- ylmethyl)-1H- indazol-3(2H)- one (prepared in a
similar manner to Example #1 using 6-bromo-2- (pyridin-4-
ylmethyl)-1H- indazol-3(2H)- one (Preparation #73) and 1-
##STR00311## 27.7* 1.88 (a) 568 B (bromomethyl)-
2-chlorobenzene)
Example #46*
(R)-1-(2-(Difluoromethoxy)benzyl)-6-(2-(4-(2-hydroxyacetyl)-3-methylpipera-
zin-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one
##STR00312##
[1042] The reaction was performed in a similar fashion to Example
#30 using
(R)-6-(2-(4-(2-(tert-butoxy)acetyl)-3-methylpiperazin-1-yl)pyrimidi-
n-5-yl)-1-(2-(difluoromethoxy)benzyl)-2-methyl-1H-indazol-3(2H)-one
(prepared in a similar fashion to Preparation #26, step 4 from
(R)-6-(2-(4-(2-(tert-butoxy)acetyl)-3-methylpiperazin-1-yl)pyrimidin-5-yl-
)-5,7-difluoro-2-methyl-1H-indazol-3(2H)-one), prepared in a
similar fashion to as Preparation #26, step 3 from
(R)-2-(tert-butoxy)-1-(2-methyl-4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaboro-
lan-2-yl)pyrimidin-2-yl)piperazin-1-yl)ethanone (Preparation #30)
and 6-bromo-5,7-difluoro-2-methyl-1H-indazol-3(2H)-one (Preparation
#25) to yield the title product (93%); (Table A, Method j)
R.sub.t=1.25 min; MS m/z: 575 (M+H).sup.+. (TNF IC.sub.50=A).
Example #47*
(R)-1-(2-(Difluoromethoxy)benzyl)-6-(2-(4-(2-hydroxyacetyl)-3-methylpipera-
zin-1-yl)pyrimidin-5-yl)-5-methoxy-2-methyl-1H-indazol-3(2H)-one
##STR00313##
[1044] The reaction was prepared in a similar fashion to Example
#30 using
(R)-6-(2-(4-(2-(tert-butoxy)acetyl)-3-methylpiperazin-1-yl)pyrimidin-5-yl-
)-1-(2-(difluoromethoxy)benzyl)-5-methoxy-2-methyl-1H-indazol-3(2H)-one
(prepared in a fashion similar to Preparation #26, step 3 using
(R)-2-(tert-butoxy)-1-(2-methyl-4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaboro-
lan-2-yl)pyrimidin-2-yl)piperazin-1-yl)ethanone (Preparation #30)
and
6-chloro-1-(2-(difluoromethoxy)benzyl)-5-methoxy-2-methyl-1H-indazol-3(2H-
)-one), prepared in a fashion similar to Example #1 using
6-chloro-5-methoxy-2-methyl-1H-indazol-3(2H)-one (Preparation #31)
to yield the title product (82%); (Table A, Method i) R.sub.t=1.17
min; MS m/z: 569 (M+H).sup.+. (TNF IC.sub.50=B).
Example #48*
(R)-6-(2-(4-Acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-1-(2-(difluorome-
thoxy)-6-(hydroxymethyl)benzyl)-2-methyl-1H-indazol-3(2H)-one
##STR00314##
[1046] The reaction was performed in a similar fashion to Example
#33, step 9 using
(R)-1-(4-(5-bromopyrimidin-2-yl)-2-methylpiperazin-1-yl)ethanone
(Preparation #16) and
6-chloro-1-(2-(difluoromethoxy)-6-(hydroxymethyl)benzyl)-2-methyl-1H-inda-
zol-3(2H)-one (Example #33, step 7) to yield the title product
(72%); (Table A, Method i) R.sub.t=1.10 min; MS m/z: 553
(M+H).sup.+. (TNF IC.sub.50=A).
Example #49*
(R)-2-(2-((6-(2-(4-Acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl--
3-oxo-2,3-dihydro-1H-indazol-1-yl)methyl)-3-(difluoromethoxy)phenyl)aceton-
itrile
##STR00315##
[1048] The reaction was performed in a similar fashion to
Preparation #20, step 4 using
(R)-6-(2-(4-acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-1-(2-(bromometh-
yl)-6-(difluoromethoxy)benzyl)-2-methyl-1H-indazol-3(2H)-one
(prepared in a similar fashion to Preparation #20, step 3 from
(R)-6-(2-(4-acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-1-(2-(difluorom-
ethoxy)-6-(hydroxymethyl)benzyl)-2-methyl-1H-indazol-3(2H)-one
(Example #48)) to yield the title product (44% over 2 steps);
(Table A, Method i) R.sub.t=1.93 min; MS m/z: 562 (M+H).sup.+. (TNF
IC.sub.50=A).
Example #50*
(R)-4-((R)-4-(5-(1-(2-(Difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro--
1H-indazol-6-yl)pyrimidin-2-yl)-2-methylpiperazin-1-yl)-3-hydroxy-4-oxobut-
anoic acid
##STR00316##
[1050] 10% Aq. sodium carbonate (20 mL) was added to (R)-methyl
4-((R)-4-(5-(1-(2-(difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-1H--
indazol-6-yl)pyrimidin-2-yl)-2-methylpiperazin-1-yl)-3-hydroxy-4-oxobutano-
ate (0.145 g, 0.237 mmol) (synthesized in a manner similar to
Preparation #15 from (R)-2-hydroxy-4-methoxy-4-oxobutanoic acid (US
20090312342 A1) and
(R)-1-(2-(difluoromethoxy)benzyl)-2-methyl-6-(2-(3-methylpiperazin-1--
yl)pyrimidin-5-yl)-1H-indazol-3(2H)-one (Preparation #33)) in MeOH
(2.6 mL). After about 16 h, the pH was adjusted to 3 with 2 N aq.
HCl. The MeOH was removed under reduced pressure. The residue was
partitioned between EtOAc (40 mL) and water (10 mL). The aqueous
layer was extracted with EtOAc (2.times.5 mL). The combined organic
layers were washed with water (5 mL) and sat. aq. NaCl (5 mL),
dried over MgSO.sub.4, filtered, and concentrated. The residue was
purified on silica gel (0-6% MeOH/DCM) to afford the title product
(47 mg, 32%); LC/MS (Table A, Method a) R.sub.t=1.62 min; MS m/z:
597 (M+H).sup.+. (TNF IC.sub.50=A).
Example #51*
(S)-4-((R)-4-(5-(1-(2-(Difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro--
1H-indazol-6-yl)pyrimidin-2-yl)-2-methylpiperazin-1-yl)-3-hydroxy-4-oxobut-
anoic acid
##STR00317##
[1052] The reaction was performed using (S)-methyl
4-((R)-4-(5-(1-(2-(difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-1H--
indazol-6-yl)pyrimidin-2-yl)-2-methylpiperazin-1-yl)-3-hydroxy-4-oxobutano-
ate (synthesized in a manner similar to Preparation #15 from
(S)-2-hydroxy-4-methoxy-4-oxobutanoic acid (US 20090312342 A1) and
(R)-1-(2-(difluoromethoxy)benzyl)-2-methyl-6-(2-(3-methylpiperazin-1-yl)p-
yrimidin-5-yl)-1H-indazol-3(2H)-one (Preparation #33)) in a similar
fashion to Example #51 to afford the title product (20 mg, 23%);
LC/MS (Table A, Method a) R.sub.t=1.62 min; MS m/z: 597
(M+H).sup.+. (TNF IC.sub.50=A).
Example #52*
(R)-9-((6-(2-(4-Acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-3-o-
xo-2,3-dihydro-1H-indazol-1-yl)methyl)-4,5-dihydrobenzo[f][1,4]thiazepin-3-
(2H)-one
##STR00318##
[1054] The reaction was performed using
(R)-6-(2-(4-acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-1H-ind-
azol-3(2H)-one (Preparation #28) and
9-(bromomethyl)-4,5-dihydrobenzo[f][1,4]thiazepin-3(2H)-one
(Preparation #32) in a similar fashion to Preparation #4, step 1 to
afford the title product (90 mg, 52%); LC/MS (Table A, Method h)
R.sub.t=0.94 min; MS m/z: 558 (M+H).sup.+. (TNF IC.sub.50=B).
Example #53
1-(2-Chloro-5-((pyridin-3-ylmethyl)amino)benzyl)-6-(2-(2-hydroxypropan-2-y-
l)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one
##STR00319##
[1056]
1-(2-Chloro-5-((pyridin-3-ylmethyl)amino)benzyl)-6-(2-(2-hydroxypro-
pan-2-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one was prepared
in a similar fashion to Example #42, step 3 using
1-(5-amino-2-chlorobenzyl)-6-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-2-m-
ethyl-1H-indazol-3(2H)-one (Example #42, step 2 and nicotinaldehyde
to give the title compound (0.020 g, 20%); LC/MS (Table A, Method
i) R.sub.t=1.10 min; MS m/z: 515 (M+H).sup.+. (TNF
IC.sub.50=B).
Example #54
(R)-6-(2-(4-Acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-1-(2-(difluorome-
thoxy)-5-methylbenzyl)-2-methyl-1H-indazol-3(2H)-one
##STR00320##
[1058]
6-(2-(4-Acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-1-(2-(difluor-
omethoxy)-5-methylbenzyl)-2-methyl-1H-indazol-3(2H)-one (0.173 g,
0.323 mmol) (Preparation #58) was submitted for chiral separation
(Table B, Method c). Fractions from the first eluting component
were combined and concentrated. The residue was dissolved in MeCN
(0.5 mL) then water (5 mL) was added. The mixture was sonicated
then frozen. The resulting solid was lyophilized to afford the
title product (0.055 g, 32%) with undetermined optical rotation.
LC/MS (Table A, Method a) R.sub.t=1.97 min; MS m/z: 537
(M+H).sup.+. (TNF IC.sub.50=A).
Example #55
(S)-6-(2-(4-Acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-1-(2-(difluorome-
thoxy)-5-methylbenzyl)-2-methyl-1H-indazol-3(2H)-one
##STR00321##
[1060]
6-(2-(4-Acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-1-(2-(difluor-
omethoxy)-5-methylbenzyl)-2-methyl-1H-indazol-3(2H)-one (0.173 g,
0.323 mmol) (Preparation #58) was submitted for chiral separation
(Table B, Method c). Fractions from the second eluting component
were combined and concentrated. The residue was dissolved in MeCN
(0.5 mL) then water (5 mL) was added. The mixture was sonicated
then frozen. The resulting solid was lyophilized to afford the
title product (0.062 g, 34%) with undetermined optical rotation.
LC/MS (Table A, Method a) R.sub.t=1.97 min; MS m/z: 537
(M+H).sup.+. (TNF IC.sub.50=A).
Example #56
1-(5-(Hydroxymethyl)-2-methylbenzyl)-2-methyl-6-(2-morpholinopyrimidin-5-y-
l)-1H-indazol-3(2H)-one
##STR00322##
[1062] The reaction was prepared in a similar fashion to
Preparation #14, step 5 using methyl
4-methyl-3-((2-methyl-6-(2-morpholinopyrimidin-5-yl)-3-oxo-2,3-dihydro-1H-
-indazol-1-yl)methyl)benzoate (prepared in a fashion similar to
Example #1 using
2-methyl-6-(2-morpholinopyrimidin-5-yl)-1H-indazol-3(2H)-one
(Preparation #2) and methyl 3-(bromomethyl)-4-methylbenzoate
(prepared in a fashion similar to Preparation #3, step 2 using
methyl 3-(hydroxymethyl)-4-methylbenzoate (prepared in a fashion
similar to Example #9, step 1 using
(5-bromo-2-methylphenyl)methanol (prepared in a fashion similar to
Preparation #49, step 1 using 5-bromo-2-methylbenzoic acid)))) to
yield the title product (13%); LC/MS (Table A, Method a)
R.sub.t=1.72 min; MS m/z: 446 (M+H).sup.+. (TNF IC.sub.50=B).
Example #57*
(R)-7-(5-(1-(2-(Difluoromethoxy)-5-methylbenzyl)-2-(methyl-d.sub.3)-3-oxo--
2,3-dihydro-1H-indazol-6-yl)pyrimidin-2-yl)hexahydro-3H-oxazolo[3,4-a]pyra-
zin-3-one
##STR00323##
[1064]
(R)-7-(5-(1-(2-(Difluoromethoxy)-5-methylbenzyl)-2-(methyl-d.sub.3)-
-3-oxo-2,3-dihydro-1H-indazol-6-yl)pyrimidin-2-yl)hexahydro-3H-oxazolo[3,4-
-a]pyrazin-3-one was prepared in a similar fashion to Example #14,
step 4 using
1-(2-(difluoromethoxy)-5-methylbenzyl)-2-(methyl-d.sub.3)-6-(4,4,5,-
5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3(2H)-one
(Preparation #59) and
(R)-7-(5-bromopyrimidin-2-yl)tetrahydro-1H-oxazolo[3,4-a]pyrazin-
-3(5H)-one (prepared in a similar fashion to Example #2 using
5-bromo-2-chlorpyrimidine and (R)-hexahydro-oxazolo[pyrazine-3-one
HCl) to give the title compound (74%); LC/MS (Table A, Method a)
R.sub.t=1.98 min; MS m/z: 540 (M+H).sup.+. (TNF IC.sub.50=A).
[1065] The compounds shown in Table 28 were synthesized in a manner
similar to Example #30 from the corresponding tert-butyl ether.
TABLE-US-00034 TABLE 28 R.sub.t min (Table A, m/z ESI+ TNF
tert-Butyl Ether Product Example # Method) (M + H).sup.+ IC.sub.50
6-(2-((R)-4-(2-(tert- Butoxy)acetyl)-3- methylpiperazin-1-
yl)pyrimidin-5-yl)-1- (1-(2,6-difluorophenyl) ethyl)-2-methyl-1H-
indazol-3(2H)-one (prepared in a manner similar to Example #18 from
(R)-6-(2-(4-(2- (tert-butoxy)acetyl)-3- methylpiperazin-1-
yl)pyrimidin-5-yl)-2- methyl-1H-indazol- 3(2H)-one (Preparation
##STR00324## 28.1 1.17 (j) 573 A #60) and 2-(1- bromoethyl)-1,3-
dimethylbenzene (prepared from 1-(2,6- dimethylphenyl)ethanol in a
similar manner to Preparation #21, step 2)) 6-(2-((R)-4-(2-(tert-
Butoxy)acetyl)-3- methylpiperazin-1- yl)pyrimidin-5-yl)-2-
methyl-1-(1- phenylethyl)-1H-indazol- 3(2H)-one (prepared in a
similar manner to Example #1 using (R)- 6-(2-(4-(2-(tert-
butoxy)acetyl)-3- methylpiperazin-1- yl)pyrimidin-5-yl)-
2-methyl-1H-indazol- 3(2H)-one (Preparation ##STR00325## 28.2 1.19
(j) 487 A #60) and (1- bromoethyl)benzene 6-(2-((R)-4-(2-(tert-
Butoxy)acetyl)-3- methylpiperazin-1- yl)pyrimidin-5-yl)-1-
(1-(2-fluorophenyl) ethyl)-2-methyl-1H- indazol-3(2H)-one (prepared
in a similar fashion to Preparation #4, step 1 using (R)-
6-(2-(4-(2-(tert- butoxy)acetyl)-3- methylpiperazin-1-
yl)pyrimidin-5-yl)-2- methyl-1H-indazol- ##STR00326## 28.3 1.16 (i)
505 A 3(2H)-one (Preparation #60) and 1-(1- bromoethyl)-2-
fluorobenzene (prepared in a similar fashion to Preparation #21,
step 2 using 1-(2- fluorophenyl)ethanol)) 6-(2-((R)-4-(2-(tert-
Butoxy)acetyl)-3- methylpiperazin-1- yl)pyrimidin-5-yl)-1-
(1-(2-chlorophenyl) ethyl)-2-methyl-1H- indazol-3(2H)-one (prepared
in a similar fashion to Preparation #4, step 1 using (R)-
6-(2-(4-(2-(tert- butoxy)acetyl)-3- methylpiperazin-1-
yl)pyrimidin-5-yl)-2- methyl-1H-indazol- ##STR00327## 28.4 1.24 (i)
521 B 3(2H)-one (Preparation #60) and 1-(1- bromoethyl)-2-
chlorobenzene (prepared in a similar fashion to Preparation #21,
step 2 using 1-(2- chlorophenyl)ethanol))
Example #58
1-((S)-1-(2,6-Difluorophenyl)ethyl)-6-(2-((R)-4-(2-hydroxyacetyl)-3-methyl-
piperazin-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one
##STR00328##
[1067]
1-(1-(2,6-Difluorophenyl)ethyl)-6-(2-((R)-4-(2-hydroxyacetyl)-3-met-
hylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one
(250 mg) (Example #28.1) was submitted for chiral separation (Table
C, Method b). The product fractions from the second eluting
component were concentrated under reduced pressure. The residue was
concentrated from methanol (25 mL), and then concentrated from
ether (25 mL) to yield the title product (0.083 g, 33%) with
negative optical rotation. LC/MS (Table A, Method j) R.sub.t=1.17
min; MS m/z: 523 (M+H).sup.+. (TNF IC.sub.50=A).
Example #59*
(R)-1-(2-(Difluoromethoxy)benzyl)-5-fluoro-6-(2-(4-(2-hydroxyacetyl)-3-met-
hylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one
##STR00329##
[1068] Step 1:
(R)-2-(4-(5-(1-(2-(Difluoromethoxy)benzyl)-5-fluoro-2-methyl-3-oxo-2,3-di-
hydro-1H-indazol-6-yl)pyrimidin-2-yl)-2-methylpiperazin-1-yl)-2-oxoethyl
acetate
[1069]
(R)-1-(2-(Difluoromethoxy)benzyl)-5-fluoro-2-methyl-6-(2-(3-methylp-
iperazin-1-yl)pyrimidin-5-yl)-1H-indazol-3(2H)-one dihydrochloride
(0.5 g, 0.875 mmol) (synthesized in a manner similar to Example #3,
step 1 from (R)-tert-butyl
4-(5-(1-(2-(difluoromethoxy)benzyl)-5-fluoro-2-methyl-3-oxo-2,3-dihydro-1-
H-indazol-6-yl)pyrimidin-2-yl)-2-methylpiperazine-1-carboxylate
(synthesized in a manner similar to Example #8 from
6-bromo-1-(2-(difluoromethoxy)benzyl)-5-fluoro-2-methyl-1H-indazol-3(2H)--
one (Preparation #40) and (R)-tert-butyl
4-(5-bromopyrimidin-2-yl)-2-methylpiperazine-1-carboxylate
(synthesized in a manner similar to Preparation #13 from
(R)-tert-butyl 2-methylpiperazine-1-carboxylate and
5-bromo-2-chloropyrimidine))) in DCM (8 mL) with TEA (0.46 mL, 3.3
mmol) was cooled in an ice/water bath then treated with
2-chloro-2-oxoethyl acetate (0.179 g, 1.31 mmol). The mixture was
stirred for about 15 min then washed twice with water (10 mL),
dried over magnesium sulfate, filtered and concentrated to give the
title compound (0.498 g, 95%); LC/MS (Table A, Method i)
R.sub.t=1.33 min; MS m/z: 599 (M+H).sup.+.
Step 2:
(R)-1-(2-(Difluoromethoxy)benzyl)-5-fluoro-6-(2-(4-(2-hydroxyacety-
l)-3-methylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one
[1070]
(R)-2-(4-(5-(1-(2-(Difluoromethoxy)benzyl)-5-fluoro-2-methyl-3-oxo--
2,3-dihydro-1H-indazol-6-yl)pyrimidin-2-yl)-2-methylpiperazin-1-yl)-2-oxoe-
thyl acetate (10.0 g, 16.7 mmol) in ethanol (150 mL) with
4-methylbenzenesulfonic acid hydrate (0.186 g, 0.978 mmol) was
heated at about 77.degree. C. for about 30 h. The mixture was
cooled and concentrated under reduced pressure then dissolved in
EtOAc (250 mL). The organic solution was washed with water (50 mL)
then with sat. aq. sodium bicarbonate (30 mL), dried over magnesium
sulfate, filtered and concentrated. The material was purified by
supercritical fluid chromatography (Table C, Method a) to give the
title compound
(R)-1-(2-(difluoromethoxy)benzyl)-5-fluoro-6-(2-(4-(2-hydroxyacetyl)-3-me-
thylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one
(7.88 g, 81%); LC/MS (Table A, Method a) R.sub.t=1.86 min; MS m/z:
557 (M+H).sup.+. (TNF IC.sub.50=A).
Example #60*
(R)-1-(2-(Difluoromethoxy)benzyl)-5-fluoro-6-(6-(4-(2-hydroxyacetyl)-3-met-
hylpiperazin-1-yl)pyridin-3-yl)-2-methyl-1H-indazol-3(2H)-one
##STR00330##
[1072] The title compound was synthesized in a manner similar to
Example #8 from
6-bromo-1-(2-(difluoromethoxy)benzyl)-5-fluoro-2-methyl-1H-indazo-
l-3(2H)-one (Preparation #40) and
(R)-1-(4-(5-bromopyridin-2-yl)-2-methylpiperazin-1-yl)-2-hydroxyethanone
(Preparation #55); LC/MS (Table A, Method a) R.sub.t=1.88 min; MS
m/z: 556 (M+H).sup.+. (TNF IC.sub.50=A).
Example #61*
(R)-2-(6-((6-(2-(4-Acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl--
3-oxo-2,3-dihydro-1H-indazol-1-yl)methyl)-5-(trifluoromethyl)pyridin-2-yl)-
acetonitrile
##STR00331##
[1074]
(R)-6-(2-(4-Acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-1-((6-(hy-
droxymethyl)-3-(trifluoromethyl)pyridin-2-yl)methyl)-2-methyl-1H-indazol-3-
(2H)-one (55 mg, 0.099 mmol) (synthesized in a manner similar to
Example #18 from
(R)-6-(2-(4-acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-2-meth-
yl-1-((3-(trifluoromethyl)-6-((trityloxy)methyl)pyridin-2-yl)methyl)-1H-in-
dazol-3(2H)-one (synthesized in a manner similar to Preparation #4,
step 1 from
2-(bromomethyl)-3-(trifluoromethyl)-6-((trityloxy)methyl)pyridine
(Preparation #61) and
(R)-6-(2-(4-acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-1H-ind-
azol-3(2H)-one (Preparation #28))) in DCM (2 mL) with DIEA (0.026
mL, 0.15 mmol) was cooled in an ice/water bath then MsCl (0.012 mL,
0.16 mmol) was added. The mixture was warmed to rt then stirred for
about 15 min. A second portion of DIEA (0.026 mL, 0.15 mmol) and
MsCl (0.012 mL, 0.16 mmol) were added. After about 5 min, the
mixture was concentrated under reduced pressure then DMF (2 mL) and
NaCN (28 mg, 0.57 mmol) were added. The mixture was stirred for
about 90 min then a second portion of NaCN (30 mg, 0.61 mmol) was
added. The mixture was stirred for about 90 min then purified
directly by preparative reverse phase HPLC (Hypersil HS C18 column,
250 mm.times.21.2 mm, 8 .mu.m paticle size, flow rate 21 mL/min,
detection 254 nm, A=0.05 N NH.sub.4OAc pH 4.5 buffer, B=MeCN, 10 to
100% over 25 min) to afford the title compound; LC/MS (Table A,
Method i) R.sub.t=2.31 min; MS m/z: 243 (M+H).sup.+. (TNF
IC.sub.50=A).
Example #62*
(R)-1-(2-(Difluoromethoxy)-5-methylbenzyl)-6-(2-(4-(2-hydroxyacetyl)-3-met-
hylpiperazin-1-yl)pyrimidin-5-yl)-2-(methyl-d.sub.3)-1H-indazol-3(2H)-one
##STR00332##
[1076]
(R)-1-(2-(Difluoromethoxy)-5-methylbenzyl)-6-(2-(4-(2-hydroxyacetyl-
)-3-methylpiperazin-1-yl)pyrimidin-5-yl)-2-(methyl-d.sub.3)-1H-indazol-3(2-
H)-one was prepared in a similar fashion to Example #14, step 4
using
1-(2-(difluoromethoxy)-5-methylbenzyl)-2-(methyl-d.sub.3)-6-(4,4,5,5-tetr-
amethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3(2H)-one (Preparation
#59) and
(R)-1-(4-(5-bromopyrimidin-2-yl)-2-methylpiperazin-1-yl)-2-hydroxyeth-
anone (Preparation #15) to give the title compound (41%); LC/MS
(Table A, Method a) R.sub.t=1.88 min; MS m/z: 556 (M+H).sup.+. (TNF
IC.sub.50=A).
Example #63*
(R)-6-(2-(4-Acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-1-(2-(difluorome-
thoxy)-5-methylbenzyl)-2-methyl-d.sub.3-1H-indazol-3(2H)-one
##STR00333##
[1078] The reaction was performed using
1-(2-(difluoromethoxy)-5-methylbenzyl)-2-methyl-d.sub.3-6-(4,4,5,5-tetram-
ethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3(2H)-one (Preparation
#59) and
(R)-1-(4-(5-bromopyrimidin-2-yl)-2-methylpiperazin-1-yl)ethanone
(Preparation #16) in a similar fashion to Example #15, step 4 to
afford the title product (48 mg, 49%); LC/MS (Table A, Method a)
R.sub.t=1.97 min; MS m/z: 540 (M+H).sup.+. (TNF IC.sub.50=A).
Example #64*
(R)-6-(2-(4-Acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-1-((1-(2-hydroxy-
ethyl)-4-(trifluoromethyl)-1H-pyrrol-3-yl)methyl)-2-methyl-1H-indazol-3(2H-
)-one
##STR00334## ##STR00335##
[1079] Step 1: Ethyl
1-(2-((tert-butyldimethylsilyl)oxy)ethyl)-4-(trifluoromethyl)-1H-pyrrole--
3-carboxylate
[1080] To a solution of ethyl
4-(trifluoromethyl)-1H-pyrrole-3-carboxylate (1.00 g, 4.83
mmol)(synthesized according to WO 2009147167 A1) and THF (10 mL)
under N.sub.2 at about 0.degree. C. was added NaH (60% dispersion
in mineral oil) (0.212 g, 5.31 mmol) in one portion. After about 5
min, (2-bromoethoxy)(tert-butyl)dimethylsilane (1.50 g, 6.28 mmol)
was added and the mixture was stirred at rt for about 72 h. The
reaction was quenched with NaHCO.sub.3 (20 mL), extracted with
EtOAc (2.times.50 mL). The organic layer was dried over MgSO.sub.4,
filtered, and concentrated. The residue was purified on silica gel
(0-5% EtOAc/DCM) to afford the title product (1.16 g, 66%); LC/MS
(Table A, Method i) R.sub.t=2.21 min; MS m/z: 366 (M+H).sup.+.
Step 2:
(1-(2-((tert-Butyldimethylsilyl)oxy)ethyl)-4-(trifluoromethyl)-1H--
pyrrol-3-yl)methanol
[1081] The reaction was performed using ethyl
1-(2-((tert-butyldimethylsilyl)oxy)ethyl)-4-(trifluoromethyl)-1H-pyrrole--
3-carboxylate in a similar fashion to Preparation #52, step 2 to
afford the title product (1.00 g, 70%); LC/MS (Table A, Method i)
R.sub.t=1.41 min; MS m/z: 324 (M+H).sup.+.
Step 3:
1-(2-((tert-Butyldimethylsilyl)oxy)ethyl)-3-(chloromethyl)-4-(trif-
luoromethyl)-1H-pyrrole
[1082] A solution of thionyl chloride (368 mg, 3.09 mmol) in DCM
(5.00 mL) was added portionwise to a solution of
(1-(2-((tert-butyldimethylsilyl)oxy)ethyl)-4-(trifluoromethyl)-1H-pyrrol--
3-yl)methanol (500 mg, 1.55 mmol) and 2,6-dimethylpyridine (994 mg,
9.28 mmol) in DCM (10 mL). The reaction was stirred at rt for about
10 min. The volatiles were removed at rt under reduced pressure to
afford the title product (529 mg, 100%). For analytical purposes, a
sample of the title product was quenched with MeOH; LC/MS (Table A,
Method i) R.sub.t=2.22 min; MS m/z: 338 (M+H-Cl+MeO).sup.+.
Step 4:
6-Bromo-1-((1-(2-((tert-butyldimethylsilyl)oxy)ethyl)-4-(trifluorm-
ethyl)-1H-pyrrol-3-yl)methyl)-2-methyl-1H-indazol-3(2H)-one
[1083] The reaction was performed using
1-(2-((tert-butyldimethylsilyl)oxy)ethyl)-3-(chloromethyl)-4-(trifluorome-
thyl)-1H-pyrrole and 6-bromo-2-methyl-1H-indazol-3(2H)-one
(Preparation #1) in a similar fashion to Preparation #4, step 1 to
afford the title product (0.48 g, 85%); LC/MS (Table A, Method i)
R.sub.t=2.19 min; MS m/z: 532 and 534 (M+H).sup.+.
Step 5:
(R)-6-(2-(4-Acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-1-((1-(2-
-((tert-butyldimethylsilyl)oxy)ethyl)-4-(trifluoromethyl)-1H-pyrrol-3-yl)m-
ethyl)-2-methyl-1H-indazol-3(2H)-one
[1084] The reaction was performed using
6-bromo-1-((1-(2-((tert-butyldimethylsilyl)oxy)ethyl)-4-(trifluoromethyl)-
-1H-pyrrol-3-yl)methyl)-2-methyl-1H-indazol-3(2H)-one and
(R)-1-(4-(5-bromopyrimidin-2-yl)-2-methylpiperazin-1-yl)ethanone
(Preparation #16) in a similar fashion to Example #8 to afford the
title product (0.157 g, 69%); LC/MS (Table A, Method i)
R.sub.t=1.89 min; MS m/z: 672 (M+H).sup.+.
Step 6:
(R)-6-(2-(4-Acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-1-((1-(2-
-hydroxyethyl)-4-(trifluoromethyl)-1H-pyrrol-3-yl)methyl)-2-methyl-1H-inda-
zol-3(2H)-one
[1085] The reaction was performed using
(R)-6-(2-(4-acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-1-((1-(2-((tert-
-butyldimethylsilyl)oxy)ethyl)-4-(trifluoromethyl)-1H-pyrrol-3-yl)methyl)--
2-methyl-1H-indazol-3(2H)-one in a similar fashion to Example #35,
step 3 to afford the title product (0.102 g, 77%); LC/MS (Table A,
Method a) R.sub.t=1.70 min; MS m/z: 558 (M+H).sup.+. (TNF
IC.sub.50=A).
Example #65*
(R)-6-(2-(4-acetyl-2-methylpiperazin-1-yl)pyrimidin-5-yl)-1-(2-(difluorome-
thoxy)-6-(hydroxymethyl)benzyl)-2-methyl-1H-indazol-3(2H)-one
##STR00336##
[1087]
(R)-6-(2-(4-Acetyl-2-methylpiperazin-1-yl)pyrimidin-5-yl)-1-(2-(dif-
luoromethoxy)-6-(hydroxymethyl)benzyl)-2-methyl-1H-indazol-3(2H)-one
was prepared in a similar fashion to Example #33, step 9 using
6-chloro-1-(2-(difluoromethoxy)-6-(hydroxymethyl)benzyl)-2-methyl-1H-inda-
zol-3(2H)-one (Example #33, step 7) and
(R)-1-(4-(5-bromopyrimidin-2-yl)-3-methylpiperazin-1-yl)ethanone
(prepared in a similar fashion to Preparation #13 using
5-bromo-2-chloropyrimidine and
(R)-1-(3-methylpiperazin-1-yl)ethanone, trifluoroacetic acid salt
(prepared in a similar fashion to Preparation #19, step 4 using
(R)-tert-butyl 4-acetyl-2-methylpiperazine-1-carboxylate (prepared
in a similar fashion to Preparation #16 using (R)-tert-butyl
2-methylpiperazine-1-carboxylate))) to give the title compound
(0.060 g, 38%); LC/MS (Table A, Method e) R.sub.t=1.68 min; MS m/z:
553 (M+H).sup.+. (TNF IC.sub.50=A).
Example #66
(R)-7-(5-(1-(2-(difluoromethoxy)-6-(hydroxymethyl)benzyl)-2-methyl-3-oxo-2-
,3-dihydro-1H-indazol-6-yl)pyrimidin-2-yl)hexahydroimidazo[1,5-a]pyrazin-3-
(2H)-one
##STR00337##
[1089]
(R)-6-(2-(4-Acetyl-2-methylpiperazin-1-yl)pyrimidin-5-yl)-1-(2-(dif-
luoromethoxy)-6-(hydroxymethyl)benzyl)-2-methyl-1H-indazol-3(2H)-one
was prepared in a similar fashion to Example #33, step 9 using
6-chloro-1-(2-(difluoromethoxy)-6-(hydroxymethyl)benzyl)-2-methyl-1H-inda-
zol-3(2H)-one (Example #33, step 7) and
(R)-1-(4-(5-bromopyrimidin-2-yl)-3-methylpiperazin-1-yl)ethanone
(prepared in a similar fashion to Preparation #13 using
5-bromo-2-chloropyrimidine and
(R)-1-(3-methylpiperazin-1-yl)ethanone, trifluoroacetic acid salt
(prepared in a similar fashion to Preparation #19, step 4 using
(R)-tert-butyl 4-acetyl-2-methylpiperazine-1-carboxylate (prepared
in a similar fashion to Preparation #16 using (R)-tert-butyl
2-methylpiperazine-1-carboxylate))) to give the title compound
(0.060 g, 38%); LC/MS (Table A, Method e) R.sub.t=1.68 min; MS m/z:
553 (M+H).sup.+. (TNF IC.sub.50=A).
[1090] The compounds shown in Table 29 were synthesized in a manner
similar to Example #2 from
(R)-hexahydroimidazo[1,5-a]pyrazin-3(2H)-one (Preparation #46) and
the corresponding 2-chloropyrimidines.
TABLE-US-00035 TABLE 29 R.sub.t min (Table A, m/z ESI+ TNF
2-Chloropyrimidine Product Example # Method) (M + H).sup.+
IC.sub.50 6-(2-Chloropyrimidin-5- yl)-2-methyl-1-((5-methyl-
2-(trifluoromethyl)pyridin- 3-yl)methyl)-1,2-dihydro-
3H-indazol-3-one (Preparation #47) ##STR00338## 29.1 1.68 (a) 539 B
6-(2-Chloropyrimidin-5- yl)-2-methyl-1-((2-
(trifluoromethyl)pyridin- 3-yl)methyl)-1,2-dihydro-
3H-indazol-3-one (Preparation #48) ##STR00339## 29.2 1.61 (a) 525 B
6-(2-Chloropyrimidin-5- yl)-2-methyl-1-(5-methyl-
2-(trifluoromethyl)benzyl)- 1,2-dihydro-3H-indazol- 3-one
(Preparation #49) ##STR00340## 29.3 1.96 (a) 538 A
1-((5-Chloro-1,3- dihydroisobenzofuran-4- yl)methyl)-6-(2-
chloropyrimidin-5-yl)- 2-methyl-1,2-dihydro- 3H-indazol-3-one
(Preparation #50) ##STR00341## 29.4 1.81 (a) 532 A 1-(5-Chloro-2-
(trifluoromethyl)benzyl)- 6-(2-chloropyrimidin- 5-yl)-2-methyl-
1H-indazol-3(2H)-one (prepared in a similar manner to Example #1
using 6-(2- chloropyrimidin-5- yl)-2-methyl-1H- indazol-3(2H)-one
(Preparation #23) and 2-(bromomethyl)-4- chloro-1- ##STR00342##
29.5 2.02 (a) 558 A (trifluoromethyl)benzene 6-(2-Chloropyrimidin-
5-yl)-1-((3- (difluoromethoxy)-6- methylpyridin-2-yl)
methyl)-2-methyl-1H- indazol-3(2H)-one (Preparation #57)
##STR00343## 29.6 1.66 (a) 537 B
Example #67
(R)-4-(Difluoromethoxy)-3-((2-methyl-3-oxo-6-(2-(3-oxohexahydroimidazo[1,5-
-a]pyrazin-7(1H)-yl)pyrimidin-5-yl)-2,3-dihydro-1H-indazol-1-yl)methyl)ben-
zyl dimethylcarbamate
##STR00344##
[1092] A solution of 4-nitrophenyl chloroformate (0.058 g, 0.29
mmol) and DIEA (0.076 mL, 0.44 mmol) in DCM (0.725 mL) was treated
with a solution of
(R)-7-(5-(1-(2-(difluoromethoxy)-5-(hydroxymethyl)benzyl)-2-methyl-3-o-
xo-2,3-dihydro-1H-indazol-6-yl)pyrimidin-2-yl)hexahydroimidazo[1,5-a]pyraz-
in-3(2H)-one (0.080 g, 0.14 mmol) (Example #16.1) in DMF (0.725 mL)
and the resulting solution was allowed to stir at ambient
temperature for about 45 min. Additional 4-nitrophenyl
chloroformate (0.058 g, 0.29 mmol) and DIEA (0.076 mL, 0.44 mmol)
were each added and stirring was continued for about 16 h.
Dimethylamine (2 M in THF) (1.0 mL, 2.0 mmol) was added dropwise
via syringe and stirring was continued for about 10 min. The
reaction mixture was partitioned between EtOAc (10 mL) and water
(10 mL). The organic phase was washed with sat. aq. NaCl (5 mL),
dried over Na.sub.2SO.sub.4, filtered, and concentrated under
reduced pressure. The sample was purified on silica gel using a
gradient of 0-5% MeOH in DCM to give the title product (0.052 g,
58%); LC/MS (Table A, Method a) R.sub.t=1.73 min; MS m/z: 623
(M+H).sup.+. (TNF IC.sub.50=A).
Example #68
(R)-2-(4-(Difluoromethoxy)-3-((2-methyl-3-oxo-6-(2-(3-oxohexahydroimidazo[-
1,5-a]pyrazin-7(1H)-yl)pyrimidin-5-yl)-2,3-dihydro-1H-indazol-1-yl)methyl)-
phenyl)acetonitrile
##STR00345##
[1094] The reaction was performed using
2-(3-((6-bromo-2-methyl-3-oxo-2,3-dihydro-1H-indazol-1-yl)methyl)-4-(difl-
uoromethoxy)phenyl)acetonitrile (Preparation #20) and
(R)-7-(5-bromopyrimidin-2-yl)hexahydroimidazo[1,5-a]pyrazin-3(2H)-one
(Preparation #13) in a similar fashion to Example #8 to give the
title product (46%); LC/MS (Table A, Method a) R.sub.t=1.68 min; MS
m/z: 561 (M+H).sup.+. (TNF IC.sub.50=A).
Example #69*
(R)-2-(4-(5-(1-(2-(Difluoromethoxy)-5-methylbenzyl)-2-methyl-3-oxo-2,3-dih-
ydro-1H-indazol-6-yl)pyrimidin-2-yl)-2-methyl dihydrogen
phosphate
##STR00346##
[1096] The reaction was performed using
(R)-1-(2-(difluoromethoxy)-5-methylbenzyl)-6-(2-(4-(2-hydroxyacetyl)-3-me-
thylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-1,2-dihydro-3H-indazol-3-one
(Example #22.1) in a similar fashion to Example #31 to give the
title product (37%); LC/MS (Table A, Method a) R.sub.t=1.57 min; MS
m/z: 633 (M+H).sup.+. (TNF IC.sub.50=A).
Example #70*
(R)-1-(2-(Difluoromethoxy)benzyl)-6-(2-(4-(2-hydroxyacetyl)-3-methylpipera-
zin-1-yl)pyrimidin-5-yl)-7-methoxy-2-methyl-1H-indazol-3(2H)-one
##STR00347##
[1098]
(R)-1-(2-(Difluoromethoxy)benzyl)-6-(2-(4-(2-hydroxyacetyl)-3-methy-
lpiperazin-1-yl)pyrimidin-5-yl)-7-methoxy-2-methyl-1H-indazol-3(2H)-one
was prepared in a similar fashion to Example #14, step 4 using
(R)-1-(4-(5-bromopyrimidin-2-yl)-2-methylpiperazin-1-yl)-2-hydroxyethanon-
e (Preparation #15) and
1-(2-(difluoromethoxy)benzyl)-7-methoxy-2-methyl-6-(4,4,5,5-tetramethyl-1-
,3,2-dioxaborolan-2-yl)-1H-indazol-3(2H)-one (prepared in a similar
fashion to Preparation #4, step 2 using
6-bromo-1-(2-(difluoromethoxy)benzyl)-7-methoxy-2-methyl-1H-indazol-3(2H)-
-one (Preparation #66)) to afford the title compound (52%); LC/MS
(Table A, Method a) R.sub.t=1.86 min; MS m/z: 569 (M+H).sup.+. (TNF
IC.sub.50=A).
Example #71*
(R)-1-(2-Chlorobenzyl)-6-(2-(4-(2-hydroxyacetyl)-3-methylpiperazin-1-yl)py-
rimidin-5-yl)-2-methyl-3-oxo-2,3-dihydro-1H-indazole-7-carbonitrile
##STR00348##
[1100]
(R)-1-(2-Chlorobenzyl)-6-(2-(4-(2-hydroxyacetyl)-3-methylpiperazin--
1-yl)pyrimidin-5-yl)-2-methyl-3-oxo-2,3-dihydro-1H-indazole-7-carbonitrile
was prepared in a similar manner to Preparation #15 using
(R)-1-(2-chlorobenzyl)-2-methyl-6-(2-(3-methylpiperazin-1-yl)pyrimidin-5--
yl)-3-oxo-2,3-dihydro-1H-indazole-7-carbonitrile, 2 hydrochloric
acid (prepared in a similar manner to Example #3, step 1 using
(R)-tert-butyl
4-(5-(1-(2-chlorobenzyl)-7-cyano-2-methyl-3-oxo-2,3-dihydro-1H-indazol-6--
yl)pyrimidin-2-yl)-2-methylpiperazine-1-carboxylate (prepared in a
similar manner to Example #1 using 2-chlorobenzyl bromide and
(R)-tert-butyl
4-(5-(7-cyano-2-methyl-3-oxo-2,3-dihydro-1H-indazol-6-yl)pyrimidin-2-yl)--
2-methylpiperazine-1-carboxylate (prepared in a similar manner to
Example #33, step 9 using
6-chloro-2-methyl-3-oxo-2,3-dihydro-1H-indazole-7-carbonitrile
(Preparation #67) and (R)-tert-butyl
4-(5-bromopyrimidin-2-yl)-2-methylpiperazine-1-carboxylate
(prepared in a similar manner to Preparation #13, step 1 using
(R)-1-N-Boc-2-methylpiperazine)))) to afford the title compound
(66%); LC/MS (Table A, Method a) R.sub.t=1.84 min; MS m/z: 532
(M+H).sup.+. (TNF IC.sub.50=B).
Example #72
(S)-7-(5-(2-methyl-1-((1-methyl-4-(trifluoromethyl)-1H-pyrazol-3-yl)methyl-
)-3-oxo-2,3-dihydro-1H-indazol-6-yl)pyrimidin-2-yl)hexahydroimidazo[1,5-a]-
pyrazin-3(2H)-one
##STR00349##
[1102] The reaction was performed in a similar manner to Example #8
using
(S)-7-(5-bromopyrimidin-2-yl)hexahydroimidazo[1,5-a]pyrazin-3(2H)-one
(0.108 g, 0.361 mmol (Preparation #13) and
6-bromo-2-methyl-1-((1-methyl-4-(trifluoromethyl)-1H-pyrazol-3-yl)methyl)-
-1H-indazol-3(2H)-one (0.108 g, 0.278 mmol) (synthesized in a
similar fashion to Example #1 from
6-bromo-2-methyl-1H-indazol-3(2H)-one (Preparation #1) and
3-(bromomethyl)-1-methyl-4-(trifluoromethyl)-1H-pyrazole
(synthesized in a similar fashion to Preparation #21, step 2 from
(1-methyl-4-(trifluoromethyl)-1H-pyrazol-3-yl)methanol (Preparation
#35, step 2) to give the title product (72%); (Table A, Method a)
R.sub.t=1.58 min; MS m/z: 528 (M+H).sup.+. (TNF IC.sub.50=B).
Example #73*
(R)-6-(2-(4-Acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-1-((6-m-
ethyl-3-(trifluoromethyl)pyridin-2-yl)methyl)-1H-pyrazolo[3,4-b]pyridin-3(-
2H)-one
##STR00350##
[1104] The reaction was performed in a similar manner to Example #1
using
(R)-6-(2-(4-acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-1H-pyr-
azolo[3,4-b]pyridin-3(2H)-one (synthesized in a similar manner to
Example #8 using
6-chloro-2-methyl-1H-pyrazolo[3,4-b]pyridin-3(2H)-one (Example #15,
step 2) and
(R)-1-(4-(5-bromopyrimidin-2-yl)-2-methylpiperazin-1-yl)ethanone
(Preparation #16)) and
2-(bromomethyl)-6-methyl-3-(trifluoromethyl)pyridine (synthesized
in a similar fashion to Preparation #14, step 6 from
(6-methyl-3-(trifluoromethyl)pyridin-2-yl)methanol (Preparation
#17)) to give the title product (20%); (Table A, Method a)
R.sub.t=1.92 min; MS m/z: 541 (M+H).sup.+. (TNF IC.sub.50=A).
Example #74*
(R)-6-(2-(4-Acetyl-2-methylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-1-((6-m-
ethyl-3-(trifluoromethyl)pyridin-2-yl)methyl)-1H-indazol-3(2H)-one
##STR00351##
[1106] The reaction was performed in a similar manner to Example #1
using
(R)-6-(2-(4-acetyl-2-methylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-1H-ind-
azol-3(2H)-one (synthesized in a similar fashion to Example #8 from
6-bromo-2-methyl-1H-indazol-3(2H)-one (Preparation #1) and
(R)-1-(4-(5-bromopyrimidin-2-yl)-3-methylpiperazin-1-yl)ethanone
(prepared in a similar fashion to Preparation #13, step 1 using
(R)-1-(3-methylpiperazin-1-yl)ethanone, trifluoroacetic acid salt
(prepared in a similar fashion to Preparation #19, step 4 using
(R)-tert-butyl 4-acetyl-2-methylpiperazine-1-carboxylate (prepared
in a similar fashion to Preparation #16 using (R)-tert-butyl
2-methylpiperazine-1-carboxylate))) and
2-(bromomethyl)-6-methyl-3-(trifluoromethyl)pyridine (synthesized
in a similar fashion to Preparation #14, step 6 from
(6-methyl-3-(trifluoromethyl)pyridin-2-yl)methanol (Preparation
#17)) to give the title product (63%); (Table A, Method a)
R.sub.t=1.89 min; MS m/z: 540 (M+H).sup.+. (TNF IC.sub.50=A).
Example #75*
(R)-6-(2-(4-Acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-1-((3-(difluorom-
ethoxy)-6-methylpyridin-2-yl)methyl)-2-methyl-1H-indazol-3(2H)-one
##STR00352##
[1108]
(R)-6-(2-(4-Acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-1-((3-(di-
fluoromethoxy)-6-methylpyridin-2-yl)methyl)-2-methyl-1H-indazol-3(2H)-one
was prepared in a similar fashion to Preparation #16 from
(R)-1-((3-(difluoromethoxy)-6-methylpyridin-2-yl)methyl)-2-methyl-6-(2-(3-
-methylpiperazin-1-yl)pyrimidin-5-yl)-1H-indazol-3(2H)-one
(prepared from tert-butyl (R)-2-methylpiperazine-1-carboxylate and
6-(2-chloropyrimidin-5-yl)-1-((3-(difluoromethoxy)-6-methylpyridin-2-yl)m-
ethyl)-2-methyl-1H-indazol-3(2H)-one (Preparation #57) in a similar
fashion to Preparation #13, step 1); LC/MS (Table A, Method a)
R.sub.t=1.81 min; MS m/z: 539 (M+H).sup.+. (TNF IC.sub.50=A).
Example #76*
(R)-1-((3-(Difluoromethoxy)-6-methylpyridin-2-yl)methyl)-6-(2-(4-(2-hydrox-
yacetyl)-3-methylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)--
one
##STR00353##
[1110]
(R)-1-((3-(Difluoromethoxy)-6-methylpyridin-2-yl)methyl)-6-(2-(4-(2-
-hydroxyacetyl)-3-methylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-
-3(2H)-one was prepared from
(R)-1-((3-(difluoromethoxy)-6-methylpyridin-2-yl)methyl)-2-methyl-6-(2-(3-
-methylpiperazin-1-yl)pyrimidin-5-yl)-1H-indazol-3(2H)-one
(prepared from tert-butyl (R)-2-methylpiperazine-1-carboxylate and
6-(2-chloropyrimidin-5-yl)-1-((3-(difluoromethoxy)-6-methylpyridin-2-yl)m-
ethyl)-2-methyl-1H-indazol-3(2H)-one (Preparation #57) in a similar
fashion to Preparation #13, step 1) in a similar fashion to
Preparation #15. LC/MS (Table A, Method a) R.sub.t=1.72 min; MS
m/z: 554 (M+H).sup.+. (TNF IC.sub.50=A).
Example #77
1-(2-(Difluoromethoxy)-6-(methoxymethyl)benzyl)-6-(2-(2-hydroxypropan-2-yl-
)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one
##STR00354##
[1112]
1-(2-(Difluoromethoxy)-6-(methoxymethyl)benzyl)-6-(2-(2-hydroxyprop-
an-2-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one was prepared
from
6-chloro-1-(2-(difluoromethoxy)-6-(methoxymethyl)benzyl)-2-methyl-1H-inda-
zol-3(2H)-one (Example #33, step 8) and
2-(5-bromopyrimidin-2-yl)propan-2-ol in a similar fashion to
Example #33, step 9. LC/MS (Table A, Method a) R.sub.t=1.92 min; MS
m/z: 485 (M+H).sup.+. (TNF IC.sub.50=B).
Example #78*
(R)-2-(4-(difluoromethoxy)-3-((6-(2-(4-(2-hydroxy
acetyl)-2-methylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-3-oxo-2,3-dihydro-
-1H-indazol-1-yl)methyl)phenyl)acetonitrile
##STR00355##
[1114]
(R)-2-(4-(Difluoromethoxy)-3-((6-(2-(4-(2-hydroxyacetyl)-2-methylpi-
perazin-1-yl)pyrimidin-5-yl)-2-methyl-3-oxo-2,3-dihydro-1H-indazol-1-yl)me-
thyl)phenyl)acetonitrile was prepared from
2-(3-((6-bromo-2-methyl-3-oxo-2,3-dihydro-1H-indazol-1-yl)methyl)-4-(difl-
uoromethoxy)phenyl)acetonitrile (Preparation #20) and
(R)-1-(4-(5-bromopyrimidin-2-yl)-3-methylpiperazin-1-yl)-2-hydroxyethanon-
e (Preparation #22) in a similar fashion to Example #8. LC/MS
(Table A, Method a) R.sub.t=1.72 min; MS m/z: 578 (M+H).sup.+. (TNF
IC.sub.50=A).
Example #79*
(R)-2-(4-(Difluoromethoxy)-3-((2-methyl-3-oxo-6-(2-(3-oxotetrahydro-1H-oxa-
zolo[3,4-a]pyrazin-7(3H)-yl)pyrimidin-5-yl)-2,3-dihydro-1H-indazol-1-yl)me-
thyl)phenyl)acetonitrile
##STR00356##
[1116]
(R)-2-(4-(Difluoromethoxy)-3-((2-methyl-3-oxo-6-(2-(3-oxotetrahydro-
-1H-oxazolo[3,4-a]pyrazin-7(3H)-yl)pyrimidin-5-yl)-2,3-dihydro-1H-indazol--
1-yl)methyl)phenyl)acetronitrile was prepared from
2-(3-((6-bromo-2-methyl-3-oxo-2,3-dihydro-1H-indazol-1-yl)methyl)-4-(difl-
uoromethoxy)phenyl)acetonitrile (Preparation #20) and
(R)-7-(5-bromopyrimidin-2-yl)tetrahydro-1H-oxazolo[3,4-a]pyrazin-3(5H)-on-
e (prepared from 5-bromo-2-chloropyrimidine and
(R)-tetrahydro-1H-oxazolo[3,4-a]pyrazin-3(5H)-one in a similar
fashion to Preparation #13, step 1) in a similar fashion to Example
#8. LC/MS (Table A, Method a) R.sub.t=1.84 min; MS m/z: 562
(M+H).sup.+. (TNF IC.sub.50=A).
Example #80*
(R)-1-(2-(Difluoromethoxy)-5-methylbenzyl)-6-(2-(4-(2-hydroxyacetyl)-2-met-
hylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-1H-pyrazolo[3,4-b]pyridin-3(2H)-
-one
##STR00357##
[1118] The compound was prepared in a manner similar to Example #8
from
(R)-1-(4-(5-bromopyrimidin-2-yl)-3-methylpiperazin-1-yl)-2-hydroxyethanon-
e (Preparation #22) and
6-chloro-1-(2-(difluoromethoxy)-5-methylbenzyl)-2-methyl-1H-pyrazolo[3,4--
b]pyridin-3(2H)-one (prepared in a manner similar to Example #1
from 6-chloro-2-methyl-1H-pyrazolo[3,4-b]pyridin-3(2H)-one (Example
#15, step 2) and
2-(bromomethyl)-1-(difluoromethoxy)-4-methylbenzene (prepared in a
manner similar to Preparation #3, step 2 from
(2-(difluoromethoxy)-5-methylphenyl)methanol)) (35%); LC/MS (Table
A, Method e) R.sub.t=1.93 min.; MS m/z 554 (M+H).sup.+. (TNF
IC.sub.50=A).
Example #81*
(R)-1-(2-Chloro-5-methylbenzyl)-6-(2-(4-(2-hydroxyacetyl)-2-methylpiperazi-
n-1-yl)pyrimidin-5-yl)-2-methyl-1H-pyrazolo[3,4-b]pyridin-3(2H)-one
##STR00358##
[1120] The compound was synthesized in a manner similar to Example
#8 from
(R)-1-(4-(5-bromopyrimidin-2-yl)-3-methylpiperazin-1-yl)-2-hydroxyethanon-
e (Preparation #22) and
6-chloro-1-(2-chloro-5-methylbenzyl)-2-methyl-1H-pyrazolo[3,4-b]pyridin-3-
(2H)-one (prepared in a manner similar to Example #1 from
6-chloro-2-methyl-1H-pyrazolo[3,4-b]pyridin-3(2H)-one (Example #15,
step 2) and 2-(bromomethyl)-1-chloro-4-methylbenzene (prepared in a
manner similar to Preparation #3, step 2 from
(2-chloro-5-methylphenyl)methanol (prepared in a manner similar to
Preparation #32, step 4 from methyl 2-chloro-5-methylbenzoate)))
(45%); LC/MS (Table A, Method e) R.sub.t=2.02 min.; MS m/z: 522
(M+H).sup.+. (TNF IC.sub.50=A).
Example #82*
(R)-6-(2-(4-Acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-1-(2-((difluorom-
ethyl)thio)-4-methylbenzyl)-2-methyl-1H-indazol-3(2H)-one
##STR00359##
[1122] The compound was prepared in a manner similar to Example #1
from
(R)-6-(2-(4-acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-1H-ind-
azol-3(2H)-one (Preparation #28) and
(2-(bromomethyl)-4-methylphenyl)(difluoromethyl)sulfane (prepared
in a manner similar to Preparation #14, step 6 from
(2-((difluoromethyl)thio)-5-methylphenyl)methanol (Preparation
#18)) (63%); LC/MS (Table A, Method e) R.sub.t=2.10 min; MS m/z 553
(M+H).sup.+. (TNF IC.sub.50=A).
Example #83
1-(2-Chloro-5-((1-methyl-2-oxopiperidin-3-yl)amino)benzyl)-6-(2-(2-hydroxy-
propan-2-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one
##STR00360##
[1124] PPh.sub.3 (156 mg, 0.600 mmol) and
3-((4-chloro-3-(hydroxymethyl)phenyl)amino)-1-methylpiperidin-2-one
(Preparation #43) (0.100 g, 0.370 mmol) were combined in DCM (2
mL). Carbon tetrabromide (197 mg, 0.600 mmol) was added and the
reaction was stirred for about 5 min at rt. K.sub.2CO.sub.3 (154
mg, 1.12 mmol),
6-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one
(Preparation #19) (106 mg, 0.370 mmol), and DMF (2 mL) were added.
DCM was removed in vacuo, then the reaction was heated to about
45.degree. C. for about 90 min. The reaction was cooled and
partitioned between EtOAc (10 mL) and water (10 mL). The organic
layer was washed with water (10 mL) and sat. aq. NaCl (10 mL), then
dried over MgSO.sub.4, filtered, and concentrated in vacuo. Further
purification via flash chromatography (0-10% MeOH in DCM) yielded
the title compound (83 mg, 42%); LC/MS (Table A, Method e)
R.sub.t=1.75 min; MS m/z 535 (M+H).sup.+. (TNF IC.sub.50=B).
Example #84
((R)-7-(5-(1-((3-(Difluoromethoxy)-6-(hydroxymethyl)pyridin-2-yl)methyl)-2-
-methyl-3-oxo-2,3-dihydro-1H-indazol-6-yl)pyrimidin-2-yl)hexahydroimidazo[-
1,5-a]pyrazin-3(2H)-one
##STR00361##
[1125] Step 1:
6-(2-Chloropyrimidin-5-yl)-1-((3-(difluoromethoxy)-6-vinylpyridin-2-yl)me-
thyl)-2-methyl-1H-indazol-3(2H)-one
[1126] The title compound was synthesized in a manner similar to
Preparation #4, step 1 from
6-(2-chloropyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one
(Preparation #23) and
2-(bromomethyl)-3-(difluoromethoxy)-6-vinylpyridine (synthesized in
a manner similar to Preparation #14, step 6 from
(3-(difluoromethoxy)-6-vinylpyridin-2-yl)methanol (synthesized in a
manner similar to Preparation #61, step 1 from
tributyl(vinyl)stannane and
(6-chloro-3-(difluoromethoxy)pyridin-2-yl)methanol (synthesized in
a manner similar to Preparation #9 from
6-chloro-3-(difluoromethoxy)picolinaldehyde (synthesized in a
manner similar to Example #4, step 1 from
6-chloro-3-(difluoromethoxy)-2-vinylpyridine (synthesized in a
manner similar to Example #14, step 4 from
6-chloro-3-(difluoromethoxy)-2-iodopyridine and
4,4,5,5-tetramethyl-2-vinyl-1,3,2-dioxaborolane))))); LC/MS (Table
A, Method i) R.sub.t=1.19 min; MS m/z: 444 (M+H).sup.+.
Step 2:
6-((6-(2-Chloropyrimidin-5-yl)-2-methyl-3-oxo-2,3-dihydro-1H-indaz-
ol-1-yl)methyl)-5-(difluoromethoxy)picolinaldehyde
[1127] The title compound was synthesized in a manner similar to
Example #4, step 1 from
6-(2-chloropyrimidin-5-yl)-1-((3-(difluoromethoxy)-6-vinylpyridin-2-yl)me-
thyl)-2-methyl-1H-indazol-3(2H)-one; LC/MS (Table A, Method i)
R.sub.t=1.05 min; MS m/z: 446 (M+H).sup.+.
Step 3:
6-(2-Chloro-1,6-dihydropyrimidin-5-yl)-1-((3-(difluoromethoxy)-6-(-
hydroxymethyl)pyridin-2-yl)methyl)-2-methyl-1H-indazol-3(2H)-one
[1128]
6-((6-(2-Chloropyrimidin-5-yl)-2-methyl-3-oxo-2,3-dihydro-1H-indazo-
l-1-yl)methyl)-5-(difluoromethoxy)picolinaldehyde (68 mg, 0.15
mmol) in MeOH (2 mL) was cooled in an ice/water bath then sodium
tetrahydroborate (8.1 mg, 0.21 mmol) was added. After about 15 min,
the mixture was concentrated under reduced pressure then
partitioned between EtOAc and water. The organic solution was dried
over magnesium sulfate, filtered and concentrated to give the title
compound (60 mg, 87%); LC/MS (Table A, Method i) R.sub.t=0.78 min;
MS m/z: 450 (M+H).sup.+.
Step 4:
6-(2-Chloropyrimidin-5-yl)-1-((3-(difluoromethoxy)-6-(hydroxymethy-
l)pyridin-2-yl)methyl)-2-methyl-1H-indazol-3(2H)-one
[1129]
6-(2-Chloro-1,6-dihydropyrimidin-5-yl)-1-((3-(difluoromethoxy)-6-(h-
ydroxymethyl)pyridin-2-yl)methyl)-2-methyl-1H-indazol-3(2H)-one (55
mg, 0.12 mmol) suspendered in 1,4-dioxane (10 mL) was treated with
chloranil (58 mg, 0.24 mmol) then stirred at rt for about 12 h. The
mixture was concentrated under reduced pressure then purified via
flash chromatography on silica gel (0-10% DCM/MeOH) to give the
title compound (22.2 mg, 41%); LC/MS (Table A, Method i)
R.sub.t=0.96 min; MS m/z: 448 (M+H).sup.+.
Step 5:
((R)-7-(5-(1-((3-(Difluoromethoxy)-6-(hydroxymethyl)pyridin-2-yl)m-
ethyl)-2-methyl-3-oxo-2,3-dihydro-1H-indazol-6-yl)pyrimidin-2-yl)hexahydro-
imidazo[1,5-a]pyrazin-3(2H)-one
[1130] The title compound was synthesized in a manner similar to
Preparation #13 from
6-(2-chloropyrimidin-5-yl)-1-((3-(difluoromethoxy)-6-(hydroxymethyl)pyrid-
in-2-yl)methyl)-2-methyl-1H-indazol-3(2H)-one and
(S)-hexahydroimidazo[1,5-a]pyrazin-3(2H)-one hydrochloride
(Preparation #46); LC/MS (Table A, Method a) R.sub.t=1.49 min; MS
m/z: 553 (M+H).sup.+. (TNF IC.sub.50=A).
Example #85
1-((S)-1-(2-Fluorophenyl)ethyl)-6-(2-((R)-4-(2-hydroxyacetyl)-3-methylpipe-
razin-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one
##STR00362##
[1132]
1-(1-(2-Fluorophenyl)ethyl)-6-(2-((R)-4-(2-hydroxyacetyl)-3-methylp-
iperazin-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one (0.154
g, 0.275 mmol) (Example #28.3) was submitted for chiral separation
(Table C, Method d). Fractions from the first eluting component
were combined, concentrated and frozen. The resulting solid was
lyophilized to afford the title product (0.080 g, 58%) with
undetermined optical rotation. LC/MS (Table A, Method e)
R.sub.t=1.81 min; MS m/z: 505 (M+H).sup.+. (TNF IC.sub.50=A).
Example #86
1-((R)-1-(2-Fluorophenyl)ethyl)-6-(2-((R)-4-(2-hydroxyacetyl)-3-methylpipe-
razin-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one
##STR00363##
[1134]
1-(1-(2-Fluorophenyl)ethyl)-6-(2-((R)-4-(2-hydroxyacetyl)-3-methylp-
iperazin-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one (0.154
g, 0.275 mmol) (Example #28.3) was submitted for chiral separation
(Table C, Method d). Fractions from the second eluting component
were combined, concentrated and frozen. The resulting solid was
lyophilized to afford the title product (0.083 g, 60%) with
undetermined optical rotation. LC/MS (Table A, Method e)
R.sub.t=1.81 min; MS m/z: 505 (M+H).sup.+. (TNF IC.sub.50=B).
Example #87
1-(2-(Difluoromethoxy)-5-methylbenzyl)-2-methyl-6-(2-(3-methylpyrrolidin-3-
-yl)pyrimidin-5-yl)-1H-indazol-3(2H)-one
##STR00364##
[1135] Step 1:
6-(2-(1-Benzyl-3-methylpyrrolidin-3-yl)pyrimidin-5-yl)-1-(2-(difluorometh-
oxy)-5-methylbenzyl)-2-methyl-1H-indazol-3(2H)-one
[1136]
6-(2-(1-Benzyl-3-methylpyrrolidin-3-yl)pyrimidin-5-yl)-1-(2-(difluo-
romethoxy)-5-methylbenzyl)-2-methyl-1H-indazol-3(2H)-one was
prepared in a similar fashion to Example #14, step 4 using
1-(2-(difluoromethoxy)-5-methylbenzyl)-2-methyl-6-(4,4,5,5-tetramethyl-1,-
3,2-dioxaborolan-2-yl)-1H-indazol-3(2H)-one (Example #22, step 2)
and 2-(1-benzyl-3-methylpyrrolidin-3-yl)-5-bromopyrimidine
(Preparation #69) to give the title compound (0.127 g, 32%); LC/MS
(Table A, Method j) R.sub.t=1.24 min; MS m/z: 570 (M+H).sup.+.
Step 2:
1-(2-(Difluoromethoxy)-5-methylbenzyl)-2-methyl-6-(2-(3-methylpyrr-
olidin-3-yl)pyrimidin-5-yl)-1H-indazol-3(2H)-one
[1137] A mixture of
6-(2-(1-benzyl-3-methylpyrrolidin-3-yl)pyrimidin-5-yl)-1-(2-(difluorometh-
oxy)-5-methylbenzyl)-2-methyl-1H-indazol-3(2H)-one (0.125 g, 0.219
mmol), TEA (44.0 .mu.L, 0.316 mmol) in DCM (2 mL) was cooled to
about 0.degree. C. 1-Chloroethyl chloroformate (55 .mu.L, 0.50
mmol) was added and the reaction was stirred at about 0.degree. C.
for about 1 h. The reaction was concentrated under reduced pressure
to remove the DCM. MeOH (5 mL) was added and the reaction was
stirred at about 60.degree. C. for about 5 h. The reaction was
allowed to cool to rt then was concentrated under reduced pressure.
The reaction was partitioned between DCM (20 mL) and sat. aq.
NaHCO.sub.3 (20 mL), the layers were separated and the aqueous
layer was extracted with DCM (20 mL). The combined organic layers
were dried over Na.sub.2SO.sub.4, filtered and concentrated under
reduced pressure. The residue was purified on neutral alumina using
a gradient of 1-5% MeOH/DCM to give the title compound (0.039 g,
36%); LC/MS (Table A, Method j) R.sub.t=0.95 min; MS m/z: 480
(M+H).sup.+. (TNF IC.sub.50=A).
Example #88
1-(2-(Difluoromethoxy)-5-methylbenzyl)-6-(2-(1,3-dimethylpyrrolidin-3-yl)p-
yrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one
##STR00365##
[1139] A drop of AcOH was added to a mixture of
1-(2-(difluoromethoxy)-5-methylbenzyl)-2-methyl-6-(2-(3-methylpyrrolidin--
3-yl)pyrimidin-5-yl)-1H-indazol-3(2H)-one (0.030 g, 0.063 mmol)
(Example #87, step 2), formaldehyde (0.025 g, 0.31 mmol) and sodium
cyanotrihydroborate (9.8 mg, 0.16 mmol) in MeOH (0.5 mL). The
reaction was stirred at rt for about 2 h. The reaction was diluted
with MeOH (2.times.10 mL) and concentrated under reduced pressure.
The residue was purified using reverse phase HPLC (Table A, Method
I). The appropriate fractions were concentrated then frozen. The
resulting solid was lyophilized to afford the acetic acid salt of
the title product (0.006 g, 18%); LC/MS (Table A, Method j)
R.sub.t=0.96 min; MS m/z: 494 (M+H).sup.+. (TNF IC.sub.50=B).
Example #89
6-(6-(2-Aminopropan-2-yl)pyridin-3-yl)-1-(2-(difluoromethoxy)-5-methylbenz-
yl)-5-fluoro-2-methyl-1H-indazol-3(2H)-one
2,2,2-trifluoroacetate
##STR00366##
[1141]
6-(6-(2-Aminopropan-2-yl)pyridin-3-yl)-1-(2-(difluoromethoxy)-5-met-
hylbenzyl)-5-fluoro-2-methyl-1H-indazol-3(2H)-one
2,2,2-trifluoroacetate was prepared in a similar fashion to
Preparation #19, step 4 using tert-butyl
(2-(5-(1-(2-(difluoromethoxy)-5-methylbenzyl)-5-fluoro-2-methyl-3-oxo-2,3-
-dihydro-1H-indazol-6-yl)pyridin-2-yl)propan-2-yl)carbamate
(prepared in a similar fashion to Example #8 using tert-butyl
(2-(5-bromopyridin-2-yl)propan-2-yl)carbamate (Preparation #68) and
6-bromo-1-(2-(difluoromethoxy)benzyl)-5-fluoro-2-methyl-1H-indazol-3(2H)--
one (synthesized in a similar fashion to Preparation #4, step 1
from 6-bromo-5-fluoro-2-methyl-1H-indazol-3(2H)-one (synthesized in
a similar fashion to Preparation #1 from
4-bromo-2,5-difluorobenzoic acid) and
2-(bromomethyl)-1-(difluoromethoxy)-4-methylbenzene (synthesized in
a similar fashion to Preparation #3, step 2 from
(2-(difluoromethoxy)-5-methylphenyl)methanol (Preparation #11))) to
give the title compound (0.061 g, 67%); LC/MS (Table A, Method e)
Rt=0.99 min; MS m/z: 471 (M+H).sup.+. (TNF IC.sub.50=A).
Example #90
6-(2-(4-Acetylpiperazin-1-yl)pyrimidin-5-yl)-1-(2-(difluoromethoxy)-5-(met-
hoxymethyl)benzyl)-2-methyl-1H-indazol-3(2H)-one
##STR00367##
[1143]
6-(2-(4-Acetylpiperazin-1-yl)pyrimidin-5-yl)-1-(2-(difluoromethoxy)-
-5-(methoxymethyl)benzyl)-2-methyl-1H-indazol-3(2H)-one was
synthesized in a similar manner to Example #33, step 8 using
6-(2-(4-acetylpiperazin-1-yl)pyrimidin-5-yl)-1-(2-(difluoromethoxy)-5-(hy-
droxymethyl)benzyl)-2-methyl-1H-indazol-3(2H)-one (Example #16.8)
to afford the title compound (34%); LC/MS (Table A, Method e)
R.sub.t=1.82 min; MS m/z: 553 (M+H).sup.+. (TNF IC.sub.50=B).
Example #91
1-(2-(Difluoromethoxy)benzyl)-6-(2-(3-hydroxy-1-(2-hydroxyacetyl)azetidin--
3-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one
##STR00368##
[1145]
1-(2-(Difluoromethoxy)benzyl)-6-(2-(3-hydroxy-1-(2-hydroxyacetyl)az-
etidin-3-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one was
prepared in a similar manner to Preparation #15 using
1-(2-(difluoromethoxy)benzyl)-6-(2-(3-hydroxyazetidin-3-yl)pyrimidin-5-yl-
)-2-methyl-1H-indazol-3(2H)-one hydrochloride (prepared in a
similar manner to Example #3, step 1 using tert-butyl
3-(5-(1-(2-(difluoromethoxy)benzyl)-2-methyl-3-oxo-2,3-dihydro-1H-indazol-
-6-yl)pyrimidin-2-yl)-3-hydroxyazetidine-1-carboxylate (prepared in
a similar manner to Example #14, step 4 using
1-(2-(difluoromethoxy)benzyl)-2-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxa-
borolan-2-yl)-1H-indazol-3(2H)-one (Preparation #4, step 2) and
tert-butyl
3-(5-bromopyrimidin-2-yl)-3-hydroxyazetidine-1-carboxylate
(prepared in a similar manner to Example #20, step 1 using
tert-butyl 3-oxoazetidine-1-carboxylate))) to afford the title
compound (45%); LC/MS (Table A, Method a) R.sub.t=1.46 min; MS m/z:
512 (M+H).sup.+. (TNF IC.sub.50=B).
Example #92
1-(2-(Difluoromethoxy)-5-((5-oxo-1H-1,2,4-triazol-4-(5H)-yl)methy)benzyl)--
6-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one
##STR00369##
[1146] Step 1:
6-Bromo-1-(2-(difluoromethoxy)-5-(isocyanatomethyl)benzyl)-2-methyl-1H-in-
dazol-3(2H)-one
[1147] Phosgene (20% in toluene) (1.25 mL, 1.75 mmol) was added
dropwise to a vigorously stirring mixture of
1-(5-(aminomethyl)-2-(difluoromethoxy)benzyl)-6-bromo-2-methyl-1H-indazol-
-3(2H)-one (0.180 g, 0.437 mmol) (Preparation #39, step 2) in DCM
(2 mL) and sat. aq. NaHCO.sub.3 (2 mL) at about 0.degree. C. After
about 3 h, DCM and sat. aq. NH.sub.4Cl were added. The layers were
separated. The organic layer was filtered then concentrated at rt
in vacuo. The residue (0.199 g) was used without further
purification. LC/MS (Table A, Method j) R.sub.t=1.51 min; MS m/z:
438 and 440 (M+H).sup.+.
Step 2:
N-(3-((6-Bromo-2-methyl-3-oxo-2,3-dihydro-1H-indazol-1-yl)methyl)--
4-(difluoromethoxy)benzyl)-2-formylhydrazinecarboxamide
[1148]
6-Bromo-1-(2-(difluoromethoxy)-5-(isocyanatomethyl)benzyl)-2-methyl-
-1H-indazol-3(2H)-one (0.190 g, 0.434 mmol) was dissolved in MeCN
(3 mL) and treated with formohydrazide (0.078 g, 1.3 mmol) at rt.
After about 20 min, EtOAc and aq. HCl were added. The layers were
separated and the organic layer was dried over Na.sub.2SO.sub.4,
filtered, and concentrated under reduced pressure. The residue (192
mg) was used without further purification. LC/MS (Table A, Method
j) R.sub.t=1.06 min; MS m/z: 498 and 500 (M+H).sup.+.
Step 3:
6-Bromo-1-(2-(difluoromethoxy)-5-((5-oxo-1H-1,2,4-triazol-4(5H)-yl-
)methyl)benzyl)-2-methyl-1H-indazol-3(2H)-one
[1149] Bromotrimethylsilane (0.500 mL, 3.85 mmol) was added to a
stirring mixture of
N-(3-((6-bromo-2-methyl-3-oxo-2,3-dihydro-1H-indazol-1-yl)methyl)-4-(difl-
uoromethoxy)benzyl)-2-formylhydrazinecarboxamide (0.192 g, 0.385
mmol) and ammonium sulfate (0.020 g, 0.15 mmol) in
hexamethyldisilazane (2.42 mL, 11.6 mmol). The mixture was warmed
to about 114.degree. C. After about 16 h, EtOAc (20 mL) was added
then washed with 1M aq. HCl. The layers were separated and the
organic layer was dried over Na.sub.2SO.sub.4, filtered, and
concentrated. The residue was purified by flash chromatography on
silica gel eluting with a gradient of 50-100% EtOAc/DCM to provide
the title compound (25 mg, 14%); LC/MS (Table A, Method j)
R.sub.t=1.05 min; MS m/z: 480 and 482 (M+H).sup.+.
Step 4:
1-(2-(Difluoromethoxy)-5-((5-oxo-1H-1,2,4-triazol-4(5H)-yl)methyl)-
benzyl)-6-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2-
H)-one
[1150] PdCl.sub.2(dppf) (2.7 mg, 3.6 .mu.mol) was added to a
mixture of 2-(5-bromopyrimidin-2-yl)propan-2-ol (0.015 g, 0.068
mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane)
(0.024 g, 0.094 mmol), KOAc (0.015 g, 0.16 mmol) and 1,4-dioxane (2
mL) under N.sub.2. The reaction vessel was evacuated then
back-filled with N.sub.2 and flushed with N.sub.2. The mixture
heated to about 95.degree. C. for about 2 h then cooled to rt.
6-Bromo-1-(2-(difluoromethoxy)-5-((5-oxo-1H-1,2,4-triazol-4(5H)-yl)methyl-
)benzyl)-2-methyl-1H-indazol-3(2H)-one (25 mg, 0.052 mmol), cesium
carbonate (42 mg, 0.13 mmol), PdCl.sub.2(PPh.sub.3).sub.2(2.5 mg,
3.6 .mu.mol), and water (0.5 mL) were added. The reaction vessel
was evacuated then back-filled with N.sub.2 and flushed with
N.sub.2. The mixture heated to about 80.degree. C. for about 2 h.
The mixture was cooled to rt. DCM (20 mL) and water were added. The
layers were separated and the aqueous layer was extracted with DCM
(20 mL). The combined organic layers were dried over
Na.sub.2SO.sub.4, filtered, and concentrated. The residue was
purified by flash chromatography on silica gel eluting with 100%
EtOAc for 5 min then a gradient of 0-60% MeOH/DCM to afford the
title compound (0.017 g, 61%); LC/MS (Table A, Method h)
R.sub.t=0.92 min; MS m/z: 538 (M+H).sup.+. (TNF IC.sub.50=B).
Example #93
(S)-7-(5-(1-(5-((4H-1,2,4-triazol-4-yl)methyl)-2-(difluoromethoxy)benzyl)--
2-methyl-3-oxo-2,3-dihydro-1H-indazol-6-yl)pyrimidin-2-yl)hexahydroimidazo-
[1,5-a]pyrazin-3(2H)-one
##STR00370##
[1151] Step 1:
1-(5-((4H-1,2,4-Triazol-4-yl)methyl)-2-(difluoromethoxy)benzyl)-6-bromo-2-
-methyl-1,2-dihydro-3H-indazol-3-one
[1152] A mixture of
6-bromo-1-(5-(bromomethyl)-2-(difluoromethoxy)benzyl)-2-methyl-1,2-dihydr-
o-3H-indazol-3-one (Preparation #20, step 3) (0.100 g, 0.210 mmol)
and 2-(1H-1,2,4-triazol-1-yl)acetonitrile (Synthesis 1995, 9,
1183-1189) (0.026 g, 0.210 mmol) in MeCN (1 mL) was heated at about
reflux for about 6 h, after which additional
2-(1H-1,2,4-triazol-1-yl)acetonitrile (0.020 g, 0.164 mmol) was
added and heating continued for about 24 h. The reaction mixture
was concentrated under reduced pressure and the residue was treated
with 2 M aq. sodium hydroxide (2 mL, 4 mmol). After stirring for
about 1 h, the mixture was extracted with EtOAc (3.times.5 mL) and
the combined organic phases were washed with sat. aq. NaCl (5 mL),
dried over Na.sub.2SO.sub.4, filtered, and concentrated under
reduced pressure. The sample was purified on silica gel using 0-5%
MeOH with DCM to give the title compound (0.053 g, 54%); LC/MS
(Table A, Method i) R.sub.t=1.04 min; MS m/z: 464 and 466
(M+H).sup.+.
Step 2:
(S)-7-(5-(1-(5-((4H-1,2,4-Triazol-4-yl)methyl)-2-(difluoromethoxy)-
benzyl)-2-methyl-3-oxo-2,3-dihydro-1H-indazol-6-yl)pyrimidin-2-yl)hexahydr-
oimidazo[1,5-a]pyrazin-3(2H)-one
[1153] The reaction was performed using
1-(5-((4H-1,2,4-triazol-4-yl)methyl)-2-(difluoromethoxy)benzyl)-6-bromo-2-
-methyl-1,2-dihydro-3H-indazol-3-one and
(S)-7-(5-bromopyrimidin-2-yl)hexahydroimidazo[1,5-a]pyrazin-3(2H)-one
(Preparation #13) in a fashion similar to Example #8 to give the
title product (13%); LC/MS (Table A, Method a) R.sub.t=1.48 min; MS
m/z: 603 (M+H).sup.+. (TNF IC.sub.50=A).
Example #94
(R)--N-(3-((6-(2-(4-Acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-
-3-oxo-2,3-dihydro-1H-indazol-1-yl)methyl)-4-(difluoromethoxy)benzyl)-N-et-
hylacetamide
##STR00371##
[1154] Step 1:
6-Bromo-1-(2-(difluoromethoxy)-5-((ethylamino)methyl)benzyl)-2-methyl-1,2-
-dihydro-3H-indazol-3-one
[1155] A solution of
6-bromo-1-(5-(bromomethyl)-2-(difluoromethoxy)benzyl)-2-methyl-1,2-dihydr-
o-3H-indazol-3-one (Preparation #20, step 3) (0.120 g, 0.252 mmol)
in THF (2 mL) was added to ethylamine (2 M in THF) (10 mL, 20 mmol)
and the resulting solution was stirred at about ambient temperature
for about 2 min. The reaction mixture was concentrated under
reduced pressure to give the title compound (0.11 g, 100%); LC/MS
(Table A, Method i) R.sub.t=0.94 min; MS m/z: 440 and 442
(M+H).sup.+.
Step 2:
N-(3-((6-Bromo-2-methyl-3-oxo-2,3-dihydro-1H-indazol-1-yl)methyl)--
4-(difluoromethoxy)benzyl)-N-ethylacetamide
[1156] The reaction was performed using
6-bromo-1-(2-(difluoromethoxy)-5-((ethylamino)methyl)benzyl)-2-methyl-1,2-
-dihydro-3H-indazol-3-one with acetyl chloride in a fashion similar
to Preparation #16 to give the title product (89%); LC/MS (Table A,
Method i) R.sub.t=1.26 min; MS m/z: 482 and 484 (M+H).sup.+.
Step 3:
(R)--N-(3-((6-(2-(4-acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)--
2-methyl-3-oxo-2,3-dihydro-1H-indazol-1-yl)methyl)-4-(difluoromethoxy)benz-
yl)-N-ethylacetamide
[1157] The reaction was performed using
N-(3-((6-bromo-2-methyl-3-oxo-2,3-dihydro-1H-indazol-1-yl)methyl)-4-(difl-
uoromethoxy)benzyl)-N-ethylacetamide and
(R)-1-(4-(5-bromopyrimidin-2-yl)-2-methylpiperazin-1-yl)ethan-1-one
(Preparation #16) in a fashion similar to Example #8 to give the
title product (59%); LC/MS (Table A, Method a) R.sub.t=1.75 min; MS
m/z: 622 (M+H).sup.+. (TNF IC.sub.50=B).
Example #95
1-(2-(Difluoromethoxy)-5-methylbenzyl)-6-(2-(2-hydroxypropan-2-yl)-4-methy-
lpyrimidin-5-yl)-2-methyl-1,2-dihydro-3H-pyrazolo[3,4-b]pyridin-3-one
##STR00372##
[1159] The reaction was performed using
6-chloro-1-(2-(difluoromethoxy)-5-methylbenzyl)-2-methyl-1,2-dihydro-3H-p-
yrazolo[3,4-b]pyridin-3-one (prepared using
2-(bromomethyl)-1-(difluoromethoxy)-4-methylbenzene (prepared from
(2-(difluoromethoxy)-5-methylphenyl)methanol (Preparation #11) in a
fashion similar to Preparation #3, step 2) and
6-chloro-2-methyl-1,2-dihydro-3H-pyrazolo[3,4-b]pyridin-3-one
(Example #15, step 2) in a fashion similar to Example #14, step 2)
and 2-(5-bromo-4-methylpyrimidin-2-yl)propan-2-ol (WO2015/86506 A1)
in a fashion similar to Example #8 to give the title product (56%);
LC/MS (Table A, Method a) R.sub.t=2.12 min; MS m/z: 470
(M+H).sup.+. (TNF IC.sub.50=B).
Example #96
rac-(1R,3S)-3-(4-(Difluoromethoxy)-3-((6-(2-(2-hydroxypropan-2-yl)pyrimidi-
n-5-yl)-2-methyl-3-oxo-2,3-dihydro-1H-indazol-1-yl)methyl)phenyl)cyclopent-
ane-1-carbonitrile and
Example #97
rac-(1R,3R)-3-(4-(difluoromethoxy)-3-((6-(2-(2-hydroxypropan-2-yl)pyrimidi-
n-5-yl)-2-methyl-3-oxo-2,3-dihydro-1H-indazol-1-yl)methyl)phenyl)cyclopent-
ane-1-carbonitrile
##STR00373## ##STR00374##
[1160] Step 1:
3-(3-(((tert-Butyldimethylsilyl)oxy)methyl)-4-(difluoromethoxy)phenyl)cyc-
lopentan-1-one
[1161] A solution of 2-cyclopenten-1-one (0.83 mL, 9.9 mmol),
tert-butyl((2-(difluoromethoxy)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-
-2-yl)benzyl)oxy)dimethylsilane (prepared from
((5-bromo-2-(difluoromethoxy)benzyl)oxy)(tert-butyl)dimethylsilane
(prepared from (5-bromo-2-(difluoromethoxy)phenyl)methanol
(Preparation #12) in a fashion similar to Preparation #43, step 1)
in a fashion similar to Preparation #4, step 2) (2.05 g, 4.95 mmol)
and DIEA (2.59 mL, 14.8 mmol) in 10:1 dioxane/water (22 mL) was
degassed with nitrogen sparge for about 10 min and then added to a
vessel containing chloro(1,5-cyclooctadiene)rhodium(I) dimer (0.122
g, 0.247 mmol) and 2,2'-bis(diphenylphosphanyl)-1,1'-binaphthalene
(0.308 g, 0.495 mmol) under a nitrogen atmosphere. The reaction was
heated at about 80.degree. C. for about 1.5 h and then allowed to
cool. The mixture was concentrated and the residue was purified on
silica gel using 0-30% EtOAc in heptane to give the title compound
(1.05 g, 57%); .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.45 (d,
J=2.3 Hz, 1H), 7.13 (dd, J=8.3, 2.3 Hz, 1H), 7.05 (d, J=8.3 Hz,
1H), 6.49 (t, J=74.3 Hz, 1H), 4.78 (s, 2H), 3.53-3.33 (m, 1H),
2.75-2.57 (m, 1H), 2.54-2.39 (m, 2H), 2.38-2.22 (m, 2H), 2.07-1.87
(m, 1H), 0.95 (s, 9H), 0.12 (s, 6H).
Step 2:
3-(3-(((tert-Butyldimethylsilyl)oxy)methyl)-4-(difluoromethoxy)phe-
nyl)cyclopentan-1-ol
[1162] The reaction was performed using
3-(3-(((tert-butyldimethylsilyl)oxy)methyl)-4-(difluoromethoxy)phenyl)cyc-
lopentan-1-one in a fashion similar to Preparation #14, step 2 to
give the title product (100%) as a mixture of cis- and
trans-isomers. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.50-7.38
(m, 1H), 7.22-7.04 (m, 1H), 7.04-6.92 (m, 1H), 6.47 (t, J=74.6 Hz,
1H), 4.76 (s, 2H), 4.61-4.38 (m, 1H), 3.51-2.95 (m, 1H), 2.54-1.55
(m, 6H), 0.95 (s, 9H), 0.11 (s, 6H).
Step 3:
3-(3-(((tert-butyldimethylsilyl)oxy)methyl)-4-(difluoromethoxy)phe-
nyl)cyclopentyl methanesulfonate
[1163] The reaction was performed using
3-(3-(((tert-butyldimethylsilyl)oxy)methyl)-4-(difluoromethoxy)phenyl)cyc-
lopentan-1-ol in a fashion similar to Example #24 to give the title
product (92%) as a mixture of cis- and trans-isomers; LC/MS (Table
A, Method i) R.sub.t=2.20 min; MS m/z: 451 (M+H).sup.+.
Step 4:
3-(3-(((tert-Butyldimethylsilyl)oxy)methyl)-4-(difluoromethoxy)phe-
nyl)cyclopentane-1-carbonitrile
[1164] A solution of
3-(3-(((tert-butyldimethylsilyl)oxy)methyl)-4-(difluoromethoxy)phenyl)cyc-
lopentyl methanesulfonate (0.480 g, 1.06 mmol) and sodium cyanide
(0.078 g, 1.6 mmol) in DMF (6 mL) was heated at about 50.degree. C.
for about 21 h. The mixture was concentrated under reduced pressure
and then the mixture was partitioned between EtOAc (50 mL) and
water (50 mL). After separating the layers, the aqueous phase was
extracted with EtOAc (2.times.25 mL). The combined organic phases
were washed with sat. aq. NaCl (2.times.50 mL), dried over
Na.sub.2SO.sub.4, filtered, and concentrated under reduced
pressure. The sample was purified on silica gel using 0-50% EtOAc
in heptane to give the title product (0.157 g, 39%). LC/MS (Table
A, Method i) R.sub.t=2.25 min; MS m/z: 382 (M+H).sup.+.
Step 5:
3-(4-(Difluoromethoxy)-3-(hydroxymethyl)phenyl)cyclopentane-1-carb-
onitrile
[1165] The reaction was performed using
3-(3-(((tert-butyldimethylsilyl)oxy)methyl)-4-(difluoromethoxy)phenyl)cyc-
lopentane-1-carbonitrile in a fashion similar to Example #35, step
3 to give the title product (96%) as a mixture of cis- and
trans-isomers; LC/MS (Table A, Method i) R.sub.t=1.25 min; MS m/z:
326 (M+AcO).sup.-.
Step 6:
rac-(1R,3S)-3-(4-(Difluoromethoxy)-3-((6-(2-(2-hydroxypropan-2-yl)-
pyrimidin-5-yl)-2-methyl-3-oxo-2,3-dihydro-1H-indazol-1-yl)methyl)phenyl)c-
yclopentane-1-carbonitrile and
rac-(1R,3R)-3-(4-(difluoromethoxy)-3-((6-(2-(2-hydroxypropan-2-yl)pyrimid-
in-5-yl)-2-methyl-3-oxo-2,3-dihydro-1H-indazol-1-yl)methyl)phenyl)cyclopen-
tane-1-carbonitrile
[1166] The reaction was performed using
3-(3-(bromomethyl)-4-(difluoromethoxy)phenyl)cyclopentane-1-carbonitrile
(prepared from
3-(4-(difluoromethoxy)-3-(hydroxymethyl)phenyl)cyclopentane-1-carbonitril-
e in a fashion similar to Preparation #14, step 6) with
6-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-2-methyl-1,2-dihydro-3H-indazo-
l-3-one (Preparation #19) in a fashion similar to Example #1 to
give a mixture of cis- and trans-isomers. The mixture was separated
using HPLC (Table A, Method m) to give (in a corresponding order of
elution) the title compounds; (Table A, Method h) R.sub.t=1.29 min;
MS m/z: 534 (M+H).sup.+ (TNF IC.sub.50=B) and R.sub.t=1.29 min; MS
m/z: 534 (M+H).sup.+ (TNF IC.sub.50=A).
Example #98
1-(2-(Difluoromethoxy)-5-methylbenzyl)-5-fluoro-6-(2-(2-hydroxypropan-2-yl-
)-4-methylpyrimidin-5-yl)-2-methyl-1,2-dihydro-3H-pyrazolo[3,4-b]pyridin-3-
-one
##STR00375##
[1167] Step 1:
6-Chloro-5-fluoro-2-methyl-1,2-dihydro-3H-pyrazolo[3,4-b]pyridin-3-one
[1168] 2,6-Dichloro-5-fluoronicotinic acid was treated in a fashion
similar to Example #17, step 1 to afford
2,6-dichloro-5-fluoro-N-methylnicotinohydrazide which was used in a
fashion similar to Example #15, step 2 to give the title compound
(33%); LC/MS (Table A, Method i) R.sub.t=0.49 min; MS m/z: 200
(M-H).sup.-.
Step 2:
6-Chloro-1-(2-(difluoromethoxy)-5-methylbenzyl)-5-fluoro-2-methyl--
1,2-dihydro-3H-pyrazolo[3,4-b]pyridin-3-one
[1169] The reaction was performed using
6-chloro-5-fluoro-2-methyl-1,2-dihydro-3H-pyrazolo[3,4-b]pyridin-3-one
and 2-(bromomethyl)-1-(difluoromethoxy)-4-methylbenzene (prepared
from (2-(difluoromethoxy)-5-methylphenyl)methanol (Preparation #11)
in a fashion similar to Preparation #3, step 2) in a fashion
similar to Example #14, step 2 to give the title product (68%);
LC/MS (Table A, Method i) R.sub.t=1.54 min; MS m/z: 372
(M+H).sup.+.
Step 3:
1-(2-(Difluoromethoxy)-5-methylbenzyl)-5-fluoro-6-(2-(2-hydroxypro
pan-2-yl)-4-methylpyrimidin-5-yl)-2-methyl-1,2-dihydro-3H-pyrazolo[3,4-b]-
pyridin-3-one
[1170] The reaction was performed using
6-chloro-1-(2-(difluoromethoxy)-5-methylbenzyl)-5-fluoro-2-methyl-1,2-dih-
ydro-3H-pyrazolo[3,4-b]pyridin-3-one and
2-(5-bromo-4-methylpyrimidin-2-yl)propan-2-ol (WO2015/86506 A1) in
a fashion similar to Example #8 to give the title product (63%);
LC/MS (Table A, Method a) R.sub.t=2.21 min; MS m/z: 488
(M+H).sup.+. (TNF IC.sub.50=A).
Example #99
1-(2-Chloro-5-methylbenzyl)-6-(2-(2-hydroxypropan-2-yl)-4-methylpyrimidin--
5-yl)-2-methyl-1,2-dihydro-3H-pyrazolo[3,4-b]pyridin-3-one
##STR00376##
[1172]
1-(2-Chloro-5-methylbenzyl)-6-(2-(2-hydroxypropan-2-yl)-4-methylpyr-
imidin-5-yl)-2-methyl-1,2-dihydro-3H-pyrazolo[3,4-b]pyridin-3-one
was prepared from
6-chloro-1-(2-chloro-5-methylbenzyl)-2-methyl-1H-pyrazolo[3,4-b]pyridin-3-
(2H)-one (prepared in a manner similar to Example #1 from
6-chloro-2-methyl-1H-pyrazolo[3,4-b]pyridin-3(2H)-one (Example #15,
step 2) and 2-(bromomethyl)-1-chloro-4-methylbenzene (prepared in a
manner similar to Preparation #3, step 2 from
(2-chloro-5-methylphenyl)methanol (prepared in a manner similar to
Preparation #32, step 4 from methyl 2-chloro-5-methylbenzoate)))
and 2-(5-bromo-4-methylpyrimidin-2-yl)propan-2-ol (WO2015/86506 A1)
in a manner similar to Example #8 to give the title product (62%);
LC/MS (Table A, Method a) R.sub.t=2.25 min; MS m/z: 438
(M+H).sup.+. (TNF IC.sub.50=A)
Example #100
2-(4-(Difluoromethoxy)-3-((5-fluoro-6-(2-(2-hydroxypropan-2-yl)pyrimidin-5-
-yl)-2-methyl-3-oxo-2,3-dihydro-1H-indazol-1-yl)methyl)phenyl)acetonitrile
##STR00377##
[1174]
2-(4-(Difluoromethoxy)-3-((5-fluoro-6-(2-(2-hydroxypropan-2-yl)pyri-
midin-5-yl)-2-methyl-3-oxo-2,3-dihydro-1H-indazol-1-yl)methyl)phenyl)aceto-
nitrile was prepared using
2-(3-((6-bromo-5-fluoro-2-methyl-3-oxo-2,3-dihydro-1H-indazol-1-yl)methyl-
)-4-(difluoromethoxy)phenyl)acetonitrile (prepared using
6-bromo-1-(5-(bromomethyl)-2-(difluoromethoxy)benzyl)-5-fluoro-2-methyl-1-
H-indazol-3(2H)-one (synthesized in a manner similar to Preparation
#14, step 6 from
6-bromo-1-(2-(difluoromethoxy)-5-(hydroxymethyl)benzyl)-5-fluoro-2-methyl-
-1H-indazol-3(2H)-one (synthesized in a manner similar to Example
#18 from
6-bromo-1-(2-(difluoromethoxy)-5-((trityloxy)methyl)benzyl)-5-fluoro-2-me-
thyl-1H-indazol-3(2H)-one (synthesized in a manner similar to
Preparation #4, step 1 from
6-bromo-5-fluoro-2-methyl-1H-indazol-3(2H)-one (synthesized in a
manner similar to Preparation #1 from 4-bromo-2,5-difluorobenzoic
acid) and
(((3-(bromomethyl)-4-(difluoromethoxy)benzyl)oxy)methanetriyl)tribenzene
(Preparation #14)))) in a manner similar to Preparation #20) and
2-(5-bromopyrimidin-2-yl)propan-2-ol in a manner similar to Example
#8 to give the title product (35%); LC/MS (Table A, Method a)
R.sub.t=1.87 min; MS m/z: 498 (M+H).sup.+. (TNF IC.sub.50=B)
Example #101
(R)-6-(2-(4-Acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-1-(2-(difluorome-
thoxy)-5-((3-oxo-2,3-dihydro-1H-pyrazol-1-yl)methyl)benzyl)-2-methyl-1,2-d-
ihydro-3H-indazol-3-one and
Example #102
(R)-1-(5-(((1H-pyrazol-5-yl)oxy)methyl)-2-(difluoromethoxy)benzyl)-6-(2-(4-
-acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-1,2-dihydro-3H-ind-
azol-3-one
##STR00378##
[1175] Step 1:
6-Bromo-1-(2-(difluoromethoxy)-5-((3-oxo-2,3-dihydro-1H-pyrazol-1-yl)meth-
yl)benzyl)-2-methyl-1,2-dihydro-3H-indazol-3-one and
1-(5-((1H-pyrazol-5-yl)oxy)methyl)-2-(difluoromethoxy)benzyl)-6-bromo-2-m-
ethyl-1,2-dihydro-3H-indazol-3-one
[1176] A solution of 1H-pyrazol-5-ol (0.047 g, 0.55 mmol) in DMF (1
mL) was cooled at about -15.degree. C. before sodium hydride (60%
dispersion in mineral oil) (12 mg, 0.30 mmol) was added in one
portion and the mixture was stirred for about 5 min. The mixture
was allowed to stir at ambient temperature for about 30 min and
then was cooled to about -15.degree. C.
6-Bromo-1-(5-(bromomethyl)-2-(difluoromethoxy)benzyl)-2-methyl-1,2-dihydr-
o-3H-indazol-3-one (Preparation #20, step 3) (0.120 g, 0.252 mmol)
in DMF (1 mL) was added drop-wise via syringe. The mixture was
stirred in the bath for about 1.5 h. The reaction was quenched by
addition of water (3 mL), followed by EtOAc (2 mL). The reaction
mixture was partitioned between EtOAc (5 mL) and sat. aq.
NH.sub.4Cl (5 mL). After separating the layers, the aqueous phase
was extracted with EtOAc (2.times.5 mL). The combined organic
phases were washed with sat. aq. NaCl (10 mL), dried over
Na.sub.2SO.sub.4, filtered, and concentrated under reduced
pressure. The material was purified on silica using 50-100% EtOAc
in heptane to give the title compounds as a mixture (92 mg, 76%);
LC/MS (Table A, Method i) R.sub.t=1.08 and 1.17 min; MS m/z: 479
and 481 (M+H).sup.+.
Step 2:
(R)-6-(2-(4-Acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-1-(2-(di-
fluoromethoxy)-5-((3-oxo-2,3-dihydro-1H-pyrazol-1-yl)methyl)benzyl)-2-meth-
yl-1,2-dihydro-3H-indazol-3-one and
(R)-1-(5-(((1H-pyrazol-5-yl)oxy)methyl)-2-(difluoromethoxy)benzyl)-6-(2-(-
4-acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-1,2-dihydro-3H-in-
dazol-3-one
[1177] The reaction was performed using a mixture of
6-bromo-1-(2-(difluoromethoxy)-5-((3-oxo-2,3-dihydro-1H-pyrazol-1-yl)meth-
yl)benzyl)-2-methyl-1,2-dihydro-3H-indazol-3-one and
1-(5-(((1H-pyrazol-5-yl)oxy)methyl)-2-(difluoromethoxy)benzyl)-6-bromo-2--
methyl-1,2-dihydro-3H-indazol-3-one with
(R)-1-(4-(5-bromopyrimidin-2-yl)-2-methylpiperazin-1-yl)ethan-1-one
(Preparation #16) in a fashion similar to Example #8 to give
(R)-6-(2-(4-acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-1-(2-(difluorom-
ethoxy)-5-((3-oxo-2,3-dihydro-1H-pyrazol-1-yl)methyl)benzyl)-2-methyl-1,2--
dihydro-3H-indazol-3-one (21%); LC/MS (Table A, Method a)
R.sub.t=1.69 min; MS m/z: 619 (M+H).sup.+; (TNF IC.sub.50=B) and
(R)-1-(5-(((1H-pyrazol-5-yl)oxy)methyl)-2-(difluoromethoxy)benzyl)-6-(2-(-
4-acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-1,2-dihydro-3H-in-
dazol-3-one (13%); LC/MS (Table A, Method a) R.sub.t=1.78 min; MS
m/z: 619 (M+H).sup.+; (TNF IC.sub.50=A).
Example #103
(S)-7-(5-(1-(2-Chloro-5-methylbenzyl)-2-methyl-3-oxo-2,3-dihydro-1H-indazo-
l-6-yl)pyrimidin-2-yl)hexahydroimidazo[1,5-a]pyrazin-3(2H)-one
##STR00379##
[1179]
(S)-7-(5-(1-(2-Chloro-5-methylbenzyl)-2-methyl-3-oxo-2,3-dihydro-1H-
-indazol-6-yl)pyrimidin-2-yl)hexahydroimidazo[1,5-a]pyrazin-3(2H)-one
was prepared using
1-(2-chloro-5-methylbenzyl)-6-(2-chloropyrimidin-5-yl)-2-methyl-1,2-dihyd-
ro-3H-indazol-3-one (prepared using
1-chloro-2-(chloromethyl)-4-methylbenzene (synthesized in a manner
similar to Preparation #50, step 6 from
(2-chloro-5-methylphenyl)methanol (synthesized in a manner similar
to Preparation #32, step 4 from methyl 2-chloro-5-methylbenzoate))
with
6-(2-chloropyrimidin-5-yl)-2-methyl-1,2-dihydro-3H-indazol-3-one
(Preparation #23) in a manner similar to Example #1) with
(R)-hexahydroimidazo[1,5-a]pyrazin-3(2H)-one (Preparation #46) in a
manner similar to Example #2 to give the title product (87%); LC/MS
(Table A, Method a) R.sub.t=1.94 min; MS m/z: 504 (M+H).sup.+. (TNF
IC.sub.50=A)
Example #104
1-(5-((1H-1,2,4-triazol-1-yl)methyl)-2-(difluoromethoxy)benzyl)-6-(2-(2-hy-
droxypropan-2-yl)pyrimidin-5-yl)-2-methyl-1,2-dihydro-3H-indazol-3-one
##STR00380##
[1180] Step 1:
1-(5-((1H-1,2,4-Triazol-1-yl)methyl)-2-(difluoromethoxy)benzyl)-6-bromo-2-
-methyl-1,2-dihydro-3H-indazol-3-one
[1181] A mixture of
6-bromo-1-(5-(bromomethyl)-2-(difluoromethoxy)benzyl)-2-methyl-1,2-dihydr-
o-3H-indazol-3-one (0.100 g, 0.210 mmol) (Preparation #20, step 3),
1,2,4-triazole (0.031 g, 0.449 mmol), and potassium carbonate
(0.035 g, 0.25 mmol) in MeCN (2 mL) was heated at about 50.degree.
C. for about 1.5 h. The reaction mixture was partitioned between
water (5 mL) and EtOAc (2 mL). After separating the layers, the
aqueous phase was extracted with EtOAc (2.times.2 mL). The combined
organic phases were washed with saturated aqueous NaCl (5 mL),
dried over Na.sub.2SO.sub.4, filtered, and concentrated under
reduced pressure to give the title compound (0.193 g, 99%) as a
mixture together with a minor isomer; LC/MS (Table A, Method i)
R.sub.t=1.12 min; MS m/z: 464, 466 (M+H).sup.+.
Step 2:
1-(5-((1H-1,2,4-Triazol-1-yl)methyl)-2-(difluoromethoxy)benzyl)-6--
(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-2-methyl-1,2-dihydro-3H-indazol-3-
-one
[1182] The reaction was performed using
1-(5-((1H-1,2,4-triazol-1-yl)methyl)-2-(difluoromethoxy)benzyl)-6-(2-(2-h-
ydroxypropan-2-yl)pyrimidin-5-yl)-2-methyl-1,2-dihydro-3H-indazol-3-one
with 2-(5-bromopyrimidin-2-yl)propan-2-ol in a fashion similar to
Example #8 to give the title product (54%); LC/MS (Table A, Method
a) R.sub.t=1.59 min; MS m/z: 522 (M+H).sup.+. (TNF
IC.sub.50=A).
Example #105*
(R)-6-(2-(4-Acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-1-((3-chloro-6-m-
ethylpyridin-2-yl)methyl)-2-methyl-1,2-dihydro-3H-indazol-3-one
##STR00381##
[1183] Step 1: 2-Bromo-3-chloro-6-methylpyridine
[1184] A suspension of 3-amino-2-bromo-6-picoline (2.50 g, 13.4
mmol) and copper(I) chloride (5.29 g, 53.5 mmol) in concentrated
HCl (28 mL) at about 0.degree. C. was treated with sodium nitrite
(0.922 g, 13.4 mmol) and stirred for about 5 min. Water (28.0 mL)
was added and the mixture was stirred for about 10 min, and then
additional sodium nitrite (0.922 g, 13.4 mmol) in water (2 mL) was
added drop-wise. The ice bath was removed and stirring was
continued overnight. The reaction mixture was poured into ice water
(100 mL) and then extracted with diethyl ether (3.times.50 mL). The
combined organic phases were washed with sat. aq. NaHCO.sub.3 and
sat. aq. NaCl (75 mL each), dried over Na.sub.2SO.sub.4, filtered,
and concentrated under reduced pressure to give the title compound
(0.733 g, 27%); LC/MS (Table A, Method i) R.sub.t=1.16 min; MS m/z:
206 and 208 (M+H).sup.+.
Step 2:
(R)-6-(2-(4-Acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-1-((3-ch-
loro-6-methylpyridin-2-yl)methyl)-2-methyl-1,2-dihydro-3H-indazol-3-one
[1185] The reaction was performed using
2-(bromomethyl)-3-chloro-6-methylpyridine (prepared in a fashion
similar to Preparation #3, step 2 from
(3-chloro-6-methylpyridin-2-yl)methanol (prepared in a fashion
similar to Preparation #9 from 3-chloro-6-methylpicolinaldehyde
(prepared in a fashion similar to Example #4, step 1 from
(E)-3-chloro-6-methyl-2-styrylpyridine (prepared in a fashion
similar to Example #14, step 4 from
2-bromo-3-chloro-6-methylpyridine and (E)-styrylboronic acid))))
with
(R)-6-(2-(4-acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-1,2-di-
hydro-3H-indazol-3-one (Preparation #28) in a fashion similar to
Example #1 to give the title product (64%); (Table A, Method a)
R.sub.t=1.82 min; MS m/z: 506 (M+H).sup.+. (TNF IC.sub.50=A).
Example #106
1-(2-(Difluoromethoxy)-5-methylbenzyl)-6-(3-(1-hydroxyethyl)imidazo[1,2-b]-
pyridazin-7-yl)-2-methyl-1H-indazol-3(2H)-one
##STR00382##
[1187] 1-(7-Chloroimidazo[1,2-b]pyridazin-3-yl)ethanol (Preparation
#45) (208 mg, 1.06 mmol), cesium carbonate (857 mg, 2.64 mmol),
2.sup.nd generation XPhos precatalyst (41 mg, 0.052 mmol), and
1-(2-(difluoromethoxy)-5-methylbenzyl)-2-methyl-6-(4,4,5,5-tetramethyl-1,-
3,2-dioxaborolan-2-yl)-1H-indazol-3(2H)-one (Example #22, Step 2)
(561 mg, 1.27 mmol) were combined in a reaction vessel. The vessel
was evacuated and back-filled with N.sub.2 three times, then a
degassed mixture of 1,4-dioxane (5.5 mL) and water (1.1 mL) was
added and the reaction was heated to about 80.degree. C. for about
1 h. The reaction was cooled and partitioned between EtOAc (20 mL)
and water (20 mL). The aqueous layer was extracted with additional
EtOAc (20 mL), then the combined organic layers were washed with
sat. aq. NaCl (10 mL), dried over MgSO.sub.4, filtered, and
concentrated in vacuo. Further purification via flash
chromatography (0-8% DCM:MeOH) yielded the title compound (395 mg,
78%); LC/MS (Table A, Method h) R.sub.t=1.15 min; MS m/z: 480
(M+H).sup.+. (TNF IC.sub.50=A).
Example #107
(R)-1-(2-(Difluoromethoxy)-5-methylbenzyl)-6-(3-(1-hydroxyethyl)imidazo[1,-
2-b]pyridazin-7-yl)-2-methyl-1H-indazol-3(2H)-one
##STR00383##
[1189] Racemic
1-(2-(difluoromethoxy)-5-methylbenzyl)-6-(3-(1-hydroxyethyl)imidazo[1,2-b-
]pyridazin-7-yl)-2-methyl-1H-indazol-3(2H)-one (Example #106) (248
mg, 0.52 mmol) was submitted for chiral SFC HPLC separation (Table
C, Method f). The fractions containing the first component to elute
(positive optical rotation) were concentrated, then dried in a
vacuum oven for about 3 h, yielding the title compound (107 mg,
43%); LC/MS (Table A, Method h) R.sub.t=1.16 min; MS m/z: 480
(M+H).sup.+. (TNF IC.sub.50=A).
Example #108
(S)-1-(2-(Difluoromethoxy)-5-methylbenzyl)-6-(3-(1-hydroxyethyl)imidazo[1,-
2-b]pyridazin-7-yl)-2-methyl-1H-indazol-3(2H)-one
##STR00384##
[1191] Racemic
1-(2-(difluoromethoxy)-5-methylbenzyl)-6-(3-(1-hydroxyethyl)imidazo[1,2-b-
]pyridazin-7-yl)-2-methyl-1H-indazol-3(2H)-one (Example #106) (248
mg, 0.52 mmol) was submitted for chiral SFC HPLC separation (Table
C, Method f). Isolation of the second component to elute (negative
optical rotation), followed by concentration and drying in a vacuum
oven for about 3 h, yielded the title compound (112 mg, 45%); LC/MS
(Table A, Method h) R.sub.t=1.16 min; MS m/z: 480 (M+H).sup.+. (TNF
IC.sub.50=B)
Example #109
1-(2-Chloro-5-((1-methyl-2-oxopyrrolidin-3-yl)amino)benzyl)-6-(2-(2-hydrox-
ypropan-2-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one
##STR00385##
[1193] The compound was synthesized in a manner similar to Example
#83 from
6-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-
-one (Preparation #19) and
3-((4-chloro-3-(hydroxymethyl)phenyl)amino)-1-methylpyrrolidin-2-one
(Preparation #44) (11%); LC/MS (Table A, Method e) R.sub.t=1.70
min; MS m/z: 521 (M+H).sup.+. (TNF IC.sub.50=B).
Example #110*
(R)-1-(5-((1H-Pyrazol-4-yl)methyl)-2-(difluoromethoxy)benzyl)-6-(2-(4-acet-
yl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one
##STR00386##
[1195]
(R)-6-(2-(4-Acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-1-(2-(dif-
luoromethoxy)-5-((1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-yl)met-
hyl)benzyl)-2-methyl-1H-indazol-3(2H)-one (synthesized in a manner
similar to Example #83 from
(R)-6-(2-(4-acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-1H-ind-
azol-3(2H)-one (Preparation #28) and
(2-(difluoromethoxy)-5-((1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol--
4-yl)methyl)phenyl)methanol (Preparation #70)) (136 mg, 0.186 mmol)
was dissolved in DCM (0.6 mL), then cooled to about 0.degree. C.
TFA (0.286 mL, 2.54 mmol) was added and the reaction was stirred at
about 0.degree. C. for about 5 h. The reaction was quenched with
sat. aq. NaHCO.sub.3 solution (6 mL), then additional DCM (6 mL)
was added. The organic layer was washed with sat. aq. NaCl (5 mL)
and concentrated. The resulting residue was purified via reverse
phase preparative HPLC (Table A, Method I). The relevant fractions
were concentrated to dryness, redissolved in EtOAc (10 mL), and
washed with sat. aq. Na.sub.2CO.sub.3 (5 mL). The organic layer was
dried over MgSO.sub.4, filtered, and concentrated. The residue was
redissolved in methanol (5 mL) and heated to about 40.degree. C.
for about 2 h. Removal of the solvent in vacuo yielded the title
compound (72 mg, 65%); LC/MS (Table A, Method e) R.sub.t=1.76 min;
MS m/z: 603 (M+H).sup.+. (TNF IC.sub.50=A).
Example #111
1-(5-((1H-Pyrazol-4-yl)methyl)-2-(difluoromethoxy)benzyl)-6-(2-(2-hydroxyp-
ropan-2-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one
##STR00387##
[1197] The compound was synthesized in a manner similar to Example
#110 from
1-(2-(difluoromethoxy)-5-((1-((2-(trimethylsilyl)ethoxy)methyl)-1H-p-
yrazol-4-yl)methyl)benzyl)-6-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-2-me-
thyl-1H-indazol-3(2H)-one (synthesized in a manner similar to
Example #83 from
6-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-
-one (Preparation #19) and
(2-(difluoromethoxy)-5-((1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol--
4-yl)methyl)phenyl)methanol (Preparation #70)) (65%); LC/MS (Table
A, Method e) R.sub.t=1.73 min; MS m/z: 521 (M+H).sup.+. (TNF
IC.sub.50=A)
Example #112
2-(4-(Difluoromethoxy)-3-((6-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-2-me-
thyl-3-oxo-2,3-dihydro-1H-indazol-1-yl)methyl)phenyl)cyclopentanecarbonitr-
ile
##STR00388##
[1198] Step 1:
2-(3-(((tert-Butyldimethylsilyl)oxy)methyl)-4-(difluoromethoxy)phenyl)cyc-
lopentanecarbonitrile
[1199] A flask, purged with nitrogen, was charged with
bis((1,5-cyclooctadiene)(hydroxo)rhodium) (145 mg, 0.317 mmol),
dioxane (10 mL), H.sub.2O (1.5 mL) and potassium hydroxide (36.0
mg, 0.642 mmol). The mixture was stirred at room temperature for
about 15 min, then
tert-butyl((2-(difluoromethoxy)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-
-2-yl)benzyl)oxy)dimethylsilane (505 mg, 1.21 mmol) (prepared from
((5-bromo-2-(difluoromethoxy)benzyl)oxy)(tert-butyl)dimethylsilane
(prepared from (5-bromo-2-(difluoromethoxy)phenyl)methanol
(Preparation #12) in a similar fashion to Preparation #43, step 1)
in a similar fashion to preparation #4, step 2) and
1-cyanocyclopentene (145 mg, 1.56 mmol) were added. The mixture was
stirred at 60.degree. C. for about 2 h, and then concentrated under
reduced pressure. The residue was purified on silica gel (0-60%
EtOAc/heptane) to afford the title product (152 mg, 33%); cis:
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.48 (s, 1H), 7.22 (dd,
J=8.0, 4.0 Hz, 1H), 7.05 (d, J=8.0 Hz, 1H), 6.50 (d, J=76.0 Hz,
1H), 4.78 (s, 2H), 3.32-3.27 (m, 1H), 3.18 (ddd, J=12.0, 4.0, 4.0
Hz, 1H), 2.22-2.07 (m, 4H), 1.96-1.80 (m, 2H), 0.96 (s, 9H), 0.13
(s, 6H).
Step 2:
2-(4-(Difluormethoxy)-3-((6-(2-(2-hydroxypropan-2-yl)pyrimidin-5-y-
l)-2-methyl-3-oxo-2,3-dihydro-1H-indazol-1-yl)methyl)phenyl)cyclopentaneca-
rbonitrile
[1200] A flask was charged with
2-(3-(((tert-butyldimethylsilyl)oxy)methyl)-4-(difluoromethoxy)phenyl)cyc-
lopentanecarbonitrile (150 mg, 0.39 mmol), THF (1 mL) and
tetrabutylammonium fluoride (1 M in THF) (2 mL, 2 mmol) at room
temperature. The solution was stirred for about 1 h, and then
passed through a pad of silica. The filter cake was rinsed with
EtOAc, and the filtrate was concentrated under reduced pressure.
The residue was dissolved in DCM (2 mL) and carbon tetrabromide
(130 mg, 0.39 mmol) and PPh.sub.3 (110 mg, 0.42 mmol) were added.
The solution was stirred at room temperature for about 2 h. A
solution of
6-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one
(110 mg, 0.39 mmol) and potassium carbonate (64 mg, 0.46 mmol) in
DMF (2 mL) was added and the mixture was stirred at about
40.degree. C. for about 1 h. The mixture was diluted with H.sub.2O
(20 mL), and extracted with 10% MeOH in CH.sub.2Cl.sub.2
(3.times.10 mL). The organic layer was dried over Na.sub.2SO.sub.4,
filtered and concentrated. The residue was purified on silica gel
(0-10% MeOH/CH.sub.2Cl.sub.2) to afford the title product (110 mg,
56%); LC/MS (Table A, Method a) R.sub.t=1.99 min; MS m/z: 534
(M+H).sup.+. (TNF IC.sub.50=B)
Example #113
(R)-7-(5-(1-(5-((1H-1,2,4-Triazol-1-yl)methyl)-2-(difluoromethoxy)benzyl)--
2-methyl-3-oxo-2,3-dihydro-1H-indazol-6-yl)pyrimidin-2-yl)hexahydroimidazo-
[1,5-a]pyrazin-3(2H)-one
##STR00389##
[1202]
(R)-7-(5-(1-(5-((1H-1,2,4-Triazol-1-yl)methyl)-2-(difluoromethoxy)b-
enzyl)-2-methyl-3-oxo-2,3-dihydro-1H-indazol-6-yl)pyrimidin-2-yl)hexahydro-
imidazo[1,5-a]pyrazin-3(2H)-one was prepared from
1-(5-((1H-1,2,4-triazol-1-yl)methyl)-2-(difluoromethoxy)benzyl)-6-bromo-2-
-methyl-1H-indazol-3(2H)-one (Example #104, step 1) and
(R)-7-(5-bromopyrimidin-2-yl)hexahydroimidazo[1,5-a]pyrazin-3(2H)-one
(Preparation #13) in a similar fashion to Example #8. LC/MS (Table
A, Method a) R.sub.t=1.52 min; MS m/z: 603 (M+H).sup.+. (TNF
IC.sub.50=A)
Example #114
6-(2-((R)-4-Acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-1-(2-(difluorome-
thoxy)-5-(2-hydroxypropyl)benzyl)-2-methyl-1H-indazol-3(2H)-one
##STR00390## ##STR00391##
[1203] Step 1:
((5-Allyl-2-(difluoromethoxy)benzyl)oxy)(tert-butyl)dimethylsilane
[1204] A flask, purged with nitrogen, was charged with
allyltributylstannane (126 mg, 0.381 mmol),
((5-bromo-2-(difluoromethoxy)benzyl)oxy)(tert-butyl)dimethylsilane
(111 mg, 0.302 mmol) (prepared from
(5-bromo-2-(difluoromethoxy)phenyl)methanol (Preparation #12) in a
similar fashion to Preparation #43, step 1), DMF (2 mL),
Pd.sub.2dba.sub.3 (9.0 mg, 9.8 .mu.mol), PPh.sub.3 (16 mg, 0.061
mmol) at rt. The mixture was stirred at 100.degree. C. for about 4
h, cooled to rt, and then diluted with H.sub.2O (20 mL). The
mixture was extracted with EtOAc (2.times.10 mL), dried over
Na.sub.2SO.sub.4, filtered and concentrated. The residue was
purified by flash chromatography on silica gel (0-50%
EtOAc/heptane) to afford the title product (84 mg, 85%); .sup.1H
NMR (400 MHz, CDCl.sub.3) .delta. 7.36 (d, J=2.2 Hz, 1H), 7.07 (dd,
J=8.3, 2.3 Hz, 1H), 6.99 (dt, J=8.2, 1.1 Hz, 1H), 6.47 (t, J=74.6
Hz, 1H), 6.06-5.76 (m, 1H), 5.13-5.08 (m, 1H), 5.07 (t, J=1.4 Hz,
1H), 4.76 (s, 2H), 3.38 (dt, J=6.8, 1.4 Hz, 2H), 0.95 (s, 9H), 0.11
(s, 6H).
Step 2:
1-(3-(((tert-Butyldimethylsilyl)oxy)methyl)-4-(difluoromethoxy)phe-
nyl)propan-2-ol
[1205] A flask was charged with mercuric acetate (2.8 g, 8.8 mmol),
H.sub.2O (4 mL), and a solution of
((5-allyl-2-(difluoromethoxy)benzyl)oxy)(tert-butyl)dimethylsilane
(2.02 g, 6.15 mmol) in THF (12 mL) at room temperature. The mixture
was stirred for about 24 h then cooled to about 0.degree. C. An
aqueous solution of NaOH (5M, 15 mL) was added, followed by a
solution of NaBH.sub.4 (0.20 g, 5.3 mmol) in aqueous NaOH (2.5 M, 5
mL). The mixture was stirred at about 0.degree. C. for about 30 min
then at rt for about 16 h. The mixture was extracted with EtOAc
(3.times.25 mL), dried over Na.sub.2SO.sub.4, filtered and
concentrated. The residue was purified by flash chromatography on
silica gel (0-60% EtOAc/heptane) to afford the title product (820
mg, 39%); .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.38 (d, J=2.2
Hz, 1H), 7.10 (dd, J=8.5, 2.2 Hz, 1H), 7.02 (d, J=8.3 Hz, 1H), 6.49
(td, J=74.4, 0.9 Hz, 1H), 4.87-4.66 (m, 2H), 4.01 (q, J=5.7 Hz,
1H), 2.78 (dd, J=13.6, 5.0 Hz, 1H), 2.70 (dd, J=13.6, 7.8 Hz, 1H),
1.25 (dd, J=6.2, 0.9 Hz, 3H), 0.95 (d, J=0.9 Hz, 9H), 0.12 (d,
J=0.8 Hz, 6H).
Step 3: tert-Butyl
(1-(3-(((tert-butyldimethylsilyl)oxy)methyl)-4-(difluoromethoxy)phenyl)pr-
opan-2-yl) carbonate
[1206] A flask was charged with
1-(3-(((tert-butyldimethylsilyl)oxy)methyl)-4-(difluoromethoxy)phenyl)pro-
pan-2-ol (390 mg, 1.1 mmol), CH.sub.2Cl.sub.2 (7 mL), Boc.sub.2O
(310 mg, 1.4 mmol), DMAP (22 mg, 0.18 mmol) and TEA (0.05 mL, 0.4
mmol), and stirred at rt for about 1.5 h. The solution was diluted
with H.sub.2O (10 mL), the layers were separated, and the aqueous
layer was extracted with CH.sub.2Cl.sub.2 (5 mL). The combined
organic layers were dried over Na.sub.2SO.sub.4, filtered and
concentrated. The residue was purified by flash chromatography on
silica gel (0-30% EtOAc/heptane) to afford the title product (440
mg, 88%); .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.35 (d, J=2.3
Hz, 1H), 7.15-6.93 (m, 2H), 6.69-6.24 (m, 1H), 4.90 (d, J=6.5 Hz,
1H), 4.74 (s, 2H), 3.05-2.89 (m, 1H), 2.75 (dt, J=14.2, 7.3 Hz,
1H), 1.45 (s, 9H), 1.25 (d, J=6.3 Hz, 3H), 0.94 (d, J=0.7 Hz, 9H),
0.11 (dd, J=1.3, 0.7 Hz, 6H).
Step 4: tert-Butyl
(1-(4-(difluoromethoxy)-3-(hydroxymethyl)phenyl)propan-2-yl)
carbonate
[1207] A flask was charged with tert-butyl
(1-(3-(((tert-butyldimethylsilyl)oxy)methyl)-4-(difluoromethoxy)phenyl)pr-
opan-2-yl) carbonate (440 mg, 0.99 mmol). THF (4 mL) then cooled to
about 10.degree. C. A solution of tetrabutylammonium fluoride in
THF (1 M, 2.5 mL) was added and the solution was stirred for about
20 min then diluted with EtOAc (10 mL). The solution was filtered
through a pad of silica gel and the filtrate was concentrated under
reduced pressure. The residue was purified by flash chromatography
on silica gel (0-50% EtOAc/heptane) to afford the title product (50
mg, 15%); .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.31 (d, J=2.2
Hz, 1H), 7.15 (dd. J=8.3, 2.2 Hz, 1H), 7.08-7.01 (m, 1H), 6.52 (td,
J=74.1, 1.0 Hz, 1H), 4.91 (h, J=6.4 Hz, 1H), 4.72 (d, J=5.0 Hz,
2H), 2.97 (dd, J=13.7, 6.6 Hz, 1H), 2.76 (dd, J=13.7, 6.7 Hz, 1H),
1.44 (d, J=1.0 Hz, 9H), 1.26 (d, J=6.4 Hz, 3H).
Step 5: 1-(3-(Bromomethyl)-4-(difluoromethoxy)phenyl)propan-2-yl
tert-butyl carbonate
[1208] 1-(3-(Bromomethyl)-4-(difluoromethoxy)phenyl)propan-2-yl
tert-butyl carbonate was prepared in a similar fashion to
Preparation #14, step 6. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.
7.28 (d, J=2.2 Hz, 1H), 7.16 (d, J=2.2 Hz, 1H), 7.07 (d, J=8.5 Hz,
1H), 6.54 (t, J=73.8 Hz, 1H), 4.90 (q, J=6.4 Hz, 1H), 4.51 (d,
J=1.6 Hz, 2H), 2.95 (dd, J=13.8, 6.7 Hz, 1H), 2.75 (dd, J=13.8, 6.5
Hz, 1H), 1.44 (s, 9H), 1.26 (d, J=6.3 Hz, 3H).
Step 6:
1-(3-((6-(2-((R)-4-Acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-2-
-methyl-3-oxo-2,3-dihydro-1H-indazol-1-yl)methyl)-4-(difluoromethoxy)pheny-
l)propan-2-yl tert-butyl carbonate
[1209]
1-(3-((6-(2-((R)-4-Acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-2--
methyl-3-oxo-2,3-dihydro-1H-indazol-1-yl)methyl)-4-(difluoromethoxy)phenyl-
)propan-2-yl tert-butyl carbonate was prepared from
(R)-6-(2-(4-acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-1H-ind-
azol-3(2H)-one (Preparation #28) and
1-(3-(bromomethyl)-4-(difluoromethoxy)phenyl)propan-2-yl tert-butyl
carbonate in a similar fashion to Example #1. LC/MS (Table A,
Method i) R.sub.t=2.31 min; MS m/z: 681 (M+H).sup.+.
Step 7:
6-(2-((R)-4-Acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-1-(2-(di-
fluoromethoxy)-5-(2-hydroxypropyl)benzyl)-2-methyl-1H-indazol-3(2H)-one
[1210]
6-(2-((R)-4-Acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-1-(2-(dif-
luoromethoxy)-5-(2-hydroxypropyl)benzyl)-2-methyl-1H-indazol-3(2H)-one
was prepared in a similar fashion to Example #3, step 1. LC/MS
(Table A, Method a) R.sub.t=1.75 min; MS m/z: 581 (M+H).sup.+. (TNF
IC.sub.50=B).
Example #115
6-(2-(4-Acetylpiperazin-1-yl)pyrimidin-5-yl)-1-(5-(hydroxymethyl)-2-(trifl-
uoromethyl)benzyl)-2-methyl-1H-indazol-3(2H)-one
##STR00392##
[1211] Step 1:
4-Bromo-2-(bromomethyl)-1-(trifluoromethyl)benzene
[1212] 4-Bromo-2-methyl-1-(trifluoromethyl)benzene (2.00 g, 8.37
mmol), 1-bromopyrrolidine-2,5-dione (1.49 g, 8.37 mmol) and benzoic
peroxyanhydride (0.101 g, 0.418 mmol) in CCl.sub.4 (10 mL) was
heated to reflux under nitrogen for about 48 h. The reaction was
cooled to rt, diluted with DCM (25 mL) and washed with sat. aq.
NaHCO.sub.3 (20 mL) and water (20 mL). The organic layer was dried
over MgSO.sub.4, filtered, and concentrated. The residue was
purified on silica gel (0-10% EtOAc/Heptane) to afford the title
product (1.7 g, 64%); .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.
7.77-7.74 (m, 1H), 7.59-7.38 (m, 2H), 4.57 (s, 2H).
Step 2:
1-(5-Bromo-2-(trifluoromethyl)benzyl)-6-chloro-2-methyl-1H-indazol-
-3(2H)-one
[1213] The reaction was performed using
4-bromo-2-(bromomethyl)-1-(trifluoromethyl)benzene and
6-chloro-2-methyl-1H-indazol-3(2H)-one (Preparation #29) in a
similar fashion to Example #1 to afford the title product (1.3 g,
58%); LC/MS (Table A, Method e) R.sub.t=2.51 min; MS m/z: 419 and
421 (M+H).sup.+.
Step 3:
6-Chloro-2-methyl-1-(2-(trifluoromethyl)-5-vinylbenzyl)-1H-indazol-
-3(2H)-one
[1214] The reaction was performed using
1-(5-bromo-2-(trifluoromethyl)benzyl)-6-chloro-2-methyl-1H-indazol-3(2H)--
one in a similar fashion to Example #14, step 4 to afford the title
product (0.70 g, 89%); LC/MS (Table A, Method i) R.sub.t=1.67 min;
MS m/z: 367 (M+H).sup.+.
Step 4:
6-(2-(4-Acetylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-1-(2-(triflu-
oromethyl)-5-vinylbenzyl)-1H-indazol-3(2H)-one
[1215] The reaction was performed using
6-chloro-2-methyl-1-(2-(trifluoromethyl)-5-vinylbenzyl)-1H-indazol-3(2H)--
one and 1-(4-(5-bromopyrimidin-2-yl)piperazin-1-yl)ethanone
(prepared in a similar fashion to Preparation #13, step 1 using
1-(piperazin-1-yl)ethanone) in a similar fashion to Example #33,
step 9 to afford the title product (0.15 g, 63%); LC/MS (Table A,
Method i) R.sub.t=1.40 min; MS m/z: 537 (M+H).sup.+.
Step 5:
6-(2-(4-Acetylpiperazin-1-yl)pyrimidin-5-yl)-1-(5-(1,2-dihydroxyet-
hyl)-2-(trifluoromethyl)benzyl)-2-methyl-1H-indazol-3(2H)-one
[1216] 4-Methylmorpholine 4-oxide (72.0 mg, 0.615 mmol) was added
to a solution of
6-(2-(4-acetylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-1-(2-(trifluorometh-
yl)-5-vinylbenzyl)-1H-indazol-3(2H)-one (110 mg, 0.205 mmol) in THF
(4 mL). After cooling to about 0.degree. C., osmium tetroxide (4%
in water) (65.2 mg, 10.3 .mu.mol) was added. The reaction was
stirred at about 0.degree. C. for about 30 min and at rt for about
18 h. The reaction was quenched with 10% aq. Na.sub.2S.sub.2O.sub.5
(10 mL). After stirring for about 15 min, EtOAc (20 mL) was added.
The mixture was filtered. The layers were separated and the aqueous
layer was extracted with EtOAc (2.times.10 mL). The combined
organic layers were dried over MgSO.sub.4, filtered and
concentrated to give the title product (0.12 g, 100%); LC/MS (Table
A, Method i) R.sub.t=1.03 min; MS m/z: 571 (M+H).sup.+.
Step 6:
3-((6-(2-(4-Acetylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-3-oxo-2,-
3-dihydro-1H-indazol-1-yl)methyl)-4-(trifluoromethyl)benzaldehyde
[1217] THF (4 mL) and water (1 mL) were added to
6-(2-(4-acetylpiperazin-1-yl)pyrimidin-5-yl)-1-(5-(1,2-dihydroxyethyl)-2--
(trifluoromethyl)benzyl)-2-methyl-1H-indazol-3(2H)-one (175 mg,
0.307 mmol). Sodium periodate (98 mg, 0.46 mmol) was added. After
about 20 min, the reaction was quenched with EtOAc (30 mL) and
water (10 mL), the layers were separated, and the organic layer was
washed with sat. aq. NaCl (10 mL), dried over MgSO.sub.4, and
concentrated to give the title product (0.10 g, 63%); LC/MS (Table
A, Method i) R.sub.t=1.18 min; MS m/z: 539 (M+H).sup.+.
Step 7:
6-(2-(4-Acetylpiperazin-1-yl)pyrimidin-5-yl)-1-(5-(hydroxymethyl)--
2-(trifluoromethyl)benzyl)-2-methyl-1H-indazol-3(2H)-one
[1218] The reaction was performed using
3-((6-(2-(4-acetylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-3-oxo-2,3-dihyd-
ro-1H-indazol-1-yl)methyl)-4-(trifluoromethyl)benzaldehyde in a
similar fashion to Preparation #9 to afford the title product (38
mg, 35%); LC/MS (Table A, Method a) R.sub.t=1.71 min; MS m/z: 541
(M+H).sup.+. (TNF IC.sub.50=A).
Example #116
6-(2-((R)-4-(2-hydroxyacetyl)-3-methylpiperazin-1-yl)pyrimidin-5-yl)-2-met-
hyl-1-(1-(m-tolyl)ethyl)-1H-indazol-3(2H)-one
##STR00393##
[1220] The reaction was performed using
6-(2-((R)-4-(2-(tert-butoxy)acetyl)-3-methylpiperazin-1-yl)pyrimidin-5-yl-
)-2-methyl-1-(1-(m-tolyl)ethyl)-1H-indazol-3(2H)-one (synthesized
in a manner similar to Preparation #4, step 1 from
(R)-6-(2-(4-(2-(tert-butoxy)acetyl)-3-methylpiperazin-1-yl)pyrimidin-5-yl-
)-2-methyl-1H-indazol-3(2H)-one (Preparation #60) and
1-(1-bromoethyl)-3-methylbenzene (synthesized in a manner similar
to Preparation #21, step 2 from 1-(m-tolyl)ethanol (synthesized in
a manner similar to Preparation #9 from 1-(m-tolyl)ethanone))) in a
similar fashion to Example #30 to afford the title product (28 mg,
44%); LC/MS (Table A, Method a) R.sub.t=1.94 min; MS m/z: 501
(M+H).sup.+. (TNF IC.sub.50=A)
Example #117
6-(2-((R)-4-(2-Hydroxyacetyl)-3-methylpiperazin-1-yl)pyrimidin-5-yl)-2-met-
hyl-1-((S)-1-(m-tolyl)ethyl)-1H-indazol-3(2H)-one
##STR00394##
[1222]
6-(2-((R)-4-(2-Hydroxyacetyl)-3-methylpiperazin-1-yl)pyrimidin-5-yl-
)-2-methyl-1-(1-(m-tolyl)ethyl)-1H-indazol-3(2H)-one (0.28 g, 0.54
mmol) (Example#116) was submitted for chiral separation (Table C,
Method e). Fractions from the first eluding component were combined
and concentrated. The residue was dissolved in MeCN (0.5 mL) then
water (5 mL) was added. The mixture was sonicated then frozen. The
resulting solid was lyophilized to afford the title product (0.085
g, 31%) with negative optical rotation. LC/MS (Table A, Method h)
R.sub.t=1.25 min; MS m/z: 501 (M+H).sup.+. (TNF IC.sub.50=A).
Example #118
6-(2-((R)-4-(2-Hydroxyacetyl)-3-methylpiperazin-1-yl)pyrimidin-5-yl)-2-met-
hyl-1-((R)-1-(m-tolyl)ethyl)-1H-indazol-3(2H)-one
##STR00395##
[1224]
6-(2-((R)-4-(2-Hydroxyacetyl)-3-methylpiperazin-1-yl)pyrimidin-5-yl-
)-2-methyl-1-(1-(m-tolyl)ethyl)-1H-indazol-3(2H)-one (0.28 g, 0.54
mmol) (Example#116) was submitted for chiral separation (Table C,
Method e). Fractions from the second eluding component were
combined and concentrated. The residue was dissolved in MeCN (0.5
mL) then water (5 mL) was added. The mixture was sonicated then
frozen. The resulting solid was lyophilized to afford the title
product (0.090 g, 33%) with positive optical rotation. LC/MS (Table
A, Method h) R.sub.t=1.25 min; MS m/z: 501 (M+H).sup.+. (TNF
IC.sub.50=B).
Example #119*
(R)-6-(2-(4-Acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-1-((1-acetyl-4-(-
trifluoromethyl)-1H-pyrrol-3-yl)methyl)-2-methyl-1H-indazol-3(2H)-one
##STR00396##
[1226] Sodium hydride (60% dispersion in mineral oil) (6.5 mg, 0.16
mmol) in THF (1 mL) was cooled to about 0.degree. C. A solution of
(R)-6-(2-(4-acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-1-((4--
(trifluoromethyl)-1H-pyrrol-3-yl)methyl)-1H-indazol-3(2H)-one (120
mg, 0.234 mmol) (Example #27.5) in THF (1 mL) was added dropwise
via syringe and the reaction was stirred for about 15 min at about
0.degree. C. A solution of acetyl chloride (12.8 mg, 0.16 mmol) in
THF (1 mL) was added dropwise via syringe at about 0.degree. C. and
the reaction was stirred at rt for about 18 h. The reaction was
quenched with sat. aq. NH.sub.4Cl (2 mL) and extracted with DCM (10
mL). The organic layer was dried over MgSO.sub.4, filtered, and
concentrated. The residue was purified on silica gel (0-8%
MeOH/CH2Cl2) to afford the title product (14 mg, 10%); LC/MS (Table
A, Method a) R.sub.t=1.85 min; MS m/z: 556 (M+H).sup.+. (TNF
IC.sub.50=A).
Example #120
6-(2-(2-Aminopropan-2-yl)pyrimidin-5-yl)-1-(2-(difluoromethoxy)-5-methylbe-
nzyl)-2-methyl-1H-indazol-3(2H)-one
##STR00397##
[1228]
1-(2-(Difluoromethoxy)-5-methylbenzyl)-2-methyl-6-(4,4,5,5-tetramet-
hyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3(2H)-one (Example #22,
step 2) (452 mg, 1.02 mmol),
2-(5-bromopyrimidin-2-yl)propan-2-amine (prepared in a manner
similar to conditions found in WO201586526 A1) (200 mg, 0.93 mmol),
cesium carbonate (754 mg, 2.31 mmol), and
bis(triphenylphosphine)palladium(II) dichloride (39 mg, 0.056 mmol)
were combined, then the vessel was evacuated and back-filled with
N.sub.2 three times. A degassed mixture of dioxane (4.8 mL) and
water (1.0 mL) was added and the reaction was heated to about
80.degree. C. and stirred for about 90 min. Additional
bis(triphenylphosphine)palladium(II) dichloride (39 mg, 0.056 mmol)
was added and the reaction was stirred at about 85.degree. C. for
about 2.5 h. The reaction was cooled and partitioned between EtOAc
(20 mL) and water (20 mL). The aqueous layer was extracted with
additional EtOAc (20 mL) then the combined organic layers were
dried over MgSO.sub.4, filtered, and concentrated. The resulting
residue was purified via reverse phase preparative HPLC (Table A,
Method I). The relevant fractions were concentrated, redissolved in
DCM (20 mL) and washed with sat. aq. Na.sub.2CO.sub.3 solution (10
mL). The organic layer was dried over MgSO.sub.4, filtered, and
concentrated to yield the title compound (130 mg, 31%); LC/MS
(Table A, Method h) R.sub.t=0.95 min.; MS m/z: 454 (M+H).sup.+.
(TNF IC.sub.50=A)
Example #121*
(R)-1-(2-(Difluoromethoxy)benzyl)-7-fluoro-6-(2-(4-(2-hydroxyacetyl)-2-met-
hylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one
##STR00398##
[1230] The reaction was performed in a similar manner to Example #8
using
(R)-1-(4-(5-bromopyrimidin-2-yl)-3-methylpiperazin-1-yl)-2-hydroxyethanon-
e (Preparation #22) and
6-Bromo-1-(2-(difluoromethoxy)benzyl)-7-fluoro-2-methyl-1H-indazol-3(2H)--
one (prepared in a similar fashion to Preparation #4, step 1 using
6-bromo-7-fluoro-2-methyl-1H indazol-3(2H)-one (Preparation #38)
and 1-(bromomethyl)-2-(difluoromethoxy)benzene)) to give the title
product (34%); (Table A, Method a) R.sub.t=1.87 min; MS m/z: 557
(M+H).sup.+. (TNF IC.sub.50=A)
Example #122
1-(2-Chloro-5-((2-hydroxy-2-methylpropyl)amino)benzyl)-6-(2-(2-hydroxyprop-
an-2-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one
##STR00399##
[1232] A scintillation vial was charged with
1-(5-amino-2-chlorobenzyl)-6-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-2-m-
ethyl-1H-indazol-3(2H)-one (0.140 g, 0.304 mmol) (Example #42, step
2), trifluoroethanol (0.65 mL) and 2,2-dimethyloxirane (0.136 mL,
1.52 mmol). The system was sealed then heated to about 60.degree.
C. for about 16 h. After cooling to rt, the solvent was removed
under reduced pressure. The residue was concentrated from EtOAc (5
mL) twice. The material was purified via flash chromatography on
silica gel (0-4% MeOH/DCM). The appropriate fractions were
collected and concentrated under reduced pressure to provide the
title product (0.025 g, 17%); LC/MS (Table A, Method h)
R.sub.t=1.14 min.; MS m/z: 496 (M+H).sup.+. (TNF IC.sub.50=B)
[1233] The compounds shown in Table 30 were synthesized in a manner
similar to Example #122 from
1-(5-amino-2-chlorobenzyl)-6-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-2-m-
ethyl-1H-indazol-3(2H)-one (Example #42, step 2) and the
corresponding epoxide.
TABLE-US-00036 TABLE 30 R.sub.t min (Table A, m/z ESI+ TNF Epoxide
Product Example # Method) (M + H).sup.+ IC.sub.50
(S)-2-Methyloxirane ##STR00400## 30.1* 1.08 (h) 482 B
(R)-2-Methyloxirane ##STR00401## 30.2* 1.08 (h) 482 B
Example #123
(S)-7-(5-(2-Methyl-1-((1-methyl-4-(trifluoromethyl)-1H-pyrrol-3-yl)methyl)-
-3-oxo-2,3-dihydro-1H-indazol-6-yl)pyrimidin-2-yl)hexahydroimidazo[1,5-a]p-
yrazin-3(2H)-one
##STR00402##
[1235]
(S)-7-(5-(2-Methyl-1-((1-methyl-4-(trifluoromethyl)-1H-pyrrol-3-yl)-
methyl)-3-oxo-2,3-dihydro-1H-indazol-6-yl)pyrimidin-2-yl)hexahydroimidazo[-
1,5-a]pyrazin-3(2H)-one was prepared in a manner similar to Example
#8 using
(S)-7-(5-bromopyrimidin-2-yl)hexahydroimidazo[1,5-a]pyrazin-3(2H)-o-
ne (Preparation #13) and
6-bromo-2-methyl-1-((1-methyl-4-(trifluoromethyl)-1H-pyrrol-3-yl)methyl)--
1H-indazol-3(2H)-one (prepared in a similar manner to Example #1
using 6-bromo-2-methyl-1H-indazol-3(2H)-one (Preparation #1) and
3-(chloromethyl)-1-methyl-4-(trifluoromethyl)-1H-pyrrole,
hydrochloric acid (prepared in a similar manner to Preparation #50,
step 6 using (1-methyl-4-(trifluoromethyl)-1H-pyrrol-3-yl)methanol
(prepared in a similar manner to Preparation #32, step 4 using
ethyl 1-methyl-4-(trifluoromethyl)-1H-pyrrole-3-carboxylate (WO
2001049664 A1)))) to afford the title compound (84%); LC/MS (Table
A, Method a) R.sub.t=1.75 min; MS m/z: 527 (M+H).sup.+. (TNF
IC.sub.50=A).
Example #124
1-(2-(Difluoromethoxy)-5-methylbenzyl)-6-(2-isopropylpyrimidin-5-yl)-2-met-
hyl-1H-indazol-3(2H)-one
##STR00403##
[1236] Step 1: 5-Bromo-2-(prop-1-en-2-yl)pyrimidine
[1237] SOCl.sub.2 (3.50 mL, 48.0 mmol) was added to a solution of
2-(5-bromopyrimidin-2-yl)propan-2-ol (1.00 g, 4.61 mmol) and DCM
(10.0 mL). After about 90 min, pyridine (1.10 mL, 13.6 mmol) was
added in one portion. After about 18 h, the volatiles were removed
under reduced pressure. The residue was dissolved in DCM (50 mL),
sat. aq. NH.sub.4Cl (50 mL), and water (10 mL). The layers were
separated. The organic layer was dried over Na.sub.2SO.sub.4,
filtered, and concentrated under reduced pressure. The residue was
purified using flash chromatography on silica gel (0-15%
EtOAc/heptane). The appropriate fractions were collected and
concentrated under reduced pressure to afford the title product
(54%); .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 8.95 (s, 2H),
6.37 (dq, J=2.2, 0.9 Hz, 1H), 5.58 (dq, J=2.3, 1.6 Hz, 1H), 2.14
(dd, J=1.5, 0.9 Hz, 3H).
Step 2:
1-(2-(Difluoromethoxy)-5-methylbenzyl)-2-methyl-6-(2-(prop-1-en-2--
yl)pyrimidin-5-yl)-1H-indazol-3(2H)-one
[1238]
1-(2-(Difluoromethoxy)-5-methylbenzyl)-2-methyl-6-(2-(prop-1-en-2-y-
l)pyrimidin-5-yl)-1H-indazol-3(2H)-one was prepared in a manner
similar to Example #15, step 4 using
5-bromo-2-(prop-1-en-2-yl)pyrimidine and
1-(2-(difluoromethoxy)-5-methylbenzyl)-2-methyl-6-(4,4,5,5-tetramethyl-1,-
3,2-dioxaborolan-2-yl)-1H-indazol-3(2H)-one (Example #22, step 2)
to afford the title product (51%); LC/MS (Table A, Method i)
R.sub.t=1.64 min; MS m/z: 437 (M+H).sup.+.
Step 3:
1-(2-(Difluoromethoxy)-5-methylbenzyl)-6-(2-isopropylpyrimidin-5-y-
l)-2-methyl-1H-indazol-3(2H)-one
[1239] MeOH (3.50 mL) was added to a mixture of
1-(2-(difluoromethoxy)-5-methylbenzyl)-2-methyl-6-(2-(prop-1-en-2-yl)pyri-
midin-5-yl)-1H-indazol-3(2H)-one (0.150 g, 0.344 mmol) and 10%
palladium on carbon (wet) (0.073 g) under N.sub.2. The mixture was
placed under H.sub.2 (balloon). After about 2 h, the atmosphere was
evacuated and the reaction mixture was filtered through Celite.RTM.
rinsing with 50% MeOH/DCM (30 mL). The volatiles were removed under
reduced pressure. The residue was purified on silica gel using a
gradient of 0-80% EtOAc/DCM. The appropriate fractions were
collected and concentrated to afford the title product (95.8 mg,
63%); LC/MS (Table A, Method a) R.sub.t=2.28 min; MS m/z: 439
(M+H).sup.+. (TNF IC.sub.50=A).
Example #125
1-(2-(Difluoromethoxy)-5-morpholinobenzyl)-6-(2-(2-hydroxypropan-2-yl)pyri-
midin-5-yl)-2-methyl-1H-indazol-3(2H)-one
##STR00404##
[1240] Step 1:
4-(3-(((tert-Butyldimethylsilyl)oxy)methyl)-4-(difluoromethoxy)phenyl)mor-
pholine
[1241] Sodium tert-butoxide (1.60 g, 16.65 mmol) was added to a
solution of
((5-bromo-2-(difluoromethoxy)benzyl)oxy)(tert-butyl)dimethylsilane
(2.46 g, 6.70 mmol) (prepared in a similar manner to Preparation
#43, step 1 from (5-bromo-2-(difluoromethoxy)phenyl)methanol
(Preparation #12)), morpholine (1.80 mL, 20.1 mmol), and toluene
(60.0 mL) under N.sub.2. Pd.sub.2dba.sub.3 (0.305 g, 0.333 mmol)
and 1,1'-binaphthalene-2,2'-diyl)bis(diphenylphosphine (0.628 g,
1.009 mmol) were added. The reaction vessel was evacuated and
back-filled with N.sub.2 three times then purged with N.sub.2 for
about 20 min. The mixture was warmed to about 100.degree. C. After
about 3 h, the mixture was allowed to cool to rt. Water (50 mL) and
EtOAc (100 mL) were added. The layers were separated and the
organic layer was washed with sat. aq. NaCl (50 mL). The organic
layer was dried over Na.sub.2SO.sub.4, filtered, and concentrated
under reduced pressure. The residue was purified by flash
chromatography on silica gel eluding with a gradient of 0-20%
EtOAc/heptane. The appropriate fractions were collected and
concentrated under reduced pressure to afford the title compound
(0.689 g, 28%); LC/MS (Table A, Method i) R.sub.t=2.22 min; MS m/z:
374 (M+H).sup.+.
Step 2: 4-(3-(Chloromethyl)-4-(difluoromethoxy)phenyl)morpholine,
hydrochloric acid
[1242] 4-(3-(Chloromethyl)-4-(difluoromethoxy)phenyl)morpholine,
hydrochloric acid was prepared in a similar manner to Preparation
#50, step 6 using (2-(difluoromethoxy)-5-morpholinophenyl)methanol
(prepared in a similar manner to Preparation #43, step 1 using
4-(3-(((tert-butyldimethylsilyl)oxy)methyl)-4-(difluoromethoxy)phenyl)mor-
pholine) to afford the title product; (95%); LC/MS (Table A, Method
i) R.sub.t=1.46 min; MS m/z: 278 (M+H).sup.+.
Step 3:
1-(2-(Difluoromethoxy)-5-morpholinobenzyl)-6-(2-(2-hydroxypropan-2-
-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one
[1243]
1-(2-(Difluoromethoxy)-5-morpholinobenzyl)-6-(2-(2-hydroxypropan-2--
yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one was prepared in a
similar manner to Example #15, step 4 using
2-(5-bromopyrimidin-2-yl)propan-2-ol and
1-(2-(difluoromethoxy)-5-morpholinobenzyl)-2-methyl-6-(4,4,5,5-tetram-
ethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3(2H)-one (prepared in a
similar manner to Preparation #4, step 2 using
6-bromo-1-(2-(difluoromethoxy)-5-morpholinobenzyl)-2-methyl-1H-indazol-3(-
2H)-one (prepared in a similar manner to Example 1 using
6-bromo-2-methyl-1H-indazol-3(2H)-one (Preparation #1) and
4-(3-(chloromethyl)-4-(difluoromethoxy)phenyl)morpholine,
hydrochloric acid)) to afford the title product (71%); LC/MS (Table
A, Method a) R.sub.t=1.81 min; MS m/z: 526 (M+H).sup.+. (TNF
IC.sub.50=B).
Example #126*
(R)-1-(2-(Difluoromethoxy)benzyl)-5-fluoro-6-(2-(4-(2-hydroxyacetyl)-2-met-
hylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one
##STR00405##
[1245]
(R)-1-(2-(Difluoromethoxy)benzyl)-5-fluoro-6-(2-(4-(2-hydroxyacetyl-
)-2-methylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one
was synthesized in a manner similar to Example #8 from
6-bromo-1-(2-(difluoromethoxy)benzyl)-5-fluoro-2-methyl-1H-indazol-3(2H)--
one (Preparation #40) and
(R)-1-(4-(5-bromopyrimidin-2-yl)-3-methylpiperazin-1-yl)-2-hydroxyethanon-
e (Preparation #22) to afford the title compound (37%); LC/MS
(Table A, Method a) R.sub.t=1.84 min; MS m/z: 557 (M+H).sup.+. (TNF
IC.sub.50=A).
Example #127
6-(2-(2-Hydroxypropan-2-yl)pyrimidin-5-yl)-2-methyl-1-((1-(pyridin-3-ylmet-
hyl)-4-(trifluoromethyl)-1H-pyrrol-3-yl)methyl)-1H-indazol-3(2H)-one
##STR00406##
[1246] Step 1:
6-Bromo-2-methyl-1-((1-(pyridin-3-ylmethyl)-4-(trifluoromethyl)-1H-pyrrol-
-3-yl)methyl)-1H-indazol-3(2H)-one
[1247] NaH (60% dispersion in mineral oil) (0.0240 g, 0.600 mmol)
was added in one portion to a mixture of
6-bromo-2-methyl-1-((4-(trifluoromethyl)-1H-pyrrol-3-yl)methyl)-1H-indazo-
l-3(2H)-one (0.100 g, 0.267 mmol) (Preparation #72),
3-(bromomethyl)pyridine hydrobromide (0.0890 g, 0.352 mmol), and
THF (2.50 mL) under N.sub.2 at about 0.degree. C. After about 1 h,
sat. aq. NaHCO.sub.3 (2.5 mL), water (2.5 mL) and DCM (10 mL) were
added. The layers were separated and the aqueous layer was
extracted with DCM (2.times.5 mL). The combined organic layers were
dried over Na.sub.2SO.sub.4, filtered, and concentrated. The
residue was purified by flash chromatography on silica gel eluding
with a gradient of 10-80% (10% MeOH/DCM)/DCM). The appropriate
fractions were collected and concentrated under reduced pressure to
afford the title compound (0.080 g, 65%); LC/MS (Table A, Method i)
R.sub.t=1.35 min; MS m/z: 465 and 467 (M+H).sup.+.
Step 2:
6-(2-(2-Hydroxypropan-2-yl)pyrimidin-5-yl)-2-methyl-1-((1-(pyridin-
-3-ylmethyl)-4-(trifluoromethyl)-1H-pyrrol-3-yl)methyl)-1H-indazol-3(2H)-o-
ne
[1248]
6-(2-(2-Hydroxypropan-2-yl)pyrimidin-5-yl)-2-methyl-1-((1-(pyridin--
3-ylmethyl)-4-(trifluoromethyl)-1H-pyrrol-3-yl)methyl)-1H-indazol-3(2H)-on-
e was prepared in a similar manner to Example #8 using
6-bromo-2-methyl-1-((1-(pyridin-3-ylmethyl)-4-(trifluoromethyl)-1H-pyrrol-
-3-yl)methyl)-1H-indazol-3(2H)-one and
2-(5-bromopyrimidin-2-yl)propan-2-ol to afford the title compound
(61%); LC/MS (Table A, Method a) R.sub.t=1.78 min; MS m/z: 523
(M+H).sup.+. (TNF IC.sub.50=A).
Example #128
1-((1-((4-Ethylpyridin-3-yl)methyl)-4-(trifluoromethyl)-1H-pyrrol-3-yl)met-
hyl)-6-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)--
one
##STR00407##
[1249] Step 1: Ethyl 4-ethylnicotinate
[1250] Copper(I) bromide dimethyl sulfide complex (0.753 g, 3.66
mmol) was added to a solution of ethyl nicotinate (5.00 mL, 36.6
mmol) and THF (80 mL) under N.sub.2. The solution was cooled to
about -78.degree. C. Phenyl chloroformate (5.00 mL, 39.8 mmol) was
added over about 10 min. After about 20 min, ethylmagnesium bromide
(1 M solution in THF) (40.0 mL, 40.0 mmol) was added dropwise over
about 40 min. After about 1 h, the cold bath was removed and sat.
aq. NH.sub.4Cl (120 mL) then isopropyl acetate (80 mL) were added.
After warming to about rt, the layers were separated. The organic
layer was washed with 1 M aq. HCl (120 mL). The aqueous layers were
extracted with isopropyl acetate (80 mL). The combined organic
layers were dried over Na.sub.2SO.sub.4, filtered, and concentrated
under reduced pressure. The residue was dissolved in isopropyl
acetate (80 mL). 2,3-Dichloro-5,6-dicyano-1,4-benzoquinone (5.82 g,
25.6 mmol) was added. After about 30 min, 1 M aq. HCl (100 mL) was
added. The layers were separated and the organic layer was
extracted with 1 M aq. HCl (100 mL). The combined aqueous layers
were adjusted to about pH 10 with 5 N aq. NaOH (45 mL). The aqueous
mixture was extracted with DCM (2.times.100 mL). The combined
organic layers were dried over Na.sub.2SO.sub.4, filtered, and
concentrated under reduced pressure. The residue was purified on
silica gel (0-20% EtOAc/DCM). The appropriate fractions were
collected and concentrated under reduced pressure to afford the
title compound (2.36 g, 36%); LC/MS (Table A, Method i)
R.sub.t=1.03 min; MS m/z: 180 (M+H).sup.+.
Step 2: (4-Ethylpyridin-3-yl)methanol
[1251] (4-Ethylpyridin-3-yl)methanol was prepared in a similar
manner to Preparation #32, step 4 using ethyl 4-ethylnicotinate to
afford the title compound (99%); LC/MS (Table A, Method i)
R.sub.t=0.12 min; MS m/z: 138 (M+H).sup.+.
Step 3: 3-(Chloromethyl)-4-ethylpyridine, hydrochloric acid
[1252] 3-(Chloromethyl)-4-ethylpyridine, hydrochloric acid was
prepared in a similar manner to Preparation #50, step 6 using
(4-ethylpyridin-3-yl)methanol to afford the title compound (86%);
LC/MS (Table A, Method i) R.sub.t=0.74 min; MS m/z: 156
(M+H).sup.+.
Step 4:
6-Bromo-1-((1-((4-ethylpyridin-3-yl)methyl)-4-(trifluoromethyl)-1H-
-pyrrol-3-yl)methyl)-2-methyl-1H-indazol-3(2H)-one
[1253]
6-Bromo-1-((1-((4-ethylpyridin-3-yl)methyl)-4-(trifluoromethyl)-1H--
pyrrol-3-yl)methyl)-2-methyl-1H-indazol-3(2H)-one was prepared in a
similar manner to Example #127, step 1 using
3-(chloromethyl)-4-ethylpyridine, hydrochloric acid and
6-bromo-2-methyl-1-((4-(trifluoromethyl)-1H-pyrrol-3-yl)methyl)-1H-indazo-
l-3(2H)-one (Preparation #72) to afford the title compound (50%);
LC/MS (Table A, Method i) R.sub.t=1.47 min; MS m/z: 493 and 495
(M+H).sup.+.
Step 5:
1-((1-((4-Ethylpyridin-3-yl)methyl)-4-(trifluoromethyl)-1H-pyrrol--
3-yl)methyl)-6-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-2-methyl-1H-indazo-
l-3(2H)-one
[1254]
1-((1-((4-Ethylpyridin-3-yl)methyl)-4-(trifluoromethyl)-1H-pyrrol-3-
-yl)methyl)-6-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-
-3(2H)-one was prepared in a similar manner to Example #8 using
6-bromo-1-((1-((4-ethylpyridin-3-yl)methyl)-4-(trifluoromethyl)-1H-pyrrol-
-3-yl)methyl)-2-methyl-1H-indazol-3(2H)-one and
2-(5-bromopyrimidin-2-yl)propan-2-ol to afford the title compound
(68%); LC/MS (Table A, Method a) R.sub.t=1.90 min; MS m/z: 551
(M+H).sup.+. (TNF IC.sub.50=B).
Example #128
6-(2-(2-Hydroxypropan-2-yl)pyrimidin-5-yl)-2-methyl-1-((1-(pyridazin-4-ylm-
ethyl)-4-(trifluoromethyl)-1H-pyrrol-3-yl)methyl)-1H-indazol-3(2H)-one
##STR00408##
[1255] Step 1: 4-(Chloromethyl)pyridazine, hydrochloric acid
[1256] 4-(Chloromethyl)pyridazine, hydrochloric acid was prepared
in a similar manner to Preparation #50, step 6 using
4-pyridazinemethanol to afford the title compound (84%); LC/MS
(Table A, Method j) R.sub.t=0.23 min; MS m/z: 129 (M+H).sup.+.
Step 2:
6-Bromo-2-methyl-1-((1-(pyridazin-4-ylmethyl)-4-(trifluoromethyl)--
1H-pyrrol-3-yl)methyl)-1H-indazol-3(2H)-one
[1257]
6-Bromo-2-methyl-1-((1-(pyridazin-4-ylmethyl)-4-(trifluoromethyl)-1-
H-pyrrol-3-yl)methyl)-1H-indazol-3(2H)-one was prepared in a
similar manner to Example #127, step 1 using
4-(chloromethyl)pyridazine, hydrochloric acid and
6-bromo-2-methyl-1-((4-(trifluoromethyl)-1H-pyrrol-3-yl)methyl)-1H-indazo-
l-3(2H)-one (Preparation #72) to afford the title compound (11%);
LC/MS (Table A, Method i) R.sub.t=1.22 min; MS m/z: 466 and 468
(M+H).sup.+.
Step 3:
6-(2-(2-Hydroxypropan-2-yl)pyrimidin-5-yl)-2-methyl-1-((1-(pyridaz-
in-4-ylmethyl)-4-(trifluoromethyl)-1H-pyrrol-3-yl)methyl)-1H-indazol-3(2H)-
-one
[1258]
6-(2-(2-Hydroxypropan-2-yl)pyrimidin-5-yl)-2-methyl-1-((1-(pyridazi-
n-4-ylmethyl)-4-(trifluoromethyl)-1H-pyrrol-3-yl)methyl)-1H-indazol-3(2H)--
one was prepared in a similar manner to Example #8 using
6-bromo-2-methyl-1-((1-(pyridazin-4-ylmethyl)-4-(trifluoromethyl)-1H-pyrr-
ol-3-yl)methyl)-1H-indazol-3(2H)-one and
2-(5-bromopyrimidin-2-yl)propan-2-ol to afford the title compound
(68%); LC/MS (Table A, Method a) R.sub.t=1.63 min; MS m/z: 524
(M+H).sup.+. (TNF IC.sub.50=B).
Example #129*
(R)-6-(2-(4-Acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-1-(2-(difluorome-
thoxy)-5-((3-methyl-2-oxoimidazolidin-1-yl)methyl)benzyl)-2-methyl-1H-inda-
zol-3(2H)-one
##STR00409##
[1260] A flask was charged with sodium hydride (13.2 mg, 0.330
mmol), DMF (1 mL) and 1-methylimidazolidin-2-one (41 mg, 0.41 mmol)
at rt. After about 30 min, the mixture was cooled to about
-7.degree. C. After about 20 min,
(R)-6-(2-(4-acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-1-(5-(b-
romomethyl)-2-(difluoromethoxy)benzyl)-2-methyl-1H-indazol-3(2H)-one
(prepared from
(R)-6-(2-(4-acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-1-(2-(difluorom-
ethoxy)-5-(hydroxymethyl)benzyl)-2-methyl-1H-indazol-3(2H)-one
(prepared from
(R)-6-(2-(4-acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-1-(2-(difl-
uoromethoxy)-5-((trityloxy)methyl)benzyl)-2-methyl-1H-indazol-3(2H)-one
(prepared from
(R)-6-(2-(4-acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-2-methyl-1H-ind-
azol-3(2H)-one (Preparation #28) and
(((3-(bromomethyl)-4-(difluoromethoxy)benzyl)oxy)methanetriyl)tribenzene
(Preparation #14) in a similar fashion to Example #1) in a similar
fashion to Example #18) in a similar fashion to Preparation #14,
step 6) was added. After about 1 min, the reaction was quenched
with H.sub.2O (10 mL) and diluted further with additional H.sub.2O
(10 mL). The mixture was extracted with 10% MeOH in
CH.sub.2Cl.sub.2 (2.times.10 mL), dried over Na.sub.2SO.sub.4,
filtered and concentrated. The residue was purified by flash
chromatography on silica gel (0-10% MeOH/CH.sub.2Cl.sub.2) to
afford the title product (18 mg, 29%); LC/MS (Table A, Method a)
R.sub.t=1.72 min; MS m/z: 635 (M+H).sup.+. (TNF IC.sub.50=B).
Example #130
6-(2-(2-Hydroxypropan-2-yl)pyrimidin-5-yl)-1-((1-((4-methoxy-1H-pyrazol-3--
yl)methyl)-4-(trifluoromethyl)-1H-pyrrol-3-yl)methyl)-2-methyl-1H-indazol--
3(2H)-one
##STR00410##
[1261] Step 1:
4-Methoxy-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole-3-carboxylic
acid
[1262] n-Butyllithium (2.5 M solution in hexanes) (15.0 mL, 37.5
mmol) was added dropwise over about 15 min to a solution of
4-methoxy-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole (6.92 g,
30.3 mmol) (WO 2015095767 A1) and THF (100 mL) under N.sub.2 at
about -65.degree. C. After stirring at about -60 to -65.degree. C.
for about 1 h, the solution was cooled to about -78.degree. C. The
solution was saturated with carbon dioxide by bubbling carbon
dioxide through the solution for about 15 min. The cold bath was
allowed to thaw to rt over about 2 h. After stirring at rt for
about 1 h, sat. aq. NH.sub.4Cl (14 mL) was added. 1 M aq. HCl (31.5
mL) was added to adjust the pH to about 4. EtOAc (150 mL) was
added. The layers were separated and the aqueous layer was
extracted with EtOAc (150 mL). The combined organic layers were
dried over Na.sub.2SO.sub.4, filtered, and concentrated. The
resulting solid was dried under reduced pressure for about 15 h to
afford the title compound (7.95 g, 96%); LC/MS (Table A, Method i)
R.sub.t=1.01 min; MS m/z: 271 (M-H).sup.-.
Step 2:
(4-Methoxy-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)me-
thanol
[1263]
(4-Methoxy-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)met-
hanol was prepared in a similar manner to Preparation #32, step 4
using
4-methoxy-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole-3-carboxylic
acid to afford the title compound (78%); LC/MS (Table A, Method i)
R.sub.t=1.23 min; MS m/z: 259 (M+H).sup.+.
Step 3:
3-(Bromomethyl)-4-methoxy-1-((2-(trimethylsilyl)ethoxy)methyl)-1H--
pyrazole
[1264]
3-(Bromomethyl)-4-methoxy-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-p-
yrazole was prepared in a similar manner to Preparation #20, step 3
using
(4-methoxy-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)methanol
acid to afford the title compound (28%); LC/MS (Table A, Method i)
R.sub.t=1.77 min; MS m/z: 321 and 323 (M+H).sup.+.
Step 4:
6-Bromo-1-((1-((4-methoxy-1-((2-(trimethylsilyl)ethoxy)methyl)-1H--
pyrazol-3-yl)methyl)-4-(trifluoromethyl)-1H-pyrrol-3-yl)methyl)-2-methyl-1-
H-indazol-3(2H)-one
[1265]
6-Bromo-1-((1-((4-methoxy-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-p-
yrazol-3-yl)methyl)-4-(trifluoromethyl)-1H-pyrrol-3-yl)methyl)-2-methyl-1H-
-indazol-3(2H)-one was prepared in a similar manner to Example
#127, step 1 using
3-(bromomethyl)-4-methoxy-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-
-pyrazole and
6-bromo-2-methyl-1-((4-(trifluoromethyl)-1H-pyrrol-3-yl)methyl)-1H-indazo-
l-3(2H)-one (Preparation #72) to afford the title compound (49%);
LC/MS (Table A, Method i) R.sub.t=2.02 min; MS m/z: 614 and 616
(M+H).sup.+.
Step 5:
6-(2-(2-Hydroxypropan-2-yl)pyrimidin-5-yl)-1-((1-((4-methoxy-1H-py-
razol-3-yl)methyl)-4-(trifluoromethyl)-1H-pyrrol-3-yl)methyl)-2-methyl-1H--
indazol-3(2H)-one
[1266] TFA (0.900 mL, 11.7 mmol) was added to a solution of
6-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-1-((1-((4-methoxy-1-((2-(trime-
thylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)methyl)-4-(trifluoromethyl)-1H-py-
rrol-3-yl)methyl)-2-methyl-1H-indazol-3(2H)-one (0.153 g, 0.228
mmol) and DCM (0.900 mL). After about 2.5 h, the volatiles were
removed under reduced pressure. The residue was concentrated from
MeOH (5 mL) twice. The residue was purified by flash chromatography
on silica gel (2-8% MeOH/DCM). The appropriate fractions were
combined and concentrated to afford a pale yellow film. The residue
was dissolved in 0.5 mL MeCN. 5 mL of water was added. The mixture
was frozen and the resulting solid was lyophilized to afford the
title compound (109 mg, 87%); LC/MS (Table A, Method a)
R.sub.t=1.78 min; MS m/z: 542 (M+H).sup.+. (TNF IC.sub.50=A).
Example #131
1-(2-(Difluoromethoxy)-5-methylbenzyl)-5-fluoro-6-(6-(1-hydroxyethyl)-5,6--
dihydro-2H-pyran-3-yl)-2-methyl-1H-indazol-3(2H)-one
##STR00411##
[1267] Step 1:
6-(1-((tert-Butyldiphenylsilyl)oxy)ethyl)tetrahydro-2H-pyran-3-ol
[1268] Borane tetrahydrofuran complex (1 M solution in THF) (84.0
mL, 84 mmol) was added over about 20 min to a solution of
tert-butyl(1-(3,4-dihydro-2H-pyran-2-yl)ethoxy)diphenylsilane (20.6
g, 56.2 mmol) (prepared in a similar manner to Preparation #43,
step 1 using TBDPSCl and 1-(3,4-dihydro-2H-pyran-2-yl)ethanol
(prepared in a similar manner to Preparation #21, step 1 using
3,4-dihydro-2H-pyran-2-carbaldehyde and methylmagnesium bromide))
and THF (280 mL) under N.sub.2 at about 0.degree. C. After
completion of the addition, the ice bath was removed. After
stirring at rt for about 15 h, the solution was cooled to about
0.degree. C. A solution of 2 M aq. sodium hydroxide (50.0 mL, 100
mmol) and hydrogen peroxide (30 wt %) (14.0 mL, 137 mmol) was added
dropwise over about 45 min. After completion of addition, the ice
bath was removed. After about 30 min, the mixture was warmed to
about 55.degree. C. After about 1 h, the mixture was allowed to
cool to rt. Sat. aq. NaHCO.sub.3 (100 mL), water (200 mL) and EtOAc
(200 mL) were added. The layers were separated and the organic
layer was washed with water (200 mL) and sat. aq. NaCl (200 mL).
The combined organic layers were dried over Na.sub.2SO.sub.4,
filtered, and concentrated under reduced pressure. The residue was
purified by flash chromatography on silica gel (0-40%
EtOAc/heptane). The appropriate fractions were collected and
concentrated to afford, after drying under reduced pressure for
about 5 h, the title compound (16.9 g, 78%); .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 7.75-7.62 (m, 4H), 7.46-7.31 (m, 6H), 4.03-2.88
(m, 5H), 2.21-1.20 (m, 7H), 1.12-0.98 (m, 12H).
Step 2:
6-(1-((tert-Butyldiphenylsilyl)oxy)ethyl)dihydro-2H-pyran-3(4H)-on-
e
[1269] Dess-Martin periodinane (24.6 g, 58.0 mmol) was added in one
portion to a solution of
6-(1-((tert-butyldiphenylsilyl)oxy)ethyl)tetrahydro-2H-pyran-3-ol
(16.9 g, 43.9 mmol) and DCM (200 mL) under N.sub.2 at about
0.degree. C. After about 5 min, the ice bath was removed. After
about 23 h, a solution of 10% aq. Na.sub.2S.sub.2O.sub.3 (200 mL)
and sat. aq. NaHCO.sub.3 (200 mL) was slowly added. After
vigorously stirring for about 2 h, the layers were separated and
the organic layer was washed with water (200 mL) then sat. aq. NaCl
(200 mL). The aqueous layers were extracted with DCM (200 mL). The
combined organic layers were dried over Na.sub.2SO.sub.4, filtered,
and concentrated. The residue was purified on silica gel (0-40%
EtOAc/heptane). The appropriate fractions were collected and
concentrated to afford the title compound (15.3 g, 91%); .sup.1H
NMR (400 MHz, CDCl.sub.3) .delta. 7.77-7.62 (m, 4H), 7.49-7.31 (m,
6H), 4.16-3.68 (m, 3H), 3.59-3.45 (m, 1H), 2.65-2.49 (m, 1H),
2.45-2.33 (m, 1H), 2.17-1.84 (m, 2H), 1.14-0.99 (m, 12H).
Step 3:
6-(1-((tert-Butyldiphenylsilyl)oxy)ethyl)-5,6-dihydro-2H-pyran-3-y-
l trifluoromethanesulfonate
[1270] A solution of
6-(1-((tert-butyldiphenylsilyl)oxy)ethyl)dihydro-2H-pyran-3(4H)-one
(14.8 g, 38.7 mmol),
2-[N,N-bis(trifluoromethanesulfonyl)amino]-5-chloropyridine (17.2
g, 43.8 mmol), and THF (300 mL) under N.sub.2 was cooled to about
-78.degree. C. Potassium bis(trimethylsilyl)amide (1 M solution in
tert-butyl methyl ether) (43.0 mL, 43.0 mmol) was added dropwise
over about 25 min. After about 2 h, the cold bath was removed. Sat.
aq. NH.sub.4Cl (300 mL) was added. EtOAc (300 mL) was added. The
mixture was allowed to warm to rt. Water (50 mL) was added and the
layers were separated. The organic layer was dried over
Na.sub.2SO.sub.4, filtered and concentrated. The material was
slurried in DCM (20 mL) and filtered rinsing with DCM (2.times.10
mL). The organic volatiles were removed under reduced pressure. The
material was slurried in DCM (5 mL) then filtered rinsing with DCM
(5 mL). The solution was purified on silica gel (0-10%
EtOAc/heptane). The appropriate fractions were collected and
concentrated to afford the title product (15.8 g, 79%); .sup.1H NMR
(400 MHz, CDCl.sub.3) .delta. 7.75-7.59 (m, 4H), 7.46-7.28 (m, 6H),
5.91-5.76 (m, 1H), 4.20-4.07 (m, 1H), 4.07-3.94 (m, 1H), 3.95-3.77
(m, 1H), 3.47-3.28 (m, 1H), 2.41-2.08 (m, 2H), 1.09-1.00 (m,
12H).
Step 4:
tert-Butyldiphenyl(1-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2--
yl)-3,6-dihydro-2H-pyran-2-yl)ethoxy)silane
[1271] PdCl.sub.2(dppf) DCM complex (2.51 g, 3.07 mmol) was added
to a mixture of
6-(1-((tert-butyldiphenylsilyl)oxy)ethyl)-5,6-dihydro-2H-pyran-3-yl
trifluoromethanesulfonate (15.8 g, 30.7 mmol), KOAc (9.21 g, 94
mmol), bis(pinacolato)diboron (9.46 g, 37.3 mmol), and dioxane (250
mL) under N.sub.2. The reaction vessel was evacuated then
back-filled with N.sub.2 three times then purged with N.sub.2 for
about 15 min. The reaction mixture was warmed to about 95.degree.
C. After about 15 h, the mixture was allowed to cool to rt. The
mixture was diluted with water (300 mL) and EtOAc (300 mL). The
layers were separated. The organics were dried over
Na.sub.2SO.sub.4, filtered, and concentrated. The residue was
purified on silica gel (0-5% EtOAc/heptane). The appropriate
fractions were collected and concentrated to afford the title
product (11.6 g, 77%); LC/MS (Table A, Method k) R.sub.t=1.88 min;
MS m/z: 415 (M+H).sup.+.
Step 5:
6-(6-(1-((tert-Butyldiphenylsilyl)oxy)ethyl)-5,6-dihydro-2H-pyran--
3-yl)-5-fluoro-2-methyl-1H-indazol-3(2H)-one
[1272] Bis(triphenylphosphine)palladium(II) dichloride (0.231 g,
0.329 mmol) was added to a mixture of
6-bromo-5-fluoro-2-methyl-1H-indazol-3(2H)-one (1.00 g, 4.08 mmol)
(prepared in a similar manner to Preparation #1 using
4-bromo-2,5-difluorobenzoic acid),
tert-butyldiphenyl(1-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-
-dihydro-2H-pyran-2-yl)ethoxy)silane (3.01 g, 6.12 mmol), cesium
carbonate (3.45 g, 10.6 mmol), dioxane (32.0 mL), and water (8.00
mL). The mixture was evacuated then back-filled with N.sub.2 three
times then purged with N.sub.2 for about 15 min. The mixture was
warmed to about 75.degree. C. After about 2 h, the mixture was
warmed to about 85.degree. C. After about 5 h, the mixture was
allowed to cool to it. Water (40 mL) and EtOAc (40 mL) were added.
The layers were separated and the aqueous layer was extracted with
EtOAc (20 mL). The combined organic layers were dried over
Na.sub.2SO.sub.4, filtered and concentrated. The residue was
purified on silica gel (0-8% (MeOH/DCM). The appropriate fractions
were collected and concentrated to afford the title product (1.76
g, 81%); LC/MS (Table A, Method j) R.sub.t=2.16 min; MS m/z: 531
(M+H).sup.+.
Step 6:
5-Fluoro-6-(6-(1-hydroxyethyl)-5,6-dihydro-2H-pyran-3-yl)-2-methyl-
-1H-indazol-3(2H)-one
[1273] Tetrabutylammonium fluoride (1.0 M solution in THF) (10.0
mL, 10.00 mmol) was added in one portion to a mixture of
6-(6-(1-((tert-butyldiphenylsilyl)oxy)ethyl)-5,6-dihydro-2H-pyran-3-yl)-5-
-fluoro-2-methyl-1H-indazol-3(2H)-one (2.00 g, 3.77 mmol) and THF
(10.0 mL). The reaction vessel was sealed and the solution was
warmed to about 60.degree. C. After about 20 h, EtOAc (50 mL) was
added. AcOH (1 mL) was added. The solution was washed with water
(2.times.50 mL) and sat. aq. NaCl (50 mL). The aqueous layers were
extracted with EtOAc (3.times.50 mL). The combined organic layers
were dried over Na.sub.2SO.sub.4, filtered, and concentrated. The
residue was purified on silic gel (2-10% (MeOH/DCM). The
appropriate fractions were collected and concentrated to afford the
title compound (0.502 g, 44%); LC/MS (Table A, Method j)
R.sub.t=0.64 min; MS m/z: 293 (M+H).sup.+.
Step 7:
1-(2-(Difluoromethoxy)-5-methylbenzyl)-5-fluoro-6-(6-(1-hydroxyeth-
yl)-5,6-dihydro-2H-pyran-3-yl)-2-methyl-1H-indazol-3(2H)-one
[1274]
1-(2-(Difluoromethoxy)-5-methylbenzyl)-5-fluoro-6-(6-(1-hydroxyethy-
l)-5,6-dihydro-2H-pyran-3-yl)-2-methyl-1H-indazol-3(2H)-one was
prepared in a similar manner to Example #1 using
5-fluoro-6-(6-(1-hydroxyethyl)-5,6-dihydro-2H-pyran-3-yl)-2-methyl-1H-ind-
azol-3(2H)-one and
2-(bromomethyl)-1-(difluoromethoxy)-4-methylbenzene (prepared in a
similar manner to Preparation #3, step 2 using
(2-(difluoromethoxy)-5-methylphenyl)methanol (Preparation #11)) to
afford the title compound (67%); LC/MS (Table A, Method h)
R.sub.t=1.29 min; MS m/z: 463 (M+H).sup.+. (TNF IC.sub.50=A).
Example #132
1-(2-(Difluoromethoxy)-5-methylbenzyl)-5-fluoro-6-(6-(2-hydroxypropan-2-yl-
)-5,6-dihydro-2H-pyran-3-yl)-2-methyl-1H-indazol-3(2H)-one
##STR00412##
[1275] Step 1:
6-(6-Acetyl-5,6-dihydro-2H-pyran-3-yl)-1-(2-(difluoromethoxy)-5-methylben-
zyl)-5-fluoro-2-methyl-1H-indazol-3(2H)-one
[1276]
6-(6-Acetyl-5,6-dihydro-2H-pyran-3-yl)-1-(2-(difluoromethoxy)-5-met-
hylbenzyl)-5-fluoro-2-methyl-1H-indazol-3(2H)-one was prepared in a
similar manner to Example #131, step 2 using
1-(2-(difluoromethoxy)-5-methylbenzyl)-5-fluoro-6-(6-(1-hydroxyethyl)-5,6-
-dihydro-2H-pyran-3-yl)-2-methyl-1H-indazol-3(2H)-one (Example
#131) to afford the title product (63%); LC/MS (Table A, Method j)
R.sub.t=1.44 min; MS m/z: 461 (M+H).sup.+.
Step 2:
1-(2-(Difluoromethoxy)-5-methylbenzyl)-5-fluoro-6-(6-(2-hydroxypro-
pan-2-yl)-5,6-dihydro-2H-pyran-3-yl)-2-methyl-1H-indazol-3(2H)-one
[1277] Methylmagnesium bromide (3.0 M in diethyl ether) (0.030 mL,
0.090 mmol) was added dropwise to a solution of
6-(6-acetyl-5,6-dihydro-2H-pyran-3-yl)-1-(2-(difluoromethoxy)-5-methylben-
zyl)-5-fluoro-2-methyl-1H-indazol-3(2H)-one (0.0506 g, 0.110 mmol)
and THF (1.50 mL) under N.sub.2 at about -78.degree. C. After about
30 min, sat. aq. NH.sub.4Cl (5 mL) was added. The cold bath was
removed. EtOAc (5 mL) was added. After warming to rt, the layers
were separated and the aqueous layer was extracted with EtOAc (5
mL). The combined organic layers were dried over Na.sub.2SO.sub.4,
filtered, and concentrated. The residue was purified on silica gel
(25-100% EtOAc/heptane). The appropriate fractions were collected
and concentrated to afford the title compound (22 mg, 42%); LC/MS
(Table A, Method h) R.sub.t=1.40 min; MS m/z: 477 (M+H).sup.+. (TNF
IC.sub.50=A).
Example #133
1-(5-((1H-Pyrazol-5-yl)methyl)-2-(difluoromethoxy)benzyl)-6-(2-(2-hydroxyp-
ropan-2-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one
##STR00413## ##STR00414##
[1278] Step 1:
5-(4-(Benzyloxy)benzyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole
[1279] 1-(Tetrahydro-2H-pyran-2-yl)-1H-pyrazole (6.00 g, 39.4 mmol)
in THF (180 mL) was cooled to about -78.degree. C. n-Butyllithium
(1.6 M in hexane) (27.1 mL, 43.4 mmol) was added dropwise over
about 1 h. The reaction was stirred at about -78.degree. C. for
about 1 h. 1-(Benzyloxy)-4-(bromomethyl)benzene (12.0 g, 43.4 mmol)
(prepared in a similar fashion to Preparation #3, step 2 from
(4-(benzyloxy)phenyl)methanol) was added and the reaction was
allowed to warm to about -50.degree. C. The mixture was diluted
with sat. aq. NaHCO.sub.3 (75 mL) and water (50 mL). The aqueous
layer was extracted with DCM (3.times.50 mL). The combined organic
layers were dried over MgSO.sub.4, filtered, and concentrated. The
residue was purified on silica gel (5-20% EtOAc/heptane) to give
the title product (10.2 g, 74.3%); LC/MS (Table A, Method j)
R.sub.t=1.77 min; MS m/z: 347 (M+H).sup.-.
Step 2:
4-((1-(Tetrahydro-2H-pyran-2-yl)-1H-pyrazol-5-yl)methyl)phenol
[1280]
5-(4-(Benzyloxy)benzyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole
(10.2 g, 29.3 mmol) and 10% dihydroxypalladium on carbon (4.11 g)
in MeOH (500 mL) were evacuated and purged with N.sub.2 three
times. The reaction vessel was evacuated and back-filled with
H.sub.2 then the reaction mixture was stirred under a ballon of
H.sub.2 for about 1 h at rt. The suspension was filtered through
Celite.RTM. and washed with MeOH (50 mL). The filtrate was
concentrated and purified on silica gel (0-4% MeOH/DCM) to give the
title product (6.5 g, 86%); LC/MS (Table A, Method j) R.sub.t=0.99
min; MS m/z: 257 (M+H).sup.-.
Step 3:
2-Hydroxy-5-((1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-5-yl)methyl)-
benzaldehyde
[1281]
4-((1-(Tetrahydro-2H-pyran-2-yl)-1H-pyrazol-5-yl)methyl)phenol
(2.00 g, 7.74 mmol), anhydrous MgCl.sub.2 (1.11 g, 11.6 mmol),
anhydrous TEA (3.13 g, 31.0 mmol) and paraformaldehyde (1.63 g,
54.2 mmol) were suspended in anhydrous MeCN (30 mL). The resulting
suspension was stirred vigorously and heated to about 77.degree. C.
for about 30 min. The reaction was cooled to rt, quenched with
water (50 mL), and extracted with EtOAc (150 mL). The aqueous layer
was acidified with 1 N HCl to about pH 7 and extracted with EtOAc
(50 mL). The combined organic layers were dried over MgSO.sub.4,
filtered, and concentrated. The residue was purified on silica gel
(0-10% EtOAc/DCM) to give the title product (1.7 g, 77%); LC/MS
(Table A, Method j) R.sub.t=1.18 min; MS m/z: 285 (M+H).sup.+.
Step 4:
2-(Difluoromethoxy)-5-((1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-5--
yl)methyl)benzaldehyde
[1282] The reaction was performed using
2-hydroxy-5-((1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-5-yl)methyl)benzald-
ehyde in a similar fashion to Example #33, step 1 to afford the
title product (0.95 g, 48%); LC/MS (Table A, Method j) R.sub.t=1.38
min; MS m/z: 337 (M+H).sup.+.
Step 5:
(2-(Difluoromethoxy)-5-((1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-5-
-yl)methyl)phenyl)methanol
[1283] The reaction was performed using
2-(difluoromethoxy)-5-((1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-5-yl)meth-
yl)benzaldehyde in a similar fashion to Preparation #9 to afford
the title product (0.96 g, 100%); LC/MS (Table A, Method j)
R.sub.t=1.20 min; MS m/z: 339 (M+H).sup.+.
Step 6:
5-(3-(Bromomethyl)-4-(difluoromethoxy)benzyl)-1-(tetrahydro-2H-pyr-
an-2-yl)-1H-pyrazole
[1284] The reaction was performed using
(2-(difluoromethoxy)-5-((1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-5-yl)met-
hyl)phenyl)methanol in a similar fashion to Preparation #21, step 2
to afford the title product (82 mg, 38%); LC/MS (Table A, Method j)
R.sub.t=1.65 min; MS m/z: 317 and 319 (M+H-THP).sup.+.
Step 7:
1-(2-(Difluoromethoxy)-5-((1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-
-5-yl)methyl)benzyl)-6-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-2-methyl-1-
H-indazol-3(2H)-one
[1285] The reaction was performed using
5-(3-(bromomethyl)-4-(difluoromethoxy)benzyl)-1-(tetrahydro-2H-pyran-2-yl-
)-1H-pyrazole and
6-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one
(Preparation #19) in a similar fashion to Preparation #4, step 1 to
afford the title product (100 mg, 94%); LC/MS (Table A, Method j)
R.sub.t=1.25 min; MS m/z: 605 (M+H).sup.+.
Step 8: 1-(5
((1H-Pyrazol-5-yl)methyl)-2-(difluoromethoxy)benzyl)-6-(2-(2-hydroxypropa-
n-2-yl)pyrimidin-5-yl)-2-methyl-1H-indazol-3(2H)-one
[1286]
1-(2-(Difluoromethoxy)-5-((1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol--
5-yl)methyl)benzyl)-6-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-2-methyl-1H-
-indazol-3(2H)-one (100 mg, 0.165 mmol) in THF (2 mL) was added 1 N
aq.HCl (0.992 mL, 0.992 mmol) and stirred for about 2 h at rt. 1 N
aq.HCl (0.992 mL, 0.992 mmol) was added and the reaction was
stirred for about 20 h at rt then quenched with sat. aq.
NaHCO.sub.3 to about pH 8 and extracted with EtOAc (50 mL). The
organic layer was washed with water (5 mL), sat. aq. NaCl (5 mL),
dried over MgSO.sub.4, filtered, and concentrated. The residue was
purified on silica gel (0-9% MeOH/DCM) to afford the title product
(48 mg, 55%); LC/MS (Table A, Method h) R.sub.t=1.07 min; MS m/z:
521 (M+H).sup.+. (TNF IC.sub.50=A).
Example #134*
(R)-3-((6-(2-(4-Acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-1-(2-chlorob-
enzyl)-3-oxo-1H-indazol-2(3H)-yl)methyl)benzonitrile
##STR00415##
[1287] Step 1: tert-Butyl 2-(3-cyanobenzyl)hydrazinecarboxylate
[1288] 3-Cyanobenzyl bromide (4.9 g, 25 mmol) and tert-butyl
carbazate (6.61 g, 50.0 mmol) were dissolved in MeCN (100 mL).
Potassium carbonate (6.91 g, 50.0 mmol) was added. The mixture was
heated to about 70.degree. C. for about 3 h. The mixture was cooled
to rt then concentrated. Water (100 mL) was added to the residue.
The mixture was extracted with EtOAc (2.times.200 mL). The combined
organic layers were dried over sodium sulfate, filtered and
concentrated under reduced pressure. The material was purified on
silica gel (0-30% EtOAc/DCM). The appropriate fractions were
combined and concentrated under reduced pressure to afford the
title product (3.47 g, 52% yield); LC/MS (Table A, Method i)
R.sub.t=1.07 min; MS m/z: 248 (M+H).sup.+.
Step 2: 3-(Hydrazinylmethyl)benzonitrile, 2 hydrochloric acid
[1289] tert-Butyl 2-(3-cyanobenzyl)hydrazinecarboxylate (3.47 g,
12.9 mmol) was dissolved in DCM (25.8 mL). Hydrogen chloride (4 M
in dioxane) (12.9 mL, 51.6 mmol) was added. After about 4 h,
additional hydrogen chloride (4 M in dioxane) (12.9 mL, 51.6 mmol)
was added. After about 16 h, the mixture was diluted with diethyl
ether (50 mL) and the solid was collected by filtration. The solid
was dried in a vacuum oven at about 55.degree. C. for about 2 h to
afford the title product (2.61 g, 92%); LC/MS (Table A, Method i)
R.sub.t=0.12 min; MS m/z: 148 (M+H).sup.+.
Step 3: 4-Bromo-N-(3-cyanobenzyl)-2-fluorobenzohydrazide
[1290] 3-(Hydrazinylmethyl)benzonitrile, 2 hydrochloric acid (0.500
g, 2.27 mmol) was suspended in DCM (5.0 mL). DIEA (1.6 mL, 9.0
mmol) was added. After cooling to about -50.degree. C. a solution
of 4-bromo-2-fluorobenzoyl chloride (0.539 g, 2.27 mmol) in DCM
(5.0 mL) was added dropwise over about 5 min. The mixture was
allowed to warm to ambient temperature over about 30 min. MeOH (5
mL) was added. The mixture was diluted with sat. aq. sodium
bicarbonate (150 mL) and then extracted with DCM (2.times.100 mL).
The combined organic layers were dried over sodium sulfate,
filtered and concentrated under reduced pressure to afford the
title product (0.79 g, 100%); LC/MS (Table A, Method i)
R.sub.t=1.27 min; MS m/z: 348 and 350 (M+H).sup.+.
Step 4:
3-((6-Bromo-1-(2-chlorobenzyl)-3-oxo-1H-indazol-2(3H)-yl)methyl)be-
nzonitrile
[1291] Potassium tert-butoxide (0.560 g, 4.99 mmol) was added in
one portion to a solution of
4-bromo-N-(3-cyanobenzyl)-2-fluorobenzohydrazide (0.79 g, 2.3 mmol)
and DMF (5.4 mL). After about 30 min, the reaction vessel was
transferred to an ice bath and after about 5 min, 2-chlorobenzyl
bromide (0.32 mL, 2.5 mmol) in DMF (0.5 mL) was added dropwise over
about 1 min. The ice bath was removed. After warming to rt, the
mixture was diluted with sat. aq. sodium bicarbonate (75 mL) and
then extracted with DCM (3.times.50 mL). The combined organic
layers were dried over sodium sulfate, filtered and concentrated
under reduced pressure. The material was purified on silica gel
(0-50% EtOAc/DCM) to afford the title product (189 mg, 18%); LC/MS
(Table A, Method i) R.sub.t=1.73 min; MS m/z: 452 and 454
(M+H).sup.+.
Step 5:
(R)-3-((6-(2-(4-Acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-1-(2-
-chlorobenzyl)-3-oxo-1H-indazol-2(3H)-yl)methyl)benzonitrile
[1292]
(R)-3-((6-(2-(4-Acetyl-3-methylpiperazin-1-yl)pyrimidin-5-yl)-1-(2--
chlorobenzyl)-3-oxo-1H-indazol-2(3H)-yl)methyl)benzonitrile was
prepared in a similar manner to Example #8 using
3-((6-bromo-1-(2-chlorobenzyl)-3-oxo-1H-indazol-2(3H)-yl)methyl)benzonitr-
ile and
(R)-1-(4-(5-bromopyrimidin-2-yl)-2-methylpiperazin-1-yl)ethanone
(Preparation #16) to afford the title compound (50%); LC/MS (Table
A, Method a) R.sub.t=2.17 min; MS m/z: 592 (M+H).sup.+. (TNF
IC.sub.50=B).
Example #135
1-(2-(Difluoromethoxy)-5-methylbenzyl)-6-(3-(2-hydroxypropan-2-yl)imidazo[-
1,2-b]pyridazin-7-yl)-2-methyl-1H-indazol-3(2H)-one
##STR00416##
[1293] Step 1: 1-(7-Chloroimidazo[1,2-b]pyridazin-3-yl)ethanone
[1294] 7-Chloro-3-iodoimidazo[1,2-b]pyridazine (1.5 g, 5.37 mmol)
(synthesized as described in US2012/165305 A1, 2012), dioxane (30
mL), tributyl(1-ethoxyvinyl)stannane (2.03 g, 5.64 mmol) and
PdCl.sub.2(PPh.sub.3).sub.2(0.188 g, 0.268 mmol) were heated at
about 100.degree. C. for about 14 h. The mixture was cooled to rt
then 6 N hydrochloric acid (2 mL, 12 mmol) was added. The mixture
was stirred for about 5 min then EtOAc (75 mL) and sat. aq.
NaHCO.sub.3 were added. The layers were separated then the aqueous
layer was extracted three times with EtOAc (40 mL). The combined
organic layers were dried over magnesium sulfate, filtered and
concentrated. The material was purified via flash chromatography on
silica gel (0-100% EtOAc/CH.sub.2Cl.sub.2) to give the title
compound (0.615 g, 59%); LC/MS (Table A, Method j) R.sub.t=0.50
min; MS m/z: 196 (M+H).sup.+.
Step 2: 2-(7-Chloroimidazo[1,2-b]pyridazin-3-yl)propan-2-ol
[1295] 1-(7-Chloroimidazo[1,2-b]pyridazin-3-yl)ethanone (0.615 g,
3.14 mmol) in THF (15 mL) was cooled to about 0.degree. C. then
methylmagnesium iodide (3M in ether) (1.20 mL, 3.60 mmol) was
added. The mixture was warmed to rt for about 30 min then AcOH
(.about.1 mL), water (.about.20 mL) and sat. aq. NaCl (15 mL) were
added. The mixture was extracted with EtOAc (2.times.25 mL) then
the combined organic layers were dried over magnesium sulfate,
filtered and concentrated under reduced pressure. The material was
purified via flash chromatography on silica gel (0-10%
MeOH/CH.sub.2Cl.sub.2) to give the title compound (0.365 g, 55%);
LC/MS (Table A, Method j) R.sub.t=0.74 min; MS m/z: 212
(M+H).sup.+.
Step 3:
1-(2-(Difluoromethoxy)-5-methylbenzyl)-6-(3-(2-hydroxypropan-2-yl)-
imidazo[1,2-b]pyridazin-7-yl)-2-methyl-1H-indazol-3(2H)-one
[1296] A mixture of
2-(7-chloroimidazo[1,2-b]pyridazin-3-yl)propan-2-ol (0.140 g, 0.661
mmol),
1-(2-(difluoromethoxy)-5-methylbenzyl)-2-methyl-6-(4,4,5,5-tetramethyl-1,-
3,2-dioxaborolan-2-yl)-1H-indazol-3(2H)-one (0.280 g, 0.630 mmol)
(Example #22, step 2), 1,4-dioxane (5 mL), water (1.25 mL), cesium
carbonate (0.513 g, 1.58 mmol) and 2nd generation XPhos precatalyst
(0.025 g, 0.032 mmol) was heated at about 80.degree. C. under an
atmosphere of nitrogen for about 30 min. The mixture was cooled to
rt then diluted with EtOAc (25 mL) and water (20 mL). The layers
were separated then the aqueous layer was extracted with EtOAc (20
mL). The organic layers were combined then dried over magnesium
sulfate, filtered and concentrated. The material was purified via
flash chromatography on silica gel (0-10% MeOH/CH.sub.2Cl.sub.2) to
give the title compound (0.133 g, 42%); LC/MS (Table A, Method h)
R.sub.t=0.50 min; MS m/z: 196 (M+H).sup.+. (TNF IC.sub.50=A).
* * * * *